Treatment	O
of	O
patent	B
ductus	I
arteriosus	I
:	O
indomethacin	O
or	O
ibuprofen	O
?	O

Persistent	O
patent	B
ductus	I
arteriosus	I
(	O
PDA	B
)	O
in	O
preterm	O
infants	O
can	O
result	O
in	O
serious	O
hemodynamic	O
changes	O
causing	O
respiratory	O
,	O
gastrointestinal	O
and	O
renal	O
morbidities	O
if	O
not	O
treated	O
within	O
the	O
first	O
week	O
of	O
life	O
.	O

The	O
treatment	O
options	O
available	O
are	O
a	O
conservative	O
approach	O
,	O
pharmacological	O
treatment	O
with	O
cyclo	O
-	O
oxygenase	O
(	O
COX	O
)	O
inhibitors	O
and	O
surgical	O
ligation	O
.	O

The	O
COX	O
inhibitors	O
approved	O
for	O
use	O
in	O
the	O
United	O
States	O
are	O
indomethacin	O
and	O
ibuprofen	O
lysine	O
.	O

Both	O
of	O
these	O
drugs	O
are	O
equally	O
effective	O
in	O
closing	O
the	O
PDA	B
.	O

Subtle	O
differences	O
exist	O
between	O
these	O
two	O
preparations	O
.	O

Indomethacin	O
has	O
a	O
protective	O
effect	O
on	O
the	O
incidence	O
of	O
intraventricular	B
hemorrhage	I
(	O
IVH	B
)	O
but	O
reduces	O
the	O
blood	O
flow	O
to	O
the	O
kidneys	O
and	O
the	O
brain	O
.	O

Ibuprofen	O
is	O
less	O
toxic	O
but	O
has	O
no	O
effect	O
on	O
IVH	B
.	O

Efficacy	O
of	O
pharmacological	O
treatment	O
is	O
influenced	O
by	O
timing	O
of	O
initiation	O
of	O
therapy	O
.	O

Surgical	O
treatment	O
is	O
the	O
only	O
option	O
when	O
pharmacological	O
treatment	O
fails	O
to	O
close	O
the	O
PDA	B
in	O
symptomatic	O
infants	O
.	O

Long	O
-	O
term	O
neurological	O
and	O
respiratory	O
morbidities	O
are	O
associated	O
with	O
surgical	O
ligation	O
.	O

This	O
paper	O
reviews	O
these	O
medical	O
considerations	O
in	O
the	O
treatment	O
options	O
for	O
PDA	B
in	O
premature	O
infants	O
.	O

An	O
update	O
on	O
clinical	O
drug	O
interactions	O
with	O
the	O
herbal	O
antidepressant	O
St	O
.	O

John	O
's	O
wort	O
.	O

St	O
.	O

John	O
's	O
wort	O
(	O
Hypericum	O
perforatum	O
,	O
SJW	O
)	O
is	O
one	O
of	O
the	O
most	O
commonly	O
used	O
herbal	O
antidepressants	O
for	O
the	O
treatment	O
of	O
minor	O
to	O
moderate	O
depression	B
.	O

Limited	O
clinical	O
trials	O
suggest	O
that	O
hypericum	O
and	O
standard	O
antidepressants	O
have	O
similar	O
beneficial	O
effects	O
,	O
but	O
current	O
evidence	O
regarding	O
the	O
antidepression	O
effects	O
of	O
SJW	O
extracts	O
is	O
inconsistent	O
.	O

A	O
major	O
safety	O
concern	O
about	O
SJW	O
is	O
its	O
ability	O
to	O
alter	O
the	O
pharmacokinetics	O
and	O
/	O
or	O
clinical	O
response	O
of	O
a	O
variety	O
of	O
clinically	O
important	O
drugs	O
.	O

This	O
review	O
highlights	O
and	O
updates	O
the	O
knowledge	O
regarding	O
drug	O
interactions	O
with	O
SJW	O
by	O
a	O
systematic	O
review	O
of	O
all	O
the	O
available	O
evidence	O
,	O
including	O
worldwide	O
published	O
literature	O
and	O
spontaneous	O
case	O
reports	O
.	O

A	O
number	O
of	O
clinically	O
significant	O
interactions	O
of	O
SJW	O
have	O
been	O
identified	O
with	O
conventional	O
drugs	O
.	O

These	O
interactions	O
often	O
result	O
in	O
a	O
decrease	O
in	O
the	O
concentration	O
or	O
effect	O
of	O
the	O
combined	O
drug	O
,	O
most	O
probably	O
due	O
to	O
the	O
induction	O
of	O
cytochrome	O
P450s	O
(	O
CYPs	O
)	O
and	O
the	O
key	O
drug	O
transporter	O
P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
by	O
the	O
major	O
active	O
constituents	O
in	O
SJW	O
.	O

SJW	O
is	O
a	O
potent	O
inducer	O
of	O
human	O
CYP3A4	O
and	O
P	O
-	O
gp	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
addition	O
,	O
pharmacodynamic	O
interactions	O
of	O
SJW	O
with	O
some	O
drugs	O
(	O
e.g.	O
selective	O
serotonin	O
re	O
-	O
uptake	O
inhibitors	O
)	O
have	O
been	O
identified	O
,	O
which	O
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
adverse	O
reactions	O
.	O

Since	O
potential	O
interactions	O
of	O
SJW	O
with	O
conventional	O
drugs	O
is	O
a	O
major	O
safety	O
concern	O
,	O
it	O
is	O
important	O
to	O
minimize	O
and	O
avoid	O
these	O
interactions	O
by	O
taking	O
appropriate	O
approaches	O
.	O

These	O
include	O
systematic	O
research	O
to	O
identify	O
SJW	O
-	O
drug	O
interaction	O
;	O
close	O
therapeutic	O
drug	O
monitoring	O
when	O
SJW	O
is	O
combined	O
with	O
conventional	O
drugs	O
with	O
a	O
narrow	O
therapeutic	O
window	O
;	O
proper	O
dose	O
and	O
regimen	O
adjustment	O
;	O
patient	O
education	O
and	O
communication	O
between	O
the	O
patient	O
and	O
physician	O
;	O
design	O
of	O
new	O
preparations	O
of	O
SJW	O
without	O
inducing	O
ability	O
of	O
CYP3A4	O
and	O
P	O
-	O
gp	O
while	O
retaining	O
its	O
bioactivity	O
;	O
and	O
appropriate	O
regulation	O
in	O
herbal	O
safety	O
and	O
efficacy	O
.	O

Further	O
clinical	O
and	O
mechanistic	O
studies	O
are	O
warranted	O
to	O
explore	O
the	O
interaction	O
of	O
SJW	O
with	O
other	O
important	O
drugs	O
and	O
clinical	O
significance	O
.	O

Effect	O
of	O
treatment	O
with	O
epoetin	O
-	O
beta	O
on	O
survival	O
,	O
tumour	B
progression	I
and	O
thromboembolic	B
events	I
in	O
patients	O
with	O
cancer	B
:	O
an	O
updated	O
meta	O
-	O
analysis	O
of	O
12	O
randomised	O
controlled	O
studies	O
including	O
2301	O
patients	O
.	O

Epoetin	O
-	O
beta	O
is	O
used	O
to	O
treat	O
patients	O
with	O
metastatic	B
cancer	I
undergoing	O
chemotherapy	O
to	O
alleviate	O
the	O
symptoms	O
of	O
anaemia	B
,	O
reduce	O
the	O
risk	O
of	O
blood	O
transfusions	O
and	O
improve	O
quality	O
of	O
life	O
.	O

This	O
meta	O
-	O
analysis	O
of	O
12	O
randomised	O
,	O
controlled	O
studies	O
evaluated	O
the	O
impact	O
of	O
epoetin	O
-	O
beta	O
on	O
overall	O
survival	O
,	O
tumour	B
progression	I
and	O
thromboembolic	B
events	I
(	O
TEEs	B
)	O
.	O

A	O
total	O
of	O
2297	O
patients	O
were	O
included	O
in	O
the	O
analysis	O
(	O
epoetin	O
-	O
beta	O
,	O
n	O
=	O
1244	O
;	O
control	O
,	O
n	O
=	O
1053	O
;	O
65	O
%	O
solid	O
and	O
35	O
%	O
nonmyeloid	B
haematological	I
malignancies	I
)	O
.	O

A	O
prespecified	O
subgroup	O
analysis	O
assessed	O
the	O
effects	O
in	O
patients	O
with	O
a	O
baseline	O
Hb	O
<	O
or	O
=	O
11	O
g	O
dl	O
(	O
-	O
1	O
)	O
,	O
corresponding	O
to	O
current	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	B
(	O
EORTC	O
)	O
guidelines	O
.	O

No	O
statistically	O
significant	O
effect	O
on	O
mortality	O
was	O
observed	O
with	O
epoetin	O
-	O
beta	O
vs	O
control	O
,	O
both	O
overall	O
(	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
1.13	O
;	O
95	O
%	O
CI	O
:	O
0.87	O
,	O
1.46	O
;	O
P	O
=	O
0.355	O
)	O
and	O
in	O
patients	O
with	O
baseline	O
Hb	O
<	O
or	O
=	O
11	O
g	O
dl	O
(	O
-	O
1	O
)	O
(	O
HR	O
=	O
1.09	O
;	O
95	O
%	O
CI	O
:	O
0.80	O
,	O
1.47	O
;	O
P	O
=	O
0.579	O
)	O
.	O

A	O
trend	O
for	O
a	O
beneficial	O
effect	O
on	O
tumour	B
progression	I
was	O
seen	O
overall	O
(	O
HR	O
=	O
0.85	O
;	O
95	O
%	O
CI	O
:	O
0.72	O
,	O
1.01	O
;	O
P	O
=	O
0.072	O
)	O
and	O
in	O
patients	O
with	O
an	O
Hb	O
<	O
or	O
=	O
11	O
g	O
dl	O
(	O
-	O
1	O
)	O
(	O
HR	O
=	O
0.80	O
;	O
95	O
%	O
CI	O
:	O
0.65	O
,	O
0.99	O
;	O
P	O
=	O
0.041	O
)	O
.	O

An	O
increased	O
frequency	O
of	O
TEEs	B
was	O
seen	O
with	O
epoetin	O
-	O
beta	O
vs	O
control	O
(	O
7	O
vs	O
4	O
%	O
of	O
patients	O
)	O
;	O
however	O
,	O
TEEs	B
-	O
related	O
mortality	O
was	O
similar	O
in	O
both	O
groups	O
(	O
1	O
%	O
each	O
)	O
.	O

The	O
results	O
of	O
this	O
meta	O
-	O
analysis	O
indicate	O
that	O
when	O
used	O
within	O
current	O
EORTC	O
treatment	O
guidelines	O
,	O
epoetin	O
-	O
beta	O
has	O
no	O
negative	O
impact	O
on	O
survival	O
,	O
tumour	B
progression	I
or	O
TEEs	B
-	O
related	O
mortality	O
.	O

Points	O
to	O
consider	O
on	O
the	O
non	O
-	O
clinical	O
safety	O
evaluation	O
of	O
anticancer	O
drugs	O
.	O

Since	O
malignant	B
tumors	I
are	O
life	O
-	O
threatening	O
,	O
the	O
death	O
rate	O
from	O
these	O
diseases	O
is	O
high	O
,	O
and	O
existing	O
therapies	O
have	O
limited	O
effectiveness	O
,	O
it	O
is	O
desired	O
to	O
provide	O
new	O
effective	O
anticancer	O
drugs	O
to	O
tumor	O
patients	O
sooner	O
.	O

However	O
,	O
there	O
is	O
no	O
guideline	O
regarding	O
non	O
-	O
clinical	O
safety	O
studies	O
on	O
the	O
development	O
of	O
anticancer	O
drugs	O
required	O
for	O
the	O
first	O
in	O
human	O
clinical	O
trials	O
and	O
for	O
the	O
approval	O
applications	O
in	O
Japan	O
.	O

Then	O
,	O
the	O
Ministry	O
of	O
Health	O
,	O
Labour	O
and	O
Welfare	O
(	O
MHLW	O
)	O
established	O
the	O
collaboration	O
group	O
including	O
regulatory	O
,	O
academic	O
and	O
industrial	O
scientists	O
to	O
prepare	O
the	O
guideline	O
on	O
the	O
non	O
-	O
clinical	O
safety	O
evaluation	O
of	O
anticancer	O
drugs	O
in	O
2004	O
.	O

As	O
a	O
guide	O
for	O
basic	O
concept	O
of	O
non	O
-	O
clinical	O
safety	O
studies	O
on	O
anticancer	O
drugs	O
,	O
the	O
""""	O
Points	O
to	O
Consider	O
""""	O
document	O
was	O
prepared	O
by	O
this	O
group	O
in	O
2007	O
.	O

Detailing	O
the	O
role	O
of	O
Bax	O
translocation	O
,	O
cytochrome	O
c	O
release	O
,	O
and	O
perinuclear	O
clustering	O
of	O
the	O
mitochondria	O
in	O
the	O
killing	O
of	O
HeLa	O
cells	O
by	O
TNF	O
.	O

Induction	O
of	O
cell	O
death	O
in	O
HeLa	O
cells	O
with	O
TNF	O
and	O
cycloheximide	O
(	O
CHX	O
)	O
required	O
an	O
adequate	O
ATP	O
supply	O
and	O
was	O
accompanied	O
by	O
decrease	O
in	O
intracellular	O
pH	O
,	O
translocation	O
of	O
Bax	O
,	O
perinuclear	O
clustering	O
of	O
the	O
mitochondria	O
,	O
and	O
cytochrome	O
c	O
release	O
.	O

The	O
chloride	O
channel	O
inhibitor	O
furosemide	O
prevented	O
the	O
intracellular	O
acidification	O
,	O
the	O
translocation	O
of	O
Bax	O
and	O
the	O
cell	O
death	O
.	O

Cyclosporin	O
A	O
(	O
CyA	O
)	O
or	O
bongkrekic	O
acid	O
(	O
BK	O
)	O
inhibited	O
the	O
induction	O
of	O
the	O
MPT	O
,	O
the	O
release	O
of	O
cytochrome	O
c	O
and	O
the	O
cell	O
death	O
without	O
affecting	O
the	O
perinuclear	O
clustering	O
of	O
the	O
mitochondria	O
or	O
the	O
translocation	O
of	O
Bax	O
.	O

Energy	O
depletion	O
with	O
the	O
ATP	O
synthase	O
inhibitor	O
oligomycin	O
or	O
the	O
uncoupler	O
FCCP	O
in	O
the	O
presence	O
of	O
2	O
-	O
deoxy	O
-	O
glucose	O
prevented	O
the	O
perinuclear	O
clustering	O
of	O
the	O
mitochondria	O
and	O
the	O
cell	O
killing	O
.	O

However	O
,	O
mitochondrial	O
translocation	O
of	O
Bax	O
was	O
still	O
observed	O
.	O

By	O
contrast	O
,	O
cytochrome	O
c	O
was	O
released	O
in	O
the	O
oligomycin	O
-	O
treated	O
cells	O
but	O
not	O
in	O
the	O
same	O
cells	O
treated	O
with	O
FCCP	O
.	O

The	O
data	O
demonstrate	O
that	O
apoptosis	O
in	O
HeLa	O
cells	O
is	O
ATP	O
dependent	O
and	O
requires	O
the	O
translocation	O
of	O
Bax	O
.	O

The	O
movement	O
of	O
Bax	O
to	O
the	O
mitochondria	O
occurs	O
before	O
and	O
during	O
the	O
perinuclear	O
clustering	O
of	O
these	O
organelles	O
and	O
does	O
not	O
require	O
the	O
presence	O
of	O
ATP	O
.	O

The	O
release	O
of	O
cytochrome	O
c	O
depends	O
on	O
the	O
induction	O
of	O
the	O
mitochondrial	O
permeability	O
transition	O
but	O
not	O
ATP	O
content	O
.	O

Maximum	O
effect	O
of	O
triptans	O
in	O
migraine	B
?	O

A	O
comment	O
.	O

The	O
efficacy	O
of	O
triptans	O
in	O
the	O
treatment	O
of	O
migraine	B
was	O
recently	O
contested	O
.	O

How	O
high	O
is	O
then	O
the	O
maximum	O
effect	O
of	O
a	O
triptan	O
?	O

After	O
subcutaneous	O
naratriptan	O
10	O
mg	O
a	O
88	O
%	O
pain	O
-	O
free	O
response	O
was	O
observed	O
.	O

This	O
result	O
was	O
obtained	O
despite	O
the	O
fact	O
that	O
more	O
half	O
of	O
the	O
patients	O
had	O
a	O
migraine	B
duration	O
of	O
>	O
4	O
h	O
.	O

These	O
results	O
indicate	O
that	O
subcutaneous	O
naratriptan	O
in	O
a	O
high	O
dose	O
can	O
overcome	O
central	O
sensitization	O
that	O
occurs	O
in	O
migraine	B
attacks	O
.	O

Effect	O
of	O
Efalizumab	O
on	O
neutrophil	O
and	O
monocyte	O
functions	O
in	O
patients	O
with	O
psoriasis	B
.	O

We	O
evaluated	O
the	O
effect	O
of	O
efalizumab	O
on	O
neutrophil	O
and	O
monocyte	O
functions	O
.	O

The	O
in	O
vitro	O
pre	O
-	O
incubation	O
with	O
efalizumab	O
concentrations	O
similar	O
to	O
those	O
reached	O
during	O
in	O
vivo	O
therapy	O
almost	O
completely	O
saturated	O
CD11a	O
binding	O
sites	O
without	O
affecting	O
the	O
membrane	O
expression	O
of	O
CD11b	O
,	O
CD128a	O
or	O
CD128b	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
chemotactic	O
activity	O
of	O
the	O
pre	O
-	O
treated	O
cells	O
toward	O
three	O
different	O
chemo	O
-	O
attractants	O
,	O
whereas	O
their	O
phagocytic	O
capacity	O
and	O
production	O
of	O
oxygen	O
radicals	O
remained	O
unchanged	O
.	O

One	O
month	O
after	O
the	O
administration	O
of	O
efalizumab	O
to	O
five	O
patients	O
with	O
psoriasis	B
(	O
T1	O
)	O
circulating	O
neutrophil	O
counts	O
increased	O
by	O
34	O
%	O
from	O
pre	O
-	O
therapy	O
(	O
T0	O
)	O
with	O
no	O
change	O
in	O
the	O
number	O
of	O
monocytes	O
.	O

In	O
the	O
same	O
patients	O
the	O
CD11a	O
binding	O
sites	O
on	O
phagocytes	O
were	O
>	O
90	O
%	O
saturated	O
,	O
and	O
there	O
was	O
also	O
a	O
significant	O
down	O
-	O
modulation	O
on	O
neutrophils	O
(	O
44	O
%	O
of	O
T0	O
)	O
and	O
monocytes	O
(	O
63	O
%	O
of	O
T0	O
)	O
.	O

In	O
line	O
with	O
in	O
vitro	O
results	O
,	O
efalizumab	O
treatment	O
caused	O
a	O
significant	O
deficiency	O
in	O
the	O
chemotactic	O
properties	O
of	O
neutrophils	O
and	O
monocytes	O
,	O
but	O
no	O
changes	O
in	O
phagocytosis	O
,	O
oxidative	O
burst	O
,	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
or	O
the	O
membrane	O
expression	O
of	O
CD11b	O
,	O
CD128a	O
and	O
CD128b	O
.	O

Our	O
findings	O
suggest	O
that	O
neutrophils	O
and	O
monocytes	O
may	O
be	O
among	O
the	O
targets	O
of	O
efalizumab	O
activity	O
in	O
patients	O
with	O
psoriasis	B
.	O

Lisdexamfetamine	O
dimesylate	O
for	O
childhood	O
ADHD	B
.	O

Stimulants	O
are	O
extremely	O
effective	O
and	O
safe	O
and	O
have	O
been	O
the	O
mainstay	O
for	O
the	O
pharmacological	O
treatment	O
of	O
attention	B
deficit	I
hyperactivity	I
disorder	I
(	O
ADHD	B
)	O
for	O
many	O
years	O
.	O

However	O
,	O
there	O
have	O
been	O
some	O
concerns	O
regarding	O
their	O
abuse	O
,	O
especially	O
by	O
teenagers	O
and	O
young	O
adults	O
.	O

Lisdexamfetamine	O
was	O
recently	O
approved	O
for	O
the	O
treatment	O
of	O
ADHD	B
in	O
6	O
-	O
12	O
-	O
year	O
-	O
olds	O
and	O
provides	O
a	O
novel	O
approach	O
to	O
the	O
treatment	O
of	O
ADHD	B
.	O

Lisdexamfetamine	O
is	O
a	O
prodrug	O
comprised	O
of	O
dextroamphetamine	O
covalently	O
attached	O
to	O
an	O
essential	O
amino	O
acid	O
,	O
L	O
-	O
lysine	O
.	O

Following	O
oral	O
administration	O
,	O
the	O
amide	O
linkage	O
between	O
the	O
two	O
molecules	O
is	O
enzymatically	O
hydrolyzed	O
in	O
the	O
gastrointestinal	O
tract	O
,	O
thus	O
releasing	O
active	O
dextroamphetamine	O
,	O
which	O
mediates	O
the	O
therapeutic	O
effect	O
in	O
a	O
fashion	O
similar	O
to	O
other	O
stimulants	O
.	O

The	O
parent	O
drug	O
does	O
not	O
bind	O
to	O
sites	O
responsible	O
for	O
the	O
reuptake	O
of	O
norepinephrine	O
and	O
dopamine	O
in	O
vitro	O
.	O

Lisdexamfetamine	O
does	O
not	O
produce	O
high	O
dextroamphetamine	O
levels	O
when	O
injected	O
or	O
snorted	O
,	O
and	O
thus	O
may	O
have	O
lower	O
abuse	O
potential	O
compared	O
to	O
conventional	O
stimulants	O
.	O

Lisdexamfetamine	O
appears	O
to	O
have	O
efficacy	O
and	O
tolerability	O
comparable	O
to	O
other	O
extended	O
-	O
release	O
stimulant	O
formulations	O
used	O
to	O
treat	O
ADHD	B
,	O
but	O
reduced	O
potential	O
for	O
abuse	O
-	O
related	O
liking	O
effects	O
.	O

Compared	O
to	O
equivalent	O
amounts	O
of	O
immediate	O
-	O
release	O
dextroamphetamine	O
.	O

Proteasome	O
activation	O
by	O
hepatitis	O
C	O
core	O
protein	O
is	O
reversed	O
by	O
ethanol	O
-	O
induced	O
oxidative	O
stress	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
The	O
proteasome	O
is	O
a	O
major	O
cellular	O
proteinase	O
.	O

Its	O
activity	O
is	O
modulated	O
by	O
cellular	O
oxidants	O
.	O

Hepatitis	O
C	O
core	O
protein	O
and	O
ethanol	O
exposure	O
both	O
cause	O
enhanced	O
oxidant	O
generation	O
.	O

The	O
aim	O
was	O
to	O
investigate	O
whether	O
core	O
protein	O
,	O
by	O
its	O
ability	O
to	O
generate	O
oxidants	O
,	O
alters	O
proteasome	O
activity	O
and	O
whether	O
these	O
alterations	O
are	O
further	O
affected	O
by	O
ethanol	O
exposure	O
.	O

METHODS	O
:	O
These	O
interactions	O
were	O
examined	O
in	O
Huh	O
-	O
7	O
cell	O
lines	O
that	O
expressed	O
inducible	O
HCV	O
core	O
protein	O
and	O
/	O
or	O
constitutive	O
cytochrome	O
P450	O
2E1	O
(	O
CYP2E1	O
)	O
and	O
as	O
purified	O
components	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

Chymotrypsin	O
-	O
like	O
proteasome	O
activity	O
was	O
measured	O
fluorometrically	O
.	O

RESULTS	O
:	O
Proteasome	O
activity	O
in	O
core	O
-	O
positive	O
191	O
-	O
20	O
cells	O
was	O
20	O
%	O
higher	O
than	O
that	O
in	O
core	O
-	O
negative	O
cells	O
and	O
was	O
enhanced	O
3	O
-	O
fold	O
in	O
CYP2E1	O
-	O
expressing	O
L14	O
cells	O
.	O

Exposure	O
of	O
core	O
-	O
positive	O
cells	O
to	O
glutathione	O
ethyl	O
ester	O
,	O
catalase	O
,	O
or	O
the	O
CYP2E1	O
inhibitor	O
diallyl	O
sulfide	O
partially	O
reversed	O
the	O
elevation	O
of	O
proteasome	O
activity	O
in	O
core	O
-	O
positive	O
cells	O
,	O
whereas	O
ethanol	O
exposure	O
suppressed	O
proteasome	O
activity	O
.	O

The	O
results	O
indicate	O
that	O
proteasome	O
activity	O
was	O
up	O
-	O
regulated	O
by	O
low	O
levels	O
of	O
core	O
-	O
induced	O
oxidative	O
stress	O
but	O
down	O
-	O
regulated	O
by	O
high	O
levels	O
of	O
ethanol	O
-	O
elicited	O
stress	O
.	O

These	O
findings	O
were	O
partially	O
mimicked	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

Addition	O
of	O
core	O
protein	O
enhanced	O
the	O
peptidase	O
activity	O
of	O
purified	O
20S	O
proteasome	O
containing	O
the	O
proteasome	O
activator	O
PA28	O
and	O
was	O
further	O
potentiated	O
by	O
addition	O
of	O
liver	O
mitochondrial	O
and	O
/	O
or	O
microsome	O
fractions	O
.	O

However	O
,	O
proteasome	O
activation	O
was	O
significantly	O
attenuated	O
when	O
fractions	O
were	O
obtained	O
from	O
ethanol	O
-	O
fed	O
animals	O
.	O

CONCLUSIONS	O
:	O
HCV	O
core	O
protein	O
interacts	O
with	O
PA28	O
,	O
mitochondrial	O
,	O
and	O
endoplasmic	O
reticulum	O
proteins	O
to	O
cause	O
low	O
levels	O
of	O
oxidant	O
stress	O
and	O
proteasome	O
activation	O
,	O
which	O
is	O
dampened	O
during	O
ethanol	O
metabolism	O
when	O
oxidant	O
generation	O
is	O
higher	O
.	O

Moxifloxacin	O
for	O
the	O
treatment	O
of	O
HIV	B
-	I
associated	I
tuberculosis	I
in	O
patients	O
with	O
contraindications	O
or	O
intolerance	O
to	O
rifamycins	O
.	O

Administration	O
of	O
rifampicin	O
or	O
rifabutin	O
in	O
the	O
treatment	O
of	O
HIV	B
-	I
associated	I
tuberculosis	I
(	O
TB	B
)	O
is	O
made	O
rather	O
complex	O
by	O
the	O
risk	O
of	O
drug	O
-	O
drug	O
interactions	O
with	O
most	O
antiretrovirals	O
and	O
/	O
or	O
for	O
reasons	O
of	O
toxicity	O
.	O

While	O
in	O
selecting	O
the	O
appropriate	O
concomitant	O
regimens	O
the	O
priority	O
usually	O
goes	O
to	O
rifamycins	O
with	O
exclusion	O
of	O
interacting	O
antiretrovirals	O
,	O
in	O
some	O
circumstances	O
the	O
former	O
can	O
not	O
be	O
used	O
and	O
anti	O
-	O
TB	O
rifamycin	O
-	O
free	O
regimens	O
must	O
be	O
administered	O
.	O

We	O
describe	O
here	O
the	O
clinical	O
course	O
of	O
two	O
patients	O
with	O
HIV	B
-	I
associated	I
TB	I
in	O
whom	O
the	O
last	O
generation	O
fluorquinolone	O
moxifloxacin	O
(	O
found	O
to	O
exert	O
significant	O
activity	O
against	O
Mycobacterium	O
tuberculosis	O
)	O
successfully	O
replaced	O
rifamycins	O
.	O

Kinetic	O
analysis	O
of	O
superoxide	O
anion	O
radical	O
-	O
scavenging	O
and	O
hydroxyl	O
radical	O
-	O
scavenging	O
activities	O
of	O
platinum	O
nanoparticles	O
.	O

There	O
are	O
few	O
reports	O
on	O
the	O
physiological	O
effects	O
of	O
metal	O
nanoparticles	O
(	O
nps	O
)	O
,	O
especially	O
with	O
respect	O
to	O
their	O
functions	O
as	O
scavengers	O
for	O
superoxide	O
anion	O
radical	O
(	O
O2	O
(	O
.	O
-	O
)	O
)	O
and	O
hydroxyl	O
radical	O
(	O
.	O

OH	O
)	O
.	O

We	O
tried	O
to	O
detect	O
the	O
scavenging	O
activity	O
of	O
Pt	O
nps	O
using	O
a	O
hypoxanthine	O
-	O
xanthine	O
oxidase	O
system	O
for	O
O2	O
(	O
.	O
-	O
)	O
and	O
using	O
a	O
Fenton	O
and	O
a	O
UV	O
/	O
H2O2	O
system	O
for	O
.	O

OH	O
.	O

Electron	O
spin	O
resonance	O
analysis	O
revealed	O
that	O
2	O
nm	O
particle	O
size	O
Pt	O
nps	O
have	O
the	O
ability	O
to	O
scavenge	O
O2	O
(	O
.	O
-	O
)	O
and	O
.	O

OH	O
.	O

The	O
calculated	O
rate	O
constant	O
for	O
the	O
O2	O
(	O
.	O
-	O
)	O
-	O
scavenging	O
reaction	O
was	O
5.03	O
+	O
/	O
-	O
0.03	O
x	O
10	O
(	O
7	O
)	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
.	O

However	O
,	O
the	O
analysis	O
of	O
the	O
Fenton	O
and	O
UV	O
/	O
H	O
2O	O
2	O
system	O
in	O
the	O
presence	O
of	O
Pt	O
nps	O
suggested	O
that	O
the	O
.	O

OH	O
-	O
scavenging	O
reaction	O
can	O
not	O
be	O
determined	O
in	O
both	O
systems	O
.	O

Among	O
particle	O
sizes	O
tested	O
from	O
1	O
to	O
5	O
nm	O
,	O
1	O
nm	O
Pt	O
nps	O
showed	O
the	O
highest	O
O2	O
(	O
.	O
-	O
)	O
-	O
scavenging	O
ability	O
.	O

Almost	O
no	O
cytotoxicity	O
was	O
observed	O
even	O
after	O
adherent	O
cells	O
(	O
TIG	O
-	O
1	O
,	O
HeLa	O
,	O
HepG2	O
,	O
WI	O
-	O
38	O
,	O
and	O
MRC	O
-	O
5	O
)	O
were	O
exposed	O
to	O
Pt	O
nps	O
at	O
concentrations	O
as	O
high	O
as	O
50	O
mg	O
/	O
L	O
.	O

Pt	O
nps	O
scavenged	O
intrinsically	O
generated	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
HeLa	O
cells	O
.	O

Additionally	O
,	O
Pt	O
nps	O
significantly	O
reduced	O
the	O
levels	O
of	O
intracellular	O
O2	O
(	O
.	O
-	O
)	O
generated	O
by	O
UVA	O
irradiation	O
and	O
subsequently	O
protected	O
HeLa	O
cells	O
from	O
ROS	O
damage	O
-	O
induced	O
cell	O
death	O
.	O

These	O
findings	O
suggest	O
that	O
Pt	O
nps	O
may	O
be	O
a	O
new	O
type	O
of	O
antioxidant	O
capable	O
of	O
circumventing	O
the	O
paradoxical	O
effects	O
of	O
conventional	O
antioxidants	O
.	O

Efavirenz	O
replacement	O
by	O
immediate	O
full	O
-	O
dose	O
nevirapine	O
is	O
safe	O
in	O
HIV	O
-	O
1	O
-	O
infected	O
patients	O
in	O
Cambodia	O
.	O

BACKGROUND	O
:	O
Efavirenz	O
is	O
used	O
for	O
the	O
antiretroviral	O
treatment	O
of	O
HIV	B
/	O
tuberculosis	B
-	O
coinfected	O
patients	O
in	O
developing	O
countries	O
.	O

A	O
switch	O
to	O
nevirapine	O
is	O
regularly	O
carried	O
out	O
because	O
of	O
the	O
cost	O
and	O
side	O
effects	O
of	O
efavirenz	O
.	O

Pharmacokinetic	O
studies	O
suggested	O
that	O
nevirapine	O
should	O
be	O
initiated	O
at	O
full	O
dose	O
when	O
used	O
as	O
a	O
substitute	O
for	O
efavirenz	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
measure	O
the	O
cumulative	O
incidence	O
of	O
adverse	O
events	O
(	O
AEs	O
)	O
related	O
to	O
nevirapine	O
in	O
patients	O
switched	O
from	O
efavirenz	O
to	O
immediate	O
full	O
-	O
dose	O
nevirapine	O
(	O
FDN	O
)	O
.	O

METHODS	O
:	O
In	O
2001	O
an	O
antiretroviral	O
treatment	O
programme	O
was	O
initiated	O
with	O
the	O
first	O
-	O
line	O
regimen	O
stavudine	O
,	O
lamivudine	O
and	O
efavirenz	O
.	O

In	O
2003	O
,	O
the	O
fixed	O
-	O
dose	O
combination	O
of	O
stavudine	O
,	O
lamivudine	O
and	O
nevirapine	O
was	O
recommended	O
.	O

Thus	O
,	O
first	O
-	O
line	O
therapy	O
was	O
changed	O
and	O
FDN	O
was	O
initiated	O
when	O
patients	O
were	O
switched	O
from	O
efavirenz	O
to	O
nevirapine	O
.	O

RESULTS	O
:	O
Between	O
April	O
and	O
December	O
2004	O
,	O
394	O
patients	O
were	O
switched	O
from	O
efavirenz	O
to	O
FDN	O
.	O

The	O
cumulative	O
incidence	O
of	O
AEs	O
related	O
to	O
nevirapine	O
was	O
13.2	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
10.2	O
-	O
16.7	O
]	O
and	O
that	O
of	O
severe	O
AEs	O
was	O
8.9	O
%	O
(	O
95	O
%	O
CI	O
6.5	O
-	O
11.9	O
)	O
.	O

In	O
women	O
the	O
incidence	O
of	O
AEs	O
was	O
17.6	O
%	O
(	O
95	O
%	O
CI	O
12.1	O
-	O
24.3	O
)	O
and	O
that	O
of	O
severe	O
AEs	O
was	O
12.2	O
%	O
(	O
95	O
%	O
CI	O
7.7	O
-	O
18.2	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
an	O
FDN	O
switch	O
from	O
efavirenz	O
does	O
not	O
appear	O
to	O
result	O
in	O
more	O
AEs	O
than	O
when	O
nevirapine	O
is	O
initiated	O
with	O
escalating	O
doses	O
.	O

These	O
data	O
are	O
particularly	O
relevant	O
in	O
resource	O
-	O
limited	O
settings	O
.	O

Styrene	O
induces	O
an	O
inflammatory	O
response	O
in	O
human	O
lung	O
epithelial	O
cells	O
via	O
oxidative	O
stress	O
and	O
NF	O
-	O
kappaB	O
activation	O
.	O

Styrene	O
is	O
a	O
volatile	O
organic	O
compound	O
(	O
VOC	O
)	O
that	O
is	O
widely	O
used	O
as	O
a	O
solvent	O
in	O
many	O
industrial	O
settings	O
.	O

Chronic	O
exposure	O
to	O
styrene	O
can	O
result	O
in	O
irritation	B
of	I
the	I
mucosa	I
of	O
the	O
upper	O
respiratory	O
tract	O
.	O

Contact	O
of	O
styrene	O
with	O
epithelial	O
cells	O
stimulates	O
the	O
expression	O
of	O
a	O
variety	O
of	O
inflammatory	O
mediators	O
,	O
including	O
the	O
chemotactic	O
cytokine	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
(	O
MCP	O
-	O
1	O
)	O
.	O

To	O
characterise	O
the	O
underlying	O
mechanisms	O
of	O
the	O
induction	O
of	O
inflammatory	O
signals	O
by	O
styrene	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
this	O
compound	O
on	O
the	O
induction	O
of	O
oxidative	O
stress	O
and	O
the	O
activation	O
of	O
the	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
signalling	O
pathway	O
in	O
human	O
lung	O
epithelial	O
cells	O
(	O
A549	O
)	O
.	O

The	O
results	O
demonstrate	O
that	O
styrene	O
-	O
induced	O
MCP	O
-	O
1	O
expression	O
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
the	O
oxidative	O
stress	O
marker	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
,	O
is	O
associated	O
with	O
a	O
concentration	O
dependent	O
pattern	O
of	O
NF	O
-	O
kappaB	O
activity	O
.	O

An	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
,	O
IKK	O
-	O
NBD	O
,	O
and	O
the	O
anti	O
-	O
inflammatory	O
antioxidant	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
were	O
both	O
effective	O
in	O
suppressing	O
styrene	O
-	O
induced	O
MCP	O
-	O
1	O
secretion	O
.	O

In	O
addition	O
,	O
NAC	O
was	O
capable	O
of	O
inhibiting	O
the	O
upregulation	O
of	O
GST	O
expression	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
signalling	O
pathway	O
by	O
styrene	O
is	O
mediated	O
via	O
a	O
redox	O
-	O
sensitive	O
mechanism	O
.	O

High	O
dose	O
chemotherapy	O
and	O
autologous	O
stem	O
cell	O
transplantation	O
in	O
patients	O
with	O
multiple	B
myeloma	I
:	O
the	O
experience	O
of	O
a	O
single	O
haematological	O
unit	O
.	O

PURPOSE	O
:	O
To	O
study	O
the	O
toxicity	O
of	O
high	O
dose	O
chemotherapy	O
(	O
HDCT	O
)	O
in	O
multiple	B
myeloma	I
(	O
MM	B
)	O
patients	O
and	O
its	O
impact	O
on	O
event	O
free	O
survival	O
(	O
EFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
and	O
also	O
the	O
impact	O
of	O
thalidomide	O
maintenance	O
therapy	O
on	O
EFS	O
and	O
OS	O
after	O
HDCT	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
From	O
April	O
1999	O
to	O
November	O
2006	O
37	O
patients	O
(	O
29	O
males	O
,	O
8	O
females	O
)	O
out	O
of	O
a	O
total	O
of	O
38	O
scheduled	O
were	O
treated	O
with	O
HDCT	O
and	O
autologous	O
peripheral	O
stem	O
cell	O
transplantation	O
(	O
APSCT	O
)	O
,	O
as	O
consolidation	O
treatment	O
after	O
first	O
-	O
or	O
second	O
-	O
line	O
chemotherapy	O
.	O

Their	O
median	O
age	O
was	O
55	O
years	O
(	O
range	O
38	O
-	O
71	O
)	O
.	O

HDCT	O
regimen	O
used	O
was	O
melphalan	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

Following	O
HDCT	O
thalidomide	O
100	O
mg	O
/	O
day	O
was	O
administered	O
as	O
maintenance	O
therapy	O
to	O
28	O
patients	O
in	O
a	O
random	O
fashion	O
.	O

RESULTS	O
:	O
All	O
patients	O
tolerated	O
well	O
HDCT	O
and	O
APSCT	O
.	O

There	O
was	O
no	O
treatment	O
-	O
related	O
mortality	O
.	O

The	O
median	O
time	O
interval	O
for	O
neutrophil	O
recovery	O
(	O
>	O
500	O
/	O
mm	O
(	O
3	O
)	O
)	O
was	O
10	O
days	O
(	O
range	O
8	O
-	O
20	O
)	O
,	O
while	O
the	O
median	O
time	O
interval	O
for	O
platelets	O
to	O
recover	O
to	O
>	O
20.000	O
/	O
mm	O
(	O
3	O
)	O
was	O
14	O
days	O
(	O
range	O
9	O
-	O
32	O
)	O
.	O

Twenty	O
(	O
54	O
%	O
)	O
patients	O
achieved	O
complete	O
response	O
(	O
CR	O
)	O
,	O
15	O
(	O
40	O
%	O
)	O
partial	O
response	O
(	O
PR	O
)	O
,	O
and	O
2	O
(	O
6	O
%	O
)	O
stable	O
disease	O
(	O
SD	O
)	O
.	O

Before	O
receiving	O
thalidomide	O
as	O
maintenance	O
treatment	O
12	O
(	O
42	O
%	O
)	O
patients	O
were	O
in	O
CR	O
,	O
while	O
all	O
the	O
others	O
,	O
except	O
one	O
who	O
had	O
progressive	O
disease	O
(	O
PD	O
)	O
,	O
were	O
in	O
PR	O
.	O

CR	O
correlated	O
with	O
better	O
EFS	O
and	O
probably	O
OS	O
.	O

Thalidomide	O
maintenance	O
treatment	O
correlated	O
with	O
better	O
EFS	O
.	O

CONCLUSION	O
:	O
In	O
our	O
series	O
of	O
patients	O
HDCT	O
appears	O
to	O
be	O
a	O
totally	O
feasible	O
,	O
safe	O
and	O
without	O
treatment	O
-	O
related	O
mortality	O
procedure	O
,	O
even	O
in	O
patients	O
older	O
than	O
60	O
years	O
of	O
age	O
.	O

It	O
has	O
a	O
major	O
impact	O
in	O
terms	O
of	O
CR	O
achievement	O
,	O
which	O
seems	O
to	O
strongly	O
correlate	O
with	O
a	O
prolonged	O
EFS	O
and	O
OS	O
.	O

The	O
use	O
of	O
thalidomide	O
as	O
a	O
maintenance	O
therapy	O
induces	O
a	O
greater	O
EFS	O
which	O
could	O
possibly	O
yield	O
an	O
improved	O
OS	O
.	O

Comparison	O
of	O
oxime	O
reactivation	O
and	O
aging	O
of	O
nerve	O
agent	O
-	O
inhibited	O
monkey	O
and	O
human	O
acetylcholinesterases	O
.	O

Non	O
-	O
human	O
primates	O
are	O
valuable	O
animal	O
models	O
that	O
are	O
used	O
for	O
the	O
evaluation	O
of	O
nerve	B
agent	I
toxicity	I
as	O
well	O
as	O
antidotes	O
and	O
results	O
from	O
animal	O
experiments	O
are	O
extrapolated	O
to	O
humans	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
the	O
efficacy	O
of	O
an	O
oxime	O
primarily	O
depends	O
on	O
its	O
ability	O
to	O
reactivate	O
nerve	O
agent	O
-	O
inhibited	O
acetylcholinesterase	O
(	O
AChE	O
)	O
.	O

If	O
the	O
in	O
vitro	O
oxime	O
reactivation	O
of	O
nerve	O
agent	O
-	O
inhibited	O
animal	O
AChE	O
is	O
similar	O
to	O
that	O
of	O
human	O
AChE	O
,	O
it	O
is	O
likely	O
that	O
the	O
results	O
of	O
an	O
in	O
vivo	O
animal	O
study	O
will	O
reliably	O
extrapolate	O
to	O
humans	O
.	O

Therefore	O
,	O
the	O
goal	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
aging	O
and	O
reactivation	O
of	O
human	O
and	O
different	O
monkey	O
(	O
Rhesus	O
,	O
Cynomolgus	O
,	O
and	O
African	O
Green	O
)	O
AChEs	O
inhibited	O
by	O
GF	O
,	O
GD	O
,	O
and	O
VR	O
.	O

The	O
oximes	O
examined	O
include	O
the	O
traditional	O
oxime	O
2	O
-	O
PAM	O
,	O
two	O
H	O
-	O
oximes	O
HI	O
-	O
6	O
and	O
HLo	O
-	O
7	O
,	O
and	O
the	O
new	O
candidate	O
oxime	O
MMB4	O
.	O

Results	O
indicate	O
that	O
oxime	O
reactivation	O
of	O
all	O
three	O
monkey	O
AChEs	O
was	O
very	O
similar	O
to	O
human	O
AChE	O
.	O

The	O
maximum	O
difference	O
in	O
the	O
second	O
-	O
order	O
reactivation	O
rate	O
constant	O
between	O
human	O
and	O
three	O
monkey	O
AChEs	O
or	O
between	O
AChEs	O
from	O
different	O
monkey	O
species	O
was	O
5	O
-	O
fold	O
.	O

Aging	O
rate	O
constants	O
of	O
GF	O
-	O
,	O
GD	O
-	O
,	O
and	O
VR	O
-	O
inhibited	O
monkey	O
AChEs	O
were	O
very	O
similar	O
to	O
human	O
AChE	O
except	O
for	O
GF	O
-	O
inhibited	O
monkey	O
AChEs	O
,	O
which	O
aged	O
2	O
-	O
3	O
times	O
faster	O
than	O
the	O
human	O
enzyme	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
all	O
three	O
monkey	O
species	O
are	O
suitable	O
animal	O
models	O
for	O
nerve	O
agent	O
antidote	O
evaluation	O
since	O
monkey	O
AChEs	O
possess	O
similar	O
biochemical	O
/	O
pharmacological	O
properties	O
to	O
human	O
AChE	O
.	O

Dose	O
escalation	O
of	O
gemcitabine	O
is	O
possible	O
with	O
concurrent	O
chest	O
three	O
-	O
dimensional	O
rather	O
than	O
two	O
-	O
dimensional	O
radiotherapy	O
:	O
a	O
phase	O
I	O
trial	O
in	O
patients	O
with	O
stage	O
III	O
non	B
-	I
small	I
-	I
cell	I
lung	I
cancer	I
.	O

PURPOSE	O
:	O
To	O
determine	O
in	O
a	O
Phase	O
I	O
study	O
the	O
maximum	O
tolerated	O
dose	O
of	O
weekly	O
gemcitabine	O
concurrent	O
with	O
radiotherapy	O
in	O
locally	O
advanced	O
non	B
-	I
small	I
-	I
cell	I
lung	I
cancer	I
(	O
NSCLC	B
)	O
,	O
as	O
well	O
as	O
the	O
relationship	O
between	O
the	O
volume	O
of	O
the	O
esophagus	O
irradiated	O
and	O
severe	O
esophagitis	B
.	O

METHODS	O
AND	O
MATERIALS	O
:	O
Twenty	O
-	O
one	O
patients	O
with	O
Stage	O
III	O
NSCLC	B
received	O
gemcitabine	O
initially	O
at	O
150	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
wk	O
over	O
7	O
weeks	O
concurrently	O
with	O
chest	O
radiotherapy	O
to	O
63	O
Gy	O
in	O
34	O
fractions	O
.	O

The	O
first	O
9	O
patients	O
underwent	O
treatment	O
with	O
two	O
-	O
dimensional	O
(	O
2D	O
)	O
radiotherapy	O
;	O
the	O
remaining	O
12	O
patients	O
,	O
with	O
three	O
-	O
dimensional	O
conformal	O
radiotherapy	O
(	O
3D	O
-	O
CRT	O
)	O
and	O
target	O
volume	O
reduced	O
to	O
clinically	O
apparent	O
disease	O
.	O

Consolidation	O
was	O
4	O
cycles	O
of	O
gemcitabine	O
at	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
wk	O
and	O
cisplatin	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

RESULTS	O
:	O
In	O
the	O
2D	O
group	O
,	O
the	O
dose	B
-	I
limiting	I
toxicity	I
,	O
Grade	O
3	O
esophagitis	B
,	O
occurred	O
in	O
3	O
of	O
6	O
patients	O
in	O
the	O
150	O
-	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
wk	O
cohort	O
and	O
2	O
of	O
3	O
patients	O
in	O
the	O
125	O
-	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
wk	O
cohort	O
.	O

No	O
cases	O
of	O
Grade	O
3	O
esophagitis	B
occurred	O
at	O
these	O
doses	O
in	O
the	O
3D	O
group	O
.	O

At	O
gemcitabine	O
190	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
wk	O
,	O
2	O
of	O
6	O
patients	O
in	O
the	O
3D	O
cohort	O
had	O
Grade	O
3	O
esophagitis	B
.	O

The	O
mean	O
percentages	O
of	O
esophagus	O
irradiated	O
to	O
60	O
Gy	O
were	O
68	O
%	O
in	O
the	O
2D	O
cohort	O
and	O
18	O
%	O
in	O
the	O
3D	O
cohort	O
.	O

CONCLUSIONS	O
:	O
We	O
could	O
not	O
escalate	O
the	O
dose	O
of	O
gemcitabine	O
with	O
concurrent	O
radiotherapy	O
when	O
using	O
2D	O
planning	O
because	O
of	O
severe	O
acute	B
esophagitis	I
.	O

However	O
,	O
we	O
could	O
escalate	O
the	O
dose	O
of	O
gemcitabine	O
to	O
190	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
wk	O
when	O
using	O
3D	O
planning	O
.	O

The	O
Phase	O
II	O
dose	O
is	O
150	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
wk	O
.	O

Three	O
-	O
dimensional	O
CRT	O
permitted	O
the	O
use	O
of	O
higher	O
doses	O
of	O
gemcitabine	O
.	O

Natural	O
anti	O
-	O
Siglec	O
autoantibodies	O
mediate	O
potential	O
immunoregulatory	O
mechanisms	O
:	O
implications	O
for	O
the	O
clinical	O
use	O
of	O
intravenous	O
immunoglobulins	O
(	O
IVIg	O
)	O
.	O

Human	O
intravenous	O
immunoglobulins	O
(	O
IVIg	O
)	O
contain	O
natural	O
autoantibodies	O
against	O
the	O
inhibitory	O
lectin	O
-	O
receptors	O
Siglec	O
-	O
8	O
and	O
Siglec	O
-	O
9	O
.	O

These	O
two	O
members	O
of	O
the	O
Siglec	O
family	O
are	O
known	O
to	O
mediate	O
both	O
inhibitory	O
and	O
death	O
signals	O
.	O

Here	O
,	O
we	O
discuss	O
recent	O
findings	O
regarding	O
the	O
cytotoxic	B
effects	I
of	O
natural	O
anti	O
-	O
Siglec	O
autoantibodies	O
on	O
both	O
neutrophils	O
and	O
eosinophils	O
,	O
and	O
present	O
the	O
concept	O
of	O
a	O
novel	O
regulatory	O
mechanism	O
exhibiting	O
anti	O
-	O
inflammatory	O
properties	O
.	O

Consequently	O
,	O
IVIg	O
may	O
amplify	O
this	O
regulatory	O
pathway	O
by	O
increasing	O
the	O
concentration	O
of	O
natural	O
anti	O
-	O
Siglec	O
autoantibodies	O
in	O
blood	O
and	O
tissues	O
.	O

Partial	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
agonist	O
angiotensin	O
receptor	O
blockers	O
.	O

Potential	O
multipronged	O
strategy	O
in	O
stroke	B
prevention	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Although	O
their	O
primary	O
mechanism	O
of	O
action	O
is	O
blood	O
pressure	O
lowering	O
,	O
emerging	O
data	O
suggest	O
that	O
select	O
angiotensin	O
receptor	O
blockers	O
(	O
ARBs	O
)	O
,	O
which	O
partially	O
activate	O
the	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
(	O
PPAR	O
-	O
gamma	O
)	O
,	O
may	O
effectively	O
treat	O
insulin	B
resistance	I
and	O
dyslipidemia	B
without	O
the	O
toxicity	O
sometimes	O
associated	O
with	O
full	O
PPAR	O
-	O
gamma	O
agonists	O
.	O

Since	O
up	O
to	O
50	O
%	O
of	O
the	O
patients	O
with	O
ischemic	B
stroke	I
and	O
transient	B
ischemic	I
attack	I
harbor	O
insulin	B
resistance	I
,	O
drugs	O
that	O
simultaneously	O
control	O
hypertension	B
and	O
insulin	B
resistance	I
could	O
be	O
particularly	O
useful	O
for	O
stroke	B
prevention	O
.	O

SUMMARY	O
OF	O
REVIEW	O
:	O
This	O
review	O
presents	O
the	O
experimental	O
and	O
preliminary	O
clinical	O
evidence	O
supporting	O
a	O
promising	O
role	O
for	O
partial	O
PPAR	O
-	O
gamma	O
agonist	O
ARBs	O
in	O
treating	O
insulin	B
resistance	I
and	O
the	O
metabolic	B
syndrome	I
in	O
patients	O
with	O
ischemic	B
cerebrovascular	I
disease	I
.	O

CONCLUSION	O
:	O
Partial	O
PPAR	O
-	O
gamma	O
agonist	O
ARBs	O
by	O
virtue	O
of	O
their	O
multiple	O
beneficial	O
mechanisms	O
of	O
action	O
could	O
provide	O
a	O
single	O
multipronged	O
strategy	O
for	O
reducing	O
future	O
vascular	O
events	O
in	O
persons	O
with	O
,	O
or	O
at	O
risk	O
for	O
,	O
stroke	B
.	O

Transcriptome	O
analyses	O
in	O
normal	O
prostate	O
epithelial	O
cells	O
exposed	O
to	O
low	O
-	O
dose	O
cadmium	O
:	O
oncogenic	O
and	O
immunomodulations	O
involving	O
the	O
action	O
of	O
tumor	O
necrosis	O
factor	O
.	O

BACKGROUND	O
:	O
Cadmium	O
is	O
implicated	O
in	O
prostate	B
carcinogenesis	I
,	O
but	O
its	O
oncogenic	O
action	O
remains	O
unclear	O
.	O

OBJECTIVES	O
:	O
In	O
this	O
study	O
we	O
aimed	O
to	O
decipher	O
changes	O
in	O
cell	O
growth	O
and	O
the	O
transcriptome	O
in	O
an	O
immortalized	O
human	O
normal	O
prostate	O
epithelial	O
cell	O
line	O
(	O
NPrEC	O
)	O
following	O
exposure	O
to	O
low	O
-	O
dose	O
Cd	O
.	O

METHODS	O
:	O
Synchronized	O
NPrEC	O
cells	O
were	O
exposed	O
to	O
different	O
doses	O
of	O
Cd	O
and	O
assayed	O
for	O
cell	O
viability	O
and	O
cell	O
-	O
cycle	O
progression	O
.	O

We	O
investigated	O
changes	O
in	O
transcriptome	O
by	O
global	O
profiling	O
and	O
used	O
Ingenuity	O
Pathways	O
Analysis	O
software	O
to	O
develop	O
propositions	O
about	O
functional	O
connections	O
among	O
differentially	O
expressed	O
genes	O
.	O

A	O
neutralizing	O
antibody	O
was	O
used	O
to	O
negate	O
the	O
effect	O
of	O
Cd	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
in	O
NPrEC	O
cells	O
.	O

RESULTS	O
:	O
Exposure	O
of	O
NPrEC	O
to	O
2.5	O
microM	O
Cd	O
enhanced	O
cell	O
viability	O
and	O
accelerated	O
cell	O
-	O
cycle	O
progression	O
.	O

Global	O
expression	O
profiling	O
identified	O
48	O
genes	O
that	O
exhibited	O
>	O
or	O
=	O
1.5	O
-	O
fold	O
changes	O
in	O
expression	O
after	O
4	O
,	O
8	O
,	O
16	O
,	O
and	O
32	O
hr	O
of	O
Cd	O
treatment	O
.	O

Pathway	O
analyses	O
inferred	O
a	O
functional	O
connection	O
among	O
35	O
of	O
these	O
genes	O
in	O
one	O
major	O
network	O
,	O
with	O
TNF	O
as	O
the	O
most	O
prominent	O
node	O
.	O

Fourteen	O
of	O
the	O
35	O
genes	O
are	O
related	O
to	O
TNF	O
,	O
and	O
11	O
exhibited	O
an	O
average	O
of	O
>	O
2	O
-	O
fold	O
changes	O
in	O
gene	O
expression	O
.	O

Real	O
-	O
time	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
confirmed	O
the	O
up	O
-	O
regulation	O
of	O
7	O
of	O
the	O
11	O
genes	O
(	O
ADAM8	O
,	O
EDN1	O
,	O
IL8	O
,	O
IL24	O
,	O
IL13RA2	O
,	O
COX2	O
/	O
PTGS2	O
,	O
and	O
SERPINB2	O
)	O
and	O
uncovered	O
a	O
28	O
-	O
fold	O
transient	O
increase	O
in	O
TNF	O
expression	O
in	O
Cd	O
-	O
treated	O
NPrEC	O
cells	O
.	O

A	O
TNF	O
-	O
neutralizing	O
antibody	O
effectively	O
blocked	O
Cd	O
-	O
induced	O
elevations	O
in	O
the	O
expression	O
of	O
these	O
genes	O
.	O

CONCLUSIONS	O
:	O
Noncytotoxic	O
,	O
low	O
-	O
dose	O
Cd	O
has	O
growth	O
-	O
promoting	O
effects	O
on	O
NPrEC	O
cells	O
and	O
induces	O
transient	O
overexpression	O
of	O
TNF	O
,	O
leading	O
to	O
up	O
-	O
regulation	O
of	O
genes	O
with	O
oncogenic	O
and	O
immunomodulation	O
functions	O
.	O

Genetic	O
variation	O
in	O
the	O
serotonin	O
pathway	O
and	O
smoking	O
cessation	O
with	O
nicotine	O
replacement	O
therapy	O
:	O
new	O
data	O
from	O
the	O
Patch	O
in	O
Practice	O
trial	O
and	O
pooled	O
analyses	O
.	O

The	O
serotonin	O
pathway	O
has	O
been	O
implicated	O
in	O
nicotine	B
dependence	I
and	O
may	O
influence	O
smoking	O
cessation	O
.	O

Therefore	O
,	O
792	O
cigarette	O
smokers	O
from	O
the	O
Patch	O
in	O
Practice	O
trial	O
were	O
genotyped	O
for	O
the	O
tryptophan	O
hydroxylase	O
(	O
TPH1	O
A779C	O
)	O
,	O
serotonin	O
transporter	O
(	O
SLC6A45	O
-	O
HTTLPR	O
)	O
,	O
and	O
5	O
-	O
HT1A	O
(	O
HTR1A	O
C	O
-	O
1019	O
G	O
)	O
polymorphisms	O
.	O

Cox	O
regression	O
analysis	O
did	O
not	O
demonstrate	O
significant	O
effects	O
of	O
any	O
of	O
the	O
three	O
genotypes	O
on	O
relapse	O
to	O
smoking	O
:	O
TPH1	O
(	O
Reference	O
AA	O
;	O
AC	O
:	O
hazard	O
ratio	O
(	O
HR	O
)	O
0.99	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.78	O
,	O
1.24	O
,	O
p	O
=	O
0.90	O
;	O
CC	O
:	O
HR	O
0.93	O
,	O
95	O
%	O
CI	O
0.73	O
,	O
1.18	O
,	O
p	O
=	O
0.55	O
)	O
;	O
5	O
-	O
HTTLPR	O
(	O
Reference	O
LL	O
;	O
SL	O
:	O
HR	O
1.01	O
,	O
95	O
%	O
CI	O
0.85	O
,	O
1.20	O
,	O
p	O
=	O
0.90	O
;	O
SS	O
:	O
HR	O
1.13	O
,	O
95	O
%	O
CI	O
0.91	O
,	O
1.39	O
,	O
p	O
=	O
0.27	O
)	O
;	O
HTR1A	O
(	O
Reference	O
CC	O
;	O
CG	O
:	O
HR	O
1.04	O
,	O
95	O
%	O
CI	O
0.86	O
,	O
1.25	O
,	O
p	O
=	O
0.70	O
;	O
GG	O
:	O
HR	O
1.01	O
,	O
95	O
%	O
CI	O
0.82	O
,	O
1.24	O
,	O
p	O
=	O
0.93	O
)	O
.	O

Moreover	O
,	O
pooled	O
analyses	O
of	O
data	O
from	O
all	O
three	O
extant	O
pharmacogenetic	O
NRT	O
trials	O
(	O
N	O
=	O
1398	O
)	O
found	O
no	O
significant	O
effect	O
of	O
5	O
-	O
HTTLPR	O
genotype	O
on	O
continuous	O
abstinence	O
at	O
12	O
-	O
week	O
(	O
Reference	O
LL	O
;	O
SL	O
:	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.25	O
,	O
95	O
%	O
CI	O
0.89	O
,	O
1.74	O
,	O
p	O
=	O
0.19	O
;	O
SS	O
:	O
OR	O
=	O
1.31	O
,	O
95	O
%	O
CI	O
0.86	O
,	O
1.98	O
,	O
p	O
=	O
0.21	O
)	O
or	O
26	O
-	O
week	O
follow	O
-	O
up	O
(	O
Reference	O
LL	O
;	O
SL	O
:	O
OR	O
=	O
0.93	O
,	O
95	O
%	O
CI	O
0.64	O
,	O
1.33	O
,	O
p	O
=	O
0.68	O
;	O
SS	O
:	O
OR	O
=	O
1.00	O
,	O
95	O
%	O
CI	O
0.63	O
,	O
1.58	O
,	O
p	O
=	O
1.00	O
)	O
.	O

These	O
data	O
do	O
not	O
support	O
a	O
statistically	O
or	O
clinically	O
significant	O
moderating	O
effect	O
of	O
these	O
specific	O
5	O
-	O
HT	O
pathway	O
genetic	O
variants	O
on	O
smoking	O
cessation	O
.	O

However	O
,	O
the	O
possibility	O
remains	O
that	O
other	O
variants	O
in	O
these	O
or	O
other	O
5	O
-	O
HT	O
genes	O
may	O
influence	O
NRT	O
efficacy	O
for	O
smoking	O
cessation	O
in	O
treatment	O
seeking	O
smokers	O
.	O

No	O
occurrence	O
of	O
Pneumocystis	B
jiroveci	I
(	I
carinii	I
)	I
pneumonia	I
in	O
120	O
adults	O
undergoing	O
myeloablative	O
unrelated	O
cord	O
blood	O
transplantation	O
.	O

The	O
incidence	O
of	O
pneumonia	B
caused	O
by	O
Pneumocystis	O
carinii	O
(	O
PCP	B
)	O
(	O
organism	O
now	O
renamed	O
Pneumocystis	O
jiroveci	O
)	O
during	O
the	O
early	O
period	O
after	O
cord	O
blood	O
transplantation	O
(	O
CBT	O
)	O
was	O
studied	O
in	O
120	O
adults	O
.	O

Initially	O
89	O
patients	O
(	O
74	O
%	O
)	O
received	O
oral	O
administration	O
of	O
2	O
single	O
-	O
strength	O
trimethoprim	O
-	O
sulfamethoxazole	O
(	O
TMP	O
-	O
SMZ	O
)	O
tablets	O
twice	O
daily	O
from	O
day	O
-	O
21	O
.	O

In	O
45	O
of	O
89	O
patients	O
(	O
51	O
%	O
)	O
,	O
TMP	O
-	O
SMZ	O
administration	O
for	O
a	O
scheduled	O
duration	O
was	O
completed	O
.	O

In	O
the	O
remaining	O
44	O
patients	O
(	O
49	O
%	O
)	O
,	O
however	O
,	O
TMP	O
-	O
SMZ	O
administration	O
was	O
discontinued	O
prior	O
to	O
day	O
-	O
3	O
because	O
of	O
toxicity	O
.	O

Among	O
these	O
patients	O
,	O
42	O
subsequently	O
received	O
aerosolized	O
pentamidine	O
(	O
AP	O
)	O
on	O
a	O
median	O
of	O
day	O
-	O
13	O
(	O
range	O
,	O
-	O
20	O
to	O
-	O
6	O
)	O
.	O

Thirty	O
-	O
one	O
patients	O
(	O
26	O
%	O
)	O
received	O
AP	O
without	O
TMP	O
-	O
SMZ	O
administration	O
on	O
a	O
median	O
of	O
day	O
-	O
14	O
(	O
range	O
,	O
-	O
21	O
to	O
-	O
9	O
)	O
.	O

None	O
of	O
the	O
120	O
patients	O
were	O
diagnosed	O
with	O
PCP	B
within	O
100	O
days	O
or	O
2	O
years	O
after	O
CBT	O
;	O
however	O
,	O
one	O
patient	O
who	O
received	O
AP	O
before	O
CBT	O
but	O
no	O
prophylaxis	O
after	O
CBT	O
developed	O
cerebral	B
toxoplasmosis	I
on	O
day	O
+	O
91	O
.	O

Pre	O
-	O
transplant	O
prophylaxis	O
against	O
PCP	B
did	O
not	O
significantly	O
affect	O
transplantation	O
-	O
related	O
mortality	O
or	O
disease	O
-	O
free	O
survival	O
at	O
2	O
years	O
after	O
CBT	O
.	O

The	O
results	O
suggest	O
that	O
PCP	B
during	O
the	O
early	O
period	O
after	O
CBT	O
can	O
be	O
effectively	O
prevented	O
by	O
any	O
pre	O
-	O
transplant	O
prophylactic	O
method	O
.	O

Local	O
tissue	O
destruction	O
and	O
procoagulation	O
properties	O
of	O
Echis	O
carinatus	O
venom	O
:	O
inhibition	O
by	O
Vitis	O
vinifera	O
seed	O
methanol	O
extract	O
.	O

Plant	O
extracts	O
are	O
extensively	O
used	O
against	O
snakebites	O
in	O
Indian	O
folk	O
medicine	O
.	O

In	O
this	O
study	O
,	O
one	O
such	O
traditionally	O
used	O
plant	O
,	O
Vitis	O
vinifera	O
L	O
.	O

(	O
Vitaceae	O
)	O
seed	O
methanol	O
extract	O
has	O
been	O
studied	O
for	O
its	O
ability	O
to	O
neutralize	O
Indian	O
Echis	O
carinatus	O
(	O
saw	O
-	O
scaled	O
viper	O
)	O
venom	O
.	O

The	O
extract	O
effectively	O
inhibited	O
toxic	O
effects	O
,	O
such	O
as	O
oedema	B
,	O
haemorrhage	B
,	O
myonecrosis	B
and	O
coagulation	B
of	I
citrated	I
human	I
plasma	I
.	O

Further	O
,	O
the	O
extract	O
inhibited	O
the	O
caseinolytic	O
,	O
hyaluronolytic	O
and	O
fibrinogenolytic	O
activities	O
of	O
the	O
venom	O
.	O

The	O
extract	O
caused	O
dose	O
dependent	O
inhibition	O
of	O
the	O
toxic	O
activities	O
studied	O
,	O
suggesting	O
venom	O
inhibition	O
.	O

Thus	O
,	O
the	O
anti	O
-	O
snake	O
venom	O
property	O
of	O
the	O
extract	O
appears	O
to	O
be	O
highly	O
promising	O
for	O
further	O
investigation	O
in	O
order	O
to	O
achieve	O
better	O
neutralization	O
of	O
Indian	O
E	O
.	O

carinatus	O
venom	B
poisoning	I
.	O

Menorrhagia	B
and	O
severe	O
menstrual	B
pain	I
related	O
to	O
the	O
use	O
of	O
adalimumab	O
in	O
a	O
psoriatic	O
.	O

The	O
case	O
is	O
reported	O
of	O
a	O
32	O
-	O
year	O
-	O
old	O
morbidly	O
obese	O
white	O
woman	O
who	O
used	O
adalimumab	O
40	O
mg	O
every	O
other	O
week	O
for	O
4	O
months	O
for	O
psoriatic	B
arthritis	I
,	O
psoriasis	B
vulgaris	I
and	O
inverse	B
psoriasis	I
with	O
total	O
clearance	O
of	O
her	O
psoriasis	B
who	O
developed	O
menorrhagia	B
(	O
at	O
least	O
twice	O
the	O
number	O
of	O
pads	O
used	O
daily	O
for	O
4	O
-	O
6	O
days	O
as	O
opposed	O
to	O
3	O
-	O
5	O
days	O
previously	O
)	O
and	O
severe	O
menstrual	B
pain	I
.	O

Treatment	O
with	O
Aviane	O
(	O
ethinyl	O
estradiol	O
and	O
levonorgestrel	O
)	O
abated	O
some	O
of	O
these	O
menstrual	B
symptoms	I
.	O

The	O
symptoms	O
resolved	O
altogether	O
when	O
the	O
adalimumab	O
was	O
discontinued	O
.	O

Menstrual	O
disorders	O
are	O
listed	O
as	O
possible	O
side	O
effects	O
from	O
the	O
use	O
of	O
infliximab	O
and	O
adalimumab	O
in	O
their	O
respective	O
package	O
inserts	O
and	O
also	O
for	O
adalimumab	O
and	O
etanercept	O
in	O
the	O
United	O
Kingdom	O
's	O
Medicines	O
and	O
Healthcare	O
products	O
Regulatory	O
Agency	O
's	O
drug	O
side	O
-	O
effect	O
database	O
,	O
but	O
few	O
case	O
reports	O
of	O
menstrual	B
side	I
effects	I
exist	O
from	O
including	O
tumor	O
necrosis	O
alpha	O
(	O
TNFalpha	O
)	O
blockers	O
.	O

Physicians	O
should	O
be	O
aware	O
of	O
the	O
menstrual	B
side	I
effects	I
of	O
adalimumab	O
and	O
the	O
role	O
of	O
oral	O
contraceptive	O
pills	O
in	O
treating	O
such	O
menstrual	B
side	I
effects	I
.	O

Gene	O
expression	O
changes	O
after	O
exposure	O
to	O
six	O
-	O
mix	O
in	O
a	O
mouse	O
model	O
.	O

The	O
exposure	O
of	O
Libby	O
MT	O
residents	O
to	O
amphibole	O
-	O
contaminated	O
vermiculite	O
is	O
well	O
known	O
.	O

To	O
explore	O
the	O
gene	O
-	O
environment	O
interactions	O
in	O
the	O
development	O
of	O
asbestos	O
-	O
related	O
diseases	O
(	O
ARD	O
)	O
,	O
a	O
mouse	O
model	O
of	O
asbestos	O
exposure	O
using	O
Six	O
-	O
mix	O
(	O
a	O
combination	O
of	O
amphibole	O
fibers	O
gathered	O
from	O
six	O
sites	O
at	O
the	O
Libby	O
vermiculite	O
mine	O
)	O
,	O
crocidolite	O
asbestos	O
,	O
or	O
saline	O
as	O
a	O
negative	O
control	O
was	O
used	O
to	O
determine	O
both	O
gene	O
expression	O
responses	O
by	O
using	O
mouse	O
10,000	O
oligonucleotide	O
array	O
and	O
to	O
visualize	O
these	O
changes	O
histologically	O
.	O

Mice	O
were	O
sacrificed	O
and	O
whole	O
lungs	O
harvested	O
for	O
histology	O
and	O
microarray	O
analysis	O
six	O
months	O
following	O
exposure	O
via	O
intratracheal	O
instillation	O
.	O

Using	O
an	O
arbitrary	O
cutoff	O
of	O
1.25	O
-	O
fold	O
change	O
,	O
genes	O
whose	O
RNA	O
expression	O
levels	O
were	O
specifically	O
altered	O
in	O
response	O
to	O
the	O
different	O
amphibole	O
exposures	O
were	O
grouped	O
into	O
categories	O
by	O
a	O
gene	O
ontology	O
analysis	O
program	O
,	O
GoMiner	O
.	O

Our	O
hypothesis	O
was	O
that	O
assessment	O
of	O
asbestos	O
-	O
responsive	O
genes	O
would	O
provide	O
a	O
better	O
understanding	O
of	O
response	O
mechanisms	O
.	O

These	O
experiments	O
have	O
provided	O
new	O
candidates	O
for	O
genes	O
involved	O
in	O
the	O
asbestos	O
response	O
pathways	O
.	O

Genotoxicity	B
evaluation	O
of	O
drinking	O
water	O
sources	O
in	O
human	O
peripheral	O
blood	O
lymphocytes	O
using	O
the	O
comet	O
assay	O
.	O

The	O
potential	O
harm	O
of	O
organic	O
pollutants	O
in	O
drinking	O
water	O
to	O
human	O
health	O
is	O
widely	O
focused	O
on	O
in	O
the	O
world	O
;	O
more	O
and	O
more	O
pollutants	O
with	O
genotoxic	O
substances	O
are	O
released	O
into	O
the	O
aquatic	O
environment	O
.	O

Water	O
source	O
samples	O
were	O
collected	O
from	O
7	O
different	O
localities	O
of	O
Nanjing	O
City	O
.	O

The	O
potential	O
genotoxicity	B
of	O
organic	O
extracts	O
from	O
drinking	O
water	O
sources	O
were	O
investigated	O
by	O
means	O
of	O
the	O
comet	O
assay	O
in	O
human	O
peripheral	O
lymphocytes	O
.	O

The	O
results	O
showed	O
that	O
all	O
the	O
organic	O
extracts	O
from	O
all	O
the	O
water	O
source	O
samples	O
could	O
induce	O
DNA	O
damages	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
at	O
different	O
levels	O
.	O

A	O
significant	O
difference	O
(	O
P	O
<	O
0.01	O
)	O
was	O
observed	O
when	O
compared	O
with	O
the	O
solvent	O
control	O
.	O

The	O
DNA	O
damage	O
increased	O
with	O
the	O
increase	O
of	O
the	O
dosage	O
of	O
the	O
original	O
water	O
source	O
.	O

Significant	O
differences	O
of	O
DNA	O
damage	O
were	O
observed	O
in	O
different	O
drinking	O
water	O
sources	O
,	O
as	O
shown	O
by	O
the	O
multiple	O
comparisons	O
analysis	O
at	O
the	O
dosage	O
of	O
100x	O
;	O
the	O
degree	O
of	O
DNA	O
damage	O
treated	O
by	O
Hushu	O
waterworks	O
(	O
at	O
town	O
level	O
)	O
was	O
the	O
most	O
serious	O
,	O
the	O
arbitrary	O
units	O
(	O
AU	O
)	O
was	O
141.62	O
+	O
/	O
-	O
6.96	O
,	O
however	O
,	O
that	O
of	O
Shangyuanmen	O
waterworks	O
(	O
at	O
city	O
level	O
)	O
was	O
only	O
109.64	O
+	O
/	O
-	O
2.97	O
.	O

The	O
analysis	O
also	O
revealed	O
that	O
the	O
genotoxicity	B
of	O
town	O
's	O
water	O
sources	O
was	O
higher	O
than	O
that	O
of	O
the	O
city	O
.	O

The	O
results	O
demonstrated	O
that	O
the	O
comet	O
assay	O
can	O
be	O
successfully	O
applied	O
to	O
the	O
genotoxicity	B
monitoring	O
programs	O
of	O
drinking	O
water	O
sources	O
.	O

Safe	O
use	O
of	O
rectal	O
suppositories	O
and	O
enemas	O
with	O
adult	O
patients	O
.	O

Medications	O
that	O
are	O
given	O
via	O
the	O
rectal	O
route	O
are	O
prescribed	O
for	O
a	O
variety	O
of	O
reasons	O
and	O
have	O
either	O
a	O
local	O
or	O
systemic	O
effect	O
.	O

The	O
administration	O
of	O
suppositories	O
and	O
enemas	O
is	O
an	O
intimate	O
procedure	O
which	O
has	O
the	O
potential	O
to	O
cause	O
embarrassment	B
and	O
discomfort	B
for	O
the	O
patient	O
.	O

This	O
article	O
outlines	O
the	O
reasons	O
for	O
the	O
use	O
of	O
rectal	O
medications	O
and	O
recommends	O
a	O
procedure	O
to	O
be	O
followed	O
when	O
giving	O
them	O
.	O

Prognostic	O
role	O
of	O
glutathione	O
S	O
-	O
transferase	O
polymorphisms	O
in	O
acute	B
myeloid	I
leukemia	I
.	O

Glutathione	O
S	O
-	O
transferases	O
(	O
GSTs	O
)	O
are	O
phase	O
II	O
detoxification	O
enzymes	O
involved	O
in	O
the	O
metabolism	O
of	O
carcinogens	O
and	O
anticancer	O
drugs	O
,	O
known	O
also	O
to	O
interact	O
with	O
kinase	O
complexes	O
during	O
oxidative	O
or	O
chemical	O
stress	O
-	O
induced	O
apoptosis	O
.	O

We	O
were	O
interested	O
whether	O
their	O
polymorphic	O
variants	O
may	O
account	O
for	O
differences	O
in	O
outcome	O
of	O
patients	O
with	O
acute	B
myeloid	I
leukemia	I
(	O
AML	B
)	O
following	O
chemotherapy	O
.	O

We	O
studied	O
the	O
prognostic	O
role	O
of	O
polymorphisms	O
in	O
three	O
GST	O
genes	O
(	O
GSTP1	O
/	O
M1	O
/	O
T1	O
)	O
in	O
a	O
large	O
patient	O
cohort	O
of	O
the	O
German	O
Austrian	O
Acute	B
Myeloid	I
Leukemia	I
Study	O
Group	O
,	O
treated	O
according	O
to	O
prospective	O
multicenter	O
clinical	O
trials	O
(	O
AML	B
HD98A	O
:	O
254	O
patients	O
;	O
AML	B
HD98	O
-	O
B	O
:	O
100	O
patients	O
)	O
,	O
with	O
a	O
median	O
follow	O
-	O
up	O
of	O
46	O
months	O
.	O

Looking	O
at	O
short	O
-	O
term	O
adverse	O
drug	O
reactions	O
,	O
homozygous	O
carriers	O
of	O
the	O
GSTP1	O
*	O
105	O
Val	O
allele	O
had	O
a	O
faster	O
neutrophil	O
and	O
platelet	O
recovery	O
(	O
P	O
=	O
0.002	O
and	O
0.02	O
,	O
respectively	O
)	O
and	O
a	O
reduced	O
need	O
of	O
red	O
cell	O
and	O
platelet	O
transfusions	O
(	O
P	O
=	O
0.01	O
and	O
0.03	O
,	O
respectively	O
)	O
.	O

Response	O
to	O
induction	O
chemotherapy	O
did	O
not	O
vary	O
according	O
to	O
GST	O
polymorphisms	O
.	O

Multivariable	O
Cox	O
regression	O
models	O
revealed	O
a	O
significant	O
better	O
relapse	O
-	O
free	O
(	O
RFS	O
)	O
and	O
overall	O
survival	O
for	O
the	O
GSTP1	O
(	O
*	O
)	O
105	O
Val	O
(	O
P	O
=	O
0.003	O
and	O
0.03	O
,	O
respectively	O
)	O
,	O
whereas	O
GSTT1	O
and	O
GSTM1	O
genotypes	O
had	O
no	O
significant	O
impact	O
.	O

The	O
favorable	O
impact	O
of	O
GSTP1	O
(	O
*	O
)	O
105	O
Val	O
on	O
RFS	O
seems	O
to	O
be	O
restricted	O
to	O
the	O
subgroup	O
of	O
patients	O
exhibiting	O
a	O
normal	O
karyotype	O
.	O

Pharmacokinetic	O
,	O
pharmacodynamic	O
and	O
intracellular	O
effects	O
of	O
PEG	O
-	O
asparaginase	O
in	O
newly	O
diagnosed	O
childhood	O
acute	B
lymphoblastic	I
leukemia	I
:	O
results	O
from	O
a	O
single	O
agent	O
window	O
study	O
.	O

L	O
-	O
asparaginase	O
is	O
an	O
effective	O
drug	O
for	O
treatment	O
of	O
children	O
with	O
acute	B
lymphoblastic	I
leukemia	I
(	O
ALL	B
)	O
.	O

The	O
effectiveness	O
is	O
thought	O
to	O
result	O
from	O
depletion	O
of	O
asparagine	O
in	O
serum	O
and	O
cells	O
.	O

We	O
investigated	O
the	O
clinical	O
response	O
in	O
vivo	O
of	O
1000	O
IU	O
/	O
m	O
(	O
2	O
)	O
pegylated	O
(	O
PEG	O
)	O
-	O
asparaginase	O
and	O
its	O
pharmacokinetic	O
,	O
pharmacodynamic	O
and	O
intracellular	O
effects	O
in	O
children	O
with	O
newly	O
diagnosed	O
ALL	B
before	O
start	O
of	O
combination	O
chemotherapy	O
.	O

The	O
in	O
vivo	O
window	O
response	O
was	O
significantly	O
related	O
to	O
immunophenotype	O
and	O
genotype	O
:	O
26	O
/	O
38	O
common	O
/	O
pre	O
B	O
-	O
ALL	O
cases	O
,	O
especially	O
those	O
with	O
hyperdiploidy	O
and	O
TELAML1	O
rearrangement	O
,	O
demonstrated	O
a	O
good	O
clinical	O
response	O
compared	O
to	O
8	O
/	O
17	O
T	O
-	O
ALL	O
(	O
P	O
=	O
0.01	O
)	O
and	O
BCRABL	O
-	O
positive	O
ALL	B
(	O
P	O
=	O
0.04	O
)	O
.	O

A	O
poor	O
in	O
vivo	O
clinical	O
window	O
response	O
was	O
related	O
to	O
in	O
vitro	O
resistance	O
to	O
L	O
-	O
asparaginase	O
(	O
P	O
=	O
0.02	O
)	O
and	O
both	O
were	O
prognostic	O
factors	O
for	O
long	O
-	O
term	O
event	O
-	O
free	O
survival	O
(	O
hazard	O
ratio	O
6.4	O
,	O
P	O
=	O
0.004	O
;	O
hazard	O
ratio	O
3.7	O
,	O
P	O
=	O
0.01	O
)	O
.	O

After	O
administration	O
of	O
one	O
in	O
vivo	O
dose	O
of	O
PEG	O
-	O
asparaginase	O
no	O
changes	O
in	O
apoptotic	O
parameters	O
or	O
in	O
intracellular	O
levels	O
of	O
twenty	O
amino	O
acids	O
in	O
leukemic	O
cells	O
could	O
be	O
measured	O
,	O
in	O
contradiction	O
to	O
the	O
changes	O
found	O
after	O
in	O
vitro	O
exposure	O
.	O

This	O
may	O
be	O
explained	O
by	O
the	O
rapid	O
removal	O
of	O
apoptotic	O
cells	O
from	O
the	O
circulation	O
in	O
vivo	O
.	O

One	O
additional	O
dose	O
of	O
PEG	O
-	O
asparaginase	O
upfront	O
ALL	B
treatment	O
did	O
not	O
lead	O
to	O
other	O
severe	O
toxicities	O
.	O

Acute	B
generalised	I
exanthematous	I
pustulosis	I
and	O
toxic	B
epidermal	I
necrolysis	I
induced	O
by	O
carbamazepine	O
.	O

Acute	B
generalised	I
exanthematous	I
pustulosis	I
and	O
Stevens	B
-	I
Johnson	I
syndrome	I
(	O
toxic	B
epidermal	I
necrolysis	I
spectrum	O
of	O
severe	O
cutaneous	O
drug	O
reactions	O
)	O
are	O
believed	O
to	O
have	O
distinct	O
underlying	O
pathophysiologies	O
.	O

Our	O
patient	O
,	O
a	O
28	O
-	O
year	O
-	O
old	O
Chinese	O
woman	O
,	O
represents	O
the	O
first	O
known	O
reported	O
case	O
of	O
clinically	O
-	O
consistent	O
and	O
histologically	O
-	O
proven	O
acute	B
generalised	I
exanthematous	I
pustulosis	I
and	O
toxic	B
epidermal	I
necrolysis	I
overlap	O
induced	O
by	O
carbamazepine	O
in	O
the	O
English	O
literature	O
.	O

Methods	O
to	O
evaluate	O
the	O
pharmacology	O
of	O
oral	O
antiplatelet	O
drugs	O
.	O

Principally	O
,	O
there	O
are	O
two	O
reasons	O
why	O
the	O
pharmacological	O
response	O
to	O
antiplatelet	O
drugs	O
should	O
be	O
measured	O
:	O
on	O
the	O
one	O
hand	O
,	O
an	O
insufficient	O
inhibition	O
of	O
platelet	O
function	O
may	O
result	O
in	O
atherothrombotic	B
complications	I
;	O
on	O
the	O
other	O
hand	O
,	O
an	O
excessive	O
inhibition	O
of	O
platelet	O
function	O
may	O
lead	O
to	O
bleeding	B
complications	I
.	O

The	O
clinical	O
importance	O
to	O
measure	O
the	O
effects	O
of	O
antiplatelet	O
drugs	O
is	O
demonstrated	O
by	O
increasingly	O
growing	O
evidence	O
for	O
an	O
association	O
of	O
resistance	O
to	O
antiplatelet	O
drugs	O
with	O
thromboembolic	B
events	I
.	O

It	O
is	O
often	O
claimed	O
that	O
there	O
is	O
no	O
generally	O
accepted	O
definition	O
of	O
""""	O
resistance	O
""""	O
and	O
,	O
instead	O
,	O
there	O
is	O
an	O
ongoing	O
semantic	O
discussion	O
about	O
the	O
correct	O
term	O
to	O
be	O
used	O
to	O
describe	O
this	O
phenomenon	O
.	O

From	O
the	O
pharmacological	O
point	O
of	O
view	O
,	O
there	O
is	O
only	O
one	O
acceptable	O
definition	O
of	O
""""	O
resistance	O
""""	O
to	O
antiplatelet	O
drugs	O
:	O
the	O
term	O
""""	O
resistance	O
""""	O
should	O
be	O
used	O
when	O
a	O
drug	O
is	O
unable	O
to	O
hit	O
its	O
pharmacological	O
target	O
.	O

Thus	O
,	O
laboratory	O
methods	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
antiplatelet	O
drugs	O
should	O
be	O
designed	O
to	O
measure	O
the	O
direct	O
pharmacodynamic	O
effect	O
of	O
a	O
drug	O
,	O
rather	O
than	O
the	O
consequences	O
for	O
global	O
platelet	O
function	O
.	O

Based	O
on	O
physiological	O
/	O
pathophysiological	O
,	O
pharmacological	O
,	O
and	O
practical	O
considerations	O
,	O
the	O
authors	O
propose	O
the	O
following	O
assays	O
to	O
be	O
used	O
to	O
measure	O
the	O
effects	O
of	O
oral	O
antiplatelet	O
drugs	O
:	O
for	O
the	O
detection	O
of	O
aspirin	O
actions	O
,	O
thromboxane	O
or	O
arachidonic	O
acid	O
-	O
induced	O
responses	O
(	O
light	O
aggregometry	O
,	O
whole	O
-	O
blood	O
aggregometry	O
)	O
should	O
be	O
measured	O
;	O
for	O
the	O
detection	O
of	O
clopidogrel	O
actions	O
,	O
VASP	O
(	O
vasodilator	O
-	O
stimulated	O
phosphoprotein	O
)	O
phosphorylation	O
(	O
flow	O
cytometry	O
)	O
or	O
ADP	O
-	O
(	O
adenosine	O
diphosphate	O
-	O
)	O
induced	O
responses	O
(	O
light	O
aggregometry	O
,	O
whole	O
-	O
blood	O
aggregometry	O
,	O
possibly	O
also	O
flow	O
cytometry	O
)	O
should	O
be	O
measured	O
.	O

Drug	O
-	O
induced	O
urinary	B
incontinence	I
.	O

Physiological	O
urinary	O
continence	O
depends	O
on	O
many	O
factors	O
that	O
are	O
potentially	O
vulnerable	O
to	O
adverse	O
drug	O
effects	O
,	O
which	O
may	O
lead	O
to	O
incontinence	B
.	O

In	O
principle	O
,	O
drugs	O
could	O
cause	O
incontinence	B
by	O
lowering	O
bladder	O
outlet	O
resistance	O
and	O
/	O
or	O
by	O
increasing	O
intravesical	O
pressure	O
,	O
which	O
disrupts	O
the	O
normal	O
pressure	O
relationship	O
between	O
the	O
bladder	O
and	O
urethra	O
and	O
leads	O
to	O
urinary	O
leakage	O
;	O
other	O
possibilities	O
include	O
disturbances	O
of	O
central	O
nervous	O
control	O
of	O
voiding	O
or	O
an	O
overproduction	O
of	O
urine	O
.	O

While	O
many	O
drug	O
groups	O
could	O
theoretically	O
induce	O
urinary	B
incontinence	I
based	O
upon	O
pathophysiological	O
considerations	O
,	O
evidence	O
demonstrating	O
a	O
cause	O
-	O
effect	O
relationship	O
between	O
drug	O
usage	O
and	O
incontinence	B
is	O
sparse	O
.	O

Drug	O
classes	O
in	O
which	O
induction	O
of	O
incontinence	B
has	O
been	O
proposed	O
include	O
alpha	O
(	O
1	O
)	O
-	O
adrenoceptor	O
antagonists	O
,	O
antipsychotics	O
,	O
benzodiazepines	O
,	O
antidepressants	O
and	O
hormone	O
replacement	O
therapy	O
in	O
postmenopausal	O
women	O
.	O

However	O
,	O
other	O
drug	O
classes	O
are	O
not	O
innocent	O
in	O
terms	O
of	O
causing	O
urinary	B
incontinence	I
and	O
physicians	O
are	O
well	O
advised	O
to	O
closely	O
monitor	O
patients	O
for	O
the	O
occurrence	O
of	O
incontinence	B
after	O
new	O
prescriptions	O
and	O
/	O
or	O
major	O
dosage	O
changes	O
.	O

Risk	O
assessment	O
of	O
dietary	O
exposures	O
to	O
compounds	O
that	O
are	O
genotoxic	O
and	O
carcinogenic	O
-	O
-	O
an	O
overview	O
.	O

The	O
process	O
of	O
risk	O
assessment	O
of	O
dietary	O
exposures	O
to	O
genotoxic	O
carcinogens	O
is	O
summarised	O
.	O

Exposures	O
to	O
six	O
genotoxic	O
carcinogens	O
in	O
food	O
(	O
acrylamide	O
,	O
aflatoxin	O
B1	O
,	O
benzo	O
(	O
a	O
)	O
pyrene	O
,	O
dimethylnitrosamine	O
,	O
ethyl	O
carbamate	O
,	O
PhIP	O
)	O
have	O
been	O
used	O
to	O
illustrate	O
the	O
process	O
.	O

The	O
margin	O
of	O
exposure	O
(	O
MOE	O
)	O
approach	O
is	O
seen	O
as	O
a	O
useful	O
method	O
to	O
be	O
used	O
in	O
the	O
risk	O
characterisation	O
step	O
of	O
assessing	O
exposures	O
to	O
genotoxic	O
carcinogens	O
.	O

This	O
approach	O
combines	O
information	O
on	O
animal	O
potency	O
and	O
human	O
exposure	O
,	O
and	O
can	O
be	O
used	O
to	O
indicate	O
levels	O
of	O
concern	O
and	O
also	O
the	O
ranking	O
between	O
various	O
exposures	O
to	O
such	O
agents	O
.	O

Both	O
the	O
T25	O
and	O
the	O
BMDL10	O
methods	O
may	O
be	O
used	O
as	O
a	O
reference	O
point	O
.	O

Should	O
a	O
specific	O
MOE	O
value	O
be	O
developed	O
as	O
a	O
cut	O
-	O
off	O
between	O
levels	O
of	O
concern	O
and	O
levels	O
of	O
low	O
concern	O
,	O
the	O
value	O
using	O
T25	O
data	O
is	O
proposed	O
to	O
be	O
2.5	O
-	O
times	O
higher	O
than	O
using	O
BMDL10	O
data	O
.	O

Linear	O
low	O
-	O
dose	O
extrapolation	O
using	O
either	O
T25	O
or	O
BMDL10	O
,	O
may	O
also	O
be	O
applied	O
.	O

However	O
,	O
it	O
should	O
be	O
understood	O
that	O
this	O
approach	O
should	O
not	O
be	O
interpreted	O
as	O
giving	O
a	O
precise	O
estimate	O
of	O
human	O
risk	O
.	O

For	O
exposures	O
to	O
mutagens	O
in	O
food	O
lacking	O
carcinogenicity	B
data	O
,	O
it	O
is	O
proposed	O
to	O
apply	O
the	O
MOE	O
approach	O
to	O
the	O
lowest	O
effective	O
dose	O
(	O
LED	O
)	O
for	O
in	O
vivo	O
genotoxicity	B
.	O

Cabergoline	O
-	O
induced	O
psychotic	B
exacerbation	I
in	O
schizophrenic	O
patients	O
.	O

INTRODUCTION	O
:	O
Hyperprolactinemia	B
is	O
a	O
well	O
-	O
recognized	O
side	O
effect	O
of	O
antipsychotic	O
treatment	O
.	O

Cabergoline	O
,	O
a	O
dopamine	O
agonist	O
,	O
has	O
been	O
introduced	O
on	O
the	O
market	O
to	O
treat	O
hyperprolactinemia	B
,	O
even	O
secondary	O
to	O
antipsychotic	O
use	O
.	O

CASE	O
REPORT	O
:	O
In	O
this	O
article	O
,	O
we	O
described	O
two	O
schizophrenic	O
patients	O
who	O
received	O
cabergoline	O
to	O
treat	O
their	O
antipsychotic	O
-	O
induced	O
hyperprolactinemia	B
and	O
developed	O
a	O
subsequent	O
psychotic	B
exacerbation	I
.	O

The	O
first	O
patient	O
received	O
amisulpride	O
as	O
antipsychotic	O
medication	O
,	O
and	O
the	O
second	O
one	O
took	O
risperidone	O
and	O
fluoxetine	O
for	O
her	O
psychotic	O
and	O
depressive	B
symptoms	I
,	O
respectively	O
.	O

Both	O
patients	O
improved	O
significantly	O
their	O
psychotic	B
symptoms	I
in	O
1	O
week	O
without	O
changing	O
their	O
former	O
antipsychotic	O
regimens	O
.	O

DISCUSSION	O
:	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
we	O
found	O
no	O
previous	O
report	O
of	O
cabergoline	O
-	O
induced	O
psychotic	B
exacerbation	I
in	O
schizophrenic	O
patients	O
who	O
received	O
antipsychotics	O
.	O

We	O
brought	O
up	O
questions	O
whether	O
schizophrenic	O
patients	O
on	O
amisulpride	O
or	O
with	O
the	O
addition	O
of	O
fluoxetine	O
may	O
have	O
higher	O
risk	O
to	O
experience	O
psychotic	B
worsening	I
.	O

We	O
also	O
highlighted	O
the	O
possible	O
role	O
of	O
dose	O
-	O
dependent	O
nature	O
in	O
cabergoline	O
-	O
induced	O
psychotic	B
exacerbation	I
,	O
suggesting	O
that	O
the	O
single	O
starting	O
dose	O
of	O
0.5	O
mg	O
or	O
higher	O
might	O
be	O
unsafe	O
in	O
schizophrenic	O
patients	O
.	O

CONCLUSION	O
:	O
These	O
cases	O
suggest	O
that	O
cabergoline	O
,	O
like	O
other	O
dopaminergic	O
agents	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
psychotic	O
patients	O
and	O
the	O
dose	O
should	O
be	O
as	O
low	O
as	O
possible	O
.	O

Cyclin	O
D1	O
in	O
excitatory	O
neurons	O
of	O
the	O
adult	O
brain	O
enhances	O
kainate	O
-	O
induced	O
neurotoxicity	B
.	O

G1	O
-	O
phase	O
cyclin	O
D1	O
(	O
cD1	O
)	O
expression	O
has	O
been	O
documented	O
in	O
post	O
-	O
mitotic	O
neurons	O
undergoing	O
apoptosis	O
,	O
leading	O
others	O
to	O
propose	O
that	O
attempted	O
cell	O
cycle	O
re	O
-	O
entry	O
may	O
induce	O
cell	O
death	O
.	O

Here	O
,	O
cD1	O
immunoreactivity	O
was	O
found	O
in	O
a	O
subpopulation	O
of	O
healthy	O
excitatory	O
neurons	O
throughout	O
the	O
brain	O
.	O

Most	O
striking	O
was	O
the	O
selective	O
cD1	O
expression	O
in	O
hippocampal	O
pyramidal	O
neurons	O
,	O
an	O
especially	O
vulnerable	O
cell	O
group	O
.	O

Seizure	B
threshold	O
,	O
cD1	O
induction	O
and	O
CA1	O
neuron	O
death	O
were	O
examined	O
following	O
application	O
of	O
kainate	O
(	O
KA	O
)	O
or	O
pentylenetetrazole	O
(	O
PTZ	O
)	O
in	O
cD1	O
heterozygous	O
(	O
+	O
/	O
-	O
)	O
and	O
wildtype	O
mice	O
to	O
determine	O
whether	O
baseline	O
cD1	O
correlates	O
with	O
pathology	O
.	O

cD1	O
+	O
/	O
-	O
mice	O
displayed	O
resistance	O
to	O
KA	O
,	O
but	O
not	O
PTZ	O
-	O
induced	O
seizures	B
and	O
had	O
reduced	O
or	O
equivalent	O
cytotoxicity	B
respectively	O
,	O
compared	O
with	O
wildtype	O
.	O

KA	O
administration	O
,	O
but	O
not	O
PTZ	O
,	O
induced	O
cD1	O
expression	O
.	O

These	O
findings	O
suggest	O
that	O
basal	O
cD1	O
expression	O
may	O
render	O
hippocampal	O
circuits	O
more	O
susceptible	O
to	O
particular	O
epileptogenic	O
agents	O
and	O
excitotoxic	O
cell	O
death	O
,	O
though	O
cD1	O
is	O
not	O
a	O
direct	O
precipitant	O
in	O
apoptosis	O
.	O

Increased	O
circulating	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
imbalanced	O
regulatory	O
T	O
-	O
cell	O
cytokines	O
production	O
in	O
chronic	B
idiopathic	I
urticaria	I
.	O

The	O
immunologic	O
characterization	O
of	O
chronic	B
idiopathic	I
urticaria	I
(	O
CIU	B
)	O
,	O
mainly	O
regarding	O
cytokine	O
profile	O
needs	O
more	O
investigation	O
.	O

We	O
examined	O
circulating	O
inflammatory	O
cytokine	O
levels	O
,	O
T	O
-	O
cell	O
induced	O
secretion	O
,	O
and	O
cytokine	O
mRNA	O
expression	O
in	O
patients	O
with	O
CIU	B
subjected	O
to	O
the	O
intradermal	O
autologous	O
serum	O
skin	O
test	O
(	O
ASST	O
)	O
.	O

Increased	O
levels	O
of	O
circulating	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
12p70	O
,	O
and	O
IL	O
-	O
6	O
have	O
been	O
observed	O
in	O
most	O
of	O
patients	O
with	O
CIU	B
,	O
together	O
with	O
an	O
enhancement	O
of	O
IL	O
-	O
2	O
secretion	O
following	O
T	O
-	O
cell	O
stimulation	O
.	O

Highlighting	O
the	O
inflammatory	O
profile	O
in	O
CIU	B
found	O
in	O
ASST	O
positive	O
,	O
is	O
the	O
enhanced	O
B	O
-	O
cell	O
proliferative	O
responsiveness	O
and	O
increased	O
IL	O
-	O
17	O
secretion	O
levels	O
.	O

ASST	O
-	O
positive	O
patients	O
also	O
exhibited	O
impaired	O
IL	O
-	O
4	O
secretion	O
associated	O
with	O
increased	O
IL	O
-	O
10	O
production	O
.	O

Altered	O
cytokine	O
expression	O
in	O
patients	O
with	O
ASST	O
-	O
negative	O
,	O
was	O
the	O
down	O
-	O
modulation	O
of	O
spontaneous	O
IL	O
-	O
10	O
mRNA	O
expression	O
levels	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Our	O
findings	O
support	O
the	O
concept	O
of	O
immunologic	O
dysregulation	O
in	O
CIU	B
,	O
revealing	O
a	O
systemic	O
inflammatory	O
profile	O
associated	O
with	O
disturbed	O
cytokine	O
production	O
by	O
T	O
cells	O
,	O
mainly	O
related	O
to	O
IL	O
-	O
17	O
and	O
IL	O
-	O
10	O
production	O
.	O

Magnetic	O
resonance	O
imaging	O
appearance	O
of	O
the	O
shoulder	O
after	O
subacromial	O
injection	O
with	O
corticosteroids	O
can	O
mimic	O
a	O
rotator	B
cuff	I
tear	I
.	O

Subacromial	O
injections	O
have	O
been	O
used	O
to	O
treat	O
rotator	B
cuff	I
problems	I
.	O

Previous	O
studies	O
have	O
noted	O
the	O
difficulty	O
in	O
performing	O
accurate	O
injections	O
into	O
this	O
area	O
.	O

In	O
addition	O
,	O
one	O
must	O
also	O
question	O
the	O
effects	O
that	O
misplaced	O
corticosteroids	O
could	O
have	O
on	O
the	O
surrounding	O
tissues	O
.	O

In	O
this	O
case	O
,	O
a	O
51	O
-	O
year	O
-	O
old	O
woman	O
presented	O
with	O
several	O
weeks	O
of	O
left	O
shoulder	B
pain	I
and	O
was	O
diagnosed	O
with	O
rotator	B
cuff	I
tendonitis	I
.	O

After	O
a	O
subacromial	O
injection	O
with	O
betamethasone	O
and	O
lidocaine	O
,	O
the	O
patient	O
noted	O
3	O
weeks	O
of	O
near	O
complete	O
pain	B
relief	O
,	O
followed	O
by	O
a	O
return	O
of	O
her	O
symptoms	O
.	O

A	O
magnetic	O
resonance	O
imaging	O
scan	O
obtained	O
7	O
weeks	O
after	O
the	O
injection	O
showed	O
a	O
full	O
-	O
thickness	O
tear	O
of	O
the	O
supraspinatus	O
tendon	O
.	O

Five	O
weeks	O
later	O
,	O
the	O
patient	O
underwent	O
arthroscopic	O
evaluation	O
of	O
the	O
shoulder	O
and	O
subacromial	O
decompression	O
.	O

The	O
rotator	O
cuff	O
tendons	O
were	O
noted	O
to	O
be	O
intact	O
and	O
normal	O
in	O
appearance	O
.	O

The	O
patient	O
eventually	O
had	O
full	O
resolution	O
of	O
her	O
symptoms	O
.	O

Six	O
months	O
postoperatively	O
,	O
she	O
underwent	O
a	O
new	O
scan	O
that	O
showed	O
a	O
normal	O
supraspinatus	O
tendon	O
.	O

Apparently	O
,	O
the	O
subacromial	O
injection	O
penetrated	O
the	O
anterior	O
half	O
of	O
the	O
supraspinatus	O
tendon	O
,	O
causing	O
a	O
transient	O
effect	O
and	O
signal	O
change	O
.	O

One	O
should	O
use	O
caution	O
in	O
the	O
interpretation	O
of	O
magnetic	O
resonance	O
imaging	O
scans	O
of	O
the	O
shoulder	O
soon	O
after	O
the	O
injection	O
of	O
corticosteroids	O
.	O

Insulin	O
glargine	O
versus	O
intermediate	O
-	O
acting	O
insulin	O
as	O
the	O
basal	O
component	O
of	O
multiple	O
daily	O
injection	O
regimens	O
for	O
adolescents	O
with	O
type	B
1	I
diabetes	I
mellitus	I
.	O

OBJECTIVES	O
:	O
To	O
compare	O
long	O
-	O
acting	O
insulin	O
glargine	O
(	O
Lantus	O
)	O
with	O
intermediate	O
-	O
acting	O
insulin	O
(	O
neutral	O
protamine	O
Hagedorn	O
[	O
NPH	O
]	O
/	O
Lente	O
)	O
when	O
used	O
as	O
the	O
basal	O
component	O
of	O
a	O
multiple	O
daily	O
injection	O
(	O
MDI	O
)	O
regimen	O
with	O
prandial	O
insulin	O
lispro	O
(	O
Humalog	O
)	O
in	O
adolescents	O
with	O
type	B
1	I
diabetes	I
mellitus	I
(	O
T1DM	B
)	O
.	O

STUDY	O
DESIGN	O
:	O
This	O
was	O
an	O
active	O
-	O
controlled	O
,	O
randomized	O
,	O
open	O
-	O
label	O
,	O
sex	O
-	O
stratified	O
,	O
2	O
-	O
arm	O
,	O
parallel	O
-	O
group	O
comparison	O
of	O
once	O
-	O
daily	O
insulin	O
glargine	O
with	O
twice	O
-	O
daily	O
NPH	O
/	O
Lente	O
in	O
an	O
MDI	O
regimen	O
.	O

Changes	O
in	O
glycated	O
hemoglobin	O
A1C	O
(	O
A1C	O
)	O
,	O
occurrence	O
of	O
hypoglycemia	B
,	O
and	O
adverse	O
events	O
were	O
assessed	O
in	O
175	O
patients	O
(	O
age	O
9	O
to	O
17	O
years	O
)	O
with	O
T1DM	O
.	O

RESULTS	O
:	O
The	O
overall	O
mean	O
change	O
in	O
A1C	O
from	O
baseline	O
to	O
week	O
24	O
was	O
similar	O
in	O
the	O
2	O
groups	O
:	O
insulin	O
glargine	O
(	O
n	O
=	O
76	O
)	O
,	O
-	O
0.25	O
%	O
+	O
/	O
-	O
0.14	O
%	O
;	O
NPH	O
/	O
Lente	O
(	O
n	O
=	O
81	O
)	O
,	O
0.05	O
%	O
+	O
/	O
-	O
0.13	O
%	O
(	O
P	O
=	O
.1725	O
)	O
.	O

However	O
,	O
an	O
analysis	O
of	O
covariance	O
,	O
adjusting	O
for	O
baseline	O
A1C	O
,	O
revealed	O
a	O
strong	O
study	O
arm	O
effect	O
on	O
the	O
slopes	O
of	O
the	O
regression	O
lines	O
,	O
indicating	O
that	O
the	O
reduction	O
in	O
A1C	O
was	O
significantly	O
greater	O
with	O
insulin	O
glargine	O
in	O
those	O
patients	O
with	O
higher	O
baseline	O
A1C	O
values	O
.	O

The	O
rate	O
of	O
confirmed	O
glucose	O
values	O
<	O
70	O
mg	O
/	O
dL	O
was	O
higher	O
in	O
the	O
patients	O
receiving	O
insulin	O
glargine	O
(	O
P	O
=	O
.0298	O
)	O
.	O

No	O
differences	O
in	O
the	O
rate	O
of	O
severe	O
hypoglycemia	B
(	O
P	O
=	O
.1814	O
)	O
or	O
the	O
occurrence	O
of	O
glucose	O
levels	O
<	O
50	O
mg	O
/	O
dL	O
(	O
P	O
=	O
.82	O
)	O
or	O
<	O
36	O
mg	O
/	O
dL	O
(	O
P	O
=	O
.32	O
)	O
were	O
found	O
between	O
the	O
2	O
groups	O
.	O

CONCLUSIONS	O
:	O
Insulin	O
glargine	O
is	O
well	O
tolerated	O
in	O
MDI	O
regimens	O
for	O
pediatric	O
patients	O
with	O
T1DM	B
and	O
may	O
be	O
more	O
efficacious	O
than	O
NPH	O
/	O
Lente	O
in	O
those	O
with	O
elevated	O
A1C	O
.	O

Perception	O
of	O
validity	O
of	O
clinical	O
and	O
preclinical	O
methods	O
for	O
assessment	O
of	O
torsades	B
de	I
pointes	I
liability	O
.	O

In	O
2007	O
a	O
meeting	O
on	O
drug	O
-	O
induced	O
torsades	B
de	I
pointes	I
(	O
TdP	B
)	O
was	O
held	O
in	O
London	O
,	O
UK	O
,	O
under	O
the	O
auspices	O
of	O
the	O
British	O
Society	O
for	O
Cardiovascular	O
Research	O
(	O
BSCR	O
)	O
.	O

One	O
of	O
the	O
objectives	O
was	O
to	O
explore	O
the	O
validity	O
of	O
available	O
biomarkers	O
,	O
risk	O
factors	O
and	O
preclinical	O
investigational	O
methods	O
for	O
the	O
detection	O
of	O
drug	O
-	O
induced	O
TdP	B
liability	O
-	O
preclinical	O
methods	O
and	O
clinical	O
'	O
t	O
horough	O
QT	O
'	O
testing	O
.	O

The	O
first	O
symposium	O
was	O
entitled	O
""""	O
How	O
validated	O
are	O
current	O
models	O
and	O
biomarkers	O
for	O
testing	O
drug	O
-	O
induced	O
torsades	B
de	I
pointes	I
liability	O
?	O
""""	O
Validation	O
,	O
as	O
far	O
as	O
the	O
symposium	O
was	O
concerned	O
,	O
meant	O
that	O
the	O
endpoints	O
measured	O
in	O
the	O
method	O
predict	O
TdP	B
liability	O
specifically	O
,	O
selectively	O
and	O
quantitatively	O
.	O

Topics	O
(	O
and	O
the	O
publications	O
derived	O
from	O
the	O
presentations	O
)	O
were	O
:	O
human	O
volunteer	O
phase	O
1	O
studies	O
[	O
Vik	O
,	O
T	O
.	O
,	O
Pollard	O
,	O
C	O
.	O
,	O
&	O
Sager	O
,	O
P	O
.	O

(	O
2008	O
-	O
this	O
issue	O
)	O
,	O
the	O
anaesthetized	O
rabbit	O
TDP	O
model	O
[	O
Carlsson	O
,	O
L	O
.	O

(	O
2008	O
-	O
this	O
issue	O
)	O
,	O
the	O
AV	O
blocked	O
canine	O
preparation	O
[	O
Oros	O
,	O
A	O
.	O
,	O
Beekman	O
,	O
J	O
.	O

D	O
.	O

M	O
.	O
,	O
&	O
Vos	O
,	O
M	O
.	O

A	O
.	O

(	O
2008	O
-	O
this	O
issue	O
)	O
,	O
QT	O
interval	O
and	O
its	O
corrections	O
in	O
the	O
in	O
vivo	O
conscious	O
canine	O
[	O
Fossa	O
,	O
A	O
.	O

A	O
.	O

(	O
2008	O
-	O
this	O
issue	O
)	O
,	O
the	O
rabbit	O
heart	B
failure	I
model	O
[	O
Hamlin	O
,	O
R	O
.	O

L	O
.	O
,	O
&	O
Kijtawornrat	O
,	O
A	O
.	O

(	O
2008	O
-	O
this	O
issue	O
)	O
,	O
the	O
rabbit	O
Langendorff	O
preparation	O
and	O
the	O
Screenit	O
approach	O
[	O
Dumotier	O
,	O
B	O
.	O

M	O
.	O
,	O
Deurinck	O
,	O
M	O
.	O
,	O
Yang	O
,	O
Y	O
.	O
,	O
Traebert	O
,	O
M	O
.	O
,	O
&	O
Suter	O
,	O
W	O
.	O

(	O
2008	O
-	O
this	O
issue	O
)	O
,	O
the	O
wedge	O
preparation	O
[	O
Yan	O
G	O
.	O

-	O
X	O
.	O

(	O
2008	O
-	O
this	O
issue	O
)	O
]	O
and	O
hERG	O
screens	O
[	O
Hancox	O
,	O
J	O
.	O

C	O
.	O
,	O
McPate	O
,	O
M	O
.	O

J	O
.	O
,	O
El	O
Harchi	O
,	O
A	O
.	O
,	O
&	O
Zhang	O
,	O
Y	O
.	O
h	O
.	O

(	O
2008	O
-	O
this	O
issue	O
)	O
.	O

Unbeknownst	O
to	O
the	O
speakers	O
before	O
the	O
start	O
of	O
the	O
sessions	O
,	O
the	O
audience	O
were	O
invited	O
,	O
during	O
the	O
session	O
,	O
to	O
rate	O
each	O
approach	O
on	O
a	O
0	O
to	O
10	O
scale	O
in	O
terms	O
of	O
the	O
extent	O
to	O
which	O
each	O
approach	O
appeared	O
to	O
be	O
validated	O
.	O

The	O
outcome	O
of	O
this	O
exercise	O
forms	O
the	O
basis	O
of	O
this	O
article	O
.	O

We	O
invite	O
you	O
to	O
evaluate	O
for	O
yourselves	O
the	O
accompanying	O
reviews	O
in	O
this	O
edition	O
of	O
Pharmacology	O
and	O
Therapeutics	O
.	O

Amiodarone	O
increases	O
the	O
accumulation	O
of	O
DEA	O
in	O
a	O
human	O
alveolar	O
epithelium	O
-	O
derived	O
cell	O
line	O
.	O

Amiodarone	O
(	O
AMD	O
)	O
-	O
induced	O
pulmonary	B
toxicity	I
(	O
AIPT	B
)	O
is	O
the	O
most	O
life	O
-	O
threatening	O
side	O
-	O
effect	O
of	O
AMD	O
treatment	O
.	O

N	O
-	O
Monodesethylamiodarone	O
(	O
DEA	O
)	O
,	O
an	O
active	O
metabolite	O
of	O
AMD	O
,	O
also	O
exhibits	O
cytotoxicity	O
and	O
tends	O
to	O
accumulate	O
in	O
the	O
lung	O
more	O
intensively	O
than	O
AMD	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
the	O
mechanism	O
of	O
DEA	O
accumulation	O
using	O
A549	O
cells	O
as	O
a	O
model	O
of	O
the	O
alveolar	O
epithelium	O
.	O

Typical	O
ATP	O
-	O
depletion	O
compounds	O
caused	O
an	O
approximately	O
30	O
%	O
increase	O
in	O
the	O
accumulation	O
of	O
DEA	O
in	O
A549	O
cells	O
,	O
although	O
these	O
effects	O
were	O
less	O
than	O
those	O
in	O
Caco	O
-	O
2	O
cells	O
.	O

Triiodothyronine	O
(	O
T	O
(	O
3	O
)	O
)	O
,	O
which	O
exhibited	O
an	O
inhibitory	O
effect	O
on	O
DEA	O
efflux	O
in	O
Caco	O
-	O
2	O
cells	O
,	O
did	O
not	O
affect	O
the	O
accumulation	O
of	O
DEA	O
in	O
A549	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
100	O
microM	O
AMD	O
caused	O
an	O
approximately	O
200	O
%	O
increase	O
in	O
DEA	O
content	O
in	O
A549	O
cells	O
,	O
although	O
AMD	O
accumulation	O
was	O
not	O
affected	O
by	O
100	O
microM	O
DEA	O
.	O

Since	O
the	O
reducing	O
effect	O
of	O
AMD	O
on	O
cellular	O
ATP	O
levels	O
and	O
that	O
of	O
FCCP	O
were	O
similar	O
,	O
the	O
mechanism	O
by	O
which	O
DEA	O
accumulation	O
is	O
increased	O
by	O
AMD	O
might	O
be	O
different	O
from	O
the	O
ATP	O
-	O
dependent	O
DEA	O
efflux	O
mechanism	O
.	O

The	O
decrease	O
in	O
cell	O
viability	O
by	O
DEA	O
in	O
the	O
presence	O
of	O
AMD	O
(	O
IC	O
(	O
50	O
)	O
value	O
of	O
DEA	O
for	O
A549	O
cell	O
viability	O
:	O
25.4	O
+	O
/	O
-	O
2.4	O
microM	O
)	O
was	O
more	O
pronounced	O
than	O
that	O
by	O
DEA	O
alone	O
(	O
IC	O
(	O
50	O
)	O
value	O
:	O
11.5	O
+	O
/	O
-	O
3.0	O
microM	O
)	O
.	O

This	O
further	O
DEA	O
accumulation	O
by	O
AMD	O
might	O
be	O
a	O
factor	O
responsible	O
for	O
the	O
greater	O
accumulation	O
of	O
DEA	O
than	O
that	O
of	O
AMD	O
in	O
the	O
lung	O
in	O
long	O
-	O
term	O
AMD	O
-	O
treated	O
patients	O
.	O

Simvastatin	O
-	O
induced	O
rhabdomyolysis	B
and	O
acute	B
renal	I
injury	I
.	O

Simvastatin	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescribed	O
CoA	O
reductase	O
inhibitors	O
.	O

The	O
safety	O
profile	O
of	O
this	O
drug	O
has	O
been	O
widely	O
discussed	O
in	O
the	O
medical	O
and	O
consumer	O
advocacy	O
communities	O
.	O

Like	O
other	O
statins	O
,	O
simvastatin	O
can	O
cause	O
a	O
serious	O
and	O
potentially	O
life	O
-	O
threatening	O
complication	O
:	O
rhabdomyolysis	B
.	O

We	O
describe	O
a	O
case	O
of	O
simvastatin	O
-	O
induced	O
rhabdomyolysis	B
complicated	O
by	O
acute	B
renal	I
failure	I
requiring	O
urgent	O
hemodialysis	O
.	O

The	O
relative	O
safety	O
of	O
simvastatin	O
compared	O
to	O
other	O
HMG	O
-	O
CoA	O
reductase	O
inhibitors	O
and	O
the	O
conditions	O
that	O
can	O
potentiate	O
its	O
toxicity	O
are	O
discussed	O
.	O

The	O
clinical	O
features	O
of	O
rhabdomyolysis	B
,	O
and	O
subsequent	O
acute	B
renal	I
failure	I
,	O
and	O
their	O
treatment	O
modalities	O
are	O
presented	O
.	O

Chemoprevention	O
in	O
postmenopausal	O
women	O
.	O

Several	O
large	O
,	O
prospective	O
trials	O
have	O
evaluated	O
tamoxifen	O
compared	O
with	O
placebo	O
for	O
breast	B
cancer	I
risk	O
reduction	O
in	O
women	O
at	O
increased	O
risk	O
of	O
breast	B
cancer	I
.	O

Combined	O
results	O
from	O
these	O
trials	O
demonstrate	O
that	O
tamoxifen	O
at	O
20	O
mg	O
/	O
d	O
reduced	O
the	O
incidence	O
of	O
breast	B
cancer	I
by	O
38	O
%	O
.	O

The	O
risk	O
of	O
developing	O
breast	B
cancer	I
is	O
the	O
primary	O
determinant	O
of	O
net	O
benefit	O
,	O
with	O
greater	O
benefits	O
accrued	O
to	O
women	O
with	O
the	O
highest	O
risk	O
of	O
breast	B
cancer	I
.	O

Age	O
and	O
the	O
presence	O
of	O
risk	O
factors	O
for	O
increased	O
toxicity	O
also	O
have	O
an	O
effect	O
on	O
the	O
net	O
benefit	O
associated	O
with	O
tamoxifen	O
.	O

The	O
greatest	O
clinical	O
benefit	O
from	O
tamoxifen	O
is	O
evident	O
for	O
younger	O
women	O
who	O
are	O
at	O
lower	O
risk	O
of	O
thromboembolic	B
complications	I
and	O
uterine	B
cancer	I
,	O
women	O
without	O
a	O
uterus	O
,	O
and	O
women	O
with	O
breast	O
biopsy	O
results	O
indicative	O
of	O
atypical	B
hyperplasia	I
or	O
lobular	B
carcinoma	I
in	O
situ	O
.	O

Raloxifene	O
has	O
also	O
been	O
shown	O
to	O
reduce	O
the	O
risk	O
of	O
invasive	O
breast	B
cancer	I
in	O
women	O
with	O
osteoporosis	B
and	O
is	O
as	O
effective	O
as	O
tamoxifen	O
for	O
reducing	O
the	O
risk	O
of	O
invasive	O
breast	B
cancer	I
in	O
postmenopausal	O
women	O
at	O
increased	O
risk	O
of	O
breast	B
cancer	I
.	O

In	O
high	O
-	O
risk	O
younger	O
,	O
postmenopausal	O
women	O
,	O
raloxifene	O
seems	O
to	O
offer	O
a	O
net	O
benefit	O
when	O
comparing	O
the	O
reduction	O
of	O
risk	O
of	O
breast	B
cancer	I
and	O
prevention	O
of	O
fractures	O
with	O
the	O
risk	O
of	O
stroke	B
,	O
venous	B
thromboembolic	I
events	I
,	O
uterine	B
events	I
,	O
and	O
symptomatic	B
side	I
effects	I
.	O

Raloxifene	O
offers	O
an	O
acceptable	O
option	O
for	O
breast	B
cancer	I
risk	O
reduction	O
in	O
postmenopausal	O
women	O
.	O

Pharmacogenetics	O
of	O
Crohn	B
's	I
disease	I
.	O

The	O
considerable	O
interindividual	O
differences	O
in	O
efficacy	O
and	O
side	O
effects	O
of	O
commonly	O
used	O
medications	O
in	O
Crohn	B
's	I
disease	I
are	O
partly	O
owing	O
to	O
genetic	O
polymorphisms	O
.	O

Many	O
genetic	O
variants	O
have	O
been	O
studied	O
in	O
genes	O
possibly	O
involved	O
in	O
the	O
metabolism	O
or	O
mechanism	O
of	O
action	O
of	O
therapeutic	O
agents	O
such	O
as	O
glucocorticosteroids	O
,	O
azathioprine	O
/	O
6	O
-	O
mercaptopurine	O
,	O
methotrexate	O
,	O
calcineurin	O
inhibitors	O
or	O
anti	O
-	O
TNF	O
agents	O
.	O

However	O
,	O
the	O
only	O
test	O
translated	O
into	O
clinical	O
practice	O
is	O
thiopurine	O
S	O
-	O
methyltransferase	O
(	O
TPMT	O
)	O
genotyping	O
for	O
hematological	B
toxicity	I
of	O
thiopurine	O
treatment	O
.	O

To	O
date	O
,	O
there	O
are	O
no	O
other	O
meaningful	O
applications	O
for	O
pharmacogenomics	O
in	O
clinical	O
practice	O
of	O
Crohn	B
's	I
disease	I
.	O

In	O
the	O
future	O
,	O
designed	O
therapeutic	O
trials	O
should	O
possibly	O
permit	O
the	O
development	O
of	O
predictive	O
models	O
including	O
genotypic	O
markers	O
,	O
such	O
as	O
that	O
proposed	O
for	O
the	O
clinical	O
outcome	O
after	O
infliximab	O
therapy	O
,	O
which	O
includes	O
an	O
apoptotic	O
pharmacogenetic	O
index	O
.	O

The	O
recent	O
identification	O
of	O
new	O
susceptibility	O
genes	O
provides	O
additional	O
candidate	O
markers	O
that	O
have	O
possible	O
effects	O
on	O
the	O
outcomes	O
of	O
therapies	O
,	O
and	O
prioritizes	O
new	O
therapeutic	O
targets	O
,	O
such	O
as	O
the	O
IL	O
-	O
23	O
pathway	O
.	O

Further	O
innovative	O
approaches	O
might	O
be	O
relevant	O
for	O
the	O
pharmacogenetic	O
investigation	O
of	O
gene	O
variants	O
implied	O
in	O
innate	O
immune	O
pattern	O
recognition	O
and	O
autophagy	O
.	O

Risk	O
of	O
thrombogenicity	B
among	O
nonionic	O
radiocontrast	O
agents	O
.	O

Several	O
contrast	O
agents	O
have	O
been	O
approved	O
in	O
the	O
United	O
States	O
for	O
radiographic	O
imaging	O
purposes	O
.	O

Most	O
of	O
the	O
older	O
ionic	O
,	O
high	O
-	O
osmolar	O
contrast	O
agents	O
are	O
no	O
longer	O
used	O
because	O
of	O
their	O
side	O
effect	O
profile	O
.	O

Therefore	O
,	O
newer	O
nonionic	O
,	O
low	O
or	O
iso	O
-	O
osmolar	O
contrast	O
agents	O
have	O
been	O
widely	O
accepted	O
as	O
an	O
alternative	O
due	O
to	O
their	O
improved	O
tolerability	O
and	O
safety	O
.	O

We	O
investigated	O
the	O
thrombogenicity	B
of	O
the	O
6	O
different	O
nonionic	O
radiocontrast	O
media	O
in	O
terms	O
of	O
their	O
platelet	O
reactivity	O
and	O
noted	O
some	O
minor	O
differences	O
among	O
them	O
.	O

In	O
the	O
50	O
%	O
contrast	O
concentration	O
group	O
,	O
all	O
of	O
the	O
nonionic	O
contrast	O
agents	O
inhibited	O
aggregation	O
,	O
whereas	O
in	O
the	O
10	O
%	O
contrast	O
concentration	O
group	O
,	O
all	O
agents	O
showed	O
similar	O
aggregation	O
curves	O
in	O
comparison	O
to	O
the	O
normal	O
control	O
.	O

At	O
50	O
%	O
contrast	O
concentration	O
,	O
the	O
inhibitory	O
effect	O
of	O
aggregation	O
appeared	O
to	O
be	O
related	O
to	O
the	O
inhibition	O
of	O
calcium	O
mobilization	O
,	O
which	O
may	O
be	O
one	O
of	O
the	O
mechanistic	O
effects	O
.	O

Morphine	O
-	O
6	O
-	O
glucuronide	O
,	O
an	O
active	O
morphine	O
metabolite	O
for	O
the	O
potential	O
treatment	O
of	O
post	B
-	I
operative	I
pain	I
.	O

Morphine	O
-	O
6	O
-	O
glucuronide	O
(	O
M6	O
G	O
)	O
is	O
an	O
active	O
metabolite	O
of	O
morphine	O
that	O
is	O
being	O
developed	O
by	O
CeNeS	O
Pharmaceuticals	O
as	O
an	O
alternative	O
to	O
morphine	O
(	O
the	O
most	O
commonly	O
used	O
opioid	O
)	O
for	O
the	O
management	O
of	O
postoperative	B
pain	I
.	O

M6	O
G	O
is	O
currently	O
undergoing	O
phase	O
III	O
clinical	O
trials	O
in	O
patients	O
with	O
postoperative	B
pain	I
.	O

Gene	O
expression	O
profiles	O
in	O
the	O
cerebellum	O
and	O
hippocampus	O
following	O
exposure	O
to	O
a	O
neurotoxicant	O
,	O
Aroclor	O
1254	O
:	O
developmental	O
effects	O
.	O

The	O
developmental	O
consequences	O
of	O
exposure	O
to	O
the	O
polychlorinated	O
biphenyls	O
(	O
PCBs	O
)	O
have	O
been	O
widely	O
studied	O
,	O
making	O
PCBs	O
a	O
unique	O
model	O
to	O
understand	O
issues	O
related	O
to	O
environmental	O
mixture	O
of	O
persistent	O
chemicals	O
.	O

PCB	O
exposure	O
in	O
humans	O
adversely	O
affects	O
neurocognitive	O
development	O
,	O
causes	O
psychomotor	O
difficulties	O
,	O
and	O
contributes	O
to	O
attention	O
deficits	O
in	O
children	O
,	O
all	O
of	O
which	O
seem	O
to	O
be	O
associated	O
with	O
altered	O
patterns	O
of	O
neuronal	O
connectivity	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
gene	O
expression	O
profiles	O
in	O
the	O
rat	O
nervous	O
system	O
following	O
PCB	O
developmental	O
exposure	O
.	O

Pregnant	O
rats	O
(	O
Long	O
-	O
Evans	O
)	O
were	O
dosed	O
perinatally	O
with	O
0	O
or	O
6	O
mg	O
/	O
kg	O
/	O
day	O
of	O
Aroclor	O
1254	O
from	O
gestation	O
day	O
6	O
through	O
postnatal	O
day	O
(	O
PND	O
)	O
21	O
.	O

Gene	O
expression	O
in	O
cerebellum	O
and	O
hippocampus	O
from	O
PND7	O
and	O
PND14	O
animals	O
was	O
analyzed	O
with	O
an	O
emphasis	O
on	O
developmental	O
aspects	O
.	O

Changes	O
in	O
gene	O
expression	O
(	O
>	O
or	O
=	O
1.5	O
fold	O
)	O
in	O
control	O
animals	O
identified	O
normal	O
developmental	O
changes	O
.	O

These	O
basal	O
levels	O
of	O
expression	O
were	O
compared	O
to	O
data	O
from	O
Aroclor	O
1254	O
-	O
treated	O
animals	O
to	O
determine	O
the	O
impact	O
of	O
gestational	O
PCB	O
exposure	O
on	O
developmental	O
parameters	O
.	O

The	O
results	O
indicate	O
that	O
the	O
expression	O
of	O
a	O
number	O
of	O
developmental	O
genes	O
related	O
to	O
cell	O
cycle	O
,	O
synaptic	O
function	O
,	O
cell	O
maintenance	O
,	O
and	O
neurogenesis	O
is	O
significantly	O
altered	O
from	O
PND7	O
to	O
PND14	O
.	O

Aroclor	O
1254	O
treatment	O
appears	O
to	O
dampen	O
the	O
overall	O
growth	O
-	O
related	O
gene	O
expression	O
levels	O
in	O
both	O
regions	O
with	O
the	O
effect	O
being	O
more	O
pronounced	O
in	O
the	O
cerebellum	O
.	O

Functional	O
analysis	O
suggests	O
that	O
Aroclor	O
1254	O
delays	O
maturation	O
of	O
the	O
developing	O
nervous	O
system	O
,	O
with	O
the	O
consequences	O
dependent	O
on	O
the	O
ontological	O
state	O
of	O
the	O
brain	O
area	O
and	O
the	O
functional	O
role	O
of	O
the	O
individual	O
gene	O
.	O

Such	O
changes	O
may	O
underlie	O
learning	O
and	O
memory	O
deficits	O
observed	O
in	O
PCB	O
exposed	O
animals	O
and	O
humans	O
.	O

Novel	O
therapies	O
in	O
lupus	O
-	O
focus	O
on	O
nephritis	B
.	O

Lupus	B
nephritis	I
(	O
LN	B
)	O
is	O
one	O
of	O
the	O
major	O
complications	O
of	O
Systemic	B
Lupus	I
Erythematosus	I
(	O
SLE	B
)	O
and	O
its	O
treatment	O
remains	O
a	O
challenge	O
.	O

Although	O
the	O
classical	O
and	O
widely	O
used	O
immunosuppressive	O
agents	O
have	O
accounted	O
for	O
a	O
significant	O
improvement	O
in	O
the	O
survival	O
and	O
decreased	O
the	O
progression	O
to	O
end	O
-	O
stage	O
renal	B
failure	I
they	O
lack	O
selectivity	O
for	O
the	O
underlying	O
immune	O
dysregulation	O
.	O

In	O
addition	O
the	O
toxicity	O
related	O
to	O
their	O
use	O
and	O
the	O
relapses	O
after	O
treatment	O
are	O
of	O
major	O
concern	O
not	O
least	O
because	O
of	O
the	O
adverse	O
effect	O
on	O
the	O
prognosis	O
of	O
the	O
patients	O
with	O
SLE	B
who	O
have	O
kidney	O
involvement	O
.	O

The	O
development	O
of	O
more	O
specific	O
pharmacological	O
agents	O
for	O
patients	O
with	O
SLE	B
is	O
still	O
a	O
major	O
research	O
goal	O
.	O

Ideally	O
these	O
agents	O
should	O
provide	O
a	O
better	O
long	O
-	O
term	O
prognosis	O
for	O
SLE	B
patients	O
and	O
be	O
less	O
toxic	O
.	O

In	O
this	O
review	O
we	O
summarise	O
the	O
mechanism	O
of	O
action	O
and	O
the	O
results	O
obtained	O
with	O
a	O
variety	O
of	O
drugs	O
that	O
have	O
recently	O
been	O
utilized	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
lupus	O
especially	O
those	O
with	O
nephritis	B
.	O

We	O
discuss	O
the	O
clinical	O
usefulness	O
of	O
B	O
-	O
-	O
cell	O
depletion	O
principally	O
anti	O
-	O
CD20	O
antibodies	O
blockage	O
of	O
co	O
-	O
stimulatory	O
pathways	O
(	O
anti	O
-	O
CD40	O
ligand	O
antibody	O
CTLA4Ig	O
)	O
the	O
induction	O
of	O
immune	O
tolerance	O
(	O
LJP	O
394	O
peptide	O
specific	O
vaccination	O
)	O
and	O
therapy	O
targeting	O
cytokines	O
(	O
anti	O
-	O
IL10	O
antibody	O
BLyS	O
blockage	O
)	O
and	O
the	O
complement	O
system	O
(	O
anti	O
-	O
C5	O
antibody	O
)	O
.	O

Immunoablative	O
doses	O
of	O
Cyclophosphamide	O
(	O
CyC	O
)	O
with	O
or	O
without	O
Haematopoietic	O
Stem	O
Cell	O
Transplantation	O
(	O
HSCT	O
)	O
and	O
the	O
possibilities	O
of	O
gene	O
therapy	O
are	O
also	O
reviewed	O
.	O

The	O
use	O
of	O
intravenous	O
immunoglobulin	O
(	O
IVIg	O
)	O
and	O
plasmapheresis	O
are	O
not	O
discussed	O
because	O
these	O
treatments	O
have	O
been	O
used	O
in	O
clinical	O
practice	O
for	O
several	O
years	O
.	O

Comparison	O
of	O
three	O
different	O
chemotherapy	O
regimens	O
containing	O
epirubicin	O
in	O
hormone	B
-	I
refractory	I
prostate	I
cancer	I
patients	O
.	O

We	O
compared	O
three	O
different	O
chemotherapy	O
regimens	O
containing	O
epirubicin	O
in	O
hormone	B
-	I
refractory	I
prostate	I
cancer	I
(	O
HRPC	B
)	O
patients	O
.	O

Sixty	O
-	O
nine	O
patients	O
with	O
HRPC	O
were	O
randomized	O
into	O
three	O
groups	O
.	O

The	O
first	O
group	O
(	O
22	O
patients	O
)	O
received	O
30	O
mg	O
/	O
m2	O
/	O
week	O
i	O
.	O

v	O
.	O

epirubicin	O
for	O
8	O
weeks	O
.	O

The	O
second	O
group	O
(	O
24	O
patients	O
)	O
received	O
30	O
mg	O
/	O
m2	O
/	O
week	O
i	O
.	O

v	O
.	O

epirubicin	O
for	O
8	O
weeks	O
followed	O
by	O
monthly	O
maintenance	O
therapy	O
for	O
4	O
-	O
6	O
months	O
.	O

The	O
third	O
group	O
(	O
23	O
patients	O
)	O
received	O
oral	O
estramustine	O
phosphate	O
(	O
EMP	O
)	O
at	O
a	O
dose	O
of	O
840	O
mg	O
/	O
day	O
together	O
with	O
weekly	O
and	O
monthly	O
maintenance	O
epirubicin	O
.	O

The	O
response	O
rates	O
,	O
mean	O
survival	O
times	O
,	O
and	O
toxicity	O
were	O
determined	O
.	O

Within	O
the	O
first	O
3	O
months	O
,	O
pain	B
and	O
performance	O
scores	O
were	O
improved	O
by	O
at	O
least	O
one	O
degree	O
in	O
all	O
the	O
groups	O
.	O

One	O
patient	O
in	O
group	O
two	O
and	O
three	O
patients	O
in	O
group	O
three	O
had	O
complete	O
response	O
.	O

Partial	O
response	O
rates	O
were	O
23	O
%	O
in	O
group	O
1	O
,	O
25	O
%	O
in	O
group	O
2	O
,	O
and	O
17	O
%	O
in	O
group	O
3	O
.	O

Stable	O
disease	O
rates	O
were	O
41	O
%	O
in	O
group	O
1	O
,	O
33	O
%	O
in	O
group	O
2	O
,	O
and	O
26	O
%	O
in	O
group	O
3	O
.	O

The	O
progression	O
rates	O
within	O
the	O
first	O
3	O
months	O
were	O
36	O
%	O
in	O
group	O
1	O
,	O
38	O
%	O
in	O
group	O
2	O
,	O
and	O
44	O
%	O
in	O
group	O
3	O
.	O

None	O
of	O
the	O
patients	O
developed	O
complications	O
that	O
were	O
significant	O
enough	O
to	O
terminate	O
the	O
treatment	O
.	O

Two	O
patients	O
in	O
group	O
3	O
died	O
of	O
cardiotoxicity	B
.	O

The	O
mean	O
survival	O
times	O
were	O
10.1	O
,	O
15.8	O
,	O
and	O
16.1	O
months	O
in	O
groups	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
respectively	O
.	O

It	O
was	O
determined	O
that	O
weekly	O
and	O
maintenance	O
epirubicin	O
treatment	O
protocol	O
,	O
and	O
estramustine	O
treatment	O
protocol	O
in	O
addition	O
to	O
this	O
treatment	O
,	O
was	O
only	O
meaningfully	O
more	O
effective	O
against	O
weekly	O
epirubicin	O
treatment	O
in	O
the	O
statistical	O
sense	O
(	O
0.01	O
<	O
p	O
<	O
0.05	O
)	O
.	O

However	O
,	O
due	O
to	O
the	O
complications	O
of	O
EMP	O
,	O
which	O
influence	O
the	O
quality	O
of	O
life	O
,	O
we	O
believe	O
that	O
this	O
was	O
usable	O
only	O
when	O
measures	O
were	O
adopted	O
against	O
these	O
effects	O
.	O

Paraquat	O
and	O
maneb	O
induced	O
neurotoxicity	B
.	O

Parkinson	B
's	I
disease	I
is	O
a	O
progressive	O
neurological	B
disorder	I
associated	O
with	O
selective	O
degeneration	O
of	O
nigrostriatal	O
dopaminergic	O
neurons	O
.	O

It	O
is	O
the	O
most	O
common	O
of	O
the	O
neurodegenerative	B
movement	I
disorders	I
,	O
affecting	O
approximately	O
1	O
%	O
of	O
the	O
population	O
over	O
age	O
65	O
.	O

Though	O
the	O
exact	O
cause	O
of	O
the	O
neurodegeneration	B
is	O
unknown	O
,	O
it	O
has	O
been	O
shown	O
that	O
environmental	O
factors	O
can	O
contribute	O
to	O
the	O
onset	O
of	O
Parkinson	B
's	I
disease	I
.	O

Parkinsonian	B
symptoms	I
are	O
seen	O
following	O
exposure	O
to	O
the	O
herbicide	O
paraquat	O
,	O
and	O
the	O
fungicide	O
maneb	O
.	O

Furthermore	O
,	O
evidence	O
clearly	O
shows	O
that	O
neurodegeneration	B
develops	O
in	O
environments	O
where	O
workers	O
are	O
co	O
-	O
exposed	O
to	O
paraquat	O
and	O
maneb	O
.	O

These	O
neurotoxins	O
cause	O
a	O
pesticide	O
-	O
induced	O
loss	O
of	O
dopaminergic	O
neurons	O
,	O
inducing	O
a	O
Parkinsonian	O
phenotype	O
.	O

The	O
specific	O
mechanisms	O
by	O
which	O
these	O
environmental	O
neurotoxins	O
affect	O
the	O
nigral	O
dopaminergic	O
neurons	O
are	O
unknown	O
.	O

This	O
gap	O
in	O
mechanistic	O
understanding	O
raises	O
a	O
need	O
for	O
further	O
examination	O
of	O
their	O
cytotoxic	B
effects	I
.	O

Despite	O
advances	O
in	O
pharmacotherapy	O
that	O
have	O
improved	O
quality	O
of	O
life	O
,	O
the	O
mortality	O
rate	O
among	O
Parkinson	B
's	I
disease	I
sufferers	O
remains	O
largely	O
unchanged	O
.	O

There	O
is	O
need	O
for	O
a	O
proactive	O
treatment	O
strategy	O
that	O
could	O
provide	O
neuroprotection	O
or	O
neurorestoration	O
.	O

Since	O
evidence	O
has	O
shown	O
that	O
environmental	O
neurotoxins	O
play	O
an	O
important	O
role	O
in	O
nigral	O
degeneration	O
,	O
there	O
is	O
obviously	O
a	O
need	O
to	O
take	O
a	O
closer	O
look	O
at	O
such	O
toxins	O
since	O
a	O
greater	O
understanding	O
could	O
aid	O
in	O
development	O
of	O
novel	O
pharmacological	O
agents	O
with	O
anti	O
-	O
parkinson	O
and	O
neuroprotective	O
effects	O
.	O

In	O
this	O
review	O
,	O
we	O
intend	O
to	O
examine	O
the	O
role	O
of	O
environmental	O
toxins	O
,	O
namely	O
paraquat	O
and	O
maneb	O
,	O
in	O
the	O
neurotoxicity	B
that	O
leads	O
to	O
dopamine	O
depletion	O
.	O

Efficient	O
clearance	O
of	O
Aspergillus	O
fumigatus	O
in	O
murine	O
lungs	O
by	O
an	O
ultrashort	O
antimicrobial	O
lipopeptide	O
,	O
palmitoyl	O
-	O
lys	O
-	O
ala	O
-	O
DAla	O
-	O
lys	O
.	O

Aspergillus	O
fumigatus	O
is	O
an	O
opportunistic	O
fungal	O
pathogen	O
responsible	O
for	O
invasive	O
aspergillosis	B
in	O
immunocompromised	O
individuals	O
.	O

The	O
inefficiency	O
of	O
antifungal	O
agents	O
and	O
high	O
mortality	O
rate	O
resulting	O
from	O
invasive	O
aspergillosis	B
remain	O
major	O
clinical	O
concerns	O
.	O

Recently	O
,	O
we	O
reported	O
on	O
a	O
new	O
family	O
of	O
ultrashort	O
cationic	O
lipopeptides	O
active	O
in	O
vitro	O
against	O
fungi	O
.	O

Mode	O
of	O
action	O
studies	O
supported	O
a	O
membranolytic	O
or	O
a	O
detergent	O
-	O
like	O
effect	O
.	O

Here	O
,	O
we	O
screened	O
several	O
lipopeptides	O
in	O
vitro	O
for	O
their	O
anti	O
-	O
A	O
.	O

fumigatus	O
activity	O
.	O

To	O
investigate	O
the	O
therapeutic	O
properties	O
of	O
the	O
selected	O
peptides	O
in	O
vivo	O
,	O
we	O
challenged	O
immunosuppressed	O
C57BL	O
/	O
6	O
wild	O
-	O
type	O
mice	O
intranasally	O
with	O
DsRed	O
-	O
labeled	O
A	O
.	O

fumigatus	O
conidia	O
and	O
subsequently	O
treated	O
the	O
animals	O
locally	O
with	O
the	O
lipopeptides	O
.	O

Confocal	O
microscopic	O
analysis	O
revealed	O
the	O
degradation	O
of	O
DsRed	O
-	O
labeled	O
hyphal	O
forms	O
and	O
residual	O
conidia	O
in	O
the	O
lungs	O
of	O
the	O
mice	O
.	O

The	O
most	O
efficient	O
peptide	O
was	O
tested	O
further	O
using	O
a	O
survival	O
assay	O
and	O
was	O
found	O
to	O
significantly	O
prolong	O
the	O
life	O
of	O
the	O
treated	O
animals	O
,	O
whereas	O
no	O
mice	O
survived	O
with	O
the	O
current	O
standard	O
antifungal	O
treatment	O
with	O
amphotericin	O
B	O
.	O

Moreover	O
,	O
as	O
opposed	O
to	O
the	O
drug	O
-	O
treated	O
lungs	O
,	O
the	O
peptide	O
-	O
treated	O
lungs	O
did	O
not	O
display	O
any	O
toxicity	O
of	O
the	O
peptide	O
.	O

Our	O
results	O
highlight	O
the	O
potential	O
of	O
this	O
family	O
of	O
lipopeptides	O
for	O
the	O
treatment	O
of	O
pulmonary	O
invasive	O
aspergillosis	B
.	O

Mechanisms	O
of	O
action	O
of	O
disease	O
-	O
modifying	O
agents	O
and	O
brain	O
volume	O
changes	O
in	O
multiple	B
sclerosis	I
.	O

Disease	O
-	O
modifying	O
agents	O
(	O
DMAs	O
)	O
,	O
including	O
interferon	O
beta	O
(	O
IFNbeta	O
)	O
and	O
glatiramer	O
acetate	O
(	O
GA	O
)	O
,	O
are	O
the	O
mainstays	O
of	O
long	O
-	O
term	O
treatment	O
of	O
multiple	B
sclerosis	I
(	O
MS	B
)	O
.	O

Other	O
potent	O
anti	O
-	O
inflammatory	O
agents	O
like	O
natalizumab	O
and	O
different	O
types	O
of	O
chemotherapeutics	O
are	O
increasingly	O
being	O
used	O
for	O
treatment	O
of	O
MS	B
,	O
particularly	O
in	O
patients	O
with	O
breakthrough	O
disease	O
activity	O
.	O

Brain	O
volume	O
(	O
BV	O
)	O
loss	O
occurs	O
early	O
in	O
the	O
disease	O
process	O
,	O
accelerates	O
over	O
time	O
,	O
and	O
may	O
be	O
only	O
partially	O
affected	O
by	O
DMA	O
therapy	O
.	O

Low	O
-	O
dose	O
,	O
low	O
frequency	O
IFNbeta	O
administered	O
once	O
weekly	O
and	O
GA	O
appear	O
to	O
partially	O
reduce	O
BV	O
decline	O
over	O
the	O
second	O
and	O
third	O
years	O
of	O
treatment	O
.	O

High	O
dose	O
,	O
high	O
frequency	O
IFNbeta	O
demonstrated	O
no	O
clear	O
effect	O
on	O
BV	O
loss	O
during	O
this	O
time	O
period	O
.	O

Current	O
evidence	O
suggests	O
that	O
changes	O
in	O
BV	O
after	O
immunoablation	O
may	O
not	O
be	O
due	O
entirely	O
to	O
the	O
resolution	O
of	O
edema	B
but	O
may	O
be	O
related	O
to	O
potential	O
chemotoxicity	B
of	O
high	O
dose	O
cyclophosphamide	O
.	O

Natalizumab	O
reduces	O
the	O
development	O
of	O
BV	O
decline	O
in	O
the	O
second	O
and	O
third	O
years	O
of	O
treatment	O
.	O

IV	O
immunoglobulin	O
showed	O
a	O
positive	O
effect	O
on	O
decelerating	O
BV	O
reduction	O
in	O
relapsing	O
and	O
advanced	O
stages	O
of	O
MS	B
.	O

These	O
differences	O
between	O
DMAs	O
may	O
be	O
explained	O
by	O
the	O
extent	O
of	O
their	O
therapeutic	O
effects	O
on	O
inflammation	B
and	O
on	O
the	O
balance	O
between	O
inhibition	O
or	O
promotion	O
of	O
remyelination	O
and	O
neuronal	O
repair	O
in	O
the	O
CNS	O
.	O

We	O
described	O
the	O
mechanisms	O
of	O
action	O
by	O
which	O
DMAs	O
induce	O
accelerated	O
,	O
non	O
-	O
tissue	O
-	O
related	O
BV	O
loss	O
(	O
pseudoatrophy	B
)	O
in	O
the	O
short	O
term	O
but	O
,	O
in	O
the	O
long	O
run	O
,	O
may	O
still	O
potentially	O
lead	O
to	O
permanent	O
BV	O
decline	O
.	O

The	O
effects	O
of	O
corticosteroid	O
therapy	O
on	O
changes	O
in	O
BV	O
in	O
patients	O
with	O
MS	B
help	O
clarify	O
the	O
mechanisms	O
through	O
which	O
potent	O
anti	O
-	O
inflammatory	O
treatments	O
may	O
prevent	O
,	O
stabilize	O
,	O
or	O
induce	O
BV	O
loss	O
.	O

Denbinobin	O
induces	O
apoptosis	O
by	O
apoptosis	O
-	O
inducing	O
factor	O
releasing	O
and	O
DNA	O
damage	O
in	O
human	O
colorectal	O
cancer	O
HCT	O
-	O
116	O
cells	O
.	O

Denbinobin	O
is	O
a	O
phenanthraquinone	O
derivative	O
present	O
in	O
the	O
stems	O
of	O
Ephemerantha	O
lonchophylla	O
.	O

We	O
showed	O
that	O
denbinobin	O
induces	O
apoptosis	O
in	O
human	O
colorectal	O
cancer	O
cells	O
(	O
HCT	O
-	O
116	O
)	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

The	O
addition	O
of	O
a	O
pan	O
-	O
caspase	O
inhibitor	O
(	O
zVAD	O
-	O
fmk	O
)	O
did	O
not	O
suppress	O
the	O
denbinobin	O
-	O
induced	O
apoptotic	O
effect	O
,	O
and	O
denbinobin	O
-	O
induced	O
apoptosis	O
was	O
not	O
accompanied	O
by	O
processing	O
of	O
procaspase	O
-	O
3	O
,	O
-	O
6	O
,	O
-	O
7	O
,	O
-	O
9	O
,	O
and	O
-	O
8	O
.	O

However	O
,	O
denbinobin	O
triggered	O
the	O
translocation	O
of	O
the	O
apoptosis	O
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
from	O
the	O
mitochondria	O
into	O
the	O
nucleus	O
.	O

Small	O
interfering	O
RNA	O
targeting	O
of	O
AIF	O
effectively	O
protected	O
HCT	O
-	O
116	O
cells	O
against	O
denbinobin	O
-	O
induced	O
apoptosis	O
.	O

Denbinobin	O
treatment	O
also	O
caused	O
DNA	O
damage	O
,	O
activation	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
,	O
and	O
upregulation	O
of	O
numerous	O
downstream	O
effectors	O
(	O
p21WAF1	O
/	O
CIP1	O
,	O
Bax	O
,	O
PUMA	O
,	O
and	O
NOXA	O
)	O
.	O

A	O
HCT	O
-	O
116	O
xenograft	O
model	O
demonstrated	O
the	O
in	O
vivo	O
efficacy	O
and	O
low	O
toxicity	O
of	O
denbinobin	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
denbinobin	O
induces	O
apoptosis	O
of	O
human	O
colorectal	O
cancer	O
HCT	O
-	O
116	O
cells	O
via	O
DNA	O
damage	O
and	O
an	O
AIF	O
-	O
mediated	O
pathway	O
.	O

These	O
results	O
indicate	O
that	O
denbinobin	O
has	O
potential	O
as	O
a	O
novel	O
anticancer	O
agent	O
.	O

Statin	O
-	O
induced	O
inhibition	O
of	O
MCF	O
-	O
7	O
breast	O
cancer	O
cell	O
proliferation	O
is	O
related	O
to	O
cell	O
cycle	O
arrest	O
and	O
apoptotic	O
and	O
necrotic	O
cell	O
death	O
mediated	O
by	O
an	O
enhanced	O
oxidative	O
stress	O
.	O

Statins	O
have	O
antiproliferative	O
and	O
anti	O
-	O
tumoral	O
effects	O
in	O
MCF	O
-	O
7	O
cells	O
.	O

We	O
determined	O
the	O
effect	O
of	O
statins	O
upon	O
MCF	O
-	O
7	O
cell	O
cycle	O
,	O
toxicity	O
,	O
cell	O
death	O
,	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
and	O
mitochondrial	O
membrane	O
potential	O
.	O

Fluvastatin	O
,	O
simvastatin	O
and	O
atorvastatin	O
inhibited	O
cell	O
proliferation	O
.	O

Antiproliferation	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
DNA	O
synthesis	O
and	O
a	O
cell	O
cycle	O
arrest	O
in	O
the	O
G1	O
and	O
G2	O
/	O
M	O
phases	O
.	O

A	O
loss	O
in	O
the	O
mitochondrial	O
membrane	O
potential	O
was	O
observed	O
with	O
fluvastatin	O
.	O

Statins	O
induced	O
increase	O
in	O
ROS	O
production	O
that	O
was	O
associated	O
with	O
cell	O
death	O
,	O
which	O
was	O
abrogated	O
by	O
the	O
antioxidant	O
NAC	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
cytotoxic	O
effect	O
observed	O
is	O
mediated	O
by	O
an	O
oxidative	O
stress	O
.	O

Clinical	O
and	O
radiological	O
features	O
of	O
brain	B
neurotoxicity	I
caused	O
by	O
antitumor	O
and	O
immunosuppressant	O
treatments	O
.	O

Antitumor	O
and	O
immunosuppressant	O
treatment	O
-	O
related	O
neurotoxicity	B
can	O
determine	O
nonspecific	O
clinical	O
syndromes	O
.	O

Exclusion	O
of	O
other	O
possible	O
causes	O
,	O
among	O
which	O
tumor	B
progression	I
,	O
appearance	O
of	O
paraneoplastic	B
disease	I
,	O
renal	O
or	O
hepatic	B
failure	I
,	O
diabetes	B
or	O
hypertension	B
,	O
is	O
relevant	O
.	O

We	O
report	O
clinical	O
and	O
neuroradiological	O
features	O
in	O
five	O
patients	O
with	O
neurotoxic	B
syndromes	I
due	O
to	O
chemotherapy	O
/	O
radiotherapy	O
or	O
immunosuppression	O
in	O
the	O
context	O
of	O
neoplastic	O
disease	O
/	O
organ	O
transplantation	O
.	O

Acute	B
neurological	I
syndrome	I
developed	O
in	O
three	O
patients	O
after	O
methotrexate	O
(	O
MTX	O
)	O
,	O
cyclosporine	O
A	O
,	O
and	O
L	O
-	O
asparaginase	O
therapy	O
,	O
respectively	O
.	O

MRI	O
showed	O
posterior	B
reversible	I
encephalopathy	I
in	O
two	O
cases	O
and	O
venous	B
thrombosis	I
with	O
intraparenchymal	B
hematoma	I
in	O
the	O
third	O
patient	O
.	O

Late	O
onset	O
clinical	O
syndrome	O
occurred	O
in	O
the	O
last	O
two	O
patients	O
,	O
treated	O
with	O
MTX	O
or	O
radiation	O
therapy	O
for	O
breast	B
cancer	I
metastasis	I
and	O
pituitary	B
adenoma	I
.	O

Neuroimaging	O
showed	O
brain	O
diffuse	O
abnormalities	O
.	O

Patients	O
affected	O
by	O
tumors	B
suffer	O
from	O
increased	O
risk	O
for	O
treatment	O
-	O
related	O
toxicities	O
.	O

Appearance	O
or	O
worsening	O
of	O
neurological	O
signs	O
and	O
symptoms	O
challenge	O
the	O
clinician	O
to	O
discriminate	O
between	O
CNS	O
involvement	O
by	O
the	O
tumor	O
,	O
toxicity	O
of	O
drugs	O
,	O
parane	O
-	O
oplastic	O
disease	O
and	O
infections	O
.	O

MRI	O
has	O
a	O
key	O
role	O
in	O
differential	O
diagnosis	O
.	O

Close	O
interaction	O
between	O
the	O
neurologist	O
,	O
the	O
oncologist	O
and	O
the	O
neuroradiologist	O
leads	O
to	O
the	O
optimal	O
management	O
of	O
patients	O
.	O

Alert	O
:	O
inaccurate	O
lithium	O
assay	O
results	O
.	O

OBJECTIVES	O
:	O
A	O
patient	O
who	O
had	O
experienced	O
bipolar	B
disorder	I
for	O
over	O
20	O
years	O
and	O
who	O
had	O
been	O
euthymic	O
for	O
most	O
of	O
that	O
period	O
while	O
highly	O
compliant	O
with	O
lithium	O
,	O
had	O
falsely	O
low	O
lithium	O
levels	O
reported	O
over	O
two	O
periods	O
,	O
6	O
years	O
apart	O
,	O
and	O
was	O
actually	O
lithium	O
toxic	O
on	O
the	O
most	O
recent	O
occasion	O
.	O

At	O
that	O
latter	O
time	O
the	O
spuriously	O
low	O
lithium	O
levels	O
reported	O
on	O
the	O
assay	O
risked	O
dispelling	O
any	O
clinical	O
suspicion	O
of	O
lithium	B
toxicity	I
,	O
although	O
toxicity	O
was	O
later	O
confirmed	O
.	O

METHOD	O
:	O
Case	O
report	O
.	O

RESULTS	O
:	O
The	O
latter	O
incident	O
identified	O
a	O
serious	O
problem	O
,	O
whereby	O
it	O
is	O
likely	O
that	O
the	O
particular	O
assay	O
risks	O
generating	O
spuriously	O
low	O
values	O
when	O
high	O
serum	O
levels	O
of	O
lithium	O
are	O
present	O
-	O
-	O
a	O
so	O
-	O
called	O
'	O
hook	O
phenomenon	O
'	O
that	O
has	O
been	O
described	O
for	O
some	O
quantitative	O
immunoassays	O
.	O

CONCLUSIONS	O
:	O
It	O
is	O
in	O
situations	O
of	O
high	O
potential	O
gravity	O
-	O
-	O
when	O
lithium	B
toxicity	I
is	O
present	O
-	O
-	O
that	O
lithium	O
quantification	O
is	O
most	O
likely	O
to	O
be	O
compromised	O
and	O
low	O
values	O
generated	O
.	O

Also	O
of	O
grave	O
concern	O
is	O
the	O
fact	O
that	O
there	O
are	O
no	O
regulatory	O
processes	O
in	O
place	O
to	O
communicate	O
this	O
problem	O
to	O
lithium	O
prescribers	O
.	O

Association	O
between	O
serious	O
ischemic	O
cardiac	O
outcomes	O
and	O
medications	O
used	O
to	O
treat	O
diabetes	B
.	O

PURPOSE	O
:	O
Data	O
on	O
cardiovascular	O
outcomes	O
among	O
treated	O
diabetics	O
have	O
been	O
inconsistent	O
.	O

Our	O
goal	O
was	O
to	O
compare	O
cardiovascular	O
outcomes	O
associated	O
with	O
different	O
treatments	O
for	O
diabetes	B
.	O

METHODS	O
:	O
This	O
is	O
a	O
retrospective	O
cohort	O
study	O
of	O
diabetic	O
patients	O
at	O
least	O
40	O
years	O
of	O
age	O
treated	O
in	O
general	O
practices	O
participating	O
in	O
The	O
Health	O
Information	O
Network	O
(	O
THIN	O
)	O
data	O
system	O
between	O
2002	O
and	O
2006	O
.	O

Our	O
primary	O
outcome	O
was	O
serious	O
atherosclerotic	B
vascular	I
disease	I
of	O
the	O
heart	O
.	O

RESULTS	O
:	O
Among	O
all	O
diabetics	O
(	O
N	O
=	O
63	O
579	O
)	O
,	O
the	O
fully	O
adjusted	O
hazard	O
ratios	O
of	O
association	O
with	O
our	O
outcome	O
were	O
1.2	O
(	O
1.1	O
,	O
1.3	O
)	O
for	O
insulin	O
,	O
1.03	O
(	O
0.97	O
,	O
1.09	O
)	O
for	O
sulfonylureas	O
,	O
0.8	O
(	O
0.7	O
,	O
0.8	O
)	O
for	O
biguanide	O
,	O
1.2	O
(	O
0.99	O
,	O
1.5	O
)	O
for	O
meglitinide	O
,	O
0.5	O
(	O
0.5	O
,	O
0.6	O
)	O
for	O
thiazolidinediones	O
,	O
and	O
individually	O
0.6	O
(	O
0.5	O
,	O
0.6	O
)	O
for	O
rosiglitazone	O
,	O
and	O
0.5	O
(	O
0.4	O
,	O
0.7	O
)	O
for	O
pioglitazone	O
.	O

Among	O
those	O
individuals	O
newly	O
diagnosed	O
and	O
treated	O
for	O
diabetes	B
after	O
2002	O
(	O
N	O
=	O
13	O
576	O
)	O
,	O
the	O
adjusted	O
hazard	O
ratios	O
of	O
association	O
with	O
our	O
outcome	O
were	O
2.4	O
(	O
2.0	O
,	O
2.9	O
)	O
for	O
insulin	O
,	O
1.4	O
(	O
1.2	O
,	O
1.7	O
)	O
for	O
sulfonylureas	O
,	O
0.5	O
(	O
0.4	O
,	O
0.5	O
)	O
for	O
biguanide	O
,	O
0.9	O
(	O
0.4	O
,	O
2.1	O
)	O
for	O
meglitinide	O
,	O
0.8	O
(	O
0.7	O
,	O
1.0	O
)	O
for	O
thiazolidinediones	O
,	O
and	O
individually	O
0.8	O
(	O
0.6	O
,	O
1.0	O
)	O
for	O
rosiglitazone	O
,	O
and	O
0.9	O
(	O
0.6	O
,	O
1.4	O
)	O
for	O
pioglitazone	O
.	O

Risk	O
increased	O
as	O
total	O
duration	O
of	O
therapy	O
increased	O
for	O
insulin	O
,	O
sulfonylureas	O
,	O
and	O
biguanide	O
,	O
but	O
decreased	O
with	O
duration	O
for	O
rosiglitazone	O
and	O
pioglitazone	O
.	O

CONCLUSIONS	O
:	O
Overall	O
,	O
insulin	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
myocardial	B
infarction	I
.	O

Its	O
risk	O
increased	O
with	O
longer	O
use	O
,	O
and	O
risk	O
emerged	O
with	O
longer	O
use	O
of	O
sulfonylureas	O
and	O
biguanide	O
.	O

Conversely	O
,	O
a	O
protective	O
effect	O
emerged	O
with	O
longer	O
use	O
of	O
rosiglitazone	O
or	O
pioglitazone	O
.	O

Effects	O
of	O
mosapride	O
citrate	O
on	O
patients	O
after	O
vagal	O
nerve	O
,	O
lower	O
esophageal	O
sphincter	O
,	O
and	O
pyloric	O
sphincter	O
-	O
preserving	O
nearly	O
total	O
gastrectomy	O
reconstructed	O
by	O
jejunal	O
J	O
pouch	O
interposition	O
,	O
and	O
postoperative	O
quality	O
of	O
life	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
Vagal	O
nerve	O
and	O
pylorus	O
-	O
preserving	O
nearly	O
total	O
gastrectomy	O
reconstructed	O
by	O
interposition	O
of	O
a	O
jejunal	O
J	O
pouch	O
(	O
hereinafter	O
called	O
NTGP	O
)	O
is	O
a	O
function	O
-	O
preserving	O
operation	O
for	O
early	O
gastric	B
cancer	I
.	O

However	O
,	O
some	O
patients	O
after	O
NTGP	O
have	O
suffered	O
from	O
postprandial	O
food	O
stasis	O
in	O
the	O
substitute	O
stomach	O
,	O
and	O
postprandial	O
stasis	O
leads	O
to	O
abdominal	B
symptoms	I
.	O

To	O
clarify	O
the	O
clinical	O
effect	O
of	O
mosapride	O
citrate	O
(	O
hereinafter	O
called	O
MS	O
)	O
for	O
prevention	O
of	O
food	O
stasis	O
in	O
the	O
substitute	O
stomach	O
for	O
patients	O
after	O
NTGP	O
,	O
we	O
studied	O
the	O
clinical	O
effects	O
of	O
MS	O
before	O
and	O
after	O
administration	O
of	O
MS	O
.	O

METHODOLOGY	O
:	O
In	O
a	O
total	O
of	O
24	O
patients	O
(	O
18	O
males	O
,	O
6	O
females	O
;	O
aged	O
44	O
-	O
70	O
years	O
,	O
average	O
58.1	O
years	O
)	O
during	O
5	O
years	O
after	O
NTGP	O
for	O
early	O
gastric	B
cancer	I
(	O
D1	O
lymph	O
node	O
dissection	O
,	O
curability	O
A	O
)	O
,	O
the	O
relationship	O
between	O
their	O
postoperative	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
and	O
emptying	O
function	O
of	O
the	O
substitute	O
stomach	O
(	O
hereinafter	O
called	O
EFS	O
)	O
was	O
compared	O
using	O
a	O
radioisotope	O
method	O
before	O
MS	O
therapy	O
and	O
after	O
MS	O
therapy	O
at	O
an	O
oral	O
dose	O
of	O
15	O
mg	O
/	O
day	O
for	O
3	O
months	O
.	O

RESULTS	O
:	O
The	O
interviews	O
showd	O
that	O
after	O
MS	O
therapy	O
,	O
patients	O
had	O
more	O
evident	O
appetite	O
and	O
ate	O
more	O
food	O
with	O
a	O
slight	O
increase	O
in	O
body	O
weight	O
(	O
0.52	O
Kg	O
)	O
compared	O
with	O
patients	O
before	O
MS	O
therapy	O
.	O

Before	O
and	O
after	O
MS	O
therapy	O
,	O
patients	O
had	O
no	O
early	O
dumping	O
symtoms	O
,	O
while	O
patients	O
after	O
MS	O
therapy	O
clearly	O
had	O
fewer	O
symptoms	O
such	O
as	O
reflux	B
esophagitis	I
,	O
nausea	B
,	O
and	O
abdominal	B
pain	I
compared	O
with	O
before	O
MS	O
therapy	O
.	O

After	O
MS	O
therapy	O
,	O
patients	O
also	O
had	O
significantly	O
decreased	O
abdominal	B
fullness	I
compared	O
with	O
before	O
MS	O
therapy	O
(	O
p	O
=	O
0.0046	O
)	O
.	O

Endoscopically	O
,	O
we	O
found	O
reflux	B
esophagitis	I
in	O
4	O
patients	O
before	O
MS	O
therapy	O
but	O
in	O
no	O
patients	O
after	O
MS	O
therapy	O
.	O

All	O
patients	O
before	O
MS	O
therapy	O
showed	O
residual	O
contents	O
in	O
the	O
substitute	O
stomach	O
,	O
but	O
only	O
10	O
patients	O
after	O
MS	O
therapy	O
showed	O
residual	O
contents	O
in	O
the	O
substitute	O
stomach	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
before	O
and	O
after	O
MS	O
therapy	O
(	O
p	O
=	O
0.0016	O
)	O
.	O

Regarding	O
EFS	O
,	O
the	O
time	O
to	O
50	O
%	O
residual	O
rate	O
before	O
MS	O
therapy	O
(	O
98.7	O
+	O
/	O
-	O
13.0	O
min	O
)	O
was	O
significantly	O
slower	O
than	O
that	O
after	O
MS	O
therapy	O
(	O
83.2	O
+	O
/	O
-	O
13.8	O
min	O
)	O
(	O
p	O
=	O
0.0134	O
)	O
.	O

After	O
MS	O
therapy	O
(	O
37.0	O
+	O
/	O
-	O
4.9	O
%	O
)	O
,	O
the	O
residual	O
rates	O
at	O
120	O
minutes	O
were	O
significantly	O
decreased	O
compared	O
with	O
patients	O
before	O
MS	O
therapy	O
(	O
44.8	O
+	O
/	O
-	O
5.3	O
%	O
)	O
(	O
p	O
=	O
0.0028	O
)	O
.	O

Patients	O
after	O
MS	O
therapy	O
clearly	O
had	O
improved	O
stasis	O
of	O
substitute	O
stomach	O
compared	O
with	O
before	O
MS	O
therapy	O
.	O

CONCLUSIONS	O
:	O
It	O
was	O
considered	O
that	O
MS	O
therapy	O
subsequently	O
improves	O
abdominal	B
fullness	I
due	O
to	O
the	O
postprandial	O
food	O
stasis	O
in	O
the	O
substitute	O
stomach	O
,	O
contributing	O
to	O
the	O
improvement	O
of	O
QOL	O
of	O
patients	O
after	O
NTGP	O
.	O

Current	O
regulatory	O
toxicology	O
perspectives	O
on	O
the	O
development	O
of	O
herbal	O
medicines	O
to	O
prescription	O
drug	O
products	O
in	O
the	O
United	O
States	O
.	O

Toxicological	O
studies	O
constitute	O
an	O
essential	O
part	O
of	O
the	O
effort	O
in	O
developing	O
an	O
herbal	O
medicine	O
into	O
a	O
drug	O
product	O
.	O

The	O
US	O
food	O
and	O
drug	O
administration	O
(	O
FDA	O
)	O
published	O
a	O
guidance	O
to	O
assist	O
academic	O
and	O
industry	O
sponsors	O
in	O
the	O
development	O
of	O
this	O
unique	O
group	O
of	O
drug	O
products	O
,	O
and	O
has	O
recently	O
approved	O
an	O
new	O
drug	O
application	O
(	O
NDA	O
)	O
based	O
on	O
green	O
tea	O
extract	O
(	O
Veregen	O
)	O
for	O
topical	O
treatment	O
of	O
genital	O
and	O
perianal	B
warts	I
.	O

In	O
this	O
article	O
,	O
current	O
regulatory	O
views	O
on	O
issues	O
related	O
to	O
requirements	O
and	O
recommendations	O
on	O
various	O
types	O
of	O
nonclinical	O
toxicity	O
studies	O
in	O
support	O
of	O
clinical	O
trials	O
and	O
filing	O
an	O
NDA	O
for	O
a	O
herbal	O
medicine	O
,	O
including	O
pharm	O
/	O
tox	O
aspects	O
of	O
green	O
tea	O
extract	O
(	O
Veregen	O
)	O
NDA	O
,	O
are	O
discussed	O
.	O

Topics	O
include	O
nonclinical	O
pharmacology	O
/	O
toxicology	O
perspectives	O
on	O
herbal	O
nomenclature	O
and	O
its	O
identification	O
,	O
previous	O
human	O
experience	O
and	O
initial	O
clinical	O
trial	O
proposal	O
,	O
regulatory	O
aspects	O
of	O
acute	B
toxicity	I
studies	O
,	O
chronic	B
toxicity	I
studies	O
,	O
mutagenicity	B
studies	O
,	O
reproductive	B
toxicity	I
studies	O
,	O
and	O
carcinogenicity	B
studies	O
on	O
botanicals	O
.	O

Certain	O
regulatory	O
review	O
-	O
related	O
issues	O
are	O
also	O
presented	O
.	O

It	O
is	O
anticipated	O
that	O
through	O
a	O
proactive	O
two	O
-	O
way	O
communication	O
between	O
the	O
Agency	O
and	O
the	O
sponsor	O
,	O
toxicological	O
development	O
of	O
botanical	O
drug	O
product	O
can	O
be	O
significantly	O
facilitated	O
.	O

Effect	O
of	O
fluticasone	O
propionate	O
/	O
salmeterol	O
(	O
250	O
/	O
50	O
microg	O
)	O
or	O
salmeterol	O
(	O
50	O
microg	O
)	O
on	O
COPD	B
exacerbations	I
.	O

OBJECTIVES	O
:	O
COPD	B
exacerbations	I
are	O
associated	O
with	O
significant	O
morbidity	O
and	O
mortality	O
.	O

This	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
-	O
group	O
,	O
multicenter	O
study	O
evaluated	O
the	O
effect	O
of	O
fluticasone	O
propionate	O
/	O
salmeterol	O
250	O
/	O
50	O
and	O
salmeterol	O
50	O
microg	O
twice	O
daily	O
on	O
moderate	O
to	O
severe	O
exacerbations	O
.	O

METHODS	O
:	O
Patients	O
received	O
standardized	O
treatment	O
with	O
fluticasone	O
propionate	O
/	O
salmeterol	O
250	O
/	O
50	O
during	O
a	O
1	O
-	O
month	O
run	O
-	O
in	O
,	O
followed	O
by	O
randomization	O
to	O
fluticasone	O
propionate	O
/	O
salmeterol	O
250	O
/	O
50	O
or	O
salmeterol	O
for	O
12	O
months	O
.	O

Moderate	O
to	O
severe	O
exacerbations	O
were	O
defined	O
as	O
worsening	O
symptoms	O
of	O
COPD	B
requiring	O
treatment	O
with	O
oral	O
corticosteroids	O
,	O
antibiotics	O
,	O
or	O
hospitalization	O
.	O

RESULTS	O
:	O
In	O
782	O
patients	O
with	O
COPD	B
(	O
mean	O
FEV	O
(	O
1	O
)	O
=	O
0.94	O
+	O
/	O
-	O
0.36	O
L	O
,	O
33	O
%	O
predicted	O
normal	O
)	O
,	O
treatment	O
with	O
fluticasone	O
propionate	O
/	O
salmeterol	O
250	O
/	O
50	O
significantly	O
reduced	O
(	O
1	O
)	O
the	O
annual	O
rate	O
of	O
moderate	O
to	O
severe	O
exacerbations	O
by	O
30.5	O
%	O
compared	O
with	O
salmeterol	O
(	O
1.06	O
and	O
1.53	O
per	O
subject	O
per	O
year	O
,	O
respectively	O
,	O
p	O
<	O
0.001	O
)	O
,	O
(	O
2	O
)	O
the	O
risk	O
of	O
time	O
to	O
first	O
exacerbation	O
by	O
25	O
%	O
(	O
hazard	O
ratio	O
=	O
0.750	O
,	O
p	O
=	O
0.003	O
)	O
and	O
(	O
3	O
)	O
the	O
annual	O
rate	O
of	O
exacerbations	O
requiring	O
oral	O
corticosteroids	O
by	O
40	O
%	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Clinical	O
improvements	O
observed	O
during	O
run	O
-	O
in	O
treatment	O
with	O
fluticasone	O
propionate	O
/	O
salmeterol	O
250	O
/	O
50	O
were	O
better	O
maintained	O
over	O
12	O
months	O
with	O
fluticasone	O
propionate	O
/	O
salmeterol	O
250	O
/	O
50	O
than	O
salmeterol	O
.	O

Adverse	O
events	O
were	O
reported	O
for	O
a	O
similar	O
percentage	O
of	O
subjects	O
across	O
groups	O
.	O

A	O
higher	O
reporting	O
of	O
pneumonia	B
was	O
observed	O
with	O
fluticasone	O
propionate	O
/	O
salmeterol	O
250	O
/	O
50	O
than	O
salmeterol	O
(	O
7	O
%	O
vs.	O
4	O
%	O
)	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
fluticasone	O
propionate	O
/	O
salmeterol	O
250	O
/	O
50	O
is	O
more	O
effective	O
than	O
salmeterol	O
at	O
reducing	O
the	O
rate	O
of	O
moderate	O
to	O
severe	O
exacerbations	O
over	O
1	O
year	O
.	O

The	O
benefits	O
of	O
this	O
reduction	O
relative	O
to	O
the	O
risk	O
of	O
a	O
higher	O
incidence	O
of	O
reported	O
pneumonia	B
should	O
be	O
considered	O
.	O

This	O
study	O
supports	O
the	O
use	O
of	O
fluticasone	O
propionate	O
/	O
salmeterol	O
250	O
/	O
50	O
for	O
the	O
reduction	O
of	O
COPD	B
exacerbations	I
in	O
patients	O
with	O
COPD	B
.	O

Do	O
doctors	O
discuss	O
fertility	O
issues	O
before	O
they	O
treat	O
young	O
patients	O
with	O
cancer	B
?	O

BACKGROUND	O
:	O
Many	O
children	O
treated	O
for	O
cancer	B
are	O
at	O
risk	O
of	O
infertility	B
,	O
but	O
for	O
girls	O
and	O
prepubertal	O
boys	O
,	O
all	O
fertility	O
preservation	O
techniques	O
remain	O
experimental	O
.	O

We	O
have	O
assessed	O
UK	O
practice	O
relating	O
to	O
information	O
provision	O
about	O
the	O
effects	O
of	O
cancer	B
treatment	O
on	O
fertility	O
and	O
options	O
for	O
fertility	O
preservation	O
.	O

METHODS	O
:	O
Paediatric	O
oncologists	O
prospectively	O
completed	O
a	O
data	O
form	O
for	O
each	O
new	O
patient	O
registered	O
over	O
a	O
12	O
month	O
period	O
.	O

RESULTS	O
:	O
Data	O
were	O
available	O
on	O
1030	O
patients	O
(	O
68	O
%	O
of	O
total	O
registered	O
)	O
.	O

The	O
effect	O
of	O
cancer	B
treatment	O
on	O
fertility	O
was	O
discussed	O
with	O
63	O
%	O
of	O
patients	O
.	O

Of	O
these	O
,	O
61	O
%	O
were	O
judged	O
to	O
be	O
at	O
high	O
or	O
medium	O
risk	O
of	O
fertility	O
problems	O
.	O

Discussions	O
took	O
place	O
more	O
commonly	O
with	O
boys	O
than	O
girls	O
;	O
the	O
commonest	O
reason	O
for	O
discussion	O
not	O
occurring	O
was	O
young	O
age	O
.	O

The	O
majority	O
(	O
83	O
%	O
)	O
of	O
post	O
-	O
pubertal	O
boys	O
assessed	O
as	O
high	O
/	O
medium	O
risk	O
of	O
infertility	B
were	O
referred	O
for	O
semen	O
cryopreservation	O
.	O

This	O
rate	O
fell	O
to	O
39	O
%	O
of	O
those	O
in	O
early	O
puberty	O
.	O

Only	O
1	O
%	O
(	O
n	O
=	O
4	O
)	O
of	O
girls	O
were	O
referred	O
to	O
an	O
assisted	O
conception	O
unit	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
indicate	O
a	O
high	O
awareness	O
of	O
the	O
potential	O
adverse	O
effects	O
of	O
therapy	O
on	O
fertility	O
among	O
UK	O
paediatric	O
oncologists	O
.	O

High	O
referral	O
rates	O
for	O
older	O
boys	O
indicate	O
that	O
current	O
guidelines	O
are	O
followed	O
,	O
but	O
there	O
is	O
a	O
need	O
for	O
fertility	O
preservation	O
techniques	O
for	O
girls	O
and	O
younger	O
boys	O
.	O

Triplet	O
combination	O
of	O
gemcitabine	O
,	O
paclitaxel	O
,	O
and	O
carboplatin	O
followed	O
by	O
maintenance	O
5	O
-	O
fluorouracil	O
and	O
folinic	O
acid	O
in	O
patients	O
with	O
metastatic	B
nasopharyngeal	I
carcinoma	I
.	O

BACKGROUND	O
:	O
Nasopharyngeal	B
carcinoma	I
(	O
NPC	B
)	O
is	O
a	O
disease	O
that	O
is	O
highly	O
responsive	O
to	O
various	O
chemotherapeutic	O
agents	O
.	O

In	O
the	O
metastatic	O
setting	O
,	O
2	O
-	O
drug	O
combination	O
chemotherapy	O
generally	O
provides	O
a	O
response	O
rate	O
of	O
55	O
%	O
to	O
75	O
%	O
,	O
and	O
median	O
survival	O
of	O
10	O
to	O
12	O
months	O
.	O

The	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
of	O
a	O
3	O
-	O
drug	O
combination	O
followed	O
by	O
maintenance	O
treatment	O
in	O
patients	O
with	O
metastatic	B
NPC	I
.	O

METHODS	O
:	O
Patients	O
with	O
metastatic	B
NPC	I
were	O
treated	O
with	O
a	O
combination	O
of	O
gemcitabine	O
at	O
a	O
dose	O
of	O
1,000	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
paclitaxel	O
at	O
a	O
dose	O
of	O
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
and	O
carboplatin	O
at	O
an	O
area	O
under	O
the	O
concentration	O
-	O
time	O
-	O
curve	O
(	O
AUC	O
)	O
of	O
2.5	O
on	O
Days	O
1	O
and	O
8	O
every	O
21	O
days	O
.	O

Patients	O
who	O
achieved	O
partial	O
or	O
complete	O
response	O
continued	O
to	O
receive	O
weekly	O
5	O
-	O
fluorouracil	O
at	O
a	O
dose	O
of	O
450	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
leucovorin	O
at	O
a	O
dose	O
of	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
48	O
weeks	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
eight	O
patients	O
were	O
recruited	O
.	O

Twenty	O
-	O
two	O
(	O
79	O
%	O
)	O
patients	O
had	O
>	O
or	O
=	O
2	O
sites	O
of	O
disease	O
.	O

Toxicities	O
were	O
mainly	O
from	O
bone	B
marrow	I
suppression	I
,	O
with	O
79	O
%	O
grade	O
3	O
/	O
4	O
neutropenia	B
,	O
32	O
%	O
grade	O
3	O
/	O
4	O
anemia	B
,	O
and	O
29	O
%	O
grade	O
3	O
/	O
4	O
thrombocytopenia	B
(	O
according	O
to	O
the	O
National	O
Cancer	B
Institute	O
Common	O
Toxicity	O
Criteria	O
)	O
.	O

The	O
overall	O
response	O
rate	O
to	O
the	O
3	O
-	O
drug	O
regimen	O
was	O
86	O
%	O
,	O
with	O
a	O
complete	O
response	O
rate	O
of	O
11	O
%	O
.	O

The	O
median	O
duration	O
of	O
response	O
was	O
8	O
months	O
and	O
the	O
median	O
overall	O
survival	O
was	O
22	O
months	O
.	O

CONCLUSIONS	O
:	O
This	O
regimen	O
of	O
a	O
3	O
-	O
drug	O
combination	O
followed	O
by	O
maintenance	O
is	O
feasible	O
and	O
has	O
demonstrated	O
an	O
encouraging	O
response	O
rate	O
and	O
overall	O
survival	O
.	O

Zebrafish	O
whole	O
-	O
adult	O
-	O
organism	O
chemogenomics	O
for	O
large	O
-	O
scale	O
predictive	O
and	O
discovery	O
chemical	O
biology	O
.	O

The	O
ability	O
to	O
perform	O
large	O
-	O
scale	O
,	O
expression	O
-	O
based	O
chemogenomics	O
on	O
whole	O
adult	O
organisms	O
,	O
as	O
in	O
invertebrate	O
models	O
(	O
worm	O
and	O
fly	O
)	O
,	O
is	O
highly	O
desirable	O
for	O
a	O
vertebrate	O
model	O
but	O
its	O
feasibility	O
and	O
potential	O
has	O
not	O
been	O
demonstrated	O
.	O

We	O
performed	O
expression	O
-	O
based	O
chemogenomics	O
on	O
the	O
whole	O
adult	O
organism	O
of	O
a	O
vertebrate	O
model	O
,	O
the	O
zebrafish	O
,	O
and	O
demonstrated	O
its	O
potential	O
for	O
large	O
-	O
scale	O
predictive	O
and	O
discovery	O
chemical	O
biology	O
.	O

Focusing	O
on	O
two	O
classes	O
of	O
compounds	O
with	O
wide	O
implications	O
to	O
human	O
health	O
,	O
polycyclic	O
(	O
halogenated	O
)	O
aromatic	O
hydrocarbons	O
[	O
P	O
(	O
H	O
)	O
AHs	O
]	O
and	O
estrogenic	O
compounds	O
(	O
ECs	O
)	O
,	O
we	O
generated	O
robust	O
prediction	O
models	O
that	O
can	O
discriminate	O
compounds	O
of	O
the	O
same	O
class	O
from	O
those	O
of	O
different	O
classes	O
in	O
two	O
large	O
independent	O
experiments	O
.	O

The	O
robust	O
expression	O
signatures	O
led	O
to	O
the	O
identification	O
of	O
biomarkers	O
for	O
potent	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AHR	O
)	O
and	O
estrogen	O
receptor	O
(	O
ER	O
)	O
agonists	O
,	O
respectively	O
,	O
and	O
were	O
validated	O
in	O
multiple	O
targeted	O
tissues	O
.	O

Knowledge	O
-	O
based	O
data	O
mining	O
of	O
human	O
homologs	O
of	O
zebrafish	O
genes	O
revealed	O
highly	O
conserved	O
chemical	O
-	O
induced	O
biological	O
responses	O
/	O
effects	O
,	O
health	O
risks	O
,	O
and	O
novel	O
biological	O
insights	O
associated	O
with	O
AHR	O
and	O
ER	O
that	O
could	O
be	O
inferred	O
to	O
humans	O
.	O

Thus	O
,	O
our	O
study	O
presents	O
an	O
effective	O
,	O
high	O
-	O
throughput	O
strategy	O
of	O
capturing	O
molecular	O
snapshots	O
of	O
chemical	O
-	O
induced	O
biological	O
states	O
of	O
a	O
whole	O
adult	O
vertebrate	O
that	O
provides	O
information	O
on	O
biomarkers	O
of	O
effects	O
,	O
deregulated	O
signaling	O
pathways	O
,	O
and	O
possible	O
affected	O
biological	O
functions	O
,	O
perturbed	O
physiological	O
systems	O
,	O
and	O
increased	O
health	O
risks	O
.	O

These	O
findings	O
place	O
zebrafish	O
in	O
a	O
strategic	O
position	O
to	O
bridge	O
the	O
wide	O
gap	O
between	O
cell	O
-	O
based	O
and	O
rodent	O
models	O
in	O
chemogenomics	O
research	O
and	O
applications	O
,	O
especially	O
in	O
preclinical	O
drug	O
discovery	O
and	O
toxicology	O
.	O

Recent	O
developments	O
in	O
the	O
treatment	O
of	O
aggressive	O
non	B
-	I
Hodgkin	I
lymphoma	I
.	O

SUMMARY	O
:	O
Options	O
for	O
treating	O
aggressive	O
non	B
-	I
Hodgkin	I
lymphoma	I
(	O
NHL	B
)	O
have	O
expanded	O
in	O
recent	O
years	O
.	O

In	O
phase	O
3	O
clinical	O
trials	O
,	O
giving	O
rituximab	O
with	O
cyclophosphamide	O
,	O
vincristine	O
,	O
doxorubicin	O
,	O
and	O
prednisone	O
(	O
CHOP	O
)	O
every	O
3	O
weeks	O
(	O
R	O
-	O
CHOP	O
-	O
21	O
)	O
has	O
been	O
associated	O
with	O
improved	O
survival	O
,	O
without	O
increased	O
toxicity	O
,	O
in	O
all	O
patient	O
groups	O
studied	O
.	O

Giving	O
dose	O
-	O
dense	O
CHOP	O
-	O
-	O
CHOP	O
every	O
2	O
weeks	O
(	O
CHOP	O
-	O
14	O
)	O
-	O
-	O
has	O
also	O
proved	O
appropriate	O
for	O
all	O
patients	O
18	O
-	O
75	O
years	O
old	O
.	O

Studies	O
combining	O
these	O
approaches	O
-	O
-	O
dose	O
-	O
dense	O
CHOP	O
with	O
rituximab	O
(	O
R	O
-	O
CHOP	O
-	O
14	O
)	O
-	O
-	O
have	O
shown	O
improved	O
survival	O
over	O
CHOP	O
-	O
14	O
in	O
patients	O
60	O
-	O
81	O
years	O
old	O
.	O

These	O
results	O
also	O
indicate	O
the	O
importance	O
of	O
delivering	O
chemotherapy	O
at	O
full	O
dose	O
and	O
on	O
schedule	O
,	O
which	O
can	O
improve	O
survival	O
in	O
aggressive	O
NHL	B
.	O

Effective	O
delivery	O
of	O
dose	O
-	O
dense	O
regimens	O
requires	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
support	O
,	O
which	O
should	O
also	O
be	O
considered	O
for	O
standard	O
CHOP	O
.	O

A	O
key	O
question	O
for	O
the	O
future	O
is	O
whether	O
R	O
-	O
CHOP	O
-	O
14	O
is	O
superior	O
to	O
R	O
-	O
CHOP	O
-	O
21	O
.	O

Considerations	O
on	O
the	O
physiopathological	O
mechanism	O
of	O
inner	B
ear	I
damage	I
induced	O
by	O
intravenous	O
cocaine	O
abuse	O
:	O
cues	O
from	O
a	O
case	O
report	O
.	O

OBJECTIVE	O
:	O
Aim	O
of	O
the	O
following	O
paper	O
is	O
to	O
discuss	O
about	O
the	O
possible	O
etiopathogenetic	O
mechanisms	O
of	O
inner	B
ear	I
damage	I
induced	O
by	O
cocaine	O
abuse	O
.	O

Unfortunately	O
the	O
data	O
concerning	O
this	O
topic	O
are	O
very	O
limited	O
;	O
the	O
authors	O
are	O
then	O
presenting	O
a	O
literature	O
review	O
,	O
also	O
discussing	O
the	O
clinical	O
presentation	O
and	O
the	O
possible	O
therapeutical	O
approach	O
of	O
a	O
clinical	O
case	O
of	O
bilateral	B
sudden	I
sensorineural	I
hearing	I
loss	I
following	O
i	O
.	O

v	O
.	O

injection	O
of	O
cocaine	O
.	O

PATIENTS	O
:	O
Case	O
report	O
.	O

INTERVENTION	O
:	O
A	O
strictly	O
audiological	O
evaluation	O
has	O
been	O
performed	O
,	O
in	O
order	O
to	O
identify	O
the	O
cochlear	O
lesion	O
site	O
(	O
s	O
)	O
and	O
to	O
provide	O
the	O
best	O
medical	O
treatment	O
.	O

CONCLUSIONS	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
acute	B
cocaine	I
intoxication	I
with	O
sudden	O
bilateral	B
hearing	I
loss	I
.	O

Further	O
studies	O
are	O
required	O
in	O
order	O
to	O
understand	O
the	O
effects	O
of	O
these	O
substances	O
on	O
the	O
inner	O
ear	O
cells	O
and	O
metabolism	O
.	O

Adjuvant	O
therapy	O
with	O
pegylated	O
interferon	O
alfa	O
-	O
2b	O
versus	O
observation	O
alone	O
in	O
resected	O
stage	O
III	O
melanoma	B
:	O
final	O
results	O
of	O
EORTC	O
18991	O
,	O
a	O
randomised	O
phase	O
III	O
trial	O
.	O

BACKGROUND	O
:	O
Any	O
benefit	O
of	O
adjuvant	O
interferon	O
alfa	O
-	O
2b	O
for	O
melanoma	B
could	O
depend	O
on	O
dose	O
and	O
duration	O
of	O
treatment	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
whether	O
pegylated	O
interferon	O
alfa	O
-	O
2b	O
can	O
facilitate	O
prolonged	O
exposure	O
while	O
maintaining	O
tolerability	O
.	O

METHODS	O
:	O
1256	O
patients	O
with	O
resected	O
stage	O
III	O
melanoma	B
were	O
randomly	O
assigned	O
to	O
observation	O
(	O
n	O
=	O
629	O
)	O
or	O
pegylated	O
interferon	O
alfa	O
-	O
2b	O
(	O
n	O
=	O
627	O
)	O
6	O
mug	O
/	O
kg	O
per	O
week	O
for	O
8	O
weeks	O
(	O
induction	O
)	O
then	O
3	O
mug	O
/	O
kg	O
per	O
week	O
(	O
maintenance	O
)	O
for	O
an	O
intended	O
duration	O
of	O
5	O
years	O
.	O

Randomisation	O
was	O
stratified	O
for	O
microscopic	O
(	O
N1	O
)	O
versus	O
macroscopic	O
(	O
N2	O
)	O
nodal	O
involvement	O
,	O
number	O
of	O
positive	O
nodes	O
,	O
ulceration	O
and	O
tumour	O
thickness	O
,	O
sex	O
,	O
and	O
centre	O
.	O

Randomisation	O
was	O
done	O
with	O
a	O
minimisation	O
technique	O
.	O

The	O
primary	O
endpoint	O
was	O
recurrence	O
-	O
free	O
survival	O
.	O

Analyses	O
were	O
done	O
by	O
intention	O
to	O
treat	O
.	O

This	O
study	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O

gov	O
,	O
number	O
NCT00006249	O
.	O

FINDINGS	O
:	O
All	O
randomised	O
patients	O
were	O
included	O
in	O
the	O
primary	O
efficacy	O
analysis	O
.	O

608	O
patients	O
in	O
the	O
interferon	O
group	O
and	O
613	O
patients	O
in	O
the	O
observation	O
group	O
were	O
included	O
in	O
safety	O
analyses	O
.	O

The	O
median	O
length	O
of	O
treatment	O
with	O
pegylated	O
interferon	O
alfa	O
-	O
2b	O
was	O
12	O
(	O
IQR	O
3.8	O
-	O
33.4	O
)	O
months	O
.	O

At	O
3.8	O
(	O
3.2	O
-	O
4.2	O
)	O
years	O
median	O
follow	O
-	O
up	O
,	O
328	O
recurrence	O
events	O
had	O
occurred	O
in	O
the	O
interferon	O
group	O
compared	O
with	O
368	O
in	O
the	O
observation	O
group	O
(	O
hazard	O
ratio	O
0.82	O
,	O
95	O
%	O
CI	O
0.71	O
-	O
0.96	O
;	O
p	O
=	O
0.01	O
)	O
;	O
the	O
4	O
-	O
year	O
rate	O
of	O
recurrence	O
-	O
free	O
survival	O
was	O
45.6	O
%	O
(	O
SE	O
2.2	O
)	O
in	O
the	O
interferon	O
group	O
and	O
38.9	O
%	O
(	O
2.2	O
)	O
in	O
the	O
observation	O
group	O
.	O

There	O
was	O
no	O
difference	O
in	O
overall	O
survival	O
between	O
the	O
groups	O
.	O

Grade	O
3	O
adverse	O
events	O
occurred	O
in	O
246	O
(	O
40	O
%	O
)	O
patients	O
in	O
the	O
interferon	O
group	O
and	O
60	O
(	O
10	O
%	O
)	O
in	O
the	O
observation	O
group	O
;	O
grade	O
4	O
adverse	O
events	O
occurred	O
in	O
32	O
(	O
5	O
%	O
)	O
patients	O
in	O
the	O
interferon	O
group	O
and	O
14	O
(	O
2	O
%	O
)	O
in	O
the	O
observation	O
group	O
.	O

In	O
the	O
interferon	O
group	O
,	O
the	O
most	O
common	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
were	O
fatigue	B
(	O
97	O
patients	O
,	O
16	O
%	O
)	O
,	O
hepatotoxicity	B
(	O
66	O
,	O
11	O
%	O
)	O
,	O
and	O
depression	B
(	O
39	O
,	O
6	O
%	O
)	O
.	O

Treatment	O
with	O
pegylated	O
interferon	O
alfa	O
-	O
2b	O
was	O
discontinued	O
because	O
of	O
toxicity	O
in	O
191	O
(	O
31	O
%	O
)	O
patients	O
.	O

INTERPRETATION	O
:	O
Adjuvant	O
pegylated	O
interferon	O
alfa	O
-	O
2b	O
for	O
stage	O
III	O
melanoma	B
has	O
a	O
significant	O
,	O
sustained	O
effect	O
on	O
recurrence	O
-	O
free	O
survival	O
.	O

Increased	O
damage	O
of	O
exon	O
5	O
of	O
p53	O
gene	O
in	O
workers	O
from	O
an	O
arsenic	O
plant	O
.	O

Mutagenesis	O
is	O
a	O
multistage	O
process	O
.	O

Substitution	O
mutations	O
can	O
be	O
induced	O
by	O
base	O
modified	O
through	O
alteration	O
of	O
pairing	O
property	O
.	O

Mutations	O
of	O
exon	O
5	O
and	O
8	O
of	O
p53	O
gene	O
have	O
been	O
found	O
in	O
most	O
arsenicosis	O
patients	O
with	O
precarcinomas	B
and	O
carcinomas	B
,	O
but	O
never	O
in	O
arsenicosis	O
individuals	O
without	O
precarcinomas	B
and	O
carcinomas	B
.	O

This	O
study	O
investigates	O
whether	O
base	O
modification	O
exists	O
in	O
exon	O
5	O
and	O
8	O
of	O
p53	O
gene	O
,	O
and	O
explores	O
the	O
dose	O
-	O
effect	O
relationship	O
between	O
damage	O
of	O
exon	O
5	O
of	O
p53	O
gene	O
and	O
urinary	O
arsenic	O
.	O

Concentrations	O
of	O
urinary	O
8	O
-	O
hydroxydeoxyguanine	O
(	O
8	O
-	O
OHdG	O
)	O
are	O
analyzed	O
to	O
identify	O
the	O
occurrence	O
of	O
DNA	O
damage	O
.	O

The	O
real	O
-	O
time	O
PCR	O
developed	O
by	O
Sikorsky	O
et	O
al.	O
is	O
applied	O
to	O
detect	O
base	O
modification	O
in	O
exon	O
5	O
and	O
8	O
of	O
p53	O
gene	O
for	O
apparently	O
healthy	O
participants	O
.	O

Our	O
results	O
show	O
that	O
the	O
mean	O
total	O
arsenic	O
concentrations	O
of	O
two	O
exposed	O
groups	O
from	O
an	O
arsenic	O
plant	O
are	O
significantly	O
elevated	O
compared	O
with	O
the	O
control	O
group	O
,	O
and	O
the	O
damage	O
level	O
of	O
exon	O
5	O
of	O
the	O
high	O
-	O
exposed	O
group	O
is	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
,	O
but	O
which	O
does	O
not	O
happen	O
in	O
exon	O
8	O
.	O

The	O
closely	O
correlation	O
between	O
the	O
damage	O
index	O
of	O
exon	O
5	O
and	O
urinary	O
organic	O
arsenic	O
concentration	O
are	O
found	O
.	O

Concentration	O
of	O
8	O
-	O
OHdG	O
of	O
the	O
high	O
-	O
exposed	O
group	O
is	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
.	O

These	O
results	O
imply	O
that	O
base	O
modification	O
in	O
exon	O
5	O
of	O
p53	O
gene	O
can	O
be	O
induced	O
by	O
arsenic	O
.	O

In	O
addition	O
,	O
our	O
study	O
suggests	O
that	O
the	O
damage	O
level	O
of	O
exon	O
5	O
is	O
a	O
useful	O
biomarker	O
to	O
assess	O
adverse	O
health	O
effect	O
levels	O
caused	O
by	O
chronic	O
exposure	O
to	O
arsenic	O
.	O

Effect	O
of	O
linezolid	O
against	O
postneurosurgical	B
meningitis	I
caused	O
by	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
epidermidis	O
:	O
case	O
report	O
.	O

A	O
67	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
twice	O
previously	O
undergone	O
operations	O
for	O
a	O
tuberculum	B
sellae	I
meningioma	I
was	O
admitted	O
to	O
hospital	O
for	O
further	O
treatment	O
.	O

After	O
the	O
third	O
surgical	O
intervention	O
,	O
the	O
patient	O
developed	O
persistent	O
low	O
-	O
grade	O
fever	B
and	O
impaired	B
consciousness	I
.	O

Computed	O
tomography	O
,	O
1	O
week	O
after	O
surgery	O
,	O
showed	O
postsurgical	B
hydrocephalus	I
.	O

Cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
studies	O
revealed	O
high	O
intracranial	O
pressure	O
(	O
above	O
30	O
cm	O
H2O	O
)	O
,	O
and	O
increased	O
cell	O
count	O
(	O
1232	O
/	O
3	O
)	O
.	O

One	O
week	O
after	O
the	O
ventricular	O
drainage	O
,	O
coagulase	O
-	O
negative	O
Staphylococcus	O
epidermidis	O
was	O
recovered	O
from	O
his	O
CSF	O
,	O
and	O
antimicrobial	O
susceptibility	O
results	O
indicated	O
that	O
the	O
organism	O
was	O
methicillin	O
-	O
resistant	O
.	O

After	O
14	O
days	O
of	O
intravenous	O
vancomycin	O
(	O
VCM	O
)	O
administration	O
failed	O
,	O
linezolid	O
(	O
LZD	O
)	O
was	O
initialized	O
intravenously	O
,	O
resulting	O
in	O
a	O
resolution	O
of	O
the	O
meningitis	B
.	O

After	O
a	O
ventriculoperitoneal	O
shunt	O
procedure	O
was	O
performed	O
,	O
LZD	O
was	O
continued	O
orally	O
,	O
which	O
resulted	O
in	O
a	O
cure	O
.	O

CSF	O
penetration	O
by	O
VCM	O
is	O
reported	O
to	O
be	O
poor	O
,	O
i.e.	O
,	O
approximately	O
10	O
%	O
of	O
serum	O
concentration	O
,	O
which	O
may	O
explain	O
its	O
lack	O
of	O
efficacy	O
.	O

In	O
this	O
case	O
,	O
the	O
penetration	O
of	O
LZD	O
into	O
the	O
CSF	O
was	O
58.9	O
%	O
of	O
the	O
peak	O
value	O
and	O
133	O
%	O
of	O
the	O
trough	O
value	O
of	O
serum	O
concentrations	O
.	O

LZD	O
must	O
be	O
considered	O
one	O
of	O
the	O
first	O
-	O
line	O
treatments	O
against	O
surgical	B
-	I
site	I
infection	I
in	O
neurosurgery	O
caused	O
by	O
methicillin	O
-	O
resistant	O
Staphylococci	O
.	O

Ibuprofen	O
slow	O
-	O
release	O
foam	O
dressing	O
reduces	O
wound	B
pain	I
in	O
painful	O
exuding	O
wounds	O
:	O
preliminary	O
findings	O
from	O
an	O
international	O
real	O
-	O
life	O
study	O
.	O

BACKGROUND	O
:	O
Wound	B
pain	I
is	O
a	O
serious	O
problem	O
for	O
people	O
with	O
chronic	B
wounds	I
.	O

The	O
aim	O
of	O
this	O
real	O
-	O
life	O
study	O
was	O
to	O
compare	O
the	O
effect	O
of	O
a	O
foam	O
dressing	O
that	O
releases	O
ibuprofen	O
(	O
Biatain	O
Ibu	O
)	O
with	O
local	O
best	O
practice	O
on	O
the	O
treatment	O
of	O
painful	B
exuding	I
wounds	I
.	O

METHODS	O
:	O
A	O
total	O
of	O
185	O
patients	O
with	O
painful	B
exuding	I
wounds	I
were	O
randomized	O
to	O
either	O
ibuprofen	O
foam	O
treatment	O
(	O
n	O
=	O
98	O
)	O
or	O
local	O
best	O
practice	O
(	O
n	O
=	O
87	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
pain	B
relief	O
over	O
7	O
days	O
of	O
treatment	O
,	O
assessed	O
daily	O
using	O
a	O
5	O
-	O
point	O
verbal	O
rating	O
scale	O
(	O
no	O
relief	O
,	O
slight	O
relief	O
,	O
moderate	O
relief	O
,	O
lots	O
of	O
relief	O
,	O
and	O
complete	O
relief	O
)	O
.	O

Secondary	O
endpoints	O
included	O
a	O
total	O
reduction	O
in	O
pain	B
intensity	O
for	O
the	O
whole	O
study	O
period	O
(	O
using	O
an	O
11	O
-	O
point	O
Numeric	O
Box	O
Scale	O
:	O
0	O
=	O
no	O
pain	B
to	O
10	O
=	O
worst	O
possible	O
pain	B
)	O
and	O
incidence	O
of	O
adverse	O
events	O
(	O
AEs	O
)	O
.	O

RESULTS	O
:	O
More	O
patients	O
in	O
the	O
ibuprofen	O
foam	O
treatment	O
group	O
reported	O
wound	B
pain	I
relief	O
and	O
lower	O
wound	B
pain	I
intensity	O
values	O
after	O
7	O
days	O
(	O
p	O
<	O
0.0001	O
for	O
both	O
variables	O
)	O
.	O

Within	O
the	O
four	O
most	O
common	O
ulcer	B
aetiolgies	I
,	O
patients	O
reported	O
significantly	O
more	O
effective	O
pain	B
relief	O
with	O
ibuprofen	O
foam	O
treatment	O
(	O
venous	O
:	O
p	O
=	O
0.009	O
,	O
mixed	O
arterial	O
venous	O
:	O
p	O
<	O
0.0001	O
,	O
arterial	O
:	O
p	O
=	O
0.0009	O
,	O
and	O
vasculitis	B
:	O
p	O
=	O
0.009	O
)	O
.	O

In	O
all	O
groups	O
,	O
patients	O
from	O
the	O
ibuprofen	O
foam	O
group	O
reported	O
lower	O
pain	B
intensities	O
.	O

The	O
results	O
were	O
significant	O
for	O
patients	O
with	O
venous	O
(	O
p	O
<	O
0.002	O
)	O
and	O
arterial	O
(	O
p	O
<	O
0.0001	O
)	O
leg	B
ulcers	I
.	O

Two	O
AEs	O
were	O
reported	O
.	O

CONCLUSIONS	O
:	O
The	O
ibuprofen	O
foam	O
represents	O
an	O
effective	O
and	O
safe	O
alternative	O
to	O
local	O
best	O
practice	O
in	O
the	O
management	O
of	O
painful	B
exuding	I
wounds	I
.	O

Dose	O
intensive	O
melphalan	O
and	O
cyclophosphamide	O
with	O
autologous	O
hematopoietic	O
stem	O
cells	O
for	O
recurrent	B
medulloblastoma	I
or	O
germinoma	B
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
response	O
,	O
toxicity	O
,	O
and	O
survival	O
for	O
children	O
with	O
progressive	O
or	O
recurrent	B
medulloblastoma	I
and	O
germinoma	B
using	O
a	O
single	O
myeloablative	O
course	O
of	O
chemotherapy	O
supported	O
by	O
autologous	O
hematopoietic	O
stem	O
cells	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Subjects	O
were	O
in	O
second	O
remission	O
or	O
had	O
minimal	O
residual	O
disease	O
at	O
the	O
time	O
of	O
study	O
entry	O
.	O

The	O
conditioning	O
regimen	O
consisted	O
of	O
cyclophosphamide	O
6,000	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
melphalan	O
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
nine	O
evaluable	O
pediatric	O
patients	O
were	O
accrued	O
.	O

The	O
most	O
frequent	O
major	O
toxicities	O
were	O
myelosuppression	B
,	O
infections	B
,	O
and	O
stomatitis	B
,	O
but	O
no	O
toxic	O
deaths	O
were	O
recorded	O
.	O

Best	O
responses	O
were	O
:	O
CR	O
=	O
6	O
,	O
CCR	O
=	O
13	O
,	O
PR	O
=	O
6	O
,	O
SD	O
=	O
2	O
,	O
and	O
PD	O
=	O
2	O
.	O

There	O
were	O
6	O
medulloblastoma	B
and	O
3	O
germinoma	B
survivors	O
with	O
a	O
median	O
follow	O
-	O
up	O
of	O
7.5	O
years	O
(	O
range	O
=	O
2.8	O
-	O
10	O
)	O
.	O

Two	O
germinoma	B
survivors	O
received	O
radiotherapy	O
after	O
autografting	O
for	O
presumptive	O
progressive	O
disease	O
.	O

CONCLUSION	O
:	O
Myeloablative	O
chemotherapy	O
consisting	O
of	O
cyclophosphamide	O
and	O
melphalan	O
was	O
tolerable	O
in	O
the	O
relapsed	B
brain	I
tumor	I
setting	O
with	O
19	O
/	O
29	O
cases	O
achieving	O
CR	O
or	O
CCR	O
status	O
and	O
9	O
/	O
29	O
becoming	O
long	O
-	O
term	O
survivors	O
.	O

Bisphosphonate	O
-	O
induced	O
necrosis	B
of	I
the	I
jaws	I
:	O
a	O
reconstructive	O
nightmare	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
Bisphosphonates	O
are	O
used	O
for	O
the	O
management	O
of	O
metastatic	B
bone	I
disease	I
,	O
prevention	O
and	O
treatment	O
of	O
osteoporosis	B
and	O
Paget	B
's	I
disease	I
of	O
bone	O
.	O

An	O
increasing	O
number	O
of	O
reports	O
have	O
associated	O
the	O
use	O
of	O
bisphosphonates	O
with	O
the	O
occurrence	O
of	O
osteoradionecrosis	B
of	I
the	I
jaw	I
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
summarize	O
the	O
recent	O
literature	O
in	O
this	O
area	O
,	O
specifically	O
focusing	O
on	O
its	O
management	O
.	O

RECENT	O
FINDINGS	O
:	O
Osteoradionecrosis	B
of	I
the	I
jaw	I
mostly	O
results	O
from	O
the	O
use	O
of	O
intravenous	O
bisphosphonates	O
for	O
metastatic	B
bone	I
disease	I
and	O
multiple	B
myeloma	I
;	O
cases	O
from	O
oral	O
treatment	O
for	O
osteoporosis	B
and	O
Paget	B
's	I
disease	I
have	O
also	O
been	O
reported	O
.	O

It	O
mostly	O
affects	O
the	O
posterior	O
maxilla	O
,	O
followed	O
by	O
the	O
posterior	O
mandible	O
.	O

In	O
more	O
than	O
half	O
of	O
the	O
affected	O
patients	O
,	O
there	O
has	O
been	O
preceding	O
dental	B
trauma	I
or	O
procedure	O
.	O

Many	O
treatment	O
modalities	O
have	O
been	O
attempted	O
in	O
order	O
to	O
limit	O
disease	O
progression	O
.	O

Conservative	O
management	O
with	O
antibiotic	O
therapy	O
and	O
mouthwashes	O
seems	O
to	O
be	O
most	O
beneficial	O
.	O

Surgery	O
should	O
be	O
reserved	O
for	O
refractory	O
and	O
symptomatic	O
cases	O
.	O

SUMMARY	O
:	O
It	O
is	O
important	O
for	O
the	O
reconstructive	O
head	O
and	O
neck	O
surgeon	O
to	O
recognize	O
the	O
clinical	O
presentation	O
of	O
bisphosphonate	O
-	O
induced	O
osteoradionecrosis	B
of	I
the	I
jaw	I
and	O
the	O
role	O
of	O
conservative	O
management	O
in	O
consistently	O
achieving	O
good	O
results	O
.	O

Aging	O
and	O
infectious	B
diseases	I
:	O
workshop	O
on	O
HIV	B
infection	I
and	O
aging	O
:	O
what	O
is	O
known	O
and	O
future	O
research	O
directions	O
.	O

Highly	O
active	O
antiretroviral	O
treatment	O
has	O
resulted	O
in	O
dramatically	O
increased	O
life	O
expectancy	O
among	O
patients	O
with	O
HIV	B
infection	I
who	O
are	O
now	O
aging	O
while	O
receiving	O
treatment	O
and	O
are	O
at	O
risk	O
of	O
developing	O
chronic	B
diseases	I
associated	O
with	O
advanced	O
age	O
.	O

Similarities	O
between	O
aging	O
and	O
the	O
courses	O
of	O
human	B
immunodeficiency	I
virus	I
(	I
HIV	I
)	I
infection	I
and	O
acquired	B
immunodeficiency	I
syndrome	I
suggest	O
that	O
HIV	B
infection	I
compresses	O
the	O
aging	O
process	O
,	O
perhaps	O
accelerating	O
comorbidities	B
and	O
frailty	B
.	O

In	O
a	O
workshop	O
organized	O
by	O
the	O
Association	O
of	O
Specialty	O
Professors	O
,	O
the	O
Infectious	B
Diseases	I
Society	O
of	O
America	O
,	O
the	O
HIV	O
Medical	O
Association	O
,	O
the	O
National	O
Institute	O
on	O
Aging	O
,	O
and	O
the	O
National	O
Institute	O
on	O
Allergy	B
and	O
Infectious	B
Diseases	I
,	O
researchers	O
in	O
infectious	B
diseases	I
,	O
geriatrics	O
,	O
immunology	O
,	O
and	O
gerontology	O
met	O
to	O
review	O
what	O
is	O
known	O
about	O
HIV	B
infection	I
and	O
aging	O
,	O
to	O
identify	O
research	O
gaps	O
,	O
and	O
to	O
suggest	O
high	O
priority	O
topics	O
for	O
future	O
research	O
.	O

Answers	O
to	O
the	O
questions	O
posed	O
are	O
likely	O
to	O
help	O
prioritize	O
and	O
balance	O
strategies	O
to	O
slow	O
the	O
progression	O
of	O
HIV	B
infection	I
,	O
to	O
address	O
comorbidities	O
and	O
drug	B
toxicity	I
,	O
and	O
to	O
enhance	O
understanding	O
about	O
both	O
HIV	B
infection	I
and	O
aging	O
.	O

Interactive	O
transport	O
,	O
subcellular	O
relocation	O
and	O
enhanced	O
phototoxicity	B
of	O
hypericin	O
encapsulated	O
in	O
guanidinylated	O
liposomes	O
via	O
molecular	O
recognition	O
.	O

Hypericin	O
(	O
HYP	O
)	O
,	O
a	O
photocytotoxic	O
phenanthroperylenquinone	O
was	O
encapsulated	O
in	O
liposomes	O
outfitted	O
with	O
guanidinium	O
-	O
bearing	O
lipids	O
to	O
ensure	O
efficient	O
cell	O
binding	O
through	O
molecular	O
recognition	O
with	O
anionic	O
groups	O
resident	O
on	O
the	O
plasma	O
membrane	O
.	O

The	O
uptake	O
of	O
HYP	O
encapsulated	O
in	O
these	O
liposomes	O
by	O
DU145	O
human	O
prostate	O
cancer	O
cells	O
,	O
was	O
studied	O
employing	O
fluorescence	O
,	O
versus	O
nonguadinylated	O
liposomes	O
and	O
free	O
HYP	O
.	O

The	O
subcellular	O
localization	O
was	O
in	O
all	O
cases	O
studied	O
by	O
confocal	O
microscopy	O
employing	O
specific	O
subcellular	O
organelle	O
probes	O
.	O

The	O
photocytotoxicity	O
of	O
HYP	O
was	O
assessed	O
,	O
24	O
h	O
following	O
irradiation	O
with	O
15	O
mWcm	O
(	O
-	O
2	O
)	O
light	O
through	O
a	O
GG	O
495	O
Schott	O
filter	O
,	O
by	O
a	O
standard	O
tetrazolium	O
to	O
formazan	O
assay	O
(	O
XTT	O
)	O
.	O

HYP	O
uptake	O
by	O
DU145	O
cells	O
was	O
found	O
to	O
be	O
profoundly	O
enhanced	O
by	O
using	O
guanidinylated	O
liposomes	O
.	O

Also	O
the	O
distance	O
of	O
the	O
guanidinium	O
group	O
from	O
the	O
liposomal	O
surface	O
was	O
found	O
to	O
significantly	O
affect	O
HYP	O
loading	O
,	O
subcellular	O
localization	O
and	O
phototoxicity	B
.	O

The	O
two	O
different	O
modes	O
of	O
liposome	O
cell	O
internalization	O
observed	O
,	O
i.e.	O
plasma	O
membrane	O
fusion	O
and	O
endocytosis	O
,	O
were	O
found	O
to	O
greatly	O
affect	O
the	O
phototoxicity	B
of	O
HYP	O
.	O

Molecular	O
recognition	O
was	O
overall	O
appraised	O
as	O
a	O
promising	O
,	O
novel	O
route	O
for	O
photodynamic	O
therapy	O
,	O
profoundly	O
enhancing	O
its	O
efficacy	O
.	O

HYP	O
encapsulated	O
in	O
liposomes	O
-	O
bearing	O
guanidinium	O
groups	O
was	O
more	O
efficiently	O
taken	O
up	O
by	O
cells	O
,	O
leading	O
to	O
enhanced	O
phototoxicity	B
,	O
in	O
contrast	O
to	O
HYP	O
encapsulated	O
in	O
their	O
nonguanidinylated	O
counterparts	O
.	O

Histone	O
deacetylase	O
inhibitors	O
:	O
mechanism	O
of	O
action	O
and	O
therapeutic	O
use	O
in	O
cancer	B
.	O

Histone	O
deacetylases	O
(	O
HDACs	O
)	O
remove	O
the	O
acetyl	O
groups	O
of	O
lysine	O
residues	O
of	O
histone	O
tails	O
leading	O
to	O
chromatin	O
compaction	O
and	O
transcriptional	O
repression	O
.	O

In	O
addition	O
,	O
HDACs	O
can	O
also	O
influence	O
transcription	O
-	O
independent	O
events	O
such	O
as	O
mitosis	O
or	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
repair	O
and	O
deacetylate	O
nonhistone	O
proteins	O
involved	O
in	O
cell	O
proliferation	O
and	O
death	O
,	O
altering	O
their	O
function	O
.	O

Histone	O
deacetylase	O
inhibitors	O
(	O
HDACi	O
)	O
constitute	O
a	O
promising	O
treatment	O
for	O
cancer	B
therapy	O
due	O
to	O
their	O
low	O
toxicity	O
.	O

HDACi	O
have	O
been	O
shown	O
to	O
induce	O
differentiation	O
,	O
cell	O
-	O
cycle	O
arrest	O
,	O
and	O
apoptosis	O
and	O
to	O
inhibit	O
migration	O
,	O
invasion	O
,	O
and	O
angiogenesis	O
in	O
many	O
cancer	O
cell	O
lines	O
.	O

In	O
addition	O
,	O
these	O
compounds	O
inhibit	O
tumor	O
growth	O
in	O
animal	O
models	O
and	O
show	O
antitumor	O
activity	O
in	O
patients	O
.	O

HDACi	O
alone	O
and	O
in	O
combination	O
with	O
a	O
variety	O
of	O
anticancer	O
drugs	O
are	O
being	O
tested	O
in	O
clinical	O
trials	O
,	O
showing	O
significant	O
anticancer	O
activity	O
both	O
in	O
hematological	O
and	O
solid	O
tumors	O
.	O

SAHA	O
(	O
vorinostat	O
,	O
Zolinza	O
)	O
was	O
the	O
first	O
HDACi	O
approved	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
to	O
enter	O
the	O
clinical	O
oncology	O
market	O
for	O
treating	O
cutaneous	B
T	I
-	I
cell	I
lymphoma	I
(	O
CTCL	B
)	O
and	O
is	O
being	O
tested	O
for	O
other	O
malignancies	B
.	O

Angio	B
-	I
oedema	I
as	O
an	O
unusual	O
tolerable	O
side	O
effect	O
of	O
voriconazole	O
therapy	O
.	O

Voriconazole	O
(	O
VRC	O
)	O
has	O
not	O
previously	O
been	O
reported	O
to	O
cause	O
angio	B
-	I
oedema	I
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
angio	B
-	I
oedema	I
associated	O
with	O
VRC	O
therapy	O
.	O

A	O
37	O
-	O
year	O
-	O
old	O
woman	O
with	O
relapsing	O
invasive	O
vertebral	O
aspergillosis	B
received	O
intravenous	O
VRC	O
and	O
developed	O
angio	O
-	O
oedema	O
10	O
days	O
after	O
starting	O
therapy	O
.	O

This	O
condition	O
rapidly	O
diminished	O
after	O
administration	O
of	O
intravenous	O
antihistaminics	O
and	O
did	O
not	O
necessitate	O
cessation	O
of	O
VRC	O
treatment	O
.	O

The	O
treatment	O
was	O
continued	O
for	O
6	O
months	O
without	O
recurrence	O
of	O
the	O
symptoms	O
.	O

After	O
18	O
months	O
,	O
the	O
patient	O
was	O
in	O
good	O
health	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
angio	B
-	I
oedema	I
associated	O
with	O
VRC	O
.	O

A	O
comparison	O
of	O
two	O
orally	O
bioavailable	O
anti	O
-	O
cancer	O
agents	O
,	O
IRC	O
-	O
110160	O
and	O
STX140	O
.	O

This	O
study	O
characterises	O
two	O
recently	O
developed	O
anticancer	O
agents	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
2	O
-	O
methoxyoestra	O
-	O
1,3,5	O
(	O
10	O
)	O
,	O
16	O
-	O
tetraene	O
-	O
3	O
-	O
carboxamide	O
(	O
IRC	O
-	O
110160	O
)	O
and	O
STX140	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Hormone	O
-	O
dependent	O
(	O
MCF	O
-	O
7	O
)	O
,	O
hormone	O
-	O
independent	O
(	O
MDA	O
-	O
MB	O
-	O
231	O
)	O
and	O
P	O
-	O
glycoprotein	O
overexpressing	O
(	O
MCF	O
-	O
7Dox	O
)	O
cells	O
were	O
used	O
for	O
proliferation	O
experiments	O
.	O

For	O
the	O
tumour	O
efficacy	O
studies	O
,	O
female	O
nude	O
mice	O
were	O
inoculated	O
with	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

RESULTS	O
:	O
IRC	O
-	O
110160	O
is	O
a	O
potent	O
inhibitor	O
of	O
both	O
MCF	O
-	O
7	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
cell	O
proliferation	O
.	O

Furthermore	O
,	O
the	O
potency	O
of	O
IRC	O
-	O
110160	O
was	O
unaffected	O
by	O
the	O
over	O
-	O
expression	O
of	O
the	O
P	O
-	O
glycoprotein	O
drug	O
efflux	O
pump	O
.	O

IRC	O
-	O
110160	O
and	O
2	O
-	O
methoxyoestradiol	O
-	O
3,17	O
-	O
O	O
,	O
O	O
-	O
bis	O
-	O
sulfamate	O
(	O
STX140	O
)	O
induced	O
apoptosis	O
in	O
a	O
similar	O
timeframe	O
in	O
the	O
MDA	O
-	O
MB	O
-	O
231	O
cell	O
line	O
,	O
but	O
only	O
STX140	O
caused	O
G2	O
/	O
M	O
arrest	O
in	O
these	O
cells	O
.	O

In	O
the	O
MDA	O
-	O
MB	O
-	O
231	O
xenograft	O
model	O
300	O
mg	O
/	O
kg	O
p	O
.	O

o	O
.	O

(	O
daily	O
)	O
of	O
IRC	O
-	O
110160	O
and	O
20	O
mg	O
/	O
kg	O
p	O
.	O

o	O
.	O

STX140	O
(	O
daily	O
)	O
both	O
completely	O
inhibited	O
tumour	B
growth	O
;	O
however	O
some	O
toxicity	O
was	O
observed	O
with	O
IRC	O
-	O
110160	O
.	O

After	O
28	O
days	O
of	O
daily	O
dosing	O
STX140	O
(	O
20	O
mg	O
/	O
kg	O
p	O
.	O

o	O
.	O
)	O
had	O
minimal	O
effect	O
on	O
the	O
white	O
blood	O
population	O
of	O
mice	O
with	O
tumours	B
.	O

The	O
masking	O
of	O
STX140	O
from	O
white	O
blood	O
cells	O
may	O
be	O
due	O
to	O
its	O
interaction	O
with	O
carbonic	O
anhydrase	O
II	O
(	O
CAII	O
)	O
in	O
the	O
red	O
blood	O
cells	O
.	O

In	O
contrast	O
to	O
STX140	O
,	O
IRC	O
-	O
110160	O
does	O
not	O
inhibit	O
CAII	O
.	O

These	O
studies	O
highlight	O
the	O
activity	O
of	O
two	O
orally	O
bioavailable	O
anti	O
-	O
cancer	O
agents	O
one	O
of	O
which	O
,	O
STX140	O
,	O
may	O
offer	O
a	O
significant	O
clinical	O
advantage	O
over	O
existing	O
drugs	O
as	O
a	O
common	O
dose	O
limiting	O
factor	O
,	O
haemotoxicity	B
,	O
may	O
be	O
minimised	O
.	O

The	O
impact	O
of	O
olanzapine	O
on	O
tardive	B
dyskinetic	I
symptoms	I
in	O
a	O
state	O
hospital	O
population	O
.	O

BACKGROUND	O
:	O
Tardive	B
dyskinesia	I
is	O
a	O
serious	O
adverse	O
event	O
,	O
which	O
is	O
associated	O
mainly	O
with	O
the	O
use	O
of	O
the	O
first	O
-	O
generation	O
antipsychotic	O
agents	O
.	O

Convergent	O
data	O
from	O
clinical	O
trials	O
suggest	O
that	O
second	O
-	O
generation	O
antipsychotic	O
agents	O
are	O
less	O
likely	O
to	O
cause	O
tardive	B
dyskinesia	I
.	O

However	O
,	O
the	O
data	O
with	O
regard	O
to	O
the	O
effect	O
of	O
switching	O
from	O
first	O
-	O
to	O
second	O
-	O
generation	O
antipsychotic	O
agents	O
on	O
pre	O
-	O
existing	O
dyskinetic	O
symptoms	O
during	O
routine	O
clinical	O
care	O
is	O
sparse	O
.	O

METHODS	O
:	O
Sixty	O
-	O
three	O
patients	O
with	O
DSM	B
-	I
IV	I
schizophrenia	I
or	O
schizoaffective	B
disorder	I
(	O
n	O
=	O
61	O
)	O
or	O
bipolar	B
I	I
disorder	I
(	O
n	O
=	O
2	O
)	O
consecutively	O
admitted	O
to	O
a	O
state	O
hospital	O
,	O
who	O
were	O
treated	O
either	O
with	O
olanzapine	O
(	O
n	O
=	O
35	O
)	O
or	O
conventional	O
antipsychotic	O
agents	O
(	O
n	O
=	O
28	O
)	O
by	O
physician	O
choice	O
,	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

The	O
severity	O
and	O
frequency	O
of	O
tardive	B
dyskinetic	I
symptoms	I
using	O
the	O
Abnormal	B
Involuntary	I
Movement	I
Scale	O
were	O
assessed	O
in	O
the	O
two	O
medication	O
groups	O
at	O
baseline	O
,	O
8	O
weeks	O
,	O
and	O
6	O
months	O
.	O

RESULTS	O
:	O
There	O
were	O
statistically	O
significant	O
reductions	O
in	O
the	O
prevalence	O
and	O
severity	O
of	O
dyskinetic	B
symptoms	I
at	O
8	O
weeks	O
and	O
6	O
months	O
for	O
the	O
group	O
treated	O
with	O
olanzapine	O
but	O
not	O
for	O
those	O
treated	O
with	O
conventional	O
agents	O
.	O

CONCLUSIONS	O
:	O
These	O
preliminary	O
data	O
suggest	O
that	O
olanzapine	O
may	O
be	O
a	O
treatment	O
option	O
for	O
subjects	O
with	O
tardive	B
dyskinesia	I
.	O

However	O
,	O
the	O
question	O
whether	O
olanzapine	O
treats	O
,	O
ameliorates	O
,	O
or	O
masks	O
preexisting	O
tardive	B
dyskinesia	I
was	O
difficult	O
to	O
answer	O
,	O
as	O
no	O
dosage	O
reduction	O
or	O
withdrawal	O
was	O
undertaken	O
.	O

Hydrogen	O
peroxide	O
induces	O
heme	O
oxygenase	O
-	O
1	O
and	O
dentin	O
sialophosphoprotein	O
mRNA	O
in	O
human	O
pulp	O
cells	O
.	O

Although	O
the	O
induction	O
of	O
heme	O
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
by	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
has	O
been	O
reported	O
,	O
the	O
HO	O
-	O
1	O
and	O
odontoblastic	O
differentiation	O
-	O
inducing	O
effects	O
against	O
H2O2	O
have	O
not	O
been	O
clarified	O
in	O
human	O
pulp	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
HO	O
-	O
1	O
is	O
involved	O
in	O
the	O
protective	O
mechanisms	O
against	O
the	O
cytotoxic	O
effects	O
of	O
H2O2	O
by	O
using	O
a	O
cell	O
viability	O
assay	O
,	O
and	O
we	O
examined	O
the	O
production	O
of	O
dentin	O
sialophosphoprotein	O
(	O
DSPP	O
)	O
and	O
other	O
mineralization	O
markers	O
by	O
using	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
in	O
human	O
pulp	O
cells	O
.	O

H2O2	O
decreased	O
cell	O
viability	O
but	O
increased	O
HO	O
-	O
1	O
and	O
DSPP	O
expression	O
in	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Antioxidants	O
and	O
inhibitors	O
of	O
HO	O
-	O
1	O
,	O
phosphatidylinositol	O
-	O
3	O
'	O
-	O
kinase	O
,	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
,	O
and	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
blocked	O
H2O2	O
-	O
induced	O
cytotoxicity	O
and	O
the	O
expression	O
of	O
HO	O
-	O
1	O
and	O
DSPP	O
mRNA	O
in	O
pulp	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
the	O
induction	O
of	O
HO	O
-	O
1	O
by	O
H2O2	O
in	O
pulp	O
cells	O
plays	O
a	O
protective	O
role	O
against	O
the	O
cytotoxic	O
effects	O
of	O
H2O2	O
and	O
stimulates	O
DSPP	O
expression	O
,	O
resulting	O
in	O
premature	O
odontoblast	O
differentiation	O
through	O
pathways	O
that	O
involve	O
phosphatidylinositol	O
-	O
3	O
'	O
-	O
kinase	O
,	O
p38	O
,	O
and	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
.	O

A	O
phase	O
II	O
trial	O
of	O
gemcitabine	O
plus	O
capecitabine	O
for	O
metastatic	B
renal	I
cell	I
cancer	I
previously	O
treated	O
with	O
immunotherapy	O
and	O
targeted	O
agents	O
.	O

PURPOSE	O
:	O
We	O
assessed	O
the	O
clinical	O
activity	O
and	O
safety	O
of	O
gemcitabine	O
plus	O
capecitabine	O
in	O
patients	O
with	O
metastatic	B
renal	I
cell	I
cancer	I
previously	O
treated	O
with	O
immunotherapy	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
In	O
this	O
phase	O
II	O
trial	O
patients	O
received	O
1,000	O
mg	O
/	O
m	O
(	O
2	O
)	O
gemcitabine	O
intravenously	O
on	O
days	O
1	O
,	O
8	O
and	O
15	O
,	O
plus	O
830	O
mg	O
/	O
m	O
(	O
2	O
)	O
capecitabine	O
orally	O
twice	O
daily	O
on	O
days	O
1	O
to	O
21	O
of	O
28	O
-	O
day	O
cycles	O
.	O

The	O
primary	O
end	O
point	O
was	O
progression	O
-	O
free	O
survival	O
time	O
.	O

Secondary	O
end	O
points	O
included	O
overall	O
survival	O
time	O
,	O
objective	O
response	O
rate	O
and	O
toxicity	O
.	O

RESULTS	O
:	O
Of	O
84	O
patients	O
enrolled	O
83	O
were	O
evaluable	O
for	O
response	O
and	O
toxicity	O
.	O

A	O
total	O
of	O
65	O
patients	O
had	O
intermediate	O
or	O
poor	O
risk	O
prognosis	O
.	O

Median	O
progression	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
were	O
4.6	O
(	O
95	O
%	O
CI	O
3.7	O
-	O
7.3	O
)	O
and	O
17.9	O
months	O
(	O
95	O
%	O
CI	O
13.2	O
-	O
23.6	O
)	O
,	O
respectively	O
.	O

There	O
were	O
6	O
partial	O
responses	O
and	O
1	O
complete	O
response	O
(	O
objective	O
response	O
rate	O
8.4	O
%	O
[	O
95	O
%	O
CI	O
3.5	O
-	O
16.6	O
]	O
)	O
.	O

Two	O
patients	O
remain	O
in	O
unmaintained	O
remission	O
close	O
to	O
3	O
years	O
from	O
the	O
initiation	O
of	O
gemcitabine	O
plus	O
capecitabine	O
treatment	O
.	O

On	O
multivariate	O
analysis	O
more	O
than	O
3	O
disease	O
sites	O
were	O
significantly	O
associated	O
with	O
shorter	O
progression	O
-	O
free	O
survival	O
and	O
patients	O
with	O
thrombocytosis	B
,	O
more	O
than	O
3	O
disease	O
sites	O
or	O
anemia	B
had	O
a	O
significantly	O
increased	O
risk	O
of	O
death	O
.	O

Adverse	O
events	O
occurring	O
at	O
least	O
once	O
in	O
more	O
than	O
5	O
%	O
of	O
patients	O
included	O
grade	O
3	O
or	O
greater	O
neutropenia	B
(	O
83	O
%	O
)	O
,	O
grade	O
2	O
or	O
greater	O
hand	B
-	I
foot	I
syndrome	I
(	O
13	O
%	O
)	O
,	O
grade	O
3	O
or	O
greater	O
thrombocytopenia	B
(	O
12	O
%	O
)	O
,	O
grade	O
3	O
or	O
greater	O
thromboembolic	B
events	I
(	O
8	O
%	O
)	O
,	O
grade	O
3	O
or	O
greater	O
fatigue	B
(	O
8	O
%	O
)	O
and	O
grade	O
2	O
or	O
greater	O
mucositis	B
(	O
6	O
%	O
)	O
.	O

CONCLUSIONS	O
:	O
At	O
the	O
doses	O
and	O
schedule	O
tested	O
gemcitabine	O
plus	O
capecitabine	O
demonstrated	O
modest	O
clinical	O
activity	O
in	O
metastatic	B
renal	I
cell	I
cancer	I
after	O
cytokine	O
failure	O
and	O
produced	O
significant	O
neutropenia	B
.	O

A	O
modified	O
gemcitabine	O
plus	O
capecitabine	O
regimen	O
may	O
be	O
evaluated	O
in	O
patients	O
with	O
metastatic	B
renal	I
cell	I
cancer	I
after	O
failure	O
of	O
approved	O
targeted	O
therapies	O
.	O

Pharmacological	O
interventions	O
for	O
the	O
prevention	O
of	O
relapse	O
in	O
bipolar	B
disorder	I
:	O
a	O
systematic	O
review	O
of	O
controlled	O
trials	O
.	O

We	O
conducted	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
randomised	O
and	O
quasi	O
-	O
randomised	O
controlled	O
trials	O
evaluating	O
all	O
clinically	O
relevant	O
pharmacological	O
interventions	O
for	O
the	O
prevention	O
of	O
relapse	O
in	O
people	O
with	O
bipolar	B
disorder	I
.	O

Thirty	O
-	O
four	O
trials	O
were	O
included	O
in	O
the	O
review	O
.	O

Direct	O
comparisons	O
with	O
placebo	O
and	O
with	O
lithium	O
were	O
available	O
for	O
most	O
drugs	O
.	O

In	O
addition	O
,	O
there	O
were	O
direct	O
comparisons	O
of	O
valproate	O
vs.	O
olanzapine	O
,	O
imipramine	O
vs.	O
lithium	O
plus	O
imipramine	O
,	O
olanzapine	O
plus	O
mood	O
stabilisers	O
vs.	O
mood	O
stabilisers	O
and	O
perphenazine	O
plus	O
mood	O
stabilisers	O
vs.	O
mood	O
stabilisers	O
.	O

Methodological	O
quality	O
varied	O
across	O
studies	O
and	O
the	O
strength	O
of	O
evidence	O
was	O
not	O
equal	O
for	O
all	O
treatments	O
or	O
for	O
all	O
comparisons	O
.	O

There	O
is	O
evidence	O
from	O
placebo	O
-	O
controlled	O
trials	O
for	O
the	O
efficacy	O
of	O
lithium	O
,	O
valproate	O
and	O
lamotrigine	O
as	O
maintenance	O
therapy	O
for	O
the	O
prevention	O
of	O
relapse	O
in	O
bipolar	B
disorder	I
.	O

Three	O
drugs	O
have	O
a	O
significant	O
effect	O
in	O
the	O
prevention	O
of	O
manic	B
relapses	I
(	O
lithium	O
,	O
olanzapine	O
and	O
aripiprazole	O
)	O
and	O
three	O
in	O
the	O
prevention	O
of	O
depressive	B
symptoms	I
(	O
valproate	O
,	O
lamotrigine	O
and	O
imipramine	O
)	O
.	O

Imipramine	O
is	O
little	O
used	O
in	O
practice	O
,	O
because	O
of	O
concern	O
about	O
adverse	O
effects	O
.	O

The	O
significant	O
effects	O
of	O
olanzapine	O
and	O
aripiprazole	O
were	O
demonstrated	O
in	O
selected	O
responsive	O
bipolar	O
I	O
patients	O
only	O
.	O

Despite	O
widespread	O
use	O
in	O
clinical	O
practice	O
,	O
there	O
is	O
little	O
evidence	O
to	O
support	O
the	O
efficacy	O
of	O
combination	O
therapy	O
.	O

Integrated	O
disinfection	O
by	O
-	O
products	O
research	O
:	O
assessing	O
reproductive	O
and	O
developmental	O
risks	O
posed	O
by	O
complex	O
disinfection	O
by	O
-	O
product	O
mixtures	O
.	O

This	O
article	O
presents	O
a	O
toxicologically	O
-	O
based	O
risk	O
assessment	O
strategy	O
for	O
identifying	O
the	O
individual	O
components	O
or	O
fractions	O
of	O
a	O
complex	O
mixture	O
that	O
are	O
associated	O
with	O
its	O
toxicity	O
.	O

The	O
strategy	O
relies	O
on	O
conventional	O
component	O
-	O
based	O
mixtures	O
risk	O
approaches	O
such	O
as	O
dose	O
addition	O
,	O
response	O
addition	O
,	O
and	O
analyses	O
of	O
interactions	O
.	O

Developmental	B
toxicity	I
data	O
from	O
two	O
drinking	O
-	O
water	O
concentrates	O
containing	O
disinfection	O
by	O
-	O
products	O
(	O
DBP	O
)	O
mixtures	O
were	O
used	O
to	O
illustrate	O
the	O
strategy	O
.	O

The	O
results	O
of	O
this	O
study	O
showed	O
that	O
future	O
studies	O
of	O
DBP	O
concentrates	O
using	O
the	O
Chernoff	O
-	O
Kavlock	O
bioassay	O
need	O
to	O
consider	O
evaluating	O
DBP	O
that	O
are	O
concentrated	O
more	O
than	O
130	O
-	O
fold	O
and	O
using	O
a	O
rat	O
strain	O
that	O
is	O
more	O
sensitive	O
to	O
chemically	O
-	O
induced	O
pregnancy	O
loss	O
than	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

The	O
results	O
support	O
the	O
planned	O
experimental	O
design	O
of	O
a	O
multigeneration	O
reproductive	O
and	O
developmental	O
study	O
of	O
DBP	O
concentrates	O
.	O

Finally	O
,	O
this	O
article	O
discusses	O
the	O
need	O
for	O
a	O
systematic	O
evaluation	O
of	O
DBP	O
concentrates	O
obtained	O
from	O
multiple	O
source	O
waters	O
and	O
treatment	O
types	O
.	O

The	O
development	O
of	O
such	O
a	O
database	O
could	O
be	O
useful	O
in	O
evaluating	O
whether	O
a	O
specific	O
DBP	O
concentrate	O
is	O
sufficiently	O
similar	O
to	O
tested	O
combinations	O
of	O
source	O
waters	O
and	O
treatment	O
alternatives	O
so	O
that	O
health	O
risks	O
for	O
the	O
former	O
may	O
be	O
estimated	O
using	O
data	O
on	O
the	O
latter	O
.	O

In	O
vitro	O
evaluation	O
of	O
the	O
chemoprotective	O
action	O
mechanisms	O
of	O
leontopodic	O
acid	O
against	O
aflatoxin	O
B1	O
and	O
deoxynivalenol	O
-	O
induced	O
cell	O
damage	O
.	O

Several	O
in	O
vitro	O
studies	O
showed	O
that	O
free	O
radical	O
scavengers	O
possess	O
chemopreventive	O
properties	O
against	O
mycotoxin	O
-	O
induced	O
cell	O
damage	O
which	O
are	O
at	O
least	O
partially	O
associated	O
with	O
the	O
induction	O
of	O
phase	O
II	O
detoxifying	O
enzymes	O
and	O
antioxidant	O
enzymes	O
like	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
and	O
glutathione	O
peroxidase	O
(	O
GPx	O
)	O
.	O

The	O
aim	O
of	O
this	O
project	O
was	O
to	O
study	O
the	O
chemopreventive	O
effects	O
of	O
leontopodic	O
acid	O
(	O
LA	O
)	O
,	O
a	O
potent	O
natural	O
occurring	O
free	O
radical	O
scavenger	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
Leontopodium	O
alpinum	O
.	O

Different	O
mycotoxins	O
were	O
evaluated	O
in	O
two	O
different	O
cell	O
lines	O
on	O
the	O
basis	O
of	O
their	O
specific	O
toxicity	O
:	O
aflatoxin	O
B1	O
(	O
AFB1	O
)	O
on	O
HepG2	O
cells	O
and	O
deoxynivalenol	O
(	O
DON	O
)	O
on	O
U937	O
cells	O
.	O

Cell	O
viability	O
and	O
reactive	O
oxygen	O
species	O
concentration	O
were	O
determined	O
,	O
and	O
the	O
effects	O
of	O
pre	O
-	O
treatment	O
with	O
LA	O
on	O
these	O
parameters	O
were	O
investigated	O
together	O
with	O
the	O
GST	O
and	O
GPx	O
activity	O
as	O
well	O
as	O
the	O
concentration	O
of	O
reduced	O
glutathione	O
.	O

The	O
results	O
show	O
that	O
LA	O
protects	O
U937	O
cells	O
from	O
DON	O
-	O
induced	O
cell	O
damage	O
but	O
not	O
HepG2	O
cells	O
from	O
AFB1	O
.	O

Moreover	O
LA	O
is	O
able	O
to	O
enhance	O
GPx	O
activity	O
in	O
U937	O
,	O
but	O
not	O
GST	O
activity	O
in	O
HepG2	O
.	O

We	O
hypothesize	O
that	O
the	O
increase	O
in	O
detoxifying	O
enzymes	O
is	O
probably	O
the	O
main	O
mechanism	O
of	O
antioxidant	O
mediated	O
chemoprevention	O
.	O

Identifying	O
patterns	O
of	O
adverse	O
event	O
reporting	O
for	O
four	O
members	O
of	O
the	O
angiotensin	O
II	O
receptor	O
blockers	O
class	O
of	O
drugs	O
:	O
revisiting	O
the	O
Weber	O
effect	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
evidence	O
for	O
temporal	O
reporting	O
patterns	O
,	O
such	O
as	O
the	O
Weber	O
effect	O
,	O
in	O
spontaneous	O
post	O
-	O
marketing	O
adverse	O
event	O
(	O
AE	O
)	O
reports	O
submitted	O
to	O
the	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
,	O
for	O
four	O
members	O
of	O
the	O
angiotensin	O
II	O
receptor	O
blockers	O
drug	O
class	O
(	O
ARBs	O
)	O
.	O

METHODS	O
:	O
For	O
losartan	O
,	O
valsartan	O
,	O
irbesartan	O
,	O
and	O
candesartan	O
,	O
we	O
evaluated	O
temporal	O
trends	O
in	O
reporting	O
for	O
the	O
total	O
number	O
of	O
AE	O
reports	O
,	O
serious	O
AE	O
reports	O
,	O
and	O
direct	O
reports	O
from	O
consumers	O
or	O
health	O
care	O
providers	O
(	O
direct	O
reports	O
)	O
to	O
FDA	O
.	O

Reporting	O
patterns	O
were	O
considered	O
consistent	O
with	O
the	O
Weber	O
effect	O
when	O
the	O
peak	O
occurred	O
2	O
years	O
after	O
US	O
marketing	O
and	O
the	O
number	O
of	O
reports	O
declined	O
thereafter	O
.	O

We	O
tabulated	O
the	O
number	O
of	O
reports	O
by	O
year	O
since	O
the	O
first	O
report	O
.	O

We	O
adjusted	O
the	O
total	O
number	O
of	O
reports	O
,	O
number	O
of	O
serious	O
AE	O
reports	O
,	O
and	O
number	O
of	O
direct	O
reports	O
by	O
the	O
number	O
of	O
US	O
dispensed	O
prescriptions	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
clear	O
temporal	O
reporting	O
patterns	O
for	O
the	O
total	O
number	O
of	O
reports	O
,	O
direct	O
reports	O
,	O
or	O
serious	O
AE	O
reports	O
.	O

We	O
observed	O
a	O
consistent	O
trend	O
for	O
the	O
adjusted	O
number	O
of	O
direct	O
and	O
serious	O
AE	O
reports	O
.	O

The	O
adjusted	O
number	O
was	O
highest	O
in	O
the	O
first	O
year	O
and	O
continually	O
decreased	O
over	O
time	O
for	O
all	O
four	O
ARBs	O
.	O

For	O
the	O
adjusted	O
total	O
number	O
of	O
reports	O
,	O
the	O
decline	O
was	O
not	O
constant	O
over	O
time	O
.	O

CONCLUSION	O
:	O
A	O
characteristic	O
temporal	O
pattern	O
in	O
the	O
adjusted	O
number	O
of	O
reports	O
,	O
in	O
which	O
the	O
adjusted	O
number	O
was	O
highest	O
in	O
the	O
first	O
year	O
and	O
declined	O
thereafter	O
,	O
was	O
identified	O
.	O

However	O
,	O
we	O
did	O
not	O
observe	O
a	O
pattern	O
consistent	O
with	O
the	O
Weber	O
effect	O
for	O
these	O
four	O
ARBs	O
.	O

Effects	O
of	O
stratification	O
on	O
data	O
mining	O
in	O
the	O
US	O
Vaccine	O
Adverse	O
Event	O
Reporting	O
System	O
(	O
VAERS	O
)	O
.	O

BACKGROUND	O
:	O
Vaccines	O
are	O
administered	O
differentially	O
according	O
to	O
age	O
and	O
sex	O
,	O
and	O
disease	O
patterns	O
also	O
vary	O
among	O
people	O
of	O
different	O
age	O
and	O
sex	O
groups	O
.	O

Estimates	O
of	O
disproportionality	O
should	O
be	O
calculated	O
based	O
on	O
comparisons	O
of	O
groups	O
that	O
have	O
a	O
similar	O
likelihood	O
of	O
receiving	O
similar	O
vaccines	O
and	O
experiencing	O
similar	O
adverse	O
events	O
,	O
to	O
prevent	O
false	O
disproportionality	O
from	O
occurring	O
.	O

Stratified	O
empirical	O
Bayesian	O
(	O
EB	O
)	O
methods	O
have	O
been	O
compared	O
with	O
crude	O
,	O
but	O
not	O
stratified	O
,	O
proportional	O
reporting	O
ratios	O
(	O
PRRs	O
)	O
in	O
their	O
performance	O
on	O
adverse	O
event	O
data	O
.	O

OBJECTIVES	O
:	O
(	O
i	O
)	O
to	O
implement	O
stratification	O
of	O
PRR	O
;	O
(	O
ii	O
)	O
to	O
quantify	O
and	O
compare	O
vaccine	O
-	O
event	O
pairs	O
that	O
are	O
highlighted	O
by	O
PRR	O
and	O
EB05	O
(	O
the	O
lower	O
bound	O
of	O
the	O
90	O
%	O
CI	O
of	O
the	O
EB	O
geometric	O
mean	O
)	O
,	O
for	O
both	O
crude	O
and	O
stratified	O
;	O
and	O
(	O
iii	O
)	O
to	O
evaluate	O
the	O
effects	O
of	O
stratification	O
by	O
age	O
and	O
sex	O
,	O
in	O
identifying	O
adverse	O
events	O
that	O
are	O
accepted	O
to	O
be	O
caused	O
by	O
vaccines	O
.	O

METHODS	O
:	O
We	O
applied	O
EB	O
and	O
PRR	O
data	O
mining	O
methods	O
to	O
data	O
from	O
the	O
US	O
Vaccine	O
Adverse	O
Event	O
Reporting	O
System	O
(	O
VAERS	O
)	O
.	O

We	O
stratified	O
PRR	O
and	O
EB05	O
by	O
age	O
and	O
sex	O
.	O

To	O
study	O
the	O
effects	O
of	O
stratification	O
,	O
we	O
compared	O
the	O
crude	O
PRR	O
and	O
stratified	O
PRR	O
.	O

We	O
also	O
assessed	O
the	O
crude	O
EB05	O
and	O
stratified	O
EB05	O
,	O
and	O
then	O
compared	O
the	O
effects	O
of	O
stratification	O
on	O
EB05	O
and	O
PRR	O
.	O

RESULTS	O
:	O
Stratification	O
not	O
only	O
changed	O
the	O
number	O
of	O
vaccine	O
-	O
event	O
pairs	O
that	O
were	O
highlighted	O
,	O
but	O
also	O
changed	O
which	O
pairs	O
were	O
highlighted	O
.	O

There	O
were	O
283	O
vaccine	O
-	O
event	O
pairs	O
that	O
were	O
highlighted	O
by	O
the	O
crude	O
EB05	O
,	O
but	O
not	O
the	O
stratified	O
;	O
12	O
that	O
were	O
highlighted	O
by	O
the	O
stratified	O
EB05	O
,	O
but	O
not	O
the	O
crude	O
;	O
and	O
162	O
that	O
were	O
highlighted	O
by	O
both	O
.	O

Similarly	O
,	O
there	O
were	O
701	O
vaccine	O
-	O
event	O
pairs	O
that	O
were	O
highlighted	O
by	O
the	O
crude	O
PRR	O
,	O
but	O
not	O
the	O
stratified	O
;	O
139	O
that	O
were	O
highlighted	O
by	O
the	O
stratified	O
PRR	O
,	O
but	O
not	O
the	O
crude	O
;	O
and	O
895	O
that	O
were	O
highlighted	O
by	O
both	O
.	O

There	O
were	O
1466	O
vaccine	O
-	O
event	O
pairs	O
in	O
which	O
the	O
effect	O
of	O
stratification	O
was	O
different	O
for	O
EB05	O
and	O
PRR	O
.	O

CONCLUSION	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
published	O
analysis	O
using	O
stratified	O
PRRs	O
.	O

In	O
this	O
analysis	O
of	O
passive	O
surveillance	O
data	O
,	O
stratification	O
revealed	O
and	O
reduced	O
confounding	O
in	O
EB	O
and	O
PRR	O
,	O
and	O
also	O
unmasked	O
some	O
vaccine	O
-	O
event	O
pairs	O
that	O
the	O
crude	O
values	O
did	O
not	O
highlight	O
.	O

Stratification	O
should	O
be	O
applied	O
if	O
confounding	O
is	O
suspected	O
.	O

By	O
decreasing	O
the	O
total	O
number	O
of	O
highlighted	O
vaccine	O
-	O
event	O
pairs	O
,	O
stratification	O
is	O
likely	O
to	O
increase	O
efficiency	O
and	O
therefore	O
might	O
reduce	O
workload	O
.	O

A	O
systematic	O
review	O
of	O
phase	O
II	O
trials	O
of	O
thalidomide	O
/	O
dexamethasone	O
combination	O
therapy	O
in	O
patients	O
with	O
relapsed	O
or	O
refractory	B
multiple	I
myeloma	I
.	O

Thalidomide	O
monotherapy	O
in	O
relapsed	B
/	I
refractory	I
multiple	I
myeloma	I
(	O
MM	B
)	O
has	O
a	O
response	O
rate	O
of	O
30	O
%	O
.	O

The	O
combination	O
of	O
thalidomide	O
with	O
dexamethasone	O
(	O
Thal	O
/	O
Dex	O
)	O
is	O
expected	O
to	O
improve	O
responses	O
,	O
but	O
it	O
is	O
unknown	O
if	O
the	O
combination	O
increases	O
the	O
rate	O
of	O
adverse	O
events	O
.	O

Here	O
,	O
we	O
conducted	O
a	O
systematic	O
review	O
of	O
studies	O
evaluating	O
Thal	O
/	O
Dex	O
in	O
relapsed	B
/	I
refractory	I
MM	I
.	O

Twelve	O
studies	O
were	O
included	O
,	O
comprising	O
451	O
patients	O
.	O

The	O
response	O
rate	O
(	O
CR	O
and	O
PR	O
)	O
was	O
46	O
%	O
(	O
95	O
%	O
CI	O
42	O
-	O
51	O
%	O
)	O
.	O

Therapy	B
-	I
related	I
toxicity	I
was	O
comparable	O
to	O
thalidomide	O
monotherapy	O
and	O
included	O
somnolence	B
(	O
26	O
%	O
,	O
95	O
%	O
CI	O
22	O
-	O
31	O
%	O
)	O
,	O
constipation	B
(	O
37	O
%	O
,	O
95	O
%	O
CI	O
32	O
-	O
42	O
%	O
)	O
and	O
peripheral	B
neuropathy	I
(	O
27	O
%	O
,	O
95	O
%	O
CI	O
23	O
-	O
32	O
%	O
)	O
.	O

Only	O
venous	B
thromboembolism	I
appeared	O
to	O
occur	O
more	O
often	O
with	O
Thal	O
/	O
Dex	O
(	O
5	O
%	O
,	O
95	O
%	O
CI	O
3	O
-	O
8	O
%	O
)	O
.	O

Thus	O
,	O
using	O
Thal	O
/	O
Dex	O
results	O
in	O
an	O
improved	O
response	O
rate	O
in	O
relapsed	B
/	I
refractory	I
MM	I
,	O
with	O
a	O
toxicity	O
rate	O
comparable	O
to	O
thalidomide	O
monotherapy	O
.	O

Methemoglobin	O
levels	O
during	O
epidural	O
anesthesia	O
for	O
renal	O
transplantation	O
-	O
-	O
comparison	O
of	O
prilocaine	O
with	O
bupivacaine	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
One	O
goal	O
of	O
anesthesia	O
for	O
renal	O
transplantation	O
is	O
to	O
avoid	O
an	O
excess	O
load	O
to	O
be	O
imposed	O
on	O
the	O
newly	O
functioning	O
kidney	O
,	O
by	O
using	O
appropriate	O
agents	O
and	O
dosages	O
in	O
the	O
perioperative	O
management	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
prilocaine	O
on	O
serum	O
methemoglobin	O
levels	O
when	O
used	O
as	O
the	O
local	O
anesthetic	O
in	O
epidural	O
anesthesia	O
for	O
renal	O
transplantation	O
,	O
and	O
to	O
compare	O
its	O
effects	O
with	O
that	O
of	O
bupivacaine	O
,	O
which	O
is	O
the	O
standard	O
local	O
anesthetic	O
used	O
.	O

METHODS	O
:	O
26	O
adult	O
renal	O
recipients	O
were	O
randomized	O
into	O
2	O
equal	O
groups	O
according	O
to	O
the	O
local	O
anesthetic	O
used	O
for	O
epidural	O
anesthesia	O
during	O
the	O
operation	O
.	O

Patients	O
in	O
group	O
P	O
(	O
n	O
=	O
13	O
)	O
were	O
given	O
prilocaine	O
and	O
those	O
in	O
group	O
B	O
(	O
control	O
,	O
n	O
=	O
13	O
)	O
received	O
bupivacaine	O
.	O

The	O
methemoglobin	O
measurement	O
intervals	O
were	O
at	O
:	O
baseline	O
before	O
administration	O
of	O
local	O
anesthetic	O
,	O
and	O
then	O
at	O
2	O
hours	O
,	O
5	O
hours	O
,	O
and	O
12	O
hours	O
of	O
local	O
anesthetic	O
administration	O
.	O

RESULTS	O
:	O
Methemoglobin	O
levels	O
in	O
the	O
prilocaine	O
group	O
were	O
above	O
the	O
normal	O
range	O
in	O
all	O
measurements	O
other	O
than	O
baseline	O
.	O

In	O
the	O
bupivacaine	O
group	O
,	O
methemoglobin	O
levels	O
increased	O
only	O
at	O
5	O
hours	O
of	O
local	O
anesthetic	O
administration	O
.	O

However	O
,	O
methemoglobin	O
concentrations	O
and	O
hemoglobin	O
levels	O
were	O
comparable	O
between	O
the	O
two	O
groups	O
at	O
all	O
time	O
intervals	O
,	O
and	O
none	O
of	O
the	O
patients	O
demonstrated	O
clinical	O
symptoms	O
.	O

CONCLUSION	O
:	O
The	O
use	O
of	O
prilocaine	O
in	O
epidural	O
anesthesia	O
for	O
renal	O
transplantation	O
surgery	O
resulted	O
in	O
an	O
increase	O
in	O
methemoglobin	O
levels	O
,	O
which	O
did	O
not	O
cause	O
any	O
clinical	O
symptoms	O
and	O
was	O
similar	O
to	O
those	O
of	O
bupivacaine	O
at	O
all	O
time	O
measurements	O
.	O

Population	O
pharmacokinetic	O
and	O
pharmacodynamic	O
analysis	O
to	O
support	O
treatment	O
optimization	O
of	O
combination	O
chemotherapy	O
with	O
indisulam	O
and	O
carboplatin	O
.	O

AIMS	O
:	O
Indisulam	O
and	O
carboplatin	O
have	O
shown	O
synergistic	O
activity	O
in	O
preclinical	O
studies	O
.	O

In	O
a	O
dose	O
escalation	O
study	O
of	O
the	O
combination	O
,	O
a	O
treatment	O
delay	O
was	O
frequently	O
required	O
in	O
a	O
3	O
-	O
weekly	O
regimen	O
to	O
allow	O
recovery	O
from	O
myelosuppression	B
from	O
previous	O
cycles	O
.	O

A	O
4	O
-	O
weekly	O
regimen	O
was	O
better	O
tolerated	O
,	O
but	O
had	O
a	O
decreased	O
dose	O
-	O
intensity	O
which	O
may	O
compromise	O
efficacy	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
(	O
i	O
)	O
to	O
develop	O
a	O
pharmacokinetic	O
-	O
pharmacodynamic	O
(	O
PK	O
-	O
PD	O
)	O
model	O
to	O
describe	O
the	O
myelosuppressive	B
effect	I
of	O
the	O
combination	O
,	O
and	O
(	O
ii	O
)	O
to	O
use	O
this	O
model	O
to	O
select	O
a	O
dosing	O
regimen	O
for	O
Phase	O
II	O
evaluation	O
.	O

METHODS	O
:	O
Sixteen	O
patients	O
were	O
treated	O
at	O
four	O
different	O
dose	O
levels	O
of	O
indisulam	O
(	O
1	O
-	O
h	O
infusion	O
on	O
day	O
1	O
)	O
and	O
carboplatin	O
(	O
30	O
-	O
min	O
infusion	O
on	O
day	O
2	O
)	O
.	O

Pharmacokinetic	O
data	O
were	O
analysed	O
with	O
nonlinear	O
mixed	O
effects	O
modelling	O
.	O

A	O
semiphysiological	O
model	O
describing	O
chemotherapy	O
-	O
induced	O
myelosuppression	B
characterized	O
the	O
relationship	O
between	O
the	O
pharmacokinetics	O
and	O
the	O
haematological	B
toxicity	I
of	O
indisulam	O
and	O
carboplatin	O
.	O

A	O
simulation	O
study	O
was	O
performed	O
to	O
evaluate	O
the	O
tolerability	O
and	O
dose	O
-	O
intensity	O
for	O
3	O
-	O
weekly	O
and	O
4	O
-	O
weekly	O
treatment	O
regimens	O
.	O

RESULTS	O
:	O
The	O
PK	O
-	O
PD	O
model	O
described	O
the	O
pharmacokinetics	O
and	O
the	O
myelosuppressive	B
effect	I
of	O
indisulam	O
and	O
carboplatin	O
.	O

The	O
risk	O
of	O
a	O
treatment	O
delay	O
at	O
cycle	O
2	O
due	O
to	O
myelosuppression	B
was	O
unacceptably	O
high	O
(	O
34	O
-	O
65	O
%	O
)	O
in	O
a	O
3	O
-	O
weekly	O
regimen	O
for	O
various	O
dose	O
levels	O
(	O
350	O
-	O
600	O
mg	O
m	O
(	O
-	O
2	O
)	O
indisulam	O
in	O
combination	O
with	O
carboplatin	O
to	O
achieve	O
an	O
AUC	O
of	O
4	O
-	O
6	O
mg	O
min	O
(	O
-	O
1	O
)	O
ml	O
(	O
-	O
1	O
)	O
)	O
.	O

This	O
risk	O
was	O
acceptable	O
for	O
a	O
4	O
-	O
weekly	O
regimen	O
(	O
9	O
-	O
24	O
%	O
)	O
,	O
which	O
is	O
in	O
line	O
with	O
the	O
clinical	O
study	O
results	O
.	O

CONCLUSIONS	O
:	O
This	O
PK	O
-	O
PD	O
study	O
supports	O
the	O
selection	O
of	O
indisulam	O
500	O
mg	O
m	O
(	O
-	O
2	O
)	O
and	O
a	O
dose	O
of	O
carboplatin	O
to	O
achieve	O
an	O
AUC	O
of	O
6	O
mg	O
min	O
(	O
-	O
1	O
)	O
ml	O
(	O
-	O
1	O
)	O
in	O
a	O
4	O
-	O
weekly	O
regimen	O
as	O
the	O
recommended	O
dose	O
for	O
future	O
studies	O
.	O

Dioxin	O
interferes	O
in	O
chromosomal	O
positioning	O
through	O
the	O
aryl	O
hydrocarbon	O
receptor	O
.	O

Each	O
chromosome	O
occupies	O
its	O
own	O
-	O
specific	O
space	O
called	O
a	O
'	O
t	O
erritory	O
'	O
within	O
the	O
interphase	O
nucleus	O
,	O
and	O
the	O
arrangement	O
of	O
chromosome	O
territories	O
(	O
CTs	O
)	O
is	O
important	O
in	O
epigenetic	O
mechanisms	O
.	O

The	O
molecular	O
mechanism	O
to	O
determine	O
the	O
positioning	O
of	O
CTs	O
,	O
however	O
,	O
remains	O
unknown	O
.	O

On	O
the	O
other	O
hand	O
,	O
dioxin	O
is	O
known	O
to	O
be	O
the	O
typical	O
environmental	O
pollutant	O
that	O
affects	O
a	O
wide	O
variety	O
of	O
biological	O
events	O
in	O
many	O
species	O
.	O

Here	O
,	O
we	O
show	O
that	O
dioxin	O
enlarges	O
the	O
minimum	O
distance	O
between	O
chromosome	O
12	O
and	O
chromosome	O
16	O
territories	O
in	O
human	O
preadipocyte	O
cells	O
,	O
and	O
the	O
alteration	O
of	O
chromosome	O
positioning	O
is	O
canceled	O
by	O
an	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
antagonist	O
alpha	O
-	O
naphthoflavone	O
.	O

Thus	O
,	O
AhR	O
may	O
be	O
a	O
key	O
molecule	O
to	O
regulate	O
chromosome	O
positioning	O
.	O

Our	O
results	O
suggest	O
a	O
novel	O
effect	O
of	O
dioxin	B
toxicity	I
,	O
and	O
demonstrate	O
a	O
clue	O
to	O
reveal	O
the	O
novel	O
molecular	O
mechanism	O
for	O
the	O
arrangement	O
of	O
CTs	O
.	O

Radiation	O
-	O
induced	O
bystander	O
effects	O
enhanced	O
by	O
elevated	O
sodium	O
chloride	O
through	O
sensitizing	O
cells	O
to	O
bystander	O
factors	O
.	O

Radiation	O
-	O
induced	O
bystander	O
effects	O
(	O
RIBE	O
)	O
have	O
been	O
demonstrated	O
to	O
occur	O
widely	O
in	O
various	O
cell	O
lines	O
.	O

However	O
,	O
very	O
little	O
data	O
is	O
available	O
on	O
the	O
genotoxic	O
effects	O
of	O
RIBE	O
combined	O
with	O
other	O
factor	O
(	O
s	O
)	O
.	O

We	O
reported	O
previously	O
that	O
with	O
a	O
low	O
dose	O
of	O
alpha	O
-	O
particle	O
irradiation	O
,	O
the	O
fraction	O
of	O
gamma	O
-	O
H2AX	O
foci	O
-	O
positive	O
cells	O
in	O
non	O
-	O
irradiated	O
bystander	O
cells	O
was	O
significantly	O
increased	O
under	O
elevated	O
NaCl	O
culture	O
conditions	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
investigated	O
the	O
functional	O
role	O
of	O
NaCl	O
in	O
the	O
enhancement	O
of	O
RIBE	O
using	O
a	O
specially	O
designed	O
co	O
-	O
culture	O
system	O
and	O
micronucleus	O
(	O
MN	O
)	O
test	O
.	O

It	O
was	O
shown	O
that	O
the	O
MN	O
frequency	O
was	O
not	O
increased	O
significantly	O
by	O
elevated	O
NaCl	O
(	O
9.0	O
g	O
/	O
L	O
)	O
alone	O
or	O
by	O
medium	O
exposure	O
.	O

However	O
,	O
with	O
1.0	O
cGy	O
alpha	O
-	O
particle	O
irradiation	O
,	O
the	O
induced	O
MN	O
frequency	O
increased	O
significantly	O
in	O
both	O
irradiated	O
and	O
non	O
-	O
irradiated	O
bystander	O
regions	O
.	O

Additional	O
studies	O
showed	O
that	O
elevated	O
NaCl	O
made	O
the	O
non	O
-	O
irradiated	O
bystander	O
cells	O
more	O
vulnerable	O
to	O
bystander	O
factors	O
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
the	O
induced	O
MN	O
frequency	O
in	O
cells	O
both	O
in	O
irradiated	O
and	O
non	O
-	O
irradiated	O
bystander	O
regions	O
was	O
weakened	O
when	O
the	O
hypertonic	O
medium	O
was	O
changed	O
to	O
normotonic	O
medium	O
for	O
2h	O
before	O
irradiation	O
.	O

Such	O
observations	O
were	O
quite	O
similar	O
to	O
the	O
co	O
-	O
effect	O
of	O
NaCl	O
and	O
hydrogen	O
peroxide	O
(	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
)	O
,	O
indicating	O
that	O
elevated	O
NaCl	O
might	O
sensitize	O
non	O
-	O
irradiated	O
cells	O
to	O
bystander	O
factors	O
-	O
induced	O
oxidative	O
stress	O
.	O

Fragrance	O
material	O
review	O
on	O
l	O
-	O
borneol	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
l	O
-	O
borneol	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

Fragrance	O
material	O
review	O
on	O
tetrahydromuguol	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
tetrahydromuguol	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

Fragrance	O
material	O
review	O
on	O
alpha	O
-	O
bisabolol	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
alpha	O
-	O
bisabolol	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

AcylMPAG	O
plasma	O
concentrations	O
and	O
mycophenolic	B
acid	I
-	I
related	I
side	I
effects	I
in	O
patients	O
undergoing	O
renal	O
transplantation	O
are	O
not	O
related	O
to	O
the	O
UGT2B7	O
-	O
840	O
G	O
>	O
A	O
gene	O
polymorphism	O
.	O

Mycophenolic	O
acid	O
(	O
MPA	O
)	O
is	O
metabolized	O
primarily	O
by	O
glucuronidation	O
to	O
form	O
the	O
biologically	O
inactive	O
7	O
-	O
O	O
-	O
glucuronide	O
conjugate	O
(	O
MPAG	O
)	O
,	O
which	O
is	O
the	O
major	O
urinary	O
excretion	O
product	O
.	O

MPA	O
is	O
also	O
converted	O
to	O
acyl	O
-	O
glucuronide	O
metabolite	O
(	O
AcylMPAG	O
)	O
,	O
which	O
has	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
generation	O
of	O
MPA	O
-	O
related	O
adverse	O
events	O
such	O
as	O
diarrhea	B
or	O
leucopenia	B
.	O

This	O
conversion	O
of	O
MPA	O
to	O
AcylMPAG	O
is	O
catalyzed	O
by	O
UDP	O
-	O
glucuronosyltransferase	O
2B7	O
(	O
UGT2B7	O
)	O
.	O

We	O
studied	O
the	O
impact	O
of	O
the	O
-	O
840	O
G	O
>	O
A	O
polymorphisms	O
in	O
the	O
UGT2B7	O
gene	O
on	O
the	O
pharmacokinetics	O
of	O
AcylMPAG	O
.	O

We	O
also	O
investigated	O
whether	O
the	O
plasma	O
concentrations	O
of	O
AcylMPAG	O
are	O
correlated	O
with	O
MPA	B
-	I
related	I
toxicity	I
to	O
further	O
evaluate	O
its	O
potential	O
clinical	O
significance	O
.	O

In	O
a	O
randomized	O
,	O
controlled	O
trial	O
,	O
comparing	O
fixed	O
-	O
dose	O
mycophenolate	O
mofetil	O
(	O
MMF	O
)	O
with	O
concentration	O
-	O
controlled	O
MMF	O
therapy	O
,	O
patients	O
undergoing	O
renal	O
transplantation	O
were	O
treated	O
with	O
a	O
calcineurin	O
inhibitor	O
,	O
MMF	O
,	O
and	O
corticosteroids	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
332	O
patients	O
for	O
genotyping	O
.	O

In	O
all	O
patients	O
,	O
blood	O
samples	O
were	O
drawn	O
(	O
three	O
samples	O
within	O
the	O
first	O
2	O
hours	O
after	O
administration	O
)	O
on	O
Day	O
3	O
,	O
Day	O
10	O
,	O
Week	O
4	O
,	O
and	O
Months	O
3	O
,	O
6	O
,	O
and	O
12	O
to	O
measure	O
MPA	O
and	O
AcylMPAG	O
plasma	O
concentrations	O
.	O

The	O
pharmacokinetics	O
of	O
AcylMPAG	O
were	O
correlated	O
with	O
the	O
-	O
840	O
G	O
>	O
A	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
the	O
UGT2B7	O
gene	O
.	O

Heterozygosity	O
for	O
the	O
-	O
840	O
G	O
>	O
A	O
SNP	O
in	O
the	O
UGT2B7	O
gene	O
was	O
found	O
in	O
145	O
patients	O
(	O
145	O
of	O
332	O
[	O
44	O
%	O
]	O
)	O
and	O
93	O
(	O
93	O
of	O
332	O
[	O
28	O
%	O
]	O
)	O
patients	O
were	O
homozygous	O
for	O
the	O
-	O
840	O
G	O
>	O
A	O
allele	O
.	O

No	O
difference	O
was	O
found	O
in	O
the	O
dose	O
-	O
normalized	O
AcylMPAG	O
trough	O
(	O
C0	O
)	O
levels	O
and	O
dose	O
-	O
normalized	O
AcylMPAG	O
areas	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
(	O
AUCs	O
)	O
at	O
each	O
visit	O
between	O
carriers	O
and	O
noncarriers	O
of	O
the	O
-	O
840	O
G	O
>	O
A	O
SNP	O
.	O

Also	O
,	O
metabolic	O
ratios	O
,	O
expressed	O
as	O
AcylMPAG	O
/	O
MPA	O
and	O
AcylMPAG	O
/	O
MPAG	O
,	O
were	O
not	O
related	O
to	O
UGT2B7	O
genotype	O
.	O

The	O
dose	O
-	O
normalized	O
AcylMPAG	O
-	O
C0	O
and	O
AcylMPAG	O
AUC	O
were	O
higher	O
in	O
the	O
cyclosporine	O
-	O
treated	O
group	O
compared	O
with	O
the	O
tacrolimus	O
-	O
treated	O
patients	O
at	O
each	O
visit	O
.	O

There	O
was	O
no	O
difference	O
in	O
AcylMPAG	O
concentrations	O
(	O
trough	O
or	O
AUC	O
)	O
or	O
AcylMPAG	O
/	O
MPAG	O
ratio	O
between	O
patients	O
with	O
compared	O
with	O
patients	O
without	O
diarrhea	B
.	O

None	O
of	O
the	O
-	O
840	O
G	O
>	O
A	O
UGT2B7	O
SNPs	O
was	O
disproportionately	O
present	O
among	O
the	O
patients	O
with	O
diarrhea	B
.	O

There	O
was	O
a	O
higher	O
incidence	O
of	O
diarrhea	B
in	O
tacrolimus	O
-	O
treated	O
patients	O
[	O
26	O
of	O
163	O
(	O
16.0	O
%	O
)	O
]	O
compared	O
with	O
cyclosporine	O
-	O
treated	O
individuals	O
[	O
five	O
of	O
51	O
(	O
9.8	O
%	O
)	O
]	O
,	O
although	O
AcylMPAG	O
concentrations	O
were	O
lower	O
in	O
tacrolimus	O
-	O
treated	O
patients	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
found	O
no	O
influence	O
of	O
the	O
-	O
840	O
G	O
>	O
A	O
UGT2B7	O
SNP	O
on	O
AcylMPAG	O
exposure	O
in	O
patients	O
undergoing	O
renal	O
transplantation	O
.	O

There	O
also	O
was	O
no	O
association	O
between	O
this	O
variant	O
genotype	O
and	O
the	O
incidence	O
of	O
diarrhea	B
or	O
leucopenia	B
,	O
two	O
adverse	O
events	O
for	O
which	O
a	O
role	O
for	O
AcylMPAG	O
has	O
been	O
suggested	O
.	O

A	O
phase	O
I	O
trial	O
of	O
PTK787	O
/	O
ZK222584	O
in	O
combination	O
with	O
pemetrexed	O
and	O
cisplatin	O
in	O
patients	O
with	O
advanced	O
solid	B
tumors	I
.	O

Angiogenesis	O
is	O
recognized	O
as	O
an	O
important	O
biological	O
process	O
that	O
allows	O
growth	O
of	O
a	O
tumor	B
beyond	O
an	O
initial	O
small	O
size	O
.	O

PTK787	O
/	O
ZK222584	O
,	O
a	O
potent	O
orally	O
active	O
angiogenesis	O
inhibitor	O
capable	O
of	O
inhibiting	O
all	O
known	O
isoforms	O
of	O
Vascular	O
Endothelial	O
Growth	O
Factor	O
(	O
VEGF	O
)	O
receptor	O
,	O
belongs	O
to	O
the	O
class	O
of	O
aminophthalazines	O
.	O

This	O
study	O
investigated	O
a	O
combination	O
of	O
chemotherapy	O
(	O
Cisplatin	O
and	O
Pemetrexed	O
)	O
with	O
PTK787	O
/	O
ZK222584	O
.	O

Eight	O
patients	O
were	O
enrolled	O
but	O
PTK787	O
/	O
ZK222584	O
dose	O
could	O
not	O
be	O
escalated	O
as	O
planned	O
because	O
of	O
dose	B
limiting	I
toxicities	I
(	O
DLTs	B
)	O
observed	O
on	O
the	O
first	O
dose	O
level	O
.	O

Limited	O
pharmacokinetic	O
profiling	O
of	O
PTK787	O
/	O
ZK222584	O
revealed	O
no	O
evidence	O
of	O
drug	O
-	O
drug	O
interactions	O
.	O

No	O
responses	O
were	O
seen	O
for	O
this	O
combination	O
.	O

This	O
study	O
was	O
closed	O
secondary	O
to	O
toxicity	O
and	O
lack	O
of	O
efficacy	O
of	O
the	O
designed	O
regimen	O
.	O

Impact	O
of	O
different	O
anticancer	O
regimens	O
on	O
biomarkers	O
of	O
angiogenesis	O
in	O
patients	O
with	O
advanced	O
hepatocellular	B
cancer	I
.	O

OBJECTIVE	O
:	O
Advanced	O
hepatocellular	B
cancer	I
(	O
HCC	B
)	O
is	O
a	O
highly	O
vascularised	O
tumor	O
with	O
limited	O
treatment	O
options	O
.	O

We	O
wanted	O
to	O
evaluate	O
the	O
impact	O
of	O
different	O
treatments	O
on	O
systemic	O
biomarkers	O
linked	O
to	O
angiogenesis	O
.	O

METHODS	O
:	O
Two	O
subsequent	O
prospective	O
,	O
randomised	O
,	O
phase	O
-	O
I	O
/	O
II	O
trials	O
in	O
patients	O
with	O
advanced	O
HCC	B
were	O
performed	O
.	O

A	O
total	O
of	O
38	O
patients	O
was	O
randomised	O
to	O
a	O
total	O
of	O
4	O
regimens	O
consisting	O
of	O
3	O
cycles	O
of	O
4	O
weeks	O
each	O
:	O

Trial	O
1	O
included	O
group	O
1	O
receiving	O
octreotide	O
30	O
mg	O
i	O
m	O
on	O
day	O
1	O
,	O
and	O
group	O
2	O
octreotide	O
30	O
mg	O
on	O
day	O
1	O
plus	O
Imatinib	O
400	O
mg	O
po	O
daily	O
;	O
Trial	O
2	O
included	O
group	O
3	O
with	O
oxaliplatin	O
on	O
day	O
1	O
(	O
60	O
mg	O
-	O
90	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
,	O
and	O
group	O
4	O
with	O
oxaliplatin	O
on	O
day	O
1	O
,	O
8	O
,	O
15	O
(	O
20	O
mg	O
-	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
in	O
combination	O
with	O
octreotide	O
30	O
mg	O
on	O
day	O
1	O
plus	O
imatinib	O
400	O
mg	O
po	O
daily	O
.	O

Primary	O
outcome	O
measure	O
was	O
the	O
relative	O
changes	O
in	O
plasma	O
biomarkers	O
over	O
time	O
.	O

RESULTS	O
:	O
Time	O
-	O
to	O
-	O
progression	O
and	O
overall	O
survival	O
was	O
not	O
different	O
between	O
the	O
the	O
two	O
study	O
trials	O
.	O

Within	O
group	O
1	O
-	O
4	O
,	O
the	O
mean	O
relative	O
increase	O
from	O
baseline	O
to	O
week	O
12	O
of	O
treatment	O
was	O
17	O
,	O
18	O
,	O
37	O
,	O
and	O
2	O
%	O
for	O
s	O
-	O
E	O
-	O
selectin	O
;	O
-	O
1	O
,	O
90	O
,	O
10	O
,	O
and	O
-	O
9	O
%	O
for	O
VEGF	O
-	O
A	O
;	O
18	O
,	O
84	O
,	O
141	O
,	O
and	O
74	O
%	O
for	O
PDGF	O
-	O
BB	O
,	O
and	O
111	O
,	O
142	O
,	O
30	O
,	O
and	O
7	O
%	O
for	O
serum	O
AFP	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
increase	O
of	O
plasma	O
levels	O
for	O
s	O
-	O
E	O
-	O
selectin	O
and	O
PDGF	O
-	O
BB	O
seen	O
in	O
patients	O
receiving	O
chemotherapy	O
alone	O
may	O
reflect	O
activation	O
of	O
angiogenesis	O
.	O

In	O
contrast	O
,	O
low	O
-	O
dose	O
metronomic	O
chemotherapy	O
in	O
combination	O
with	O
anti	O
-	O
angiogenic	O
drugs	O
seems	O
to	O
correlate	O
with	O
the	O
least	O
increase	O
in	O
biomarkers	O
.	O

Imatinib	O
-	O
octreotide	O
temporarily	O
leads	O
to	O
a	O
decrease	O
in	O
PDGF	O
-	O
BB	O
,	O
whereas	O
octreotide	O
alone	O
had	O
no	O
effect	O
on	O
PDGF	O
-	O
BB	O
plasma	O
levels	O
.	O

Target	O
-	O
controlled	O
infusion	O
versus	O
manually	O
-	O
controlled	O
infusion	O
of	O
propofol	O
for	O
general	O
anaesthesia	O
or	O
sedation	O
in	O
adults	O
.	O

BACKGROUND	O
:	O
Continuous	O
infusions	O
of	O
the	O
intravenous	O
anaesthetic	O
propofol	O
are	O
commonly	O
used	O
to	O
induce	O
and	O
maintain	O
sedation	O
and	O
general	O
anaesthesia	O
.	O

Infusion	O
devices	O
can	O
be	O
manually	O
controlled	O
(	O
MCI	O
)	O
where	O
the	O
anaesthetist	O
makes	O
each	O
change	O
to	O
the	O
infusion	O
rate	O
or	O
target	O
-	O
controlled	O
(	O
TCI	O
)	O
where	O
the	O
anaesthetist	O
sets	O
a	O
target	O
blood	O
or	O
effect	O
-	O
site	O
concentration	O
and	O
the	O
computerised	O
infusion	O
device	O
makes	O
the	O
necessary	O
changes	O
to	O
the	O
infusion	O
rate	O
.	O

Randomized	O
trials	O
have	O
explored	O
the	O
differences	O
in	O
quality	O
of	O
anaesthesia	O
,	O
adverse	O
event	O
rate	O
and	O
cost	O
between	O
TCI	O
and	O
MCI	O
but	O
the	O
effectiveness	O
of	O
TCI	O
compared	O
with	O
MCI	O
remains	O
controversial	O
.	O

As	O
TCI	O
is	O
in	O
widespread	O
international	O
use	O
,	O
and	O
potentially	O
may	O
be	O
more	O
expensive	O
without	O
added	O
benefit	O
,	O
a	O
systematic	O
review	O
of	O
randomized	O
controlled	O
trials	O
comparing	O
TCI	O
and	O
MCI	O
is	O
warranted	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
whether	O
TCI	O
of	O
propofol	O
is	O
as	O
effective	O
as	O
MCI	O
of	O
propofol	O
with	O
respect	O
to	O
quality	O
of	O
anaesthesia	O
or	O
sedation	O
,	O
adverse	O
events	O
and	O
propofol	O
drug	O
cost	O
.	O

SEARCH	O
STRATEGY	O

:	O
We	O
searched	O
the	O
Cochrane	O
Central	O
Register	O
of	O
Controlled	O
Trials	O
(	O
CENTRAL	O
)	O
(	O
The	O
Cochrane	O
Library	O
2007	O
,	O
Issue	O
3	O
)	O
;	O
PubMED	O
(	O
1950	O
to	O
July	O
week	O
2	O
2007	O
)	O
;	O
and	O
EMBASE	O
via	O
OVID	O
(	O
1980	O
to	O
week	O
28	O
2007	O
)	O
.	O

We	O
also	O
searched	O
LILACS	O
,	O
CINAHL	O
,	O
ISI	O
Web	O
Knowledge	O
,	O
Panteleimon	O
,	O
KoreaMed	O
and	O
IndMed	O
.	O

We	O
searched	O
for	O
ongoing	O
trials	O
via	O
the	O
National	O
Research	O
Register	O
and	O
metaRegister	O
of	O
Controlled	O
Trials	O
.	O

SELECTION	O
CRITERIA	O
:	O
We	O
planned	O
to	O
include	O
all	O
published	O
and	O
unpublished	O
randomized	O
controlled	O
trials	O
that	O
compared	O
TCI	O
of	O
propofol	O
with	O
MCI	O
of	O
propofol	O
for	O
general	O
anaesthesia	O
or	O
sedation	O
in	O
adult	O
surgical	O
patients	O
.	O

Only	O
published	O
studies	O
were	O
included	O
as	O
no	O
unpublished	O
studies	O
were	O
identified	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Two	O
authors	O
independently	O
assessed	O
trial	O
quality	O
and	O
extracted	O
outcome	O
data	O
.	O

We	O
contacted	O
study	O
authors	O
and	O
the	O
pharmaceutical	O
industry	O
for	O
additional	O
information	O
.	O

MAIN	O
RESULTS	O
:	O
Twenty	O
trials	O
of	O
poor	O
quality	O
that	O
involved	O
1759	O
patients	O
were	O
included	O
.	O

Heterogeneity	O
was	O
high	O
(	O
that	O
is	O
the	O
trials	O
were	O
not	O
comparing	O
the	O
same	O
things	O
)	O
.	O

TCI	O
was	O
associated	O
with	O
higher	O
total	O
doses	O
of	O
propofol	O
than	O
was	O
MCI	O
resulting	O
in	O
marginally	O
higher	O
propofol	O
drug	O
costs	O
.	O

However	O
,	O
fewer	O
interventions	O
were	O
required	O
by	O
the	O
anaesthetist	O
during	O
the	O
use	O
of	O
TCI	O
compared	O
with	O
MCI	O
.	O

No	O
clinically	O
significant	O
differences	O
were	O
demonstrated	O
in	O
terms	O
of	O
quality	O
of	O
anaesthesia	O
or	O
adverse	O
events	O
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
This	O
systematic	O
review	O
does	O
not	O
provide	O
sufficient	O
evidence	O
for	O
us	O
to	O
make	O
firm	O
recommendations	O
about	O
the	O
use	O
of	O
TCI	O
versus	O
MCI	O
in	O
clinical	O
anaesthetic	O
practice	O
.	O

Phase	O
II	O
study	O
of	O
9	O
-	O
aminocamptothecin	O
in	O
previously	O
treated	O
lymphomas	B
:	O
results	O
of	O
Cancer	B
and	O
Leukemia	B
Group	O
B	O
9551	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
topoisomerase	O
I	O
inhibitor	O
,	O
9	O
-	O
aminocamptothecin	O
(	O
9	O
-	O
AC	O
)	O
,	O
in	O
patients	O
with	O
relapsed	B
lymphoma	I
and	O
to	O
correlate	O
9	O
-	O
AC	O
plasma	O
concentrations	O
with	O
response	O
and	O
toxicity	O
.	O

METHODS	O
:	O
Eligible	O
patients	O
had	O
relapsed	B
Hodgkin	I
lymphoma	I
(	O
HL	B
)	O
treated	O
with	O
one	O
or	O
two	O
prior	O
regimens	O
,	O
low	O
grade	O
non	B
-	I
Hodgkin	I
's	I
lymphoma	I
(	O
NHL	B
)	O
treated	O
with	O
one	O
or	O
two	O
prior	O
regimens	O
,	O
or	O
aggressive	O
NHL	B
treated	O
with	O
one	O
prior	O
regimen	O
.	O

The	O
first	O
nine	O
patients	O
received	O
9	O
-	O
AC	O
dimethylacetamide	O
0.85	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
intravenously	O
over	O
72	O
h	O
every	O
2	O
weeks	O
and	O
the	O
remaining	O
27	O
patients	O
received	O
9	O
-	O
AC	O
/	O
colloidal	O
dispersion	O
1.1	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
.	O

Patients	O
received	O
a	O
minimum	O
of	O
three	O
cycles	O
unless	O
progression	O
or	O
intolerable	O
toxicity	O
occurred	O
.	O

Responding	O
patients	O
received	O
two	O
cycles	O
past	O
best	O
response	O
with	O
a	O
minimum	O
of	O
six	O
cycles	O
.	O

RESULTS	O
:	O
CALGB	O
9551	O
accrued	O
37	O
patients	O
from	O
April	O
1996	O
through	O
October	O
2000	O
;	O
one	O
patient	O
with	O
HD	B
,	O
18	O
patients	O
with	O
indolent	O
lymphoma	B
,	O
and	O
17	O
patients	O
with	O
aggressive	O
lymphoma	B
.	O

The	O
overall	O
response	O
rate	O
was	O
17	O
%	O
,	O
with	O
response	O
rates	O
of	O
11	O
%	O
(	O
2	O
partial	O
responses	O
)	O
in	O
patients	O
with	O
indolent	O
histologies	O
and	O
23	O
%	O
(	O
1	O
complete	O
response	O
,	O
3	O
partial	O
responses	O
)	O
in	O
patients	O
with	O
aggressive	O
histologies	O
.	O

The	O
patient	O
with	O
HD	B
did	O
not	O
respond	O
.	O

Response	O
rates	O
were	O
similar	O
for	O
both	O
drug	O
formulations	O
.	O

The	O
median	O
remission	O
duration	O
for	O
the	O
six	O
responders	O
was	O
6.5	O
months	O
,	O
with	O
one	O
remission	O
lasting	O
longer	O
than	O
12	O
months	O
.	O

Significant	O
grade	O
3	O
and	O
4	O
toxicities	O
included	O
neutropenia	B
(	O
66	O
%	O
)	O
,	O
anemia	B
(	O
31	O
%	O
)	O
,	O
and	O
thrombocytopenia	B
(	O
36	O
%	O
)	O
,	O
with	O
20	O
%	O
of	O
patients	O
experiencing	O
grade	O
3	O
or	O
4	O
infection	B
.	O

No	O
treatment	O
related	O
deaths	O
occurred	O
.	O

Steady	O
state	O
serum	O
concentrations	O
did	O
not	O
correlate	O
with	O
patient	O
response	O
or	O
toxicity	O
.	O

CONCLUSION	O
:	O
Single	O
agent	O
9	O
-	O
AC	O
has	O
modest	O
activity	O
in	O
aggressive	O
non	B
-	I
Hodgkin	I
's	I
lymphomas	I
.	O

Immunocompromised	O
hosts	O
:	O
perspectives	O
in	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
cytomegalovirus	B
disease	I
in	O
solid	O
-	O
organ	O
transplant	O
recipients	O
.	O

Cytomegalovirus	B
(	I
CMV	I
)	I
infection	I
is	O
an	O
important	O
complication	O
of	O
solid	O
-	O
organ	O
transplantation	O
.	O

The	O
availability	O
of	O
potent	O
antiviral	O
therapies	O
has	O
decreased	O
the	O
incidence	O
of	O
CMV	B
disease	I
among	O
solid	O
-	O
organ	O
transplant	O
recipients	O
but	O
has	O
also	O
led	O
to	O
challenges	O
,	O
including	O
ganciclovir	O
resistance	O
,	O
late	O
-	O
onset	O
CMV	B
disease	I
,	O
and	O
uncertainty	O
about	O
the	O
optimal	O
duration	O
of	O
prophylaxis	O
or	O
therapy	O
for	O
CMV	B
disease	I
.	O

Specific	O
therapies	O
and	O
management	O
of	O
CMV	B
resistance	O
will	O
be	O
addressed	O
here	O
.	O

The	O
best	O
approach	O
for	O
CMV	B
disease	I
in	O
solid	O
-	O
organ	O
transplant	O
recipients	O
is	O
prevention	O
,	O
but	O
which	O
strategy	O
-	O
-	O
prophylaxis	O
or	O
preemptive	O
therapy	O
-	O
-	O
is	O
optimal	O
remains	O
debatable	O
.	O

Ganciclovir	O
and	O
valganciclovir	O
remain	O
the	O
best	O
options	O
for	O
prevention	O
and	O
treatment	O
of	O
CMV	B
disease	I
in	O
solid	O
-	O
organ	O
transplant	O
recipients	O
,	O
but	O
they	O
are	O
costly	O
and	O
associated	O
with	O
toxicity	O
.	O

Foscarnet	O
and	O
cidofovir	O
,	O
indicated	O
for	O
the	O
treatment	O
of	O
patients	O
who	O
fail	O
to	O
respond	O
to	O
ganciclovir	O
,	O
are	O
less	O
attractive	O
alternatives	O
because	O
of	O
renal	B
toxicity	I
.	O

Therefore	O
,	O
new	O
therapeutic	O
agents	O
for	O
CMV	B
and	O
an	O
immunogenic	O
,	O
safe	O
CMV	B
vaccine	O
are	O
critically	O
needed	O
.	O

Cumulative	O
risk	O
assessment	O
of	O
the	O
exposure	O
to	O
organophosphorus	O
and	O
carbamate	O
insecticides	O
in	O
the	O
Dutch	O
diet	O
.	O

We	O
report	O
the	O
acute	O
cumulative	O
exposure	O
to	O
organophosphorus	O
insecticides	O
(	O
OPs	O
)	O
and	O
carbamates	O
in	O
the	O
Dutch	O
population	O
and	O
young	O
children	O
(	O
1	O
-	O
6	O
years	O
)	O
via	O
the	O
diet	O
.	O

Residue	O
data	O
were	O
derived	O
from	O
Dutch	O
monitoring	O
programmes	O
performed	O
during	O
2003	O
-	O
2005	O
,	O
and	O
food	O
consumption	O
levels	O
from	O
the	O
Dutch	O
National	O
Food	O
Consumption	O
Survey	O
1997	O
/	O
1998	O
.	O

The	O
relative	O
potency	O
factor	O
(	O
RPF	O
)	O
approach	O
was	O
used	O
to	O
cumulate	O
the	O
exposure	O
to	O
OPs	O
and	O
carbamates	O
using	O
acephate	O
and	O
oxamyl	O
as	O
index	O
compound	O
respectively	O
.	O

The	O
exposure	O
was	O
estimated	O
using	O
the	O
probabilistic	O
approach	O
,	O
including	O
unit	O
variability	O
and	O
processing	O
effects	O
.	O

We	O
demonstrate	O
that	O
about	O
3	O
%	O
of	O
the	O
composite	O
samples	O
analysed	O
for	O
OPs	O
and	O
0.2	O
%	O
for	O
carbamates	O
contain	O
combinations	O
of	O
these	O
pesticides	O
.	O

The	O
P99	O
.9	O
of	O
exposure	O
to	O
OPs	O
and	O
carbamates	O
in	O
the	O
total	O
Dutch	O
population	O
equals	O
23	O
and	O
0.64	O
microg	O
/	O
kg	O
BW	O
/	O
d	O
respectively	O
.	O

For	O
young	O
children	O
the	O
corresponding	O
exposure	O
levels	O
are	O
57	O
and	O
1.47	O
microg	O
/	O
kg	O
BW	O
/	O
d	O
.	O

When	O
comparing	O
the	O
P99	O
.9	O
of	O
exposure	O
with	O
the	O
ARfD	O
,	O
50	O
and	O
9microg	O
/	O
kg	O
BW	O
/	O
d	O
for	O
acephate	O
and	O
oxamyl	O
respectively	O
,	O
there	O
is	O
only	O
a	O
possible	O
health	O
risk	O
for	O
young	O
children	O
.	O

Spinach	O
contributed	O
most	O
to	O
the	O
exposure	O
to	O
OPs	O
in	O
both	O
age	O
groups	O
,	O
followed	O
by	O
orange	O
and	O
mandarin	O
.	O

For	O
carbamates	O
apple	O
(	O
sauce	O
)	O
was	O
the	O
main	O
product	O
determining	O
the	O
exposure	O
.	O

Methotrexate	O
and	O
leucovorin	O
double	O
-	O
modulated	O
5	O
-	O
fluorouracil	O
combined	O
with	O
cisplatin	O
(	O
MPFL	O
)	O
in	O
metastatic	B
/	I
recurrent	I
head	I
and	I
neck	I
cancer	I
.	O

BACKGROUND	O
:	O
To	O
determine	O
the	O
efficacy	O
and	O
safety	O
profile	O
of	O
the	O
combination	O
of	O
cisplatin	O
and	O
5	O
-	O
fluorouracil	O
modulated	O
both	O
by	O
methotrexate	O
and	O
leucovorin	O
in	O
metastatic	B
/	I
recurrent	I
squamous	I
cell	I
carcinoma	I
of	I
the	I
head	I
and	I
neck	I
.	O

METHODS	O
:	O
Twenty	O
-	O
eight	O
patients	O
were	O
treated	O
with	O
cisplatin	O
40	O
mg	O
/	O
m2	O
/	O
day	O
continuous	O
infusion	O
for	O
24	O
hours	O
on	O
day	O
1	O
;	O
high	O
-	O
dose	O
5	O
-	O
fluorouracil	O
2,000	O
mg	O
/	O
m2	O
/	O
day	O
and	O
leucovorin	O
100	O
mg	O
/	O
m2	O
/	O
day	O
continuous	O
infusion	O
for	O
48	O
hours	O
on	O
days	O
1	O
and	O
2	O
;	O
methotrexate	O
40	O
mg	O
/	O
m2	O
/	O
day	O
as	O
a	O
bolus	O
infusion	O
4	O
hours	O
before	O
5	O
-	O
fluorouracil	O
and	O
leucovorin	O
on	O
day	O
1	O
.	O

The	O
treatment	O
was	O
repeated	O
every	O
2	O
weeks	O
in	O
a	O
cycle	O
.	O

RESULTS	O
:	O
The	O
overall	O
response	O
rate	O
was	O
25	O
%	O
,	O
and	O
14	O
%	O
of	O
the	O
patients	O
achieved	O
stable	O
disease	O
status	O
.	O

Subgroup	O
analysis	O
demonstrated	O
significantly	O
improved	O
overall	O
survival	O
in	O
the	O
disease	O
-	O
control	O
group	O
(	O
12.0	O
months	O
vs.	O
5.3	O
months	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Only	O
3	O
(	O
10.7	O
%	O
)	O
patients	O
developed	O
grade	O
3	O
-	O
4	O
neutropenia	B
,	O
and	O
none	O
developed	O
grade	O
3	O
-	O
4	O
non	B
-	I
hematologic	I
toxicity	I
.	O

CONCLUSION	O
:	O
This	O
multiagent	O
-	O
containing	O
regimen	O
has	O
an	O
excellent	O
safety	O
profile	O
and	O
improved	O
survival	O
in	O
disease	O
-	O
control	O
group	O
of	O
patients	O
with	O
metastatic	B
/	I
recurrent	I
squamous	I
cell	I
carcinoma	I
of	I
the	I
head	I
and	I
neck	I
.	O

An	O
in	O
vivo	O
evaluation	O
of	O
Brilliant	O
Blue	O
G	O
in	O
animals	O
and	O
humans	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
To	O
evaluate	O
the	O
retinal	B
toxicity	I
of	O
Brilliant	O
Blue	O
G	O
(	O
BBG	O
)	O
following	O
intravitreal	O
injection	O
in	O
rat	O
eyes	O
and	O
examine	O
the	O
biocompatibility	O
and	O
the	O
staining	O
properties	O
in	O
humans	O
.	O

METHODS	O
:	O
BBG	O
was	O
injected	O
into	O
the	O
11	O
rat	O
eyes	O
to	O
evaluate	O
toxic	O
effects	O
with	O
balanced	O
salt	O
solution	O
(	O
BSS	O
)	O
serving	O
as	O
control	O
.	O

Retinal	B
toxicity	I
was	O
assessed	O
by	O
retinal	O
ganglion	O
cell	O
(	O
RGC	O
)	O
counts	O
and	O
by	O
light	O
microscopy	O
7	O
days	O
later	O
.	O

In	O
addition	O
,	O
BBG	O
was	O
applied	O
during	O
vitrectomy	O
for	O
macular	O
hole	O
(	O
MH	O
)	O
(	O
n	O
=	O
15	O
)	O
or	O
epiretinal	O
membranes	O
(	O
ERM	O
)	O
(	O
n	O
=	O
3	O
)	O
in	O
a	O
prospective	O
,	O
non	O
-	O
comparative	O
consecutive	O
series	O
of	O
patients	O
.	O

Before	O
and	O
after	O
surgery	O
,	O
all	O
patients	O
underwent	O
a	O
complete	O
clinical	O
examination	O
including	O
measurement	O
of	O
best	O
corrected	O
visual	O
acuity	O
(	O
VA	O
)	O
and	O
intraocular	O
pressure	O
,	O
perimetry	O
,	O
fundus	O
photography	O
and	O
optical	O
coherence	O
tomography	O
.	O

Patients	O
were	O
seen	O
1	O
day	O
before	O
surgery	O
and	O
then	O
in	O
approximately	O
four	O
weeks	O
intervals	O
.	O

RESULTS	O
:	O
No	O
significant	O
reduction	O
in	O
RGC	O
numbers	O
and	O
no	O
morphological	O
alterations	O
were	O
noted	O
.	O

A	O
sufficient	O
staining	O
of	O
the	O
internal	O
limiting	O
membrane	O
(	O
ILM	O
)	O
was	O
seen	O
in	O
patients	O
with	O
MH	O
,	O
while	O
the	O
staining	O
pattern	O
in	O
ERM	O
cases	O
was	O
patchy	O
,	O
indicating	O
that	O
parts	O
of	O
the	O
ILM	O
were	O
peeled	O
off	O
along	O
with	O
the	O
ERM	O
in	O
a	O
variable	O
extent	O
.	O

All	O
MHs	O
could	O
be	O
closed	O
successfully	O
.	O

VA	O
improved	O
in	O
10	O
eyes	O
(	O
56	O
%	O
;	O
8	O
/	O
15	O
MH	O
patients	O
,	O
2	O
/	O
3	O
ERM	O
patients	O
)	O
,	O
was	O
unchanged	O
in	O
four	O
eyes	O
(	O
22	O
%	O
;	O
all	O
MH	O
patients	O
)	O
and	O
was	O
reduced	O
in	O
four	O
eyes	O
(	O
22	O
%	O
;	O
3	O
/	O
15	O
MH	O
,	O
1	O
/	O
3	O
ERM	O
)	O
.	O

No	O
toxic	O
effects	O
attributable	O
to	O
the	O
dye	O
were	O
noted	O
during	O
patient	O
follow	O
-	O
up	O
.	O

The	O
ultrastructure	O
of	O
tissue	O
harvested	O
during	O
surgery	O
was	O
unremarkable	O
.	O

CONCLUSION	O
:	O
Brilliant	O
Blue	O
provides	O
a	O
sufficient	O
and	O
selective	O
staining	O
of	O
the	O
ILM	O
.	O

No	O
retinal	B
toxicity	I
or	O
adverse	O
effects	O
related	O
to	O
the	O
dye	O
were	O
observed	O
in	O
animal	O
and	O
human	O
studies	O
.	O

The	O
long	O
-	O
term	O
safety	O
of	O
this	O
novel	O
dye	O
will	O
have	O
to	O
be	O
evaluated	O
in	O
larger	O
patient	O
series	O
and	O
a	O
longer	O
follow	O
-	O
up	O
.	O

Acute	B
interstitial	I
nephritis	I
due	O
to	O
deferasirox	O
:	O
a	O
case	O
report	O
.	O

Deferasirox	O
is	O
a	O
new	O
oral	O
iron	O
chelator	O
used	O
to	O
treat	O
transfusional	B
iron	I
overload	I
.	O

Pre	O
-	O
marketing	O
clinical	O
trials	O
revealed	O
little	O
organ	B
-	I
specific	I
toxicity	I
.	O

Increases	O
in	O
serum	O
creatinine	O
were	O
noted	O
in	O
one	O
-	O
third	O
of	O
patients	O
but	O
were	O
mild	O
and	O
non	O
-	O
progressive	O
.	O

We	O
describe	O
a	O
62	O
-	O
year	O
-	O
old	O
man	O
with	O
myelodysplastic	B
syndrome	I
who	O
developed	O
a	O
progressive	B
decline	I
in	I
renal	I
function	I
after	O
starting	O
deferasirox	O
.	O

A	O
kidney	O
biopsy	O
showed	O
acute	B
interstitial	I
nephritis	I
with	O
increased	O
eosinophils	B
,	O
suggesting	O
drug	B
hypersensitivity	I
.	O

Deferasirox	O
was	O
discontinued	O
and	O
renal	O
function	O
returned	O
to	O
baseline	O
.	O

This	O
is	O
the	O
first	O
pathological	O
description	O
of	O
deferasirox	O
-	O
related	O
acute	B
kidney	I
injury	I
in	O
humans	O
,	O
which	O
differs	O
from	O
tubular	O
vacuolization	O
observed	O
in	O
animals	O
.	O

Extended	O
-	O
and	O
continuous	O
-	O
cycle	O
oral	O
contraceptives	O
.	O

Five	O
new	O
oral	O
contraceptives	O
,	O
classified	O
as	O
extended	O
-	O
or	O
continuous	O
-	O
cycle	O
oral	O
contraceptives	O
,	O
have	O
been	O
approved	O
by	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
.	O

These	O
agents	O
have	O
various	O
combinations	O
of	O
estrogen	O
and	O
progestin	O
,	O
and	O
different	O
effects	O
on	O
the	O
length	O
of	O
women	O
's	O
menstrual	O
cycles	O
.	O

Usually	O
they	O
shorten	O
the	O
duration	O
of	O
menses	O
,	O
decrease	O
the	O
frequency	O
of	O
menses	O
to	O
4	O
times	O
/	O
year	O
,	O
or	O
completely	O
eliminate	O
menses	O
.	O

These	O
new	O
oral	O
contraceptives	O
are	O
given	O
in	O
the	O
following	O
regimens	O
:	O
24	O
days	O
followed	O
by	O
placebo	O
for	O
4	O
days	O
(	O
24	O
/	O
4	O
)	O
,	O
84	O
days	O
followed	O
by	O
placebo	O
for	O
7	O
days	O
(	O
84	O
/	O
7	O
)	O
,	O
or	O
continuously	O
(	O
without	O
placebo	O
)	O
.	O

These	O
agents	O
contain	O
ethinyl	O
estradiol	O
20	O
microg	O
-	O
drospirenone	O
3	O
mg	O
(	O
24	O
/	O
4	O
)	O
;	O
ethinyl	O
estradiol	O
20	O
microg	O
-	O
norethindrone	O
1	O
mg	O
(	O
24	O
/	O
4	O
)	O
;	O
ethinyl	O
estradiol	O
30	O
microg	O
-	O
levonorgestrel	O
150	O
microg	O
(	O
84	O
/	O
7	O
)	O
;	O
ethinyl	O
estradiol	O
30	O
microg	O
-	O
levonorgestrel	O
150	O
microg	O
(	O
84	O
/	O
7	O
)	O
with	O
very	O
low	O
-	O
dose	O
ethinyl	O
estradiol	O
(	O
10	O
microg	O
/	O
day	O
)	O
for	O
7	O
days	O
;	O
and	O
ethinyl	O
estradiol	O
20	O
microg	O
-	O
levonorgestrel	O
90	O
microg	O
continuously	O
.	O

Clinical	O
trials	O
have	O
demonstrated	O
that	O
extended	O
-	O
and	O
continuous	O
-	O
cycle	O
oral	O
contraceptives	O
are	O
as	O
effective	O
in	O
preventing	O
pregnancy	O
as	O
traditional	O
oral	O
contraceptives	O
.	O

These	O
new	O
agents	O
also	O
have	O
similar	O
adverse	O
effects	O
;	O
however	O
,	O
the	O
only	O
significantly	O
different	O
adverse	O
effect	O
compared	O
with	O
traditional	O
oral	O
contraceptives	O
in	O
clinical	O
trials	O
was	O
change	B
in	I
bleeding	I
pattern	I
.	O

These	O
oral	O
contraceptives	O
are	O
associated	O
with	O
more	O
breakthrough	B
bleeding	I
and	O
spotting	O
than	O
the	O
traditional	O
pills	O
.	O

Long	O
-	O
term	O
effects	O
on	O
efficacy	O
and	O
safety	O
are	O
not	O
known	O
,	O
as	O
these	O
new	O
products	O
generally	O
have	O
been	O
used	O
for	O
only	O
1	O
-	O
2	O
years	O
.	O

Extended	O
-	O
and	O
continuous	O
-	O
cycle	O
oral	O
contraceptives	O
are	O
a	O
new	O
option	O
for	O
women	O
desiring	O
decreased	O
menses	O
or	O
for	O
whom	O
decreased	O
menses	O
may	O
alleviate	O
symptoms	O
of	O
coexisting	O
medical	O
conditions	O
.	O

Pharmacogenomic	O
studies	O
of	O
the	O
anticancer	O
and	O
immunosuppressive	O
thiopurines	O
mercaptopurine	O
and	O
azathioprine	O
.	O

AIMS	O
:	O
To	O
examine	O
the	O
allelic	O
variation	O
of	O
three	O
enzymes	O
involved	O
in	O
6	O
-	O
mercaptopurine	O
/	O
azathioprine	O
(	O
6	O
-	O
MP	O
/	O
AZA	O
)	O
metabolism	O
and	O
evaluate	O
the	O
influence	O
of	O
these	O
polymorphisms	O
on	O
toxicity	O
,	O
haematological	O
parameters	O
and	O
metabolite	O
levels	O
in	O
patients	O
with	O
acute	B
lymphoblastic	I
leukaemia	I
(	O
ALL	B
)	O
or	O
inflammatory	B
bowel	I
disease	I
(	O
IBD	B
)	O
.	O

METHODS	O
:	O
Clinical	O
data	O
and	O
blood	O
samples	O
were	O
collected	O
from	O
19	O
ALL	B
paediatric	O
patients	O
and	O
35	O
IBD	B
patients	O
who	O
were	O
receiving	O
6	O
-	O
MP	O
/	O
AZA	O
therapy	O
.	O

All	O
patients	O
were	O
screened	O
for	O
seven	O
genetic	O
polymorphisms	O
in	O
three	O
enzymes	O
involved	O
in	O
mercaptopurine	O
metabolism	O
[	O
xanthine	O
oxidase	O
,	O
inosine	O
triphosphatase	O
(	O
C94	O
-	O
-	O
>	O
A	O
and	O
IVS2	O
+	O
21A	O
-	O
-	O
>	O
C	O
)	O
and	O
thiopurine	O
methyltransferase	O
]	O
.	O

Erythrocyte	O
and	O
plasma	O
metabolite	O
concentrations	O
were	O
also	O
determined	O
.	O

The	O
associations	O
between	O
the	O
various	O
genotypes	O
and	O
myelotoxicity	B
,	O
haematological	O
parameters	O
and	O
metabolite	O
concentrations	O
were	O
determined	O
.	O

RESULTS	O
:	O
Thiopurine	O
methyltransferase	O
variant	O
alleles	O
were	O
associated	O
with	O
a	O
preferential	O
metabolism	O
away	O
from	O
6	O
-	O
methylmercaptopurine	O
nucleotides	O
(	O
P	O
=	O
0.008	O
in	O
ALL	B
patients	O
,	O
P	O
=	O
0.038	O
in	O
IBD	B
patients	O
)	O
favouring	O
6	O
-	O
thioguanine	O
nucleotides	O
(	O
6	O
-	O
TGNs	O
)	O
(	O
P	O
=	O
0.021	O
in	O
ALL	B
patients	O
)	O
.	O

Interestingly	O
,	O
carriers	O
of	O
inosine	O
triphosphatase	O
IVS2	O
+	O
21A	O
-	O
-	O
>	O
C	O
variants	O
among	O
ALL	B
and	O
IBD	B
patients	O
had	O
significantly	O
higher	O
concentrations	O
of	O
the	O
active	O
cytotoxic	O
metabolites	O
,	O
6	O
-	O
TGNs	O
(	O
P	O
=	O
0.008	O
in	O
ALL	B
patients	O
,	O
P	O
=	O
0.047	O
in	O
IBD	B
patients	O
)	O
.	O

The	O
study	O
confirmed	O
the	O
association	O
of	O
thiopurine	O
methyltransferase	O
heterozygosity	O
with	O
leucopenia	B
and	O
neutropenia	B
in	O
ALL	B
patients	O
and	O
reported	O
a	O
significant	O
association	O
between	O
inosine	O
triphosphatase	O
IVS2	O
+	O
21A	O
-	O
-	O
>	O
C	O
variants	O
with	O
thrombocytopenia	B
(	O
P	O
=	O
0.012	O
)	O
.	O

CONCLUSIONS	O
;	O
Pharmacogenetic	O
polymorphisms	O
in	O
the	O
6	O
-	O
MP	O
pathway	O
may	O
help	O
identify	O
patients	O
at	O
risk	O
for	O
associated	O
toxicities	O
and	O
may	O
serve	O
as	O
a	O
guide	O
for	O
dose	O
individualization	O
.	O

Fragrance	O
material	O
review	O
on	O
myrtenol	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
myrtenol	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

A	O
multiple	O
-	O
center	O
phase	O
II	O
study	O
of	O
biweekly	O
oxaliplatin	O
and	O
tegafur	O
-	O
uracil	O
/	O
leucovorin	O
for	O
chemonaive	O
patients	O
with	O
advanced	O
gastric	B
cancer	I
.	O

PURPOSE	O
:	O
The	O
current	O
study	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
biweekly	O
oxaliplatin	O
combining	O
oral	O
tegafur	O
-	O
uracil	O
/	O
leucovorin	O
in	O
treating	O
chemonaive	O
patients	O
with	O
advanced	O
gastric	B
cancer	I
.	O

METHODS	O
:	O
Eligible	O
patients	O
were	O
18	O
-	O
75	O
years	O
old	O
,	O
had	O
stage	O
IV	O
disease	O
or	O
post	O
-	O
surgery	O
recurrence	O
,	O
no	O
prior	O
palliative	O
chemotherapy	O
,	O
and	O
an	O
ECOG	O
performance	O
status	O
of	O
0	O
-	O
2	O
.	O

Patients	O
in	O
the	O
current	O
study	O
received	O
2	O
-	O
h	O
i	O
.	O

v	O
.	O

infusion	O
of	O
oxaliplatin	O
at	O
a	O
dose	O
of	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
after	O
diluting	O
in	O
500	O
mL	O
5	O
%	O
dextrose	O
/	O
water	O
(	O
dexan	O
premedication	O
)	O
,	O
and	O
5	O
-	O
HT3	O
antagonist	O
biweekly	O
.	O

Oral	O
tegafur	O
-	O
uracil	O
and	O
leucovorin	O
was	O
given	O
at	O
a	O
dose	O
of	O
300	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
and	O
60	O
mg	O
/	O
day	O
three	O
times	O
daily	O
from	O
day	O
1	O
to	O
21	O
,	O
respectively	O
,	O
followed	O
by	O
a	O
1	O
-	O
week	O
rest	O
.	O

Response	O
assessment	O
was	O
based	O
on	O
the	O
RECIST	O
criteria	O
and	O
was	O
performed	O
every	O
two	O
courses	O
.	O

Toxicity	O
was	O
assessed	O
according	O
to	O
NCI	O
common	O
toxicity	O
criteria	O
version	O
2	O
.	O

RESULTS	O
:	O
From	O
October	O
2003	O
to	O
April	O
2006	O
,	O
57	O
patients	O
were	O
evaluated	O
(	O
55	O
eligible	O
)	O
with	O
a	O
median	O
age	O
of	O
61	O
years	O
(	O
range	O
31	O
-	O
75	O
)	O
.	O

According	O
to	O
the	O
assessment	O
of	O
response	O
in	O
48	O
evaluable	O
patients	O
,	O
partial	O
response	O
rate	O
was	O
24	O
/	O
48	O
(	O
50.0	O
%	O
)	O
(	O
95	O
%	O
CI	O
:	O
35.23	O
-	O
64.73	O
%	O
)	O
and	O
stable	O
disease	O
was	O
observed	O
in	O
11	O
patients	O
(	O
22.92	O
%	O
)	O
,	O
and	O
diseased	O
progressed	O
in	O
13	O
patients	O
(	O
27.08	O
%	O
)	O
.	O

Mean	O
number	O
of	O
oxaliplatin	O
cycles	O
was	O
3	O
(	O
0.5	O
-	O
6.5	O
)	O
.	O

Median	O
time	O
to	O
progression	O
was	O
177	O
days	O
.	O

Median	O
overall	O
survival	O
was	O
318	O
days	O
.	O

Major	O
-	O
grade	O
(	O
III	O
/	O
IV	O
)	O
toxicities	O
were	O
diarrhea	B
25.5	O
%	O
,	O
vomiting	B
16.5	O
%	O
,	O
anemia	B
10.9	O
%	O
,	O
numbness	B
12.7	O
%	O
,	O
thrombocytopenia	B
7.3	O
%	O
,	O
neutropenia	B
3.6	O
%	O
and	O
leucopenia	B
1.8	O
%	O
.	O

CONCLUSIONS	O
:	O
Biweekly	O
,	O
oxaliplatin	O
combining	O
oral	O
tegafur	O
-	O
uracil	O
/	O
leucovorin	O
in	O
treating	O
patients	O
with	O
advanced	O
gastric	B
cancer	I
showed	O
acceptable	O
activity	O
and	O
manageable	O
toxicity	O
.	O

Management	O
of	O
bisphosphonate	O
-	O
induced	O
osteonecrosis	B
of	I
the	I
jaw	I
.	O

In	O
conclusion	O
,	O
careful	O
treatment	O
planning	O
minimizes	O
BIONJ	O
risk	O
in	O
patients	O
with	O
bisphosphonate	O
exposure	O
.	O

The	O
drug	O
type	O
,	O
dose	O
,	O
potency	O
,	O
and	O
duration	O
are	O
important	O
factors	O
in	O
determining	O
the	O
cumulative	O
effect	O
on	O
bone	O
remodeling	O
and	O
resultant	O
risk	O
of	O
BIONJ	O
.	O

Dentists	O
and	O
physicians	O
should	O
work	O
closely	O
to	O
balance	O
the	O
risks	O
of	O
the	O
oral	O
and	O
systemic	O
conditions	O
surrounding	O
bisphosphonate	O
use	O
.	O

A	O
critical	O
assessment	O
of	O
current	O
literature	O
is	O
necessary	O
to	O
best	O
serve	O
our	O
patients	O
.	O

DNA	O
damage	O
and	O
repair	O
detected	O
by	O
the	O
comet	O
assay	O
in	O
lymphocytes	O
of	O
african	O
petrol	O
attendants	O
:	O
a	O
pilot	O
study	O
.	O

Petrol	O
attendants	O
are	O
exposed	O
to	O
petrol	O
volatile	O
organic	O
compounds	O
(	O
VOCs	O
)	O
which	O
may	O
have	O
genotoxic	O
and	O
carcinogenic	B
effects	I
.	O

The	O
single	O
-	O
cell	O
gel	O
electrophoresis	O
assay	O
(	O
comet	O
assay	O
)	O
is	O
a	O
method	O
highly	O
sensitive	O
to	O
DNA	O
damage	O
induced	O
by	O
environmental	O
and	O
occupational	O
exposure	O
to	O
carcinogenic	O
and	O
mutagenic	O
agents	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
level	O
of	O
exposure	O
of	O
petrol	O
attendants	O
to	O
petrol	O
VOCs	O
and	O
also	O
to	O
determine	O
their	O
effect	O
on	O
DNA	O
damage	O
and	O
repair	O
in	O
lymphocytes	O
of	O
African	O
petrol	O
attendants	O
.	O

The	O
exposed	O
group	O
consisted	O
of	O
20	O
subjects	O
,	O
randomly	O
selected	O
from	O
three	O
petrol	O
stations	O
.	O

A	O
control	O
group	O
of	O
20	O
unexposed	O
subjects	O
was	O
also	O
chosen	O
and	O
matched	O
for	O
age	O
and	O
smoking	O
habits	O
with	O
the	O
exposed	O
group	O
.	O

Sorbent	O
tubes	O
were	O
used	O
to	O
assess	O
personal	O
exposure	O
of	O
petrol	O
attendants	O
.	O

The	O
comet	O
assay	O
was	O
used	O
to	O
investigate	O
the	O
basal	O
DNA	O
damage	O
and	O
repair	O
capacity	O
in	O
isolated	O
lymphocytes	O
of	O
petrol	O
attendants	O
and	O
unexposed	O
subjects	O
.	O

Blood	O
samples	O
were	O
taken	O
from	O
the	O
petrol	O
attendants	O
at	O
the	O
end	O
of	O
their	O
8	O
-	O
h	O
working	O
shift	O
and	O
also	O
from	O
the	O
unexposed	O
subjects	O
.	O

The	O
petrol	O
attendants	O
were	O
found	O
to	O
be	O
exposed	O
to	O
levels	O
of	O
petrol	O
VOCs	O
lower	O
than	O
the	O
South	O
African	O
occupational	O
exposure	O
limit	O
for	O
constituent	O
chemicals	O
.	O

A	O
significant	O
relationship	O
was	O
found	O
between	O
the	O
volume	O
of	O
petrol	O
sold	O
during	O
the	O
shift	O
and	O
the	O
average	O
concentrations	O
of	O
benzene	O
,	O
toluene	O
and	O
the	O
total	O
VOCs	O
measured	O
.	O

However	O
,	O
relative	O
humidity	O
had	O
a	O
negative	O
correlation	O
with	O
the	O
average	O
concentrations	O
of	O
benzene	O
,	O
toluene	O
,	O
xylene	O
and	O
the	O
total	O
VOCs	O
.	O

Significantly	O
higher	O
basal	O
DNA	O
damage	O
was	O
observed	O
with	O
the	O
exposed	O
group	O
compared	O
to	O
the	O
unexposed	O
group	O
.	O

The	O
period	O
of	O
exposure	O
influenced	O
the	O
level	O
of	O
DNA	O
damage	O
and	O
the	O
calculated	O
repair	O
capacity	O
.	O

Smoking	O
and	O
age	O
had	O
a	O
significant	O
influence	O
on	O
the	O
level	O
of	O
DNA	O
damage	O
.	O

DNA	O
repair	O
capacity	O
was	O
delayed	O
in	O
smokers	O
of	O
both	O
exposed	O
and	O
unexposed	O
group	O
.	O

Comparative	O
study	O
of	O
Helicobacter	O
pylori	O
eradication	O
rates	O
of	O
twice	O
-	O
versus	O
four	O
-	O
times	O
-	O
daily	O
amoxicillin	O
administered	O
with	O
proton	O
pump	O
inhibitor	O
and	O
clarithromycin	O
:	O
a	O
randomized	O
study	O
.	O

BACKGROUND	O
:	O
Proton	O
pump	O
inhibitor	O
(	O
PPI	O
)	O
-	O
containing	O
triple	O
therapy	O
with	O
clarithromycin	O
and	O
amoxicillin	O
is	O
now	O
a	O
standard	O
regimen	O
for	O
Helicobacter	O
pylori	O
eradication	O
in	O
Korea	O
.	O

Amoxicillin	O
has	O
time	O
-	O
dependent	O
bactericidal	O
activity	O
against	O
H	O
.	O

pylori	O
;	O
we	O
therefore	O
assumed	O
a	O
dosing	O
schedule	O
of	O
amoxicillin	O
would	O
affect	O
the	O
eradication	O
rate	O
of	O
H	O
.	O

pylori	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
compare	O
the	O
efficacy	O
of	O
different	O
amoxicillin	O
dosing	O
schedules	O
for	O
the	O
eradication	O
of	O
H	O
.	O

pylori	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
and	O
eighty	O
-	O
six	O
patients	O
with	O
H	B
.	I

pylori	B
infection	I
were	O
eligible	O
for	O
this	O
study	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
regimens	O
:	O
amoxicillin	O
1000	O
mg	O
with	O
clarithromycin	O
500	O
mg	O
and	O
omeprazole	O
20	O
mg	O
twice	O
daily	O
for	O
2	O
weeks	O
(	O
BID	O
group	O
,	O
n	O
=	O
93	O
)	O
,	O
or	O
amoxicillin	O
500	O
mg	O
four	O
times	O
daily	O
with	O
clarithromycin	O
500	O
mg	O
and	O
omeprazole	O
20	O
mg	O
twice	O
daily	O
for	O
2	O
weeks	O
(	O
QID	O
group	O
,	O
n	O
=	O
93	O
)	O
.	O

The	O
success	O
of	O
H	O
.	O

pylori	O
eradication	O
was	O
evaluated	O
4	O
-	O
5	O
weeks	O
after	O
completing	O
treatment	O
.	O

RESULTS	O
:	O
Overall	O
eradication	O
rate	O
was	O
90.3	O
%	O
,	O
and	O
eradication	O
rates	O
were	O
91.4	O
%	O
in	O
the	O
BID	O
group	O
and	O
89.2	O
%	O
in	O
the	O
QID	O
group	O
(	O
p	O
=	O
0.62	O
)	O
.	O

Compliances	O
was	O
95.7	O
%	O
in	O
the	O
BID	O
group	O
and	O
93.5	O
%	O
in	O
the	O
QID	O
group	O
(	O
p	O
=	O
0.516	O
)	O
;	O
this	O
was	O
the	O
only	O
factor	O
that	O
significantly	O
affected	O
H	O
.	O

pylori	O
eradication	O
in	O
this	O
study	O
.	O

Side	O
effects	O
in	O
both	O
groups	O
were	O
generally	O
mild	O
.	O

CONCLUSIONS	O
:	O
Amoxicillin	O
regimens	O
with	O
PPI	O
and	O
clarithromycin	O
are	O
found	O
to	O
be	O
equally	O
effective	O
and	O
safe	O
in	O
both	O
the	O
BID	O
and	O
QID	O
groups	O
for	O
H	O
.	O

pylori	O
eradication	O
.	O

Therefore	O
,	O
considering	O
patient	O
's	O
comfort	O
,	O
we	O
recommend	O
a	O
twice	O
daily	O
amoxicillin	O
regimen	O
.	O

Cognitive	O
effects	O
of	O
hormone	O
therapy	O
in	O
men	O
with	O
prostate	B
cancer	I
:	O
a	O
review	O
.	O

BACKGROUND	O
:	O
Men	O
who	O
receive	O
androgen	O
-	O
deprivation	O
therapy	O
(	O
ADT	O
)	O
for	O
prostate	B
cancer	I
experience	O
several	O
side	O
effects	O
from	O
this	O
treatment	O
.	O

A	O
few	O
recent	O
studies	O
have	O
examined	O
the	O
cognitive	O
implications	O
of	O
ADT	O
and	O
how	O
they	O
impact	O
a	O
patient	O
's	O
treatment	O
decision	O
-	O
making	O
,	O
occupational	O
pursuits	O
,	O
and	O
quality	O
of	O
life	O
.	O

For	O
this	O
report	O
,	O
the	O
authors	O
explored	O
possible	O
mechanisms	O
for	O
this	O
association	O
,	O
reviewed	O
research	O
in	O
animal	O
studies	O
and	O
aging	O
men	O
,	O
and	O
examined	O
the	O
growing	O
literature	O
focused	O
on	O
the	O
relation	O
between	O
ADT	O
and	O
cognitive	O
functioning	O
in	O
patients	O
with	O
prostate	B
cancer	I
.	O

METHODS	O
:	O
A	O
systematic	O
literature	O
search	O
was	O
conducted	O
using	O
the	O
PubMed	O
and	O
Information	O
Sciences	O
Institute	O
Web	O
of	O
Knowledge	O
-	O
Web	O
of	O
Science	O
databases	O
to	O
identify	O
relevant	O
studies	O
that	O
investigated	O
the	O
relation	O
between	O
ADT	O
in	O
men	O
with	O
prostate	B
cancer	I
and	O
its	O
cognitive	O
effects	O
.	O

RESULTS	O
:	O
Testosterone	O
and	O
its	O
derivatives	O
may	O
have	O
an	O
impact	O
on	O
cognition	O
through	O
several	O
mechanisms	O
in	O
the	O
brain	O
,	O
as	O
supported	O
by	O
studies	O
of	O
animals	O
and	O
in	O
aging	O
men	O
.	O

Studies	O
that	O
researched	O
the	O
impact	O
of	O
ADT	O
on	O
cognition	O
in	O
patients	O
with	O
prostate	B
cancer	I
patients	O
were	O
designed	O
relatively	O
well	O
but	O
suffered	O
from	O
small	O
sample	O
sizes	O
.	O

Between	O
47	O
%	O
and	O
69	O
%	O
of	O
men	O
on	O
ADT	O
declined	O
in	O
at	O
least	O
1	O
cognitive	O
area	O
,	O
most	O
commonly	O
in	O
visuospatial	O
abilities	O
and	O
executive	O
functioning	O
.	O

Some	O
studies	O
reported	O
contradictory	O
results	O
with	O
increased	O
functioning	O
in	O
verbal	O
memory	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
a	O
strong	O
argument	O
that	O
androgen	O
-	O
ablation	O
therapy	O
is	O
linked	O
to	O
subtle	O
but	O
significant	O
cognitive	O
declines	O
in	O
men	O
with	O
prostate	B
cancer	I
.	O

The	O
authors	O
believe	O
that	O
clinicians	O
should	O
become	O
aware	O
of	O
this	O
correlation	O
as	O
the	O
use	O
of	O
ADT	O
increases	O
and	O
should	O
inform	O
and	O
monitor	O
patients	O
for	O
this	O
possible	O
side	O
effect	O
of	O
treatment	O
.	O

Tirapazamine	O
:	O
from	O
bench	O
to	O
clinical	O
trials	O
.	O

Tumour	B
hypoxia	I
continues	O
to	O
remain	O
one	O
of	O
the	O
greatest	O
challenges	O
in	O
the	O
treatment	O
of	O
solid	B
tumours	I
.	O

An	O
important	O
avenue	O
to	O
follow	O
with	O
both	O
radiotherapy	O
and	O
chemotherapy	O
is	O
the	O
development	O
of	O
hypoxic	O
cytotoxins	O
such	O
as	O
tirapazamine	O
.	O

The	O
present	O
review	O
covers	O
the	O
history	O
of	O
tirapazamine	O
from	O
preclinical	O
models	O
to	O
clinical	O
trials	O
.	O

The	O
biochemistry	O
as	O
well	O
as	O
the	O
pharmacokinetics	O
of	O
this	O
bioreductive	O
agent	O
are	O
presented	O
.	O

Laboratory	O
data	O
demonstrating	O
the	O
enhanced	O
effect	O
of	O
radiation	O
and	O
cisplatin	O
when	O
combined	O
with	O
tirapazamine	O
are	O
also	O
discussed	O
.	O

There	O
is	O
considerable	O
evidence	O
supporting	O
the	O
potentiation	O
of	O
anti	O
-	O
tumour	O
effect	O
of	O
cisplatin	O
by	O
tirapazamine	O
.	O

Several	O
clinical	O
trials	O
for	O
various	O
tumour	B
sites	O
have	O
been	O
testing	O
the	O
synergistic	O
effect	O
of	O
cisplatin	O
-	O
tirapazamine	O
with	O
and	O
without	O
radiotherapy	O
.	O

These	O
are	O
also	O
reviewed	O
in	O
the	O
present	O
paper	O
.	O

The	O
current	O
literature	O
data	O
on	O
tirapazamine	O
leaves	O
unanswered	O
questions	O
about	O
its	O
action	O
and	O
toxicity	O
.	O

While	O
the	O
current	O
number	O
of	O
phase	O
III	O
trials	O
limits	O
comprehensive	O
conclusions	O
about	O
the	O
administration	O
of	O
this	O
drug	O
,	O
there	O
is	O
a	O
unanimous	O
indication	O
that	O
further	O
clinical	O
studies	O
are	O
warranted	O
.	O

Serum	O
lactate	O
dehydrogenase	O
is	O
a	O
novel	O
marker	O
for	O
the	O
evaluation	O
of	O
disease	O
severity	O
in	O
the	O
early	O
stage	O
of	O
toxic	B
epidermal	I
necrolysis	I
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
serum	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
and	O
its	O
correlation	O
with	O
skin	O
manifestations	O
in	O
patients	O
with	O
Stevens	B
-	I
Johnson	I
syndrome	I
(	O
SJS	B
)	O
and	O
toxic	B
epidermal	I
necrolysis	I
(	O
TEN	B
)	O
.	O

METHODS	O
:	O
Serum	O
LDH	O
levels	O
were	O
measured	O
in	O
33	O
patients	O
(	O
17	O
SJS	B
and	O
16	O
TEN	B
)	O
,	O
from	O
initial	O
hospital	O
admission	O
to	O
remission	O
stage	O
.	O

RESULTS	O
:	O
The	O
mean	O
LDH	O
level	O
was	O
920.82	O
+	O
/	O
-	O
655.50	O
U	O
/	O
l	O
in	O
TEN	B
and	O
595.35	O
+	O
/	O
-	O
182.03	O
U	O
/	O
l	O
in	O
SJS	B
(	O
normal	O
range	O
:	O
218	O
-	O
472	O
)	O
.	O

We	O
arbitrarily	O
divided	O
these	O
patients	O
into	O
2	O
groups	O
,	O
the	O
first	O
were	O
admitted	O
within	O
3	O
days	O
of	O
onset	O
(	O
early	O
stage	O
)	O
and	O
the	O
second	O
after	O
4	O
days	O
of	O
onset	O
(	O
late	O
stage	O
)	O
.	O

The	O
ratio	O
of	O
early	O
-	O
to	O
late	O
-	O
stage	O
patients	O
was	O
7	O
:	O
9	O
in	O
TEN	B
and	O
7	O
:	O
10	O
in	O
SJS	O
.	O

The	O
mean	O
LDH	O
level	O
for	O
7	O
TEN	B
patients	O
in	O
the	O
early	O
stage	O
was	O
1,319.14	O
+	O
/	O
-	O
843.10	O
U	O
/	O
l	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
SJS	B
group	O
(	O
686.71	O
+	O
/	O
-	O
171.81	O
U	O
/	O
l	O
;	O
p	O
=	O
0.024	O
)	O
.	O

In	O
the	O
late	O
-	O
stage	O
patients	O
,	O
the	O
mean	O
levels	O
of	O
TEN	B
and	O
SJS	B
patients	O
were	O
611.0	O
+	O
/	O
-	O
160.33	O
and	O
531.4	O
+	O
/	O
-	O
167.89	O
U	O
/	O
l	O
,	O
respectively	O
;	O
these	O
differences	O
between	O
TEN	B
and	O
SJS	B
were	O
not	O
significant	O
.	O

CONCLUSION	O
:	O
Serum	O
LDH	O
levels	O
can	O
be	O
used	O
as	O
a	O
marker	O
of	O
disease	O
severity	O
in	O
the	O
early	O
stage	O
of	O
TEN	B
.	O

Venlafaxine	O
versus	O
clonidine	O
for	O
the	O
treatment	O
of	O
hot	B
flashes	I
in	O
breast	B
cancer	I
patients	O
:	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
cross	O
-	O
over	O
study	O
.	O

PURPOSE	O
:	O
Breast	B
cancer	I
patients	O
with	O
treatment	O
-	O
induced	O
menopause	O
experience	O
frequent	O
and	O
severe	O
hot	B
flashes	I
(	O
HF	B
)	O
.	O

We	O
compared	O
venlafaxine	O
and	O
clonidine	O
for	O
the	O
treatment	O
of	O
HF	O
with	O
regard	O
to	O
side	O
effects	O
,	O
efficacy	O
,	O
quality	O
of	O
life	O
and	O
sexual	O
functioning	O
.	O

METHODS	O
:	O
In	O
a	O
double	O
-	O
blind	O
,	O
cross	O
-	O
over	O
study	O
,	O
60	O
breast	B
cancer	I
patients	O
experiencing	O
HF	B
were	O
randomized	O
to	O
8	O
weeks	O
venlafaxine	O
followed	O
by	O
2	O
weeks	O
wash	O
-	O
out	O
,	O
and	O
8	O
weeks	O
clonidine	O
or	O
vice	O
versa	O
.	O

HF	B
frequency	O
and	O
severity	O
,	O
side	O
effects	O
,	O
quality	O
of	O
life	O
and	O
sexuality	O
were	O
assessed	O
.	O

RESULTS	O
:	O
Thirty	O
patients	O
started	O
with	O
venlafaxine	O
and	O
30	O
with	O
clonidine	O
.	O

Premature	O
discontinuation	O
for	O
toxicity	O
occurred	O
in	O
14	O
/	O
59	O
during	O
venlafaxine	O
and	O
5	O
/	O
53	O
during	O
clonidine	O
(	O
P	O
=	O
.038	O
)	O
.	O

Venlafaxine	O
induced	O
more	O
side	O
effects	O
.	O

Median	O
reduction	O
in	O
HF	B
score	O
was	O
49	O
%	O
for	O
venlafaxine	O
and	O
55	O
%	O
for	O
clonidine	O
(	O
ns	O
)	O
.	O

CONCLUSION	O
:	O
Venlafaxine	O
and	O
clonidine	O
are	O
equally	O
,	O
but	O
moderately	O
effective	O
in	O
HF	B
reduction	O
.	O

Side	O
effects	O
are	O
the	O
main	O
reason	O
for	O
drug	O
discontinuation	O
,	O
occurring	O
more	O
often	O
with	O
venlafaxine	O
.	O

Sibutramine	O
:	O
current	O
status	O
as	O
an	O
anti	O
-	O
obesity	O
drug	O
and	O
its	O
future	O
perspectives	O
.	O

BACKGROUND	O
:	O
Obesity	B
has	O
become	O
a	O
global	O
epidemic	O
with	O
recent	O
estimates	O
of	O
>	O
400	O
million	O
obese	O
adults	O
.	O

Despite	O
this	O
,	O
there	O
are	O
few	O
safe	O
and	O
effective	O
pharmacological	O
interventions	O
for	O
obesity	B
.	O

Sibutramine	O
is	O
a	O
weight	O
loss	O
agent	O
,	O
for	O
use	O
as	O
an	O
adjuvant	O
to	O
a	O
comprehensive	O
program	O
of	O
calorie	O
restriction	O
,	O
exercise	O
and	O
behavioral	O
therapy	O
.	O

OBJECTIVE	O
:	O
The	O
goal	O
of	O
this	O
article	O
is	O
to	O
review	O
the	O
available	O
literature	O
of	O
pharmacological	O
interventions	O
for	O
obesity	B
and	O
specifically	O
to	O
examine	O
data	O
with	O
sibutramine	O
for	O
the	O
short	O
term	O
on	O
safety	O
and	O
efficacy	O
for	O
weight	O
loss	O
.	O

METHODS	O
:	O
The	O
literature	O
on	O
sibutramine	O
was	O
reviewed	O
after	O
a	O
PubMed	O
and	O
Medline	O
search	O
in	O
March	O
2008	O
.	O

All	O
randomized	O
clinical	O
trails	O
were	O
reviewed	O
.	O

RESULTS	O
/	O
CONCLUSIONS	O
:	O
Sibutramine	O
appears	O
to	O
be	O
safe	O
and	O
effective	O
in	O
producing	O
clinically	O
significant	O
weight	O
loss	O
for	O
up	O
to	O
1	O
year	O
.	O

Longer	O
prospective	O
clinical	O
studies	O
with	O
sibutramine	O
are	O
needed	O
to	O
evaluate	O
its	O
safety	O
(	O
effect	O
on	O
blood	O
pressure	O
)	O
and	O
ability	O
to	O
maintain	O
weight	O
loss	O
,	O
improve	O
metabolic	O
profiles	O
and	O
reduce	O
the	O
risk	O
of	O
cardiovascular	B
diseases	I
.	O

A	O
new	O
lipoglycopeptide	O
:	O
telavancin	O
.	O

The	O
increase	O
in	O
infections	O
caused	O
by	O
resistant	O
Gram	O
-	O
positive	O
organisms	O
has	O
led	O
to	O
an	O
urgent	O
need	O
for	O
new	O
antibiotics	O
.	O

Telavancin	O
is	O
a	O
rapidly	O
bactericidal	O
lipoglycopeptide	O
with	O
multiple	O
mechanisms	O
of	O
action	O
,	O
including	O
concentration	O
-	O
dependent	O
inhibition	O
of	O
bacterial	O
cell	O
wall	O
synthesis	O
and	O
disruption	O
of	O
the	O
functional	O
integrity	O
of	O
the	O
cell	O
membrane	O
.	O

Telavancin	O
is	O
active	O
against	O
a	O
wide	O
variety	O
of	O
Gram	O
-	O
positive	O
organisms	O
including	O
Staphylococcus	O
aureus	O
with	O
resistance	O
to	O
methicillin	O
,	O
reduced	O
susceptibility	O
to	O
vancomycin	O
,	O
and	O
full	O
resistance	O
to	O
vancomycin	O
.	O

Telavacin	O
is	O
approximately	O
90	O
%	O
protein	O
bound	O
;	O
it	O
has	O
a	O
serum	O
half	O
-	O
life	O
of	O
around	O
8	O
h	O
and	O
a	O
prolonged	O
postantibiotic	O
effect	O
,	O
allowing	O
once	O
daily	O
administration	O
.	O

Telavancin	O
is	O
eliminated	O
principally	O
through	O
the	O
urine	O
,	O
requiring	O
dose	O
adjustment	O
in	O
patients	O
with	O
renal	B
impairment	I
.	O

The	O
efficacy	O
and	O
safety	O
of	O
telavancin	O
was	O
demonstrated	O
in	O
a	O
large	O
program	O
of	O
patients	O
with	O
complicated	O
skin	O
and	O
skin	O
structure	O
infections	O
.	O

Development	O
of	O
resistance	O
has	O
not	O
been	O
detected	O
in	O
clinical	O
strains	O
.	O

Adverse	O
events	O
include	O
taste	B
disturbance	I
,	O
nausea	B
and	O
vomiting	B
;	O
a	O
small	O
proportion	O
of	O
patients	O
experienced	O
reversible	O
increase	O
in	O
serum	O
creatinine	O
.	O

Two	O
large	O
Phase	O
III	O
studies	O
in	O
patients	O
with	O
healthcare	O
associated	O
pneumonia	B
were	O
recently	O
completed	O
.	O

Telavancin	O
has	O
the	O
potential	O
to	O
become	O
an	O
important	O
therapeutic	O
option	O
to	O
treat	O
serious	O
infections	B
produced	O
by	O
resistant	O
Gram	O
-	O
positive	O
cocci	O
,	O
particularly	O
those	O
caused	O
by	O
methicillin	O
-	O
resistant	O
S	O
.	O

aureus	O
.	O

Down	O
-	O
regulation	O
of	O
asymmetric	O
arginine	O
methylation	O
during	O
replicative	O
and	O
H2O2	O
-	O
induced	O
premature	O
senescence	O
in	O
WI	O
-	O
38	O
human	O
diploid	O
fibroblasts	O
.	O

Protein	O
arginine	O
methylation	O
is	O
one	O
of	O
the	O
post	O
-	O
translational	O
modifications	O
which	O
yield	O
monomethyl	O
and	O
dimethyl	O
(	O
asymmetric	O
or	O
symmetric	O
)	O
arginines	O
in	O
proteins	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
status	O
of	O
protein	O
arginine	O
methylation	O
during	O
human	O
diploid	O
fibroblast	O
senescence	O
.	O

When	O
the	O
expression	O
of	O
protein	O
arginine	O
methyltransferases	O
(	O
PRMTs	O
)	O
,	O
namely	O
PRMT1	O
,	O
PRMT4	O
,	O
PRMT5	O
and	O
PRMT6	O
was	O
examined	O
,	O
a	O
significant	O
reduction	O
was	O
found	O
in	O
replicatively	O
senescent	O
cells	O
as	O
well	O
as	O
their	O
catalytic	O
activities	O
against	O
histone	O
mixtures	O
compared	O
with	O
the	O
young	O
cells	O
.	O

Furthermore	O
,	O
when	O
the	O
endogenous	O
level	O
of	O
arginine	O
-	O
dimethylated	O
proteins	O
was	O
determined	O
,	O
asymmetric	O
modification	O
(	O
the	O
product	O
of	O
type	O
I	O
PRMTs	O
including	O
PRMT1	O
,	O
PRMT4	O
and	O
PRMT6	O
)	O
was	O
markedly	O
down	O
-	O
regulated	O
.	O

In	O
contrast	O
,	O
both	O
up	O
-	O
and	O
down	O
-	O
regulations	O
of	O
symmetrically	O
arginine	O
-	O
methylated	O
proteins	O
(	O
the	O
product	O
of	O
type	O
II	O
PRMTs	O
including	O
PRMT5	O
)	O
during	O
replicative	O
senescence	O
were	O
found	O
.	O

Furthermore	O
,	O
when	O
young	O
fibroblasts	O
were	O
induced	O
to	O
premature	O
senescence	O
by	O
sub	O
-	O
cytotoxic	O
H2O2	O
treatment	O
,	O
results	O
similar	O
to	O
replicative	O
senescence	O
were	O
obtained	O
.	O

Finally	O
,	O
we	O
found	O
that	O
SV40	O
-	O
mediated	O
immortalized	O
WI	O
-	O
38	O
and	O
HeLa	O
cell	O
lines	O
maintained	O
a	O
higher	O
level	O
of	O
asymmetrically	O
modified	O
proteins	O
as	O
well	O
as	O
type	O
I	O
PRMTs	O
than	O
young	O
fibroblasts	O
.	O

These	O
results	O
suggest	O
that	O
the	O
maintenance	O
of	O
asymmetric	O
modification	O
in	O
the	O
expressed	O
target	O
proteins	O
of	O
type	O
I	O
PRMTs	O
might	O
be	O
critical	O
for	O
cellular	O
proliferation	O
.	O

Pluripotent	O
stem	O
cell	O
lines	O
.	O

The	O
derivation	O
of	O
human	O
embryonic	O
stem	O
cells	O
10	O
years	O
ago	O
ignited	O
an	O
explosion	O
of	O
public	O
interest	O
in	O
stem	O
cells	O
,	O
yet	O
this	O
achievement	O
depended	O
on	O
prior	O
decades	O
of	O
research	O
on	O
mouse	O
embryonic	O
carcinoma	O
cells	O
and	O
embryonic	O
stem	O
cells	O
.	O

In	O
turn	O
,	O
the	O
recent	O
derivation	O
of	O
mouse	O
and	O
human	O
induced	O
pluripotent	O
stem	O
cells	O
depended	O
on	O
the	O
prior	O
studies	O
on	O
mouse	O
and	O
human	O
embryonic	O
stem	O
cells	O
.	O

Both	O
human	O
embryonic	O
stem	O
cells	O
and	O
induced	O
pluripotent	O
stem	O
cells	O
can	O
self	O
-	O
renew	O
indefinitely	O
in	O
vitro	O
while	O
maintaining	O
the	O
ability	O
to	O
differentiate	O
into	O
advanced	O
derivatives	O
of	O
all	O
three	O
germ	O
layers	O
,	O
features	O
very	O
useful	O
for	O
understanding	O
the	O
differentiation	O
and	O
function	O
of	O
human	O
tissues	O
,	O
for	O
drug	O
screen	O
and	O
toxicity	O
testing	O
,	O
and	O
for	O
cellular	O
transplantation	O
therapies	O
.	O

Here	O
we	O
review	O
the	O
family	O
of	O
pluripotent	O
cell	O
lines	O
derived	O
from	O
early	O
embryos	O
and	O
from	O
germ	O
cells	O
,	O
and	O
compare	O
them	O
with	O
the	O
more	O
recently	O
described	O
induced	O
pluripotent	O
stem	O
cells	O
.	O

A	O
novel	O
panel	O
of	O
mouse	O
models	O
to	O
evaluate	O
the	O
role	O
of	O
human	O
pregnane	O
X	O
receptor	O
and	O
constitutive	O
androstane	O
receptor	O
in	O
drug	O
response	O
.	O

The	O
pregnane	O
X	O
receptor	O
(	O
PXR	O
)	O
and	O
the	O
constitutive	O
androstane	O
receptor	O
(	O
CAR	O
)	O
are	O
closely	O
related	O
orphan	O
nuclear	O
hormone	O
receptors	O
that	O
play	O
a	O
critical	O
role	O
as	O
xenobiotic	O
sensors	O
in	O
mammals	O
.	O

Both	O
receptors	O
regulate	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
the	O
biotransformation	O
of	O
chemicals	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
.	O

As	O
the	O
ligand	O
specificity	O
of	O
PXR	O
and	O
CAR	O
have	O
diverged	O
between	O
species	O
,	O
the	O
prediction	O
of	O
in	O
vivo	O
PXR	O
and	O
CAR	O
interactions	O
with	O
a	O
drug	O
are	O
difficult	O
to	O
extrapolate	O
from	O
animals	O
to	O
humans	O
.	O

We	O
report	O
the	O
development	O
of	O
what	O
we	O
believe	O
are	O
novel	O
PXR	O
-	O
and	O
CAR	O
-	O
humanized	O
mice	O
,	O
generated	O
using	O
a	O
knockin	O
strategy	O
,	O
and	O
Pxr	O
-	O
and	O
Car	O
-	O
KO	O
mice	O
as	O
well	O
as	O
a	O
panel	O
of	O
mice	O
including	O
all	O
possible	O
combinations	O
of	O
these	O
genetic	O
alterations	O
.	O

The	O
expression	O
of	O
human	O
CAR	O
and	O
PXR	O
was	O
in	O
the	O
predicted	O
tissues	O
at	O
physiological	O
levels	O
,	O
and	O
splice	O
variants	O
of	O
both	O
human	O
receptors	O
were	O
expressed	O
.	O

The	O
panel	O
of	O
mice	O
will	O
allow	O
the	O
dissection	O
of	O
the	O
crosstalk	O
between	O
PXR	O
and	O
CAR	O
in	O
the	O
response	O
to	O
different	O
drugs	O
.	O

To	O
demonstrate	O
the	O
utility	O
of	O
this	O
panel	O
of	O
mice	O
,	O
we	O
used	O
the	O
mice	O
to	O
show	O
that	O
the	O
in	O
vivo	O
induction	O
of	O
Cyp3a11	O
and	O
Cyp2b10	O
by	O
phenobarbital	O
was	O
only	O
mediated	O
by	O
CAR	O
,	O
although	O
this	O
compound	O
is	O
described	O
as	O
a	O
PXR	O
and	O
CAR	O
activator	O
in	O
vitro	O
.	O

This	O
panel	O
of	O
mouse	O
models	O
is	O
a	O
useful	O
tool	O
to	O
evaluate	O
the	O
roles	O
of	O
CAR	O
and	O
PXR	O
in	O
drug	O
bioavailability	O
,	O
toxicity	O
,	O
and	O
efficacy	O
in	O
humans	O
.	O

Somatic	O
pharmacogenomics	O
in	O
cancer	B
.	O

Many	O
of	O
the	O
initial	O
examples	O
of	O
the	O
clinical	O
utility	O
of	O
pharmacogenetics	O
were	O
elucidated	O
in	O
the	O
field	O
of	O
oncology	O
.	O

Those	O
examples	O
were	O
largely	O
based	O
on	O
the	O
existence	O
of	O
germline	O
genetic	O
variation	O
that	O
influences	O
the	O
metabolism	O
of	O
cytotoxic	O
drugs	O
.	O

However	O
,	O
with	O
the	O
development	O
of	O
kinase	O
inhibitors	O
,	O
drugs	O
designed	O
to	O
preferentially	O
target	O
altered	O
proteins	O
driving	O
oncogenesis	O
,	O
pharmacogenetics	O
in	O
cancer	B
has	O
shifted	O
to	O
understanding	O
the	O
somatic	O
differences	O
that	O
determine	O
response	O
to	O
these	O
targeted	O
agents	O
.	O

It	O
is	O
becoming	O
increasingly	O
clear	O
that	O
understanding	O
the	O
molecular	O
genetics	O
of	O
cancer	B
will	O
lead	O
to	O
the	O
further	O
development	O
of	O
targeted	O
therapeutics	O
.	O

Therefore	O
,	O
it	O
is	O
imperative	O
that	O
pharmacogenomics	O
researchers	O
understand	O
the	O
motivations	O
and	O
challenges	O
of	O
developing	O
targeted	O
therapies	O
to	O
treat	O
cancer	B
as	O
a	O
paradigm	O
for	O
personalized	O
medicine	O
.	O

However	O
,	O
much	O
of	O
the	O
discussion	O
in	O
the	O
pharmacogenomics	O
community	O
in	O
cancer	B
is	O
still	O
largely	O
focused	O
on	O
the	O
germline	O
variants	O
as	O
predictors	O
of	O
drug	B
toxicity	I
.	O

In	O
light	O
of	O
that	O
fact	O
,	O
this	O
review	O
presents	O
a	O
detailed	O
discussion	O
of	O
the	O
development	O
of	O
commonly	O
used	O
targeted	O
therapies	O
for	O
the	O
treatment	O
of	O
hematological	O
and	O
solid	O
tumors	O
,	O
the	O
somatic	O
mutations	O
that	O
determine	O
response	O
to	O
those	O
therapies	O
,	O
and	O
the	O
mechanisms	O
of	O
drug	O
resistance	O
.	O

Improving	O
the	O
applicability	O
of	O
(	O
Q	O
)	O
SARs	O
for	O
percutaneous	O
penetration	O
in	O
regulatory	O
risk	O
assessment	O
.	O

The	O
new	O
regulatory	O
framework	O
REACH	O
(	O
Registration	O
,	O
Evaluation	O
,	O
and	O
Authorisation	O
of	O
Chemicals	O
)	O
foresees	O
the	O
use	O
of	O
non	O
-	O
testing	O
approaches	O
,	O
such	O
as	O
read	O
-	O
across	O
,	O
chemical	O
categories	O
,	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
and	O
quantitative	O
structure	O
-	O
activity	O
relationships	O
(	O
QSARs	O
)	O
.	O

Although	O
information	O
on	O
skin	O
absorption	O
data	O
are	O
not	O
a	O
formal	O
requirement	O
under	O
REACH	O
,	O
data	O
on	O
dermal	O
absorption	O
are	O
an	O
integral	O
part	O
of	O
risk	O
assessment	O
of	O
substances	O
/	O
products	O
to	O
which	O
man	O
is	O
predominantly	O
exposed	O
via	O
the	O
dermal	O
route	O
.	O

In	O
this	O
study	O
,	O
we	O
assess	O
the	O
present	O
applicability	O
of	O
publicly	O
available	O
QSARs	O
on	O
skin	O
absorption	O
for	O
risk	O
assessment	O
purposes	O
.	O

We	O
explicitly	O
did	O
not	O
aim	O
to	O
give	O
scientific	O
judgments	O
on	O
individual	O
QSARs	O
.	O

A	O
total	O
of	O
33	O
QSARs	O
selected	O
from	O
the	O
public	O
domain	O
were	O
evaluated	O
using	O
the	O
OECD	O
(	O
Organisation	O
for	O
Economic	O
Co	O
-	O
operation	O
and	O
Development	O
)	O
Principles	O
for	O
the	O
Validation	O
of	O
(	O
Q	O
)	O
SAR	O
Models	O
.	O

Additionally	O
,	O
several	O
pragmatic	O
criteria	O
were	O
formulated	O
to	O
select	O
QSARs	O
that	O
are	O
most	O
suitable	O
for	O
their	O
use	O
in	O
regulatory	O
risk	O
assessment	O
.	O

Based	O
on	O
these	O
criteria	O
,	O
four	O
QSARs	O
were	O
selected	O
.	O

The	O
predictivity	O
of	O
these	O
QSARs	O
was	O
evaluated	O
by	O
comparing	O
their	O
outcomes	O
with	O
experimentally	O
derived	O
skin	O
absorption	O
data	O
(	O
for	O
62	O
compounds	O
)	O
.	O

The	O
predictivity	O
was	O
low	O
for	O
three	O
of	O
four	O
QSARs	O
,	O
whereas	O
one	O
model	O
gave	O
reasonable	O
predictions	O
.	O

Several	O
suggestions	O
are	O
made	O
to	O
increase	O
the	O
applicability	O
of	O
QSARs	O
for	O
skin	O
absorption	O
for	O
risk	O
assessment	O
purposes	O
.	O

Lentiviral	O
short	O
hairpin	O
RNA	O
screen	O
of	O
genes	O
associated	O
with	O
multidrug	O
resistance	O
identifies	O
PRP	O
-	O
4	O
as	O
a	O
new	O
regulator	O
of	O
chemoresistance	O
in	O
human	O
ovarian	B
cancer	I
.	O

Published	O
reports	O
implicate	O
a	O
variety	O
of	O
mechanisms	O
that	O
may	O
contribute	O
to	O
drug	O
resistance	O
in	O
ovarian	B
cancer	I
.	O

The	O
chief	O
aim	O
of	O
this	O
study	O
is	O
to	O
understand	O
the	O
relationship	O
between	O
overexpression	O
of	O
drug	O
resistance	O
associated	O
genes	O
and	O
multidrug	O
resistance	O
in	O
ovarian	B
cancer	I
.	O

Using	O
lentiviral	O
short	O
hairpin	O
RNA	O
collections	O
targeting	O
132	O
genes	O
identified	O
from	O
transcriptional	O
profiling	O
of	O
drug	O
-	O
resistant	O
cancer	O
cell	O
lines	O
,	O
individual	O
knockdown	O
experiments	O
were	O
done	O
in	O
the	O
presence	O
of	O
sublethal	O
doses	O
of	O
paclitaxel	O
.	O

Specific	O
genes	O
whose	O
knockdown	O
was	O
found	O
to	O
be	O
associated	O
with	O
cellular	B
toxicity	I
included	O
MDR1	O
(	O
ABCB1	O
)	O
,	O
survivin	O
,	O
and	O
pre	O
-	O
mRNA	O
processing	O
factor	O
-	O
4	O
(	O
PRP	O
-	O
4	O
)	O
.	O

These	O
genes	O
,	O
when	O
repressed	O
,	O
can	O
reverse	O
paclitaxel	O
resistance	O
in	O
the	O
multidrug	O
-	O
resistant	O
cell	O
line	O
SKOV	O
-	O
3	O
(	O
TR	O
)	O
and	O
OVCAR8	O
(	O
TR	O
)	O
.	O

Both	O
MDR1	O
and	O
survivin	O
have	O
been	O
reported	O
previously	O
to	O
play	O
a	O
role	O
in	O
multidrug	O
resistance	O
and	O
chemotherapy	O
-	O
induced	O
apoptosis	O
;	O
however	O
,	O
the	O
effect	O
of	O
PRP	O
-	O
4	O
expression	O
on	O
drug	O
sensitivity	O
is	O
currently	O
unrecognized	O
.	O

PRP	O
-	O
4	O
belongs	O
to	O
the	O
serine	O
/	O
threonine	O
protein	O
kinase	O
family	O
,	O
plays	O
a	O
role	O
in	O
pre	O
-	O
mRNA	O
splicing	O
and	O
cell	O
mitosis	O
,	O
and	O
interacts	O
with	O
CLK1	O
.	O

Northern	O
analysis	O
shows	O
that	O
PRP	O
-	O
4	O
is	O
overexpressed	O
in	O
several	O
paclitaxel	O
-	O
resistant	O
cell	O
lines	O
and	O
confirms	O
that	O
PRP	O
-	O
4	O
expression	O
could	O
be	O
significantly	O
repressed	O
by	O
PRP	O
-	O
4	O
lentiviral	O
short	O
hairpin	O
RNA	O
.	O

Both	O
clonogenic	O
and	O
MTT	O
assays	O
confirm	O
that	O
transcriptional	O
repression	O
of	O
PRP	O
-	O
4	O
could	O
reverse	O
paclitaxel	O
resistance	O
5	O
-	O
10	O
-	O
fold	O
in	O
SKOV	O
-	O
3	O
(	O
TR	O
)	O
.	O

Finally	O
,	O
overexpression	O
of	O
PRP	O
-	O
4	O
in	O
drug	O
-	O
sensitive	O
cells	O
could	O
induce	O
a	O
modest	O
level	O
of	O
drug	O
resistance	O
to	O
paclitaxel	O
,	O
doxorubicin	O
,	O
and	O
vincristine	O
.	O

Multicenter	O
phase	O
II	O
study	O
of	O
capecitabine	O
plus	O
oxaliplatin	O
as	O
a	O
first	O
-	O
line	O
therapy	O
in	O
Chinese	O
patients	O
with	O
advanced	O
gastric	B
cancer	I
.	O

The	O
efficacy	O
of	O
chemotherapy	O
for	O
advanced	O
gastric	B
cancer	I
with	O
palliative	O
intent	O
compared	O
with	O
supportive	O
care	O
alone	O
is	O
now	O
widely	O
accepted	O
.	O

However	O
,	O
the	O
survival	O
advantage	O
is	O
small	O
,	O
and	O
no	O
internationally	O
accepted	O
standard	O
regimen	O
has	O
emerged	O
.	O

This	O
study	O
is	O
performed	O
to	O
evaluate	O
the	O
response	O
rate	O
,	O
time	O
to	O
progression	O
,	O
and	O
safety	O
of	O
the	O
combination	O
of	O
capecitabine	O
(	O
1000	O
mg	O
/	O
m	O
twice	O
daily	O
,	O
days	O
1	O
-	O
14	O
)	O
plus	O
oxaliplatin	O
(	O
130	O
mg	O
/	O
m	O
as	O
a	O
2	O
-	O
h	O
intravenous	O
infusion	O
on	O
day	O
1	O
)	O
every	O
3	O
weeks	O
,	O
in	O
previously	O
untreated	O
Chinese	O
patients	O
with	O
advanced	O
gastric	B
cancer	I
.	O

Sixty	O
-	O
five	O
(	O
95.6	O
%	O
)	O
of	O
the	O
68	O
patients	O
were	O
assessable	O
for	O
response	O
.	O

Three	O
cases	O
of	O
complete	O
response	O
and	O
34	O
cases	O
of	O
partial	O
response	O
were	O
confirmed	O
,	O
giving	O
an	O
overall	O
response	O
rate	O
of	O
54.4	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
42.6	O
-	O
66.2	O
%	O
]	O
.	O

The	O
median	O
time	O
to	O
progression	O
and	O
overall	O
survival	O
for	O
all	O
patients	O
were	O
5.7	O
months	O
(	O
95	O
%	O
CI	O
,	O
2.0	O
-	O
8.8	O
months	O
)	O
and	O
10.5	O
months	O
(	O
95	O
%	O
CI	O
,	O
5.0	O
-	O
15.1	O
months	O
)	O
.	O

The	O
most	O
severe	O
hematologic	O
adverse	O
event	O
was	O
neutropenia	B
,	O
which	O
occurred	O
with	O
grade	O
3	O
intensity	O
in	O
three	O
(	O
4.6	O
%	O
)	O
patients	O
and	O
grade	O
4	O
in	O
one	O
(	O
1.5	O
%	O
)	O
patient	O
.	O

Thrombocytopenia	B
and	O
leukopenia	B
occurred	O
with	O
grade	O
3	O
intensity	O
in	O
five	O
(	O
7.7	O
%	O
)	O
and	O
three	O
(	O
4.6	O
%	O
)	O
patients	O
,	O
respectively	O
.	O

However	O
,	O
no	O
grade	O
4	O
thrombocytopenia	B
and	O
leukopenia	B
were	O
observed	O
.	O

Grade	O
1	O
/	O
2	O
nausea	B
/	O
vomiting	B
and	O
diarrhea	B
were	O
observed	O
in	O
33	O
(	O
50.8	O
%	O
)	O
,	O
17	O
(	O
26.2	O
%	O
)	O
,	O
26	O
(	O
40	O
%	O
)	O
,	O
44	O
(	O
67.7	O
%	O
)	O
,	O
and	O
13	O
(	O
20	O
%	O
)	O
patients	O
,	O
respectively	O
,	O
and	O
grade	O
3	O
nausea	B
/	O
vomiting	B
and	O
diarrhea	B
were	O
observed	O
in	O
one	O
(	O
1.5	O
%	O
)	O
and	O
four	O
(	O
6.2	O
%	O
)	O
patients	O
.	O

Yet	O
,	O
no	O
grade	O
4	O
nonhematologic	B
toxicity	I
was	O
observed	O
.	O

Capecitabine	O
/	O
oxaliplatin	O
combination	O
chemotherapy	O
is	O
active	O
in	O
Chinese	O
patients	O
with	O
previously	O
untreated	O
advanced	O
gastric	B
cancer	I
.	O

Clinical	O
implications	O
of	O
clopidogrel	O
resistance	O
.	O

The	O
benefits	O
of	O
clopidogrel	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
coronary	B
artery	I
disease	I
are	O
well	O
established	O
,	O
however	O
,	O
not	O
all	O
individuals	O
respond	O
in	O
the	O
same	O
way	O
to	O
clopidogrel	O
;	O
there	O
are	O
patients	O
who	O
suffer	O
adverse	O
events	O
despite	O
clopidogrel	O
treatment	O
.	O

This	O
review	O
focuses	O
on	O
the	O
definition	O
,	O
potential	O
mechanisms	O
for	O
and	O
clinical	O
implications	O
of	O
clopidogrel	O
resistance	O
,	O
as	O
well	O
as	O
the	O
strategies	O
to	O
improve	O
the	O
response	O
to	O
this	O
antiplatelet	O
drug	O
.	O

There	O
is	O
an	O
inter	O
-	O
individual	O
variability	O
in	O
response	O
to	O
clopidogrel	O
therapy	O
,	O
and	O
a	O
sub	O
-	O
optimal	O
response	O
(	O
clopidogrel	O
resistance	O
)	O
has	O
been	O
associated	O
with	O
adverse	B
cardiovascular	I
events	I
.	O

Nevertheless	O
,	O
there	O
is	O
no	O
clear	O
and	O
consensual	O
definition	O
of	O
clopidogrel	O
resistance	O
.	O

Response	O
to	O
clopidogrel	O
therapy	O
follows	O
a	O
normal	O
,	O
bell	O
-	O
shaped	O
distribution	O
,	O
so	O
a	O
more	O
appropriate	O
description	O
would	O
be	O
variable	O
response	O
rather	O
than	O
clopidogrel	O
resistance	O
.	O

Independent	O
of	O
the	O
term	O
used	O
,	O
lower	O
response	O
to	O
clopidogrel	O
therapy	O
seems	O
to	O
be	O
associated	O
with	O
a	O
higher	O
probability	O
of	O
suffering	O
thrombotic	B
events	I
.	O

Due	O
to	O
the	O
misleading	O
definition	O
of	O
resistance	O
and	O
non	O
-	O
standardized	O
method	O
for	O
assessing	O
platelet	O
inhibition	O
,	O
current	O
guidelines	O
do	O
not	O
recommend	O
the	O
use	O
of	O
platelet	O
function	O
assays	O
to	O
monitor	O
the	O
inhibitory	O
effect	O
of	O
antiplatelet	O
drugs	O
.	O

Current	O
guidelines	O
also	O
do	O
not	O
recommend	O
clopidogrel	O
loading	O
doses	O
higher	O
than	O
300	O
mg	O
and	O
daily	O
maintenance	O
doses	O
higher	O
than	O
75	O
mg	O
,	O
even	O
though	O
a	O
regimen	O
of	O
600	O
mg	O
clopidogrel	O
loading	O
dose	O
seems	O
to	O
be	O
preferred	O
for	O
patients	O
undergoing	O
percutaneous	O
coronary	O
interventions	O
.	O

Headache	B
:	O
one	O
of	O
the	O
most	O
common	O
and	O
troublesome	O
adverse	O
reactions	O
to	O
drugs	O
.	O

It	O
is	O
difficult	O
to	O
attribute	O
the	O
diagnosis	O
of	O
adverse	O
drug	O
reaction	O
to	O
a	O
condition	O
which	O
is	O
also	O
a	O
common	O
symptom	O
.	O

The	O
decision	O
might	O
be	O
arduous	O
in	O
the	O
case	O
of	O
headache	B
,	O
because	O
this	O
disorder	O
is	O
very	O
frequent	O
in	O
the	O
general	O
population	O
.	O

The	O
drugs	O
that	O
more	O
frequently	O
induce	O
headache	B
belong	O
to	O
a	O
variety	O
of	O
therapeutic	O
classes	O
with	O
different	O
mechanisms	O
of	O
action	O
and	O
different	O
toxicity	O
.	O

In	O
the	O
majority	O
of	O
cases	O
the	O
headache	B
has	O
not	O
a	O
typical	O
feature	O
,	O
it	O
is	O
dose	O
-	O
dependent	O
,	O
and	O
is	O
associated	O
to	O
other	O
symptoms	O
of	O
neurotoxicity	B
.	O

Some	O
drugs	O
cause	O
,	O
instead	O
,	O
a	O
specific	O
headache	B
:	O
this	O
is	O
the	O
case	O
of	O
NO	O
donors	O
,	O
which	O
are	O
also	O
used	O
in	O
experimental	O
studies	O
in	O
order	O
to	O
induce	O
headache	B
.	O

This	O
review	O
describes	O
the	O
classes	O
of	O
drugs	O
which	O
induce	O
headache	B
,	O
analyzes	O
the	O
frequency	O
of	O
headache	B
induction	O
among	O
the	O
drugs	O
of	O
the	O
same	O
class	O
,	O
and	O
discusses	O
the	O
possible	O
mechanisms	O
underlying	O
headache	B
induction	O
.	O

It	O
is	O
to	O
be	O
hoped	O
that	O
a	O
better	O
awareness	O
of	O
this	O
issue	O
would	O
help	O
the	O
physician	O
to	O
consider	O
it	O
in	O
the	O
differential	O
diagnosis	O
of	O
a	O
recent	O
-	O
onset	O
or	O
changed	O
headache	B
and	O
to	O
avoid	O
prescription	O
of	O
drugs	O
known	O
to	O
cause	O
headache	B
to	O
patients	O
already	O
suffering	O
from	O
this	O
disorder	O
.	O

QT	O
prolongation	O
and	O
safety	O
in	O
the	O
Indian	O
population	O
.	O

The	O
QT	O
interval	O
in	O
electrocardiogram	O
(	O
ECG	O
)	O
reflects	O
the	O
total	O
duration	O
of	O
ventricular	O
myocardial	O
depolarization	O
and	O
repolarization	O
.	O

It	O
has	O
been	O
well	O
recognized	O
that	O
many	O
condition	O
may	O
cause	O
QT	O
interval	O
prolongation	O
.	O

Unfortunately	O
,	O
numbers	O
of	O
cardiac	O
and	O
non	O
-	O
cardiac	O
drug	O
prolong	O
the	O
QT	O
interval	O
and	O
cause	O
a	O
distinctive	O
polymorphic	B
ventricular	I
tachycardia	I
termed	O
torsade	B
de	I
pointes	I
(	O
TdP	B
)	O
.	O

TdP	B
can	O
degenerate	O
into	O
ventricular	B
fibrillation	I
,	O
which	O
leads	O
to	O
sudden	B
cardiac	I
death	I
.	O

Recently	O
various	O
regulatory	O
and	O
clinical	O
bodies	O
of	O
Europe	O
,	O
USA	O
,	O
Canada	O
and	O
Australia	O
have	O
made	O
their	O
focus	O
on	O
the	O
drugs	O
that	O
induce	O
prolongation	O
of	O
QT	O
interval	O
.	O

Committee	O
for	O
Proprietary	O
Medicinal	O
Products	O
(	O
CPMP	O
)	O
of	O
the	O
European	O
Agency	O
issued	O
a	O
document	O
entitled	O
'	O
Points	O
to	O
Consider	O
:	O

The	O
assessment	O
of	O
the	O
potential	O
for	O
QT	O
interval	O
prolongation	O
by	O
non	O
-	O
cardiovascular	O
medicinal	O
products	O
'	O
[	O
1	O
,	O
2	O
]	O
.	O

In	O
addition	O
,	O
USFDA	O
adopted	O
the	O
guideline	O
'	O
Clinical	O
evaluation	O
of	O
QT	O
/	O
QTc	O
interval	O
prolongation	O
and	O
proarrhythmic	O
potential	O
for	O
non	O
-	O
anti	O
arrhythmic	O
drugs	O
'	O
[	O
3	O
]	O
.	O

These	O
documents	O
and	O
guidelines	O
are	O
primarily	O
concern	O
with	O
development	O
of	O
novel	O
agents	O
and	O
the	O
new	O
use	O
or	O
new	O
dose	O
of	O
already	O
approved	O
drugs	O
.	O

The	O
scope	O
of	O
this	O
guideline	O
is	O
to	O
study	O
the	O
effect	O
of	O
drugs	O
on	O
QT	O
prolongation	O
and	O
give	O
idea	O
of	O
evaluation	O
of	O
drug	O
's	O
effects	O
on	O
QT	O
prolongation	O
.	O

Today	O
more	O
than	O
50	O
available	O
drugs	O
(	O
both	O
old	O
and	O
new	O
)	O
have	O
been	O
identify	O
,	O
which	O
prolong	O
the	O
QT	O
interval	O
[	O
1	O
]	O
.	O

Several	O
drugs	O
have	O
been	O
withdrawn	O
from	O
many	O
countries	O
on	O
this	O
basis	O
but	O
many	O
of	O
these	O
drugs	O
are	O
still	O
available	O
in	O
Indian	O
market	O
and	O
potentially	O
creating	O
life	O
-	O
threatening	O
arrhythmias	B
.	O

This	O
article	O
will	O
focus	O
on	O
recommendation	O
of	O
study	O
on	O
the	O
normal	O
limits	O
of	O
QT	O
interval	O
in	O
Indian	O
population	O
and	O
preparation	O
of	O
the	O
database	O
,	O
which	O
can	O
be	O
helpful	O
in	O
withdrawal	O
of	O
drugs	O
from	O
the	O
market	O
that	O
produces	O
QT	O
prolongation	O
.	O

Drotrecogin	O
alfa	O
(	O
activated	O
)	O
in	O
the	O
treatment	O
of	O
severe	O
sepsis	B
.	O

Severe	O
sepsis	B
and	O
septic	B
shock	I
are	O
common	O
in	O
the	O
critically	O
ill	O
patient	O
and	O
account	O
for	O
considerable	O
morbidity	O
and	O
mortality	O
not	O
to	O
mention	O
the	O
high	O
associated	O
costs	O
.	O

Advances	O
in	O
our	O
understanding	O
of	O
sepsis	B
pathophysiology	O
and	O
in	O
the	O
important	O
link	O
between	O
the	O
inflammatory	O
response	O
to	O
sepsis	B
and	O
activation	O
of	O
coagulation	O
led	O
to	O
the	O
development	O
and	O
licensing	O
of	O
the	O
first	O
ever	O
,	O
specific	O
,	O
immunomodulatory	O
anti	O
-	O
sepsis	O
drug	O
.	O

Drotrecogin	O
alfa	O
(	O
activated	O
)	O
,	O
a	O
recombinant	O
version	O
of	O
activated	O
protein	O
C	O
,	O
was	O
shown	O
in	O
a	O
large	O
randomized	O
controlled	O
clinical	O
trial	O
to	O
reduce	O
mortality	O
rates	O
from	O
30.8	O
%	O
in	O
the	O
placebo	O
group	O
to	O
24.7	O
%	O
in	O
the	O
treatment	O
group	O
,	O
which	O
equated	O
to	O
one	O
additional	O
life	O
saved	O
for	O
every	O
16	O
patients	O
treated	O
.	O

Vasopressor	O
requirements	O
and	O
duration	O
of	O
mechanical	O
ventilation	O
were	O
also	O
reduced	O
.	O

Apart	O
from	O
an	O
expected	O
increased	O
risk	O
of	O
severe	O
bleeding	B
,	O
mostly	O
associated	O
with	O
interventions	O
,	O
drotrecogin	O
alfa	O
(	O
activated	O
)	O
was	O
not	O
associated	O
with	O
any	O
other	O
adverse	O
reactions	O
.	O

In	O
this	O
article	O
,	O
I	O
will	O
briefly	O
summarize	O
the	O
events	O
leading	O
to	O
the	O
development	O
of	O
drotrecogin	O
alfa	O
(	O
activated	O
)	O
including	O
aspects	O
of	O
sepsis	B
epidemiology	O
and	O
pathophysiology	O
and	O
the	O
results	O
of	O
early	O
animal	O
and	O
clinical	O
studies	O
.	O

The	O
results	O
of	O
the	O
large	O
multicenter	O
phase	O
III	O
PROWESS	O
study	O
will	O
then	O
be	O
reviewed	O
,	O
along	O
with	O
results	O
from	O
subsequent	O
open	O
-	O
label	O
studies	O
.	O

Finally	O
,	O
I	O
will	O
focus	O
on	O
the	O
key	O
side	O
effect	O
issue	O
with	O
drotrecogin	O
alfa	O
(	O
activated	O
)	O
,	O
that	O
of	O
increased	O
bleeding	B
,	O
drawing	O
data	O
from	O
the	O
available	O
clinical	O
studies	O
,	O
and	O
highlighting	O
the	O
contraindications	O
and	O
precautions	O
when	O
prescribing	O
this	O
drug	O
.	O

Carboplatin	O
and	O
paclitaxel	O
versus	O
cisplatin	O
,	O
paclitaxel	O
and	O
doxorubicin	O
for	O
first	O
-	O
line	O
chemotherapy	O
of	O
advanced	O
ovarian	B
cancer	I
:	O
a	O
Hellenic	O
Cooperative	O
Oncology	O
Group	O
(	O
HeCOG	O
)	O
study	O
.	O

INTRODUCTION	O
:	O
The	O
combination	O
of	O
Carboplatin	O
and	O
Paclitaxel	O
is	O
considered	O
the	O
standard	O
of	O
care	O
as	O
initial	O
chemotherapy	O
for	O
Advanced	O
Ovarian	B
Cancer	I
(	O
AOC	B
)	O
.	O

We	O
compared	O
this	O
regimen	O
with	O
the	O
combination	O
of	O
Cisplatin	O
,	O
Paclitaxel	O
and	O
Doxorubicin	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
AOC	B
were	O
randomised	O
to	O
either	O
six	O
courses	O
of	O
Paclitaxel	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
Carboplatin	O
7AUC	O
or	O
Paclitaxel	O
at	O
the	O
same	O
dose	O
plus	O
Cisplatin	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
Doxorubicin	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

RESULTS	O
:	O
Analysis	O
was	O
performed	O
on	O
451	O
patients	O
.	O

The	O
treatment	O
groups	O
were	O
well	O
balanced	O
with	O
regard	O
to	O
patient	O
and	O
disease	O
characteristics	O
.	O

Performance	O
status	O
(	O
PS	O
)	O
was	O
better	O
in	O
the	O
anthracycline	O
arm	O
.	O

In	O
terms	O
of	O
severe	O
toxicity	O
,	O
the	O
only	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
was	O
the	O
development	O
of	O
febrile	B
neutropaenia	I
in	O
the	O
anthracycline	O
arm	O
.	O

Overall	O
response	O
rate	O
was	O
similar	O
in	O
both	O
groups	O
.	O

With	O
a	O
median	O
follow	O
-	O
up	O
of	O
57.5	O
months	O
,	O
a	O
marginal	O
significance	O
towards	O
improved	O
Progression	O
-	O
Free	O
Survival	O
(	O
PFS	O
)	O
was	O
noted	O
in	O
favour	O
of	O
the	O
anthracycline	O
arm	O
,	O
whilst	O
there	O
was	O
no	O
difference	O
in	O
overall	O
survival	O
.	O

In	O
multivariate	O
analysis	O
the	O
hazard	O
of	O
disease	O
progression	O
at	O
any	O
time	O
was	O
significantly	O
decreased	O
by	O
25.5	O
%	O
for	O
patients	O
of	O
the	O
anthracycline	O
arm	O
.	O

CONCLUSION	O
:	O
The	O
combination	O
of	O
Cisplatin	O
,	O
Paclitaxel	O
and	O
Doxorubicin	O
demonstrates	O
a	O
marginal	O
PFS	O
improvement	O
,	O
but	O
no	O
additional	O
survival	O
benefit	O
when	O
compared	O
with	O
the	O
standard	O
Carboplatin	O
/	O
Paclitaxel	O
regimen	O
.	O

Adapalene	O
0.1	O
%	O
and	O
benzoyl	O
peroxide	O
2.5	O
%	O
as	O
a	O
fixed	O
-	O
dose	O
combination	O
gel	O
is	O
as	O
well	O
tolerated	O
as	O
the	O
individual	O
components	O
alone	O
in	O
terms	O
of	O
cumulative	O
irritancy	O
.	O

International	O
guidelines	O
recommend	O
the	O
combination	O
of	O
retinoids	O
(	O
e.g.	O
adapalene	O
,	O
tazarotene	O
)	O
and	O
benzoyl	O
peroxide	O
for	O
treating	O
acne	B
because	O
of	O
their	O
complementary	O
mechanisms	O
of	O
action	O
.	O

A	O
new	O
fixed	O
-	O
dose	O
combination	O
gel	O
of	O
adapalene	O
0.1	O
%	O
and	O
benzoyl	O
peroxide	O
(	O
BPO	O
)	O
2.5	O
%	O
(	O
adapalene	O
/	O
BPO	O
*	O
)	O
is	O
an	O
effective	O
acne	B
treatment	O
and	O
offers	O
the	O
advantage	O
of	O
a	O
once	O
daily	O
application	O
.	O

This	O
paper	O
reports	O
the	O
results	O
of	O
a	O
cumulative	O
irritancy	O
study	O
in	O
healthy	O
volunteers	O
comparing	O
adapalene	O
/	O
BPO	O
to	O
adapalene	O
0.1	O
%	O
and	O
BPO	O
2.5	O
%	O
applied	O
separately	O
,	O
BPO	O
10	O
%	O
gel	O
,	O
tazarotene	O
0.1	O
%	O
gel	O
and	O
the	O
gel	O
vehicle	O
as	O
a	O
control	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
mean	O
cumulative	O
irritation	O
index	O
(	O
MCII	O
)	O
for	O
adapalene	O
/	O
BPO	O
and	O
any	O
test	O
product	O
except	O
tazarotene	O
0.1	O
%	O
gel	O
,	O
which	O
had	O
a	O
significantly	O
greater	O
MCII	O
than	O
all	O
other	O
test	O
products	O
(	O
p	O
<	O
0.05	O
)	O
.	O

This	O
study	O
showed	O
that	O
adapalene	O
/	O
BPO	O
as	O
a	O
fixed	O
-	O
dose	O
combination	O
is	O
as	O
well	O
tolerated	O
as	O
BPO	O
2.5	O
%	O
gel	O
alone	O
or	O
adapalene	O
0.1	O
%	O
gel	O
alone	O
in	O
terms	O
of	O
cumulative	O
irritancy	O
.	O

*	O
Epiduo	O
,	O
Galderma	O
S	O
.	O

A	O
.	O

The	O
effect	O
of	O
implementing	O
computerized	O
provider	O
order	O
entry	O
on	O
medication	O
prescribing	O
errors	O
in	O
an	O
emergency	O
department	O
.	O

Medication	O
errors	O
are	O
a	O
major	O
concern	O
in	O
the	O
Emergency	O
Department	O
(	O
ED	O
)	O
.	O

We	O
examined	O
medication	O
prescribing	O
errors	O
among	O
consecutive	O
adult	O
ED	O
patients	O
during	O
two	O
10	O
-	O
day	O
periods	O
before	O
and	O
during	O
one	O
9	O
-	O
day	O
period	O
after	O
implementing	O
computerized	O
provider	O
order	O
entry	O
in	O
an	O
adult	O
ED	O
.	O

2,073	O
patients	O
had	O
5,950	O
,	O
orders	O
.	O

Before	O
(	O
after	O
)	O
implementation	O
there	O
were	O
3.7	O
(	O
2.8	O
)	O
potential	O
adverse	O
drug	O
events	O
,	O
222.0	O
(	O
21.0	O
)	O
medication	O
prescribing	O
errors	O
,	O
and	O
5.1	O
(	O
0	O
)	O
rule	O
violations	O
per	O
100	O
orders	O
.	O

The	O
effect	O
of	O
thiazolidinediones	O
on	O
BMD	B
and	O
osteoporosis	B
.	O

Thiazolidinediones	O
,	O
also	O
known	O
as	O
glitazones	O
,	O
are	O
insulin	O
-	O
sensitizing	O
medications	O
that	O
account	O
for	O
approximately	O
21	O
%	O
of	O
oral	O
antihyperglycemic	O
drugs	O
used	O
in	O
the	O
US	O
.	O

Although	O
the	O
main	O
therapeutic	O
effects	O
occur	O
in	O
adipose	O
tissue	O
,	O
muscles	O
and	O
the	O
liver	O
,	O
studies	O
suggest	O
effects	O
in	O
bone	O
as	O
well	O
.	O

Currently	O
,	O
two	O
thiazolidinediones	O
are	O
marketed	O
in	O
the	O
US	O
-	O
rosiglitazone	O
and	O
pioglitazone	O
-	O
and	O
several	O
others	O
are	O
under	O
investigation	O
.	O

This	O
Review	O
examines	O
the	O
evidence	O
regarding	O
the	O
effects	O
of	O
thiazolidinediones	O
on	O
skeletal	O
health	O
.	O

These	O
drugs	O
appear	O
to	O
trigger	O
preferential	O
differentiation	O
of	O
mesenchymal	O
stem	O
cells	O
into	O
adipocytes	O
rather	O
than	O
osteoblasts	O
,	O
leading	O
to	O
decreased	O
bone	O
formation	O
and	O
increased	O
adipogenesis	O
.	O

Although	O
only	O
a	O
few	O
small	O
,	O
randomized	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
thiazolidinediones	O
on	O
bone	O
in	O
humans	O
,	O
the	O
available	O
data	O
suggest	O
that	O
these	O
agents	O
contribute	O
to	O
bone	B
loss	I
in	O
postmenopausal	O
women	O
;	O
the	O
relationship	O
is	O
less	O
clear	O
in	O
men	O
.	O

On	O
the	O
basis	O
of	O
this	O
limited	O
evidence	O
,	O
the	O
absolute	O
increase	O
in	O
fracture	B
risk	O
associated	O
with	O
thiazolidinediones	O
seems	O
to	O
be	O
small	O
.	O

Pending	O
data	O
from	O
future	O
randomized	O
,	O
controlled	O
trials	O
of	O
the	O
association	O
between	O
thiazolidinediones	O
and	O
low	O
bone	O
mass	O
,	O
prescribers	O
should	O
consider	O
use	O
of	O
these	O
drugs	O
as	O
a	O
risk	O
factor	O
for	O
the	O
development	O
of	O
osteoporosis	B
in	O
postmenopausal	O
women	O
.	O

Identification	O
and	O
characterization	O
of	O
thiosemicarbazones	O
with	O
antifungal	O
and	O
antitumor	O
effects	O
:	O
cellular	O
iron	O
chelation	O
mediating	O
cytotoxic	B
activity	I
.	O

Thiosemicarbazones	O
derived	O
from	O
acetylpyrazines	O
were	O
prepared	O
by	O
condensing	O
an	O
acetylpyrazine	O
or	O
a	O
ring	O
-	O
substituted	O
acetylpyrazine	O
with	O
thiosemicarbazide	O
.	O

Using	O
the	O
same	O
procedure	O
,	O
N	O
,	O
N	O
-	O
dimethylthiosemicarbazones	O
were	O
synthesized	O
from	O
acetylpyrazines	O
and	O
N	O
,	O
N	O
-	O
dimethylthiosemicarbazide	O
.	O

A	O
total	O
of	O
20	O
compounds	O
(	O
16	O
novel	O
)	O
were	O
chemically	O
characterized	O
and	O
then	O
tested	O
for	O
antifungal	O
effects	O
on	O
eight	O
strains	O
of	O
fungi	O
and	O
also	O
for	O
antitumor	O
activity	O
against	O
SK	O
-	O
N	O
-	O
MC	O
neuroepithelioma	O
cells	O
.	O

The	O
most	O
effective	O
compound	O
identified	O
in	O
terms	O
of	O
both	O
antifungal	O
and	O
antitumor	O
activity	O
was	O
N	O
,	O
N	O
-	O
dimethyl	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrazin	O
-	O
2	O
-	O
ylethylidene	O
)	O
hydrazinecarbothioamide	O
(	O
5a	O
)	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
this	O
and	O
its	O
related	O
thiosemicarbazones	O
was	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
its	O
ability	O
to	O
act	O
as	O
a	O
tridentate	O
ligand	O
that	O
binds	O
metal	O
ions	O
.	O

This	O
was	O
deduced	O
from	O
preparation	O
of	O
the	O
related	O
thiosemicarbazones	O
[	O
acetophenone	O
thiosemicarbazone	O
(	O
6	O
)	O
and	O
acetophenone	O
N	O
,	O
N	O
-	O
dimethylthiosemicarbazone	O
(	O
7	O
)	O
]	O
that	O
do	O
not	O
possess	O
a	O
coordinating	O
ring	O
-	O
N	O
,	O
which	O
plays	O
a	O
vital	O
role	O
in	O
metal	O
ion	O
chelation	O
.	O

Furthermore	O
,	O
5a	O
and	O
several	O
other	O
thiosemicarbazones	O
that	O
showed	O
high	O
antiproliferative	O
activity	O
were	O
demonstrated	O
to	O
have	O
marked	O
iron	O
(	O
Fe	O
)	O
chelation	O
efficacy	O
.	O

In	O
fact	O
,	O
these	O
agents	O
were	O
highly	O
effective	O
at	O
mobilizing	O
(	O
59	O
)	O
Fe	O
from	O
prelabeled	O
SK	O
-	O
N	O
-	O
MC	O
cells	O
and	O
preventing	O
(	O
59	O
)	O
Fe	O
uptake	O
from	O
the	O
serum	O
Fe	O
transport	O
protein	O
,	O
transferrin	O
.	O

In	O
contrast	O
,	O
compounds	O
6	O
and	O
7	O
that	O
do	O
not	O
possess	O
a	O
tridentate	O
metal	O
-	O
binding	O
site	O
showed	O
little	O
activity	O
.	O

Further	O
studies	O
examining	O
ascorbate	O
oxidation	O
demonstrated	O
that	O
the	O
Fe	O
complexes	O
of	O
the	O
most	O
effective	O
compounds	O
were	O
redox	O
-	O
inactive	O
.	O

Thus	O
,	O
in	O
contrast	O
to	O
other	O
thiosemicarbazones	O
with	O
potent	O
antiproliferative	O
activity	O
,	O
Fe	O
chelation	O
and	O
mobilization	O
rather	O
than	O
free	O
radical	O
generation	O
played	O
a	O
significant	O
role	O
in	O
the	O
cytotoxic	B
effects	I
of	O
the	O
current	O
ligands	O
.	O

Dronedarone	O
:	O
a	O
new	O
treatment	O
for	O
atrial	B
fibrillation	I
.	O

Dronedarone	O
.	O

Dronedarone	O
is	O
a	O
benzofuran	O
derivative	O
pharmacologically	O
related	O
to	O
amiodarone	O
but	O
without	O
the	O
iodine	O
moiety	O
.	O

It	O
is	O
designed	O
for	O
the	O
treatment	O
of	O
atrial	B
fibrillation	I
and	O
atrial	B
flutter	I
.	O

Historically	O
,	O
amiodarone	O
has	O
proved	O
most	O
effective	O
in	O
maintaining	O
sinus	O
rhythm	O
and	O
has	O
been	O
used	O
safely	O
in	O
patients	O
with	O
advanced	O
heart	B
failure	I
.	O

However	O
,	O
its	O
use	O
has	O
been	O
limited	O
by	O
cumulative	O
and	O
often	O
irreversible	B
organ	I
toxicity	I
,	O
especially	O
in	O
younger	O
patients	O
.	O

Dronedarone	O
was	O
developed	O
in	O
an	O
effort	O
to	O
provide	O
equivalent	O
efficacy	O
and	O
safety	O
with	O
less	O
toxicity	O
.	O

Dronedarone	O
has	O
proved	O
efficacious	O
without	O
toxic	O
or	O
proarrhythmic	O
effects	O
and	O
has	O
minimal	O
side	O
effects	O
,	O
but	O
remaining	O
concerns	O
exist	O
regarding	O
its	O
use	O
in	O
patients	O
with	O
advanced	O
heart	B
failure	I
.	O

Cadmium	O
activates	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathway	O
via	O
induction	O
of	O
reactive	O
oxygen	O
species	O
and	O
inhibition	O
of	O
protein	O
phosphatases	O
2A	O
and	O
5	O
.	O

Cadmium	O
(	O
Cd	O
)	O
,	O
a	O
highly	O
toxic	O
environmental	O
pollutant	O
,	O
induces	O
neurodegenerative	B
diseases	I
.	O

Recently	O
we	O
have	O
demonstrated	O
that	O
Cd	O
may	O
induce	O
neuronal	O
apoptosis	O
in	O
part	O
through	O
activation	O
of	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
and	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
1	O
/	O
2	O
(	O
Erk1	O
/	O
2	O
)	O
pathways	O
.	O

However	O
,	O
the	O
underlying	O
mechanism	O
remains	O
enigmatic	O
.	O

Here	O
we	O
show	O
that	O
Cd	O
induced	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
leading	O
to	O
apoptosis	O
of	O
PC12	O
and	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Pretreatment	O
with	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
scavenged	O
Cd	O
-	O
induced	O
ROS	O
,	O
and	O
prevented	O
cell	O
death	O
,	O
suggesting	O
that	O
Cd	O
-	O
induced	O
apoptosis	O
is	O
attributed	O
to	O
its	O
induction	O
of	O
ROS	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
Cd	O
-	O
induced	O
ROS	O
inhibited	O
serine	O
/	O
threonine	O
protein	O
phosphatases	O
2A	O
(	O
PP2A	O
)	O
and	O
5	O
(	O
PP5	O
)	O
,	O
leading	O
to	O
activation	O
of	O
Erk1	O
/	O
2	O
and	O
JNK	O
,	O
which	O
was	O
abrogated	O
by	O
NAC	O
.	O

Overexpression	O
of	O
PP2A	O
or	O
PP5	O
partially	O
prevented	O
Cd	O
-	O
induced	O
activation	O
of	O
Erk1	O
/	O
2	O
and	O
JNK	O
,	O
as	O
well	O
as	O
cell	O
death	O
.	O

Cd	O
-	O
induced	O
ROS	O
was	O
also	O
linked	O
to	O
the	O
activation	O
of	O
caspase	O
-	O
3	O
.	O

Pretreatment	O
with	O
inhibitors	O
of	O
JNK	O
(	O
SP600125	O
)	O
and	O
Erk1	O
/	O
2	O
(	O
U0126	O
)	O
partially	O
blocked	O
Cd	O
-	O
induced	O
cleavage	O
of	O
caspase	O
-	O
3	O
and	O
prevented	O
cell	O
death	O
.	O

However	O
,	O
zVAD	O
-	O
fmk	O
,	O
a	O
pan	O
caspase	O
inhibitor	O
,	O
only	O
partially	O
prevented	O
Cd	O
-	O
induced	O
apoptosis	O
.	O

The	O
results	O
indicate	O
that	O
Cd	O
induction	O
of	O
ROS	O
inhibits	O
PP2A	O
and	O
PP5	O
,	O
leading	O
to	O
activation	O
of	O
JNK	O
and	O
Erk1	O
/	O
2	O
pathways	O
,	O
and	O
consequently	O
resulting	O
in	O
caspase	O
-	O
dependent	O
and	O
-	O
independent	O
apoptosis	O
of	O
neuronal	O
cells	O
.	O

The	O
findings	O
strongly	O
suggest	O
that	O
the	O
inhibitors	O
of	O
JNK	O
,	O
Erk1	O
/	O
2	O
,	O
or	O
antioxidants	O
may	O
be	O
exploited	O
for	O
prevention	O
of	O
Cd	O
-	O
induced	O
neurodegenerative	B
diseases	I
.	O

Experimental	O
models	O
of	O
sepsis	B
and	O
their	O
clinical	O
relevance	O
.	O

Sepsis	B
remains	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
mainly	O
because	O
of	O
sepsis	B
-	O
induced	O
multiple	B
organ	I
dysfunction	I
.	O

In	O
contrast	O
to	O
preclinical	O
studies	O
,	O
most	O
clinical	O
trials	O
of	O
promising	O
new	O
treatment	O
strategies	O
for	O
sepsis	B
have	O
failed	O
to	O
demonstrate	O
efficacy	O
.	O

Although	O
many	O
reasons	O
could	O
account	O
for	O
this	O
discrepancy	O
,	O
the	O
misinterpretation	O
of	O
preclinical	O
data	O
obtained	O
from	O
experimental	O
studies	O
and	O
especially	O
the	O
use	O
of	O
animal	O
models	O
that	O
do	O
not	O
adequately	O
mimic	O
human	O
sepsis	B
may	O
have	O
been	O
contributing	O
factors	O
.	O

In	O
this	O
review	O
,	O
the	O
potentials	O
and	O
limitations	O
of	O
various	O
animal	O
models	O
of	O
sepsis	B
are	O
discussed	O
to	O
clarify	O
to	O
which	O
extent	O
these	O
findings	O
are	O
relevant	O
to	O
human	O
sepsis	B
.	O

Such	O
models	O
include	O
intravascular	O
infusion	O
of	O
endotoxin	O
or	O
live	O
bacteria	O
,	O
bacterial	B
peritonitis	I
,	O
cecal	O
ligation	O
and	O
perforation	O
,	O
soft	B
tissue	I
infection	I
,	O
pneumonia	B
or	O
meningitis	B
models	O
using	O
different	O
animal	O
species	O
including	O
rats	O
,	O
mice	O
,	O
rabbits	O
,	O
dogs	O
,	O
pigs	O
,	O
sheep	O
,	O
and	O
nonhuman	O
primates	O
.	O

Despite	O
several	O
limitations	O
,	O
animal	O
models	O
remain	O
essential	O
in	O
the	O
development	O
of	O
all	O
new	O
therapies	O
for	O
sepsis	B
and	O
septic	B
shock	I
because	O
they	O
provide	O
fundamental	O
information	O
about	O
the	O
pharmacokinetics	O
,	O
toxicity	O
,	O
and	O
mechanism	O
of	O
drug	O
action	O
that	O
can	O
not	O
be	O
replaced	O
by	O
other	O
methods	O
.	O

New	O
therapeutic	O
agents	O
should	O
be	O
studied	O
in	O
infection	B
models	O
,	O
even	O
after	O
the	O
initiation	O
of	O
the	O
septic	O
process	O
.	O

Furthermore	O
,	O
debility	O
conditions	O
need	O
to	O
be	O
reproduced	O
to	O
avoid	O
the	O
exclusive	O
use	O
of	O
healthy	O
animals	O
,	O
which	O
often	O
do	O
not	O
represent	O
the	O
human	O
septic	O
patient	O
.	O

Relationship	O
between	O
airborne	O
pollen	O
count	O
and	O
treatment	O
outcome	O
in	O
Japanese	O
cedar	O
pollinosis	B
patients	O
.	O

In	O
Japan	O
,	O
information	O
on	O
daily	O
Japanese	O
cedar	O
pollen	O
counts	O
is	O
made	O
public	O
during	O
pollen	O
season	O
.	O

If	O
symptom	O
severity	O
and	O
treatment	O
outcome	O
are	O
predictable	O
according	O
to	O
these	O
pollen	O
counts	O
,	O
management	O
of	O
seasonal	B
allergic	I
rhinitis	I
may	O
become	O
more	O
precise	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
evaluate	O
the	O
relationship	O
between	O
airborne	O
pollen	O
counts	O
,	O
symptom	O
severity	O
and	O
treatment	O
outcome	O
in	O
Japanese	O
cedar	O
pollinosis	B
patients	O
.	O

In	O
the	O
randomized	O
study	O
,	O
patients	O
with	O
moderate	O
to	O
most	O
severe	O
Japanese	O
pollinosis	B
were	O
treated	O
with	O
fexofenadine	O
(	O
60	O
mg	O
BD	O
)	O
or	O
fexofenadine	O
and	O
nasal	O
corticosteroids	O
for	O
2	O
weeks	O
.	O

During	O
the	O
same	O
period	O
daily	O
airborne	O
pollen	O
counts	O
were	O
measured	O
.	O

A	O
total	O
of	O
105	O
adult	O
patients	O
were	O
enrolled	O
.	O

No	O
difference	O
of	O
treatment	O
efficacy	O
was	O
seen	O
among	O
groups	O
.	O

Detailed	O
results	O
of	O
efficacy	O
and	O
safety	O
were	O
previously	O
described	O
elsewhere	O
.	O

In	O
univariate	O
analysis	O
,	O
the	O
mean	O
cumulative	O
amount	O
of	O
airborne	O
pollen	O
exposure	O
for	O
4	O
days	O
prior	O
to	O
the	O
study	O
tended	O
to	O
affect	O
symptom	O
severity	O
(	O
P	O
=	O
0.053	O
)	O
and	O
the	O
mean	O
cumulative	O
amount	O
of	O
airborne	O
pollen	O
during	O
the	O
treatment	O
period	O
tended	O
to	O
show	O
difference	O
among	O
five	O
treatment	O
outcome	O
categories	O
(	O
P	O
=	O
0.066	O
)	O
.	O

In	O
multivariate	O
analysis	O
,	O
the	O
mean	O
cumulative	O
amount	O
of	O
airborne	O
pollen	O
exposure	O
for	O
4	O
days	O
prior	O
to	O
the	O
study	O
was	O
identified	O
as	O
the	O
only	O
significant	O
factor	O
of	O
symptom	O
severity	O
(	O
P	O
=	O
0.0327	O
)	O
and	O
cumulative	O
amount	O
of	O
airborne	O
pollen	O
during	O
the	O
treatment	O
period	O
(	O
P	O
=	O
0.027	O
)	O
and	O
allergic	O
history	O
(	O
P	O
=	O
0.027	O
)	O
were	O
significant	O
factors	O
of	O
treatment	O
outcomes	O
.	O

No	O
serious	O
adverse	O
effect	O
was	O
reported	O
during	O
the	O
study	O
.	O

The	O
amount	O
of	O
airborne	O
pollen	O
may	O
be	O
predictive	O
of	O
both	O
symptom	O
severity	O
and	O
treatment	O
outcome	O
.	O

Concurrent	O
chemoradiation	O
for	O
locally	O
advanced	O
squamous	B
cell	I
carcinoma	I
of	I
the	I
vagina	I
:	O
case	O
series	O
and	O
literature	O
review	O
.	O

BACKGROUND	O
:	O
We	O
reviewed	O
our	O
experience	O
with	O
patients	O
with	O
primary	O
squamous	B
cell	I
carcinoma	I
of	I
the	I
vagina	I
who	O
received	O
concurrent	O
chemoradiation	O
therapy	O
(	O
CCRT	O
)	O
.	O

METHODS	O
:	O
We	O
retrospectively	O
analyzed	O
six	O
patients	O
(	O
median	O
age	O
,	O
60	O
years	O
)	O
with	O
squamous	B
cell	I
carcinoma	I
of	I
the	I
vagina	I
who	O
underwent	O
CCRT	O
between	O
2002	O
and	O
2005	O
at	O
the	O
University	O
of	O
the	O
Ryukyus	O
Hospital	O
.	O

Two	O
patients	O
were	O
in	O
International	O
Federation	O
of	O
Obstetricians	O
and	O
Gynecologists	O
(	O
FIGO	O
)	O
stage	O
II	O
,	O
one	O
in	O
stage	O
III	O
,	O
and	O
three	O
in	O
stage	O
IVA	O
.	O

All	O
patients	O
had	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
of	O
2	O
or	O
less	O
.	O

Tumor	O
size	O
ranged	O
from	O
3.2	O
to	O
7.7	O
cm	O
.	O

All	O
patients	O
were	O
treated	O
with	O
true	O
pelvic	O
external	O
-	O
beam	O
radiotherapy	O
(	O
EBRT	O
)	O
at	O
50	O
Gy	O
.	O

Then	O
two	O
of	O
the	O
six	O
patients	O
underwent	O
intracavitary	O
vaginal	O
brachy	O
-	O
therapy	O
.	O

The	O
remaining	O
four	O
patients	O
received	O
boost	O
EBRT	O
with	O
shrinking	O
fields	O
.	O

Total	O
radiation	O
dose	O
to	O
the	O
vaginal	B
tumor	I
ranged	O
from	O
60	O
to	O
66	O
Gy	O
.	O

All	O
patients	O
received	O
two	O
or	O
three	O
concomitant	O
cycles	O
of	O
cisplatin	O
during	O
EBRT	O
.	O

RESULTS	O
:	O
All	O
six	O
patients	O
completed	O
their	O
scheduled	O
CCRT	O
,	O
and	O
achieved	O
a	O
clinical	O
complete	O
response	O
.	O

One	O
stage	O
II	O
patient	O
died	O
of	O
disease	O
24	O
months	O
after	O
treatment	O
,	O
and	O
the	O
stage	O
III	O
patient	O
had	O
local	O
failure	O
at	O
12	O
months	O
.	O

The	O
remaining	O
four	O
patients	O
were	O
free	O
of	O
their	O
disease	O
at	O
18	O
,	O
23	O
,	O
33	O
,	O
and	O
55	O
months	O
,	O
respectively	O
.	O

One	O
patient	O
with	O
stage	O
IVA	O
developed	O
a	O
vesicovaginal	B
fistula	I
during	O
CCRT	O
.	O

Nevertheless	O
,	O
CCRT	O
was	O
well	O
tolerated	O
by	O
all	O
six	O
patients	O
,	O
and	O
no	O
grade	O
3	O
or	O
4	O
late	O
toxicity	O
was	O
observed	O
,	O
as	O
evaluated	O
by	O
the	O
Radiation	O
Therapy	O
Oncology	O
Group	O
(	O
RTOG	O
)	O
scoring	O
system	O
.	O

CONCLUSION	O
:	O
CCRT	O
is	O
effective	O
for	O
primary	O
squamous	B
cell	I
carcinoma	I
of	I
the	I
vagina	I
and	O
should	O
be	O
considered	O
for	O
treatment	O
in	O
patients	O
with	O
high	O
-	O
risk	O
disease	O
having	O
good	O
performance	O
status	O
.	O

Weekly	O
carboplatin	O
reduces	O
toxicity	O
during	O
synchronous	O
chemoradiotherapy	O
for	O
Merkel	B
cell	I
carcinoma	I
of	I
skin	I
.	O

PURPOSE	O
:	O
The	O
toxicity	O
of	O
radiotherapy	O
(	O
RT	O
)	O
combined	O
with	O
weekly	O
carboplatin	O
and	O
adjuvant	O
carboplatin	O
and	O
etoposide	O
was	O
prospectively	O
assessed	O
in	O
a	O
group	O
of	O
patients	O
with	O
high	O
-	O
risk	O
Stage	O
I	O
and	O
II	O
Merkel	B
cell	I
carcinoma	I
of	I
the	I
skin	I
.	O

This	O
regimen	O
was	O
compared	O
with	O
the	O
Trans	O
-	O
Tasman	O
Radiation	O
Oncology	O
Group	O
96	O
:	O
07	O
study	O
,	O
which	O
used	O
identical	O
eligibility	O
criteria	O
but	O
carboplatin	O
and	O
etoposide	O
every	O
3	O
weeks	O
during	O
RT	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
were	O
eligible	O
if	O
they	O
had	O
disease	O
localized	O
to	O
the	O
primary	O
site	O
and	O
lymph	O
nodes	O
,	O
with	O
high	O
-	O
risk	O
features	O
.	O

RT	O
was	O
delivered	O
to	O
the	O
primary	O
site	O
and	O
lymph	O
nodes	O
to	O
a	O
dose	O
of	O
50	O
Gy	O
and	O
weekly	O
carboplatin	O
(	O
area	O
under	O
the	O
curve	O
of	O
2	O
)	O
was	O
given	O
during	O
RT	O
.	O

This	O
was	O
followed	O
by	O
three	O
cycles	O
of	O
carboplatin	O
and	O
etoposide	O
.	O

A	O
total	O
of	O
18	O
patients	O
were	O
entered	O
into	O
the	O
study	O
,	O
and	O
their	O
data	O
were	O
compared	O
with	O
the	O
data	O
from	O
53	O
patients	O
entered	O
into	O
the	O
Trans	O
-	O
Tasman	O
Radiation	O
Oncology	O
Group	O
96	O
:	O
07	O
study	O
.	O

RESULTS	O
:	O
Involved	O
lymph	O
nodes	O
(	O
Stage	O
II	O
)	O
were	O
present	O
in	O
14	O
patients	O
(	O
77	O
%	O
)	O
.	O

Treatment	O
was	O
completed	O
as	O
planned	O
in	O
16	O
patients	O
.	O

The	O
weekly	O
carboplatin	O
dose	O
was	O
delivered	O
in	O
17	O
patients	O
,	O
and	O
15	O
were	O
able	O
to	O
complete	O
all	O
three	O
cycles	O
of	O
adjuvant	O
carboplatin	O
and	O
etoposide	O
.	O

Grade	O
3	O
and	O
4	O
neutrophil	B
toxicity	I
occurred	O
in	O
7	O
patients	O
,	O
but	O
no	O
cases	O
of	O
febrile	B
neutropenia	I
developed	O
.	O

Compared	O
with	O
the	O
Trans	O
-	O
Tasman	O
Radiation	O
Oncology	O
Group	O
96	O
:	O
07	O
protocol	O
(	O
19	O
of	O
53	O
cases	O
of	O
febrile	B
neutropenia	I
)	O
,	O
the	O
reduction	O
in	O
the	O
febrile	B
neutropenia	I
rate	O
(	O
p	O
=	O
0.003	O
)	O
and	O
decrease	O
in	O
Grade	O
3	O
skin	B
toxicity	I
(	O
p	O
=	O
0.006	O
)	O
were	O
highly	O
statistically	O
significant	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
our	O
study	O
have	O
shown	O
that	O
weekly	O
carboplatin	O
at	O
this	O
dosage	O
is	O
a	O
safe	O
way	O
to	O
deliver	O
synchronous	O
chemotherapy	O
during	O
RT	O
for	O
MCC	O
and	O
results	O
in	O
a	O
marked	O
reduction	O
of	O
febrile	B
neutropenia	I
and	O
Grade	O
3	O
skin	B
toxicity	I
compared	O
with	O
the	O
three	O
weekly	O
regimen	O
.	O

Raltitrexed	O
(	O
Tomudex	O
)	O
versus	O
standard	O
leucovorin	O
-	O
modulated	O
bolus	O
5	O
-	O
fluorouracil	O
:	O
Results	O
from	O
the	O
randomised	O
phase	O
III	O
Pan	O
-	O
European	O
Trial	O
in	O
Adjuvant	O
Colon	B
Cancer	I
01	O
(	O
PETACC	O
-	O
1	O
)	O
.	O

OBJECTIVES	O
:	O
PETACC	O
-	O
1	O
assessed	O
if	O
raltitrexed	O
is	O
non	O
-	O
inferior	O
to	O
5	O
-	O
fluorouracil	O
and	O
leucovorin	O
for	O
relapse	O
-	O
free	O
survival	O
(	O
RFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
adjuvant	O
stage	O
III	O
colon	B
cancer	I
.	O

METHODS	O
:	O
Non	O
-	O
inferiority	O
required	O
both	O
HR	O
for	O
RFS	O
and	O
OS	O
<	O
1.25	O
at	O
1	O
-	O
sided	O
alpha	O
=	O
0.05	O
.	O

Patients	O
(	O
1921	O
)	O
were	O
randomised	O
to	O
six	O
cycles	O
of	O
5	O
-	O
FU	O
/	O
LV	O
(	O
n	O
=	O
969	O
)	O
or	O
eight	O
cycles	O
of	O
raltitrexed	O
(	O
n	O
=	O
952	O
)	O
.	O

We	O
report	O
the	O
final	O
results	O
in	O
993	O
eligible	O
patients	O
who	O
started	O
and	O
completed	O
the	O
allocated	O
treatment	O
(	O
489	O
5	O
-	O
FU	O
/	O
LV	O
and	O
n	O
=	O
504	O
Raltitrexed	O
)	O
of	O
whom	O
respectively	O
146	O
and	O
148	O
died	O
,	O
respectively	O
.	O

RESULTS	O
:	O
The	O
trial	O
closed	O
prematurely	O
when	O
17	O
(	O
1.9	O
%	O
)	O
raltitrexed	O
-	O
related	O
deaths	O
were	O
reported	O
.	O

Haematological	O
and	O
gastrointestinal	B
toxicities	I
were	O
more	O
frequent	O
with	O
5	O
-	O
FU	O
/	O
LV	O
,	O
liver	B
toxicities	I
with	O
raltitrexed	O
.	O

Raltitrexed	O
was	O
stopped	O
for	O
toxicity	O
in	O
13.2	O
%	O
and	O
5	O
-	O
FU	O
/	O
LV	O
in	O
8.5	O
%	O
.	O

Sixty	O
-	O
day	O
mortality	O
was	O
9	O
%	O
versus	O
7	O
%	O
.	O

With	O
4.1	O
years	O
median	O
follow	O
-	O
up	O
,	O
the	O
HR	O
for	O
RFS	O
was	O
1.16	O
(	O
90	O
%	O
CI	O
0.99	O
-	O
1.37	O
)	O
and	O
that	O
for	O
OS	O
was	O
1.01	O
(	O
90	O
%	O
CI	O
0.84	O
-	O
1.23	O
)	O
.	O

CONCLUSION	O
:	O
The	O
trial	O
failed	O
to	O
demonstrate	O
non	O
-	O
inferiority	O
of	O
raltitrexed	O
.	O

FUNDING	O
:	O
Free	O
drugs	O
and	O
financial	O
support	O
from	O
AstraZeneca	O
.	O

Copper	O
oxide	O
nanoparticles	O
are	O
highly	O
toxic	O
:	O
a	O
comparison	O
between	O
metal	O
oxide	O
nanoparticles	O
and	O
carbon	O
nanotubes	O
.	O

Since	O
the	O
manufacture	O
and	O
use	O
of	O
nanoparticles	O
are	O
increasing	O
,	O
humans	O
are	O
more	O
likely	O
to	O
be	O
exposed	O
occupationally	O
or	O
via	O
consumer	O
products	O
and	O
the	O
environment	O
.	O

However	O
,	O
so	O
far	O
toxicity	O
data	O
for	O
most	O
manufactured	O
nanoparticles	O
are	O
limited	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
and	O
compare	O
different	O
nanoparticles	O
and	O
nanotubes	O
regarding	O
cytotoxicity	O
and	O
ability	O
to	O
cause	O
DNA	O
damage	O
and	O
oxidative	O
stress	O
.	O

The	O
study	O
was	O
focused	O
on	O
different	O
metal	O
oxide	O
particles	O
(	O
CuO	O
,	O
TiO2	O
,	O
ZnO	O
,	O
CuZnFe2O4	O
,	O
Fe3O4	O
,	O
Fe2O3	O
)	O
,	O
and	O
the	O
toxicity	O
was	O
compared	O
to	O
that	O
of	O
carbon	O
nanoparticles	O
and	O
multiwalled	O
carbon	O
nanotubes	O
(	O
MWCNT	O
)	O
.	O

The	O
human	O
lung	O
epithelial	O
cell	O
line	O
A549	O
was	O
exposed	O
to	O
the	O
particles	O
,	O
and	O
cytotoxicity	B
was	O
analyzed	O
using	O
trypan	O
blue	O
staining	O
.	O

DNA	O
damage	O
and	O
oxidative	O
lesions	O
were	O
determined	O
using	O
the	O
comet	O
assay	O
,	O
and	O
intracellular	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
was	O
measured	O
using	O
the	O
oxidation	O
-	O
sensitive	O
fluoroprobe	O
2	O
'	O
,	O
7	O
'	O
-	O
dichlorofluorescin	O
diacetate	O
(	O
DCFH	O
-	O
DA	O
)	O
.	O

The	O
results	O
showed	O
that	O
there	O
was	O
a	O
high	O
variation	O
among	O
different	O
nanoparticles	O
concerning	O
their	O
ability	O
to	O
cause	O
toxic	O
effects	O
.	O

CuO	O
nanoparticles	O
were	O
most	O
potent	O
regarding	O
cytotoxicity	B
and	O
DNA	O
damage	O
.	O

The	O
toxicity	O
was	O
likely	O
not	O
explained	O
by	O
Cu	O
ions	O
released	O
to	O
the	O
cell	O
medium	O
.	O

These	O
particles	O
also	O
caused	O
oxidative	O
lesions	O
and	O
were	O
the	O
only	O
particles	O
that	O
induced	O
an	O
almost	O
significant	O
increase	O
(	O
p	O
=	O
0.058	O
)	O
in	O
intracellular	O
ROS	O
.	O

ZnO	O
showed	O
effects	O
on	O
cell	O
viability	O
as	O
well	O
as	O
DNA	O
damage	O
,	O
whereas	O
the	O
TiO2	O
particles	O
(	O
a	O
mix	O
of	O
rutile	O
and	O
anatase	O
)	O
only	O
caused	O
DNA	O
damage	O
.	O

For	O
iron	O
oxide	O
particles	O
(	O
Fe3O4	O
,	O
Fe2O3	O
)	O
,	O
no	O
or	O
low	O
toxicity	O
was	O
observed	O
,	O
but	O
CuZnFe2O4	O
particles	O
were	O
rather	O
potent	O
in	O
inducing	O
DNA	O
lesions	O
.	O

Finally	O
,	O
the	O
carbon	O
nanotubes	O
showed	O
cytotoxic	B
effects	I
and	O
caused	O
DNA	O
damage	O
in	O
the	O
lowest	O
dose	O
tested	O
.	O

The	O
effects	O
were	O
not	O
explained	O
by	O
soluble	O
metal	O
impurities	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
highlights	O
the	O
in	O
vitro	O
toxicity	O
of	O
CuO	O
nanoparticles	O
.	O

Use	O
of	O
flow	O
cytometry	O
in	O
an	O
apoptosis	O
assay	O
to	O
determine	O
pH	O
and	O
temperature	O
stability	O
of	O
shiga	O
-	O
like	O
toxin	O
1	O
.	O

Shiga	O
toxins	O
and	O
Shiga	O
-	O
like	O
toxins	O
(	O
Stx	O
)	O
are	O
a	O
relatively	O
large	O
group	O
of	O
cytotoxins	O
produced	O
by	O
certain	O
serotypes	O
of	O
Shigella	O
and	O
E	O
.	O

coli	O
(	O
STEC	O
)	O
.	O

These	O
toxins	O
are	O
responsible	O
for	O
diarrhea	B
,	O
hemorrhagic	B
colitis	I
and	O
may	O
induce	O
hemolytic	B
uremic	I
syndrome	I
(	O
HUS	B
)	O
with	O
serious	O
consequences	O
in	O
young	O
children	O
.	O

The	O
toxins	O
are	O
proteins	O
made	O
up	O
of	O
5	O
small	O
B	O
subunits	O
responsible	O
for	O
binding	O
to	O
an	O
outer	O
membrane	O
ligand	O
on	O
host	O
cells	O
and	O
surround	O
the	O
larger	O
,	O
biologically	O
active	O
A	O
subunit	O
.	O

For	O
Shiga	O
-	O
like	O
toxin	O
1	O
(	O
Stx1	O
)	O
,	O
the	O
cellular	O
receptor	O
is	O
the	O
carbohydrate	O
globotriose	O
.	O

Stx1was	O
purified	O
from	O
STEC	O
.	O

We	O
utilized	O
induction	O
of	O
apoptosis	O
in	O
the	O
human	O
monocyte	O
cell	O
line	O
THP	O
-	O
1	O
,	O
as	O
a	O
biological	O
endpoint	O
to	O
test	O
the	O
stability	O
of	O
Stx1	O
activity	O
added	O
to	O
fruit	O
punch	O
at	O
different	O
pH	O
(	O
2	O
-	O
9	O
)	O
and	O
temperatures	O
(	O
4	O
and	O
20	O
degrees	O
C	O
)	O
.	O

A	O
flow	O
cytometric	O
method	O
was	O
used	O
to	O
test	O
for	O
early	O
and	O
late	O
apoptotic	O
events	O
based	O
on	O
binding	O
of	O
R	O
-	O
phycoerytherin	O
-	O
labeled	O
annexin	O
V	O
to	O
exposed	O
membrane	O
phosphatidyl	O
serine	O
.	O

Membrane	O
permeability	O
to	O
7	O
-	O
Amino	O
-	O
actinomycin	O
corresponds	O
with	O
late	O
apoptosis	O
or	O
necrosis	O
.	O

The	O
combination	O
of	O
acid	O
pH	O
and	O
higher	O
storage	O
temperature	O
resulted	O
in	O
greatest	O
degree	O
of	O
toxin	O
inactivation	O
.	O

This	O
approach	O
provides	O
a	O
rapid	O
and	O
high	O
throughput	O
method	O
to	O
determine	O
the	O
functional	O
activity	O
of	O
Stx1	O
,	O
and	O
related	O
toxins	O
in	O
a	O
food	O
matrix	O
.	O

Allogeneic	O
SCT	O
in	O
refractory	O
or	O
relapsed	B
adult	I
ALL	I
is	O
effective	O
without	O
prior	O
reinduction	O
chemotherapy	O
.	O

We	O
present	O
60	O
patients	O
with	O
refractory	O
(	O
n	O
=	O
8	O
)	O
or	O
relapsed	O
(	O
n	O
=	O
52	O
)	O
adult	O
ALL	B
who	O
received	O
allogeneic	O
hematopoietic	O
SCT	O
(	O
HSCT	O
)	O
with	O
(	O
n	O
=	O
41	O
)	O
or	O
without	O
(	O
n	O
=	O
19	O
)	O
prior	O
reinduction	O
chemotherapy	O
.	O

In	O
our	O
center	O
,	O
omission	O
of	O
reinduction	O
is	O
recommended	O
if	O
a	O
suitable	O
donor	O
is	O
promptly	O
available	O
,	O
tumor	B
burden	O
is	O
moderate	O
and	O
disease	O
features	O
suggest	O
a	O
highly	O
aggressive	O
course	O
.	O

Overall	O
survival	O
(	O
OS	O
)	O
of	O
the	O
whole	O
cohort	O
at	O
1	O
,	O
2	O
and	O
5	O
years	O
was	O
42	O
,	O
33	O
and	O
28	O
%	O
,	O
respectively	O
.	O

Leukemia	B
-	O
free	O
survival	O
at	O
1	O
,	O
2	O
and	O
5	O
years	O
was	O
37	O
,	O
33	O
and	O
24	O
%	O
.	O

Deaths	O
were	O
due	O
to	O
relapse	O
(	O
n	O
=	O
25	O
)	O
,	O
acute	O
or	O
chronic	B
GVHD	I
(	O
n	O
=	O
7	O
)	O
,	O
infections	B
(	O
n	O
=	O
8	O
)	O
or	O
toxicity	O
(	O
n	O
=	O
4	O
)	O
.	O

Interestingly	O
,	O
patients	O
who	O
did	O
not	O
receive	O
reinduction	O
before	O
HSCT	O
had	O
better	O
outcomes	O
than	O
patients	O
who	O
received	O
reinduction	O
with	O
OS	O
at	O
1	O
,	O
2	O
and	O
5	O
years	O
being	O
58	O
vs	O
34	O
%	O
,	O
47	O
vs	O
25	O
%	O
and	O
47	O
vs	O
18	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.039	O
)	O
.	O

Importantly	O
,	O
even	O
achievement	O
of	O
a	O
second	O
CR	O
after	O
reinduction	O
was	O
not	O
associated	O
with	O
improved	O
survival	O
compared	O
to	O
patients	O
directly	O
proceeding	O
to	O
HSCT	O
.	O

We	O
conclude	O
that	O
patients	O
who	O
undergo	O
HSCT	O
for	O
refractory	O
or	O
relapsed	B
ALL	I
can	O
achieve	O
long	O
-	O
term	O
survival	O
.	O

In	O
selected	O
patients	O
,	O
reinduction	O
chemotherapy	O
can	O
be	O
omitted	O
if	O
immediate	O
HSCT	O
is	O
feasible	O
.	O

Mutual	O
stimulation	O
of	O
beta	O
-	O
amyloid	O
fibrillogenesis	O
by	O
clioquinol	O
and	O
divalent	O
metals	O
.	O

As	O
reported	O
by	O
some	O
authors	O
,	O
clioquinol	O
(	O
CQ	O
)	O
,	O
a	O
8	O
-	O
hydroxyquinoline	O
derivative	O
,	O
has	O
produced	O
very	O
encouraging	O
results	O
in	O
the	O
treatment	O
of	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
.	O

Its	O
biological	O
effects	O
are	O
most	O
likely	O
ascribed	O
to	O
complexation	O
of	O
specific	O
metal	O
ions	O
,	O
such	O
as	O
copper	O
(	O
II	O
)	O
and	O
zinc	O
(	O
II	O
)	O
,	O
critically	O
associated	O
with	O
beta	O
-	O
amyloid	O
(	O
A	O
beta	O
)	O
aggregation	O
/	O
fibrillogenesis	O
and	O
degeneration	O
processes	O
in	O
the	O
brain	O
.	O

The	O
present	O
study	O
was	O
aimed	O
at	O
assessing	O
the	O
in	O
vitro	O
effects	O
of	O
CQ	O
on	O
the	O
aggregation	O
/	O
fibrillogenesis	O
properties	O
of	O
human	O
A	O
beta	O
either	O
alone	O
or	O
complexed	O
with	O
Cu	O
(	O
2	O
+	O
)	O
and	O
Zn	O
(	O
2	O
+	O
)	O
.	O

Surprisingly	O
,	O
our	O
data	O
indicated	O
that	O
CQ	O
promoted	O
rather	O
than	O
inhibited	O
the	O
formation	O
of	O
A	O
beta	O
fibrillar	O
aggregates	O
when	O
added	O
metal	O
ions	O
were	O
present	O
.	O

To	O
understand	O
whether	O
the	O
latter	O
effects	O
were	O
related	O
to	O
the	O
peptide	O
amino	O
acid	O
sequence	O
,	O
we	O
also	O
investigated	O
the	O
aggregational	O
profile	O
of	O
rat	O
A	O
beta	O
,	O
which	O
differs	O
from	O
the	O
human	O
homologous	O
for	O
three	O
amino	O
acidic	O
substitutions	O
.	O

Such	O
a	O
sequence	O
alteration	O
drastically	O
reduced	O
the	O
tendency	O
of	O
the	O
peptide	O
to	O
undergo	O
spontaneous	O
aggregation	O
/	O
fibrillization	O
.	O

In	O
the	O
presence	O
of	O
CQ	O
and	O
metals	O
,	O
however	O
,	O
also	O
rat	O
A	O
beta	O
showed	O
a	O
strong	O
propensity	O
to	O
generate	O
fibrillar	O
aggregates	O
.	O

In	O
agreement	O
with	O
the	O
pro	O
-	O
aggregation	O
effects	O
observed	O
in	O
solution	O
,	O
studies	O
with	O
neuroblastoma	O
cells	O
demonstrated	O
an	O
impairment	O
of	O
cell	O
functioning	O
only	O
in	O
the	O
presence	O
of	O
CQ	O
+	O
A	O
beta	O
-	O
metals	O
.	O

Based	O
on	O
the	O
present	O
findings	O
,	O
the	O
literature	O
data	O
on	O
the	O
potential	O
effectiveness	O
of	O
CQ	O
-	O
based	O
chelation	O
therapy	O
in	O
AD	B
should	O
be	O
re	O
-	O
interpreted	O
.	O

Polyanhydrides	O
as	O
localized	O
drug	O
delivery	O
carrier	O
:	O
an	O
update	O
.	O

BACKGROUND	O
:	O
There	O
is	O
a	O
continuing	O
thrust	O
to	O
increase	O
the	O
efficacy	O
and	O
reduce	O
the	O
toxicity	O
of	O
existing	O
and	O
new	O
drug	O
molecules	O
for	O
their	O
better	O
usage	O
to	O
treat	O
disease	O
.	O

Localized	O
drug	O
delivery	O
has	O
been	O
explored	O
in	O
the	O
same	O
way	O
,	O
which	O
can	O
provide	O
a	O
platform	O
to	O
target	O
local	O
diseased	O
tissues	O
and	O
can	O
reduce	O
the	O
burden	O
on	O
the	O
body	O
by	O
reducing	O
the	O
dose	O
size	O
and	O
hence	O
the	O
dose	B
-	I
related	I
toxicity	I
of	O
the	O
molecules	O
.	O

Various	O
polymers	O
have	O
evolved	O
for	O
the	O
purpose	O
of	O
localized	O
drug	O
delivery	O
,	O
however	O
,	O
polyanhydrides	O
are	O
considered	O
the	O
best	O
,	O
supported	O
by	O
products	O
in	O
the	O
clinical	O
phases	O
.	O

OBJECTIVE	O
:	O
To	O
demonstrate	O
the	O
advantages	O
of	O
localized	O
delivery	O
using	O
basic	O
concepts	O
and	O
describing	O
polyanhydride	O
carrier	O
with	O
products	O
such	O
as	O
Gliadel	O
and	O
Septacin	O
.	O

METHODS	O
:	O
The	O
rationale	O
behind	O
localized	O
drug	O
delivery	O
and	O
the	O
carrier	O
for	O
the	O
same	O
are	O
dealt	O
with	O
.	O

Polyanhydrides	O
discussed	O
in	O
detail	O
are	O
those	O
from	O
subclasses	O
that	O
have	O
been	O
given	O
less	O
emphasis	O
previously	O
and	O
have	O
been	O
developed	O
or	O
investigated	O
in	O
the	O
last	O
5	O
years	O
.	O

RESULTS	O
/	O
CONCLUSION	O
:	O
From	O
the	O
recent	O
update	O
on	O
polyanhydrides	O
,	O
it	O
can	O
be	O
concluded	O
that	O
these	O
polymers	O
have	O
great	O
potential	O
as	O
localized	O
drug	O
delivery	O
carriers	O
due	O
to	O
the	O
versatility	O
of	O
their	O
properties	O
.	O

However	O
,	O
the	O
quest	O
to	O
stabilize	O
the	O
system	O
in	O
order	O
to	O
achieve	O
a	O
long	O
shelf	O
life	O
remains	O
ongoing	O
.	O

Testosterone	O
and	O
the	O
breast	O
.	O

Although	O
women	O
have	O
been	O
treated	O
with	O
testosterone	O
(	O
T	O
)	O
for	O
female	B
sexual	I
dysfunction	I
since	O
the	O
1950s	O
,	O
the	O
role	O
of	O
T	O
in	O
normal	O
female	O
physiology	O
is	O
not	O
yet	O
fully	O
defined	O
.	O

One	O
of	O
the	O
major	O
safety	O
concerns	O
of	O
androgen	O
therapy	O
is	O
whether	O
androgens	O
have	O
a	O
stimulatory	O
effect	O
on	O
the	O
breast	O
that	O
could	O
lead	O
to	O
breast	B
carcinomas	I
.	O

The	O
proposed	O
mechanisms	O
for	O
such	O
stimulation	O
include	O
local	O
estrogen	O
production	O
from	O
the	O
aromatase	O
enzyme	O
complex	O
present	O
in	O
the	O
breast	O
tissue	O
or	O
by	O
the	O
direct	O
stimulation	O
of	O
the	O
androgen	O
receptor	O
.	O

Predominant	O
data	O
from	O
in	O
vitro	O
studies	O
have	O
shown	O
that	O
androgens	O
actually	O
have	O
apoptotic	O
and	O
antiproliferative	O
effects	O
and	O
not	O
stimulatory	O
effects	O
.	O

Animal	O
models	O
have	O
shown	O
similar	O
results	O
to	O
in	O
vitro	O
studies	O
,	O
finding	O
that	O
androgens	O
inhibit	O
breast	B
cancer	I
growth	O
.	O

Prospective	O
and	O
retrospective	O
epidemiological	O
analyses	O
have	O
shown	O
mixed	O
outcomes	O
,	O
with	O
no	O
clear	O
consensus	O
regarding	O
androgen	O
use	O
and	O
breast	B
cancer	I
risk	O
.	O

Hyperandrogenism	B
in	O
patients	O
with	O
polycystic	B
ovarian	I
syndrome	I
with	O
elevated	O
levels	O
of	O
endogenous	O
T	O
is	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	B
cancer	I
and	O
may	O
,	O
in	O
fact	O
,	O
be	O
protective	O
.	O

Another	O
human	O
model	O
with	O
excess	O
of	O
T	O
is	O
female	O
-	O
to	O
-	O
male	O
transgenderism	O
,	O
in	O
which	O
genotypic	O
women	O
are	O
treated	O
with	O
large	O
doses	O
of	O
exogenous	O
T	O
with	O
no	O
increased	O
risk	O
.	O

High	O
-	O
dose	O
androgen	O
therapy	O
also	O
has	O
been	O
effective	O
in	O
treating	O
patients	O
with	O
advanced	O
breast	B
cancer	I
.	O

Thus	O
,	O
the	O
preponderance	O
of	O
data	O
suggests	O
that	O
T	O
use	O
in	O
females	O
is	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	B
carcinoma	I
.	O

Bendamustine	O
,	O
but	O
not	O
fludarabine	O
,	O
exhibits	O
a	O
low	O
stem	B
cell	I
toxicity	I
in	O
vitro	O
.	O

PURPOSE	O
:	O
We	O
investigated	O
the	O
in	O
vitro	O
toxicity	O
of	O
bendamustine	O
and	O
fludarabine	O
to	O
hematopoietic	O
progenitors	O
and	O
stem	O
cells	O
from	O
healthy	O
donors	O
.	O

METHODS	O
:	O
Clonogenic	O
agar	O
colony	O
assays	O
,	O
non	O
-	O
clonogenic	O
long	O
-	O
term	O
liquid	O
cultures	O
(	O
LTC	O
)	O
and	O
apoptosis	O
assays	O
were	O
used	O
to	O
assess	O
the	O
cytotoxicity	B
of	O
both	O
the	O
agents	O
.	O

RESULTS	O
:	O
Total	O
colony	O
-	O
forming	O
units	O
(	O
CFU	O
)	O
were	O
more	O
sensitive	O
to	O
fludarabine	O
than	O
to	O
bendamustine	O
in	O
agar	O
colony	O
assays	O
(	O
IC	O
(	O
50	O
)	O
0.7	O
microM	O
/	O
L	O
and	O
8.5	O
microM	O
/	O
L	O
,	O
respectively	O
)	O
.	O

Using	O
the	O
Bliss	O
independence	O
model	O
and	O
combining	O
the	O
two	O
agents	O
yielded	O
additive	O
inhibition	O
of	O
progenitors	O
.	O

Non	O
-	O
clonogenic	O
assays	O
,	O
including	O
LTC	O
and	O
an	O
apoptosis	O
assay	O
detecting	O
activated	O
caspases	O
showed	O
that	O
stem	O
cells	O
are	O
characterized	O
by	O
low	O
sensitivity	O
to	O
bendamustine	O
.	O

In	O
contrast	O
,	O
fludarabine	O
strongly	O
inhibited	O
the	O
viability	O
and	O
growth	O
of	O
stem	O
cells	O
in	O
LTC	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
show	O
that	O
bendamustine	O
is	O
characterized	O
by	O
lower	O
in	O
vitro	O
toxicity	O
to	O
hematopoietic	O
progenitors	O
and	O
stem	O
cells	O
than	O
fludarabine	O
and	O
might	O
thus	O
be	O
preferable	O
in	O
regimens	O
prior	O
to	O
stem	O
cells	O
apheresis	O
.	O

Chloroquine	O
psychosis	B
masquerading	O
as	O
PCP	O
:	O
a	O
case	O
report	O
.	O

Chloroquine	O
and	O
its	O
derivatives	O
have	O
been	O
drugs	O
of	O
choice	O
in	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
malaria	B
for	O
over	O
50	O
years	O
.	O

These	O
drugs	O
are	O
also	O
frequently	O
used	O
in	O
the	O
treatment	O
of	O
various	O
rheumatologic	B
disorders	I
.	O

Because	O
many	O
Americans	O
now	O
travel	O
abroad	O
and	O
may	O
require	O
chloroquine	O
prophylaxis	O
,	O
as	O
well	O
as	O
the	O
fact	O
that	O
such	O
medications	O
are	O
readily	O
available	O
through	O
Internet	O
-	O
based	O
supply	O
houses	O
,	O
clinicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
toxicity	O
associated	O
with	O
the	O
use	O
of	O
these	O
agents	O
.	O

We	O
present	O
the	O
case	O
of	O
an	O
adolescent	O
female	O
who	O
presented	O
with	O
acute	O
,	O
chloroquine	O
-	O
induced	O
toxic	B
psychosis	I
resembling	O
that	O
induced	O
by	O
phencyclidine	O
(	O
PCP	O
)	O
in	O
clinical	O
presentation	O
and	O
laboratory	O
findings	O
.	O

In	O
the	O
acute	O
setting	O
,	O
the	O
differentiation	O
between	O
chloroquine	O
toxic	B
psychosis	I
and	O
PCP	B
psychosis	I
may	O
be	O
difficult	O
.	O

Therefore	O
,	O
the	O
syndrome	O
of	O
chloroquine	O
-	O
induced	O
psychosis	B
is	O
reviewed	O
and	O
its	O
differentiation	O
from	O
PCP	B
psychosis	I
highlighted	O
as	O
it	O
relates	O
to	O
important	O
aspects	O
of	O
this	O
case	O
.	O

Inhibition	O
of	O
atopic	B
dermatitis	I
-	I
like	I
skin	I
lesions	I
by	O
topical	O
application	O
of	O
a	O
novel	O
ceramide	O
derivative	O
,	O
K6PC	O
-	O
9p	O
,	O
in	O
NC	O
/	O
Nga	O
mice	O
.	O

Atopic	B
dermatitis	I
(	O
AD	B
)	O
is	O
a	O
chronic	B
inflammatory	I
skin	I
disease	I
that	O
commonly	O
begins	O
in	O
childhood	O
.	O

K6PC	O
-	O
9p	O
(	O
N	O
-	O
(	O
Ethyl	O
dihydrogenphosphate	O
)	O
-	O
2	O
-	O
hexyl	O
-	O
3	O
-	O
oxo	O
-	O
decanamide	O
)	O
is	O
a	O
synthetic	O
ceramide	O
derivative	O
of	O
PC	O
-	O
9S	O
(	O
N	O
-	O
Ethanol	O
-	O
2	O
-	O
mirystyl	O
-	O
3	O
-	O
oxo	O
-	O
staramide	O
)	O
,	O
which	O
was	O
known	O
to	O
be	O
effective	O
in	O
atopic	O
patients	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
topical	O
application	O
of	O
K6PC	O
-	O
9p	O
on	O
skin	B
inflammation	I
and	O
AD	B
-	I
like	I
skin	I
lesions	I
in	O
mouse	O
models	O
.	O

K6PC	O
-	O
9p	O
dose	O
-	O
dependently	O
inhibited	O
phorbol	O
ester	O
-	O
induced	O
increase	O
in	O
ear	O
thickness	O
in	O
BALB	O
/	O
c	O
mice	O
.	O

Moreover	O
,	O
topical	O
application	O
of	O
K6PC	O
-	O
9p	O
suppressed	O
dust	O
mite	O
extract	O
-	O
induced	O
AD	B
-	I
like	I
skin	I
lesions	I
in	O
NC	O
/	O
Nga	O
mice	O
.	O

Histopathological	O
analysis	O
revealed	O
that	O
both	O
ear	B
swelling	I
and	O
leucocyte	O
infiltration	O
were	O
suppressed	O
by	O
K6PC	O
-	O
9p	O
treatment	O
.	O

K6PC	O
-	O
9p	O
also	O
suppressed	O
IL	O
-	O
4	O
and	O
TNF	O
-	O
alpha	O
expression	O
in	O
the	O
ears	O
and	O
mast	O
cell	O
infiltration	O
into	O
the	O
ears	O
in	O
NC	O
/	O
Nga	O
mice	O
.	O

Further	O
study	O
demonstrated	O
that	O
K6PC	O
-	O
9p	O
inhibited	O
ConA	O
-	O
induced	O
IL	O
-	O
4	O
secretion	O
and	O
LPS	O
-	O
induced	O
macrophage	O
activation	O
.	O

Taken	O
together	O
,	O
our	O
results	O
showed	O
that	O
topical	O
application	O
of	O
K6PC	O
-	O
9p	O
exerts	O
beneficial	O
effects	O
in	O
animal	O
model	O
of	O
skin	B
inflammation	I
and	O
AD	B
,	O
suggesting	O
that	O
K6PC	O
-	O
9p	O
might	O
be	O
a	O
promising	O
topical	O
agent	O
for	O
the	O
treatment	O
of	O
inflammatory	B
skin	I
diseases	I
.	O

18beta	O
-	O
Glycyrrhetinic	O
acid	O
induces	O
apoptotic	O
cell	O
death	O
in	O
SiHa	O
cells	O
and	O
exhibits	O
a	O
synergistic	O
effect	O
against	O
antibiotic	O
anti	O
-	O
cancer	O
drug	B
toxicity	I
.	O

Defects	O
in	O
mitochondrial	O
function	O
have	O
been	O
shown	O
to	O
participate	O
in	O
the	O
induction	O
of	O
cell	O
death	O
in	O
cancer	O
cells	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
assess	O
the	O
toxic	O
effect	O
of	O
18beta	O
-	O
glycyrrhetinic	O
acid	O
against	O
human	O
cervix	O
and	O
uterus	O
tumor	O
cell	O
line	O
SiHa	O
cells	O
in	O
relation	O
to	O
the	O
mitochondria	O
-	O
mediated	O
cell	O
-	O
death	O
process	O
and	O
evaluate	O
the	O
combined	O
toxic	O
effect	O
of	O
18beta	O
-	O
glycyrrhetinic	O
acid	O
and	O
anti	O
-	O
cancer	O
drugs	O
.	O

18beta	O
-	O
Glycyrrhetinic	O
acid	O
induced	O
the	O
nuclear	O
damage	O
,	O
changes	O
in	O
the	O
mitochondrial	O
membrane	O
permeability	O
,	O
formation	O
of	O
reactive	O
oxygen	O
species	O
and	O
depletion	O
of	O
glutathione	O
in	O
SiHa	O
cells	O
.	O

It	O
caused	O
cell	O
death	O
by	O
inducing	O
the	O
increase	O
in	O
the	O
pro	O
-	O
apoptotic	O
Bax	O
protein	O
and	O
cytochrome	O
c	O
levels	O
,	O
reduction	O
in	O
anti	O
-	O
apoptotic	O
Bcl	O
-	O
2	O
level	O
,	O
subsequent	O
caspase	O
-	O
3	O
activation	O
and	O
loss	O
of	O
the	O
mitochondrial	O
transmembrane	O
potential	O
.	O

Unlike	O
18beta	O
-	O
glycyrrhetinic	O
acid	O
,	O
a	O
pro	O
-	O
compound	O
glycyrrhizin	O
up	O
to	O
100	O
microM	O
did	O
not	O
induce	O
cell	O
death	O
and	O
depletion	O
of	O
glutathione	O
.	O

Combined	O
treatment	O
of	O
mitomycin	O
c	O
(	O
or	O
doxorubicin	O
)	O
and	O
18beta	O
-	O
glycyrrhetinic	O
acid	O
revealed	O
a	O
synergistic	B
toxic	I
effect	I
.	O

Meanwhile	O
,	O
combination	O
of	O
camptothecin	O
and	O
18beta	O
-	O
glycyrrhetinic	O
acid	O
exhibited	O
an	O
additive	O
cytotoxic	B
effect	I
.	O

Results	O
suggest	O
that	O
18beta	O
-	O
glycyrrhetinic	O
acid	O
may	O
cause	O
cell	O
death	O
in	O
SiHa	O
cells	O
by	O
inducing	O
the	O
mitochondrial	O
membrane	O
permeability	O
change	O
,	O
leading	O
to	O
cytochrome	O
c	O
release	O
and	O
caspase	O
-	O
3	O
activation	O
.	O

The	O
effect	O
may	O
be	O
associated	O
with	O
increased	O
formation	O
of	O
reactive	O
oxygen	O
species	O
and	O
depletion	O
of	O
glutathione	O
.	O

Combined	O
treatment	O
of	O
antibiotic	O
anti	O
-	O
cancer	O
drug	O
and	O
18beta	O
-	O
glycyrrhetinic	O
acid	O
seems	O
to	O
exhibit	O
a	O
synergistic	B
toxic	I
effect	I
.	O

Genotoxic	B
damage	I
in	O
pathology	O
anatomy	O
laboratory	O
workers	O
exposed	O
to	O
formaldehyde	O
.	O

Formaldehyde	O
(	O
FA	O
)	O
is	O
a	O
chemical	O
traditionally	O
used	O
in	O
pathology	O
and	O
anatomy	O
laboratories	O
as	O
a	O
tissue	O
preservative	O
.	O

Several	O
epidemiological	O
studies	O
of	O
occupational	O
exposure	O
to	O
FA	O
have	O
indicated	O
an	O
increased	O
risk	O
of	O
nasopharyngeal	B
cancers	I
in	O
industrial	O
workers	O
,	O
embalmers	O
and	O
pathology	O
anatomists	O
.	O

There	O
is	O
also	O
a	O
clear	O
evidence	O
of	O
nasal	B
squamous	I
cell	I
carcinomas	I
from	O
inhalation	O
studies	O
in	O
the	O
rat	O
.	O

The	O
postulated	O
mode	O
of	O
action	O
for	O
nasal	O
tumours	O
in	O
rats	O
was	O
considered	O
biologically	O
plausible	O
and	O
considered	O
likely	O
to	O
be	O
relevant	O
to	O
humans	O
.	O

Based	O
on	O
the	O
available	O
data	O
IARC	O
,	O
the	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer	B
,	O
has	O
recently	O
classified	O
FA	O
as	O
a	O
human	O
carcinogen	O
.	O

Although	O
the	O
in	O
vitro	O
genotoxic	O
as	O
well	O
as	O
the	O
in	O
vivo	O
carcinogenic	O
potentials	O
of	O
FA	O
are	O
well	O
documented	O
in	O
mammalian	O
cells	O
and	O
in	O
rodents	O
,	O
evidence	O
for	O
genotoxic	B
effects	I
and	O
carcinogenic	O
properties	O
in	O
humans	O
is	O
insufficient	O
and	O
conflicting	O
thus	O
remains	O
to	O
be	O
more	O
documented	O
.	O

To	O
evaluate	O
the	O
genetic	O
effects	O
of	O
long	O
-	O
term	O
occupational	O
exposure	O
to	O
FA	O
a	O
group	O
of	O
30	O
Pathological	O
Anatomy	O
laboratory	O
workers	O
was	O
tested	O
for	O
a	O
variety	O
of	O
biological	O
endpoints	O
,	O
cytogenetic	O
tests	O
(	O
micronuclei	O
,	O
MN	O
;	O
sister	O
chromatid	O
exchange	O
,	O
SCE	O
)	O
and	O
comet	O
assay	O
.	O

The	O
level	O
of	O
exposure	O
to	O
FA	O
was	O
evaluated	O
near	O
the	O
breathing	O
zone	O
of	O
workers	O
,	O
time	O
weighted	O
average	O
of	O
exposure	O
was	O
calculated	O
for	O
each	O
subject	O
.	O

The	O
association	O
between	O
the	O
biomarkers	O
and	O
polymorphic	O
genes	O
of	O
xenobiotic	O
metabolising	O
and	O
DNA	O
repair	O
enzymes	O
was	O
also	O
assessed	O
.	O

The	O
mean	O
level	O
of	O
exposure	O
was	O
0.44	O
+	O
/	O
-	O
0.08	O
ppm	O
(	O
0.04	O
-	O
1.58	O
ppm	O
)	O
.	O

MN	O
frequency	O
was	O
significantly	O
higher	O
(	O
p	O
=	O
0.003	O
)	O
in	O
the	O
exposed	O
subjects	O
(	O
5.47	O
+	O
/	O
-	O
0.76	O
)	O
when	O
compared	O
with	O
controls	O
(	O
3.27	O
+	O
/	O
-	O
0.69	O
)	O
.	O

SCE	O
mean	O
value	O
was	O
significantly	O
higher	O
(	O
p	O
<	O
0.05	O
)	O
among	O
the	O
exposed	O
group	O
(	O
6.13	O
+	O
/	O
-	O
0.29	O
)	O
compared	O
with	O
control	O
group	O
(	O
4.49	O
+	O
/	O
-	O
0.16	O
)	O
.	O

Comet	O
assay	O
data	O
showed	O
a	O
significant	O
increase	O
(	O
p	O
<	O
0.05	O
)	O
of	O
TL	O
in	O
FA	O
-	O
exposed	O
workers	O
(	O
60.00	O
+	O
/	O
-	O
2.31	O
)	O
with	O
respect	O
to	O
the	O
control	O
group	O
(	O
41.85	O
+	O
/	O
-	O
1.97	O
)	O
.	O

A	O
positive	O
correlation	O
was	O
found	O
between	O
FA	O
exposure	O
levels	O
and	O
MN	O
frequency	O
(	O
r	O
=	O
0.384	O
,	O
p	O
=	O
0.001	O
)	O
and	O
TL	O
(	O
r	O
=	O
0.333	O
,	O
p	O
=	O
0.005	O
)	O
.	O

Regarding	O
the	O
genetic	O
polymorphisms	O
studied	O
,	O
no	O
significant	O
effect	O
was	O
found	O
on	O
the	O
genotoxic	O
endpoints	O
.	O

The	O
results	O
of	O
the	O
present	O
biomonitoring	O
study	O
emphasize	O
the	O
need	O
to	O
develop	O
safety	O
programs	O
.	O

Adverse	O
effects	O
of	O
topical	O
papaverine	O
on	O
auditory	O
nerve	O
function	O
.	O

BACKGROUND	O
:	O
Papaverine	O
hydrochloride	O
is	O
a	O
direct	O
-	O
acting	O
vasodilator	O
used	O
to	O
manage	O
vasospasm	B
during	O
various	O
neurosurgical	O
operations	O
.	O

Transient	O
cranial	O
nerve	O
dysfunction	O
has	O
been	O
described	O
in	O
a	O
few	O
cases	O
with	O
topical	O
papaverine	O
.	O

This	O
study	O
supports	O
previous	O
reports	O
and	O
provides	O
neurophysiological	O
evidence	O
of	O
an	O
adverse	O
effect	O
on	O
the	O
auditory	O
nerve	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
review	O
of	O
70	O
consecutive	O
microvascular	O
decompression	O
operations	O
and	O
studied	O
those	O
patients	O
who	O
received	O
topical	O
papaverine	O
for	O
vasospasm	B
.	O

Topical	O
papaverine	O
was	O
used	O
as	O
a	O
direct	O
therapeutic	O
action	O
to	O
manage	O
vasospasm	B
in	O
a	O
total	O
of	O
11	O
patients	O
.	O

The	O
timing	O
of	O
papaverine	O
application	O
and	O
ongoing	O
operative	O
events	O
was	O
reviewed	O
relative	O
to	O
changes	O
in	O
neurophysiological	O
recordings	O
.	O

Brainstem	O
auditory	O
evoked	O
potentials	O
(	O
BAEPs	O
)	O
were	O
routinely	O
used	O
to	O
monitor	O
cochlear	O
nerve	O
function	O
during	O
these	O
operations	O
.	O

FINDINGS	O
:	O
A	O
temporal	O
relationship	O
was	O
found	O
between	O
topical	O
papaverine	O
and	O
BAEP	O
changes	O
leading	O
to	O
complete	O
waveform	O
loss	O
.	O

The	O
average	O
temporal	O
delay	O
between	O
papaverine	O
and	O
the	O
onset	O
of	O
an	O
adverse	O
BAEP	O
change	O
was	O
5	O
min	O
.	O

In	O
10	O
of	O
11	O
patients	O
,	O
BAEP	O
waves	O
II	O
/	O
III	O
-	O
V	O
completely	O
disappeared	O
within	O
2	O
to	O
25	O
min	O
after	O
papaverine	O
.	O

Eight	O
of	O
these	O
10	O
patients	O
had	O
complete	O
loss	O
of	O
BAEP	O
waveforms	O
within	O
10	O
min	O
.	O

One	O
patient	O
showed	O
no	O
recovery	O
of	O
later	O
waves	O
and	O
a	O
delayed	O
profound	O
sensorineural	B
hearing	I
loss	I
.	O

The	O
average	O
recovery	O
time	O
of	O
BAEP	O
waveforms	O
to	O
pre	O
-	O
papaverine	O
baseline	O
values	O
was	O
39	O
min	O
.	O

CONCLUSIONS	O
:	O
Topical	O
papaverine	O
for	O
the	O
treatment	O
of	O
vasospasm	B
was	O
associated	O
with	O
the	O
onset	O
of	O
a	O
transient	O
disturbance	O
in	O
neurophysiological	O
function	O
of	O
the	O
ascending	O
auditory	O
brainstem	O
pathway	O
.	O

The	O
complete	O
disappearance	O
of	O
BAEP	O
waveforms	O
with	O
a	O
consistent	O
temporal	O
delay	O
suggests	O
a	O
possible	O
adverse	O
effect	O
on	O
the	O
proximal	O
eighth	O
nerve	O
.	O

Recommendations	O
to	O
avoid	O
potential	O
cranial	O
nerve	O
deficits	O
from	O
papaverine	O
are	O
provided	O
.	O

CNS	O
delivery	O
via	O
adsorptive	O
transcytosis	O
.	O

Adsorptive	O
-	O
mediated	O
transcytosis	O
(	O
AMT	O
)	O
provides	O
a	O
means	O
for	O
brain	O
delivery	O
of	O
medicines	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
.	O

The	O
BBB	O
is	O
readily	O
equipped	O
for	O
the	O
AMT	O
process	O
:	O
it	O
provides	O
both	O
the	O
potential	O
for	O
binding	O
and	O
uptake	O
of	O
cationic	O
molecules	O
to	O
the	O
luminal	O
surface	O
of	O
endothelial	O
cells	O
,	O
and	O
then	O
for	O
exocytosis	O
at	O
the	O
abluminal	O
surface	O
.	O

The	O
transcytotic	O
pathways	O
present	O
at	O
the	O
BBB	O
and	O
its	O
morphological	O
and	O
enzymatic	O
properties	O
provide	O
the	O
means	O
for	O
movement	O
of	O
the	O
molecules	O
through	O
the	O
endothelial	O
cytoplasm	O
.	O

AMT	O
-	O
based	O
drug	O
delivery	O
to	O
the	O
brain	O
was	O
performed	O
using	O
cationic	O
proteins	O
and	O
cell	O
-	O
penetrating	O
peptides	O
(	O
CPPs	O
)	O
.	O

Protein	O
cationization	O
using	O
either	O
synthetic	O
or	O
natural	O
polyamines	O
is	O
discussed	O
and	O
some	O
examples	O
of	O
diamine	O
/	O
polyamine	O
modified	O
proteins	O
that	O
cross	O
BBB	O
are	O
described	O
.	O

Two	O
main	O
families	O
of	O
CPPs	O
belonging	O
to	O
the	O
Tat	O
-	O
derived	O
peptides	O
and	O
Syn	O
-	O
B	O
vectors	O
have	O
been	O
extensively	O
used	O
in	O
CPP	O
vector	O
-	O
mediated	O
strategies	O
allowing	O
delivery	O
of	O
a	O
large	O
variety	O
of	O
small	O
molecules	O
as	O
well	O
as	O
proteins	O
across	O
cell	O
membranes	O
in	O
vitro	O
and	O
the	O
BBB	O
in	O
vivo	O
.	O

CPP	O
strategy	O
suffers	O
from	O
several	O
limitations	O
such	O
as	O
toxicity	O
and	O
immunogenicity	B
-	O
-	O
like	O
the	O
cationization	O
strategy	O
-	O
-	O
as	O
well	O
as	O
the	O
instability	O
of	O
peptide	O
vectors	O
in	O
biological	O
media	O
.	O

The	O
review	O
concludes	O
by	O
stressing	O
the	O
need	O
to	O
improve	O
the	O
understanding	O
of	O
AMT	O
mechanisms	O
at	O
BBB	O
and	O
the	O
effectiveness	O
of	O
cationized	O
proteins	O
and	O
CPP	O
-	O
vectorized	O
proteins	O
as	O
neurotherapeutics	O
.	O

Weekly	O
irinotecan	O
plus	O
protracted	O
venous	O
fluorouracil	O
infusion	O
(	O
WI	O
-	O
FI	O
)	O
in	O
advanced	O
colorectal	B
cancer	I
:	O
a	O
phase	O
II	O
study	O
.	O

BACKGROUND	O
:	O
Irinotecan	O
(	O
IRI	O
)	O
is	O
a	O
topoisomerase	O
I	O
inhibitor	O
active	O
as	O
first	O
-	O
or	O
second	O
-	O
line	O
chemotherapy	O
in	O
advanced	O
colorectal	B
cancer	I
(	O
ACRC	B
)	O
.	O

Its	O
combination	O
with	O
fluorouracil	O
(	O
FU	O
)	O
increases	O
the	O
response	O
rate	O
and	O
prolongs	O
survival	O
.	O

In	O
order	O
to	O
identify	O
a	O
new	O
effective	O
and	O
less	O
toxic	O
schedule	O
of	O
administration	O
,	O
we	O
planned	O
this	O
phase	O
II	O
study	O
with	O
weekly	O
IRI	O
and	O
protracted	O
venous	O
infusion	O
of	O
FU	O
(	O
WI	O
-	O
FI	O
regimen	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
objective	O
response	O
rate	O
.	O

Secondary	O
aims	O
were	O
to	O
detect	O
toxicity	O
,	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
patients	O
(	O
pts	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
On	O
May	O
2000	O
,	O
a	O
monoinstitutional	O
study	O
commenced	O
with	O
the	O
following	O
schedule	O
of	O
administration	O
:	O
IRI	O
80	O
mg	O
/	O
m2	O
on	O
days	O
1	O
,	O
8	O
,	O
15	O
,	O
22	O
,	O
29	O
plus	O
a	O
28	O
-	O
day	O
protracted	O
venous	O
infusion	O
of	O
FU	O
200	O
mg	O
/	O
m2	O
/	O
day	O
.	O

The	O
treatment	O
was	O
repeated	O
every	O
35	O
days	O
.	O

Cycles	O
were	O
administered	O
until	O
a	O
maximum	O
of	O
6	O
courses	O
,	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O

RESULTS	O
:	O
By	O
March	O
2005	O
,	O
52	O
patients	O
(	O
30	O
males	O
and	O
22	O
females	O
)	O
had	O
entered	O
the	O
study	O
.	O

Their	O
median	O
age	O
was	O
61.5	O
years	O
and	O
the	O
median	O
ECOG	O
PS	O
was	O
1	O
.	O

In	O
total	O
,	O
223	O
courses	O
were	O
administered	O
(	O
median	O
5	O
cycles	O
/	O
patient	O
)	O
.	O

Toxicity	O
was	O
low	O
:	O
neutropenia	B
G3	O
and	O
asthenia	B
G3	O
were	O
the	O
most	O
observed	O
toxicities	O
(	O
5	O
pts	O
each	O
)	O
.	O

No	O
other	O
grade	O
3	O
-	O
4	O
toxic	O
side	O
-	O
effects	O
were	O
seen	O
.	O

Weekly	O
IRI	O
was	O
interrupted	O
in	O
11	O
pts	O
,	O
mostly	O
related	O
to	O
problems	O
with	O
the	O
central	O
venous	O
catheter	O
.	O

Following	O
RECIST	O
criteria	O
,	O
we	O
observed	O
5	O
complete	O
responses	O
,	O
15	O
partial	O
responses	O
,	O
17	O
pts	O
had	O
stable	O
disease	O
,	O
while	O
in	O
15	O
disease	O
progressed	O
.	O

The	O
overall	O
response	O
rate	O
was	O
38.5	O
%	O
and	O
the	O
disease	O
control	O
rate	O
was	O
71.2	O
%	O
.	O

Thirteen	O
pts	O
underwent	O
surgical	O
resection	O
of	O
their	O
relapsing	O
disease	O
.	O

The	O
median	O
PFS	O
was	O
8.2	O
months	O
and	O
the	O
median	O
OS	O
was	O
16.3	O
months	O
.	O

CONCLUSION	O
:	O
The	O
WI	O
-	O
FI	O
regimen	O
is	O
an	O
active	O
treatment	O
with	O
a	O
good	O
safety	O
profile	O
in	O
patients	O
with	O
CRC	B
.	O

The	O
low	O
incidence	O
of	O
grade	O
3	O
-	O
4	O
toxicities	O
justifies	O
further	O
evaluation	O
of	O
this	O
combination	O
.	O

Paclitaxel	O
and	O
pegylated	O
liposomal	O
doxorubicin	O
in	O
recurrent	B
head	I
and	I
neck	I
cancer	I
:	O
clinical	O
and	O
unexpected	O
pharmacokinetic	O
interactions	O
.	O

BACKGROUND	O
:	O
The	O
combination	O
of	O
paclitaxel	O
(	O
PTX	O
)	O
with	O
pegylated	O
liposomal	O
doxorubicin	O
(	O
PLD	O
)	O
is	O
an	O
interesting	O
treatment	O
for	O
recurrent	B
head	I
and	I
neck	I
cancer	I
.	O

The	O
pharmacokinetic	O
behavior	O
may	O
depend	O
on	O
the	O
interval	O
between	O
the	O
intravenous	O
administration	O
of	O
the	O
two	O
drugs	O
.	O

This	O
study	O
evaluates	O
the	O
clinical	O
efficacy	O
,	O
toxicity	O
and	O
any	O
possible	O
interval	O
-	O
dependent	O
pharmacokinetic	O
interactions	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Thirty	O
patients	O
were	O
randomized	O
to	O
receive	O
80	O
mg	O
/	O
m2	O
PTX	O
weekly	O
and	O
12.5	O
mg	O
/	O
m2	O
PLD	O
every	O
two	O
weeks	O
at	O
administration	O
intervals	O
of	O
0	O
,	O
1	O
,	O
3	O
,	O
12	O
or	O
24	O
hours	O
.	O

Blood	O
sampling	O
was	O
performed	O
at	O
day	O
1	O
and	O
15	O
and	O
pharmacokinetics	O
of	O
PTX	O
,	O
PLD	O
and	O
Cremophor	O
EL	O
were	O
evaluated	O
by	O
non	O
-	O
compartmental	O
analysis	O
.	O

RESULTS	O
:	O
Neutropenia	B
was	O
the	O
most	O
frequent	O
side	O
-	O
effect	O
(	O
100	O
%	O
of	O
patients	O
;	O
30	O
%	O
grade	O
3	O
-	O
4	O
)	O
.	O

Hand	B
-	I
foot	I
syndrome	I
was	O
severe	O
in	O
only	O
3	O
%	O
of	O
patients	O
.	O

Overall	O
response	O
rate	O
was	O
30	O
%	O
,	O
with	O
3	O
%	O
complete	O
responses	O
and	O
27	O
%	O
partial	O
responses	O
.	O

Stable	O
disease	O
and	O
progression	O
were	O
43	O
%	O
and	O
27	O
%	O
,	O
respectively	O
.	O

Median	O
response	O
duration	O
and	O
overall	O
median	O
survival	O
were	O
5.5	O
and	O
10	O
months	O
respectively	O
.	O

Co	O
-	O
administration	O
of	O
PLD	O
markedly	O
reduced	O
Cmax	O
and	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
,	O
and	O
increased	O
PTX	O
clearance	O
.	O

The	O
differences	O
in	O
the	O
PTX	O
AUC	O
and	O
clearance	O
between	O
the	O
0	O
h	O
and	O
the	O
24	O
h	O
experimental	O
arms	O
were	O
statistically	O
significant	O
.	O

CONCLUSION	O
:	O
The	O
PTX	O
/	O
PLD	O
combination	O
plays	O
a	O
palliative	O
role	O
(	O
clinical	O
benefit	O
in	O
73	O
%	O
of	O
patients	O
)	O
and	O
has	O
good	O
tolerability	O
.	O

The	O
PTX	O
pharmacokinetic	O
profile	O
was	O
unexpectedly	O
affected	O
by	O
different	O
administration	O
time	O
intervals	O
;	O
in	O
the	O
0	O
h	O
arm	O
the	O
AUC	O
was	O
reduced	O
to	O
one	O
fourth	O
,	O
therefore	O
a	O
schedule	O
with	O
PTX	O
on	O
day	O
one	O
,	O
PLD	O
on	O
day	O
two	O
may	O
be	O
preferred	O
.	O

The	O
novel	O
cholinesterase	O
-	O
monoamine	O
oxidase	O
inhibitor	O
and	O
antioxidant	O
,	O
ladostigil	O
,	O
confers	O
neuroprotection	O
in	O
neuroblastoma	O
cells	O
and	O
aged	O
rats	O
.	O

The	O
current	O
therapeutic	O
advance	O
in	O
which	O
future	O
drugs	O
are	O
designed	O
to	O
possess	O
varied	O
pharmacological	O
properties	O
and	O
act	O
on	O
multiple	O
targets	O
has	O
stimulated	O
the	O
development	O
of	O
the	O
multimodal	O
drug	O
,	O
ladostigil	O
(	O
TV3326	O
;	O
(	O
N	O
-	O
propargyl	O
-	O
(	O
3R	O
)	O
aminoindan	O
-	O
5yl	O
)	O
-	O
ethyl	O
methyl	O
carbamate	O
)	O
.	O

Ladostigil	O
combines	O
neuroprotective	O
effects	O
with	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
-	O
A	O
and	O
MAO	O
-	O
B	O
and	O
cholinesterase	O
(	O
ChE	O
)	O
inhibitory	O
activities	O
in	O
a	O
single	O
molecule	O
,	O
as	O
a	O
potential	O
treatment	O
for	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
and	O
Lewy	B
body	I
disease	I
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
ladostigil	O
(	O
10	O
(	O
-	O
6	O
)	O
-	O
10	O
muM	O
)	O
dose	O
-	O
dependently	O
increased	O
cell	O
viability	O
,	O
associated	O
with	O
increased	O
activity	O
of	O
catalase	O
and	O
glutathione	O
reductase	O
and	O
decrease	O
of	O
intracellular	O
reactive	O
oxygen	O
species	O
production	O
in	O
a	O
cytotoxic	O
model	O
of	O
human	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
exposed	O
to	O
hydrogen	O
peroxide	O
(	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
)	O
.	O

In	O
addition	O
,	O
ladostigil	O
significantly	O
upregulated	O
mRNA	O
levels	O
of	O
several	O
antioxidant	O
enzymes	O
(	O
catalase	O
,	O
NAD	O
(	O
P	O
)	O
H	O
quinone	O
oxidoreductase	O
1	O
and	O
peroxiredoxin	O
1	O
)	O
in	O
both	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
-	O
treated	O
SH	O
-	O
SY5Y	O
cells	O
,	O
as	O
well	O
as	O
in	O
the	O
high	O
-	O
density	O
human	O
SK	O
-	O
N	O
-	O
SH	O
neuroblastoma	O
cultured	O
apoptotic	O
models	O
.	O

In	O
vivo	O
chronic	O
treatment	O
with	O
ladostigil	O
(	O
1	O
mg	O
/	O
kg	O
per	O
os	O
per	O
day	O
for	O
30	O
days	O
)	O
markedly	O
upregulated	O
mRNA	O
expression	O
levels	O
of	O
various	O
enzymes	O
involved	O
in	O
metabolism	O
and	O
oxidation	O
processes	O
in	O
aged	O
rat	O
hippocampus	O
.	O

In	O
addition	O
to	O
its	O
unique	O
combination	O
of	O
ChE	O
and	O
MAO	O
enzyme	O
inhibition	O
,	O
these	O
results	O
indicate	O
that	O
ladostigil	O
displays	O
neuroprotective	O
activity	O
against	O
oxidative	O
stress	O
-	O
induced	O
cell	O
apoptosis	O
,	O
which	O
might	O
be	O
valuable	O
for	O
aging	O
and	O
age	O
-	O
associated	O
neurodegenerative	B
diseases	I
.	O

The	O
reduction	O
in	O
visceral	O
fat	O
mass	O
in	O
response	O
to	O
growth	O
hormone	O
is	O
more	O
marked	O
in	O
men	O
than	O
in	O
oestrogen	O
-	O
deficient	O
women	O
.	O

CONTEXT	O
:	O
Women	O
with	O
severe	O
growth	B
hormone	I
(	I
GH	I
)	I
deficiency	I
have	O
a	O
less	O
marked	O
response	O
to	O
GH	O
replacement	O
than	O
men	O
.	O

This	O
has	O
mostly	O
been	O
attributed	O
to	O
the	O
attenuating	O
effects	O
of	O
oestrogen	O
replacement	O
therapy	O
.	O

OBJECTIVE	O
:	O
To	O
study	O
gender	O
related	O
differences	O
in	O
the	O
response	O
to	O
GH	O
treatment	O
in	O
men	O
and	O
postmenopausal	O
women	O
.	O

METHODS	O
:	O
Fifteen	O
men	O
and	O
15	O
age	O
-	O
and	O
BMI	O
-	O
matched	O
women	O
with	O
abdominal	B
obesity	I
(	O
mean	O
age	O
:	O
58	O
;	O
range	O
51	O
-	O
64	O
years	O
)	O
were	O
treated	O
for	O
one	O
year	O
with	O
similar	O
doses	O
(	O
0.47	O
vs.	O
0.51	O
mg	O
/	O
day	O
)	O
of	O
GH	O
.	O

All	O
women	O
were	O
postmenopausal	O
not	O
receiving	O
oestrogen	O
treatment	O
.	O

Insulin	O
sensitivity	O
was	O
assessed	O
using	O
a	O
hyperinsulinemic	O
euglycemic	O
clamp	O
and	O
body	O
composition	O
by	O
computed	O
tomography	O
(	O
CT	O
)	O
scans	O
and	O
from	O
total	O
body	O
potassium	O
,	O
K	O
(	O
40	O
)	O
.	O

RESULTS	O
:	O
Men	O
and	O
women	O
were	O
comparable	O
at	O
baseline	O
in	O
terms	O
of	O
waist	O
circumference	O
,	O
IGF	O
-	O
1	O
and	O
lipid	O
levels	O
.	O

After	O
one	O
year	O
of	O
GH	O
treatment	O
,	O
there	O
was	O
a	O
18	O
%	O
reduction	O
in	O
visceral	O
adipose	O
tissue	O
(	O
VAT	O
)	O
in	O
men	O
and	O
a	O
5	O
%	O
reduction	O
in	O
women	O
(	O
P	O
=	O
0.0001	O
men	O
vs.	O
women	O
)	O
.	O

Although	O
the	O
magnitude	O
of	O
the	O
difference	O
was	O
small	O
,	O
men	O
increased	O
more	O
in	O
thigh	O
muscle	O
mass	O
(	O
P	O
<	O
0.0001	O
vs.	O
women	O
)	O
.	O

A	O
reduction	O
in	O
thigh	O
intermuscular	O
adipose	O
tissue	O
(	O
IMAT	O
)	O
and	O
diastolic	O
blood	O
pressure	O
was	O
seen	O
only	O
in	O
men	O
(	O
both	O
p	O
<	O
0.05	O
vs.	O
baseline	O
)	O
.	O

A	O
decrease	O
in	O
LDL	O
cholesterol	O
,	O
and	O
an	O
increase	O
in	O
serum	O
insulin	O
,	O
was	O
observed	O
only	O
in	O
women	O
(	O
both	O
p	O
<	O
0.05	O
vs.	O
baseline	O
)	O
.	O

CONCLUSION	O
:	O
Low	O
dose	O
GH	O
treatment	O
reduced	O
VAT	O
more	O
markedly	O
in	O
men	O
as	O
compared	O
with	O
women	O
.	O

As	O
all	O
women	O
were	O
postmenopausal	O
and	O
oestrogen	O
-	O
deficient	O
,	O
this	O
gender	O
difference	O
in	O
responsiveness	O
was	O
not	O
due	O
to	O
an	O
antagonistic	O
effect	O
of	O
oestrogen	O
on	O
peripheral	O
GH	O
action	O
.	O

Factors	O
affecting	O
sensitivity	O
of	O
distortion	O
-	O
product	O
otoacoustic	O
emissions	O
to	O
ototoxic	B
hearing	I
loss	I
.	O

OBJECTIVES	O
:	O
(	O
1	O
)	O
To	O
determine	O
the	O
ototoxicity	B
detection	O
rate	O
(	O
sensitivity	O
)	O
for	O
distortion	O
-	O
product	O
otoacoustic	O
emissions	O
(	O
DPOAEs	O
)	O
testing	O
in	O
adults	O
who	O
received	O
ototoxic	O
medications	O
and	O
experienced	O
pure	O
-	O
tone	O
threshold	O
changes	O
during	O
the	O
course	O
of	O
treatment	O
;	O
(	O
2	O
)	O
to	O
determine	O
the	O
extent	O
to	O
which	O
DPOAE	O
sensitivity	O
to	O
ototoxicity	B
depends	O
on	O
the	O
type	O
of	O
drug	O
administered	O
(	O
platinum	O
or	O
antibiotic	O
)	O
,	O
magnitude	O
of	O
ototoxic	O
threshold	O
shifts	O
,	O
pre	O
-	O
exposure	O
pure	O
-	O
tone	O
threshold	O
,	O
and	O
DPOAE	O
data	O
;	O
and	O
(	O
3	O
)	O
to	O
build	O
a	O
model	O
to	O
predict	O
DPOAE	O
sensitivity	O
.	O

DESIGN	O
:	O
DPOAE	O
and	O
audiometric	O
data	O
were	O
obtained	O
as	O
part	O
of	O
a	O
prospective	O
Veterans	O
Affairs	O
study	O
investigating	O
methods	O
of	O
ototoxicity	B
monitoring	O
.	O

Data	O
were	O
analyzed	O
from	O
90	O
ears	O
of	O
53	O
subjects	O
receiving	O
ototoxic	O
medications	O
and	O
showing	O
significant	O
hearing	O
changes	O
in	O
at	O
least	O
one	O
ear	O
.	O

Pure	O
-	O
tone	O
threshold	O
data	O
were	O
obtained	O
at	O
frequencies	O
from	O
0.5	O
to	O
20	O
kHz	O
,	O
using	O
1	O
/	O
6	O
-	O
octave	O
precision	O
near	O
the	O
upper	O
frequency	O
limit	O
of	O
hearing	O
.	O

DPOAE	O
data	O
are	O
reported	O
for	O
f2	O
's	O
from	O
0.8	O
to	O
8.0	O
kHz	O
in	O
1	O
/	O
6	O
-	O
octave	O
increments	O
using	O
primary	O
levels	O
(	O
L1	O
/	O
L2	O
)	O
of	O
65	O
/	O
59	O
dB	O
SPL	O
and	O
a	O
primary	O
frequency	O
ratio	O
(	O
f2	O
/	O
f1	O
)	O
of	O
1.2	O
.	O

Test	O
results	O
were	O
evaluated	O
at	O
various	O
times	O
during	O
drug	O
treatment	O
to	O
determine	O
whether	O
DPOAE	O
level	O
changes	O
were	O
associated	O
with	O
behavioral	O
hearing	O
changes	O
.	O

Univariate	O
and	O
multivariate	O
analysis	O
techniques	O
were	O
used	O
to	O
determine	O
factors	O
that	O
affected	O
DPOAE	O
sensitivity	O
to	O
ototoxic	B
damage	I
.	O

RESULTS	O
:	O
Of	O
the	O
90	O
ears	O
examined	O
,	O
82	O
(	O
91	O
%	O
)	O
had	O
DPOAEs	O
that	O
could	O
be	O
monitored	O
for	O
changes	O
.	O

Sixty	O
-	O
four	O
of	O
these	O
82	O
ears	O
(	O
78	O
%	O
)	O
had	O
DPOAEs	O
that	O
were	O
reduced	O
or	O
absent	O
following	O
drug	O
treatment	O
.	O

DPOAE	O
sensitivity	O
to	O
ototoxicity	B
was	O
unrelated	O
to	O
the	O
type	O
of	O
ototoxic	O
drug	O
administered	O
.	O

Rather	O
,	O
DPOAE	O
sensitivity	O
depended	O
on	O
the	O
magnitude	O
of	O
postexposure	O
hearing	O
changes	O
and	O
on	O
variables	O
related	O
to	O
pre	O
-	O
exposure	O
audiogram	O
and	O
DPOAE	O
measurements	O
.	O

Behavioral	O
hearing	O
changes	O
not	O
detected	O
by	O
DPOAEs	O
were	O
small	O
on	O
average	O
(	O
<	O
7	O
dB	O
)	O
.	O

DPOAE	O
sensitivity	O
was	O
reduced	O
in	O
ears	O
with	O
poorer	O
pre	O
-	O
exposure	O
hearing	O
,	O
and	O
in	O
ears	O
with	O
measurable	O
DPOAE	O
frequencies	O
limited	O
to	O
f2	O
's	O
below	O
2.5	O
kHz	O
or	O
more	O
than	O
one	O
octave	O
from	O
the	O
frequency	O
region	O
where	O
hearing	O
change	O
occurred	O
.	O

Results	O
of	O
logistic	O
regression	O
modeling	O
showed	O
that	O
DPOAEs	O
present	O
at	O
f2	O
's	O
greater	O
than	O
2.5	O
kHz	O
were	O
associated	O
with	O
the	O
eventual	O
success	O
of	O
ototoxicity	B
monitoring	O
with	O
DPOAEs	O
.	O

However	O
,	O
independent	O
variables	O
examined	O
could	O
not	O
explain	O
differences	O
in	O
the	O
relative	O
timing	O
of	O
behavioral	O
and	O
DPOAE	O
changes	O
.	O

A	O
roughly	O
equivalent	O
proportion	O
of	O
ears	O
experienced	O
DPOAE	O
changes	O
before	O
,	O
during	O
,	O
or	O
after	O
behavioral	O
hearing	O
changes	O
.	O

CONCLUSIONS	O
:	O
DPOAEs	O
are	O
a	O
useful	O
screening	O
tool	O
for	O
ototoxicity	B
in	O
adults	O
with	O
pre	O
-	O
exposure	O
hearing	B
loss	I
,	O
but	O
are	O
less	O
sensitive	O
compared	O
with	O
a	O
behavioral	O
test	O
method	O
that	O
targets	O
thresholds	O
near	O
the	O
upper	O
limit	O
of	O
a	O
subject	O
's	O
audible	O
frequency	O
range	O
.	O

Ears	O
successfully	O
monitored	O
for	O
ototoxicity	B
with	O
DPOAEs	O
are	O
those	O
with	O
better	O
pre	O
-	O
exposure	O
hearing	O
,	O
greater	O
postexposure	O
hearing	O
changes	O
,	O
and	O
baseline	O
DPOAEs	O
near	O
the	O
highest	O
behavioral	O
test	O
frequencies	O
and	O
present	O
at	O
high	O
f2	O
's	O
.	O

Results	O
suggest	O
that	O
successful	O
monitoring	O
of	O
ototoxicity	B
with	O
DPOAEs	O
may	O
be	O
predicted	O
clinically	O
by	O
assessing	O
the	O
measurable	O
DPOAE	O
f2	O
frequency	O
range	O
and	O
its	O
relation	O
to	O
the	O
highest	O
behavioral	O
test	O
frequencies	O
.	O

Effect	O
of	O
an	O
ibuprofen	O
-	O
releasing	O
foam	O
dressing	O
on	O
wound	B
pain	I
:	O
a	O
real	O
-	O
life	O
RCT	O
.	O

OBJECTIVE	O
:	O
To	O
compare	O
an	O
ibuprofen	O
-	O
releasing	O
foam	O
dressing	O
(	O
Biatain	O
Ibu	O
,	O
ColoplastA	O
/	O
S	O
)	O
with	O
local	O
best	O
practice	O
in	O
the	O
treatment	O
of	O
painful	B
exuding	I
wounds	I
.	O

METHOD	O
:	O
In	O
this	O
large	O
-	O
scale	O
randomised	O
comparative	O
study	O
,	O
853	O
patients	O
were	O
randomised	O
to	O
either	O
ibuprofen	O
-	O
releasing	O
foam	O
(	O
test	O
)	O
dressing	O
(	O
n	O
=	O
467	O
)	O
or	O
local	O
best	O
practice	O
(	O
n	O
=	O
386	O
)	O
.	O

Primary	O
endpoint	O
was	O
wound	B
pain	I
relief	O
from	O
day	O
1	O
-	O
7	O
,	O
assessed	O
by	O
the	O
patients	O
twice	O
daily	O
using	O
a	O
five	O
-	O
point	O
verbal	O
rating	O
scale	O
.	O

Secondary	O
endpoints	O
were	O
reduction	O
in	O
pain	B
intensity	O
from	O
day	O
0	O
-	O
7	O
(	O
assessed	O
using	O
an	O
11	O
-	O
point	O
numeric	O
box	O
scale	O
)	O
,	O
quality	O
of	O
life	O
(	O
assessed	O
using	O
the	O
WHO	O
-	O
5	O
well	O
-	O
being	O
index	O
and	O
effect	O
on	O
health	O
-	O
related	O
activities	O
of	O
daily	O
living	O
)	O
and	O
the	O
incidence	O
of	O
adverse	O
events	O
.	O

RESULTS	O
:	O
After	O
seven	O
days	O
significantly	O
more	O
patients	O
in	O
the	O
experimental	O
group	O
experienced	O
relief	O
from	O
temporary	O
and	O
persistent	O
pain	B
and	O
a	O
reduction	O
in	O
pain	B
intensity	O
,	O
when	O
compared	O
with	O
patients	O
in	O
the	O
local	O
best	O
practice	O
group	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

They	O
also	O
experienced	O
a	O
greater	O
improvement	O
in	O
quality	O
of	O
life	O
.	O

The	O
number	O
of	O
adverse	O
events	O
in	O
both	O
groups	O
was	O
low	O
.	O

CONCLUSION	O
:	O
The	O
test	O
dressing	O
provided	O
an	O
appropriate	O
wound	B
healing	O
environment	O
,	O
relieved	O
temporary	O
and	O
persistent	O
wound	B
pain	I
,	O
and	O
decreased	O
pain	B
intensity	O
.	O

It	O
was	O
also	O
associated	O
with	O
an	O
improvement	O
in	O
quality	O
of	O
life	O
.	O

Clinical	O
features	O
and	O
therapeutic	O
management	O
of	O
subglottic	B
stenosis	I
in	O
patients	O
with	O
Wegener	B
's	I
granulomatosis	I
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
clinical	O
features	O
,	O
response	O
to	O
treatment	O
,	O
and	O
long	O
-	O
term	O
outcome	O
of	O
subglottic	B
stenosis	I
(	O
SGS	B
)	O
in	O
a	O
series	O
of	O
patients	O
diagnosed	O
as	O
having	O
Wegener	B
's	I
granulomatosis	I
(	O
WG	B
)	O
at	O
a	O
single	O
institution	O
.	O

Subglottic	B
stenosis	I
developed	O
in	O
6	O
out	O
of	O
51	O
(	O
11.7	O
%	O
)	O
patients	O
,	O
in	O
four	O
of	O
them	O
in	O
the	O
absence	O
of	O
other	O
features	O
of	O
active	O
disease	O
,	O
and	O
was	O
the	O
symptom	O
that	O
leads	O
to	O
WG	B
diagnosis	O
in	O
three	O
cases	O
.	O

In	O
two	O
cases	O
,	O
SGS	B
began	O
while	O
the	O
patients	O
were	O
receiving	O
systemic	O
immunosuppressive	O
therapy	O
for	O
disease	O
activity	O
involving	O
other	O
sites	O
.	O

PR3	O
-	O
ANCAs	O
were	O
positive	O
in	O
four	O
cases	O
.	O

An	O
urgent	O
tracheostomy	O
was	O
needed	O
in	O
two	O
patients	O
.	O

Four	O
patients	O
achieved	O
SGS	B
clinical	O
remission	O
on	O
standard	O
treatment	O
with	O
glucocorticoids	O
and	O
cyclophosphamide	O
,	O
but	O
three	O
of	O
them	O
experienced	O
repeated	O
local	O
relapses	O
and	O
required	O
additional	O
immunosuppressive	O
therapy	O
and	O
mechanical	O
dilations	O
.	O

In	O
one	O
case	O
,	O
a	O
local	O
relapse	O
was	O
successfully	O
managed	O
with	O
endotracheal	O
dilation	O
of	O
the	O
stenotic	O
segment	O
and	O
intralesional	O
injection	O
of	O
a	O
long	O
-	O
acting	O
corticosteroid	O
plus	O
mechanical	O
dilation	O
of	O
the	O
stenotic	O
segment	O
(	O
ILCD	O
)	O
without	O
adding	O
supplemental	O
immunosuppressant	O
drugs	O
.	O

Two	O
patients	O
with	O
isolated	O
SGS	B
were	O
also	O
successfully	O
managed	O
with	O
ILCD	O
alone	O
and	O
did	O
not	O
require	O
the	O
institution	O
of	O
systemic	O
immunosuppressive	O
therapy	O
.	O

One	O
patient	O
underwent	O
open	O
surgical	O
repair	O
when	O
the	O
disease	O
was	O
under	O
control	O
.	O

Our	O
data	O
suggest	O
that	O
Subglottic	B
stenosis	I
often	O
occurs	O
or	O
progresses	O
independently	O
of	O
other	O
features	O
of	O
active	O
WG	B
,	O
and	O
that	O
ILCD	O
may	O
be	O
a	O
safe	O
alternative	O
to	O
conventional	O
immunosuppressive	O
therapy	O
in	O
patients	O
who	O
develop	O
SGS	B
in	O
the	O
absence	O
of	O
other	O
features	O
of	O
active	O
disease	O
,	O
allowing	O
reducing	O
the	O
treatment	B
-	I
related	I
toxicity	I
.	O

Sildenafil	O
citrate	O
and	O
Torsade	B
de	I
pointes	I
.	O

Sildenafil	O
citrate	O
is	O
a	O
drug	O
used	O
in	O
the	O
treatment	O
of	O
erectile	B
dysfunction	I
.	O

It	O
is	O
an	O
inhibitor	O
of	O
the	O
enzyme	O
phosphordiesterase	O
-	O
5	O
;	O
it	O
slows	O
down	O
the	O
breakdown	O
of	O
c	O
-	O
GMP	O
and	O
nitrous	O
oxide	O
.	O

The	O
cardiac	O
effects	O
associated	O
with	O
Sildenafil	O
citrate	O
have	O
been	O
extensively	O
studied	O
in	O
medical	O
literature	O
,	O
especially	O
its	O
potent	O
vasodilatory	O
effect	O
when	O
combined	O
with	O
nitrate	O
-	O
based	O
medications	O
,	O
producing	O
intractable	O
hypotension	B
,	O
but	O
a	O
lesser	O
known	O
and	O
potentially	O
lethal	O
side	O
effect	O
is	O
prolonged	O
cardiac	O
repolarization	O
when	O
used	O
at	O
dosage	O
greater	O
than	O
recommended	O
,	O
leading	O
to	O
QT	O
prolongation	O
that	O
could	O
theoretically	O
lead	O
to	O
dangerous	O
cardiac	O
dysrrhythmias	O
and	O
sudden	B
death	I
in	O
men	O
with	O
coronary	B
artery	I
disease	I
.	O

The	O
authors	O
present	O
the	O
case	O
of	O
a	O
49	O
-	O
year	O
-	O
old	O
hypertensive	B
Hispanic	O
man	O
who	O
arrived	O
to	O
our	O
emergency	O
department	O
with	O
the	O
chief	O
complaint	O
of	O
acute	O
epigastric	B
pain	I
for	O
3	O
hours	O
of	O
evolution	O
after	O
ingestion	O
of	O
Sildenafil	O
citrate	O
50	O
milligrams	O
(	O
mg	O
)	O
.	O

The	O
patient	O
was	O
found	O
to	O
have	O
an	O
acute	O
ST	O
elevation	O
inferior	B
myocardial	I
infarction	I
(	O
STEMI	B
)	O
.	O

Shortly	O
after	O
diagnosis	O
the	O
patient	O
developed	O
a	O
polymorphic	B
ventricular	I
tachycardia	I
(	O
Torsade	B
de	I
pointes	I
)	O
before	O
thrombolytic	O
administration	O
.	O

We	O
present	O
this	O
case	O
followed	O
by	O
a	O
brief	O
discussion	O
,	O
to	O
heighten	O
awareness	O
of	O
the	O
possible	O
association	O
of	O
acute	O
inferior	O
STEMI	B
and	O
the	O
development	O
of	O
Torsade	B
de	I
Pointes	I
after	O
the	O
use	O
of	O
Sildenafil	O
citrate	O
.	O

Descriptive	O
study	O
on	O
the	O
circumstances	O
concerning	O
confirmation	O
of	O
contraindications	O
and	O
careful	O
administration	O
upon	O
purchasing	O
over	O
-	O
the	O
-	O
counter	O
cold	B
medication	O
and	O
manifestation	O
of	O
after	O
-	O
use	O
urinary	B
disorders	I
.	O

Over	O
-	O
the	O
-	O
counter	O
medications	O
are	O
primarily	O
for	O
self	O
-	O
medication	O
,	O
where	O
the	O
seller	O
,	O
such	O
as	O
a	O
pharmacist	O
,	O
provides	O
the	O
necessary	O
information	O
and	O
the	O
consumer	O
uses	O
the	O
medication	O
at	O
his	O
or	O
her	O
own	O
discretion	O
based	O
on	O
the	O
information	O
provided	O
.	O

A	O
Web	O
survey	O
was	O
conducted	O
from	O
February	O
8	O
to	O
13	O
,	O
2006	O
,	O
involving	O
500	O
men	O
and	O
women	O
,	O
ranging	O
in	O
age	O
from	O
50	O
to	O
69	O
years	O
,	O
who	O
had	O
purchased	O
over	O
-	O
the	O
-	O
counter	O
medications	O
for	O
the	O
common	B
cold	I
within	O
the	O
past	O
3	O
years	O
.	O

Upon	O
consultation	O
with	O
and	O
purchase	O
of	O
a	O
cold	B
medication	O
from	O
a	O
pharmacist	O
,	O
84.2	O
%	O
of	O
respondents	O
reported	O
""""	O
being	O
asked	O
my	O
symptoms	O
,	O
""""	O
and	O
less	O
frequently	O
(	O
12.3	O
-	O
21.3	O
%	O
)	O
being	O
asked	O
about	O
contraindications	O
/	O
careful	O
administration	O
.	O

Most	O
respondents	O
(	O
60.8	O
%	O
)	O
when	O
asked	O
whether	O
they	O
confirmed	O
""""	O
contraindications	O
/	O
careful	O
administration	O
""""	O
responded	O
negatively	O
,	O
stating	O
they	O
""""	O
occasionally	O
do	O
not	O
confirm	O
""""	O
or	O
""""	O
do	O
not	O
confirm	O
.	O
""""	O

In	O
addition	O
,	O
among	O
men	O
aged	O
50	O
-	O
69	O
years	O
,	O
it	O
became	O
clear	O
that	O
6.0	O
%	O
had	O
experienced	O
aggravation	O
of	O
prostatic	B
hypertrophy	I
symptoms	O
after	O
taking	O
a	O
cold	B
medication	O
.	O

It	O
is	O
assumed	O
that	O
symptoms	O
are	O
usually	O
confirmed	O
upon	O
the	O
sale	O
of	O
over	O
-	O
the	O
-	O
counter	O
medications	O
,	O
but	O
the	O
rate	O
of	O
confirming	O
whether	O
the	O
consumer	O
may	O
need	O
to	O
consider	O
contraindications	O
/	O
careful	O
administration	O
is	O
low	O
.	O

Urinary	B
retention	I
is	O
a	O
preventable	O
side	O
effect	O
because	O
the	O
confirmation	O
prior	O
to	O
taking	O
the	O
medication	O
can	O
be	O
made	O
.	O

Accordingly	O
,	O
some	O
of	O
those	O
side	O
effects	O
can	O
be	O
avoided	O
by	O
ensuring	O
the	O
environment	O
for	O
confirming	O
whether	O
the	O
individual	O
corresponds	O
to	O
""""	O
contraindications	O
/	O
careful	O
administration	O
""""	O
before	O
taking	O
the	O
medication	O
.	O

Biochemical	O
mechanism	O
of	O
acetaminophen	O
(	O
APAP	O
)	O
induced	O
toxicity	O
in	O
melanoma	O
cell	O
lines	O
.	O

In	O
this	O
work	O
,	O
we	O
investigated	O
the	O
biochemical	O
mechanism	O
of	O
acetaminophen	O
(	O
APAP	O
)	O
induced	O
toxicity	O
in	O
SK	O
-	O
MEL	O
-	O
28	O
melanoma	O
cells	O
using	O
tyrosinase	O
enzyme	O
as	O
a	O
molecular	O
cancer	B
therapeutic	O
target	O
.	O

Our	O
results	O
showed	O
that	O
APAP	O
was	O
metabolized	O
87	O
%	O
by	O
tyrosinase	O
at	O
2	O
h	O
incubation	O
.	O

AA	O
and	O
NADH	O
,	O
quinone	O
reducing	O
agents	O
,	O
were	O
significantly	O
depleted	O
during	O
APAP	O
oxidation	O
by	O
tyrosinase	O
.	O

The	O
IC	O
(	O
50	O
)	O
(	O
48	O
h	O
)	O
of	O
APAP	O
towards	O
SK	O
-	O
MEL	O
-	O
28	O
,	O
MeWo	O
,	O
SK	O
-	O
MEL	O
-	O
5	O
,	O
B16	O
-	O
F0	O
,	O
and	O
B16	O
-	O
F10	O
melanoma	O
cells	O
was	O
100	O
microM	O
whereas	O
it	O
showed	O
no	O
significant	O
toxicity	O
towards	O
BJ	O
,	O
Saos	O
-	O
2	O
,	O
SW	O
-	O
620	O
,	O
and	O
PC	O
-	O
3	O
nonmelanoma	O
cells	O
,	O
demonstrating	O
selective	O
toxicity	O
towards	O
melanoma	O
cells	O
.	O

Dicoumarol	O
,	O
a	O
diaphorase	O
inhibitor	O
,	O
and	O
1	O
-	O
bromoheptane	O
,	O
a	O
GSH	O
depleting	O
agent	O
,	O
enhanced	O
APAP	O
toxicity	O
towards	O
SK	O
-	O
MEL	O
-	O
28	O
cells	O
.	O

AA	O
and	O
GSH	O
were	O
effective	O
in	O
preventing	O
APAP	O
induced	O
melanoma	B
cell	I
toxicity	I
.	O

Trifluoperazine	O
and	O
cyclosporin	O
A	O
,	O
inhibitors	O
of	O
permeability	O
transition	O
pore	O
in	O
mitochondria	O
,	O
significantly	O
prevented	O
APAP	B
melanoma	I
cell	I
toxicity	I
.	O

APAP	O
caused	O
time	O
and	O
dose	O
-	O
dependent	O
decline	O
in	O
intracellular	O
GSH	O
content	O
in	O
SK	O
-	O
MEL	O
-	O
28	O
,	O
which	O
preceded	O
cell	B
toxicity	I
.	O

APAP	O
led	O
to	O
ROS	O
formation	O
in	O
SK	O
-	O
MEL	O
-	O
28	O
cells	O
which	O
was	O
exacerbated	O
by	O
dicoumarol	O
and	O
1	O
-	O
bromoheptane	O
whereas	O
cyslosporin	O
A	O
and	O
trifluoperazine	O
prevented	O
it	O
.	O

Our	O
investigation	O
suggests	O
that	O
APAP	O
is	O
a	O
tyrosinase	O
substrate	O
,	O
and	O
that	O
intracellular	O
GSH	O
depletion	O
,	O
ROS	O
formation	O
and	O
induced	O
mitochondrial	B
toxicity	I
contributed	O
towards	O
APAP	O
's	O
selective	O
toxicity	O
in	O
SK	O
-	O
MEL	O
-	O
28	O
cells	O
.	O

Role	O
of	O
the	O
nitro	O
functionality	O
in	O
the	O
DNA	O
binding	O
of	O
3	O
-	O
nitro	O
-	O
10	O
-	O
methylbenzothiazolo	O
[	O
3,2	O
-	O
a	O
]	O
quinolinium	O
chloride	O
.	O

Interest	O
in	O
DNA	O
binding	O
drugs	O
has	O
increased	O
in	O
recent	O
years	O
due	O
to	O
their	O
importance	O
in	O
the	O
treatment	O
of	O
genome	B
-	I
related	I
diseases	I
,	O
like	O
cancer	B
.	O

A	O
new	O
family	O
of	O
water	O
-	O
soluble	O
DNA	O
binding	O
compounds	O
,	O
the	O
benzothiazolo	O
[	O
3,2	O
-	O
a	O
]	O
quinolinium	O
chlorides	O
(	O
BQCls	O
)	O
,	O
is	O
studied	O
here	O
as	O
potential	O
candidates	O
for	O
chemical	O
treatment	O
of	O
solid	O
tumor	O
cells	O
that	O
may	O
encounter	O
low	O
-	O
oxygen	O
environments	O
,	O
a	O
condition	O
known	O
as	O
hypoxia	B
.	O

These	O
compounds	O
are	O
good	O
DNA	O
intercalators	O
;	O
however	O
,	O
no	O
studies	O
have	O
been	O
made	O
of	O
these	O
compounds	O
under	O
hypoxic	O
conditions	O
.	O

This	O
work	O
demonstrates	O
the	O
importance	O
of	O
the	O
nitro	O
-	O
functionality	O
in	O
the	O
DNA	O
binding	O
of	O
3	O
-	O
nitro	O
-	O
10	O
-	O
methylbenzothiazolo	O
[	O
3,2	O
-	O
a	O
]	O
quinolinium	O
chloride	O
(	O
NBQ	O
-	O
91	O
)	O
,	O
which	O
possesses	O
nitro	O
-	O
functionality	O
,	O
and	O
10	O
-	O
methylbenzothiazolo	O
[	O
3,2	O
-	O
a	O
]	O
quinolinium	O
chloride	O
(	O
BQ	O
-	O
106	O
)	O
,	O
which	O
does	O
not	O
.	O

Both	O
NBQ	O
-	O
91	O
and	O
BQ	O
-	O
106	O
have	O
similar	O
noncovalent	O
binding	O
affinity	O
toward	O
DNA	O
.	O

Dialysis	O
experiments	O
show	O
that	O
NBQ	O
-	O
91	O
binds	O
DNA	O
under	O
N2	O
-	O
saturated	O
conditions	O
with	O
increasing	O
concentrations	O
of	O
reducing	O
agent	O
,	O
presumably	O
due	O
to	O
reduction	O
of	O
the	O
nitro	O
-	O
functionality	O
.	O

Conversely	O
,	O
because	O
of	O
the	O
lack	O
of	O
nitro	O
-	O
functionality	O
,	O
the	O
presence	O
of	O
a	O
reducing	O
agent	O
had	O
no	O
effect	O
on	O
BQ	O
-	O
106	O
binding	O
to	O
DNA	O
under	O
both	O
aerobic	O
and	O
N2	O
-	O
saturated	O
conditions	O
.	O

Clonogenic	O
assays	O
were	O
performed	O
to	O
determine	O
the	O
quinolinium	O
chloride	O
cytotoxicities	O
under	O
both	O
aerobic	O
(	O
95	O
%	O
air	O
and	O
5	O
%	O
CO2	O
)	O
and	O
hypoxic	O
(	O
80	O
%	O
N2	O
and	O
20	O
%	O
CO2	O
)	O
conditions	O
.	O

The	O
calculated	O
ratios	O
of	O
cellular	B
toxicity	I
under	O
aerobic	O
to	O
hypoxic	O
conditions	O
caused	O
by	O
the	O
same	O
concentration	O
of	O
test	O
agent	O
(	O
CTR	O
values	O
)	O
show	O
greater	O
levels	O
of	O
cell	O
death	O
under	O
hypoxia	B
than	O
under	O
aerobic	O
conditions	O
for	O
mitomycin	O
C	O
(	O
MC	O
)	O
(	O
CTR	O
=	O
0.7	O
at	O
1	O
microM	O
)	O
and	O
NBQ	O
-	O
91	O
(	O
CTR	O
=	O
0.4	O
at	O
200	O
microM	O
)	O
than	O
for	O
BQ	O
-	O
106	O
(	O
CTR	O
=	O
1.0	O
at	O
200	O
microM	O
)	O
,	O
which	O
agreed	O
with	O
the	O
previously	O
reported	O
data	O
for	O
MC	O
and	O
confirmed	O
the	O
importance	O
of	O
nitro	O
-	O
functionality	O
for	O
reactivity	O
under	O
hypoxic	O
conditions	O
.	O

There	O
was	O
no	O
correlation	O
between	O
noncovalent	O
binding	O
affinity	O
constants	O
and	O
their	O
cytotoxicity	B
under	O
hypoxic	O
conditions	O
.	O

Adduct	O
formation	O
between	O
the	O
NBQ	O
-	O
91	O
and	O
2	O
'	O
-	O
dG	O
was	O
also	O
assessed	O
by	O
reacting	O
2	O
'	O
-	O
dG	O
or	O
DNA	O
with	O
NBQ	O
-	O
91	O
and	O
BQ	O
-	O
106	O
under	O
N2	O
-	O
saturated	O
conditions	O
in	O
the	O
presence	O
of	O
hypoxanthine	O
and	O
xanthine	O
oxidase	O
(	O
HX	O
/	O
XO	O
)	O
.	O

DNA	O
covalent	O
adduct	O
formation	O
was	O
analyzed	O
by	O
two	O
techniques	O
:	O
LC	O
-	O
ESI	O
-	O
MS	O
and	O
Sephadex	O
size	O
exclusion	O
chromatography	O
.	O

LC	O
-	O
ESI	O
-	O
MS	O
results	O
clearly	O
indicate	O
the	O
formation	O
of	O
a	O
prominent	O
molecular	O
ion	O
at	O
masses	O
of	O
266.0	O
and	O
530.58	O
Da	O
,	O
corresponding	O
to	O
the	O
[	O
M	O
+	O
H	O
]	O
(	O
+	O
2	O
)	O
and	O
[	O
M	O
]	O
(	O
+	O
)	O
molecular	O
ions	O
of	O
the	O
monitored	O
2	O
'	O
-	O
dG	O
-	O
NBQ	O
-	O
91	O
adduct	O
.	O

Results	O
from	O
the	O
Sephadex	O
size	O
exclusion	O
chromatography	O
support	O
these	O
findings	O
because	O
the	O
NBQ	O
-	O
91	O
elution	O
percentage	O
increases	O
in	O
the	O
presence	O
of	O
HX	O
/	O
XO	O
due	O
to	O
the	O
reduction	O
of	O
the	O
nitro	O
-	O
functionality	O
,	O
which	O
results	O
in	O
covalent	O
binding	O
to	O
DNA	O
.	O

This	O
study	O
reports	O
evidence	O
of	O
the	O
DNA	O
binding	O
capacity	O
of	O
this	O
bioreductive	O
drug	O
.	O

The	O
preferential	O
N2	O
-	O
saturated	O
over	O
aerobic	O
conditions	O
for	O
DNA	O
binding	O
makes	O
NBQ	O
-	O
91	O
a	O
potential	O
bioreductive	O
compound	O
for	O
hypoxic	O
cell	O
killing	O
.	O

Efficacy	O
of	O
fractionated	O
gemtuzumab	O
ozogamicin	O
combined	O
with	O
cytarabine	O
in	O
advanced	O
childhood	O
myeloid	B
leukaemia	I
.	O

Gemtuzumab	O
ozogamicin	O
(	O
GO	O
)	O
monotherapy	O
is	O
reported	O
to	O
yield	O
a	O
20	O
-	O
30	O
%	O
response	O
rate	O
in	O
advanced	O
acute	B
myeloid	I
leukaemia	I
(	O
AML	B
)	O
.	O

This	O
study	O
examined	O
the	O
efficacy	O
and	O
tolerability	O
of	O
GO	O
combined	O
with	O
cytarabine	O
(	O
GOCYT	O
)	O
in	O
children	O
with	O
refractory	O
/	O
relapsed	O
CD33	O
(	O
+	O
)	O
AML	B
.	O

Seventeen	O
children	O
received	O
GO	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
4	O
and	O
7	O
plus	O
cytarabine	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
for	O
7	O
d	O
on	O
a	O
compassionate	O
-	O
use	O
basis	O
.	O

Seven	O
patients	O
then	O
received	O
GO	O
-	O
based	O
consolidation	O
.	O

At	O
the	O
outset	O
of	O
GOCYT	O
,	O
two	O
patients	O
were	O
refractory	O
;	O
eight	O
patients	O
were	O
in	O
refractory	O
first	O
relapse	O
;	O
six	O
patients	O
had	O
relapsed	O
after	O
stem	O
cell	O
transplantation	O
(	O
SCT	O
)	O
;	O
and	O
one	O
patient	O
[	O
del	O
(	O
5q	O
)	O
therapy	O
-	O
related	O
AML	B
(	O
t	O
-	O
AML	O
)	O
]	O
had	O
not	O
yet	O
been	O
treated	O
.	O

Mean	O
follow	O
-	O
up	O
was	O
17	O
months	O
(	O
8	O
-	O
33	O
months	O
)	O
.	O

Ten	O
responses	O
were	O
obtained	O
after	O
GOCYT	O
induction	O
,	O
including	O
complete	O
remission	O
(	O
CR	O
)	O
or	O
CR	O
without	O
complete	O
recovery	O
of	O
platelets	O
(	O
CRp	O
)	O
in	O
six	O
patients	O
(	O
35	O
%	O
)	O
.	O

The	O
responses	O
improved	O
in	O
three	O
children	O
who	O
received	O
GOCYT	O
consolidation	O
,	O
increasing	O
the	O
CR	O
+	O
CRp	O
rate	O
to	O
53	O
%	O
.	O

SCT	O
was	O
subsequently	O
performed	O
in	O
eight	O
responders	O
.	O

Grade	O
3	O
-	O
4	O
adverse	O
events	O
consisted	O
of	O
haematological	B
disorders	I
(	O
n	O
=	O
17	O
,	O
100	O
%	O
)	O
and	O
documented	O
infections	B
(	O
n	O
=	O
5	O
,	O
29	O
%	O
)	O
.	O

No	O
cases	O
of	O
sinusoidal	B
obstructive	I
syndrome	I
occurred	O
.	O

Three	O
patients	O
were	O
alive	O
at	O
the	O
cut	O
-	O
off	O
date	O
for	O
this	O
analysis	O
,	O
all	O
of	O
whom	O
had	O
responded	O
to	O
GOCYT	O
.	O

GOCYT	O
combination	O
therapy	O
yielded	O
a	O
high	O
response	O
rate	O
(	O
53	O
%	O
)	O
and	O
showed	O
acceptable	O
toxicity	O
in	O
heavily	O
pretreated	O
children	O
with	O
refractory	B
/	I
relapsed	I
AML	I
.	O

These	O
results	O
warrant	O
a	O
larger	O
prospective	O
study	O
.	O

Angiotensin	O
inhibition	O
in	O
renovascular	B
disease	I
:	O
a	O
population	O
-	O
based	O
cohort	O
study	O
.	O

BACKGROUND	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
and	O
angiotensin	O
receptor	O
blockers	O
effectively	O
reduce	O
blood	O
pressure	O
in	O
patients	O
with	O
renovascular	B
disease	I
(	O
RVD	B
)	O
;	O
yet	O
,	O
randomized	O
cardiovascular	O
prevention	O
trials	O
of	O
these	O
drugs	O
typically	O
exclude	O
individuals	O
with	O
this	O
condition	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
studied	O
the	O
association	O
of	O
renin	O
-	O
angiotensin	O
system	O
inhibition	O
with	O
prognosis	O
in	O
a	O
population	O
-	O
based	O
cohort	O
comprising	O
3,570	O
patients	O
with	O
RVD	B
in	O
Ontario	O
,	O
Canada	O
;	O
slightly	O
more	O
than	O
half	O
(	O
n	O
=	O
1,857	O
,	O
53	O
%	O
)	O
were	O
prescribed	O
angiotensin	O
inhibitors	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
composite	O
of	O
death	O
,	O
myocardial	B
infarction	I
,	O
or	O
stroke	B
.	O

Secondary	O
outcomes	O
included	O
individual	O
cardiovascular	O
and	O
renal	O
events	O
.	O

RESULTS	O
:	O
Patients	O
receiving	O
angiotensin	O
inhibitors	O
had	O
a	O
significantly	O
lower	O
risk	O
for	O
the	O
primary	O
outcome	O
during	O
follow	O
-	O
up	O
(	O
10.0	O
vs	O
13.0	O
events	O
per	O
100	O
patient	O
-	O
years	O
at	O
risk	O
,	O
multivariable	O
adjusted	O
hazard	O
ratio	O
[	O
HR	O
]	O
0.70	O
,	O
95	O
%	O
CI	O
0.59	O
-	O
0.82	O
)	O
.	O

In	O
addition	O
,	O
hospitalization	O
for	O
congestive	B
heart	I
failure	I
(	O
HR	O
0.69	O
,	O
95	O
%	O
CI	O
0.53	O
-	O
0.90	O
)	O
,	O
chronic	O
dialysis	O
initiation	O
(	O
HR	O
0.62	O
,	O
95	O
%	O
CI	O
0.42	O
-	O
0.92	O
)	O
,	O
and	O
mortality	O
(	O
HR	O
0.56	O
,	O
95	O
%	O
CI	O
0.47	O
-	O
0.68	O
)	O
was	O
lower	O
in	O
treated	O
patients	O
.	O

Conversely	O
,	O
patients	O
receiving	O
angiotensin	O
inhibitors	O
were	O
significantly	O
more	O
likely	O
to	O
be	O
hospitalized	O
for	O
acute	B
renal	I
failure	I
during	O
follow	O
-	O
up	O
(	O
HR	O
1.87	O
,	O
95	O
%	O
CI	O
1.05	O
-	O
3.33	O
;	O
1.2	O
vs	O
0.6	O
events	O
per	O
100	O
patient	O
-	O
years	O
at	O
risk	O
)	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
emphasize	O
the	O
high	O
vascular	O
risk	O
of	O
RVD	B
and	O
suggest	O
that	O
angiotensin	O
inhibitors	O
may	O
improve	O
prognosis	O
in	O
this	O
setting	O
at	O
the	O
expense	O
of	O
acute	B
renal	I
toxicity	I
.	O

If	O
the	O
latter	O
are	O
selected	O
in	O
the	O
management	O
of	O
RVD	B
,	O
renal	O
function	O
parameters	O
should	O
be	O
assiduously	O
followed	O
.	O

Antimicrobial	O
and	O
cytotoxic	O
arylazoenamines	O
.	O

Part	O
III	O
:	O
antiviral	O
activity	O
of	O
selected	O
classes	O
of	O
arylazoenamines	O
.	O

Eighty	O
-	O
five	O
arylazoenamines	O
,	O
characterized	O
by	O
different	O
types	O
of	O
aryl	O
and	O
basic	O
moieties	O
,	O
have	O
been	O
synthesized	O
and	O
evaluated	O
in	O
cell	O
-	O
based	O
assays	O
for	O
cytotoxicity	O
and	O
antiviral	O
activity	O
against	O
a	O
panel	O
of	O
ten	O
RNA	O
and	O
DNA	O
viruses	O
.	O

The	O
most	O
commonly	O
affected	O
viruses	O
were	O
,	O
in	O
decreasing	O
order	O
,	O
CVB	O
-	O
2	O
,	O
RSV	O
,	O
BVDV	O
,	O
YFV	O
,	O
and	O
Sb	O
-	O
1	O
;	O
the	O
remaining	O
viruses	O
were	O
either	O
not	O
affected	O
(	O
HIV	O
-	O
1	O
,	O
VSV	O
,	O
and	O
VV	O
)	O
or	O
susceptible	O
only	O
to	O
a	O
very	O
few	O
compounds	O
(	O
Reo	O
-	O
1	O
and	O
HSV	O
-	O
1	O
)	O
.	O

Thirty	O
-	O
five	O
compounds	O
exhibited	O
high	O
activity	O
,	O
with	O
EC	O
(	O
50	O
)	O
in	O
the	O
range	O
0.8	O
-	O
10	O
microM	O
,	O
and	O
other	O
28	O
compounds	O
had	O
EC	O
(	O
50	O
)	O
between	O
11	O
and	O
30	O
microM	O
,	O
thus	O
indicating	O
that	O
the	O
arylazoenamine	O
molecular	O
pattern	O
is	O
an	O
interesting	O
novel	O
pharmacophore	O
for	O
antiviral	O
agents	O
against	O
ssRNA	O
viruses	O
.	O

Moreover	O
,	O
some	O
compounds	O
(	O
as	O
28	O
,	O
32	O
,	O
42	O
,	O
and	O
53	O
)	O
appear	O
of	O
high	O
interest	O
,	O
being	O
devoid	O
of	O
toxicity	O
on	O
the	O
human	O
MT	O
-	O
4	O
cells	O
(	O
CC	O
(	O
50	O
)	O
>	O
100	O
microM	O
)	O
.	O

A	O
ligand	O
-	O
based	O
computational	O
approach	O
was	O
employed	O
to	O
identify	O
highly	O
predictive	O
pharmacophore	O
models	O
for	O
the	O
most	O
frequently	O
affected	O
viruses	O
CVB	O
-	O
2	O
,	O
RSV	O
,	O
and	O
BVDV	O
.	O

These	O
models	O
should	O
allow	O
the	O
design	O
of	O
second	O
generation	O
of	O
more	O
potent	O
inhibitors	O
of	O
these	O
human	O
and	O
veterinary	O
pathogens	O
.	O

Pharmacokinetics	O
of	O
levobupivacaine	O
0.5	O
%	O
after	O
superficial	O
or	O
combined	O
(	O
deep	O
and	O
superficial	O
)	O
cervical	O
plexus	O
block	O
in	O
patients	O
undergoing	O
minimally	O
invasive	O
parathyroidectomy	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
pharmacokinetic	O
profile	O
of	O
0.35	O
mL	O
/	O
kg	O
of	O
0.5	O
%	O
levobupivacaine	O
during	O
superficial	O
and	O
combined	O
(	O
deep	O
and	O
superficial	O
)	O
cervical	O
plexus	O
block	O
(	O
CPB	O
)	O
in	O
patients	O
undergoing	O
minimally	O
invasive	O
parathyroidectomy	O
.	O

DESIGN	O
:	O
Prospective	O
randomized	O
study	O
.	O

SETTING	O
:	O
Operating	O
theater	O
of	O
a	O
university	O
hospital	O
.	O

PATIENTS	O
:	O
12	O
ASA	O
physical	O
status	O
II	O
and	O
III	O
patients	O
(	O
11	O
women	O
and	O
1	O
man	O
)	O
,	O
scheduled	O
for	O
minimally	O
invasive	O
parathyroidectomy	O
.	O

INTERVENTIONS	O
:	O
Seven	O
and	O
5	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
superficial	O
or	O
combined	O
CPB	O
,	O
respectively	O
.	O

The	O
superficial	O
CPB	O
was	O
performed	O
with	O
an	O
injection	O
of	O
0.35	O
mL	O
/	O
kg	O
of	O
0.5	O
%	O
levobupivacaine	O
subcutaneously	O
along	O
the	O
posterior	O
border	O
of	O
the	O
sternocleidomastoid	O
muscle	O
and	O
deeper	O
on	O
its	O
medial	O
surface	O
.	O

The	O
combined	O
CPB	O
was	O
initiated	O
by	O
the	O
deep	O
block	O
at	O
the	O
C3	O
level	O
vertebra	O
by	O
injecting	O
0.2	O
mL	O
/	O
kg	O
of	O
0.5	O
%	O
levobupivacaine	O
,	O
followed	O
by	O
the	O
superficial	O
block	O
with	O
an	O
injection	O
of	O
the	O
remaining	O
0.15	O
mL	O
/	O
kg	O
.	O

After	O
completion	O
of	O
the	O
block	O
,	O
venous	O
blood	O
was	O
sampled	O
at	O
the	O
intervals	O
of	O
5	O
,	O
10	O
,	O
15	O
,	O
20	O
,	O
30	O
,	O
45	O
,	O
and	O
60	O
minutes	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
Venous	O
plasma	O
concentrations	O
were	O
measured	O
using	O
gas	O
chromatography	O
-	O
mass	O
spectroscopy	O
.	O

Mean	O
+	O
/	O
-	O
SD	O
of	O
maximal	O
concentrations	O
of	O
levobupivacaine	O
was	O
0.58	O
+	O
/	O
-	O
0.41	O
mg	O
/	O
L	O
in	O
group	O
superficial	O
and	O
0.52	O
+	O
/	O
-	O
0.28	O
mg	O
/	O
L	O
in	O
group	O
combined	O
(	O
P	O
=	O
0.71	O
)	O
.	O

The	O
median	O
(	O
range	O
)	O
time	O
required	O
to	O
reach	O
the	O
maximal	O
concentrations	O
was	O
30	O
minutes	O
(	O
20	O
-	O
30	O
min	O
)	O
in	O
group	O
superficial	O
and	O
20	O
minutes	O
(	O
15	O
-	O
30	O
min	O
)	O
in	O
group	O
combined	O
(	O
P	O
=	O
0.45	O
)	O
.	O

The	O
areas	O
under	O
the	O
drug	O
concentration	O
/	O
time	O
curve	O
(	O
AUC	O
(	O
10	O
-	O
60	O
)	O
)	O
were	O
also	O
similar	O
in	O
both	O
groups	O
.	O

No	O
signs	O
of	O
central	O
nervous	O
system	O
or	O
cardiovascular	B
toxicity	I
or	O
other	O
untoward	O
events	O
were	O
observed	O
in	O
any	O
patient	O
.	O

CONCLUSION	O
:	O
With	O
the	O
given	O
dose	O
regimen	O
,	O
levobupivacaine	O
plasma	O
concentrations	O
were	O
within	O
safe	O
ranges	O
.	O

Mycophenolate	O
mofetil	O
-	O
related	O
gastrointestinal	B
mucosal	I
injury	I
:	O
variable	O
injury	O
patterns	O
,	O
including	O
graft	B
-	I
versus	I
-	I
host	I
disease	I
-	O
like	O
changes	O
.	O

Mycophenolate	O
mofetil	O
(	O
MMF	O
)	O
is	O
a	O
commonly	O
used	O
immunosuppressive	O
drug	O
used	O
in	O
the	O
management	O
of	O
transplant	O
recipients	O
.	O

Although	O
gastrointestinal	B
(	I
GI	I
)	I
toxicity	I
is	O
a	O
known	O
complication	O
of	O
MMF	O
,	O
the	O
literature	O
characterizing	O
the	O
pathologic	O
features	O
of	O
MMF	O
in	O
the	O
GI	O
tract	O
is	O
sparse	O
.	O

This	O
study	O
characterizes	O
the	O
pathologic	O
features	O
of	O
MMF	B
toxicity	I
in	O
both	O
the	O
upper	O
and	O
lower	O
GI	O
tract	O
,	O
correlating	O
it	O
with	O
clinical	O
and	O
endoscopic	O
findings	O
.	O

Seventy	O
-	O
five	O
GI	O
biopsies	O
(	O
9	O
esophageal	O
,	O
15	O
gastric	O
,	O
16	O
duodenal	O
,	O
5	O
ileal	O
,	O
30	O
colonic	O
)	O
from	O
46	O
transplant	O
recipients	O
from	O
2002	O
to	O
2006	O
were	O
obtained	O
and	O
assessed	O
for	O
multiple	O
histologic	O
features	O
.	O

Clinical	O
features	O
were	O
recorded	O
for	O
all	O
cases	O
and	O
endoscopic	O
findings	O
.	O

Only	O
MMF	O
patients	O
showed	O
ulcerative	B
esophagitis	I
(	O
5	O
/	O
7	O
cases	O
)	O
and	O
reactive	B
gastropathy	I
(	O
4	O
/	O
10	O
cases	O
)	O
.	O

Only	O
MMF	O
patients	O
showed	O
graft	B
-	I
versus	I
-	I
host	I
disease	I
(	O
GVHD	B
)	O
-	O
like	O
features	O
in	O
duodenal	O
(	O
4	O
/	O
12	O
cases	O
)	O
and	O
ileal	O
(	O
1	O
/	O
5	O
cases	O
)	O
biopsies	O
.	O

GVHD	B
-	O
like	O
changes	O
were	O
seen	O
more	O
frequently	O
among	O
patients	O
on	O
MMF	O
compared	O
with	O
those	O
not	O
on	O
MMF	O
[	O
9	O
(	O
56	O
%	O
)	O
vs.	O
2	O
(	O
14	O
%	O
)	O
;	O
P	O
=	O
0.017	O
]	O
.	O

Crypt	B
architectural	I
disarray	I
[	O
12	O
(	O
75	O
%	O
)	O
vs.	O
2	O
(	O
14	O
%	O
)	O
;	O
P	O
=	O
0.001	O
]	O
,	O
lamina	B
propria	I
edema	I
[	O
9	O
(	O
56	O
%	O
)	O
vs.	O
2	O
(	O
14	O
%	O
)	O
;	O
P	O
=	O
0.017	O
]	O
,	O
increased	O
lamina	B
propria	I
inflammation	I
[	O
13	O
(	O
81	O
%	O
)	O
vs.	O
3	O
(	O
21	O
%	O
)	O
;	O
P	O
=	O
0.001	O
]	O
,	O
dilated	B
damaged	I
crypts	I
[	O
7	O
(	O
44	O
%	O
)	O
vs.	O
1	O
(	O
7	O
%	O
)	O
;	O
P	O
=	O
0.024	O
]	O
,	O
and	O
increased	O
crypt	O
epithelial	O
apoptosis	O
[	O
9	O
(	O
56	O
%	O
)	O
vs.	O
2	O
(	O
14	O
%	O
)	O
;	O
P	O
=	O
0.017	O
]	O
were	O
more	O
common	O
with	O
MMF	O
patients	O
compared	O
with	O
non	O
-	O
MMF	O
patients	O
.	O

In	O
conclusion	O
,	O
pathologists	O
should	O
be	O
aware	O
of	O
the	O
potential	O
manifestations	O
of	O
MMF	B
toxicity	I
throughout	O
the	O
GI	O
tract	O
,	O
including	O
ulcerative	B
esophagitis	I
,	O
reactive	B
gastropathy	I
,	O
and	O
GVHD	B
-	O
like	O
features	O
in	O
intestinal	O
biopsies	O
.	O

Effect	O
of	O
the	O
frequency	O
of	O
self	O
-	O
monitoring	O
blood	O
glucose	O
in	O
patients	O
with	O
type	B
2	I
diabetes	I
treated	O
with	O
oral	O
antidiabetic	O
drugs	O
-	O
a	O
multi	O
-	O
centre	O
,	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
:	O
Recommendations	O
on	O
the	O
frequency	O
of	O
self	O
-	O
monitoring	O
of	O
blood	O
glucose	O
(	O
SMBG	O
)	O
vary	O
widely	O
among	O
physicians	O
treating	O
patients	O
with	O
type	B
2	I
diabetes	I
(	O
T2D	B
)	O
.	O

Aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
two	O
testing	O
regimen	O
of	O
SMBG	O
in	O
patients	O
with	O
stable	O
metabolic	O
control	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
Patients	O
with	O
T2D	B
treated	O
with	O
oral	O
antidiabetic	O
drugs	O
were	O
randomized	O
to	O
two	O
groups	O
:	O
either	O
one	O
SMBG	O
(	O
low	O
)	O
or	O
four	O
SMBG	O
(	O
high	O
)	O
per	O
week	O
.	O

Subjects	O
were	O
followed	O
up	O
after	O
3	O
,	O
6	O
and	O
12	O
months	O
.	O

Primary	O
outcome	O
parameter	O
was	O
the	O
change	O
in	O
HbA1c	O
between	O
baseline	O
and	O
6	O
months	O
.	O

Primary	O
outcome	O
criterion	O
was	O
tested	O
by	O
a	O
one	O
-	O
sided	O
t	O
-	O
test	O
for	O
non	O
-	O
inferiority	O
.	O

Secondary	O
outcome	O
parameters	O
were	O
safety	O
,	O
compliance	O
and	O
HbA1c	O
at	O
3	O
and	O
12	O
months	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
differences	O
in	O
the	O
202	O
subjects	O
for	O
demographic	O
and	O
sociodemographic	O
parameters	O
and	O
drug	O
treatment	O
.	O

HbA	O
(	O
1	O
)	O
c	O
(	O
%	O
)	O
at	O
baseline	O
was	O
similar	O
in	O
both	O
groups	O
(	O
7.2	O
+	O
/	O
-	O
1.4	O
vs.	O
7.2	O
+	O
/	O
-	O
1.0	O
)	O
.	O

Non	O
-	O
inferiority	O
was	O
demonstrated	O
for	O
the	O
low	O
group	O
(	O
p	O
=	O
0.0022	O
)	O
with	O
a	O
difference	O
from	O
baseline	O
to	O
6	O
months	O
of	O
0.24	O
in	O
the	O
low	O
and	O
of	O
0.16	O
in	O
the	O
high	O
group	O
.	O

Compliance	O
with	O
the	O
testing	O
regimen	O
was	O
82	O
-	O
90	O
%	O
in	O
both	O
groups	O
.	O

There	O
were	O
no	O
statistical	O
significant	O
differences	O
for	O
compliance	O
,	O
HbA	O
(	O
1	O
)	O
c	O
at	O
3	O
and	O
12	O
months	O
and	O
serious	O
adverse	O
events	O
(	O
SAE	O
)	O
.	O

CONCLUSION	O
:	O
One	O
SMBG	O
per	O
week	O
is	O
as	O
sufficient	O
and	O
safe	O
as	O
four	O
SMBG	O
per	O
week	O
to	O
maintain	O
HbA	O
(	O
1	O
)	O
c	O
in	O
non	O
-	O
insulin	O
treated	O
T2D	B
close	O
to	O
metabolic	O
target	O
.	O

The	O
results	O
of	O
this	O
study	O
are	O
in	O
contrast	O
to	O
current	O
international	O
consensus	O
guidelines	O
.	O

TRIAL	O
REGISTRATION	O
:	O
Controlled	O
-	O
Trials	O
.	O

com	O
ISRCTN79164268	O
.	O

Mitochondrial	O
RNA	O
and	O
DNA	O
alterations	O
in	O
HIV	B
lipoatrophy	I
are	O
linked	O
to	O
antiretroviral	O
therapy	O
and	O
not	O
to	O
HIV	B
infection	I
.	O

BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
versus	O
HIV	O
on	O
mitochondria	O
in	O
fat	O
.	O

METHODS	O
:	O
Subcutaneous	O
fat	O
was	O
collected	O
from	O
45	O
HIV	O
-	O
infected	O
patients	O
on	O
ART	O
with	O
lipoatrophy	B
,	O
11	O
HIV	O
-	O
infected	O
ART	O
-	O
naive	O
patients	O
and	O
nine	O
healthy	O
controls	O
.	O

Three	O
mitochondrial	O
transcripts	O
:	O
NADH	O
dehydrogenase	O
subunit	O
1	O
(	O
ND1	O
)	O
,	O
cytochrome	O
B	O
(	O
CYTB	O
)	O
and	O
NADH	O
dehydrogenase	O
subunit	O
6	O
(	O
ND6	O
)	O
genes	O
were	O
quantitated	O
using	O
TaqMan	O
probes	O
and	O
normalized	O
to	O
nuclear	O
-	O
encoded	O
ribosomal	O
L13	O
.	O

RESULTS	O
:	O
ND1	O
/	O
L13	O
and	O
CYTB	O
/	O
L13	O
were	O
lower	O
in	O
HIV	O
-	O
positive	O
patients	O
on	O
ART	O
with	O
lipoatrophy	B
versus	O
ART	O
-	O
naive	O
patients	O
(	O
3.4	O
versus	O
7.2	O
[	O
P	O
=	O
0.017	O
]	O
and	O
2.5	O
versus	O
4.6	O
[	O
P	O
=	O
0.006	O
]	O
,	O
respectively	O
)	O
.	O

No	O
difference	O
was	O
found	O
between	O
ART	O
-	O
naive	O
patients	O
and	O
controls	O
(	O
P	O
>	O
0.70	O
)	O
.	O

ND6	O
/	O
L13	O
was	O
similar	O
between	O
all	O
groups	O
.	O

Dual	O
-	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
-	O
measured	O
limb	O
fat	O
and	O
mitochondrial	O
DNA	O
in	O
fat	O
were	O
also	O
lower	O
in	O
HIV	O
-	O
positive	O
patients	O
on	O
ART	O
with	O
lipoatrophy	B
versus	O
HIV	O
-	O
infected	O
,	O
ART	O
-	O
naive	O
patients	O
(	O
4,382	O
versus	O
7,662	O
g	O
[	O
P	O
=	O
0.02	O
]	O
and	O
726	O
versus	O
1,372	O
copies	O
/	O
cell	O
[	O
P	O
=	O
0.03	O
]	O
,	O
respectively	O
)	O
,	O
but	O
no	O
difference	O
was	O
found	O
between	O
ART	O
-	O
naive	O
and	O
controls	O
.	O

In	O
a	O
multiple	O
regression	O
analysis	O
,	O
limb	O
fat	O
correlated	O
with	O
all	O
three	O
mitochrondrial	O
RNA	O
,	O
whereas	O
mitochondrial	O
DNA	O
did	O
not	O
correlate	O
with	O
mitochondrial	O
RNA	O
or	O
limb	O
fat	O
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
ART	O
-	O
naive	O
patients	O
,	O
HIV	O
-	O
positive	O
patients	O
on	O
ART	O
with	O
lipoatrophy	B
had	O
significant	O
depletion	O
in	O
mitochondrial	O
DNA	O
in	O
fat	O
and	O
mitochondrial	O
RNAs	O
.	O

This	O
suggests	O
that	O
mitochondrial	B
toxicity	I
in	O
lipoatrophy	B
could	O
be	O
driven	O
by	O
ART	O
and	O
not	O
by	O
HIV	O
itself	O
.	O

In	O
addition	O
,	O
mitochondrial	O
RNA	O
abnormalities	O
,	O
and	O
not	O
mitochondrial	O
DNA	O
depletion	O
,	O
could	O
be	O
a	O
key	O
driving	O
force	O
behind	O
lipoatrophy	B
.	O

Serotonin	O
-	O
dopamine	O
interaction	O
in	O
the	O
induction	O
and	O
maintenance	O
of	O
L	O
-	O
DOPA	O
-	O
induced	O
dyskinesias	B
.	O

Appearance	O
of	O
dyskinesia	B
is	O
a	O
common	O
problem	O
of	O
long	O
-	O
term	O
Levodopa	O
(	O
L	O
-	O
DOPA	O
)	O
treatment	O
in	O
Parkinson	B
's	I
disease	I
(	O
PD	B
)	O
patients	O
and	O
represents	O
a	O
major	O
limitation	O
for	O
the	O
pharmacological	O
management	O
of	O
the	O
motor	O
symptoms	O
in	O
the	O
advanced	O
stages	O
of	O
disease	O
.	O

An	O
increasing	O
body	O
of	O
evidence	O
points	O
to	O
dopamine	O
released	O
as	O
a	O
false	O
neurotransmitter	O
from	O
the	O
striatal	O
serotonin	O
terminals	O
as	O
the	O
main	O
pre	O
-	O
synaptic	O
determinant	O
of	O
L	O
-	O
DOPA	O
-	O
induced	O
dyskinesia	B
.	O

Here	O
we	O
review	O
the	O
animal	O
experimental	O
and	O
human	O
clinical	O
data	O
in	O
support	O
of	O
this	O
view	O
,	O
which	O
point	O
to	O
the	O
serotonin	O
system	O
as	O
a	O
promising	O
target	O
for	O
anti	O
-	O
dyskinetic	O
therapy	O
in	O
PD	B
patients	O
under	O
L	O
-	O
DOPA	O
medication	O
.	O

La3	O
+	O
binds	O
to	O
BiP	O
/	O
GRP78	O
and	O
induces	O
unfolded	O
protein	O
response	O
in	O
HepG2	O
cells	O
.	O

The	O
effects	O
of	O
La3	O
+	O
on	O
the	O
unfolded	O
protein	O
response	O
signaling	O
pathways	O
were	O
investigated	O
in	O
human	O
hepatoblastoma	O
HepG2	O
cells	O
.	O

Our	O
data	O
showed	O
that	O
La3	O
+	O
could	O
induce	O
unfolded	O
protein	O
response	O
in	O
HepG2	O
cells	O
,	O
including	O
a	O
significant	O
increase	O
of	O
BiP	O
/	O
GRP78	O
level	O
,	O
which	O
is	O
an	O
important	O
ER	O
residential	O
chaperone	O
and	O
an	O
ER	O
stress	O
hallmark	O
,	O
in	O
a	O
concentration	O
and	O
time	O
-	O
dependent	O
manner	O
,	O
UPR	O
transducer	O
IRE1	O
phosphorylation	O
and	O
splicing	O
activation	O
IRE1	O
downstream	O
substrate	O
XBP1	O
mRNA	O
.	O

By	O
using	O
La3	O
+	O
-	O
affinity	O
chromatography	O
,	O
the	O
possible	O
cellular	O
target	O
of	O
La3	O
+	O
leading	O
to	O
UPR	O
events	O
was	O
shown	O
to	O
be	O
the	O
ER	O
residential	O
chaperone	O
BiP	O
/	O
GRP78	O
.	O

BiP	O
/	O
GRP78	O
was	O
shown	O
to	O
be	O
a	O
La3	O
+	O
binding	O
protein	O
and	O
the	O
interaction	O
of	O
La3	O
+	O
with	O
BiP	O
/	O
GRP78	O
resulted	O
in	O
dissociation	O
of	O
BiP	O
-	O
IRE1	O
complexes	O
.	O

La3	O
+	O
induced	O
dissociation	O
of	O
the	O
BiP	O
/	O
GRP78	O
-	O
IRE1	O
complex	O
was	O
in	O
a	O
time	O
and	O
concentration	O
manner	O
.	O

The	O
apparent	O
dissociation	O
constant	O
was	O
estimated	O
to	O
be	O
4	O
nM	O
.	O

In	O
addition	O
,	O
La3	O
+	O
was	O
observed	O
to	O
slightly	O
stimulate	O
the	O
production	O
of	O
cellular	O
ROS	O
and	O
cause	O
alteration	O
of	O
intracellular	O
Ca2	O
+	O
,	O
indicating	O
the	O
possible	O
involvement	O
of	O
ROS	O
and	O
Ca2	O
+	O
alteration	O
in	O
La3	O
+	O
induced	O
UPR	O
.	O

The	O
present	O
work	O
provides	O
a	O
new	O
perspective	O
for	O
understanding	O
the	O
biological	O
and	O
toxicological	O
effects	O
of	O
La3	O
+	O
.	O

Synergistic	O
cytotoxic	B
effect	I
of	O
different	O
sized	O
ZnO	O
nanoparticles	O
and	O
daunorubicin	O
against	O
leukemia	O
cancer	O
cells	O
under	O
UV	O
irradiation	O
.	O

Failure	O
of	O
chemotherapy	O
to	O
the	O
malignant	B
tumor	I
is	O
usually	O
induced	O
by	O
multidrug	O
resistance	O
(	O
MDR	O
)	O
.	O

The	O
development	O
of	O
anti	O
-	O
MDR	O
agents	O
for	O
efficient	O
drug	O
delivery	O
is	O
of	O
great	O
importance	O
in	O
cancer	B
therapy	O
.	O

Recent	O
reports	O
have	O
demonstrated	O
that	O
some	O
anticancer	O
drugs	O
could	O
be	O
readily	O
self	O
-	O
assembled	O
on	O
some	O
biocompatible	O
nanomaterials	O
covalently	O
or	O
non	O
-	O
covalently	O
,	O
which	O
could	O
effectively	O
afford	O
the	O
sustained	O
drug	O
delivery	O
for	O
the	O
target	O
cancer	O
cells	O
and	O
reduce	O
the	O
relevant	O
toxicity	O
towards	O
normal	O
cells	O
and	O
tissues	O
.	O

Thus	O
these	O
biocompatible	O
nanomaterials	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
relevant	O
biological	O
and	O
biomedical	O
system	O
.	O

In	O
this	O
paper	O
,	O
we	O
have	O
explored	O
the	O
cytotoxic	O
effect	O
of	O
anticancer	O
drug	O
daunorubicin	O
on	O
leukemia	O
cancer	O
cells	O
in	O
the	O
absence	O
and	O
presence	O
of	O
different	O
sized	O
ZnO	O
nanoparticles	O
via	O
fluorescence	O
microscopy	O
,	O
UV	O
-	O
Vis	O
absorption	O
spectroscopy	O
,	O
electrochemical	O
analysis	O
as	O
well	O
as	O
MTT	O
assay	O
.	O

Meanwhile	O
,	O
the	O
cytotoxicity	B
suppression	O
of	O
daunorubicin	O
together	O
with	O
different	O
sized	O
ZnO	O
nanoparticles	O
in	O
the	O
absence	O
and	O
presence	O
of	O
UV	O
irradiation	O
on	O
leukemia	O
cancer	O
cells	O
were	O
also	O
investigated	O
using	O
MTT	O
assay	O
.	O

The	O
results	O
indicate	O
that	O
the	O
combination	O
of	O
the	O
different	O
sized	O
ZnO	O
nanoparticles	O
and	O
daunorubicin	O
under	O
UV	O
irradiation	O
could	O
have	O
synergistic	O
cytotoxic	B
effect	I
on	O
leukemia	O
cancer	O
cells	O
,	O
indicating	O
the	O
great	O
potential	O
of	O
ZnO	O
nanoparticles	O
in	O
relevant	O
clinical	O
and	O
biomedical	O
applications	O
.	O

Broccoli	O
flower	O
head	O
extract	O
reduces	O
mitomycin	O
-	O
C	O
induced	O
sister	O
chromatid	O
exchange	O
in	O
cultured	O
human	O
lymphocytes	O
.	O

This	O
study	O
is	O
a	O
continuation	O
of	O
our	O
previous	O
work	O
[	O
Murugan	O
,	O
S	O
.	O

S	O
.	O
,	O
Balakrishnamurthy	O
,	O
P	O
.	O
,	O
Mathew	O
,	O
Y	O
.	O

J	O
.	O
,	O
2007	O
.	O

Antimutagenic	O
effect	O
of	O
broccoli	O
flower	O
head	O
by	O
the	O
Ames	O
Salmonella	O
reverse	O
mutation	O
assay	O
.	O

Phytother	O
.	O

Res	O
.	O

21	O
,	O
545	O
-	O
547	O
]	O
,	O
in	O
search	O
of	O
possible	O
antimutagenic	O
properties	O
in	O
broccoli	O
flower	O
head	O
extracts	O
.	O

In	O
the	O
present	O
investigation	O
,	O
the	O
effect	O
of	O
addition	O
of	O
ethanol	O
extract	O
of	O
broccoli	O
flower	O
head	O
on	O
mitomycin	O
-	O
C	O
(	O
MMC	O
)	O
induced	O
sister	O
chromatid	O
exchange	O
(	O
SCE	O
)	O
in	O
cultured	O
human	O
peripheral	O
blood	O
lymphocytes	O
was	O
investigated	O
.	O

Broccoli	O
flower	O
head	O
was	O
extracted	O
in	O
ethanol	O
using	O
either	O
acetone	O
or	O
ethanol	O
as	O
solvents	O
.	O

The	O
extract	O
was	O
tested	O
at	O
final	O
concentrations	O
of	O
200	O
and	O
400	O
microg	O
/	O
ml	O
culture	O
and	O
set	O
for	O
SCE	O
assay	O
.	O

MMC	O
at	O
a	O
concentration	O
of	O
1	O
microg	O
/	O
ml	O
and	O
the	O
test	O
concentrations	O
of	O
broccoli	O
flower	O
head	O
were	O
added	O
to	O
the	O
culture	O
following	O
48	O
h	O
from	O
the	O
initiation	O
of	O
culture	O
.	O

Enumeration	O
of	O
SCE	O
in	O
second	O
division	O
mitotic	O
cells	O
indicated	O
that	O
broccoli	O
flower	O
head	O
extract	O
significantly	O
reduced	O
MMC	O
induced	O
SCEs	O
at	O
both	O
the	O
concentrations	O
tested	O
.	O

This	O
observation	O
is	O
in	O
line	O
with	O
our	O
earlier	O
finding	O
and	O
confirms	O
to	O
the	O
presence	O
of	O
antimutagenic	O
principles	O
in	O
broccoli	O
flower	O
head	O
extract	O
.	O

Minimization	O
of	O
calcineurin	O
inhibitors	O
to	O
improve	O
long	O
-	O
term	O
outcomes	O
in	O
kidney	O
transplantation	O
.	O

Long	O
-	O
term	O
outcomes	O
after	O
kidney	O
transplantation	O
remain	O
suboptimal	O
,	O
despite	O
the	O
great	O
achievements	O
observed	O
in	O
recent	O
years	O
with	O
the	O
use	O
of	O
modern	O
immunosuppressive	O
drugs	O
.	O

Currently	O
,	O
the	O
calcineurin	O
inhibitors	O
(	O
CNI	O
)	O
cyclosporine	O
and	O
tacrolimus	O
remain	O
the	O
cornerstones	O
of	O
immunosuppressive	O
regimens	O
in	O
many	O
centers	O
worldwide	O
,	O
regardless	O
of	O
their	O
well	O
described	O
side	O
-	O
effects	O
,	O
including	O
nephrotoxicity	B
.	O

In	O
this	O
article	O
,	O
we	O
review	O
recent	O
CNI	O
-	O
minimization	O
strategies	O
in	O
kidney	O
transplantation	O
,	O
while	O
emphasizing	O
on	O
the	O
importance	O
of	O
long	O
-	O
term	O
follow	O
-	O
up	O
and	O
patient	O
monitoring	O
.	O

Finally	O
,	O
accumulating	O
data	O
indicate	O
that	O
low	O
-	O
dose	O
CNI	O
-	O
based	O
regimens	O
would	O
provide	O
an	O
interesting	O
balance	O
between	O
efficacy	O
and	O
toxicity	O
.	O

Structure	O
-	O
activity	O
relationships	O
of	O
stemphones	O
,	O
potentiators	O
of	O
imipenem	O
activity	O
against	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
.	O

From	O
a	O
further	O
purification	O
study	O
,	O
four	O
new	O
stemphones	O
D	O
to	O
G	O
were	O
isolated	O
along	O
with	O
previously	O
reported	O
stemphones	O
B	O
and	O
C	O
from	O
the	O
culture	O
broth	O
of	O
Aspergillus	O
sp	O
.	O

FKI	O
-	O
2136	O
.	O

Twenty	O
-	O
one	O
derivatives	O
were	O
semisynthetically	O
prepared	O
from	O
stemphones	O
C	O
,	O
E	O
and	O
G	O
.	O

Potentiation	O
of	O
imipenem	O
activity	O
against	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
by	O
all	O
the	O
stemphones	O
including	O
natural	O
and	O
semisynthetic	O
ones	O
was	O
compared	O
to	O
study	O
the	O
structure	O
-	O
activity	O
relationships	O
.	O

Derivatives	O
with	O
a	O
free	O
hydroxy	O
or	O
an	O
O	O
-	O
acyl	O
residue	O
having	O
a	O
C2	O
to	O
C5	O
carbon	O
length	O
at	O
C	O
-	O
4	O
held	O
the	O
potentiating	O
activity	O
,	O
but	O
those	O
with	O
a	O
longer	O
acyl	O
residue	O
lost	O
the	O
activity	O
.	O

The	O
presence	O
of	O
an	O
oxo	O
or	O
a	O
free	O
hydroxy	O
residue	O
at	O
C	O
-	O
10	O
is	O
important	O
for	O
the	O
potentiating	O
activity	O
because	O
introduction	O
of	O
an	O
alkyl	O
or	O
acyl	O
residue	O
at	O
this	O
position	O
resulted	O
in	O
a	O
loss	O
of	O
activity	O
.	O

Among	O
them	O
,	O
stemphone	O
E	O
exhibited	O
the	O
most	O
potent	O
potentiation	O
of	O
imipenem	O
activity	O
against	O
MRSA	O
and	O
the	O
lowest	O
cytotoxic	B
activity	I
against	O
Jurkat	O
cells	O
.	O

Adverse	O
effects	O
of	O
antiepileptic	O
drugs	O
.	O

Adverse	O
effects	O
of	O
antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
are	O
considered	O
by	O
patients	O
to	O
be	O
at	O
least	O
as	O
important	O
as	O
repetitive	B
seizures	I
in	O
terms	O
of	O
quality	O
of	O
life	O
.	O

AED	B
toxicity	I
is	O
frequent	O
and	O
contributes	O
to	O
a	O
high	O
proportion	O
of	O
treatment	O
failures	O
.	O

Despite	O
its	O
high	O
prevalence	O
and	O
clinical	O
relevance	O
,	O
screening	O
for	O
adverse	O
reactions	O
to	O
AEDs	O
is	O
not	O
systematically	O
included	O
in	O
everyday	O
clinical	O
practice	O
;	O
therefore	O
it	O
is	O
very	O
likely	O
that	O
it	O
remains	O
underestimated	O
.	O

Because	O
there	O
is	O
little	O
difference	O
among	O
AEDs	O
in	O
terms	O
of	O
efficacy	O
,	O
drug	O
selection	O
is	O
often	O
based	O
on	O
the	O
adverse	O
effects	O
profile	O
.	O

AED	B
toxicity	I
is	O
classified	O
according	O
to	O
different	O
parameters	O
,	O
such	O
as	O
severity	O
,	O
time	O
of	O
occurrence	O
,	O
organ	O
system	O
involvement	O
,	O
and	O
mechanisms	O
of	O
action	O
.	O

Although	O
most	O
toxic	O
reactions	O
to	O
drugs	O
can	O
be	O
predicted	O
from	O
cumulative	O
experience	O
,	O
prevention	O
is	O
not	O
always	O
possible	O
,	O
since	O
multiple	O
mechanisms	O
and	O
individual	O
susceptibility	O
to	O
each	O
drug	O
participate	O
in	O
the	O
final	O
outcome	O
.	O

However	O
,	O
adverse	O
effects	O
can	O
be	O
reduced	O
and	O
appropriate	O
action	O
can	O
be	O
taken	O
in	O
time	O
by	O
means	O
of	O
a	O
high	O
degree	O
of	O
suspicion	O
,	O
knowledge	O
of	O
risk	O
factors	O
,	O
and	O
close	O
follow	O
-	O
up	O
.	O

This	O
article	O
highlights	O
factors	O
to	O
consider	O
for	O
detecting	O
and	O
managing	O
AED	O
adverse	O
effects	O
.	O

Predictors	O
of	O
subjective	O
and	O
objective	O
quality	O
of	O
life	O
in	O
outpatients	O
with	O
schizophrenia	B
.	O

AIM	O
:	O
In	O
recent	O
years	O
,	O
greater	O
attention	O
has	O
been	O
given	O
to	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
in	O
schizophrenia	B
and	O
several	O
studies	O
reported	O
that	O
negative	O
and	O
depressive	B
symptoms	I
and	O
cognitive	B
dysfunction	I
are	O
related	O
to	O
patient	O
QOL	O
.	O

But	O
because	O
a	O
variety	O
of	O
QOL	O
measures	O
have	O
been	O
used	O
in	O
the	O
previous	O
studies	O
,	O
there	O
seems	O
to	O
be	O
no	O
unanimous	O
predictors	O
for	O
subjective	O
and	O
objective	O
QOL	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
elucidate	O
the	O
relationship	O
between	O
clinical	O
variables	O
and	O
subjective	O
and	O
objective	O
QOL	O
in	O
outpatients	O
with	O
schizophrenia	B
,	O
using	O
schizophrenia	B
disease	O
-	O
specific	O
QOL	O
measures	O
.	O

Particular	O
attention	O
was	O
paid	O
to	O
cognitive	O
function	O
as	O
a	O
predictor	O
of	O
QOL	O
.	O

METHODS	O
:	O
Schizophrenia	B
symptoms	I
of	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
were	O
divided	O
into	O
five	O
factors	O
:	O
positive	O
factor	O
,	O
negative	O
factor	O
,	O
cognitive	O
factor	O
,	O
emotional	B
discomfort	I
,	O
and	O
hostility	O
.	O

The	O
study	O
sample	O
consisted	O
of	O
84	O
schizophrenia	B
outpatients	O
.	O

Subjective	O
and	O
objective	O
QOL	O
were	O
assessed	O
with	O
Schizophrenia	B
Quality	O
of	O
Life	O
Scale	O
(	O
SQLS	O
)	O
and	O
the	O
Quality	O
of	O
Life	O
Scale	O
(	O
QLS	O
)	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Subjective	O
QOL	O
correlated	O
significantly	O
with	O
emotional	B
discomfort	I
,	O
positive	O
factor	O
,	O
negative	O
factor	O
,	O
extrapyramidal	B
symptoms	I
and	O
cognitive	O
factor	O
,	O
while	O
objective	O
QOL	O
correlated	O
with	O
negative	O
factor	O
,	O
cognitive	O
factor	O
,	O
emotional	B
discomfort	I
,	O
extrapyramidal	B
symptoms	I
,	O
and	O
dose	O
of	O
antipsychotics	O
.	O

Total	O
score	O
and	O
three	O
of	O
four	O
subscales	O
in	O
the	O
QLS	O
correlated	O
significantly	O
with	O
cognitive	O
factor	O
,	O
while	O
cognitive	O
factor	O
had	O
a	O
significant	O
correlation	O
with	O
only	O
one	O
of	O
three	O
scales	O
of	O
SQLS	O
.	O

Stepwise	O
regression	O
showed	O
that	O
subjective	O
QOL	O
was	O
significantly	O
predicted	O
by	O
emotional	B
discomfort	I
and	O
extrapyramidal	B
symptoms	I
,	O
while	O
negative	O
factor	O
was	O
the	O
most	O
important	O
predictor	O
of	O
objective	O
QOL	O
.	O

CONCLUSION	O
:	O
Cognitive	B
dysfunction	I
had	O
a	O
greater	O
influence	O
on	O
objective	O
QOL	O
than	O
subjective	O
QOL	O
.	O

Treating	O
depressive	O
and	O
negative	O
symptoms	O
and	O
extrapyramidal	B
symptoms	I
might	O
contribute	O
to	O
enhanced	O
subjective	O
and	O
objective	O
QOL	O
.	O

The	O
effects	O
of	O
1,4	O
-	O
benzoquinone	O
on	O
c	O
-	O
Myb	O
and	O
topoisomerase	O
II	O
in	O
K	O
-	O
562	O
cells	O
.	O

Exposure	O
to	O
benzene	O
,	O
a	O
ubiquitous	O
environmental	O
pollutant	O
,	O
has	O
been	O
linked	O
to	O
leukemia	B
,	O
although	O
the	O
mechanism	O
of	O
benzene	O
-	O
initiated	O
leukemogenesis	O
remains	O
unclear	O
.	O

Benzene	O
can	O
be	O
bioactivated	O
to	O
toxic	O
metabolites	O
such	O
as	O
1,4	O
benzoquinone	O
(	O
BQ	O
)	O
,	O
which	O
can	O
alter	O
signaling	O
pathways	O
and	O
affect	O
chromosomal	O
integrity	O
.	O

BQ	O
has	O
been	O
shown	O
to	O
increase	O
the	O
activity	O
of	O
c	O
-	O
Myb	O
,	O
which	O
is	O
an	O
important	O
transcription	O
factor	O
involved	O
in	O
hematopoiesis	O
,	O
cell	O
proliferation	O
,	O
and	O
cell	O
differentiation	O
.	O

The	O
c	O
-	O
Myb	O
protein	O
has	O
also	O
been	O
shown	O
to	O
increase	O
topoisomerase	O
IIalpha	O
(	O
Topo	O
IIalpha	O
)	O
promoter	O
activity	O
specifically	O
in	O
cell	O
lines	O
with	O
hematopoietic	O
origin	O
.	O

Topo	O
IIalpha	O
is	O
a	O
critical	O
nuclear	O
enzyme	O
that	O
removes	O
torsional	O
strain	O
by	O
cleaving	O
,	O
untangling	O
and	O
religating	O
double	O
-	O
stranded	O
DNA	O
.	O

Since	O
Topo	O
IIalpha	O
mediates	O
DNA	O
strand	O
breaks	O
,	O
aberrant	O
Topo	O
IIalpha	O
activity	O
or	O
increased	O
protein	O
levels	O
may	O
increase	O
the	O
formation	O
of	O
DNA	O
strand	O
breaks	O
,	O
leaving	O
the	O
cell	O
susceptible	O
to	O
mutational	O
events	O
.	O

We	O
hypothesized	O
that	O
BQ	O
can	O
increase	O
c	O
-	O
Myb	O
activity	O
,	O
which	O
in	O
turn	O
increases	O
Topo	O
IIalpha	O
promoter	O
activity	O
resulting	O
in	O
increased	O
DNA	O
strand	O
breaks	O
.	O

Using	O
luciferase	O
reporter	O
assays	O
in	O
K	O
-	O
562	O
cells	O
we	O
demonstrated	O
that	O
BQ	O
(	O
25	O
and	O
37microM	O
)	O
exposure	O
caused	O
an	O
increase	O
in	O
c	O
-	O
Myb	O
activity	O
after	O
24h	O
.	O

Contradictory	O
to	O
previous	O
findings	O
,	O
overexpression	O
of	O
exogenous	O
c	O
-	O
Myb	O
or	O
a	O
polypeptide	O
consisting	O
of	O
c	O
-	O
Myb	O
's	O
DNA	O
binding	O
domain	O
(	O
DBD	O
)	O
,	O
which	O
competitively	O
inhibits	O
the	O
binding	O
of	O
endogenous	O
c	O
-	O
Myb	O
to	O
DNA	O
,	O
did	O
not	O
affect	O
Topo	O
IIalpha	O
promoter	O
activity	O
.	O

However	O
,	O
BQ	O
(	O
37microM	O
for	O
24h	O
)	O
exposure	O
caused	O
a	O
significant	O
increase	O
in	O
Topo	O
IIalpha	O
promoter	O
activity	O
,	O
which	O
could	O
be	O
blocked	O
by	O
the	O
overexpression	O
of	O
the	O
DBD	O
polypeptide	O
,	O
suggesting	O
that	O
BQ	O
exposure	O
increases	O
Topo	O
IIalpha	O
promoter	O
activity	O
through	O
the	O
c	O
-	O
Myb	O
signaling	O
pathway	O
.	O

Incidence	O
and	O
predictors	O
of	O
activation	B
syndrome	I
induced	O
by	O
antidepressants	O
.	O

BACKGROUND	O
:	O
Activation	B
syndrome	I
is	O
a	O
side	O
effect	O
of	O
antidepressants	O
that	O
is	O
thought	O
to	O
carry	O
a	O
potentially	O
increased	O
risk	O
of	O
suicide	B
.	O

However	O
,	O
the	O
incidence	O
of	O
activation	B
syndrome	I
has	O
not	O
been	O
fully	O
investigated	O
and	O
little	O
has	O
been	O
reported	O
on	O
its	O
predictors	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
survey	O
the	O
incidence	O
of	O
activation	B
syndrome	I
and	O
clarify	O
its	O
predictors	O
in	O
a	O
natural	O
clinical	O
setting	O
.	O

METHODS	O
:	O
Among	O
2,521	O
new	O
outpatients	O
visiting	O
between	O
August	O
2003	O
and	O
March	O
2005	O
,	O
we	O
retrospectively	O
surveyed	O
the	O
case	O
records	O
of	O
729	O
patients	O
who	O
had	O
not	O
taken	O
any	O
antidepressants	O
during	O
the	O
1	O
month	O
before	O
presentation	O
and	O
were	O
prescribed	O
antidepressants	O
for	O
3	O
months	O
after	O
the	O
initial	O
visit	O
.	O

Patients	O
were	O
classified	O
as	O
developing	O
activation	B
syndrome	I
if	O
they	O
experienced	O
any	O
symptom	O
of	O
anxiety	B
,	O
agitation	B
,	O
panic	B
attacks	I
,	O
insomnia	B
,	O
irritability	B
,	O
hostility	B
,	O
aggressiveness	B
,	O
impulsivity	O
,	O
akathisia	B
,	O
hypomania	B
,	O
and	O
mania	B
during	O
the	O
first	O
3	O
months	O
.	O

RESULTS	O
:	O
Of	O
the	O
729	O
patients	O
,	O
31	O
(	O
4.3	O
%	O
)	O
developed	O
activation	B
syndrome	I
.	O

The	O
incidence	O
was	O
not	O
significantly	O
related	O
to	O
gender	O
,	O
age	O
,	O
class	O
of	O
antidepressant	O
,	O
combined	O
use	O
of	O
benzodiazepine	O
,	O
or	O
DSM	O
-	O
IV	O
-	O
TR	O
diagnosis	O
except	O
for	O
personality	B
disorder	I
.	O

Diagnosis	O
of	O
personality	B
disorder	I
was	O
significantly	O
associated	O
with	O
the	O
induction	O
of	O
activation	B
syndrome	I
(	O
odds	O
ratio	O
=	O
4.20	O
,	O
P	O
=	O
0.002	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
suggests	O
that	O
diagnosis	O
of	O
personality	B
disorder	I
may	O
be	O
a	O
clinical	O
predictor	O
of	O
activation	B
syndrome	I
.	O

Evaluation	O
of	O
cytotoxic	O
properties	O
of	O
organometallic	O
ferrocifens	O
on	O
melanocytes	O
,	O
primary	O
and	O
metastatic	O
melanoma	O
cell	O
lines	O
.	O

Malignant	B
melanoma	I
is	O
one	O
of	O
the	O
most	O
severe	O
forms	O
of	O
skin	B
cancer	I
,	O
and	O
chemotherapeutic	O
agents	O
currently	O
in	O
use	O
are	O
poorly	O
effective	O
in	O
curing	O
the	O
disease	O
.	O

Here	O
we	O
describe	O
the	O
properties	O
of	O
two	O
organometallic	O
ferrocenyl	O
derivatives	O
,	O
ferrocifen	O
(	O
Fc	O
-	O
OH	O
-	O
Tam	O
)	O
and	O
ferrociphenol	O
(	O
Fc	O
-	O
diOH	O
)	O
that	O
show	O
a	O
specific	O
antiproliferative	O
effect	O
on	O
melanoma	O
cells	O
.	O

After	O
a	O
short	O
incubation	O
period	O
,	O
Fc	O
-	O
OH	O
-	O
Tam	O
is	O
highly	O
cytotoxic	O
on	O
melanoma	O
cells	O
but	O
less	O
toxic	O
on	O
melanocytes	O
.	O

Fc	O
-	O
diOH	O
is	O
slightly	O
toxic	O
at	O
a	O
high	O
concentration	O
but	O
no	O
discrepancy	O
is	O
observed	O
between	O
malignant	O
and	O
normal	O
cells	O
.	O

After	O
a	O
long	O
incubation	O
time	O
the	O
latter	O
is	O
highly	O
toxic	O
for	O
malignant	O
cells	O
but	O
not	O
for	O
normal	O
cells	O
while	O
the	O
former	O
was	O
very	O
highly	O
toxic	O
for	O
primary	O
malignant	O
cells	O
and	O
significantly	O
less	O
toxic	O
for	O
normal	O
cells	O
.	O

We	O
also	O
found	O
that	O
oxidative	O
stress	O
is	O
not	O
implicated	O
in	O
the	O
mechanism	O
of	O
cytotoxicity	B
,	O
since	O
both	O
derivatives	O
neither	O
induce	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
level	O
in	O
melanocytes	O
nor	O
in	O
melanoma	O
cells	O
.	O

Finally	O
,	O
investigation	O
on	O
hair	O
follicle	O
growth	O
revealed	O
that	O
the	O
two	O
organometallic	O
derivatives	O
induced	O
an	O
irreversible	O
ejection	O
of	O
the	O
hair	O
shaft	O
,	O
thus	O
predicting	O
a	O
potential	O
hair	B
loss	I
side	O
effect	O
if	O
used	O
as	O
a	O
chemotherapeutic	O
treatment	O
.	O

Multicenter	O
prospective	O
trial	O
evaluating	O
the	O
tolerability	O
of	O
imatinib	O
for	O
Japanese	O
patients	O
with	O
chronic	B
myelogenous	I
leukemia	I
in	O
the	O
chronic	O
phase	O
:	O
does	O
body	O
weight	O
matter	O
?	O

Imatinib	O
at	O
a	O
daily	O
dose	O
of	O
400	O
mg	O
is	O
the	O
standard	O
treatment	O
for	O
chronic	B
myelogenous	I
leukemia	I
in	O
the	O
chronic	O
phase	O
.	O

However	O
,	O
the	O
feasibility	O
of	O
this	O
dose	O
for	O
small	O
Japanese	O
adults	O
has	O
not	O
been	O
clarified	O
.	O

We	O
prospectively	O
investigated	O
the	O
toxicity	O
and	O
efficacy	O
of	O
this	O
dose	O
in	O
adult	O
Japanese	O
patients	O
.	O

Among	O
the	O
89	O
evaluable	O
patients	O
with	O
a	O
median	O
body	O
weight	O
of	O
62.8	O
kg	O
,	O
imatinib	O
therapy	O
was	O
held	O
in	O
40	O
subjects	O
(	O
45	O
%	O
)	O
,	O
due	O
to	O
Grade	O
3	O
-	O
4	O
toxicities	O
in	O
30	O
patients	O
(	O
75	O
%	O
)	O
and	O
Grade	O
2	O
toxicities	O
at	O
the	O
discretion	O
of	O
the	O
attending	O
physician	O
in	O
10	O
patients	O
(	O
25	O
%	O
)	O
.	O

However	O
,	O
treatment	O
was	O
resumed	O
and	O
the	O
dose	O
was	O
gradually	O
increased	O
until	O
62	O
of	O
the	O
89	O
patients	O
tolerated	O
a	O
maintenance	O
dose	O
of	O
400	O
mg	O
.	O

Older	O
age	O
and	O
lower	O
body	O
weight	O
were	O
significant	O
independent	O
risk	O
factors	O
for	O
discontinuation	O
of	O
imatinib	O
.	O

After	O
a	O
median	O
follow	O
-	O
up	O
period	O
of	O
31	O
months	O
,	O
84	O
patients	O
were	O
alive	O
without	O
progression	O
.	O

The	O
complete	O
cytogenetic	O
response	O
rate	O
was	O
60	O
and	O
90	O
%	O
at	O
6	O
months	O
and	O
1	O
year	O
after	O
starting	O
imatinib	O
,	O
respectively	O
.	O

Older	O
patients	O
and	O
those	O
with	O
a	O
lower	O
body	O
weight	O
were	O
less	O
likely	O
to	O
achieve	O
a	O
complete	O
cytogenetic	O
response	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
body	O
weight	O
has	O
a	O
significant	O
influence	O
on	O
the	O
toxicity	O
and	O
efficacy	O
of	O
imatinib	O
in	O
patients	O
with	O
a	O
small	O
body	O
size	O
,	O
although	O
dose	O
reduction	O
in	O
proportion	O
to	O
weight	O
may	O
result	O
in	O
an	O
inadequate	O
response	O
to	O
imatinib	O
.	O

The	O
assessment	O
of	O
genotoxic	B
effects	I
of	O
wastewater	O
from	O
a	O
fertilizer	O
factory	O
.	O

In	O
this	O
study	O
we	O
investigated	O
cytotoxic	O
,	O
mutagenic	O
and	O
genotoxic	B
effects	I
of	O
different	O
concentrations	O
of	O
wastewater	O
from	O
the	O
phosphoric	O
gypsum	O
depot	O
near	O
the	O
factory	O
for	O
fertilizing	O
agents	O
'	O
INA	O
Petrokemija	O
'	O
(	O
Kutina	O
,	O
Croatia	O
)	O
.	O

The	O
Ames	O
test	O
was	O
performed	O
on	O
Salmonella	O
typhimurium	O
TA98	O
and	O
TA100	O
strains	O
,	O
in	O
the	O
presence	O
of	O
S9	O
mix	O
,	O
glutathione	O
and	O
buffer	O
,	O
respectively	O
.	O

Cytotoxicity	B
was	O
studied	O
on	O
human	O
laryngeal	O
carcinoma	O
cells	O
(	O
HEp2	O
)	O
and	O
human	O
cervical	O
cells	O
(	O
HeLa	O
)	O
.	O

The	O
level	O
of	O
lipid	O
peroxidation	O
in	O
these	O
two	O
cell	O
lines	O
was	O
evaluated	O
in	O
parallel	O
.	O

To	O
establish	O
the	O
levels	O
of	O
primary	O
DNA	O
damage	O
,	O
the	O
alkaline	O
comet	O
assay	O
was	O
performed	O
on	O
treated	O
human	O
peripheral	O
blood	O
leukocytes	O
.	O

No	O
mutagenic	O
effects	O
of	O
phosphoric	O
gypsum	O
on	O
Salmonella	O
typhimurium	O
strains	O
in	O
the	O
presence	O
of	O
S9	O
mix	O
,	O
GSH	O
or	O
PBS	O
were	O
observed	O
.	O

However	O
,	O
strong	O
cytotoxic	B
effect	I
was	O
observed	O
on	O
both	O
human	O
cell	O
lines	O
when	O
they	O
were	O
treated	O
with	O
different	O
concentrations	O
of	O
wastewater	O
.	O

Lipid	O
peroxidation	O
was	O
induced	O
and	O
increased	O
by	O
prolonged	O
time	O
of	O
incubation	O
,	O
highlighting	O
that	O
the	O
damage	O
was	O
not	O
repaired	O
,	O
but	O
increased	O
with	O
the	O
time	O
of	O
incubation	O
.	O

The	O
results	O
of	O
the	O
alkaline	O
comet	O
assay	O
indicate	O
significant	O
DNA	O
damaging	O
potential	O
of	O
wastewater	O
for	O
human	O
leukocytes	O
.	O

Since	O
phosphoric	O
gypsum	O
transport	O
water	O
in	O
its	O
present	O
composition	O
and	O
acidity	O
is	O
highly	O
toxic	O
and	O
acts	O
as	O
prooxidant	O
,	O
causing	O
free	O
radicals	O
formation	O
and	O
DNA	O
damage	O
,	O
urgent	O
neutralization	O
/	O
purification	O
of	O
the	O
wastewater	O
to	O
a	O
level	O
acceptable	O
for	O
disposal	O
into	O
the	O
environment	O
is	O
mandatory	O
.	O

Gluten	B
ataxia	I
.	O

Gluten	B
ataxia	I
is	O
an	O
immune	O
-	O
mediated	O
disease	O
triggered	O
by	O
the	O
ingestion	O
of	O
gluten	O
in	O
genetically	O
susceptible	O
individuals	O
.	O

It	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
all	O
patients	O
with	O
idiopathic	B
sporadic	I
ataxia	I
.	O

Early	O
diagnosis	O
and	O
treatment	O
with	O
a	O
gluten	O
free	O
diet	O
can	O
improve	O
ataxia	B
and	O
prevent	O
its	O
progression	O
.	O

Readily	O
available	O
and	O
sensitive	O
markers	O
of	O
gluten	B
ataxia	I
include	O
antigliadin	O
antibodies	O
.	O

IgA	O
deposits	O
against	O
TG2	O
in	O
the	O
small	O
bowel	O
and	O
at	O
extraintestinal	O
sites	O
are	O
proving	O
to	O
be	O
additional	O
reliable	O
and	O
perhaps	O
more	O
specific	O
markers	O
of	O
the	O
whole	O
spectrum	O
of	O
gluten	O
sensitivity	O
.	O

They	O
may	O
also	O
hold	O
the	O
key	O
to	O
its	O
pathogenesis	O
.	O

Blueberry	O
opposes	O
beta	O
-	O
amyloid	O
peptide	O
-	O
induced	O
microglial	O
activation	O
via	O
inhibition	O
of	O
p44	O
/	O
42	O
mitogen	O
-	O
activation	O
protein	O
kinase	O
.	O

Alzheimer	B
's	I
Disease	I
(	O
AD	B
)	O
is	O
the	O
most	O
common	O
age	O
-	O
related	O
dementia	B
,	O
with	O
a	O
current	O
prevalence	O
in	O
excess	O
of	O
five	O
million	O
individuals	O
in	O
the	O
United	O
States	O
.	O

The	O
aggregation	O
of	O
amyloid	O
-	O
beta	O
(	O
A	O
beta	O
)	O
into	O
fibrillar	O
amyloid	O
plaques	O
is	O
a	O
key	O
pathological	O
event	O
in	O
the	O
development	O
of	O
the	O
disease	O
.	O

Microglial	O
proinflammatory	O
activation	O
is	O
widely	O
known	O
to	O
cause	O
neuronal	O
and	O
synaptic	O
damage	O
that	O
correlates	O
with	O
cognitive	B
impairment	I
in	O
AD	B
.	O

However	O
,	O
current	O
pharmacological	O
attempts	O
at	O
reducing	O
neuroinflammation	O
mediated	O
via	O
microglial	O
activation	O
have	O
been	O
largely	O
negative	O
in	O
terms	O
of	O
slowing	O
AD	B
progression	O
.	O

Previously	O
,	O
we	O
have	O
shown	O
that	O
microglia	O
express	O
proinflammatory	O
cytokines	O
and	O
a	O
reduced	O
capacity	O
to	O
phagocytose	O
A	O
beta	O
in	O
the	O
context	O
of	O
CD40	O
,	O
A	O
beta	O
peptides	O
and	O
/	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
,	O
a	O
phenomenon	O
that	O
can	O
be	O
opposed	O
by	O
attenuation	O
of	O
p44	O
/	O
42	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
.	O

Other	O
groups	O
have	O
found	O
that	O
blueberry	O
(	O
BB	O
)	O
extract	O
both	O
inhibits	O
phosphorylation	O
of	O
this	O
MAPK	O
module	O
and	O
also	O
improves	O
cognitive	O
deficits	O
in	O
AD	B
model	O
mice	O
.	O

Given	O
these	O
considerations	O
and	O
the	O
lack	O
of	O
reduced	O
A	O
beta	O
quantities	O
in	O
behaviorally	O
improved	O
BB	O
-	O
fed	O
mice	O
,	O
we	O
wished	O
to	O
determine	O
whether	O
BB	O
supplementation	O
would	O
alter	O
the	O
microglial	O
proinflammatory	O
activation	O
state	O
in	O
response	O
to	O
A	O
beta	O
.	O

We	O
found	O
that	O
BB	O
significantly	O
enhances	O
microglial	O
clearance	O
of	O
A	O
beta	O
,	O
inhibits	O
aggregation	O
of	O
A	O
beta	O
(	O
1	O
-	O
42	O
)	O
,	O
and	O
suppresses	O
microglial	O
activation	O
,	O
all	O
via	O
suppression	O
of	O
the	O
p44	O
/	O
42	O
MAPK	O
module	O
.	O

Thus	O
,	O
these	O
data	O
may	O
explain	O
the	O
previously	O
observed	O
behavioral	O
recovery	O
in	O
PSAPP	O
mice	O
and	O
suggest	O
a	O
means	O
by	O
which	O
dietary	O
supplementation	O
could	O
mitigate	O
an	O
undesirable	O
microglial	O
response	O
toward	O
fibrillar	O
A	O
beta	O
.	O

Advances	O
in	O
plasma	O
skin	O
regeneration	O
.	O

Plasma	O
skin	O
regeneration	O
(	O
PSR	O
)	O
is	O
a	O
novel	O
method	O
of	O
resurfacing	O
that	O
uses	O
plasma	O
energy	O
to	O
create	O
a	O
thermal	O
effect	O
on	O
the	O
skin	O
.	O

PSR	O
is	O
different	O
from	O
lasers	O
,	O
light	O
sources	O
,	O
and	O
ablative	O
lasers	O
in	O
that	O
it	O
is	O
not	O
chromophore	O
dependent	O
and	O
does	O
not	O
vaporize	O
tissue	O
,	O
but	O
leaves	O
a	O
layer	O
of	O
intact	O
,	O
desiccated	O
epidermis	O
that	O
acts	O
as	O
a	O
natural	O
biologic	O
dressing	O
and	O
promotes	O
wound	B
healing	O
and	O
rapid	O
recovery	O
.	O

Histological	O
studies	O
performed	O
on	O
plasma	O
resurfacing	O
patients	O
have	O
confirmed	O
continued	O
collagen	O
production	O
,	O
reduction	O
of	O
elastosis	O
,	O
and	O
progressive	O
skin	O
rejuvenation	O
beyond	O
1	O
year	O
after	O
treatment	O
.	O

PSR	O
has	O
received	O
US	O
Food	O
and	O
Drug	O
Administration	O
510	O
(	O
k	O
)	O
clearance	O
for	O
treatment	O
of	O
rhytides	B
of	I
the	I
body	I
,	O
superficial	B
skin	I
lesions	I
,	O
actinic	B
keratoses	I
,	O
viral	B
papillomata	I
,	O
and	O
seborrheic	B
keratoses	I
.	O

PSR	O
also	O
has	O
beneficial	O
effects	O
in	O
the	O
treatment	O
of	O
other	O
conditions	O
including	O
dyschromias	B
,	O
photoaging	B
,	O
skin	B
laxity	I
,	O
and	O
acne	B
scars	I
.	O

The	O
safety	O
profile	O
of	O
PSR	O
is	O
excellent	O
,	O
and	O
there	O
have	O
been	O
no	O
reports	O
of	O
demarcation	O
lines	O
in	O
perioral	O
,	O
periorbital	O
,	O
or	O
jawline	O
areas	O
,	O
as	O
can	O
sometimes	O
be	O
observed	O
following	O
CO2	O
resurfacing	O
.	O

PSR	O
is	O
effective	O
in	O
improving	O
facial	O
and	O
periorbital	O
rhytides	O
and	O
can	O
be	O
used	O
on	O
nonfacial	O
sites	O
,	O
including	O
the	O
hands	O
,	O
neck	O
,	O
and	O
chest	O
.	O

Numerous	O
treatment	O
protocols	O
with	O
variable	O
energy	O
settings	O
allow	O
for	O
individualized	O
treatments	O
and	O
provide	O
the	O
operator	O
with	O
fine	O
control	O
over	O
the	O
degree	O
of	O
injury	O
and	O
length	O
of	O
subsequent	O
recovery	O
time	O
.	O

Study	O
of	O
cytotoxic	O
and	O
apoptogenic	O
properties	O
of	O
saffron	O
extract	O
in	O
human	O
cancer	O
cell	O
lines	O
.	O

Saffron	O
(	O
dried	O
stigmas	O
of	O
Crocus	O
sativus	O
L	O
.	O
)	O
has	O
been	O
used	O
as	O
a	O
spice	O
,	O
food	O
colorant	O
and	O
medicinal	O
plant	O
for	O
millennia	O
.	O

In	O
this	O
study	O
cytotoxic	B
effect	I
of	O
saffron	O
extract	O
was	O
evaluated	O
in	O
HepG2	O
and	O
HeLa	O
cell	O
lines	O
.	O

Meanwhile	O
role	O
of	O
apoptosis	O
and	O
ROS	O
were	O
explored	O
.	O

Malignant	O
and	O
non	O
-	O
malignant	O
cells	O
(	O
L929	O
)	O
were	O
cultured	O
in	O
DMEM	O
medium	O
and	O
incubated	O
with	O
different	O
concentrations	O
of	O
ethanolic	O
saffron	O
extract	O
.	O

Cell	O
viability	O
was	O
quantitated	O
by	O
MTT	O
assay	O
.	O

Apoptotic	O
cells	O
were	O
determined	O
using	O
PI	O
staining	O
of	O
DNA	O
fragmentation	O
by	O
flow	O
cytometry	O
(	O
sub	O
-	O
G1	O
peak	O
)	O
.	O

ROS	O
was	O
measured	O
using	O
DCF	O
-	O
DA	O
by	O
flow	O
cytometry	O
analysis	O
.	O

Saffron	O
could	O
decrease	O
cell	O
viability	O
in	O
malignant	O
cells	O
as	O
a	O
concentration	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

The	O
IC50	O
values	O
against	O
HeLa	O
and	O
HepG2	O
were	O
determined	O
800	O
and	O
950	O
microg	O
/	O
ml	O
after	O
48	O
h	O
,	O
respectively	O
.	O

Saffron	O
induced	O
a	O
sub	O
-	O
G1	O
peak	O
in	O
flow	O
cytometry	O
histogram	O
of	O
treated	O
cells	O
compared	O
to	O
control	O
indicating	O
apoptotic	O
cell	O
death	O
is	O
involved	O
in	O
saffron	B
toxicity	I
.	O

This	O
toxicity	O
was	O
also	O
independent	O
of	O
ROS	O
production	O
.	O

It	O
might	O
be	O
concluded	O
that	O
saffron	O
could	O
cause	O
cell	O
death	O
in	O
HeLa	O
and	O
HepG2	O
cells	O
,	O
in	O
which	O
apoptosis	O
or	O
programmed	O
cell	O
death	O
plays	O
an	O
important	O
role	O
.	O

Saffron	O
could	O
be	O
also	O
considered	O
as	O
a	O
promising	O
chemotherapeutic	O
agent	O
in	O
cancer	B
treatment	O
in	O
future	O
.	O

Establishing	O
causality	O
in	O
the	O
assessment	O
of	O
safety	O
of	O
medicines	O
for	O
children	O
.	O

BACKGROUND	O
:	O
Data	O
on	O
safety	O
of	O
medicines	O
in	O
children	O
typically	O
arises	O
from	O
various	O
sources	O
,	O
rendering	O
assessment	O
of	O
causality	O
challenging	O
.	O

METHODS	O
:	O
We	O
outline	O
these	O
sources	O
,	O
together	O
with	O
their	O
strengths	O
and	O
weaknesses	O
.	O

Bradford	O
Hill	O
proposed	O
criteria	O
for	O
assessment	O
of	O
causality	O
of	O
observed	O
associations	O
;	O
we	O
explore	O
their	O
utility	O
in	O
this	O
context	O
.	O

CONCLUSION	O
:	O
Collaborations	O
between	O
clinicians	O
,	O
epidemiologists	O
and	O
clinical	O
pharmacologists	O
,	O
making	O
intelligent	O
use	O
of	O
both	O
older	O
and	O
newer	O
methodologies	O
,	O
can	O
help	O
make	O
the	O
use	O
of	O
medicines	O
in	O
children	O
safer	O
.	O

Evolving	O
concepts	O
in	O
liver	O
tissue	O
modeling	O
and	O
implications	O
for	O
in	O
vitro	O
toxicology	O
.	O

The	O
development	O
of	O
human	O
cell	O
models	O
stably	O
expressing	O
functional	O
properties	O
of	O
the	O
in	O
vivo	O
cells	O
they	O
are	O
derived	O
from	O
for	O
predicting	O
toxicity	O
of	O
chemicals	O
is	O
a	O
major	O
challenge	O
.	O

For	O
mimicking	O
the	O
liver	O
,	O
a	O
major	O
target	O
of	O
toxic	O
chemicals	O
,	O
primary	O
hepatocytes	O
represent	O
the	O
most	O
pertinent	O
model	O
.	O

Their	O
use	O
is	O
limited	O
by	O
interdonor	O
functional	O
variability	O
and	O
early	O
phenotypic	O
changes	O
although	O
their	O
lifespan	O
can	O
be	O
extended	O
not	O
only	O
by	O
culturing	O
in	O
a	O
2D	O
dimension	O
under	O
sophisticated	O
conditions	O
but	O
also	O
by	O
the	O
use	O
of	O
synthetic	O
and	O
natural	O
scaffolds	O
as	O
3D	O
supporting	O
templates	O
that	O
allow	O
cells	O
to	O
have	O
a	O
more	O
stable	O
microenvironment	O
.	O

Hepatocytes	O
derived	O
from	O
stem	O
cells	O
could	O
be	O
the	O
most	O
appropriate	O
alternative	O
but	O
up	O
to	O
now	O
only	O
liver	O
progenitors	O
/	O
hepatoblasts	O
are	O
obtained	O
in	O
vitro	O
.	O

A	O
few	O
hepatocyte	O
cell	O
lines	O
have	O
retained	O
a	O
variable	O
set	O
of	O
liver	O
-	O
specific	O
functions	O
.	O

Among	O
them	O
are	O
the	O
human	O
hepatoma	O
HepaRG	O
cells	O
that	O
express	O
drug	O
metabolism	O
capacity	O
at	O
levels	O
close	O
to	O
those	O
found	O
in	O
primary	O
hepatocytes	O
making	O
them	O
a	O
suitable	O
model	O
for	O
both	O
acute	O
and	O
chronic	B
toxicity	I
studies	O
.	O

New	O
screening	O
strategies	O
are	O
now	O
proposed	O
based	O
on	O
miniaturized	O
and	O
automated	O
systems	O
;	O
they	O
include	O
the	O
use	O
of	O
microfluidic	O
chips	O
and	O
cell	O
chips	O
coupled	O
with	O
high	O
content	O
imaging	O
analysis	O
.	O

Toxicogenomics	O
technologies	O
(	O
particularly	O
toxicotranscriptomics	O
)	O
have	O
emerged	O
as	O
promising	O
in	O
vitro	O
approaches	O
for	O
better	O
identification	O
and	O
discrimination	O
of	O
cellular	O
responses	O
to	O
chemicals	O
.	O

They	O
should	O
allow	O
to	O
discriminate	O
compounds	O
on	O
the	O
basis	O
of	O
the	O
identification	O
of	O
a	O
set	O
of	O
markers	O
and	O
/	O
specific	O
signaling	O
pathways	O
.	O

Pulmonary	B
toxicity	I
associated	O
with	O
vinorelbine	O
-	O
based	O
chemotherapy	O
in	O
breast	B
cancer	I
.	O

A	O
41	O
-	O
year	O
-	O
old	O
woman	O
had	O
undergone	O
a	O
left	O
mastectomy	O
breast	B
cancer	I
three	O
years	O
prior	O
to	O
presentation	O
.	O

No	O
for	O
at	O
six	O
months	O
she	O
had	O
recurrence	O
,	O
this	O
time	O
in	O
the	O
right	O
breast	O
and	O
skin	O
.	O

Despite	O
first	O
-	O
and	O
second	O
-	O
line	O
chemotherapy	O
,	O
the	O
mass	O
showed	O
progression	O
of	O
the	O
disease	O
.	O

Thereafter	O
,	O
a	O
weekly	O
treatment	O
of	O
vinorelbine	O
and	O
trastuzumab	O
was	O
started	O
,	O
but	O
one	O
month	O
later	O
,	O
she	O
developed	O
a	O
slight	O
fever	B
and	O
dry	B
cough	I
.	O

A	O
chest	O
CT	O
scan	O
revealed	O
an	O
infiltration	O
shadow	O
showing	O
non	O
-	O
specific	O
interstitial	O
pattern	O
in	O
the	O
right	O
lung	O
.	O

A	O
bronchoscopic	O
examination	O
showed	O
lymphocyte	O
dominance	O
in	O
bronchial	O
lavage	O
fluid	O
,	O
and	O
lymphocyte	O
infiltration	O
into	O
the	O
interstium	O
with	O
fibrosis	B
in	O
the	O
tissue	O
specimens	O
was	O
found	O
by	O
transbronchial	O
lung	O
biopsy	O
.	O

After	O
discontinuing	O
the	O
above	O
vinorelbine	O
therapy	O
,	O
the	O
patient	O
's	O
condition	O
improved	O
.	O

We	O
therefore	O
diagnosed	O
this	O
as	O
a	O
case	O
of	O
vinorelbine	O
-	O
and	O
trastuzumab	O
-	O
induced	O
interstitial	B
pneumonia	I
.	O

Inhaled	O
sodium	O
pyruvate	O
improved	O
FEV1	O
and	O
decreased	O
expired	O
breath	O
levels	O
of	O
nitric	O
oxide	O
in	O
patients	O
with	O
chronic	B
obstructive	I
pulmonary	I
disease	I
.	O

Exogenously	O
administered	O
sodium	O
pyruvate	O
has	O
a	O
variety	O
of	O
biological	O
effects	O
including	O
antioxidant	O
/	O
anti	O
-	O
inflammatory	O
effects	O
.	O

Chronic	B
obstructive	I
pulmonary	I
disease	I
(	O
COPD	B
)	O
is	O
an	O
inflammatory	O
disease	O
of	O
the	O
airways	O
mediated	O
in	O
part	O
by	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
reactive	O
nitrogen	O
species	O
(	O
RNS	O
)	O
.	O

The	O
current	O
therapies	O
for	O
COPD	B
have	O
limited	O
efficacy	O
.	O

This	O
study	O
was	O
designed	O
to	O
test	O
the	O
safety	O
and	O
therapeutic	O
efficacy	O
of	O
inhaled	O
pyruvate	O
in	O
COPD	B
patients	O
.	O

Subjects	O
were	O
randomized	O
to	O
receive	O
either	O
sodium	O
pyruvate	O
or	O
placebo	O
three	O
times	O
per	O
day	O
over	O
a	O
6	O
-	O
week	O
period	O
.	O

Long	O
-	O
term	O
efficacy	O
was	O
evaluated	O
by	O
spirometry	O
and	O
expired	O
breath	O
nitric	O
oxide	O
(	O
NO	O
)	O
levels	O
taken	O
at	O
baseline	O
,	O
3	O
days	O
,	O
1	O
week	O
,	O
2	O
weeks	O
,	O
4	O
weeks	O
,	O
and	O
6	O
weeks	O
.	O

In	O
addition	O
,	O
acute	O
assessments	O
(	O
1	O
h	O
pre	O
-	O
and	O
1	O
h	O
postinhalation	O
of	O
compound	O
)	O
were	O
made	O
at	O
day	O
0	O
and	O
at	O
4	O
weeks	O
.	O

Subjects	O
receiving	O
inhaled	O
pyruvate	O
showed	O
significant	O
(	O
p	O
<	O
0.02	O
)	O
improvement	O
of	O
approximately	O
11	O
%	O
in	O
forced	O
expiratory	O
volume	O
in	O
1	O
sec	O
(	O
FEV	O
(	O
1	O
)	O
)	O
at	O
6	O
weeks	O
,	O
whereas	O
subjects	O
receiving	O
placebo	O
did	O
not	O
.	O

The	O
inhalation	O
of	O
pyruvate	O
or	O
placebo	O
had	O
no	O
significant	O
effect	O
on	O
expired	O
breath	O
NO	O
levels	O
at	O
any	O
of	O
the	O
long	O
-	O
term	O
outcome	O
time	O
points	O
;	O
measurements	O
were	O
made	O
12	O
h	O
after	O
the	O
last	O
inhalation	O
of	O
the	O
compound	O
.	O

In	O
contrast	O
,	O
acute	O
assessments	O
(	O
1	O
h	O
pre	O
-	O
and	O
1	O
h	O
postinhalation	O
of	O
compound	O
)	O
of	O
expired	O
breath	O
NO	O
made	O
at	O
4	O
weeks	O
demonstrated	O
that	O
inhalation	O
of	O
pyruvate	O
resulted	O
in	O
a	O
significant	O
(	O
p	O
<	O
/	O
=	O
0.01	O
)	O
decrease	O
(	O
-	O
22.7	O
+	O
/	O
-	O
6	O
%	O
)	O
in	O
expired	O
breath	O
NO	O
compared	O
to	O
placebo	O
(	O
5.0	O
+	O
/	O
-	O
7	O
%	O
)	O
.	O

Inhalation	O
of	O
pyruvate	O
was	O
well	O
tolerated	O
and	O
was	O
associated	O
with	O
improvement	O
in	O
FEV	O
(	O
1	O
)	O
and	O
expired	O
breath	O
NO	O
,	O
and	O
was	O
considered	O
clinically	O
important	O
in	O
COPD	B
.	O

These	O
beneficial	O
effects	O
of	O
inhaled	O
pyruvate	O
in	O
COPD	B
may	O
be	O
optimized	O
with	O
adjustments	O
in	O
both	O
dose	O
and	O
length	O
of	O
treatment	O
.	O

Neonatal	O
nicotine	O
exposure	O
impairs	O
development	O
of	O
auditory	O
temporal	O
processing	O
.	O

Accurate	O
temporal	O
processing	O
of	O
sound	O
is	O
essential	O
for	O
detecting	O
word	O
structures	O
in	O
speech	O
.	O

Maternal	O
smoking	O
affects	O
speech	O
processing	O
in	O
newborns	O
and	O
may	O
influence	O
child	O
language	O
development	O
;	O
however	O
,	O
it	O
is	O
unclear	O
how	O
neonatal	O
exposure	O
to	O
nicotine	O
,	O
present	O
in	O
cigarettes	O
,	O
affects	O
the	O
normal	O
development	O
of	O
temporal	O
processing	O
.	O

The	O
present	O
study	O
used	O
the	O
gap	O
-	O
induced	O
prepulse	O
inhibition	O
(	O
gap	O
-	O
PPI	O
)	O
of	O
the	O
acoustic	O
startle	O
response	O
to	O
investigate	O
the	O
effects	O
of	O
neonatal	O
nicotine	O
exposure	O
on	O
the	O
normal	O
development	O
of	O
gap	O
detection	O
,	O
a	O
behavioral	O
testing	O
procedure	O
of	O
auditory	O
temporal	O
resolution	O
.	O

Neonatal	O
rats	O
were	O
injected	O
twice	O
per	O
day	O
with	O
saline	O
(	O
control	O
)	O
,	O
1	O
mg	O
/	O
kg	O
nicotine	O
(	O
N	O
-	O
1	O
mg	O
)	O
or	O
5	O
mg	O
/	O
kg	O
nicotine	O
(	O
N	O
-	O
5	O
mg	O
)	O
from	O
postnatal	O
day	O
8	O
-	O
12	O
(	O
P8	O
-	O
P12	O
)	O
.	O

During	O
the	O
first	O
month	O
after	O
birth	O
,	O
rats	O
showed	O
poor	O
gap	O
-	O
PPI	O
in	O
all	O
three	O
groups	O
.	O

At	O
P45	O
and	O
P60	O
,	O
gap	O
-	O
PPI	O
in	O
control	O
rats	O
improved	O
significantly	O
,	O
whereas	O
rats	O
exposed	O
to	O
nicotine	O
exhibited	O
less	O
improvement	O
.	O

At	O
P60	O
,	O
the	O
gap	O
-	O
detection	O
threshold	O
in	O
the	O
N	O
-	O
5	O
mg	O
group	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
control	O
group	O
,	O
suggesting	O
that	O
neonatal	O
nicotine	O
exposure	O
affects	O
the	O
normal	O
development	O
of	O
gap	O
-	O
detection	O
acuity	O
.	O

Additionally	O
,	O
1h	O
after	O
receiving	O
an	O
acute	O
nicotine	O
injection	O
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
gap	O
-	O
PPI	O
recorded	O
in	O
adult	O
rats	O
from	O
the	O
N	O
-	O
5	O
mg	O
group	O
showed	O
a	O
temporary	O
significant	O
improvement	O
.	O

These	O
results	O
suggest	O
that	O
neonatal	O
nicotine	O
exposure	O
reduces	O
gap	O
-	O
PPI	O
implying	O
an	O
impairment	O
of	O
the	O
normal	O
development	O
of	O
auditory	O
temporal	O
processing	O
by	O
inducing	O
changes	O
in	O
cholinergic	O
systems	O
.	O

Selectins	O
ligand	O
decorated	O
drug	O
carriers	O
for	O
activated	O
endothelial	O
cell	O
targeting	O
.	O

New	O
active	O
particulate	O
polymeric	O
vectors	O
based	O
on	O
branched	O
polyester	O
copolymers	O
of	O
hydroxy	O
-	O
acid	O
and	O
allyl	O
glycidyl	O
ether	O
were	O
developed	O
to	O
target	O
drugs	O
to	O
the	O
inflammatory	O
endothelial	O
cell	O
surface	O
.	O

The	O
hydroxyl	O
and	O
carboxyl	O
derivatives	O
of	O
these	O
polymers	O
allow	O
grafting	O
of	O
ligand	O
molecules	O
on	O
the	O
polyester	O
backbones	O
at	O
different	O
densities	O
.	O

A	O
known	O
potent	O
nonselective	O
selectin	O
ligand	O
was	O
selected	O
and	O
synthesized	O
using	O
a	O
new	O
scheme	O
.	O

This	O
synthesis	O
allowed	O
the	O
grafting	O
of	O
the	O
ligand	O
to	O
the	O
polyester	O
polymers	O
,	O
preserving	O
its	O
binding	O
activity	O
as	O
assessed	O
by	O
docking	O
simulations	O
.	O

Selectin	O
expression	O
on	O
human	O
umbilical	O
cord	O
vascular	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
was	O
induced	O
with	O
the	O
pro	O
-	O
inflammatory	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
or	O
with	O
the	O
nonselective	O
inhibitor	O
of	O
nitric	O
oxide	O
synthase	O
L	O
-	O
NAME	O
.	O

Strong	O
adhesion	O
of	O
the	O
ligand	O
decorated	O
nanoparticles	O
was	O
evidenced	O
in	O
vitro	O
on	O
activated	O
HUVEC	O
.	O

Binding	O
of	O
nanoparticles	O
bearing	O
ligand	O
molecules	O
could	O
be	O
efficiently	O
inhibited	O
by	O
prior	O
incubation	O
of	O
cells	O
with	O
free	O
ligand	O
,	O
demonstrating	O
that	O
adhesion	O
of	O
the	O
nanoparticles	O
is	O
mediated	O
by	O
specific	O
interaction	O
between	O
the	O
ligand	O
and	O
the	O
selectin	O
receptors	O
.	O

These	O
nanoparticles	O
could	O
be	O
used	O
for	O
specific	O
drug	O
delivery	O
to	O
the	O
activated	O
vascular	O
endothelium	O
,	O
suggesting	O
their	O
application	O
in	O
the	O
treatment	O
of	O
diseases	O
with	O
an	O
inflammatory	O
component	O
such	O
as	O
rheumatoid	B
arthritis	I
and	O
cancer	B
.	O

Brain	O
development	O
:	O
anatomy	O
,	O
connectivity	O
,	O
adaptive	O
plasticity	O
,	O
and	O
toxicity	O
.	O

The	O
developing	O
brain	O
is	O
inherently	O
more	O
vulnerable	O
to	O
injury	O
than	O
the	O
adult	O
brain	O
because	O
brain	O
development	O
is	O
extraordinarily	O
complex	O
,	O
with	O
periods	O
of	O
unique	O
susceptibility	O
.	O

When	O
brain	O
developmental	O
processes	O
are	O
suspended	O
or	O
delayed	O
by	O
any	O
external	O
influence	O
,	O
virtually	O
no	O
potential	O
exists	O
for	O
subsequent	O
regeneration	O
and	O
repair	O
.	O

This	O
inevitably	O
leads	O
to	O
long	O
-	O
lasting	O
or	O
permanent	O
consequences	O
.	O

Recent	O
genetic	O
studies	O
have	O
contributed	O
to	O
a	O
better	O
understanding	O
of	O
the	O
dynamic	O
adaptive	O
changes	O
that	O
occur	O
in	O
the	O
developing	O
brain	O
as	O
a	O
consequence	O
of	O
genetic	O
and	O
environmental	O
processes	O
.	O

Many	O
industrial	O
and	O
environmental	O
chemicals	O
such	O
as	O
lead	O
,	O
methyl	O
-	O
mercury	O
,	O
polychlorinated	O
biphenyls	O
,	O
arsenic	O
,	O
and	O
toluene	O
are	O
recognized	O
causes	O
of	O
neurodevelopmental	B
disorders	I
that	O
lead	O
to	O
clinical	O
or	O
subclinical	B
brain	I
dysfunction	I
.	O

A	O
number	O
of	O
these	O
developmental	O
disabilities	O
arise	O
from	O
interactions	O
between	O
environmental	O
factors	O
and	O
individual	O
gene	O
susceptibility	O
.	O

In	O
addition	O
,	O
neurodevelopmental	B
disorders	I
of	O
unknown	O
origin	O
,	O
such	O
as	O
mental	B
retardation	I
,	O
attention	B
deficit	I
disorder	I
,	O
cerebral	B
palsy	I
,	O
and	O
autism	B
are	O
becoming	O
increasingly	O
prevalent	O
,	O
with	O
costly	O
consequences	O
for	O
the	O
family	O
and	O
society	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
examine	O
brain	O
developmental	O
anatomy	O
,	O
connectivity	O
,	O
adaptive	O
plasticity	O
,	O
and	O
toxicity	O
in	O
the	O
context	O
of	O
current	O
knowledge	O
and	O
future	O
trends	O
.	O

Bayesian	O
adaptive	O
non	O
-	O
inferiority	O
with	O
safety	O
assessment	O
:	O
retrospective	O
case	O
study	O
to	O
highlight	O
potential	O
benefits	O
and	O
limitations	O
of	O
the	O
approach	O
.	O

Adaptive	O
trial	O
design	O
applied	O
to	O
randomized	O
clinical	O
trials	O
of	O
psychiatric	O
medicines	O
offers	O
the	O
potential	O
to	O
make	O
clinical	O
trials	O
more	O
efficient	O
.	O

In	O
the	O
current	O
analysis	O
,	O
we	O
retrospectively	O
applied	O
Bayesian	O
adaptive	O
allocation	O
methods	O
to	O
a	O
case	O
study	O
in	O
agitated	O
patients	O
with	O
schizophrenia	B
and	O
related	O
diseases	O
.	O

The	O
original	O
study	O
used	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
design	O
.	O

The	O
objective	O
of	O
this	O
analysis	O
was	O
to	O
demonstrate	O
the	O
potential	O
benefits	O
of	O
Bayesian	O
adaptive	O
designs	O
by	O
shortening	O
the	O
study	O
duration	O
and	O
therefore	O
limiting	O
patient	O
exposure	O
to	O
ineffective	O
placebo	O
or	O
an	O
active	O
comparator	O
with	O
a	O
known	O
side	O
effect	O
.	O

Bayesian	O
methods	O
allowed	O
us	O
to	O
fully	O
leverage	O
historical	O
data	O
along	O
with	O
data	O
observed	O
as	O
the	O
study	O
was	O
ongoing	O
to	O
calculate	O
predictive	O
probabilities	O
of	O
patient	O
response	O
to	O
treatment	O
without	O
experiencing	O
a	O
specified	O
side	O
effect	O
.	O

Using	O
the	O
Bayesian	O
adaptive	O
approach	O
would	O
have	O
required	O
less	O
than	O
half	O
the	O
number	O
of	O
patients	O
as	O
the	O
original	O
study	O
to	O
draw	O
the	O
same	O
conclusion	O
.	O

Sample	O
size	O
was	O
reduced	O
from	O
311	O
to	O
156	O
patients	O
,	O
thereby	O
decreasing	O
the	O
number	O
of	O
patients	O
exposed	O
to	O
placebo	O
from	O
54	O
to	O
30	O
and	O
the	O
number	O
exposed	O
to	O
the	O
active	O
control	O
with	O
a	O
known	O
side	O
effect	O
from	O
126	O
to	O
60	O
.	O

Toward	O
experimental	O
assessment	O
of	O
receptor	O
occupancy	O
:	O
TGN1412	O
revisited	O
.	O

In	O
March	O
2006	O
,	O
6	O
healthy	O
volunteers	O
experienced	O
serious	O
adverse	O
reactions	O
during	O
a	O
first	O
-	O
in	O
-	O
human	O
clinical	O
trial	O
of	O
the	O
superagonistic	O
anti	O
-	O
CD28	O
mAb	O
TGN1412	O
.	O

A	O
first	O
investigation	O
excluded	O
contaminations	O
of	O
the	O
drug	O
product	O
or	O
protocol	O
irregularities	O
as	O
the	O
root	O
cause	O
.	O

Later	O
,	O
an	O
expert	O
scientific	O
group	O
convened	O
in	O
the	O
United	O
Kingdom	O
to	O
develop	O
recommendations	O
pertinent	O
to	O
minimizing	O
risks	O
of	O
first	O
-	O
in	O
-	O
human	O
clinical	O
trials	O
.	O

The	O
expert	O
scientific	O
group	O
concluded	O
from	O
in	O
silico	O
calculations	O
that	O
at	O
the	O
initial	O
dose	O
of	O
0.1	O
mg	O
/	O
kg	O
,	O
which	O
was	O
adjusted	O
on	O
the	O
basis	O
of	O
the	O
no	O
observed	O
adverse	O
effect	O
level	O
,	O
approximately	O
86.2	O
%	O
to	O
90.9	O
%	O
CD28	O
receptor	O
occupancy	O
was	O
obtained	O
.	O

Here	O
we	O
developed	O
a	O
flow	O
cytometric	O
method	O
that	O
revealed	O
receptor	O
occupancy	O
of	O
approximately	O
45	O
%	O
to	O
80	O
%	O
under	O
the	O
above	O
conditions	O
.	O

Thus	O
we	O
present	O
a	O
method	O
to	O
experimentally	O
determine	O
receptor	O
occupancy	O
that	O
can	O
be	O
taken	O
as	O
one	O
parameter	O
to	O
define	O
the	O
minimal	O
anticipated	O
biological	O
effect	O
level	O
as	O
the	O
basis	O
for	O
calculating	O
safer	O
starting	O
doses	O
for	O
first	O
-	O
in	O
-	O
human	O
clinical	O
trials	O
for	O
products	O
in	O
which	O
a	O
potential	O
risk	O
has	O
been	O
identified	O
.	O

Additional	O
measures	O
are	O
being	O
discussed	O
that	O
will	O
help	O
to	O
significantly	O
improve	O
safety	O
of	O
first	O
-	O
in	O
-	O
human	O
clinical	O
trials	O
.	O

An	O
approach	O
to	O
defining	O
the	O
upper	O
safe	O
limits	O
of	O
amino	O
acid	O
intake	O
.	O

The	O
existing	O
data	O
on	O
the	O
safe	O
upper	O
limits	O
of	O
amino	O
acid	O
intake	O
in	O
humans	O
is	O
essentially	O
observational	O
;	O
how	O
much	O
do	O
individuals	O
ingest	O
and	O
what	O
side	O
effects	O
do	O
they	O
have	O
?	O

There	O
are	O
numerous	O
studies	O
in	O
humans	O
comparing	O
the	O
effects	O
of	O
high	O
doses	O
of	O
amino	O
acids	O
given	O
as	O
protein	O
bound	O
vs.	O
as	O
free	O
amino	O
acids	O
.	O

These	O
studies	O
have	O
shown	O
that	O
protein	O
-	O
bound	O
amino	O
acids	O
have	O
much	O
less	O
effect	O
on	O
plasma	O
levels	O
of	O
the	O
test	O
amino	O
acid	O
,	O
because	O
protein	O
intake	O
stimulates	O
protein	O
synthesis	O
as	O
another	O
sink	O
for	O
the	O
increased	O
amino	O
acid	O
intake	O
.	O

In	O
practice	O
,	O
the	O
highest	O
amino	O
acid	O
intakes	O
occur	O
with	O
free	O
amino	O
acid	O
supplements	O
that	O
may	O
be	O
ingested	O
by	O
athletes	O
who	O
believe	O
that	O
the	O
amino	O
acids	O
will	O
benefit	O
them	O
in	O
training	O
and	O
/	O
or	O
performance	O
.	O

Previously	O
,	O
in	O
a	O
piglet	O
study	O
,	O
we	O
were	O
able	O
to	O
define	O
the	O
point	O
at	O
which	O
maximal	O
phenylalanine	O
oxidation	O
occurred	O
,	O
above	O
which	O
plasma	O
phenylalanine	O
concentration	O
and	O
body	O
balance	O
rose	O
exponentially	O
.	O

We	O
regard	O
this	O
value	O
of	O
maximal	O
disposal	O
(	O
oxidation	O
)	O
of	O
an	O
amino	O
acid	O
as	O
one	O
metabolic	O
marker	O
of	O
the	O
upper	O
limit	O
of	O
intake	O
.	O

Recently	O
,	O
others	O
have	O
demonstrated	O
a	O
similar	O
maximal	O
oxidation	O
rate	O
for	O
leucine	O
in	O
rats	O
.	O

Based	O
on	O
these	O
experimental	O
data	O
and	O
the	O
paucity	O
of	O
published	O
human	O
data	O
in	O
controlled	O
experiments	O
,	O
we	O
think	O
that	O
a	O
systematic	O
approach	O
needs	O
to	O
be	O
undertaken	O
to	O
define	O
the	O
maximal	O
oxidation	O
rate	O
for	O
all	O
dietary	O
indispensable	O
amino	O
acids	O
and	O
other	O
amino	O
acids	O
that	O
may	O
be	O
ingested	O
in	O
excess	O
by	O
humans	O
.	O

We	O
believe	O
that	O
this	O
will	O
provide	O
a	O
rational	O
basis	O
to	O
begin	O
to	O
define	O
the	O
upper	O
limits	O
of	O
tolerance	O
for	O
dietary	O
amino	O
acids	O
.	O

However	O
,	O
some	O
amino	O
acids	O
,	O
such	O
as	O
threonine	O
and	O
methionine	O
,	O
will	O
be	O
more	O
difficult	O
to	O
study	O
,	O
because	O
they	O
have	O
more	O
than	O
1	O
route	O
of	O
disposal	O
or	O
very	O
complex	O
metabolic	O
regulation	O
,	O
in	O
which	O
case	O
defining	O
their	O
upper	O
limits	O
will	O
be	O
more	O
multifaceted	O
.	O

Koshikamide	O
B	O
,	O
a	O
cytotoxic	O
peptide	O
lactone	O
from	O
a	O
marine	O
sponge	O
Theonella	O
sp	O
.	O

Koshikamide	O
B	O
(	O
1	O
)	O
has	O
been	O
isolated	O
from	O
two	O
separate	O
collections	O
of	O
the	O
marine	O
sponge	O
Theonella	O
sp	O
.	O

as	O
the	O
major	O
cytotoxic	O
constituent	O
.	O

Koshikamide	O
B	O
is	O
a	O
17	O
-	O
residue	O
peptide	O
lactone	O
composed	O
of	O
six	O
proteinogenic	O
amino	O
acids	O
,	O
two	O
D	O
-	O
isomers	O
of	O
proteinogenic	O
amino	O
acids	O
,	O
seven	O
N	O
-	O
methylated	O
amino	O
acids	O
,	O
and	O
two	O
unusual	O
amino	O
acid	O
residues	O
.	O

The	O
unusual	O
amino	O
acids	O
are	O
N	O
(	O
delta	O
)	O
-	O
carbamoylasparagine	O
and	O
2	O
-	O
(	O
3	O
-	O
amino	O
-	O
2	O
-	O
hydroxy	O
-	O
5	O
-	O
oxopyrrolidin	O
-	O
2	O
-	O
yl	O
)	O
propionic	O
acid	O
(	O
AHPP	O
)	O
;	O
the	O
former	O
is	O
first	O
found	O
as	O
the	O
constituent	O
of	O
peptides	O
,	O
whereas	O
the	O
latter	O
is	O
a	O
new	O
amino	O
acid	O
residue	O
.	O

The	O
N	O
-	O
terminus	O
of	O
koshikamide	O
B	O
is	O
blocked	O
by	O
a	O
methoxyacetyl	O
group	O
.	O

The	O
structure	O
of	O
koshikamide	O
B	O
(	O
1	O
)	O
has	O
been	O
determined	O
by	O
interpretation	O
of	O
spectral	O
data	O
and	O
analysis	O
of	O
chemical	O
degradation	O
products	O
.	O

Koshikamide	O
B	O
(	O
1	O
)	O
exhibits	O
cytotoxicity	B
against	O
P388	O
murine	O
leukemia	O
cells	O
and	O
the	O
human	O
colon	O
tumor	O
(	O
HCT	O
-	O
116	O
)	O
cell	O
line	O
with	O
an	O
IC50	O
value	O
of	O
0.45	O
and	O
7.5	O
microg	O
/	O
mL	O
,	O
respectively	O
.	O

Delivery	O
of	O
daunorubicin	O
to	O
cancer	O
cells	O
with	O
decreased	O
toxicity	O
by	O
association	O
with	O
a	O
lipidic	O
nanoemulsion	O
that	O
binds	O
to	O
LDL	O
receptors	O
.	O

A	O
lipidic	O
nanoemulsion	O
termed	O
LDE	O
concentrates	O
in	O
neoplastic	O
cells	O
after	O
injection	O
into	O
the	O
bloodstream	O
and	O
thus	O
can	O
be	O
used	O
as	O
a	O
drug	O
carrier	O
to	O
tumour	O
sites	O
.	O

The	O
chemotherapeutic	O
agent	O
daunorubicin	O
associates	O
poorly	O
with	O
LDE	O
;	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
clarify	O
whether	O
the	O
derivatization	O
of	O
daunorubicin	O
by	O
the	O
attachment	O
of	O
an	O
oleyl	O
group	O
increases	O
the	O
association	O
with	O
LDE	O
,	O
and	O
to	O
test	O
the	O
cytotoxicity	B
and	O
animal	B
toxicity	I
of	O
the	O
new	O
preparation	O
.	O

The	O
association	O
of	O
oleyl	O
-	O
daunorubicin	O
(	O
oDNR	O
)	O
to	O
LDE	O
showed	O
high	O
yield	O
(	O
93	O
+	O
/	O
-	O
2	O
%	O
and	O
84	O
+	O
/	O
-	O
4	O
%	O
at	O
1	O
:	O
10	O
and	O
1	O
:	O
5	O
drug	O
:	O
lipid	O
mass	O
,	O
respectively	O
)	O
and	O
was	O
stable	O
for	O
at	O
least	O
20	O
days	O
.	O

Association	O
with	O
oDNR	O
increased	O
the	O
LDE	O
particle	O
diameter	O
from	O
42	O
+	O
/	O
-	O
4	O
nm	O
to	O
75	O
+	O
/	O
-	O
6	O
nm	O
.	O

Cytotoxicity	O
of	O
LDE	O
-	O
oDNR	O
was	O
reduced	O
two	O
-	O
fold	O
in	O
HL	O
-	O
60	O
and	O
K	O
-	O
562	O
cell	O
lines	O
,	O
fourteen	O
-	O
fold	O
in	O
B16	O
cells	O
and	O
nine	O
-	O
fold	O
in	O
L1210	O
cells	O
when	O
compared	O
with	O
commercial	O
daunorubicin	O
.	O

When	O
tested	O
in	O
mice	O
,	O
LDE	O
-	O
oDNR	O
showed	O
remarkable	O
reduced	O
toxicity	O
(	O
maximum	O
tolerated	O
dose	O
>	O
253	O
micromol	O
kg	O
(	O
-	O
1	O
)	O
,	O
compared	O
with	O
<	O
3	O
micromol	O
kg	O
(	O
-	O
1	O
)	O
for	O
commercial	O
daunorubicin	O
)	O
.	O

At	O
high	O
doses	O
,	O
the	O
cardiac	O
tissue	O
of	O
LDE	O
-	O
oDNR	O
-	O
treated	O
animals	O
had	O
much	O
smaller	O
structural	O
lesions	O
than	O
with	O
commercial	O
daunorubicin	O
.	O

LDE	O
-	O
oDNR	O
is	O
therefore	O
a	O
promising	O
new	O
preparation	O
that	O
may	O
offer	O
superior	O
tolerability	O
compared	O
with	O
commercial	O
daunorubicin	O
.	O

Pharmacokinetic	O
interaction	O
between	O
everolimus	O
and	O
antifungal	O
triazoles	O
in	O
a	O
liver	O
transplant	O
patient	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
management	O
of	O
a	O
pharmacokinetic	O
interaction	O
between	O
azole	O
antifungals	O
(	O
fluconazole	O
and	O
voriconazole	O
)	O
and	O
everolimus	O
in	O
a	O
patient	O
who	O
underwent	O
an	O
orthotopic	O
liver	O
transplant	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
65	O
-	O
year	O
-	O
old	O
male	O
who	O
received	O
an	O
orthotopic	O
liver	O
transplant	O
experienced	O
an	O
iatrogenic	B
retroperitoneal	I
duodenal	I
perforation	I
on	O
postoperative	O
day	O
55	O
.	O

His	O
condition	O
was	O
subsequently	O
complicated	O
by	O
severe	O
sepsis	B
and	O
acute	B
renal	I
failure	I
.	O

Intravenous	O
fluconazole	O
400	O
mg	O
,	O
followed	O
by	O
100	O
mg	O
every	O
24	O
hours	O
according	O
to	O
impaired	B
renal	I
function	I
,	O
was	O
immediately	O
started	O
;	O
to	O
avoid	O
further	O
nephrotoxicity	B
,	O
immunosuppressant	O
therapy	O
was	O
switched	O
from	O
cyclosporine	O
plus	O
mycophenolate	O
mofetil	O
to	O
oral	O
everolimus	O
0.75	O
mg	O
every	O
12	O
hours	O
.	O

Satisfactory	O
steady	O
-	O
state	O
minimum	O
concentration	O
(	O
C	O
(	O
min	O
)	O
)	O
of	O
everolimus	O
was	O
achieved	O
(	O
approximately	O
5	O
ng	O
/	O
mL	O
)	O
.	O

On	O
day	O
72	O
posttransplant	O
,	O
because	O
of	O
invasive	B
aspergillosis	I
,	O
antifungal	O
therapy	O
was	O
switched	O
to	O
intravenous	O
voriconazole	O
400	O
mg	O
every	O
12	O
hours	O
on	O
the	O
first	O
day	O
,	O
followed	O
by	O
200	O
mg	O
every	O
12	O
hours	O
;	O
to	O
prevent	O
drug	B
toxicity	I
,	O
the	O
everolimus	O
dosage	O
was	O
promptly	O
lowered	O
to	O
0.25	O
mg	O
every	O
24	O
hours	O
.	O

At	O
that	O
time	O
,	O
the	O
everolimus	O
C	O
(	O
min	O
)	O
averaged	O
approximately	O
3	O
ng	O
/	O
mL	O
.	O

The	O
concentration	O
/	O
dose	O
ratio	O
of	O
everolimus	O
(	O
ie	O
,	O
C	O
(	O
min	O
)	O
reached	O
at	O
steady	O
-	O
state	O
for	O
each	O
milligram	O
per	O
kilogram	O
of	O
drug	O
administered	O
)	O
was	O
markedly	O
lower	O
during	O
fluconazole	O
versus	O
voriconazole	O
cotreatment	O
(	O
mean	O
+	O
/	O
-	O
SD	O
,	O
3.49	O
+	O
/	O
-	O
0.29	O
vs	O
11.05	O
+	O
/	O
-	O
0.81	O
ng	O
/	O
mL	O
per	O
mg	O
/	O
kg	O
/	O
daily	O
;	O
p	O
<	O
0.001	O
)	O
.	O

Despite	O
intensive	O
care	O
,	O
the	O
patient	O
's	O
condition	O
continued	O
to	O
deteriorate	O
and	O
he	O
died	O
on	O
day	O
84	O
posttransplant	O
.	O

DISCUSSION	O
:	O
Both	O
azole	O
antifungals	O
were	O
considered	O
probable	O
causative	O
agents	O
of	O
an	O
interaction	O
with	O
everolimus	O
according	O
to	O
the	O
Drug	O
Interaction	O
Probability	O
Scale	O
.	O

The	O
interaction	O
is	O
due	O
to	O
the	O
inhibition	O
of	O
CYP3A4	O
-	O
mediated	O
everolimus	O
clearance	O
.	O

Of	O
note	O
,	O
prompt	O
reduction	O
of	O
the	O
everolimus	O
dosage	O
since	O
the	O
first	O
azole	O
coadministration	O
,	O
coupled	O
with	O
intensive	O
therapeutic	O
drug	O
monitoring	O
,	O
represented	O
a	O
useful	O
strategy	O
to	O
prevent	O
drug	O
overexposure	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
during	O
everolimus	O
-	O
azole	O
cotreatment	O
,	O
a	O
dose	O
reduction	O
of	O
everolimus	O
is	O
needed	O
to	O
avoid	O
overexposure	O
.	O

According	O
to	O
the	O
different	O
inhibitory	O
potency	O
of	O
CYP3A4	O
activity	O
,	O
the	O
reduction	O
should	O
be	O
lower	O
during	O
fluconazole	O
than	O
during	O
voriconazole	O
cotreatment	O
.	O

Squalene	O
selectively	O
protects	O
mouse	O
bone	O
marrow	O
progenitors	O
against	O
cisplatin	O
and	O
carboplatin	O
-	O
induced	O
cytotoxicity	B
in	O
vivo	O
without	O
protecting	O
tumor	B
growth	O
.	O

Squalene	O
,	O
an	O
isoprenoid	O
antioxidant	O
is	O
a	O
potential	O
cytoprotective	O
agent	O
against	O
chemotherapy	O
-	O
induced	O
toxicity	O
.	O

We	O
have	O
previously	O
published	O
that	O
squalene	O
protects	O
light	O
-	O
density	O
bone	O
marrow	O
cells	O
against	O
cis	O
-	O
diamminedichloroplatinum	O
(	O
II	O
)	O
(	O
cisplatin	O
)	O
-	O
induced	O
toxicity	O
without	O
protecting	O
tumor	O
cells	O
in	O
vitro	O
.	O

Here	O
,	O
we	O
developed	O
an	O
in	O
vivo	O
mouse	O
model	O
of	O
cisplatin	O
and	O
cis	O
-	O
diammine	O
(	O
cyclobutane	O
-	O
1,1	O
-	O
dicarboxylato	O
)	O
platinum	O
(	O
II	O
)	O
(	O
carboplatin	O
)	O
-	O
induced	O
toxicity	O
to	O
further	O
investigate	O
squalene	O
-	O
mediated	O
LD	O
-	O
BM	O
cytoprotection	O
including	O
the	O
molecular	O
mechanism	O
behind	O
selective	O
cytoprotection	O
.	O

We	O
found	O
that	O
squalene	O
significantly	O
reduced	O
the	O
body	O
weight	O
loss	O
of	O
cisplatin	O
and	O
carboplatin	O
-	O
treated	O
mice	O
.	O

Light	O
-	O
density	O
bone	O
marrow	O
cells	O
from	O
squalene	O
-	O
treated	O
mice	O
exhibited	O
improved	O
formation	O
of	O
hematopoietic	O
colonies	O
(	O
colony	O
-	O
forming	O
unit	O
-	O
granulocyte	O
macrophage	O
)	O
.	O

Furthermore	O
,	O
squalene	O
also	O
protected	O
mesenchymal	O
stem	O
cell	O
colonies	O
(	O
colony	O
-	O
forming	O
unit	O
-	O
fibroblast	O
)	O
from	O
cisplatin	O
and	O
carboplatin	O
-	O
induced	O
toxicity	O
.	O

Squalene	O
-	O
induced	O
protection	O
was	O
associated	O
with	O
decreased	O
reactive	O
oxygen	O
species	O
and	O
increased	O
levels	O
of	O
glutathione	O
and	O
glutathione	O
peroxidase	O
/	O
glutathione	O
-	O
S	O
-	O
transferase	O
.	O

Importantly	O
,	O
squalene	O
did	O
not	O
protect	O
neuroblastoma	B
,	O
small	B
cell	I
carcinoma	I
,	O
or	O
medulloblastoma	B
xenografts	O
against	O
cisplatin	O
-	O
induced	O
toxicity	O
.	O

These	O
results	O
suggest	O
that	O
squalene	O
is	O
a	O
potential	O
candidate	O
for	O
future	O
development	O
as	O
a	O
cytoprotective	O
agent	O
against	O
chemotherapeutic	B
toxicity	I
.	O

Management	O
of	O
cocaine	O
-	O
induced	O
cardiac	B
arrhythmias	I
due	O
to	O
cardiac	B
ion	I
channel	I
dysfunction	I
.	O

Cocaine	O
use	O
is	O
common	O
in	O
many	O
areas	O
of	O
the	O
world	O
,	O
particularly	O
the	O
United	O
States	O
and	O
Western	O
Europe	O
.	O

Toxicity	O
following	O
the	O
use	O
of	O
cocaine	O
is	O
associated	O
with	O
a	O
wide	O
range	O
of	O
clinical	O
features	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
focus	O
on	O
the	O
cocaine	O
-	O
associated	O
cardiac	B
arrhythmias	I
and	O
,	O
in	O
particular	O
,	O
some	O
of	O
the	O
controversies	O
in	O
their	O
etiology	O
and	O
management	O
.	O

Cocaine	O
can	O
produce	O
arrhythmias	B
either	O
through	O
the	O
production	O
of	O
myocardial	B
ischemia	I
or	O
as	O
a	O
direct	O
result	O
of	O
ion	O
channel	O
alterations	O
.	O

Excessive	O
catecholamines	O
,	O
combined	O
with	O
sodium	O
and	O
potassium	O
channel	O
blockades	O
,	O
give	O
rise	O
to	O
a	O
wide	O
variety	O
of	O
supra	O
-	O
ventricular	O
and	O
ventricular	O
rhythms	O
.	O

The	O
animal	O
and	O
human	O
evidence	O
for	O
ion	B
channel	I
dysfunction	I
is	O
reviewed	O
,	O
and	O
the	O
effects	O
of	O
catecholamines	O
are	O
followed	O
from	O
the	O
cardiac	O
action	O
potential	O
to	O
the	O
development	O
of	O
arrhythmias	B
.	O

Finally	O
,	O
theoretical	O
constructs	O
are	O
combined	O
with	O
existing	O
evidence	O
to	O
develop	O
a	O
rational	O
treatment	O
strategy	O
for	O
patients	O
with	O
cocaine	O
-	O
induced	O
cardiac	B
arrhythmias	I
.	O

In	O
particular	O
,	O
we	O
review	O
the	O
evidence	O
concerning	O
the	O
controversies	O
relating	O
to	O
the	O
use	O
of	O
lidocaine	O
in	O
comparison	O
with	O
sodium	O
bicarbonate	O
,	O
in	O
terms	O
of	O
QRS	O
prolongation	O
secondary	O
to	O
sodium	O
channel	O
blockade	O
.	O

Influence	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
on	O
osseointegration	O
.	O

This	O
paper	O
reviews	O
contemporary	O
literature	O
concerning	O
the	O
possible	O
influence	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
on	O
osseointegration	O
.	O

In	O
vitro	O
studies	O
concerning	O
the	O
effect	O
of	O
NSAIDs	O
on	O
growth	O
factors	O
and	O
bone	O
-	O
generating	O
cells	O
are	O
the	O
primary	O
source	O
of	O
data	O
pertaining	O
to	O
this	O
issue	O
because	O
relatively	O
few	O
in	O
vivo	O
studies	O
have	O
been	O
conducted	O
.	O

It	O
is	O
concluded	O
that	O
prescribing	O
NSAIDs	O
during	O
the	O
early	O
postoperative	O
period	O
is	O
likely	O
not	O
without	O
negative	O
effect	O
,	O
although	O
any	O
negative	O
influence	O
appears	O
to	O
be	O
temporary	O
and	O
does	O
not	O
affect	O
the	O
final	O
outcome	O
of	O
osseointegration	O
.	O

Nonclinical	O
aspects	O
of	O
biopharmaceutical	O
development	O
:	O
discussion	O
of	O
case	O
studies	O
at	O
a	O
PhRMA	O
-	O
FDA	O
workshop	O
.	O

Robust	O
assessments	O
of	O
the	O
nonclinical	O
safety	O
profile	O
of	O
biopharmaceuticals	O
are	O
best	O
developed	O
on	O
a	O
scientifically	O
justified	O
,	O
case	O
-	O
by	O
-	O
case	O
basis	O
,	O
with	O
consideration	O
of	O
the	O
therapeutic	O
molecule	O
,	O
molecular	O
target	O
,	O
and	O
differences	O
/	O
similarities	O
between	O
nonclinical	O
species	O
and	O
humans	O
(	O
ICH	O
S6	O
)	O
.	O

Significant	O
experience	O
has	O
been	O
gained	O
in	O
the	O
10	O
years	O
ensuing	O
since	O
publication	O
of	O
the	O
ICH	O
S6	O
guidance	O
.	O

In	O
a	O
PhRMA	O
-	O
FDA	O
-	O
sponsored	O
workshop	O
,	O
""""	O
Nonclinical	O
Aspects	O
of	O
Biopharmaceutical	O
Development	O
,	O
""""	O
industry	O
and	O
US	O
regulatory	O
representatives	O
engaged	O
in	O
exploration	O
of	O
current	O
scientific	O
and	O
regulatory	O
issues	O
relating	O
to	O
the	O
nonclinical	O
development	O
of	O
biopharmaceuticals	O
in	O
order	O
to	O
share	O
scientific	O
learning	O
and	O
experience	O
and	O
to	O
work	O
towards	O
establishing	O
consistency	O
in	O
application	O
of	O
general	O
principles	O
and	O
approaches	O
.	O

The	O
proceedings	O
and	O
discussions	O
of	O
this	O
workshop	O
confirm	O
general	O
alignment	O
of	O
strategy	O
and	O
tactics	O
in	O
development	O
of	O
biopharmaceuticals	O
with	O
regard	O
to	O
such	O
areas	O
as	O
species	O
selection	O
,	O
selection	O
of	O
high	O
doses	O
in	O
toxicology	O
studies	O
,	O
selection	O
of	O
clinical	O
doses	O
,	O
the	O
conduct	O
of	O
developmental	O
and	O
reproductive	B
toxicity	I
(	O
DART	O
)	O
studies	O
,	O
and	O
assessment	O
of	O
carcinogenic	O
potential	O
.	O

However	O
,	O
several	O
important	O
aspects	O
,	O
including	O
,	O
for	O
example	O
,	O
appropriate	O
use	O
of	O
homologues	O
,	O
nonhuman	O
primates	O
,	O
and	O
/	O
or	O
in	O
vitro	O
models	O
in	O
the	O
assessment	O
of	O
risk	O
for	O
potential	O
developmental	O
and	O
carcinogenic	O
effects	O
,	O
were	O
identified	O
as	O
requiring	O
further	O
scientific	O
exploration	O
and	O
discussion	O
.	O

Lithium	O
overdose	O
with	O
electrocardiogram	O
changes	O
suggesting	O
ischemia	B
.	O

BACKGROUND	O
:	O
Lithium	B
toxicity	I
is	O
associated	O
with	O
electrocardiogram	O
(	O
ECG	O
)	O
changes	O
,	O
but	O
changes	O
suggestive	O
of	O
an	O
ST	B
segment	I
elevation	I
myocardial	I
infarction	I
have	O
not	O
been	O
reported	O
.	O

CASE	O
REPORT	O
:	O
A	O
46	O
-	O
year	O
-	O
old	O
incarcerated	O
man	O
suffering	O
from	O
diabetes	B
,	O
hypertension	B
,	O
and	O
schizoaffective	O
/	O
bipolar	B
disorder	I
was	O
treated	O
with	O
lithium	O
1,200	O
mg	O
twice	O
daily	O
.	O

Two	O
days	O
prior	O
to	O
presentation	O
the	O
patient	O
became	O
confused	O
,	O
ataxic	O
,	O
and	O
anorexic	O
in	O
jail	O
.	O

Lithium	O
level	O
was	O
4.69	O
mmol	O
/	O
L	O
.	O

He	O
was	O
transferred	O
to	O
the	O
emergency	O
department	O
.	O

On	O
arrival	O
,	O
vital	O
signs	O
were	O
normal	O
.	O

The	O
ECG	O
showed	O
a	O
normal	O
sinus	O
rhythm	O
.	O

ST	O
segments	O
were	O
elevated	O
in	O
the	O
anterior	O
leads	O
with	O
downward	O
concavity	O
.	O

T	O
waves	O
were	O
biphasic	O
.	O

Since	O
these	O
changes	O
suggested	O
cardiac	B
ischemia	I
and	O
the	O
patient	O
was	O
unable	O
to	O
respond	O
to	O
questions	O
about	O
chest	B
pain	I
,	O
cardiac	O
enzymes	O
and	O
an	O
emergent	O
echocardiogram	O
were	O
done	O
.	O

Troponin	O
I	O
was	O
less	O
than	O
0.1	O
microg	O
/	O
L	O
.	O

Echocardiogram	O
was	O
normal	O
,	O
without	O
wall	O
motion	O
abnormalities	O
.	O

Treatment	O
was	O
with	O
hemodialysis	O
and	O
whole	O
-	O
bowel	O
irrigation	O
.	O

Postdialysis	O
lithium	O
level	O
was	O
1.30	O
mmol	O
/	O
L	O
.	O

Over	O
the	O
next	O
several	O
days	O
,	O
electrocardiogram	O
normalized	O
.	O

His	O
speech	O
gradually	O
became	O
coherent	O
.	O

After	O
a	O
1	O
-	O
week	O
hospitalization	O
,	O
he	O
returned	O
to	O
jail	O
.	O

CONCLUSION	O
:	O
Lithium	B
intoxication	I
can	O
cause	O
transient	O
ST	O
segment	O
elevations	O
suggesting	O
an	O
acute	B
myocardial	I
infarction	I
.	O

In	O
the	O
absence	O
of	O
a	O
clear	O
history	O
,	O
echocardiogram	O
and	O
cardiac	O
enzymes	O
can	O
be	O
used	O
to	O
rule	O
out	O
a	O
myocardial	B
infarction	I
.	O

Gemcitabine	O
and	O
cisplatin	O
treatment	O
of	O
advanced	O
-	O
stage	O
non	B
-	I
small	I
-	I
cell	I
lung	I
cancer	I
in	O
patients	O
given	O
cisplatin	O
on	O
day	O
8	O
.	O

AIMS	O
AND	O
BACKGROUND	O
:	O
Gemcitabine	O
and	O
cisplatin	O
treatment	O
were	O
administered	O
to	O
patients	O
with	O
advanced	O
-	O
stage	O
,	O
non	B
-	I
small	I
-	I
cell	I
lung	I
cancer	I
.	O

During	O
phase	O
II	O
studies	O
,	O
the	O
treatment	O
is	O
performed	O
using	O
a	O
28	O
-	O
day	O
cycle	O
,	O
with	O
gemcitabine	O
administered	O
on	O
days	O
1	O
,	O
8	O
,	O
and	O
15	O
.	O

Although	O
it	O
is	O
advised	O
that	O
cisplatin	O
not	O
be	O
administered	O
on	O
the	O
first	O
day	O
,	O
gemcitabine	O
and	O
cisplatin	O
treatment	O
is	O
usually	O
performed	O
using	O
a	O
21	O
-	O
day	O
cycle	O
,	O
with	O
gemcitabine	O
administered	O
on	O
days	O
1	O
and	O
8	O
,	O
and	O
cisplatin	O
is	O
given	O
on	O
the	O
first	O
day	O
in	O
most	O
phase	O
III	O
studies	O
.	O

In	O
contrast	O
with	O
previous	O
phase	O
III	O
studies	O
,	O
cisplatin	O
was	O
administered	O
on	O
day	O
8	O
in	O
our	O
study	O
.	O

Dose	O
density	O
,	O
drug	B
toxicity	I
,	O
and	O
efficacy	O
were	O
analyzed	O
.	O

METHODS	O
AND	O
STUDY	O
DESIGN	O
:	O
Chemonaive	O
patients	O
with	O
stage	O
IIIB	O
or	O
stage	O
IV	O
nonsmall	B
-	I
cell	I
lung	I
cancer	I
received	O
gemcitabine	O
(	O
1250	O
mg	O
/	O
m2	O
)	O
on	O
days	O
1	O
and	O
8	O
plus	O
cisplatin	O
(	O
75	O
mg	O
/	O
m2	O
)	O
on	O
day	O
8	O
every	O
3	O
weeks	O
(	O
1	O
cycle	O
contained	O
2	O
applications	O
)	O
.	O

RESULTS	O
:	O
Sixty	O
-	O
seven	O
patients	O
received	O
a	O
total	O
of	O
293	O
applications	O
.	O

Dose	O
densities	O
were	O
92.3	O
%	O
for	O
gemcitabine	O
and	O
93.9	O
%	O
for	O
cisplatin	O
.	O

The	O
types	O
and	O
rates	O
of	O
grade	O
3	O
and	O
grade	O
4	O
hematologic	O
toxicities	O
were	O
anemia	B
(	O
6	O
%	O
)	O
,	O
granulocytopenia	B
(	O
46	O
%	O
)	O
,	O
and	O
thrombocytopenia	B
(	O
6	O
%	O
)	O
.	O

Complete	O
remission	O
was	O
seen	O
in	O
2	O
patients	O
(	O
3	O
%	O
)	O
;	O
partial	O
remission	O
was	O
40	O
%	O
,	O
stable	O
disease	O
was	O
39	O
%	O
,	O
and	O
progression	O
of	O
disease	O
,	O
10	O
%	O
.	O

The	O
median	O
overall	O
survival	O
time	O
was	O
13	O
months	O
.	O

The	O
median	O
progression	O
-	O
free	O
survival	O
time	O
was	O
9.5	O
months	O
.	O

One	O
-	O
year	O
survival	O
rate	O
was	O
54	O
%	O
and	O
2	O
-	O
year	O
survival	O
,	O
10.4	O
%	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
21	O
-	O
day	O
treatment	O
regimen	O
,	O
overall	O
survival	O
was	O
longer	O
than	O
1	O
year	O
and	O
the	O
1	O
-	O
year	O
survival	O
rate	O
was	O
more	O
than	O
50	O
%	O
.	O

Both	O
the	O
severity	O
and	O
rate	O
of	O
observed	O
thrombocytopenia	B
in	O
the	O
study	O
were	O
very	O
low	O
.	O

Other	O
adverse	O
effects	O
in	O
the	O
current	O
study	O
were	O
comparable	O
to	O
those	O
reported	O
in	O
the	O
literature	O
.	O

Orally	O
administered	O
apple	O
procyanidins	O
protect	O
against	O
experimental	O
inflammatory	B
bowel	I
disease	I
in	O
mice	O
.	O

Apple	O
procyanidins	O
(	O
ACT	O
)	O
is	O
a	O
natural	O
biologically	O
active	O
compound	O
extracted	O
from	O
apple	O
.	O

Our	O
recent	O
studies	O
have	O
shown	O
that	O
ACT	O
ameliorates	O
the	O
symptoms	O
of	O
atopic	B
dermatitis	I
and	O
inhibits	O
food	O
-	O
allergen	O
-	O
induced	O
oral	O
sensitization	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
potential	O
protective	O
effect	O
and	O
mechanism	O
of	O
action	O
of	O
ACT	O
in	O
a	O
murine	O
model	O
of	O
inflammatory	B
bowel	I
disease	I
.	O

We	O
investigated	O
the	O
preventive	O
effects	O
of	O
ACT	O
in	O
experimental	O
models	O
of	O
colitis	B
induced	O
by	O
dextran	O
sulfate	O
sodium	O
(	O
DSS	O
)	O
or	O
oxazolone	O
.	O

Oral	O
administration	O
of	O
ACT	O
before	O
DSS	O
treatment	O
attenuated	O
the	O
DSS	O
-	O
induced	O
mortality	O
rate	O
and	O
decreased	O
body	O
weight	O
loss	O
.	O

ACT	O
also	O
prevented	O
the	O
body	O
weight	O
loss	O
associated	O
with	O
oxazolone	O
-	O
induced	O
colitis	B
.	O

Next	O
we	O
examined	O
the	O
effect	O
of	O
ACT	O
on	O
intraepithelial	O
lymphocytes	O
(	O
IEL	O
)	O
,	O
which	O
is	O
a	O
major	O
T	O
cell	O
population	O
in	O
the	O
intestine	O
.	O

Oral	O
administration	O
of	O
ACT	O
increased	O
the	O
proportions	O
of	O
TCRgammadelta	O
and	O
TCRalphabeta	O
-	O
CD8alphaalpha	O
T	O
cells	O
in	O
IEL	O
and	O
suppressed	O
interferon	O
gamma	O
synthesis	O
in	O
stimulated	O
IEL	O
.	O

In	O
addition	O
,	O
ACT	O
inhibited	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
-	O
induced	O
secretion	O
of	O
interleukin	O
8	O
(	O
IL	O
-	O
8	O
)	O
in	O
intestinal	O
epithelial	O
cells	O
.	O

The	O
combined	O
anti	O
-	O
inflammatory	O
and	O
immunomodulatory	O
effects	O
of	O
ACT	O
on	O
intestinal	O
epithelial	O
cells	O
and	O
IEL	O
suggest	O
that	O
it	O
may	O
be	O
an	O
effective	O
oral	O
preventive	O
agent	O
for	O
inflammatory	B
bowel	I
diseases	I
.	O

Methylated	O
bismuth	O
,	O
but	O
not	O
bismuth	O
citrate	O
or	O
bismuth	O
glutathione	O
,	O
induces	O
cyto	O
-	O
and	O
genotoxic	B
effects	I
in	O
human	O
cells	O
in	O
vitro	O
.	O

Bismuth	O
compounds	O
are	O
widely	O
used	O
in	O
industrial	O
processes	O
and	O
products	O
.	O

In	O
medicine	O
,	O
bismuth	O
salts	O
have	O
been	O
applied	O
in	O
combination	O
with	O
antibiotics	O
for	O
the	O
treatment	O
of	O
Helicobacter	B
pylori	I
infections	I
,	O
for	O
the	O
prevention	O
of	O
diarrhea	B
,	O
and	O
in	O
radioimmunotherapy	O
.	O

In	O
the	O
environment	O
,	O
bismuth	O
ions	O
can	O
be	O
biotransformed	O
to	O
the	O
volatile	O
bismuth	O
compound	O
trimethylbismuth	O
(	O
Me3Bi	O
)	O
by	O
methanobacteria	O
.	O

Preliminary	O
in	O
-	O
house	O
studies	O
have	O
indicated	O
that	O
bismuth	O
ions	O
are	O
methylated	O
in	O
the	O
human	O
colon	O
by	O
intestinal	O
microflora	O
following	O
ingestion	O
of	O
bismuth	O
-	O
containing	O
salts	O
.	O

Information	O
concerning	O
cyto	O
-	O
and	O
genotoxicity	B
of	O
these	O
biomethylated	O
products	O
is	O
limited	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
cellular	O
uptake	O
of	O
an	O
organic	O
bismuth	O
compound	O
[	O
monomethylbismuth	O
(	O
III	O
)	O
,	O
MeBi	O
(	O
III	O
)	O
]	O
and	O
two	O
other	O
bismuth	O
compounds	O
[	O
bismuth	O
citrate	O
(	O
Bi	O
-	O
Cit	O
)	O
and	O
bismuth	O
glutathione	O
(	O
Bi	O
-	O
GS	O
)	O
]	O
in	O
human	O
hepatocytes	O
,	O
lymphocytes	O
,	O
and	O
erythrocytes	O
using	O
ICP	O
-	O
MS	O
.	O

We	O
also	O
analyzed	O
the	O
cyto	O
-	O
and	O
genotoxic	B
effects	I
of	O
these	O
compounds	O
to	O
investigate	O
their	O
toxic	O
potential	O
.	O

Our	O
results	O
show	O
that	O
the	O
methylbismuth	O
compound	O
was	O
better	O
taken	O
up	O
by	O
the	O
cells	O
than	O
Bi	O
-	O
Cit	O
and	O
Bi	O
-	O
GS	O
.	O

All	O
intracellularly	O
detected	O
bismuth	O
compounds	O
were	O
located	O
in	O
the	O
cytosol	O
of	O
the	O
cells	O
.	O

MeBi	O
(	O
III	O
)	O
was	O
best	O
taken	O
up	O
by	O
erythrocytes	O
(	O
36	O
%	O
)	O
,	O
followed	O
by	O
lymphocytes	O
(	O
17	O
%	O
)	O
and	O
hepatocytes	O
(	O
0.04	O
%	O
)	O
.	O

Erythrocytes	O
and	O
hepatocytes	O
were	O
more	O
susceptible	O
to	O
MeBi	O
(	O
III	O
)	O
exposure	O
than	O
lymphocytes	O
.	O

Cytotoxic	B
effects	I
of	O
MeBi	O
(	O
III	O
)	O
were	O
detectable	O
in	O
erythrocytes	O
at	O
concentrations	O
>	O
4	O
microM	O
,	O
in	O
hepatocytes	O
at	O
>	O
130	O
microM	O
,	O
and	O
in	O
lymphocytes	O
at	O
>	O
430	O
microM	O
after	O
24	O
h	O
of	O
exposure	O
.	O

Cytotoxic	B
effects	I
for	O
Bi	O
-	O
Cit	O
and	O
Bi	O
-	O
GS	O
were	O
much	O
lower	O
or	O
not	O
detectable	O
in	O
the	O
used	O
cell	O
lines	O
up	O
to	O
a	O
tested	O
concentration	O
of	O
500	O
microM	O
.	O

Exposure	O
of	O
lymphocytes	O
to	O
MeBi	O
(	O
III	O
)	O
(	O
250	O
microM	O
for	O
1	O
h	O
and	O
25	O
microM	O
/	O
50	O
microM	O
for	O
24	O
h	O
)	O
resulted	O
in	O
significantly	O
increased	O
frequencies	O
of	O
chromosomal	O
aberrations	O
(	O
CA	O
)	O
and	O
sister	O
chromatid	O
exchanges	O
(	O
SCE	O
)	O
,	O
whereas	O
Bi	O
-	O
Cit	O
and	O
Bi	O
-	O
GS	O
induced	O
neither	O
CA	O
nor	O
SCE	O
.	O

Our	O
study	O
also	O
showed	O
an	O
intracellular	O
production	O
of	O
free	O
radicals	O
caused	O
by	O
MeBi	O
(	O
III	O
)	O
in	O
hepatocytes	O
but	O
not	O
in	O
lymphocytes	O
.	O

These	O
data	O
suggest	O
that	O
biomethylation	O
of	O
bismuth	O
ions	O
by	O
the	O
intestinal	O
microflora	O
of	O
the	O
human	O
colon	O
leads	O
to	O
an	O
increase	O
in	O
the	O
toxicity	O
of	O
the	O
primary	O
bismuth	O
salt	O
.	O

Cellular	O
delivery	O
and	O
biological	O
activity	O
of	O
antisense	O
oligonucleotides	O
conjugated	O
to	O
a	O
targeted	O
protein	O
carrier	O
.	O

Targeted	O
delivery	O
can	O
potentially	O
improve	O
the	O
pharmacological	O
effects	O
of	O
antisense	O
and	O
siRNA	O
oligonucleotides	O
.	O

Here	O
,	O
we	O
describe	O
a	O
novel	O
bioconjugation	O
approach	O
to	O
the	O
delivery	O
of	O
splice	O
-	O
shifting	O
antisense	O
oligonucleotides	O
(	O
SSOs	O
)	O
.	O

The	O
SSOs	O
are	O
linked	O
to	O
albumin	O
via	O
reversible	O
S	O
-	O
S	O
bonds	O
.	O

The	O
albumin	O
is	O
also	O
conjugated	O
with	O
poly	O
(	O
ethylene	O
glycol	O
)	O
(	O
PEG	O
)	O
chains	O
that	O
terminate	O
in	O
an	O
RGD	O
ligand	O
that	O
selectively	O
binds	O
the	O
alphavbeta3	O
integrin	O
.	O

As	O
a	O
test	O
system	O
,	O
we	O
utilized	O
human	O
melanoma	O
cells	O
that	O
express	O
the	O
alphavbeta3	O
integrin	O
and	O
that	O
also	O
contain	O
a	O
luciferase	O
reporter	O
gene	O
that	O
can	O
be	O
induced	O
by	O
delivery	O
of	O
SSOs	O
to	O
the	O
cell	O
nucleus	O
.	O

The	O
RGD	O
-	O
PEG	O
-	O
SSO	O
-	O
albumin	O
conjugates	O
were	O
endocytosed	O
by	O
the	O
cells	O
in	O
an	O
RGD	O
-	O
dependent	O
manner	O
;	O
using	O
confocal	O
fluorescence	O
microscopy	O
,	O
evidence	O
was	O
obtained	O
that	O
the	O
SSOs	O
accumulate	O
in	O
the	O
nucleus	O
.	O

The	O
conjugates	O
were	O
able	O
to	O
robustly	O
induce	O
luciferase	O
expression	O
at	O
concentrations	O
in	O
the	O
25	O
-	O
200	O
nM	O
range	O
.	O

At	O
these	O
levels	O
,	O
little	O
short	O
-	O
term	O
or	O
long	O
-	O
term	O
toxicity	O
was	O
observed	O
.	O

Thus	O
,	O
the	O
RGD	O
-	O
PEG	O
-	O
albumin	O
conjugates	O
may	O
provide	O
an	O
effective	O
tool	O
for	O
targeted	O
delivery	O
of	O
oligonucleotides	O
to	O
certain	O
cells	O
and	O
tissues	O
.	O

Conjugated	O
chitosan	O
as	O
a	O
novel	O
platform	O
for	O
oral	O
delivery	O
of	O
paclitaxel	O
.	O

A	O
new	O
platform	O
for	O
oral	O
delivery	O
of	O
paclitaxel	O
(	O
PTX	O
)	O
was	O
developed	O
through	O
chemical	O
conjugation	O
of	O
PTX	O
to	O
a	O
low	O
molecular	O
weight	O
chitosan	O
(	O
LMWC	O
)	O
.	O

The	O
LMWC	O
-	O
PTX	O
conjugate	O
contained	O
approximately	O
12	O
wt	O
%	O
PTX	O
and	O
showed	O
greatly	O
enhanced	O
water	O
solubility	O
(	O
>	O
1	O
mg	O
/	O
mL	O
)	O
as	O
compared	O
to	O
native	O
PTX	O
.	O

The	O
conjugate	O
showed	O
comparable	O
IC	O
50	O
values	O
to	O
that	O
of	O
the	O
parent	O
PTX	O
against	O
human	O
cancer	O
cell	O
lines	O
.	O

The	O
pharmacokinetic	O
data	O
revealed	O
approximately	O
42	O
%	O
of	O
bioavailability	O
after	O
oral	O
administration	O
of	O
5	O
mg	O
PTX	O
/	O
kg	O
of	O
the	O
conjugate	O
.	O

When	O
the	O
conjugate	O
(	O
10	O
mg	O
/	O
kg	O
based	O
on	O
PTX	O
content	O
)	O
was	O
administered	O
orally	O
to	O
mice	O
bearing	O
xenograft	O
or	O
allograft	O
tumors	B
,	O
the	O
conjugate	O
-	O
treated	O
group	O
showed	O
significant	O
inhibition	O
of	O
tumor	B
growth	O
,	O
which	O
was	O
comparable	O
to	O
that	O
seen	O
with	O
PTX	O
of	O
the	O
clinically	O
available	O
injected	O
form	O
,	O
formulated	O
in	O
cremophor	O
EL	O
/	O
ethanol	O
(	O
iv	O
)	O
but	O
with	O
much	O
lower	O
toxicity	O
.	O

Tracking	O
I	O
(	O
125	O
)	O
-	O
labeled	O
conjugate	O
showed	O
that	O
LMWC	O
-	O
PTX	O
was	O
likely	O
to	O
be	O
absorbed	O
mainly	O
from	O
the	O
ileum	O
and	O
reach	O
the	O
blood	O
as	O
the	O
intact	O
conjugate	O
.	O

Phase	O
II	O
trial	O
of	O
S	O
-	O
1	O
and	O
concurrent	O
radiotherapy	O
in	O
patients	O
with	O
locally	O
advanced	O
pancreatic	B
cancer	I
.	O

PURPOSE	O
:	O
S	O
-	O
1	O
has	O
a	O
favorable	O
effect	O
in	O
unresectable	O
pancreatic	B
cancer	I
and	O
a	O
potential	O
radiosensitizer	O
.	O

In	O
addition	O
,	O
daily	O
oral	O
administration	O
of	O
S	O
-	O
1	O
is	O
more	O
convenient	O
than	O
continuous	O
infusion	O
of	O
5	O
-	O
fluorouracil	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
S	O
-	O
1	O
and	O
concurrent	O
radiotherapy	O
in	O
patients	O
with	O
locally	O
advanced	O
pancreatic	B
cancer	I
.	O

METHODS	O
:	O
Eligibility	O
criteria	O
were	O
histologically	O
proven	O
pancreatic	B
adenocarcinoma	I
,	O
locally	O
advanced	O
disease	O
,	O
and	O
no	O
previous	O
treatment	O
.	O

S	O
-	O
1	O
was	O
administered	O
orally	O
at	O
a	O
dose	O
of	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
from	O
day	O
1	O
to	O
14	O
and	O
from	O
day	O
22	O
to	O
35	O
,	O
and	O
concurrent	O
radiotherapy	O
(	O
a	O
total	O
dose	O
of	O
50.4	O
Gy	O
)	O
was	O
delivered	O
in	O
28	O
fractions	O
.	O

One	O
month	O
after	O
treatment	O
completion	O
,	O
tumor	O
response	O
was	O
evaluated	O
by	O
computed	O
tomography	O
(	O
CT	O
)	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
25	O
patients	O
were	O
evaluable	O
for	O
efficacy	O
and	O
toxicity	O
on	O
the	O
basis	O
of	O
the	O
intention	O
-	O
to	O
-	O
treat	O
analysis	O
.	O

The	O
response	O
rate	O
and	O
disease	O
control	O
rate	O
were	O
24.0	O
and	O
68.0	O
%	O
,	O
respectively	O
.	O

There	O
was	O
no	O
treatment	O
-	O
related	O
death	O
or	O
grade	O
4	O
toxicity	O
.	O

The	O
most	O
common	O
grade	O
3	O
hematologic	O
and	O
non	O
-	O
hematologic	O
toxicities	O
were	O
thrombocytopenia	B
(	O
4.0	O
%	O
)	O
and	O
anorexia	B
(	O
20	O
%	O
)	O
,	O
respectively	O
.	O

All	O
toxicities	O
were	O
tolerable	O
and	O
transient	O
.	O

The	O
median	O
time	O
-	O
to	O
-	O
progression	O
and	O
median	O
overall	O
survival	O
were	O
6.5	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
4.1	O
-	O
9.0	O
months	O
)	O
and	O
12.9	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
6.7	O
-	O
19.0	O
months	O
)	O
,	O
respectively	O
,	O
and	O
the	O
1	O
-	O
year	O
survival	O
rate	O
was	O
estimated	O
to	O
be	O
43	O
%	O
.	O

CONCLUSIONS	O
:	O
S	O
-	O
1	O
and	O
concurrent	O
radiotherapy	O
shows	O
favorable	O
efficacy	O
for	O
disease	O
control	O
against	O
locally	O
advanced	O
pancreatic	B
cancer	I
and	O
was	O
well	O
tolerated	O
with	O
no	O
severe	O
toxicities	O
.	O

Does	O
chemotherapy	O
modify	O
the	O
immune	O
surveillance	O
of	O
hematological	B
malignancies	I
?	O

Malignant	B
diseases	I
induce	O
immune	O
responses	O
against	O
them	O
which	O
have	O
variable	O
success	O
in	O
controlling	O
progression	O
of	O
disease	O
.	O

A	O
variety	O
of	O
congenital	O
and	O
acquired	O
disorders	O
provide	O
evidence	O
in	O
support	O
of	O
T	O
cell	O
or	O
NK	O
cell	O
immune	O
surveillance	O
mechanisms	O
in	O
human	O
hematological	B
malignancies	I
.	O

Furthermore	O
,	O
clinical	O
experience	O
with	O
stem	O
cell	O
transplantation	O
underlines	O
the	O
potential	O
for	O
both	O
T	O
and	O
NK	O
cell	O
-	O
mediated	O
antileukemia	O
effects	O
.	O

Animal	O
models	O
of	O
tumor	B
surveillance	O
and	O
viral	O
-	O
driven	O
lymphoproliferative	B
diseases	I
in	O
man	O
emphasize	O
the	O
dynamic	O
nature	O
of	O
the	O
equilibrium	O
between	O
tumors	O
and	O
the	O
immune	O
system	O
,	O
which	O
can	O
lead	O
to	O
tumor	B
escape	O
in	O
individuals	O
with	O
normal	O
immune	O
function	O
.	O

In	O
hematological	O
malignancies	O
the	O
implication	O
of	O
a	O
dynamic	O
immune	O
surveillance	O
model	O
is	O
that	O
chemotherapy	O
may	O
disrupt	O
potentially	O
competent	O
immune	O
surveillance	O
mechanisms	O
leading	O
to	O
disease	O
recurrence	O
following	O
successful	O
tumor	B
bulk	O
reduction	O
by	O
chemotherapy	O
.	O

This	O
possibility	O
deserves	O
further	O
investigation	O
with	O
a	O
view	O
to	O
developing	O
strategies	O
to	O
boost	O
immune	O
function	O
following	O
chemotherapy	O
so	O
as	O
to	O
combine	O
the	O
beneficial	O
effect	O
of	O
chemotherapy	O
with	O
an	O
immune	O
response	O
capable	O
of	O
sustaining	O
remissions	O
.	O

In	O
vitro	O
investigation	O
of	O
oxide	O
nanoparticle	O
and	O
carbon	O
nanotube	O
toxicity	O
and	O
intracellular	O
accumulation	O
in	O
A549	O
human	O
pneumocytes	O
.	O

If	O
released	O
in	O
the	O
environment	O
,	O
nanomaterials	O
might	O
be	O
inhaled	O
by	O
populations	O
and	O
cause	O
damage	O
to	O
the	O
deepest	O
regions	O
of	O
the	O
respiratory	O
tract	O
,	O
i.e.	O
,	O
the	O
alveolar	O
compartment	O
.	O

To	O
model	O
this	O
situation	O
,	O
we	O
studied	O
the	O
response	O
of	O
A549	O
human	O
pneumocytes	O
after	O
exposure	O
to	O
aluminium	O
oxide	O
or	O
titanium	O
oxide	O
nanoparticles	O
,	O
and	O
to	O
multi	O
-	O
walled	O
carbon	O
nanotubes	O
.	O

The	O
influence	O
of	O
size	O
,	O
crystalline	O
structure	O
and	O
chemical	O
composition	O
was	O
investigated	O
.	O

After	O
a	O
detailed	O
identification	O
of	O
nanomaterial	O
physico	O
-	O
chemical	O
characteristics	O
,	O
cells	O
were	O
exposed	O
in	O
vitro	O
and	O
viability	O
and	O
intracellular	O
accumulation	O
were	O
assessed	O
.	O

In	O
our	O
conditions	O
,	O
carbon	O
nanotubes	O
were	O
more	O
toxic	O
than	O
metal	O
oxide	O
nanoparticles	O
.	O

Our	O
results	O
confirmed	O
that	O
both	O
nanotubes	O
and	O
nanoparticles	O
are	O
able	O
to	O
rapidly	O
enter	O
into	O
cells	O
,	O
and	O
distribute	O
in	O
the	O
cytoplasm	O
and	O
intracellular	O
vesicles	O
.	O

Among	O
nanoparticles	O
,	O
we	O
demonstrate	O
significant	O
difference	O
in	O
biological	O
response	O
as	O
a	O
function	O
of	O
size	O
,	O
crystalline	O
phase	O
and	O
chemical	O
composition	O
.	O

Their	O
toxicity	O
was	O
globally	O
lower	O
than	O
nanotubes	B
toxicity	I
.	O

Among	O
nanotubes	O
,	O
the	O
length	O
did	O
not	O
influence	O
cytotoxicity	B
,	O
neither	O
the	O
presence	O
of	O
metal	O
catalyst	O
impurities	O
.	O

Up	O
-	O
regulation	O
and	O
cytoprotective	O
role	O
of	O
epithelial	O
multidrug	O
resistance	O
-	O
associated	O
protein	O
1	O
in	O
inflammatory	B
bowel	I
disease	I
.	O

MRP1	O
(	O
multidrug	O
resistance	O
-	O
associated	O
protein	O
1	O
)	O
is	O
well	O
known	O
for	O
its	O
role	O
in	O
providing	O
multidrug	O
resistance	O
to	O
cancer	O
cells	O
.	O

In	O
addition	O
,	O
MRP1	O
has	O
been	O
associated	O
with	O
both	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
functions	O
in	O
nonmalignant	O
cells	O
.	O

The	O
pro	O
-	O
inflammatory	O
function	O
is	O
evident	O
from	O
the	O
fact	O
that	O
MRP1	O
is	O
a	O
high	O
affinity	O
transporter	O
for	O
cysteinyl	O
-	O
leukotriene	O
C4	O
(	O
LTC4	O
)	O
,	O
a	O
lipid	O
mediator	O
of	O
inflammation	B
.	O

It	O
remains	O
unexplained	O
,	O
however	O
,	O
why	O
the	O
absence	O
of	O
Mrp1	O
leads	O
to	O
increased	O
intestinal	O
epithelial	O
damage	O
in	O
mice	O
treated	O
with	O
dextran	O
-	O
sodium	O
sulfate	O
,	O
a	O
model	O
for	O
inflammatory	B
bowel	I
disease	I
(	O
IBD	B
)	O
.	O

We	O
found	O
that	O
MRP1	O
expression	O
is	O
induced	O
in	O
the	O
inflamed	O
intestine	O
of	O
IBD	B
patients	O
,	O
e.g.	O
Crohn	B
disease	I
and	O
ulcerative	B
colitis	I
.	O

Increased	O
MRP1	O
expression	O
was	O
detected	O
at	O
the	O
basolateral	O
membrane	O
of	O
intestinal	O
epithelial	O
cells	O
.	O

To	O
study	O
a	O
putative	O
role	O
for	O
MRP1	O
in	O
protecting	O
epithelial	O
cells	O
against	O
inflammatory	O
cues	O
,	O
we	O
manipulated	O
MRP1	O
levels	O
in	O
human	O
epithelial	O
DLD	O
-	O
1	O
cells	O
and	O
exposed	O
these	O
cells	O
to	O
cytokines	O
and	O
anti	O
-	O
Fas	O
.	O

Inhibition	O
of	O
MRP1	O
(	O
by	O
MK571	O
or	O
RNA	O
interference	O
)	O
resulted	O
in	O
increased	O
cytokine	O
-	O
and	O
anti	O
-	O
Fas	O
-	O
induced	O
apoptosis	O
of	O
DLD	O
-	O
1	O
cells	O
.	O

Opposite	O
effects	O
,	O
e.g.	O
protection	O
of	O
DLD	O
-	O
1	O
cells	O
against	O
cytokine	O
-	O
and	O
anti	O
-	O
Fas	O
-	O
induced	O
apoptosis	O
,	O
were	O
observed	O
after	O
recombinant	O
MRP1	O
overexpression	O
.	O

Inhibition	O
of	O
LTC4	O
synthesis	O
reduced	O
anti	O
-	O
Fas	O
-	O
induced	O
apoptosis	O
when	O
MRP1	O
function	O
was	O
blocked	O
,	O
suggesting	O
that	O
LTC4	O
is	O
the	O
pro	O
-	O
apoptotic	O
compound	O
exported	O
by	O
epithelial	O
MRP1	O
during	O
inflammation	B
.	O

These	O
data	O
show	O
that	O
MRP1	O
protects	O
intestinal	O
epithelial	O
cells	O
against	O
inflammation	O
-	O
induced	O
apoptotic	O
cell	O
death	O
and	O
provides	O
a	O
functional	O
role	O
for	O
MRP1	O
in	O
the	O
inflamed	O
intestinal	O
epithelium	O
of	O
IBD	B
patients	O
.	O

Pharmacokinetic	O
and	O
safety	O
profile	O
of	O
rupatadine	O
when	O
coadministered	O
with	O
azithromycin	O
at	O
steady	O
-	O
state	O
levels	O
:	O
a	O
randomized	O
,	O
open	O
-	O
label	O
,	O
two	O
-	O
way	O
,	O
crossover	O
,	O
Phase	O
I	O
study	O
.	O

BACKGROUND	O
:	O
Rupatadine	O
is	O
an	O
oral	O
active	O
antihistamine	O
and	O
platelet	O
-	O
activating	O
factor	O
antagonist	O
indicated	O
for	O
the	O
management	O
of	O
allergic	B
rhinitis	I
and	O
chronic	B
urticaria	I
in	O
Europe	O
.	O

OBJECTIVE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
effect	O
of	O
the	O
concomitant	O
administration	O
of	O
azithromycin	O
and	O
rupatadine	O
on	O
the	O
pharmacokinetics	O
of	O
rupatadine	O
and	O
its	O
metabolites	O
after	O
repeated	O
doses	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multiple	O
-	O
dose	O
,	O
randomized	O
,	O
open	O
-	O
label	O
,	O
2	O
-	O
way	O
,	O
crossover	O
,	O
Phase	O
I	O
study	O
in	O
which	O
healthy	O
male	O
and	O
female	O
volunteers	O
received	O
rupatadine	O
10	O
mg	O
once	O
a	O
day	O
for	O
6	O
days	O
either	O
alone	O
or	O
with	O
azithromycin	O
500	O
mg	O
on	O
day	O
2	O
and	O
250	O
mg	O
from	O
day	O
3	O
to	O
day	O
6	O
.	O

Treatments	O
were	O
administered	O
after	O
a	O
fasting	O
period	O
of	O
10	O
hours	O
with	O
240	O
mL	O
of	O
water	O
,	O
and	O
fasting	O
conditions	O
were	O
kept	O
until	O
3	O
hours	O
postmedication	O
.	O

A	O
washout	O
period	O
of	O
at	O
least	O
21	O
days	O
between	O
the	O
2	O
active	O
periods	O
was	O
observed	O
.	O

Blood	O
samples	O
were	O
collected	O
and	O
plasma	O
concentrations	O
of	O
rupatadine	O
and	O
its	O
metabolites	O
desloratadine	O
and	O
3	O
-	O
hydroxydesloratadine	O
were	O
determined	O
by	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
.	O

Tolerability	O
was	O
based	O
on	O
the	O
recording	O
of	O
adverse	O
events	O
(	O
AEs	O
)	O
,	O
physical	O
examination	O
,	O
electrocardiograms	O
,	O
and	O
laboratory	O
screen	O
controls	O
at	O
baseline	O
and	O
the	O
final	O
study	O
visit	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
four	O
healthy	O
volunteers	O
(	O
15	O
males	O
,	O
9	O
females	O
;	O
mean	O
[	O
SD	O
]	O
age	O
,	O
25.67	O
[	O
5.58	O
]	O
years	O
;	O
weight	O
,	O
65.96	O
[	O
8.57	O
]	O
kg	O
)	O
completed	O
the	O
study	O
.	O

Except	O
for	O
maximum	O
observed	O
concentration	O
during	O
a	O
dosing	O
interval	O
(	O
Cmax	O
,	O
ss	O
)	O
of	O
3	O
-	O
hydroxydesloratadine	O
,	O
on	O
average	O
,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
mean	O
plasma	O
concentrations	O
in	O
any	O
of	O
the	O
main	O
pharmacokinetic	O
parameters	O
of	O
rupatadine	O
,	O
desloratadine	O
,	O
and	O
3	O
-	O
hydroxydesloratadine	O
when	O
administered	O
in	O
combination	O
with	O
azithromycin	O
or	O
alone	O
.	O

The	O
Cmax	O
,	O
ss	O
ratio	O
was	O
111	O
(	O
90	O
%	O
CI	O
,	O
91	O
-	O
136	O
)	O
and	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
during	O
a	O
dosing	O
interval	O
(	O
AUC0	O
-	O
tau	O
)	O
ratio	O
had	O
a	O
value	O
of	O
103	O
(	O
90	O
%	O
CI	O
,	O
91	O
-	O
117	O
)	O
.	O

The	O
corresponding	O
ratios	O
for	O
the	O
rupatadine	O
metabolites	O
were	O
109	O
(	O
90	O
%	O
CI	O
,	O
100	O
-	O
120	O
)	O
for	O
Cmax	O
,	O
ss	O
and	O
103	O
(	O
90	O
%	O
CI	O
,	O
96	O
-	O
110	O
)	O
for	O
AUC0	O
-	O
tau	O
for	O
desloratadine	O
and	O
109	O
(	O
90	O
%	O
CI	O
,	O
103	O
-	O
115	O
)	O
for	O
Cmax	O
,	O
ss	O
and	O
104	O
(	O
90	O
%	O
CI	O
,	O
100	O
-	O
108	O
)	O
for	O
AUC0	O
-	O
tau	O
for	O
3	O
-	O
hydroxydesloratadine	O
.	O

Point	O
estimates	O
for	O
Cmax	O
,	O
ss	O
ratios	O
using	O
paired	O
data	O
were	O
111	O
%	O
for	O
rupatadine	O
,	O
109	O
%	O
for	O
desloratadine	O
,	O
and	O
109	O
%	O
for	O
3	O
-	O
hydroxydesloratadine	O
.	O

The	O
90	O
%	O
CIs	O
were	O
included	O
in	O
the	O
interval	O
80	O
%	O
to	O
125	O
%	O
for	O
desloratadine	O
and	O
3	O
-	O
hydroxydesloratadine	O
,	O
whereas	O
90	O
%	O
CI	O
for	O
rupatadine	O
was	O
shifted	O
to	O
the	O
right	O
of	O
the	O
interval	O
used	O
for	O
comparing	O
bioavailability	O
of	O
the	O
drugs	O
.	O

A	O
total	O
of	O
5	O
subjects	O
reported	O
9	O
AEs	O
;	O
5	O
of	O
these	O
were	O
thought	O
to	O
be	O
related	O
to	O
the	O
drug	O
administration	O
and	O
all	O
were	O
categorized	O
as	O
mild	O
or	O
moderate	O
.	O

The	O
reported	O
AEs	O
were	O
somnolence	B
(	O
1	O
/	O
24	O
in	O
the	O
rupatadine	O
group	O
and	O
1	O
/	O
24	O
in	O
the	O
rupatadine	O
plus	O
azithromycin	O
group	O
)	O
,	O
diarrhea	B
(	O
1	O
/	O
24	O
in	O
the	O
rupatadine	O
plus	O
azithromycin	O
group	O
)	O
,	O
and	O
gastric	B
discomfort	I
(	O
2	O
/	O
24	O
in	O
the	O
rupatadine	O
plus	O
azithromycin	O
group	O
)	O
.	O

Four	O
AEs	O
were	O
considered	O
not	O
to	O
be	O
related	O
(	O
2	O
episodes	O
of	O
headache	B
,	O
1	O
anemia	B
,	O
1	O
cheilitis	B
)	O
.	O

All	O
were	O
resolved	O
spontaneously	O
.	O

No	O
serious	O
AEs	O
were	O
reported	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
of	O
this	O
study	O
in	O
these	O
healthy	O
volunteers	O
found	O
no	O
significant	O
differences	O
in	O
pharmacokinetic	O
parameters	O
other	O
than	O
Cmax	O
,	O
ss	O
of	O
3	O
-	O
hydroxydesloratadine	O
between	O
rupatadine	O
10	O
mg	O
administered	O
alone	O
or	O
with	O
azithromycin	O
500	O
mg	O
on	O
day	O
2	O
and	O
250	O
mg	O
from	O
day	O
3	O
to	O
day	O
6	O
.	O

The	O
administration	O
of	O
rupatadine	O
compared	O
with	O
rupatadine	O
plus	O
azithromycin	O
met	O
the	O
regulatory	O
definition	O
of	O
bioequivalence	O
in	O
terms	O
of	O
exposure	O
and	O
rate	O
parameters	O
;	O
however	O
,	O
Cmax	O
,	O
ss	O
of	O
rupatadine	O
was	O
outside	O
the	O
conventional	O
confidence	O
interval	O
.	O

Bioequivalence	O
and	O
pharmacokinetic	O
comparison	O
of	O
a	O
single	O
200	O
-	O
mg	O
dose	O
of	O
meclofenoxate	O
hydrochloride	O
capsule	O
and	O
tablet	O
formulations	O
in	O
healthy	O
Chinese	O
adult	O
male	O
volunteers	O
:	O
a	O
randomized	O
sequence	O
,	O
open	O
-	O
label	O
,	O
two	O
-	O
period	O
crossover	O
study	O
.	O

BACKGROUND	O
:	O
Meclofenoxate	O
hydrochloride	O
is	O
a	O
psychostimulant	O
in	O
the	O
nootropic	O
agent	O
group	O
available	O
in	O
capsule	O
and	O
tablet	O
formulations	O
approved	O
for	O
traumatic	B
cataphora	I
,	O
alcoholic	B
poisoning	I
,	O
anoxia	B
neonatorum	I
,	O
and	O
children	O
's	O
enuresis	B
in	O
China	O
.	O

Although	O
these	O
2	O
generic	O
formulations	O
are	O
marketed	O
in	O
China	O
,	O
information	O
regarding	O
their	O
pharmacokinetics	O
and	O
bioequivalence	O
in	O
humans	O
has	O
not	O
been	O
published	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
pharmacokinetic	O
properties	O
and	O
bioequivalence	O
of	O
the	O
capsule	O
(	O
test	O
)	O
and	O
tablet	O
(	O
reference	O
)	O
formulations	O
of	O
meclofenoxate	O
hydrochloride	O
200	O
mg	O
in	O
healthy	O
Chinese	O
volunteers	O
.	O

METHODS	O
:	O
This	O
single	O
-	O
dose	O
,	O
randomized	O
-	O
sequence	O
,	O
open	O
-	O
label	O
,	O
2	O
-	O
period	O
crossover	O
study	O
was	O
performed	O
at	O
the	O
Nanjing	O
First	O
Hospital	O
of	O
Nanjing	O
Medical	O
University	O
,	O
Nanjing	O
,	O
China	O
.	O

Eligible	O
subjects	O
were	O
healthy	O
male	O
volunteers	O
who	O
were	O
randomly	O
assigned	O
at	O
a	O
1	O
:	O
1	O
ratio	O
to	O
receive	O
a	O
single	O
200	O
-	O
mg	O
dose	O
of	O
the	O
test	O
or	O
reference	O
formulation	O
,	O
followed	O
by	O
a	O
1	O
-	O
week	O
washout	O
period	O
and	O
administration	O
of	O
the	O
alternate	O
formulation	O
.	O

The	O
study	O
drugs	O
were	O
administered	O
after	O
a	O
12	O
-	O
hour	O
overnight	O
fast	O
.	O

As	O
a	O
prodrug	O
,	O
meclofenoxate	O
is	O
hydrolyzed	O
into	O
4	O
-	O
chlorophenoxyacetic	O
acid	O
and	O
is	O
not	O
detected	O
in	O
plasma	O
.	O

The	O
active	O
metabolite	O
of	O
meclofenoxate	O
,	O
chlorophenoxyacetic	O
acid	O
,	O
was	O
assayed	O
using	O
a	O
high	O
-	O
performance	O
liquid	O
chromatography	O
method	O
.	O

For	O
analysis	O
of	O
pharmacokinetic	O
properties	O
,	O
including	O
Cmax	O
,	O
AUC0	O
-	O
24	O
,	O
and	O
AUC0	O
-	O
infinity	O
,	O
blood	O
samples	O
were	O
obtained	O
at	O
0.33	O
,	O
0.67	O
,	O
1	O
,	O
1.5	O
,	O
2	O
,	O
2.5	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
8	O
,	O
10	O
,	O
14	O
,	O
and	O
24	O
hours	O
after	O
administration	O
.	O

The	O
formulations	O
were	O
considered	O
bioequivalent	O
if	O
the	O
log	O
-	O
transformed	O
ratios	O
of	O
Cmax	O
and	O
AUC	O
were	O
within	O
the	O
predetermined	O
equivalence	O
range	O
(	O
80	O
%	O
-	O
125	O
%	O
)	O
as	O
established	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
.	O

Subjects	O
were	O
interviewed	O
concerning	O
the	O
occurrence	O
of	O
adverse	O
events	O
including	O
excitement	B
,	O
insomnia	B
,	O
lassitude	B
,	O
and	O
headache	B
.	O

Tolerability	O
was	O
assessed	O
at	O
baseline	O
(	O
before	O
administration	O
)	O
and	O
at	O
1	O
,	O
2	O
,	O
6	O
,	O
and	O
12	O
hours	O
after	O
administration	O
by	O
monitoring	O
vital	O
signs	O
and	O
laboratory	O
tests	O
(	O
hematology	O
,	O
blood	O
biochemistry	O
,	O
hepatic	O
function	O
,	O
and	O
urinalysis	O
)	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
four	O
Chinese	O
male	O
subjects	O
(	O
mean	O
[	O
range	O
]	O
age	O
,	O
23.5	O
[	O
22	O
-	O
30	O
]	O
years	O
;	O
weight	O
,	O
63.3	O
[	O
56	O
-	O
68	O
]	O
kg	O
;	O
height	O
,	O
171	O
[	O
165	O
-	O
184	O
]	O
cm	O
)	O
were	O
enrolled	O
;	O
all	O
completed	O
the	O
study	O
.	O

No	O
period	O
or	O
sequence	O
effect	O
was	O
observed	O
.	O

The	O
90	O
%	O
CIs	O
for	O
the	O
log	O
-	O
transformed	O
ratios	O
of	O
chlorophenoxyacetic	O
acid	O
Cmax	O
,	O
AUC0	O
-	O
24	O
,	O
and	O
AUC0	O
-	O
infinity	O
were	O
95.7	O
to	O
122.9	O
,	O
97.6	O
to	O
111.9	O
,	O
and	O
97.8	O
to	O
111.7	O
,	O
respectively	O
(	O
all	O
,	O
P	O
>	O
0.05	O
)	O
.	O

Similar	O
results	O
were	O
found	O
for	O
the	O
data	O
without	O
log	O
-	O
transformation	O
.	O

No	O
adverse	O
events	O
were	O
reported	O
or	O
observed	O
during	O
this	O
single	O
-	O
dose	O
study	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
small	O
study	O
in	O
healthy	O
Chinese	O
adult	O
male	O
volunteers	O
,	O
a	O
single	O
200	O
-	O
mg	O
dose	O
of	O
the	O
capsule	O
formulation	O
was	O
found	O
to	O
be	O
bioequivalent	O
to	O
a	O
single	O
200	O
-	O
mg	O
dose	O
of	O
the	O
tablet	O
formulation	O
based	O
on	O
the	O
US	O
FDA	O
's	O
regulatory	O
definition	O
(	O
rate	O
and	O
extent	O
of	O
absorption	O
)	O
.	O

Both	O
formulations	O
were	O
well	O
tolerated	O
.	O

Genotoxicity	O
of	O
topoisomerase	O
II	O
inhibitors	O
:	O
an	O
anti	O
-	O
infective	O
perspective	O
.	O

At	O
present	O
,	O
an	O
inevitable	O
consequence	O
of	O
a	O
chemical	O
's	O
inhibitory	O
activity	O
on	O
key	O
regulators	O
of	O
DNA	O
topology	O
in	O
bacteria	O
,	O
the	O
type	O
II	O
topoisomerases	O
,	O
is	O
a	O
less	O
pronounced	O
effect	O
on	O
their	O
eukaryotic	O
counterparts	O
.	O

In	O
the	O
context	O
of	O
anti	O
-	O
infectives	O
drug	O
development	O
,	O
this	O
may	O
pose	O
a	O
risk	O
to	O
patient	O
safety	O
as	O
inhibition	O
of	O
eukaryotic	O
type	O
II	O
topoisomerases	O
(	O
TOPO	O
II	O
)	O
can	O
result	O
in	O
the	O
generation	O
of	O
DNA	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
,	O
which	O
have	O
the	O
potential	O
to	O
manifest	O
as	O
mutations	O
,	O
chromosome	O
breakage	O
or	O
cell	O
death	O
.	O

The	O
biological	O
effects	O
of	O
several	O
TOPO	O
II	O
inhibitors	O
in	O
mammalian	O
cells	O
are	O
described	O
herein	O
;	O
their	O
modulation	O
of	O
DSB	O
damage	O
response	O
parameters	O
is	O
examined	O
and	O
evidence	O
for	O
the	O
existence	O
of	O
a	O
threshold	O
concept	O
for	O
genotoxicity	B
and	O
its	O
relevance	O
in	O
safety	O
assessment	O
is	O
discussed	O
.	O

The	O
potential	O
utility	O
of	O
gammaH2AX	O
,	O
a	O
promising	O
and	O
highly	O
sensitive	O
molecular	O
marker	O
for	O
DSBs	O
,	O
in	O
a	O
novel	O
genotoxicity	B
'	O
pre	O
-	O
screen	O
'	O
to	O
conventional	O
assays	O
is	O
also	O
highlighted	O
.	O

Anti	O
-	O
inflammatory	O
activity	O
of	O
Crinum	O
asiaticum	O
Linne	O
var	O
.	O

japonicum	O
extract	O
and	O
its	O
application	O
as	O
a	O
cosmeceutical	O
ingredient	O
.	O

Crinum	O
asiaticum	O
Linne	O
var	O
.	O

japonicum	O
has	O
long	O
been	O
used	O
as	O
a	O
rheumatic	O
remedy	O
,	O
as	O
an	O
anti	O
-	O
pyretic	O
and	O
as	O
an	O
anti	O
-	O
ulcer	O
treatment	O
,	O
and	O
for	O
the	O
alleviation	O
of	O
local	B
pain	I
and	O
fever	B
in	O
Korea	O
and	O
Malaysia	O
.	O

In	O
order	O
to	O
investigate	O
the	O
possibility	O
of	O
Crinum	O
asiaticum	O
Linne	O
var	O
.	O

japonicum	O
extract	O
as	O
a	O
cosmetic	O
ingredient	O
,	O
we	O
measured	O
its	O
anti	O
-	O
inflammatory	O
effect	O
by	O
its	O
inhibition	O
of	O
iNOS	O
(	O
inducible	O
nitric	O
oxide	O
synthase	O
)	O
and	O
the	O
release	O
of	O
PGE2	O
,	O
IL	O
-	O
6	O
,	O
and	O
IL	O
-	O
8	O
.	O

We	O
also	O
measured	O
its	O
anti	O
-	O
allergic	O
effect	O
by	O
its	O
inhibition	O
of	O
beta	O
-	O
hexosamidase	O
release	O
.	O

An	O
HPLC	O
experiment	O
after	O
extraction	O
with	O
95	O
%	O
EtOH	O
at	O
pH	O
3.5	O
showed	O
that	O
Crinum	O
asiaticum	O
Linne	O
var	O
.	O

japonicum	O
was	O
mainly	O
composed	O
of	O
lycorine	O
(	O
up	O
to	O
1	O
%	O
)	O
,	O
a	O
well	O
-	O
known	O
immunosuppressor	O
.	O

The	O
content	O
of	O
lycorine	O
varied	O
,	O
depending	O
on	O
the	O
type	O
of	O
plant	O
tissue	O
analyzed	O
and	O
the	O
extraction	O
method	O
.	O

In	O
an	O
anti	O
-	O
inflammatory	O
assay	O
for	O
inhibition	O
of	O
nitric	O
oxide	O
formation	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
activated	O
mouse	O
macrophage	O
RAW	O
264.7	O
cells	O
,	O
the	O
ethanol	O
extract	O
of	O
Crinum	O
asiaticum	O
showed	O
an	O
inhibitory	O
activity	O
of	O
NO	O
production	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC50	O
=	O
58.5	O
microg	O
/	O
ml	O
)	O
.	O

Additional	O
study	O
by	O
RT	O
-	O
PCR	O
demonstrated	O
that	O
the	O
extract	O
of	O
Crinum	O
asiaticum	O
significantly	O
suppressed	O
the	O
expression	O
of	O
the	O
iNOS	O
gene	O
.	O

Moreover	O
,	O
the	O
extract	O
of	O
Crinum	O
asiaticum	O
did	O
not	O
show	O
any	O
cytotoxicity	B
,	O
but	O
did	O
show	O
a	O
cell	O
proliferation	O
effect	O
against	O
LPS	O
(	O
a	O
10	O
approximately	O
60	O
%	O
increase	O
in	O
cell	O
viability	O
)	O
.	O

In	O
an	O
assay	O
to	O
determine	O
inhibition	O
of	O
the	O
H2O2	O
-	O
activated	O
release	O
of	O
PGE2	O
,	O
IL	O
-	O
6	O
,	O
and	O
IL	O
-	O
8	O
in	O
human	O
normal	O
fibroblast	O
cell	O
lines	O
,	O
the	O
release	O
of	O
PGE2	O
and	O
IL	O
-	O
6	O
was	O
almost	O
completely	O
inhibited	O
above	O
concentrations	O
of	O
0.05	O
%	O
and	O
1	O
%	O
,	O
respectively	O
.	O

Moreover	O
,	O
the	O
release	O
of	O
IL	O
-	O
8	O
was	O
completely	O
inhibited	O
over	O
the	O
entire	O
range	O
of	O
concentration	O
(	O
>	O
0.0025	O
%	O
)	O
.	O

In	O
order	O
to	O
investigate	O
the	O
skin	O
-	O
sensitizing	O
potentials	O
of	O
the	O
extract	O
of	O
Crinum	O
asiaticum	O
,	O
a	O
human	O
clinical	O
test	O
was	O
performed	O
after	O
repeated	O
epicutaneous	O
48	O
-	O
h	O
applications	O
under	O
an	O
occlusive	O
patch	O
(	O
RIPT	O
)	O
.	O

The	O
repeated	O
and	O
single	O
cutaneous	O
applications	O
of	O
Crinum	O
asiaticum	O
Linne	O
var	O
.	O

japonicum	O
extract	O
under	O
the	O
occlusive	O
patch	O
did	O
not	O
provoke	O
any	O
cumulative	O
irritation	O
and	O
sensitization	O
reactions	O
.	O

The	O
result	O
showed	O
that	O
the	O
extract	O
of	O
Crinum	O
asiaticum	O
Linne	O
var	O
.	O

japonicum	O
has	O
a	O
sufficient	O
anti	O
-	O
inflammatory	O
effect	O
.	O

Therefore	O
,	O
Crinum	O
asiaticum	O
Linne	O
var	O
.	O

japonicum	O
extract	O
may	O
be	O
useful	O
for	O
development	O
as	O
an	O
ingredient	O
in	O
cosmetic	O
products	O
.	O

WITHDRAWN	O
:	O
Multi	O
-	O
agent	O
chemotherapy	O
for	O
early	O
breast	B
cancer	I
.	O

BACKGROUND	O
:	O
There	O
have	O
been	O
many	O
randomised	O
trials	O
of	O
adjuvant	O
prolonged	O
polychemotherapy	O
among	O
women	O
with	O
early	O
breast	B
cancer	I
,	O
and	O
an	O
updated	O
overview	O
of	O
their	O
results	O
is	O
presented	O
.	O

OBJECTIVES	O
:	O
In	O
this	O
report	O
,	O
the	O
Early	O
Breast	B
Cancer	I
Trialists	O
'	O
Collaborative	O
Group	O
present	O
their	O
updated	O
systematic	O
overview	O
(	O
meta	O
-	O
analysis	O
)	O
of	O
treatment	O
with	O
polychemotherapy	O
.	O

SEARCH	O
STRATEGY	O
:	O
Trial	O
identification	O
procedures	O
for	O
the	O
EBCTCG	O
overviews	O
have	O
been	O
described	O
elsewhere	O
.	O

See	O
under	O
""""	O
EBCTCG	O
""""	O
in	O
the	O
Breast	B
Cancer	I
Collaborative	O
Review	O
Group	O
module	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
randomised	O
trials	O
that	O
began	O
before	O
1990	O
and	O
involved	O
treatment	O
groups	O
that	O
differed	O
only	O
with	O
respect	O
to	O
the	O
chemotherapy	O
regimens	O
that	O
were	O
being	O
compared	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
In	O
1995	O
,	O
information	O
was	O
sought	O
on	O
each	O
woman	O
in	O
any	O
randomised	O
trial	O
that	O
began	O
before	O
1990	O
and	O
involved	O
treatment	O
groups	O
that	O
differed	O
only	O
with	O
respect	O
to	O
the	O
chemotherapy	O
regimens	O
that	O
were	O
being	O
compared	O
.	O

Analyses	O
involved	O
about	O
18,000	O
women	O
in	O
47	O
trials	O
of	O
prolonged	O
polychemotherapy	O
versus	O
no	O
chemotherapy	O
,	O
about	O
6000	O
in	O
11	O
trials	O
of	O
longer	O
versus	O
shorter	O
polychemotherapy	O
,	O
and	O
about	O
6000	O
in	O
11	O
trials	O
of	O
anthracycline	O
-	O
containing	O
regimens	O
versus	O
CMF	O
(	O
cyclophosphamide	O
,	O
methotrexate	O
,	O
and	O
fluorouracil	O
)	O
.	O

MAIN	O
RESULTS	O
:	O
For	O
recurrence	O
,	O
polychemotherapy	O
produced	O
substantial	O
and	O
highly	O
significant	O
proportional	O
reductions	O
both	O
among	O
women	O
aged	O
under	O
50	O
at	O
randomisation	O
(	O
35	O
%	O
[	O
SD	O
4	O
]	O
reduction	O
;	O
2p	O
<	O
0.00001	O
)	O
and	O
among	O
those	O
aged	O
50	O
-	O
69	O
(	O
20	O
%	O
[	O
SD	O
3	O
]	O
reduction	O
;	O
2p	O
<	O
0.00001	O
)	O
;	O
few	O
women	O
aged	O
70	O
or	O
over	O
had	O
been	O
studied	O
.	O

For	O
mortality	O
,	O
the	O
reductions	O
were	O
also	O
significant	O
both	O
among	O
women	O
aged	O
under	O
50	O
(	O
27	O
%	O
[	O
SD	O
5	O
]	O
reduction	O
;	O
2p	O
<	O
0.00001	O
)	O
and	O
among	O
those	O
aged	O
50	O
-	O
69	O
(	O
11	O
%	O
[	O
SD	O
3	O
]	O
reduction	O
;	O
2p	O
=	O
0.0001	O
)	O
.	O

The	O
recurrence	O
reductions	O
emerged	O
chiefly	O
during	O
the	O
first	O
5	O
years	O
of	O
follow	O
-	O
up	O
,	O
whereas	O
the	O
difference	O
in	O
survival	O
grew	O
throughout	O
the	O
first	O
10	O
years	O
.	O

After	O
standardisation	O
for	O
age	O
and	O
time	O
since	O
randomisation	O
,	O
the	O
proportional	O
reductions	O
in	O
risk	O
were	O
similar	O
for	O
women	O
with	O
node	O
-	O
negative	O
and	O
node	O
-	O
positive	O
disease	O
.	O

Applying	O
the	O
proportional	O
mortality	O
reduction	O
observed	O
in	O
all	O
women	O
aged	O
under	O
50	O
at	O
randomisation	O
would	O
typically	O
change	O
a	O
10	O
-	O
year	O
survival	O
of	O
71	O
%	O
for	O
those	O
with	O
node	O
-	O
negative	O
disease	O
to	O
78	O
%	O
(	O
an	O
absolute	O
benefit	O
of	O
7	O
%	O
)	O
,	O
and	O
of	O
42	O
%	O
for	O
those	O
with	O
node	O
-	O
positive	O
disease	O
to	O
53	O
%	O
(	O
an	O
absolute	O
benefit	O
of	O
11	O
%	O
)	O
.	O

The	O
smaller	O
proportional	O
mortality	O
reduction	O
observed	O
in	O
all	O
women	O
aged	O
50	O
-	O
69	O
at	O
randomisation	O
would	O
translate	O
into	O
smaller	O
absolute	O
benefits	O
,	O
changing	O
a	O
10	O
-	O
year	O
survival	O
of	O
67	O
%	O
for	O
those	O
with	O
node	O
-	O
negative	O
disease	O
to	O
69	O
%	O
(	O
an	O
absolute	O
gain	O
of	O
2	O
%	O
)	O
and	O
of	O
46	O
%	O
for	O
those	O
with	O
node	O
-	O
positive	O
disease	O
to	O
49	O
%	O
(	O
an	O
absolute	O
gain	O
of	O
3	O
%	O
)	O
.	O

The	O
age	O
-	O
specific	O
benefits	O
of	O
polychemotherapy	O
appeared	O
to	O
be	O
largely	O
irrespective	O
of	O
menopausal	O
status	O
at	O
presentation	O
,	O
oestrogen	O
receptor	O
status	O
of	O
the	O
primary	O
tumour	O
,	O
and	O
of	O
whether	O
adjuvant	O
tamoxifen	O
had	O
been	O
given	O
.	O

In	O
terms	O
of	O
other	O
outcomes	O
,	O
there	O
was	O
a	O
reduction	O
of	O
about	O
one	O
-	O
fifth	O
(	O
2p	O
=	O
0.05	O
)	O
in	O
contralateral	B
breast	I
cancer	I
,	O
which	O
has	O
already	O
been	O
included	O
in	O
the	O
analyses	O
of	O
recurrence	O
,	O
and	O
no	O
apparent	O
adverse	O
effect	O
on	O
deaths	O
from	O
causes	O
other	O
than	O
breast	B
cancer	I
(	O
death	O
rate	O
ratio	O
0.89	O
[	O
SD	O
0.09	O
]	O
)	O
.	O

The	O
directly	O
randomised	O
comparisons	O
of	O
longer	O
versus	O
shorter	O
durations	O
of	O
polychemotherapy	O
did	O
not	O
indicate	O
any	O
survival	O
advantage	O
with	O
the	O
use	O
of	O
more	O
than	O
about	O
3	O
-	O
6	O
months	O
of	O
polychemotherapy	O
.	O

By	O
contrast	O
,	O
directly	O
randomised	O
comparisons	O
did	O
suggest	O
that	O
,	O
compared	O
with	O
CMF	O
alone	O
,	O
the	O
anthracycline	O
-	O
containing	O
regimens	O
studied	O
produced	O
somewhat	O
greater	O
effects	O
on	O
recurrence	O
(	O
2p	O
=	O
0.006	O
)	O
and	O
mortality	O
(	O
69	O
%	O
vs	O
72	O
%	O
5	O
-	O
year	O
survival	O
;	O
log	O
-	O
rank	O
2p	O
=	O
0.02	O
)	O
.	O

But	O
this	O
comparison	O
is	O
one	O
of	O
many	O
that	O
could	O
have	O
been	O
selected	O
for	O
emphasis	O
,	O
the	O
99	O
%	O
CI	O
reaches	O
zero	O
,	O
and	O
the	O
results	O
of	O
several	O
of	O
the	O
relevant	O
trials	O
are	O
not	O
yet	O
available	O
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
Some	O
months	O
of	O
adjuvant	O
polychemotherapy	O
(	O
eg	O
,	O
with	O
CMF	O
or	O
an	O
anthracycline	O
-	O
containing	O
regimen	O
)	O
typically	O
produces	O
an	O
absolute	O
improvement	O
of	O
about	O
7	O
-	O
11	O
%	O
in	O
10	O
-	O
year	O
survival	O
for	O
women	O
aged	O
under	O
50	O
at	O
presentation	O
with	O
early	O
breast	B
cancer	I
,	O
and	O
of	O
about	O
2	O
-	O
3	O
%	O
for	O
those	O
aged	O
50	O
-	O
69	O
(	O
unless	O
their	O
prognosis	O
is	O
likely	O
to	O
be	O
extremely	O
good	O
even	O
without	O
such	O
treatment	O
)	O
.	O

Treatment	O
decisions	O
involve	O
consideration	O
not	O
only	O
of	O
improvements	O
in	O
cancer	B
recurrence	O
and	O
survival	O
but	O
also	O
of	O
adverse	O
side	O
-	O
effects	O
of	O
treatment	O
,	O
and	O
this	O
report	O
makes	O
no	O
recommendations	O
as	O
to	O
who	O
should	O
or	O
should	O
not	O
be	O
treated	O
.	O

Vitamin	O
D	O
:	O
criteria	O
for	O
safety	O
and	O
efficacy	O
.	O

The	O
functional	O
status	O
indicator	O
for	O
vitamin	O
D	O
,	O
for	O
both	O
safety	O
and	O
efficacy	O
,	O
is	O
serum	O
25	O
-	O
hydroxyvitamin	O
D	O
concentration	O
.	O

Efficacy	O
for	O
several	O
health	O
endpoints	O
requires	O
levels	O
of	O
80	O
nmol	O
/	O
L	O
or	O
higher	O
.	O

Toxicity	O
occurs	O
at	O
levels	O
of	O
500	O
nmol	O
/	O
L	O
or	O
higher	O
.	O

The	O
input	O
needed	O
for	O
efficacy	O
,	O
in	O
addition	O
to	O
typical	O
food	O
and	O
cutaneous	O
inputs	O
,	O
will	O
usually	O
be	O
1000	O
-	O
2000	O
IU	O
/	O
day	O
of	O
supplemental	O
cholecalciferol	O
.	O

Toxicity	O
is	O
associated	O
only	O
with	O
excessive	O
supplemental	O
intake	O
(	O
usually	O
well	O
above	O
20,000	O
IU	O
/	O
day	O
)	O
.	O

Fragrance	O
material	O
review	O
on	O
2	O
-	O
(	O
1	O
-	O
methylpropyl	O
)	O
-	O
1	O
-	O
vinylcyclohexyl	O
acetate	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
2	O
-	O
(	O
1	O
-	O
methylpropyl	O
)	O
-	O
1	O
-	O
vinylcyclohexyl	O
acetate	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

Hg2	O
+	O
and	O
Cd2	O
+	O
interact	O
differently	O
with	O
biomimetic	O
erythrocyte	O
membranes	O
.	O

In	O
order	O
to	O
characterize	O
the	O
potentially	O
deleterious	O
effects	O
of	O
toxic	O
Hg	O
(	O
2	O
+	O
)	O
and	O
Cd	O
(	O
2	O
+	O
)	O
on	O
lipid	O
membranes	O
,	O
we	O
have	O
studied	O
their	O
binding	O
to	O
liposomes	O
whose	O
composition	O
mimicked	O
erythrocyte	O
membranes	O
.	O

Fluorescence	O
spectroscopy	O
utilizing	O
the	O
concentration	O
dependent	O
quenching	O
of	O
Phen	O
Green	O
SK	O
by	O
Hg	O
(	O
2	O
+	O
)	O
and	O
Cd	O
(	O
2	O
+	O
)	O
was	O
found	O
to	O
be	O
a	O
sensitive	O
tool	O
to	O
probe	O
these	O
interactions	O
at	O
metal	O
concentrations	O
<	O
or	O
=	O
1	O
microM	O
.	O

We	O
have	O
systematically	O
developed	O
a	O
metal	O
binding	O
affinity	O
assay	O
to	O
screen	O
for	O
the	O
interactions	O
of	O
Hg	O
(	O
2	O
+	O
)	O
or	O
Cd	O
(	O
2	O
+	O
)	O
with	O
certain	O
lipid	O
classes	O
.	O

A	O
biomimetic	O
liposome	O
system	O
was	O
developed	O
that	O
contained	O
four	O
major	O
lipid	O
classes	O
of	O
erythrocyte	O
membranes	O
(	O
zwitterionic	O
lipids	O
:	O
phosphatidylcholine	O
and	O
phosphatidylethanolamine	O
;	O
negatively	O
charged	O
:	O
phosphatidylserine	O
and	O
neutral	O
:	O
cholesterol	O
)	O
.	O

In	O
contrast	O
to	O
Hg	O
(	O
2	O
+	O
)	O
,	O
which	O
preferentially	O
bound	O
to	O
the	O
negatively	O
charged	O
phosphatidylserine	O
compared	O
to	O
the	O
zwitterionic	O
components	O
,	O
Cd	O
(	O
2	O
+	O
)	O
bound	O
stronger	O
to	O
the	O
two	O
zwitterionic	O
lipids	O
.	O

Thus	O
,	O
the	O
observed	O
distinct	O
differences	O
in	O
the	O
binding	O
affinity	O
of	O
Hg	O
(	O
2	O
+	O
)	O
and	O
Cd	O
(	O
2	O
+	O
)	O
for	O
certain	O
lipid	O
classes	O
together	O
with	O
their	O
known	O
effects	O
on	O
membrane	O
properties	O
represent	O
an	O
important	O
first	O
step	O
toward	O
a	O
better	O
understanding	O
the	O
role	O
of	O
these	O
interactions	O
in	O
the	O
chronic	B
toxicity	I
of	O
these	O
metals	O
.	O

Lack	O
of	O
therapeutic	O
effect	O
of	O
the	O
histone	O
deacetylase	O
inhibitor	O
vorinostat	O
in	O
patients	O
with	O
metastatic	B
radioiodine	I
-	I
refractory	I
thyroid	I
carcinoma	I
.	O

CONTEXT	O
:	O
Aberrant	O
histone	O
deacetylase	O
activity	O
is	O
seen	O
in	O
a	O
variety	O
of	O
malignancies	O
,	O
and	O
histone	O
deacetylase	O
inhibitors	O
such	O
as	O
vorinostat	O
have	O
been	O
shown	O
to	O
induce	O
cell	O
death	O
and	O
sensitize	O
cells	O
to	O
cytotoxic	O
chemotherapy	O
in	O
thyroid	O
cancer	O
cell	O
lines	O
.	O

This	O
phase	O
II	O
study	O
was	O
undertaken	O
to	O
assess	O
objective	O
response	O
to	O
vorinostat	O
in	O
patients	O
with	O
advanced	O
thyroid	B
cancer	I
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
A	O
total	O
of	O
19	O
patients	O
with	O
differentiated	B
thyroid	I
cancer	I
(	O
n	O
=	O
16	O
)	O
and	O
medullary	B
thyroid	I
cancer	I
(	O
n	O
=	O
3	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Patients	O
received	O
oral	O
vorinostat	O
at	O
a	O
starting	O
dose	O
of	O
200	O
mg	O
twice	O
daily	O
,	O
with	O
dose	O
adjustments	O
allowed	O
as	O
necessary	O
for	O
toxicity	O
.	O

Patients	O
were	O
treated	O
for	O
2	O
wk	O
,	O
followed	O
by	O
1	O
wk	O
off	O
therapy	O
(	O
3	O
-	O
wk	O
cycle	O
)	O
until	O
disease	O
progression	O
or	O
study	O
withdrawal	O
.	O

Responses	O
were	O
measured	O
by	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
criteria	O
and	O
correlated	O
with	O
tumor	O
markers	O
.	O

RESULTS	O
:	O
No	O
patient	O
achieved	O
a	O
partial	O
or	O
complete	O
response	O
.	O

Median	O
duration	O
of	O
therapy	O
in	O
patients	O
with	O
differentiated	B
thyroid	I
cancer	I
was	O
17	O
wk	O
,	O
whereas	O
in	O
medullary	B
thyroid	I
cancer	I
patients	O
it	O
was	O
25	O
wk	O
.	O

Reasons	O
for	O
termination	O
included	O
progression	O
of	O
disease	O
by	O
RECIST	O
criteria	O
(	O
n	O
=	O
7	O
)	O
,	O
clinical	O
progression	O
(	O
n	O
=	O
3	O
)	O
,	O
and	O
adverse	O
events	O
(	O
AEs	O
)	O
(	O
n	O
=	O
9	O
)	O
.	O

AEs	O
were	O
primarily	O
grade	O
1	O
-	O
3	O
;	O
no	O
clinical	O
grade	O
4	O
or	O
grade	O
5	O
events	O
were	O
observed	O
.	O

Clinical	O
grade	O
3	O
AEs	O
consisted	O
of	O
fatigue	B
,	O
dehydration	B
,	O
ataxia	B
,	O
pneumonia	B
,	O
bruises	B
,	O
and	O
deep	B
vein	I
thrombosis	I
.	O

Severe	O
thrombocytopenia	B
was	O
seen	O
in	O
seven	O
patients	O
(	O
grade	O
3	O
,	O
n	O
=	O
5	O
;	O
grade	O
4	O
,	O
n	O
=	O
2	O
)	O
and	O
was	O
associated	O
with	O
minor	O
bleeding	B
or	O
bruises	B
.	O

CONCLUSIONS	O
:	O
Vorinostat	O
at	O
this	O
dose	O
and	O
schedule	O
is	O
not	O
an	O
effective	O
treatment	O
for	O
advanced	O
thyroid	B
cancer	I
.	O

Changes	O
in	O
retinal	O
sensitivity	O
from	O
retained	O
subretinal	O
perfluorocarbon	O
liquid	O
.	O

PURPOSE	O
:	O
To	O
study	O
the	O
effect	O
of	O
retained	O
subretinal	O
perfluorocarbon	O
liquid	O
(	O
PFCL	O
)	O
on	O
retinal	O
function	O
.	O

METHODS	O
:	O
Scanning	O
laser	O
ophthalmoscope	O
microperimetry	O
was	O
performed	O
on	O
four	O
eyes	O
with	O
retained	O
subretinal	O
PFCL	O
after	O
vitreoretinal	O
surgery	O
for	O
complicated	O
retinal	O
detachments	O
with	O
and	O
without	O
proliferative	B
vitreoretinopathy	I
.	O

RESULTS	O
:	O
Scotomas	O
to	O
the	O
highest	O
intensity	O
stimulus	O
were	O
noted	O
in	O
the	O
area	O
of	O
the	O
subretinal	O
PFCL	O
in	O
all	O
four	O
eyes	O
.	O

All	O
scotomas	O
encompassed	O
approximately	O
the	O
same	O
area	O
as	O
the	O
retained	O
PFCL	O
droplets	O
.	O

In	O
the	O
area	O
vacated	O
by	O
a	O
migrating	O
PFCL	O
droplet	O
in	O
one	O
eye	O
,	O
the	O
highest	O
intensity	O
stimulus	O
could	O
be	O
perceived	O
,	O
but	O
a	O
relative	O
scotoma	B
(	O
to	O
a	O
lower	O
intensity	O
stimulus	O
)	O
was	O
present	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
a	O
local	O
reduction	O
in	O
retinal	O
function	O
in	O
the	O
area	O
of	O
retained	O
subretinal	O
PFCL	O
.	O

There	O
may	O
be	O
partial	O
recovery	O
of	O
retinal	O
function	O
in	O
an	O
area	O
vacated	O
by	O
the	O
subretinal	O
PFCL	O
.	O

Subretinal	O
PFCL	O
beneath	O
the	O
fovea	O
or	O
at	O
risk	O
for	O
migration	O
beneath	O
the	O
fovea	O
should	O
be	O
considered	O
for	O
removal	O
.	O

The	O
effect	O
of	O
trandolapril	O
and	O
its	O
fixed	O
-	O
dose	O
combination	O
with	O
verapamil	O
on	O
circulating	O
adhesion	O
molecules	O
levels	O
in	O
hypertensive	O
patients	O
with	O
type	B
2	I
diabetes	I
.	O

BACKGROUND	O
AND	O
AIM	O
:	O
Endothelial	B
dysfunction	I
in	O
hypertensive	O
type	O
-	O
2	O
diabetic	O
patients	O
is	O
associated	O
with	O
increased	O
levels	O
of	O
circulating	O
soluble	O
adhesion	O
molecules	O
(	O
SAM	O
)	O
.	O

SAM	O
participate	O
in	O
the	O
development	O
of	O
diabetic	B
macroangiopathy	I
and	O
microangiopathy	B
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effect	O
of	O
trandolapril	O
(	O
T	O
)	O
and	O
its	O
fixed	O
-	O
dose	O
combination	O
with	O
verapamil	O
(	O
FDTV	O
)	O
on	O
SAM	O
levels	O
in	O
hypertensive	O
type	O
-	O
2	O
diabetic	O
patients	O
.	O

METHODS	O
:	O
Forty	O
type	O
-	O
2	O
diabetic	O
patients	O
with	O
never	O
-	O
treated	O
hypertension	B
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
.	O

One	O
group	O
(	O
FDTV	O
)	O
received	O
2	O
/	O
180	O
mg	O
once	O
a	O
day	O
;	O
the	O
other	O
group	O
received	O
T	O
2	O
mg	O
once	O
a	O
day	O
.	O

Study	O
drugs	O
were	O
administered	O
for	O
three	O
months	O
in	O
both	O
groups	O
.	O

VCAM	O
-	O
1	O
,	O
ICAM	O
,	O
and	O
E	O
-	O
selectin	O
were	O
measured	O
by	O
ELISA	O
at	O
the	O
beginning	O
and	O
end	O
of	O
the	O
study	O
.	O

Patients	O
were	O
evaluated	O
monthly	O
for	O
blood	O
pressure	O
,	O
fasting	O
serum	O
glucose	O
,	O
and	O
adverse	O
events	O
.	O

Statistical	O
analysis	O
was	O
performed	O
with	O
ANOVA	O
.	O

RESULTS	O
:	O
Both	O
therapeutics	O
regimens	O
reduced	O
significantly	O
the	O
levels	O
of	O
the	O
SAM	O
tested	O
.	O

When	O
both	O
groups	O
were	O
compared	O
,	O
we	O
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
ICAM	O
and	O
E	O
-	O
selectin	O
reduction	O
.	O

However	O
,	O
VCAM	O
-	O
1	O
presented	O
a	O
significantly	O
greater	O
reduction	O
(	O
p	O
=	O
0.022	O
)	O
in	O
the	O
trandolapril	O
-	O
verapamil	O
group	O
.	O

No	O
patient	O
suffered	O
adverse	O
events	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
that	O
FDTV	O
produces	O
a	O
greater	O
reduction	O
of	O
VCAM	O
-	O
1	O
circulating	O
levels	O
than	O
trandolapril	O
alone	O
.	O

This	O
may	O
explain	O
some	O
of	O
the	O
beneficial	O
effects	O
of	O
this	O
fixed	O
dosed	O
combination	O
that	O
are	O
non	O
-	O
related	O
to	O
its	O
antihypertensive	O
effects	O
.	O

Contraception	O
in	O
women	O
with	O
epilepsy	B
:	O
pharmacokinetic	O
interactions	O
,	O
contraceptive	O
options	O
,	O
and	O
management	O
.	O

Contraceptive	O
counseling	O
is	O
a	O
critical	O
component	O
of	O
the	O
management	O
of	O
the	O
female	O
patient	O
with	O
epilepsy	B
because	O
of	O
the	O
increased	O
risk	O
of	O
pregnancy	O
associated	O
with	O
epilepsy	B
and	O
the	O
multitude	O
of	O
interactions	O
between	O
antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
and	O
hormonal	O
contraception	O
.	O

Steroid	O
hormones	O
and	O
many	O
of	O
the	O
AEDs	O
are	O
substrates	O
for	O
the	O
cytochrome	O
P450	O
enzyme	O
system	O
,	O
in	O
particular	O
,	O
the	O
3A4	O
isoenzyme	O
.	O

As	O
a	O
result	O
,	O
concomitant	O
use	O
of	O
hormonal	O
contraceptives	O
and	O
AEDs	O
may	O
pose	O
a	O
risk	O
for	O
unexpected	B
pregnancy	I
,	O
seizures	B
,	O
and	O
drug	O
-	O
related	O
adverse	O
effects	O
.	O

The	O
risk	O
of	O
combined	O
oral	O
contraceptive	O
(	O
COC	O
)	O
failure	O
is	O
slightly	O
increased	O
in	O
the	O
presence	O
of	O
cytochrome	O
P450	O
3A4	O
enzyme	O
-	O
inducing	O
AEDs	O
.	O

Several	O
AEDs	O
induce	O
the	O
production	O
of	O
sex	O
hormone	O
binding	O
globulin	O
(	O
SHBG	O
)	O
to	O
which	O
the	O
progestins	O
are	O
tightly	O
bound	O
,	O
resulting	O
in	O
lower	O
concentrations	O
of	O
free	O
progestin	O
that	O
may	O
also	O
lead	O
to	O
COC	O
failure	O
.	O

There	O
is	O
no	O
increase	O
in	O
the	O
risk	O
of	O
COC	O
failure	O
in	O
women	O
taking	O
nonenzyme	O
-	O
inducing	O
AEDs	O
.	O

Oral	O
contraceptives	O
significantly	O
increase	O
the	O
metabolism	O
of	O
lamotrigine	O
,	O
posing	O
a	O
risk	O
of	O
seizures	B
when	O
hormonal	O
agents	O
are	O
initiated	O
and	O
/	O
or	O
toxicity	O
during	O
pill	O
-	O
free	O
weeks	O
.	O

There	O
is	O
no	O
evidence	O
that	O
COCs	O
increase	O
seizures	B
in	O
women	O
with	O
epilepsy	B
.	O

While	O
higher	O
dose	O
COCs	O
are	O
one	O
contraceptive	O
option	O
for	O
women	O
on	O
enzyme	O
-	O
inducing	O
AEDs	O
,	O
a	O
variety	O
of	O
other	O
options	O
are	O
available	O
.	O

Injectable	O
contraception	O
(	O
depot	O
medroxyprogesterone	O
acetate	O
)	O
appears	O
effective	O
with	O
AED	O
use	O
,	O
but	O
the	O
potential	O
for	O
bone	O
mineral	O
density	O
loss	O
is	O
a	O
concern	O
.	O

Intrauterine	O
devices	O
(	O
IUDs	O
)	O
and	O
barrier	O
methods	O
do	O
not	O
rely	O
on	O
hormonal	O
components	O
for	O
contraceptive	O
efficacy	O
,	O
and	O
are	O
therefore	O
appropriate	O
to	O
recommend	O
for	O
use	O
in	O
women	O
using	O
enzyme	O
-	O
inducing	O
medications	O
.	O

This	O
chapter	O
reviews	O
the	O
evidence	O
regarding	O
the	O
pharmacokinetic	O
interaction	O
between	O
AEDs	O
and	O
oral	O
contraceptive	O
hormones	O
,	O
the	O
known	O
or	O
potential	O
interactions	O
with	O
alternative	O
contraceptive	O
methods	O
,	O
and	O
provides	O
practical	O
advice	O
for	O
management	O
of	O
contraceptive	O
needs	O
in	O
reproductive	O
-	O
age	O
women	O
.	O

Sexual	B
dysfunction	I
in	O
women	O
with	O
epilepsy	B
:	O
role	O
of	O
antiepileptic	O
drugs	O
and	O
psychotropic	O
medications	O
.	O

Sexual	B
dysfunction	I
is	O
a	O
frequently	O
encountered	O
comorbid	O
disorder	O
in	O
patients	O
with	O
neurological	O
and	O
psychiatric	B
disorders	I
.	O

Importantly	O
,	O
sexual	B
dysfunction	I
can	O
also	O
occur	O
as	O
a	O
treatment	O
emergent	O
adverse	O
effect	O
of	O
a	O
number	O
of	O
commonly	O
used	O
psychotropic	O
and	O
antiepileptic	O
medications	O
,	O
and	O
can	O
include	O
decreased	B
libido	I
,	O
erectile	B
dysfunction	I
,	O
disordered	B
arousal	I
,	O
delayed	B
orgasm	I
,	O
and	O
anorgasmia	B
.	O

These	O
effects	O
can	O
occur	O
in	O
both	O
men	O
and	O
women	O
,	O
and	O
can	O
be	O
seen	O
across	O
age	O
groups	O
.	O

Understanding	O
the	O
neurobiology	O
of	O
normal	O
sexual	O
response	O
,	O
as	O
well	O
as	O
the	O
pharmacologic	O
mechanisms	O
of	O
these	O
commonly	O
used	O
medications	O
can	O
enable	O
the	O
clinician	O
to	O
predict	O
how	O
medication	O
use	O
may	O
impact	O
different	O
phases	O
of	O
sexual	O
response	O
.	O

Discussion	O
of	O
the	O
current	O
treatment	O
strategies	O
for	O
female	B
sexual	I
dysfunction	I
is	O
also	O
elucidated	O
in	O
this	O
chapter	O
.	O

Parkinsonism	B
during	O
cyclosporine	O
treatment	O
in	O
liver	O
transplantation	O
:	O
an	O
unusual	O
case	O
report	O
.	O

OBJECTIVES	O
:	O
Cyclosporine	O
(	O
CyA	O
)	O
has	O
been	O
associated	O
with	O
various	O
neurological	O
reactions	O
but	O
parkinsonism	B
is	O
not	O
generally	O
recognized	O
as	O
a	O
nervous	O
system	O
side	O
effect	O
.	O

We	O
describe	O
herein	O
a	O
rare	O
case	O
,	O
in	O
that	O
the	O
patient	O
developed	O
parkinsonism	B
with	O
rest	B
tremor	I
after	O
receiving	O
CyA	O
following	O
orthotopic	O
liver	O
transplantation	O
(	O
OLT	O
)	O
.	O

METHODS	O
:	O
The	O
patient	O
was	O
a	O
42	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
liver	B
cirrhosis	I
with	O
hepatitis	B
C	I
.	O

We	O
performed	O
OLT	O
because	O
of	O
liver	B
failure	I
and	O
started	O
immunosuppressive	O
therapy	O
with	O
CyA	O
+	O
methylprednisolone	O
+	O
CD25	O
antibody	O
.	O

Ten	O
days	O
after	O
OLT	O
,	O
he	O
developed	O
parkinsonism	B
with	O
a	O
rest	B
tremor	I
.	O

The	O
patient	O
did	O
not	O
have	O
a	O
pre	O
-	O
existent	O
neurological	B
disorder	I
,	O
and	O
had	O
not	O
received	O
significant	O
amounts	O
of	O
dopamine	O
-	O
blocking	O
drugs	O
.	O

RESULTS	O
:	O
We	O
administered	O
levodopa	O
with	O
marked	O
improvement	O
.	O

Three	O
days	O
after	O
that	O
event	O
,	O
the	O
neurologist	O
suggested	O
the	O
possibility	O
of	O
drug	O
-	O
induced	O
parkinsonism	B
.	O

We	O
converted	O
the	O
immunosuppressive	O
drug	O
from	O
CyA	O
to	O
tacrolimus	O
.	O

After	O
that	O
,	O
the	O
symptom	O
disappeared	O
.	O

At	O
75	O
days	O
after	O
OLT	O
,	O
he	O
was	O
discharged	O
with	O
no	O
neurological	O
medication	O
and	O
now	O
he	O
is	O
completely	O
recovered	O
.	O

CONCLUSION	O
:	O
We	O
think	O
that	O
parkinsonism	B
may	O
be	O
an	O
occasional	O
consequence	O
of	O
CyA	O
because	O
of	O
its	O
relation	O
to	O
withdrawal	O
of	O
the	O
drug	O
and	O
the	O
lack	O
of	O
another	O
evident	O
cause	O
.	O

Medaka	O
(	O
Oryzias	O
latipes	O
)	O
as	O
a	O
sentinel	O
species	O
for	O
aquatic	O
animals	O
:	O
Medaka	O
cells	O
exhibit	O
a	O
similar	O
genotoxic	O
response	O
as	O
North	O
Atlantic	O
right	O
whale	O
cells	O
.	O

Hexavalent	O
chromium	O
(	O
Cr	O
(	O
VI	O
)	O
)	O
is	O
emerging	O
as	O
a	O
major	O
concern	O
for	O
aquatic	O
environments	O
,	O
particularly	O
marine	O
environments	O
.	O

Medaka	O
(	O
Oryzias	O
latipes	O
)	O
has	O
been	O
used	O
as	O
a	O
model	O
species	O
for	O
human	O
and	O
aquatic	O
health	O
,	O
including	O
the	O
marine	O
environment	O
,	O
though	O
few	O
studies	O
have	O
directly	O
compared	O
toxicological	O
responses	O
in	O
medaka	O
to	O
humans	O
or	O
other	O
aquatic	O
species	O
.	O

We	O
used	O
a	O
medaka	O
fin	O
cell	O
line	O
to	O
compare	O
the	O
genotoxic	O
response	O
of	O
medaka	O
to	O
Cr	O
(	O
VI	O
)	O
to	O
the	O
response	O
observed	O
in	O
North	O
Atlantic	O
right	O
whale	O
cells	O
to	O
see	O
if	O
responses	O
in	O
medaka	O
were	O
similar	O
to	O
those	O
of	O
other	O
aquatic	O
species	O
,	O
particularly	O
aquatic	O
mammals	O
.	O

We	O
used	O
the	O
production	O
of	O
chromosomal	O
aberrations	O
as	O
a	O
measure	O
of	O
genotoxicity	B
.	O

We	O
found	O
that	O
in	O
medaka	O
cells	O
,	O
concentrations	O
of	O
1	O
,	O
5	O
and	O
10	O
microM	O
sodium	O
chromate	O
damaged	O
17	O
,	O
32	O
and	O
43	O
%	O
of	O
metaphases	O
,	O
respectively	O
and	O
these	O
same	O
concentrations	O
1	O
,	O
2.5	O
,	O
5	O
and	O
10	O
microM	O
sodium	O
chromate	O
damaged	O
14	O
,	O
24	O
and	O
49	O
%	O
of	O
metaphases	O
,	O
respectively	O
,	O
in	O
North	O
Atlantic	O
right	O
whale	O
lung	O
cells	O
and	O
11	O
,	O
32	O
and	O
41	O
%	O
of	O
metaphases	O
,	O
respectively	O
,	O
in	O
North	O
Atlantic	O
right	O
whale	O
testes	O
cells	O
.	O

These	O
data	O
show	O
that	O
genotoxic	O
responses	O
in	O
medaka	O
are	O
comparable	O
to	O
those	O
seen	O
in	O
North	O
Atlantic	O
right	O
whale	O
cells	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
medaka	O
are	O
a	O
useful	O
model	O
for	O
other	O
aquatic	O
species	O
.	O

HIV	O
drug	O
resistance	O
tendencies	O
in	O
Latvia	O
.	O

The	O
treatment	O
of	O
HIV	B
infection	I
in	O
Latvia	O
by	O
using	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
was	O
started	O
in	O
1996	O
.	O

The	O
prevalence	O
and	O
tendencies	O
of	O
HIV	O
drug	O
resistance	O
among	O
treated	O
and	O
treatment	O
-	O
naive	O
patients	O
in	O
Latvia	O
in	O
the	O
years	O
2006	O
-	O
2007	O
were	O
evaluated	O
in	O
this	O
study	O
.	O

Data	O
of	O
HIV	O
genotyping	O
,	O
performed	O
in	O
132	O
HIV	O
-	O
1	O
infected	O
during	O
years	O
2006	O
-	O
2007	O
by	O
TRUGENE	O
HIV	O
-	O
1	O
genotyping	O
assay	O
(	O
BayerHealthCare	O
-	O
diagnostics	O
)	O
are	O
included	O
in	O
the	O
study	O
.	O

Analysis	O
of	O
data	O
showed	O
that	O
in	O
the	O
group	O
of	O
treatment	O
-	O
naive	O
individuals	O
majority	O
carried	O
wild	O
type	O
virus	O
.	O

Prevalence	O
of	O
resistance	O
-	O
associated	O
mutations	O
(	O
RAMs	O
)	O
in	O
the	O
treatment	O
-	O
naive	O
group	O
according	O
to	O
IAS	O
list	O
was	O
28	O
%	O
.	O

In	O
most	O
cases	O
it	O
was	O
NRTI	O
mutation	O
A62V	O
that	O
is	O
associated	O
with	O
multinucleoside	O
resistance	O
caused	O
by	O
Q151	O
M	O
,	O
its	O
effect	O
in	O
the	O
absence	O
of	O
Q151	O
M	O
is	O
not	O
known	O
.	O

By	O
many	O
authors	O
A62V	O
is	O
supposed	O
to	O
be	O
a	O
result	O
of	O
polymorphism	O
in	O
RT	O
gene	O
and	O
is	O
excluded	O
from	O
the	O
list	O
of	O
resistance	O
mutations	O
.	O

High	O
prevalence	O
of	O
A62V	O
is	O
typical	O
for	O
HIV	O
-	O
1	O
subtype	O
A	O
.	O

As	O
majority	O
of	O
treatment	O
-	O
naive	O
cases	O
(	O
89	O
%	O
)	O
in	O
this	O
study	O
were	O
with	O
HIV	O
-	O
1	O
subtypes	O
A	O
or	O
AE	O
,	O
we	O
excluded	O
A62V	O
mutation	O
and	O
estimated	O
RAMs	O
prevalence	O
in	O
group	O
of	O
treatment	O
-	O
naive	O
HIV	O
-	O
infected	O
individuals	O
as	O
7	O
%	O
.	O

Minor	O
PI	O
mutations	O
were	O
not	O
included	O
in	O
analyses	O
.	O

In	O
Europe	O
published	O
rates	O
generally	O
very	O
between	O
5	O
%	O
and	O
15	O
%	O
.	O

In	O
the	O
group	O
of	O
treatment	O
-	O
experienced	O
HIV	O
infected	O
people	O
25	O
/	O
75	O
were	O
with	O
HIV	O
-	O
1	O
subtype	O
B	O
,	O
the	O
rest	O
part	O
-	O
-	O
with	O
non	O
-	O
B	O
subtypes	O
:	O
A	O
/	O
AE	O
(	O
35	O
/	O
75	O
)	O
,	O
CRF	O
-	O
01AE	O
(	O
7	O
/	O
75	O
)	O
,	O
B	O
/	O
AE	O
(	O
4	O
/	O
75	O
)	O
and	O
others	O
.	O

In	O
treatment	O
-	O
experienced	O
patients	O
RAMs	O
prevalence	O
was	O
estimated	O
as	O
58.6	O
%	O
.	O

Most	O
frequently	O
RAMs	O
were	O
found	O
for	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
(	O
NRTI	O
)	O
(	O
49.3	O
%	O
)	O
followed	O
by	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
(	O
NNRTI	O
)	O
(	O
22.6	O
%	O
)	O
and	O
protease	O
inhibitors	O
(	O
PI	O
)	O
(	O
16	O
%	O
)	O
.	O

In	O
the	O
group	O
of	O
NRTI	O
mutations	O
M184V	O
(	O
26	O
/	O
75	O
;	O
34.6	O
%	O
)	O
,	O
A62V	O
(	O
12	O
/	O
75	O
;	O
16.0	O
%	O
)	O
and	O
T215Y	O
(	O
8	O
/	O
75	O
;	O
10.6	O
%	O
)	O
,	O
in	O
NNRTI	O
mutations	O
K103N	O
(	O
10	O
/	O
75	O
;	O
13.3	O
%	O
)	O
,	O
G190S	O
(	O
6	O
/	O
75	O
;	O
8.0	O
%	O
)	O
,	O
in	O
PI	O
group	O
mutations	O
L90	O
M	O
(	O
6	O
/	O
75	O
;	O
8.0	O
%	O
)	O
and	O
M461	O
/	O
L	O
(	O
6	O
/	O
75	O
;	O
8.0	O
%	O
)	O
occurred	O
most	O
frequently	O
.	O

The	O
following	O
drug	O
susceptibility	O
was	O
predicted	O
according	O
to	O
the	O
Trugen	O
expert	O
interpretations	O
:	O
in	O
33	O
/	O
75	O
(	O
44	O
%	O
)	O
patients	O
no	O
evidence	O
of	O
resistance	O
,	O
in	O
21	O
/	O
75	O
(	O
28	O
%	O
)	O
patients	O
resistance	O
to	O
1	O
drug	O
class	O
(	O
NRTI	O
-	O
-	O
16	O
/	O
75	O
,	O
NNRTI	O
-	O
-	O
4	O
/	O
75	O
,	O
PI	O
-	O
-	O
1	O
/	O
75	O
)	O
,	O
in	O
17	O
patients	O
(	O
22.6	O
%	O
)	O
resistance	O
to	O
2	O
drug	O
classes	O
(	O
NRTI+	O
NNRTI	O
-	O
-	O
9	O
/	O
75	O
,	O
NRTI+	O
PI	O
-	O
-	O
7	O
/	O
75	O
,	O
NNRTI+	O
PI	O
-	O
-	O
1	O
/	O
75	O
)	O
and	O
in	O
3	O
/	O
75	O
(	O
4	O
%	O
)	O
patients	O
resistance	O
to	O
all	O
3	O
classes	O
of	O
drugs	O
(	O
NRTI+	O
NNRTI+	O
PI	O
)	O
.	O

We	O
conclude	O
,	O
that	O
prevalence	O
of	O
RAMs	O
in	O
treatment	O
-	O
naive	O
HIV	O
infected	O
persons	O
in	O
Latvia	O
is	O
comparable	O
with	O
prevalence	O
in	O
Europe	O
.	O

The	O
origin	O
of	O
predominated	O
mutation	O
A62V	O
associated	O
with	O
NRTI	O
at	O
present	O
is	O
not	O
clear	O
.	O

In	O
more	O
than	O
half	O
of	O
treated	O
HIV	O
infected	O
patients	O
HIV	O
resistance	O
to	O
at	O
least	O
one	O
HAART	O
class	O
was	O
predicted	O
.	O

Distinct	O
regulatory	O
profiles	O
of	O
interleukins	O
and	O
chemokines	O
in	O
response	O
to	O
cigarette	O
smoke	O
condensate	O
in	O
normal	O
human	O
bronchial	O
epithelial	O
(	O
NHBE	O
)	O
cells	O
.	O

Bronchial	O
epithelium	O
is	O
frequently	O
exposed	O
to	O
air	O
pollutants	O
,	O
and	O
it	O
is	O
hypothesized	O
that	O
these	O
cells	O
elicit	O
inflammatory	O
responses	O
as	O
early	O
elements	O
in	O
pulmonary	O
defense	O
.	O

Our	O
purpose	O
was	O
to	O
evaluate	O
changes	O
in	O
messenger	O
RNA	O
levels	O
of	O
84	O
genes	O
representing	O
cytokines	O
and	O
receptors	O
over	O
a	O
repetitive	O
-	O
exposure	O
time	O
course	O
to	O
further	O
define	O
the	O
inflammatory	O
responses	O
associated	O
with	O
mainstream	O
cigarette	O
smoke	O
(	O
MSS	O
)	O
exposure	O
in	O
an	O
in	O
vitro	O
lung	O
model	O
.	O

Normal	O
human	O
bronchial	O
epithelial	O
cells	O
were	O
treated	O
with	O
mainstream	O
cigarette	O
smoke	O
condensate	O
(	O
CSC	O
)	O
prepared	O
from	O
Kentucky	O
2R4F	O
cigarettes	O
(	O
60	O
microg	O
total	O
particulate	O
matter	O
/	O
mL	O
media	O
,	O
0.2	O
%	O
dimethylsulfoxide	O
)	O
,	O
and	O
examined	O
by	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

Applications	O
of	O
CSC	O
were	O
designed	O
in	O
seven	O
groups	O
to	O
test	O
immediate	O
,	O
early	O
,	O
intermediate	O
,	O
and	O
late	O
responses	O
evaluated	O
at	O
the	O
end	O
of	O
alternating	O
exposure	O
/	O
recovery	O
periods	O
.	O

Three	O
predominant	O
gene	O
expression	O
responses	O
were	O
observed	O
:	O
adaptive	O
(	O
return	O
to	O
baseline	O
)	O
,	O
sustained	O
(	O
maintained	O
expression	O
during	O
treatment	O
)	O
,	O
and	O
chronic	O
(	O
maintained	O
expression	O
posttreatment	O
)	O
.	O

Overall	O
,	O
25	O
genes	O
exhibited	O
statistically	O
significant	O
changes	O
:	O
14	O
genes	O
exclusively	O
elevated	O
,	O
10	O
genes	O
exclusively	O
depressed	O
,	O
and	O
1	O
,	O
interleukin	O
-	O
8	O
(	O
IL8	O
)	O
,	O
exhibiting	O
both	O
up	O
-	O
and	O
downregulation	O
in	O
the	O
seven	O
groups	O
.	O

The	O
most	O
responsive	O
genes	O
were	O
osteopontin	O
(	O
34	O
-	O
fold	O
upregulation	O
)	O
and	O
CXCL14	O
(	O
23	O
-	O
fold	O
downregulation	O
)	O
.	O

Our	O
observations	O
suggest	O
that	O
specific	O
genes	O
involved	O
in	O
inflammatory	O
pathways	O
respond	O
to	O
CSC	O
in	O
chronic	O
,	O
sustained	O
,	O
or	O
adaptive	O
patterns	O
with	O
the	O
chronic	O
pattern	O
as	O
the	O
predominant	O
behavior	O
.	O

Individualized	O
medicine	O
for	O
renal	B
cell	I
carcinoma	I
:	O
establishment	O
of	O
primary	O
cell	O
line	O
culture	O
from	O
surgical	O
specimens	O
.	O

BACKGROUND	O
:	O
The	O
lack	O
of	O
effective	O
""""	O
in	O
vivo	O
""""	O
and	O
""""	O
in	O
vitro	O
""""	O
models	O
to	O
predict	O
success	O
of	O
pharmacological	O
therapy	O
for	O
patients	O
with	O
renal	B
cell	I
carcinoma	I
,	O
as	O
well	O
as	O
,	O
the	O
variety	O
of	O
cancer	O
cell	O
types	O
demands	O
the	O
development	O
of	O
better	O
experimental	O
models	O
to	O
understand	O
the	O
pathophysiology	O
of	O
the	O
disease	O
and	O
evaluate	O
drug	O
sensitivity	O
in	O
vitro	O
.	O

PURPOSE	O
:	O
To	O
develop	O
primary	O
renal	O
cancer	O
cell	O
culture	O
irrespective	O
of	O
tumor	B
grade	O
and	O
tumor	B
type	O
,	O
harvested	O
from	O
the	O
patient	O
's	O
pathological	O
specimen	O
immediately	O
after	O
the	O
laparoscopic	O
radical	O
nephrectomy	O
to	O
study	O
potential	O
""""	O
in	O
vivo	O
""""	O
pharmacological	O
sensitivity	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
24	O
patients	O
(	O
17	O
males	O
and	O
7	O
females	O
)	O
.	O

Mean	O
age	O
of	O
63.1	O
+	O
/	O
-	O
3.1	O
y	O
.	O

o	O
.	O

The	O
mean	O
size	O
of	O
the	O
renal	O
masses	O
was	O
7.56	O
+	O
/	O
-	O
3.1	O
cm	O
.	O

Normal	O
and	O
pathological	O
renal	O
tissue	O
was	O
collected	O
immediately	O
after	O
the	O
specimen	O
was	O
extracted	O
and	O
submitted	O
to	O
enzymatic	O
digestion	O
for	O
16	O
-	O
24	O
hours	O
.	O

Clear	O
cell	O
carcinoma	O
cells	O
were	O
selected	O
through	O
multiple	O
passages	O
in	O
DMEM	O
medium	O
supplemented	O
with	O
glucose	O
and	O
antibiotics	O
.	O

RESULTS	O
:	O
Establishment	O
of	O
cell	O
line	O
culture	O
from	O
all	O
the	O
patients	O
'	O
specimens	O
irrespective	O
of	O
tumor	B
grade	O
and	O
tumor	B
type	O
was	O
achieved	O
successfully	O
.	O

In	O
addition	O
to	O
the	O
tumor	O
cell	O
line	O
culture	O
,	O
normal	O
parenchyma	O
tissue	O
yielded	O
primary	O
cell	O
lines	O
to	O
allow	O
testing	O
the	O
response	O
of	O
tumor	B
types	O
to	O
various	O
pharmacological	O
therapeutic	O
agents	O
and	O
toxicity	O
of	O
such	O
treatments	O
to	O
healthy	O
tissue	O
.	O

From	O
the	O
initial	O
collection	O
of	O
the	O
specimens	O
obtained	O
after	O
the	O
removal	O
of	O
the	O
kidney	O
to	O
the	O
development	O
of	O
cell	O
lines	O
took	O
occurred	O
in	O
average	O
32	O
+	O
6	O
hrs	O
.	O

The	O
cells	O
in	O
culture	O
showed	O
characteristics	O
of	O
epithelial	O
cells	O
;	O
like	O
expression	O
on	O
cytokeratin	O
and	O
were	O
maintained	O
in	O
culture	O
for	O
more	O
than	O
20	O
passages	O
.	O

CONCLUSION	O
:	O
The	O
development	O
of	O
renal	O
cancer	O
cell	O
cultures	O
in	O
vitro	O
is	O
labor	O
intense	O
but	O
may	O
yield	O
a	O
more	O
realistic	O
model	O
to	O
tailor	O
pharmacological	O
therapies	O
and	O
predict	O
therapeutic	O
success	O
prior	O
to	O
""""	O
in	O
vivo	O
""""	O
application	O
-	O
a	O
step	O
in	O
the	O
direction	O
of	O
individualized	O
medicine	O
for	O
RCC	O
.	O

Clindamycin	O
phosphate	O
/	O
tretinoin	O
gel	O
formulation	O
in	O
the	O
treatment	O
of	O
acne	B
vulgaris	I
.	O

Clindamycin	O
phosphate	O
1.2	O
%	O
together	O
with	O
tretinoin	O
0.025	O
%	O
as	O
a	O
gel	O
(	O
CTG	O
)	O
is	O
a	O
topical	O
formulation	O
of	O
a	O
fixed	O
and	O
stable	O
combination	O
approved	O
by	O
the	O
FDA	O
for	O
the	O
treatment	O
of	O
acne	B
vulgaris	I
in	O
patients	O
12	O
years	O
of	O
age	O
or	O
older	O
.	O

The	O
main	O
indication	O
of	O
CTG	O
is	O
the	O
management	O
of	O
moderate	O
comedonal	O
and	O
mild	O
-	O
to	O
-	O
moderate	O
papulopustular	B
acne	I
,	O
an	O
acne	B
form	O
which	O
is	O
present	O
in	O
more	O
than	O
50	O
%	O
of	O
acne	B
patients	O
.	O

CTG	O
can	O
also	O
be	O
combined	O
with	O
systemic	O
antiacne	O
therapy	O
,	O
such	O
as	O
systemic	O
isotretinoin	O
,	O
in	O
nodulocystic	B
acne	I
.	O

The	O
product	O
combines	O
the	O
anti	O
-	O
inflammatory	O
and	O
antibacterial	O
properties	O
of	O
clindamycin	O
with	O
the	O
well	O
proven	O
and	O
beneficial	O
comedolytic	O
and	O
anticomedogenic	O
effects	O
of	O
tretinoin	O
(	O
all	O
-	O
trans	O
retinoic	O
acid	O
)	O
.	O

The	O
addition	O
of	O
clindamycin	O
to	O
tretinoin	O
enhances	O
the	O
comedolytic	O
efficacy	O
of	O
tretinoin	O
in	O
moderate	O
-	O
to	O
-	O
severe	O
acne	B
of	I
the	I
face	I
.	O

The	O
comedolytic	O
activity	O
of	O
tretinoin	O
and	O
the	O
anti	O
-	O
inflammatory	O
efficacy	O
of	O
clindamycin	O
accelerate	O
resolution	O
of	O
all	O
types	O
of	O
acne	B
lesions	I
without	O
affecting	O
the	O
safety	O
of	O
both	O
compounds	O
.	O

Discontinuation	O
rates	O
due	O
to	O
adverse	O
events	O
related	O
to	O
this	O
formulation	O
were	O
found	O
to	O
be	O
low	O
(	O
<	O
/	O
=	O
1	O
%	O
)	O
.	O

Safety	O
of	O
CTG	O
use	O
in	O
pregnancy	O
has	O
not	O
been	O
established	O
.	O

The	O
combination	O
formulation	O
is	O
mainly	O
designed	O
to	O
enhance	O
effectiveness	O
and	O
minimize	O
irritation	O
.	O

The	O
once	O
daily	O
use	O
of	O
CTG	O
,	O
its	O
rapid	O
and	O
dual	O
effect	O
and	O
good	O
tolerability	O
have	O
a	O
positive	O
impact	O
on	O
the	O
duration	O
of	O
disease	O
,	O
patients	O
'	O
compliance	O
and	O
overall	O
costs	O
of	O
therapy	O
.	O

Induction	O
of	O
mucosal	O
tolerance	O
in	O
SLE	B
:	O
a	O
sniff	O
or	O
a	O
sip	O
away	O
from	O
ameliorating	O
lupus	O
?	O

Systemic	B
lupus	I
erythematosus	I
(	O
SLE	B
)	O
is	O
an	O
autoimmune	B
disease	I
characterized	O
by	O
aberrant	O
immune	O
responses	O
against	O
intracellularly	O
derived	O
self	O
antigens	O
.	O

Treatment	O
for	O
SLE	B
relies	O
on	O
the	O
use	O
of	O
aggressive	O
immunosuppressants	O
and	O
steroids	O
that	O
are	O
nonspecific	O
and	O
can	O
cause	O
serious	O
adverse	O
effects	O
.	O

The	O
observation	O
that	O
a	O
systemic	O
immune	O
tolerance	O
to	O
self	O
antigens	O
or	O
generation	O
of	O
regulatory	O
T	O
cells	O
may	O
follow	O
mucosal	O
(	O
nasal	O
or	O
oral	O
)	O
exposure	O
to	O
self	O
proteins	O
or	O
monoclonal	O
antibody	O
against	O
CD3	O
respectively	O
suggests	O
that	O
induction	O
of	O
mucosal	O
tolerance	O
offers	O
the	O
basis	O
of	O
a	O
side	O
effect	O
-	O
free	O
therapy	O
that	O
could	O
re	O
-	O
establish	O
the	O
ability	O
to	O
distinguish	O
self	O
from	O
non	O
-	O
self	O
and	O
restore	O
peripheral	O
tolerance	O
in	O
individuals	O
susceptible	O
to	O
developing	O
autoimmune	B
diseases	I
.	O

Here	O
I	O
review	O
studies	O
on	O
mucosal	O
tolerance	O
in	O
autoimmune	B
diseases	I
and	O
discuss	O
the	O
therapeutic	O
potential	O
of	O
inducing	O
tolerance	O
for	O
the	O
treatment	O
of	O
SLE	B
.	O

Patient	O
willingness	O
to	O
undergo	O
chemotherapy	O
and	O
thoracic	O
radiotherapy	O
for	O
locally	O
advanced	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
.	O

OBJECTIVES	O
:	O
To	O
determine	O
how	O
Japanese	O
patients	O
with	O
lung	B
cancer	I
weigh	O
the	O
chance	O
of	O
cure	O
and	O
potential	O
survival	O
against	O
the	O
potential	O
toxicity	O
of	O
different	O
treatment	O
strategies	O
for	O
locally	O
advanced	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
(	O
NSCLC	O
)	O
.	O

METHODS	O
:	O
We	O
used	O
a	O
questionnaire	O
describing	O
a	O
hypothetical	O
situation	O
involving	O
locally	O
advanced	O
NSCLC	O
.	O

Seventy	O
-	O
three	O
patients	O
with	O
lung	B
cancer	I
who	O
had	O
received	O
chemotherapy	O
and	O
a	O
control	O
group	O
of	O
120	O
patients	O
without	O
cancer	B
were	O
asked	O
to	O
state	O
the	O
minimal	O
benefit	O
that	O
would	O
make	O
two	O
hypothetical	O
treatments	O
acceptable	O
.	O

RESULTS	O
:	O
Patients	O
with	O
lung	B
cancer	I
were	O
significantly	O
more	O
likely	O
than	O
were	O
patients	O
without	O
cancer	B
to	O
accept	O
either	O
intensive	O
or	O
less	O
-	O
intensive	O
chemoradiotherapy	O
for	O
a	O
potentially	O
small	O
benefit	O
for	O
'	O
chance	O
of	O
cure	O
'	O
and	O
're	O
sponse	O
but	O
not	O
cure	O
'	O
.	O

The	O
percentages	O
of	O
patients	O
who	O
would	O
accept	O
intensive	O
or	O
less	O
-	O
intensive	O
chemoradiotherapy	O
to	O
prolong	O
survival	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
.	O

When	O
the	O
chance	O
of	O
cure	O
was	O
20	O
%	O
,	O
56	O
and	O
64	O
%	O
of	O
patients	O
with	O
lung	B
cancer	I
were	O
willing	O
to	O
receive	O
intensive	O
and	O
less	O
-	O
intensive	O
chemoradiotherapy	O
,	O
respectively	O
.	O

If	O
their	O
lives	O
were	O
prolonged	O
by	O
6	O
months	O
,	O
20	O
and	O
30	O
%	O
of	O
patients	O
with	O
lung	B
cancer	I
would	O
choose	O
to	O
receive	O
intensive	O
and	O
less	O
-	O
intensive	O
chemoradiotherapy	O
,	O
respectively	O
.	O

The	O
chance	O
of	O
cure	O
and	O
the	O
survival	O
advantage	O
that	O
patients	O
require	O
for	O
accepting	O
chemoradiotherapy	O
varied	O
widely	O
.	O

No	O
factors	O
were	O
associated	O
with	O
the	O
choice	O
of	O
chemoradiotherapy	O
in	O
patients	O
with	O
lung	B
cancer	I
.	O

CONCLUSIONS	O
:	O
Physicians	O
must	O
consider	O
the	O
substantial	O
range	O
of	O
attitudes	O
to	O
chemoradiotherapy	O
among	O
patients	O
when	O
selecting	O
treatment	O
and	O
give	O
patients	O
opportunities	O
to	O
be	O
included	O
in	O
the	O
treatment	O
-	O
selection	O
process	O
.	O

Studies	O
of	O
pharmacokinetic	O
and	O
pharmacodynamic	O
properties	O
of	O
isoallopregnanolone	O
in	O
healthy	O
women	O
.	O

RATIONALE	O
:	O
The	O
pharmacokinetics	O
and	O
behavioral	O
effects	O
of	O
isoallopregnanolone	O
(	O
3beta	O
-	O
hydoxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
in	O
women	O
are	O
not	O
known	O
.	O

OBJECTIVES	O
:	O
Allopregnanolone	O
(	O
3alpha	O
-	O
hydoxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
is	O
a	O
well	O
-	O
known	O
neurosteroid	O
,	O
acting	O
via	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
in	O
the	O
human	O
brain	O
.	O

The	O
naturally	O
occurring	O
progesterone	O
metabolite	O
isoallopregnanolone	O
is	O
the	O
3beta	O
-	O
stereoisomer	O
of	O
allopregnanolone	O
.	O

Prior	O
studies	O
have	O
concluded	O
that	O
isoallopregnanolone	O
has	O
no	O
effect	O
on	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

However	O
,	O
an	O
antagonistic	O
effect	O
of	O
isoallopregnanolone	O
to	O
allopregnanolone	O
on	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
has	O
been	O
shown	O
in	O
animal	O
and	O
in	O
vitro	O
studies	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
pharmacokinetics	O
and	O
behavioral	O
effects	O
of	O
isoallopregnanolone	O
in	O
humans	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Six	O
healthy	O
women	O
were	O
given	O
three	O
increasing	O
doses	O
of	O
isoallopregnanolone	O
intravenously	O
in	O
the	O
follicular	O
phase	O
.	O

Repeated	O
blood	O
samples	O
for	O
analyses	O
of	O
isoallopregnanolone	O
and	O
allopregnanolone	O
concentrations	O
were	O
drawn	O
.	O

Saccadic	O
eye	O
movement	O
variables	O
,	O
self	O
-	O
rated	O
sedation	O
,	O
and	O
mood	O
rating	O
scales	O
were	O
used	O
during	O
the	O
test	O
day	O
.	O

A	O
Likert	O
scale	O
for	O
prospective	O
symptoms	O
was	O
used	O
to	O
measure	O
daily	O
fluctuations	O
during	O
the	O
ongoing	O
menstrual	O
cycle	O
.	O

RESULTS	O
:	O
Exogenously	O
administered	O
isoallopregnanolone	O
produced	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
serum	O
concentration	O
of	O
isoallopregnanolone	O
.	O

In	O
parallel	O
,	O
there	O
was	O
also	O
a	O
rise	O
in	O
the	O
allopregnanolone	O
concentration	O
.	O

There	O
was	O
a	O
decrease	O
in	O
saccadic	O
eye	O
movement	O
variables	O
,	O
but	O
no	O
effect	O
was	O
found	O
on	O
self	O
-	O
rated	O
sedation	O
or	O
mood	O
and	O
no	O
changes	O
were	O
seen	O
in	O
prospective	O
symptoms	O
during	O
the	O
menstrual	O
cycle	O
.	O

CONCLUSIONS	O
:	O
After	O
administration	O
of	O
isoallopregnanolone	O
at	O
a	O
cumulative	O
dose	O
of	O
0.20	O
mg	O
/	O
kg	O
,	O
no	O
adverse	O
effects	O
were	O
observed	O
.	O

There	O
is	O
a	O
metabolism	O
of	O
isoallopregnanolone	O
to	O
allopregnanolone	O
,	O
most	O
likely	O
explaining	O
the	O
effects	O
on	O
the	O
saccadic	O
eye	O
movements	O
.	O

LDL	O
reduction	O
:	O
how	O
low	O
should	O
we	O
go	O
and	O
is	O
it	O
safe	O
?	O

High	O
-	O
dose	O
statin	O
therapy	O
or	O
combination	O
statin	O
treatment	O
is	O
necessary	O
for	O
most	O
patients	O
to	O
achieve	O
aggressive	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
goals	O
.	O

Adding	O
ezetimibe	O
or	O
bile	O
acid	O
sequestrants	O
appears	O
unlikely	O
to	O
increase	O
the	O
risk	O
of	O
myopathy	B
.	O

Although	O
the	O
combination	O
of	O
niacin	O
or	O
fenofibrate	O
with	O
moderate	O
-	O
dose	O
statins	O
appears	O
to	O
be	O
reasonably	O
safe	O
,	O
the	O
safety	O
of	O
combination	O
with	O
high	O
-	O
dose	O
statins	O
has	O
yet	O
to	O
be	O
determined	O
.	O

To	O
enhance	O
patient	O
outcomes	O
,	O
attention	O
must	O
be	O
paid	O
to	O
characteristics	O
that	O
predict	O
muscle	O
and	O
hepatic	O
statin	O
toxicity	O
when	O
considering	O
using	O
high	O
-	O
dose	O
statin	O
or	O
combination	O
statin	O
therapy	O
.	O

Synthesis	O
of	O
some	O
pyrazolyl	O
benzenesulfonamide	O
derivatives	O
as	O
dual	O
anti	O
-	O
inflammatory	O
antimicrobial	O
agents	O
.	O

Four	O
series	O
of	O
pyrazolylbenzenesulfonamide	O
derivatives	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
inflammatory	O
activity	O
using	O
cotton	O
pellet	O
induced	O
granuloma	B
and	O
carrageenan	O
-	O
induced	O
rat	O
paw	O
edema	B
bioassays	O
.	O

Moreover	O
,	O
COX	O
-	O
1	O
and	O
COX	O
-	O
2	O
inhibitory	O
activity	O
,	O
ulcerogenic	B
effect	I
and	O
acute	B
toxicity	I
were	O
also	O
determined	O
.	O

Furthermore	O
,	O
the	O
target	O
compounds	O
were	O
screened	O
for	O
their	O
in	O
-	O
vitro	O
antimicrobial	O
activity	O
against	O
Eischerichia	O
coli	O
,	O
Staphylococcus	O
aureus	O
and	O
Candida	O
albicans	O
.	O

Compounds	O
4	O
-	O
(	O
3	O
-	O
Phenyl	O
-	O
4	O
-	O
cyano	O
-	O
1H	O
-	O
pyrazol	O
-	O
1	O
-	O
yl	O
)	O
benzenesulfonamide	O
9a	O
and	O
4	O
-	O
(	O
3	O
-	O
Tolyl	O
-	O
4	O
-	O
cyano	O
-	O
1H	O
-	O
pyrazol	O
-	O
1	O
-	O
yl	O
)	O
benzenesulfonamide	O
9b	O
were	O
not	O
only	O
found	O
to	O
be	O
the	O
most	O
active	O
dual	O
anti	O
-	O
inflammatory	O
antimicrobial	O
agents	O
in	O
the	O
present	O
study	O
with	O
good	O
safety	O
margin	O
and	O
minimal	O
ulcerogenic	O
effect	O
but	O
also	O
exhibited	O
good	O
selective	O
inhibitory	O
activity	O
towards	O
COX	O
-	O
2	O
.	O

A	O
docking	O
pose	O
for	O
9a	O
and	O
9b	O
separately	O
in	O
the	O
active	O
site	O
of	O
the	O
human	O
COX	O
-	O
2	O
enzyme	O
was	O
also	O
obtained	O
.	O

Therefore	O
,	O
these	O
compounds	O
would	O
represent	O
a	O
fruitful	O
matrix	O
for	O
the	O
development	O
of	O
dual	O
anti	O
-	O
inflammatory	O
antimicrobial	O
candidates	O
with	O
remarkable	O
COX	O
-	O
2	O
selectivity	O
.	O

Prolonged	O
dose	O
-	O
dense	O
epirubicin	O
and	O
cyclophosphamide	O
followed	O
by	O
paclitaxel	O
in	O
breast	B
cancer	I
is	O
feasible	O
.	O

PURPOSE	O
:	O
We	O
conducted	O
a	O
pilot	O
study	O
of	O
dose	O
-	O
dense	O
epirubicin	O
/	O
cyclophosphamide	O
(	O
EC	O
)	O
x	O
6	O
-	O
-	O
>	O
paclitaxel	O
(	O
P	O
)	O
x	O
6	O
with	O
pegfilgrastim	O
.	O

A	O
previous	O
dose	O
-	O
dense	O
trial	O
of	O
FEC	O
(	O
5	O
-	O
fluorouracil	O
[	O
5	O
-	O
FU	O
]	O
/	O
EC	O
)	O
x	O
6	O
with	O
filgrastim	O
-	O
-	O
>	O
by	O
weekly	O
paclitaxel	O
alternating	O
with	O
docetaxel	O
x	O
18	O
was	O
not	O
feasible	O
because	O
of	O
pneumonitis	B
(	O
with	O
dose	O
-	O
dense	O
FEC	O
)	O
and	O
pericardial	B
/	I
pleural	I
effusion	I
(	O
taxane	O
phase	O
)	O
.	O

Dose	O
-	O
dense	O
EC	O
(	O
without	O
the	O
5	O
-	O
FU	O
)	O
is	O
not	O
associated	O
with	O
pneumonitis	B
,	O
and	O
dose	O
-	O
dense	O
paclitaxel	O
(	O
alone	O
)	O
is	O
feasible	O
.	O

Primary	O
objective	O
was	O
feasibility	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
resectable	O
breast	B
cancer	I
were	O
enrolled	O
,	O
regardless	O
of	O
surgery	O
status	O
,	O
tumor	O
size	O
,	O
or	O
nodal	O
status	O
.	O

Treatment	O
regimen	O
consisted	O
of	O
every	O
-	O
2	O
-	O
week	O
EC	O
(	O
100	O
/	O
600	O
mg	O
/	O
m2	O
)	O
x	O
6	O
-	O
-	O
>	O
by	O
2	O
-	O
weekly	O
P	O
(	O
175	O
mg	O
/	O
m2	O
)	O
x	O
6	O
with	O
pegfilgrastim	O
6	O
mg	O
on	O
day	O
2	O
.	O

RESULTS	O
:	O
Between	O
November	O
2004	O
and	O
May	O
2005	O
,	O
38	O
patients	O
were	O
enrolled	O
.	O

The	O
median	O
age	O
was	O
47	O
years	O
(	O
range	O
,	O
30	O
-	O
72	O
years	O
)	O
;	O
33	O
of	O
38	O
(	O
87	O
%	O
)	O
were	O
treated	O
in	O
the	O
adjuvant	O
setting	O
and	O
27	O
of	O
33	O
(	O
81	O
%	O
)	O
had	O
involved	O
nodes	O
(	O
range	O
,	O
1	O
-	O
46	O
)	O
;	O
5	O
of	O
38	O
(	O
13	O
%	O
)	O
were	O
treated	O
pre	O
-	O
operatively	O
;	O
33	O
of	O
38	O
(	O
87	O
%	O
)	O
completed	O
all	O
chemotherapy	O
as	O
planned	O
;	O
the	O
remaining	O
patients	O
(	O
13	O
%	O
)	O
had	O
treatment	O
modifications	O
for	O
toxicity	O
.	O

Febrile	B
neutropenia	I
occurred	O
in	O
6	O
of	O
38	O
patients	O
(	O
16	O
%	O
)	O
and	O
only	O
during	O
EC	O
.	O

There	O
were	O
12	O
hospitalizations	O
in	O
9	O
of	O
38	O
patients	O
(	O
24	O
%	O
)	O
enrolled	O
.	O

CONCLUSION	O
:	O
Dose	O
-	O
dense	O
every	O
-	O
2	O
-	O
week	O
EC	O
x	O
6	O
-	O
-	O
>	O
P	O
x	O
6	O
with	O
pegfilgrastim	O
is	O
feasible	O
based	O
on	O
our	O
prospective	O
definition	O
.	O

Hepatic	O
safety	O
of	O
tipranavir	O
plus	O
ritonavir	O
(	O
TPV	O
/	O
r	O
)	O
-	O
based	O
antiretroviral	O
combinations	O
:	O
effect	O
of	O
hepatitis	B
virus	I
co	I
-	I
infection	I
and	O
pre	O
-	O
existing	O
fibrosis	B
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
incidence	O
and	O
risk	O
factors	O
of	O
severe	O
liver	O
events	O
among	O
HIV	O
-	O
infected	O
patients	O
treated	O
with	O
drug	O
combinations	O
including	O
tipranavir	O
boosted	O
with	O
ritonavir	O
(	O
TPV	O
/	O
r	O
)	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fifty	O
patients	O
were	O
selected	O
because	O
they	O
started	O
a	O
regimen	O
that	O
included	O
TPV	O
/	O
r	O
(	O
500	O
/	O
200	O
mg	O
twice	O
a	O
day	O
)	O
and	O
had	O
clinical	O
visits	O
at	O
least	O
every	O
3	O
months	O
.	O

Patients	O
who	O
discontinued	O
TPV	O
/	O
r	O
before	O
their	O
first	O
visit	O
were	O
included	O
.	O

RESULTS	O
:	O
Twelve	O
(	O
8	O
%	O
)	O
individuals	O
developed	O
grade	O
>	O
or	O
=	O
3	O
transaminase	O
elevation	O
(	O
G	O
>	O
or	O
=	O
3TE	O
)	O
.	O

Nine	O
(	O
6	O
%	O
)	O
patients	O
discontinued	O
TPV	O
/	O
r	O
due	O
to	O
liver	O
events	O
.	O

Six	O
(	O
8.6	O
%	O
)	O
of	O
70	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
co	O
-	O
infected	O
patients	O
and	O
6	O
(	O
7.5	O
%	O
)	O
of	O
80	O
subjects	O
without	O
HCV	O
co	O
-	O
infection	O
developed	O
G	O
>	O
or	O
=	O
3TE	O
(	O
P	O
=	O
1	O
)	O
.	O

Liver	B
fibrosis	I
was	O
evaluable	O
in	O
48	O
(	O
63	O
%	O
)	O
of	O
76	O
individuals	O
with	O
hepatitis	O
B	O
virus	O
and	O
/	O
or	O
HCV	B
infection	I
.	O

Four	O
(	O
13	O
%	O
)	O
of	O
30	O
subjects	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
fibrosis	B
and	O
none	O
of	O
18	O
with	O
mild	O
fibrosis	B
showed	O
G	O
>	O
or	O
=	O
3TE	O
(	O
P	O
=	O
0.3	O
)	O
.	O

None	O
of	O
nine	O
patients	O
with	O
cirrhosis	B
showed	O
G	O
>	O
or	O
=	O
3TE	O
.	O

CONCLUSIONS	O
:	O
Liver	O
tolerability	O
of	O
TPV	O
/	O
r	O
was	O
generally	O
good	O
in	O
a	O
cohort	O
of	O
patients	O
with	O
a	O
high	O
proportion	O
of	O
HCV	B
co	I
-	I
infection	I
,	O
including	O
subjects	O
with	O
advanced	O
fibrosis	B
.	O

The	O
presence	O
of	O
HCV	B
co	I
-	I
infection	I
was	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
severe	O
transaminase	O
elevations	O
.	O

Environmental	O
ozone	O
exposure	O
and	O
oxidative	O
DNA	O
damage	O
in	O
adult	O
residents	O
of	O
Florence	O
,	O
Italy	O
.	O

In	O
71	O
adults	O
residing	O
in	O
Florence	O
,	O
Italy	O
,	O
enrolled	O
in	O
a	O
prospective	O
study	O
,	O
we	O
investigated	O
the	O
correlation	O
between	O
individual	O
levels	O
of	O
oxidative	O
DNA	O
damage	O
detected	O
by	O
the	O
Comet	O
assay	O
in	O
circulating	O
lymphocytes	O
,	O
and	O
a	O
specific	O
ozone	O
exposure	O
score	O
calculated	O
in	O
10	O
different	O
time	O
-	O
windows	O
(	O
0	O
-	O
5	O
to	O
0	O
-	O
90	O
days	O
)	O
before	O
blood	O
drawing	O
,	O
based	O
on	O
daily	O
measurements	O
provided	O
by	O
the	O
local	O
environmental	O
monitoring	O
system	O
.	O

Overall	O
,	O
statistically	O
significant	O
positive	O
correlations	O
between	O
average	O
ozone	O
concentrations	O
and	O
DNA	O
damage	O
emerged	O
in	O
almost	O
all	O
time	O
-	O
windows	O
considered	O
;	O
correlations	O
were	O
more	O
evident	O
among	O
males	O
,	O
non	O
-	O
smokers	O
,	O
and	O
traffic	O
-	O
exposed	O
workers	O
.	O

Multivariate	O
regression	O
analyses	O
taking	O
into	O
account	O
selected	O
individual	O
characteristics	O
,	O
showed	O
an	O
independent	O
effect	O
on	O
DNA	O
damage	O
of	O
average	O
ozone	O
concentrations	O
in	O
the	O
last	O
60	O
-	O
90	O
days	O
before	O
blood	O
drawing	O
.	O

Local	O
residents	O
showed	O
a	O
divergent	O
pattern	O
with	O
correlations	O
restricted	O
to	O
shorter	O
time	O
-	O
windows	O
.	O

Our	O
results	O
suggest	O
that	O
ozone	O
concentrations	O
at	O
ground	O
levels	O
modulate	O
oxidative	O
DNA	O
damage	O
in	O
circulating	O
lymphocytes	O
of	O
residents	O
of	O
polluted	O
areas	O
.	O

Cutaneous	O
adverse	O
effects	O
of	O
biological	O
therapies	O
for	O
psoriasis	B
.	O

Psoriasis	B
is	O
a	O
common	O
immune	B
-	I
mediated	I
disease	I
that	O
affects	O
approximately	O
2	O
%	O
of	O
the	O
world	O
's	O
population	O
.	O

Most	O
patients	O
require	O
lifelong	O
treatment	O
and	O
many	O
of	O
the	O
current	O
systemic	O
therapies	O
are	O
complicated	O
by	O
significant	O
toxicities	O
or	O
inconvenience	O
when	O
administered	O
long	O
-	O
term	O
.	O

New	O
biological	O
psoriasis	B
therapies	O
have	O
been	O
developed	O
,	O
which	O
are	O
thought	O
to	O
act	O
through	O
targeted	O
molecular	O
pathways	O
,	O
so	O
as	O
to	O
administer	O
them	O
continuously	O
without	O
causing	O
any	O
relevant	O
toxicity	O
.	O

Nevertheless	O
,	O
acute	O
and	O
chronic	O
dermatological	O
adverse	O
effects	O
are	O
frequently	O
observed	O
,	O
but	O
knowledge	O
about	O
them	O
is	O
limited	O
and	O
the	O
potential	O
pathogenic	O
mechanisms	O
have	O
not	O
yet	O
been	O
identified	O
.	O

We	O
present	O
7	O
patients	O
from	O
our	O
dermatological	O
department	O
who	O
presented	O
different	O
cutaneous	O
adverse	O
effects	O
(	O
2	O
erythrodermias	B
,	O
1	O
palmoplantar	B
pustulosis	I
,	O
1	O
flexural	B
psoriasis	I
,	O
1	O
eczema	B
,	O
1	O
neutrophilic	B
dermatosis	I
and	O
1	O
papular	B
eruption	I
)	O
during	O
treatment	O
with	O
biological	O
drugs	O
(	O
4	O
patients	O
with	O
efaluzimab	O
,	O
2	O
patients	O
with	O
infliximab	O
and	O
1	O
patient	O
with	O
etanercept	O
)	O
.	O

The	O
use	O
of	O
biological	O
agents	O
is	O
expanding	O
worldwide	O
as	O
new	O
alternative	O
treatments	O
for	O
psoriasis	B
and	O
other	O
chronic	B
inflammatory	I
diseases	I
.	O

The	O
increased	O
use	O
of	O
these	O
treatments	O
has	O
allowed	O
identification	O
of	O
their	O
acute	O
and	O
chronic	O
systemic	O
adverse	O
events	O
.	O

Nevertheless	O
,	O
the	O
dermatological	O
adverse	O
events	O
of	O
these	O
biological	O
drugs	O
are	O
less	O
well	O
known	O
due	O
to	O
few	O
reports	O
about	O
them	O
and	O
lack	O
of	O
information	O
about	O
their	O
pathogenic	O
mechanisms	O
.	O

Exact	O
diagnosis	O
of	O
these	O
cutaneous	O
eruptions	O
is	O
very	O
important	O
in	O
order	O
to	O
decide	O
the	O
need	O
for	O
discontinuation	O
of	O
the	O
biological	O
treatment	O
.	O

Hepatocyte	O
growth	O
factor	O
and	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
form	O
a	O
combined	O
neovasculogenic	O
therapy	O
for	O
ischemic	B
cardiomyopathy	I
.	O

BACKGROUND	O
:	O
Myocardial	B
infarction	I
(	O
MI	B
)	O
is	O
a	O
significant	O
cause	O
of	O
heart	B
failure	I
.	O

Current	O
therapies	O
are	O
limited	O
and	O
,	O
therefore	O
,	O
the	O
development	O
of	O
novel	O
revascularization	O
methods	O
is	O
potentially	O
important	O
.	O

We	O
investigated	O
whether	O
hepatocyte	O
growth	O
factor	O
(	O
HGF	O
)	O
,	O
expressed	O
by	O
genetically	O
modified	O
mesenchymal	O
stromal	O
cells	O
(	O
MSC	O
)	O
,	O
in	O
combination	O
with	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
,	O
exhibited	O
a	O
synergistic	O
therapeutic	O
benefit	O
,	O
as	O
measured	O
8	O
weeks	O
after	O
MI	B
induction	O
in	O
a	O
rat	O
model	O
.	O

METHODS	O
:	O
Four	O
weeks	O
after	O
MI	B
,	O
rats	O
were	O
randomly	O
divided	O
into	O
a	O
control	O
group	O
(	O
n	O
=	O
11	O
)	O
,	O
HGF	O
group	O
(	O
Adenovirus	O
vector	O
carrying	O
human	O
HGF	O
(	O
Ad	O
-	O
HGF	O
)	O
-	O
transfected	O
MSC	O
transplanted	O
into	O
the	O
infarct	B
zone	O
;	O
n	O
=	O
11	O
)	O
,	O
G	O
-	O
CSF	O
group	O
(	O
intraperitoneal	O
injection	O
with	O
G	O
-	O
CSF	O
;	O
n	O
=	O
11	O
)	O
,	O
and	O
HGF	O
+	O
G	O
-	O
CSF	O
group	O
(	O
Ad	O
-	O
HGF	O
-	O
transfected	O
MSC	O
transplanted	O
into	O
the	O
infarct	B
zone	O
and	O
intraperitoneal	O
injection	O
with	O
G	O
-	O
CSF	O
;	O
n	O
=	O
11	O
)	O
.	O

Four	O
weeks	O
later	O
,	O
hearts	O
were	O
analyzed	O
for	O
endothelial	O
cell	O
density	O
and	O
angiogenesis	O
,	O
ventricular	O
geometry	O
,	O
myocardial	O
function	O
and	O
levels	O
of	O
VCAM	O
-	O
1	O
and	O
MMP	O
-	O
9	O
protein	O
.	O

RESULTS	O
:	O
The	O
HGF	O
+	O
G	O
-	O
CSF	O
group	O
exhibited	O
improved	O
left	O
ventricular	O
systolic	O
and	O
diastolic	O
function	O
and	O
experienced	O
less	O
adverse	O
ventricular	O
remodeling	O
,	O
as	O
manifested	O
by	O
decreased	O
left	O
ventricular	O
dilatation	O
and	O
increased	O
border	O
zone	O
wall	O
thickness	O
.	O

Angiogenesis	O
was	O
significantly	O
enhanced	O
in	O
HGF	O
+	O
G	O
-	O
CSF	O
rats	O
by	O
inducing	O
the	O
proliferation	O
of	O
endothelial	O
cells	O
.	O

Furthermore	O
,	O
HGF	O
induced	O
expression	O
of	O
VCAM	O
-	O
1	O
,	O
and	O
HGF	O
treatment	O
together	O
with	O
G	O
-	O
CSF	O
synergistically	O
stimulated	O
MMP	O
-	O
9	O
expression	O
in	O
ischemic	O
hearts	O
.	O

DISCUSSION	O
:	O
The	O
combination	O
of	O
G	O
-	O
CSF	O
and	O
HGF	O
exhibited	O
a	O
significant	O
synergistic	O
effect	O
and	O
enhanced	O
myocardial	O
endothelial	O
density	O
,	O
angiogenesis	O
,	O
geometric	O
preservation	O
and	O
heart	O
function	O
in	O
an	O
ischemic	B
cardiomyopathy	I
model	O
.	O

Nutritional	O
supplements	O
with	O
oral	O
amino	O
acid	O
mixtures	O
increases	O
whole	O
-	O
body	O
lean	O
mass	O
and	O
insulin	O
sensitivity	O
in	O
elderly	O
subjects	O
with	O
sarcopenia	B
.	O

Decreases	O
in	O
whole	O
-	O
body	O
lean	O
mass	O
can	O
cause	O
sarcopenia	B
,	O
a	O
disease	O
frequently	O
found	O
in	O
the	O
elderly	O
.	O

This	O
condition	O
is	O
frequently	O
associated	O
with	O
frailty	B
and	O
disability	B
in	I
aging	I
as	O
well	O
as	O
the	O
onset	O
and	O
progression	O
of	O
several	O
geriatric	B
syndromes	I
.	O

Sarcopenia	B
therefore	O
must	O
be	O
managed	O
with	O
multidimensional	O
approaches	O
that	O
include	O
physical	O
training	O
,	O
nutritional	O
support	O
,	O
and	O
metabolic	O
and	O
anabolic	O
treatment	O
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
an	O
orally	O
administered	O
special	O
mixture	O
of	O
amino	O
acids	O
(	O
AAs	O
)	O
in	O
elderly	O
subjects	O
with	O
reduced	O
lean	O
body	O
mass	O
and	O
sarcopenia	B
.	O

A	O
randomized	O
,	O
open	O
-	O
label	O
,	O
crossover	O
study	O
was	O
conducted	O
in	O
41	O
elderly	O
subjects	O
(	O
age	O
range	O
:	O
66	O
-	O
84	O
years	O
)	O
with	O
sarcopenia	B
,	O
assigned	O
to	O
2	O
distinct	O
treatments	O
(	O
AAs	O
and	O
placebo	O
)	O
.	O

All	O
subjects	O
had	O
normal	O
body	O
weight	O
(	O
body	O
mass	O
index	O
within	O
19	O
-	O
23	O
)	O
.	O

The	O
AA	O
treatment	O
consisted	O
of	O
70.6	O
kcal	O
/	O
day	O
(	O
1	O
kcal	O
=	O
4.2	O
kJ	O
)	O
of	O
8	O
g	O
of	O
essential	O
AA	O
snacks	O
,	O
given	O
at	O
10	O
:	O
00	O
am	O
and	O
5	O
:	O
00	O
pm	O
.	O

Lean	O
mass	O
was	O
measured	O
with	O
dual	O
-	O
energy	O
x	O
-	O
ray	O
absorptiometry	O
in	O
leg	O
,	O
arm	O
,	O
and	O
trunk	O
tissues	O
.	O

Significant	O
increases	O
in	O
whole	O
-	O
body	O
lean	O
mass	O
in	O
all	O
areas	O
were	O
seen	O
after	O
6	O
months	O
and	O
more	O
consistently	O
after	O
18	O
months	O
of	O
oral	O
nutritional	O
supplementation	O
with	O
AAs	O
.	O

Fasting	O
blood	O
glucose	O
,	O
serum	O
insulin	O
,	O
and	O
homeostatic	O
model	O
assessment	O
of	O
insulin	B
resistance	I
(	O
an	O
index	O
of	O
insulin	B
resistance	I
)	O
significantly	O
decreased	O
during	O
AA	O
treatment	O
.	O

Furthermore	O
,	O
a	O
significant	O
reduction	O
in	O
serum	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
a	O
significant	O
increase	O
in	O
both	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
1	O
(	O
IGF	O
-	O
1	O
)	O
serum	O
concentrations	O
and	O
in	O
the	O
IGF	O
-	O
1	O
/	O
TNF	O
-	O
alpha	O
ratio	O
were	O
also	O
found	O
.	O

No	O
significant	O
adverse	O
effects	O
were	O
observed	O
during	O
AA	O
treatment	O
.	O

These	O
preliminary	O
data	O
indicate	O
that	O
nutritional	O
supplements	O
with	O
the	O
oral	O
AA	O
mixture	O
significantly	O
increased	O
whole	O
-	O
body	O
lean	O
mass	O
in	O
elderly	O
subjects	O
with	O
sarcopenia	B
.	O

The	O
improvement	O
in	O
the	O
amount	O
of	O
whole	O
-	O
body	O
lean	O
mass	O
could	O
be	O
linked	O
to	O
increased	O
insulin	O
sensitivity	O
and	O
anabolic	O
conditions	O
related	O
to	O
IGF	O
-	O
1	O
availability	O
.	O

Variable	O
response	O
to	O
opioid	O
treatment	O
:	O
any	O
genetic	O
predictors	O
within	O
sight	O
?	O

The	O
aim	O
of	O
this	O
literature	O
review	O
is	O
to	O
summarize	O
and	O
discuss	O
the	O
available	O
evidence	O
for	O
a	O
relationship	O
between	O
polymorphisms	O
in	O
human	O
genes	O
and	O
variability	O
in	O
opioid	O
analgesia	O
and	O
side	O
effects	O
among	O
patients	O
treated	O
for	O
moderate	O
or	O
severe	O
pain	B
.	O

The	O
evidence	O
supporting	O
a	O
role	O
of	O
certain	O
alleles	O
,	O
genotypes	O
or	O
haplotypes	O
in	O
modulation	O
of	O
opioid	O
analgesia	O
is	O
derived	O
from	O
a	O
limited	O
number	O
of	O
studies	O
,	O
a	O
limited	O
number	O
of	O
genes	O
and	O
a	O
limited	O
number	O
of	O
opioids	O
.	O

Although	O
several	O
interesting	O
candidates	O
have	O
emerged	O
as	O
potentially	O
relevant	O
factors	O
,	O
only	O
for	O
one	O
polymorphism	O
,	O
the	O
prevalent	O
118A	O
>	O
G	O
of	O
the	O
micro	O
-	O
opioid	O
receptor	O
,	O
the	O
accumulated	O
evidence	O
is	O
sufficient	O
to	O
suggest	O
a	O
clinically	O
relevant	O
effect	O
for	O
an	O
opioid	O
used	O
for	O
moderate	O
or	O
severe	O
pain	B
.	O

Still	O
the	O
data	O
are	O
valid	O
only	O
at	O
the	O
group	O
level	O
and	O
can	O
not	O
be	O
used	O
to	O
predict	O
treatment	O
outcome	O
in	O
individual	O
patients	O
.	O

Only	O
a	O
few	O
of	O
the	O
symptoms	O
often	O
seen	O
as	O
opioid	O
adverse	O
effects	O
in	O
palliative	O
care	O
,	O
such	O
as	O
nausea	B
,	O
vomiting	B
,	O
constipation	B
and	O
sedation	B
,	O
have	O
been	O
associated	O
with	O
genetic	O
variants	O
in	O
various	O
genes	O
,	O
but	O
the	O
results	O
have	O
been	O
based	O
on	O
case	O
reports	O
,	O
healthy	O
volunteers	O
or	O
post	O
-	O
operative	O
patients	O
.	O

So	O
far	O
,	O
there	O
is	O
no	O
clear	O
evidence	O
that	O
genetic	O
markers	O
can	O
be	O
used	O
to	O
predict	O
opioid	O
efficacy	O
or	O
adverse	O
effects	O
in	O
palliative	O
care	O
patients	O
.	O

This	O
reflects	O
the	O
general	O
lack	O
of	O
studies	O
performed	O
in	O
the	O
context	O
of	O
palliative	O
care	O
,	O
the	O
lack	O
of	O
sufficiently	O
scaled	O
studies	O
and	O
the	O
lack	O
of	O
international	O
standards	O
for	O
the	O
assessment	O
of	O
subjective	O
symptoms	O
.	O

Design	O
of	O
potent	O
,	O
non	O
-	O
toxic	O
antimicrobial	O
agents	O
based	O
upon	O
the	O
naturally	O
occurring	O
frog	O
skin	O
peptides	O
,	O
ascaphin	O
-	O
8	O
and	O
peptide	O
XT	O
-	O
7	O
.	O

The	O
frog	O
skin	O
peptides	O
,	O
ascaphin	O
-	O
8	O
(	O
GFKDLLKGAAKALVKTVLF	O
.	O

NH	O
(	O
2	O
)	O
)	O
and	O
XT	O
-	O
7	O
(	O
GLLGPLLKIAAKVGSNLL	O
.	O

NH	O
(	O
2	O
)	O
)	O
,	O
show	O
broad	O
-	O
spectrum	O
antimicrobial	O
activity	O
but	O
their	O
therapeutic	O
potential	O
is	O
limited	O
by	O
toxicity	O
against	O
mammalian	O
cells	O
.	O

Circular	O
dichroism	O
spectra	O
demonstrate	O
that	O
the	O
peptides	O
adopt	O
an	O
amphipathic	O
alpha	O
-	O
helical	O
conformation	O
in	O
a	O
membrane	O
-	O
mimetic	O
solvent	O
.	O

This	O
study	O
has	O
investigated	O
the	O
cytolytic	O
properties	O
of	O
analogs	O
containing	O
selected	O
amino	O
acid	O
substitutions	O
that	O
increase	O
cationicity	O
while	O
maintaining	O
amphipathicity	O
.	O

Substitutions	O
at	O
Ala	O
(	O
10	O
)	O
,	O
Val	O
(	O
14	O
)	O
,	O
and	O
Leu	O
(	O
18	O
)	O
in	O
ascaphin	O
-	O
8	O
by	O
either	O
L	O
-	O
Lys	O
or	O
D	O
-	O
Lys	O
produced	O
peptides	O
that	O
retained	O
antimicrobial	O
activity	O
against	O
the	O
bacteria	O
Escherichia	O
coli	O
and	O
Staphylococcus	O
aureus	O
and	O
the	O
opportunistic	O
yeast	O
pathogen	O
,	O
Candida	O
albicans	O
but	O
showed	O
appreciably	O
reduced	O
toxicities	O
(	O
>	O
10	O
-	O
fold	O
)	O
against	O
human	O
erythrocytes	O
,	O
HepG2	O
hepatoma	O
-	O
derived	O
cells	O
,	O
and	O
L929	O
fibroblasts	O
.	O

The	O
improved	O
therapeutic	O
index	O
of	O
the	O
L	O
-	O
Lys	O
(	O
18	O
)	O
and	O
D	O
-	O
Lys	O
(	O
18	O
)	O
analogs	O
correlated	O
with	O
a	O
decrease	O
in	O
%	O
helicity	O
and	O
in	O
effective	O
hydrophobicity	O
.	O

Substitution	O
of	O
Gly	O
(	O
4	O
)	O
by	O
L	O
-	O
Lys	O
in	O
XT	O
-	O
7	O
produced	O
an	O
analog	O
with	O
high	O
potency	O
against	O
micro	O
-	O
organisms	O
(	O
MIC	O
<	O
or	O
=	O
25	O
microM	O
)	O
but	O
low	O
cytolytic	O
activity	O
against	O
erythrocytes	O
(	O
LD	O
(	O
50	O
)	O
>	O
500	O
microM	O
)	O
and	O
this	O
increase	O
in	O
therapeutic	O
index	O
also	O
correlated	O
with	O
decreased	O
helicity	O
and	O
hydrophobicity	O
.	O

Analogs	O
of	O
XT	O
-	O
7	O
with	O
increased	O
cationicity	O
,	O
containing	O
multiple	O
substitutions	O
by	O
L	O
-	O
Lys	O
,	O
not	O
only	O
displayed	O
increased	O
antimicrobial	O
potencies	O
,	O
particularly	O
against	O
Candida	O
albicans	O
(	O
MIC	O
<	O
or	O
=	O
6	O
microM	O
)	O
,	O
but	O
also	O
increased	O
hemolytic	O
activities	O
.	O

The	O
role	O
of	O
placental	O
breast	O
cancer	O
resistance	O
protein	O
in	O
the	O
efflux	O
of	O
glyburide	O
across	O
the	O
human	O
placenta	O
.	O

Gestational	B
diabetes	I
mellitus	I
is	O
a	O
common	O
medical	O
complication	O
in	O
pregnancy	O
.	O

Recent	O
findings	O
demonstrate	O
that	O
glyburide	O
is	O
effluxed	O
against	O
a	O
concentration	O
gradient	O
from	O
the	O
fetal	O
to	O
the	O
maternal	O
circulation	O
.	O

However	O
,	O
the	O
transport	O
systems	O
involved	O
in	O
the	O
active	O
efflux	O
of	O
glyburide	O
in	O
the	O
human	O
placenta	O
have	O
not	O
yet	O
been	O
identified	O
.	O

The	O
ATP	O
-	O
binding	O
cassette	O
transporter	O
,	O
breast	O
cancer	O
resistance	O
protein	O
(	O
BCRP	O
)	O
,	O
is	O
highly	O
expressed	O
in	O
placental	O
syncytiotrophoblast	O
suggesting	O
it	O
may	O
play	O
a	O
role	O
in	O
protecting	O
the	O
fetus	O
from	O
drug	B
toxicity	I
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
BCRP	O
participates	O
in	O
the	O
transport	O
of	O
glyburide	O
across	O
the	O
human	O
placenta	O
.	O

The	O
placental	O
transfer	O
of	O
glyburide	O
in	O
the	O
presence	O
of	O
specific	O
BCRP	O
inhibitor	O
,	O
nicardipine	O
,	O
was	O
investigated	O
using	O
the	O
ex	O
vivo	O
dual	O
perfusion	O
system	O
of	O
isolated	O
human	O
placental	O
lobules	O
.	O

In	O
a	O
closed	O
experiment	O
,	O
glyburide	O
was	O
added	O
(	O
200	O
ng	O
/	O
mL	O
)	O
to	O
the	O
maternal	O
and	O
fetal	O
circulations	O
and	O
the	O
BCRP	O
inhibitor	O
(	O
20	O
microM	O
)	O
was	O
added	O
to	O
the	O
maternal	O
circulation	O
.	O

Samples	O
were	O
taken	O
during	O
pre	O
-	O
control	O
,	O
experimental	O
,	O
and	O
post	O
-	O
control	O
periods	O
for	O
measurement	O
of	O
glyburide	O
and	O
markers	O
of	O
tissue	O
viability	O
.	O

Results	O
obtained	O
from	O
perfusions	O
(	O
n	O
=	O
4	O
)	O
in	O
the	O
presence	O
of	O
the	O
BCRP	O
inhibitor	O
show	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
fetal	O
-	O
to	O
-	O
maternal	O
concentration	O
ratio	O
of	O
glyburide	O
determined	O
at	O
180	O
min	O
,	O
0.56	O
+	O
/	O
-	O
0.06	O
,	O
when	O
compared	O
to	O
the	O
mean	O
ratio	O
obtained	O
in	O
the	O
absence	O
of	O
inhibitor	O
,	O
0.32	O
+	O
/	O
-	O
0.06	O
(	O
p	O
=	O
0.04	O
)	O
.	O

These	O
data	O
indicate	O
that	O
nicardipine	O
partially	O
blocked	O
the	O
transfer	O
of	O
glyburide	O
across	O
the	O
whole	O
placenta	O
through	O
its	O
inhibition	O
of	O
BCRP	O
.	O

This	O
is	O
the	O
first	O
ex	O
vivo	O
evidence	O
that	O
BCRP	O
actively	O
transports	O
glyburide	O
.	O

The	O
efficacy	O
of	O
Femal	O
in	O
women	O
with	O
premenstrual	B
syndrome	I
:	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
-	O
group	O
,	O
placebo	O
-	O
controlled	O
,	O
multicentre	O
study	O
.	O

INTRODUCTION	O
:	O
A	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomised	O
,	O
parallel	O
-	O
group	O
,	O
multicentre	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
pollen	O
-	O
based	O
herbal	O
medicinal	O
product	O
,	O
Femal	O
(	O
Sea	O
-	O
Band	O
Ltd	O
,	O
Leicestershire	O
,	O
UK	O
)	O
,	O
on	O
premenstrual	B
sleep	I
disturbances	I
(	O
PSD	B
)	O
in	O
women	O
with	O
premenstrual	B
syndrome	I
(	O
PMS	B
)	O
.	O

METHODS	O
:	O
Femal	O
,	O
160	O
mg	O
twice	O
-	O
daily	O
,	O
was	O
given	O
for	O
four	O
menstrual	O
cycles	O
to	O
50	O
women	O
,	O
and	O
placebo	O
to	O
51	O
women	O
.	O

PSD	B
were	O
evaluated	O
on	O
a	O
visual	O
analogue	O
scale	O
prior	O
to	O
and	O
after	O
the	O
four	O
cycles	O
.	O

The	O
effect	O
on	O
overall	O
PMS	B
symptoms	I
was	O
assessed	O
with	O
the	O
Steiner	O
premenstrual	B
tension	I
syndrome	I
(	O
PMTS	B
)	O
self	O
-	O
rating	O
questionnaire	O
.	O

The	O
results	O
were	O
analysed	O
statistically	O
based	O
on	O
intention	O
to	O
treat	O
.	O

RESULTS	O
:	O
Femal	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
PSD	B
(	O
P	O
<	O
0.05	O
)	O
whereas	O
placebo	O
had	O
no	O
significant	O
effect	O
(	O
P	O
>	O
0.05	O
)	O
.	O

In	O
a	O
subgroup	O
analysis	O
of	O
women	O
with	O
irritability	B
as	O
their	O
main	O
PMS	B
symptom	I
cluster	O
,	O
the	O
reduction	O
of	O
PSD	B
was	O
even	O
more	O
pronounced	O
(	O
P	O
<	O
0.001	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
overall	O
degree	O
of	O
PMS	B
symptom	I
reduction	O
between	O
Femal	O
and	O
placebo	O
when	O
all	O
participating	O
women	O
were	O
evaluated	O
(	O
P	O
>	O
0.05	O
)	O
.	O

However	O
,	O
in	O
women	O
with	O
irritability	B
as	O
their	O
main	O
PMS	B
symptom	I
cluster	O
,	O
Femal	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
Steiner	O
score	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
frequency	O
of	O
adverse	O
events	O
was	O
not	O
significantly	O
different	O
in	O
women	O
on	O
Femal	O
compared	O
to	O
women	O
on	O
placebo	O
(	O
P	O
>	O
0.05	O
)	O
.	O

No	O
serious	O
adverse	O
events	O
were	O
recorded	O
.	O

CONCLUSION	O
:	O
Femal	O
treatment	O
reduced	O
PSD	B
to	O
a	O
significant	O
degree	O
,	O
particularly	O
in	O
women	O
with	O
irritability	B
as	O
their	O
main	O
PMS	B
symptom	I
.	O

Femal	O
treatment	O
also	O
reduced	O
overall	O
PMS	B
symptoms	I
in	O
women	O
with	O
irritability	B
(	O
but	O
not	O
dysphoria	B
)	O
as	O
their	O
main	O
PMS	B
symptom	I
.	O

The	O
safety	O
of	O
Femal	O
and	O
its	O
efficacy	O
in	O
PSD	B
and	O
other	O
symptoms	O
in	O
women	O
with	O
irritability	B
as	O
the	O
main	O
symptom	O
cluster	O
makes	O
this	O
herbal	O
medicinal	O
product	O
a	O
promising	O
addition	O
to	O
the	O
therapeutic	O
arsenal	O
for	O
women	O
with	O
PMS	B
.	O

A	O
novel	O
polyherbal	O
microbicide	O
with	O
inhibitory	O
effect	O
on	O
bacterial	O
,	O
fungal	O
and	O
viral	O
genital	O
pathogens	O
.	O

A	O
polyherbal	O
cream	O
(	O
Basant	O
)	O
has	O
been	O
formulated	O
using	O
diferuloylmethane	O
(	O
curcumin	O
)	O
,	O
purified	O
extracts	O
of	O
Emblica	O
officinalis	O
(	O
Amla	O
)	O
,	O
purified	O
saponins	O
from	O
Sapindus	O
mukorossi	O
,	O
Aloe	O
vera	O
and	O
rose	O
water	O
along	O
with	O
pharmacopoeially	O
approved	O
excipients	O
and	O
preservatives	O
.	O

Basant	O
inhibits	O
the	O
growth	O
of	O
WHO	O
strains	O
and	O
clinical	O
isolates	O
of	O
Neisseria	O
gonorrhoeae	O
,	O
including	O
those	O
resistant	O
to	O
penicillin	O
,	O
tetracycline	O
,	O
nalidixic	O
acid	O
and	O
ciprofloxacin	O
.	O

It	O
has	O
pronounced	O
inhibitory	O
action	O
against	O
Candida	O
glabrata	O
,	O
Candida	O
albicans	O
and	O
Candida	O
tropicalis	O
isolated	O
from	O
women	O
with	O
vulvovaginal	B
candidiasis	I
,	O
including	O
three	O
isolates	O
resistant	O
to	O
azole	O
drugs	O
and	O
amphotericin	O
B	O
.	O

Basant	O
displayed	O
a	O
high	O
virucidal	O
action	O
against	O
human	O
immunodeficiency	O
virus	O
HIV	O
-	O
1NL4	O
.3	O
in	O
CEM	O
-	O
GFP	O
reporter	O
T	O
and	O
P4	O
(	O
Hela	O
-	O
CD4	O
-	O
LTR	O
-	O
betaGal	O
)	O
cell	O
lines	O
with	O
a	O
50	O
%	O
effective	O
concentration	O
(	O
EC50	O
)	O
of	O
1	O
:	O
20000	O
dilution	O
and	O
nearly	O
complete	O
(	O
98	O
-	O
99	O
%	O
)	O
inhibition	O
at	O
1	O
:	O
1000	O
dilution	O
.	O

It	O
also	O
prevented	O
the	O
entry	O
of	O
HIV	O
-	O
1	O
(	O
IIIB	O
)	O
virus	O
into	O
P4	O
-	O
CCR5	O
cells	O
(	O
EC50	O
approximately	O
1	O
:	O
2492	O
)	O
.	O

Two	O
ingredients	O
,	O
Aloe	O
and	O
Amla	O
,	O
inhibited	O
the	O
transduction	O
of	O
human	O
papillomavirus	O
type	O
16	O
(	O
HPV	O
-	O
16	O
)	O
pseudovirus	O
in	O
HeLa	O
cells	O
at	O
concentrations	O
far	O
below	O
those	O
that	O
are	O
cytotoxic	O
and	O
those	O
used	O
in	O
the	O
formulation	O
.	O

Basant	O
was	O
found	O
to	O
be	O
totally	O
safe	O
according	O
to	O
pre	O
-	O
clinical	O
toxicology	O
carried	O
out	O
on	O
rabbit	O
vagina	O
after	O
application	O
for	O
7	O
consecutive	O
days	O
or	O
twice	O
daily	O
for	O
3	O
weeks	O
.	O

Basant	O
has	O
the	O
potential	O
of	O
regressing	O
vulvovaginal	B
candidiasis	I
and	O
preventing	O
N	O
.	O

gonorrhoeae	O
,	O
HIV	O
and	O
HPV	B
infections	I
.	O

Neuroprotection	O
by	O
Spirulina	O
platensis	O
protean	O
extract	O
and	O
phycocyanin	O
against	O
iron	O
-	O
induced	O
toxicity	O
in	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
Spirulina	O
platensis	O
protean	O
extract	O
and	O
the	O
biliprotein	O
phycocyanin	O
isolated	O
from	O
this	O
microalga	O
,	O
on	O
the	O
activities	O
of	O
the	O
antioxidant	O
enzymes	O
SOD	O
,	O
CAT	O
,	O
GPx	O
,	O
and	O
GR	O
,	O
lipid	O
peroxidation	O
inhibitory	O
activity	O
and	O
glutathione	O
levels	O
after	O
the	O
iron	O
induced	O
oxidative	O
stress	O
in	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
.	O

Iron	O
is	O
one	O
of	O
the	O
most	O
important	O
agents	O
that	O
produce	O
oxidative	O
stress	O
and	O
decline	O
of	O
neuronal	O
functions	O
.	O

S	O
.	O

platensis	O
protean	O
extract	O
and	O
phycocyanin	O
exert	O
the	O
antioxidant	O
activity	O
by	O
protecting	O
the	O
activity	O
of	O
the	O
cellular	O
antioxidant	O
enzymes	O
total	O
GPx	O
,	O
GPx	O
-	O
Se	O
and	O
GR	O
and	O
by	O
increasing	O
reduced	O
glutathione	O
in	O
cells	O
against	O
oxidative	O
stress	O
induced	O
by	O
iron	O
.	O

These	O
results	O
suggested	O
that	O
S	O
.	O

platensis	O
protean	O
extract	O
is	O
a	O
powerful	O
antioxidant	O
through	O
a	O
mechanism	O
related	O
to	O
antioxidant	O
activity	O
,	O
capable	O
of	O
interfering	O
with	O
radical	O
-	O
mediated	O
cell	O
death	O
.	O

S	O
.	O

platensis	O
may	O
be	O
useful	O
in	O
diseases	O
known	O
to	O
be	O
aggravated	O
by	O
reactive	O
oxygen	O
species	O
and	O
in	O
the	O
development	O
of	O
novel	O
treatments	O
for	O
neurodegenerative	B
disorders	I
as	O
long	O
as	O
iron	O
has	O
been	O
implicated	O
in	O
the	O
neuropathology	O
of	O
several	O
neurodegenerative	B
disorders	I
such	O
as	O
Alzheimer	O
's	O
or	O
Parkinson	B
diseases	I
.	O

Safety	O
and	O
pharmacodynamics	O
of	O
lansoprazole	O
in	O
patients	O
with	O
gastroesophageal	B
reflux	I
disease	I
aged	O
<	O
1	O
year	O
.	O

BACKGROUND	O
:	O
The	O
use	O
of	O
proton	O
pump	O
inhibitors	O
(	O
PPIs	O
)	O
for	O
the	O
treatment	O
of	O
gastroesophageal	B
reflux	I
disease	I
(	O
GERD	B
)	O
in	O
pediatric	O
patients	O
<	O
1	O
year	O
of	O
age	O
is	O
increasing	O
.	O

However	O
,	O
few	O
studies	O
with	O
PPIs	O
have	O
been	O
reported	O
in	O
such	O
patients	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
effect	O
of	O
once	O
-	O
daily	O
lansoprazole	O
on	O
safety	O
and	O
to	O
characterize	O
the	O
pharmacodynamic	O
profile	O
of	O
lansoprazole	O
in	O
a	O
subset	O
of	O
subjects	O
<	O
1	O
year	O
of	O
age	O
.	O

The	O
effect	O
of	O
lansoprazole	O
on	O
predefined	O
GERD	B
-	I
associated	I
symptoms	I
was	O
also	O
assessed	O
.	O

METHODS	O
:	O
Two	O
phase	O
I	O
,	O
single	O
-	O
and	O
repeated	O
-	O
dose	O
,	O
randomized	O
,	O
parallel	O
-	O
group	O
,	O
open	O
-	O
label	O
,	O
multicenter	O
studies	O
were	O
performed	O
.	O

Both	O
studies	O
involved	O
either	O
a	O
7	O
-	O
or	O
14	O
-	O
day	O
pre	O
-	O
treatment	O
period	O
,	O
with	O
a	O
dose	O
administration	O
period	O
of	O
5	O
days	O
,	O
and	O
a	O
follow	O
-	O
up	O
period	O
of	O
30	O
days	O
for	O
adverse	O
events	O
collection	O
.	O

A	O
total	O
of	O
six	O
investigative	O
sites	O
were	O
involved	O
:	O
four	O
university	O
hospital	O
/	O
medical	O
centers	O
(	O
three	O
in	O
Poland	O
,	O
one	O
in	O
the	O
US	O
)	O
,	O
one	O
large	O
regional	O
medical	O
center	O
(	O
Poland	O
)	O
,	O
and	O
one	O
private	O
practice	O
(	O
US	O
)	O
.	O

The	O
studies	O
involved	O
24	O
neonates	O
(	O
<	O
or	O
=	O
28	O
days	O
of	O
age	O
)	O
and	O
24	O
infants	O
(	O
>	O
28	O
days	O
but	O
<	O
1	O
year	O
of	O
age	O
)	O
with	O
GERD	O
-	O
associated	O
symptoms	O
diagnosed	O
by	O
medical	O
history	O
and	O
the	O
clinical	O
judgment	O
of	O
the	O
treating	O
physician	O
.	O

Eligible	O
subjects	O
were	O
randomized	O
to	O
receive	O
either	O
lansoprazole	O
0.5	O
or	O
1.0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
neonates	O
)	O
,	O
or	O
1.0	O
or	O
2.0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
infants	O
)	O
,	O
for	O
5	O
days	O
.	O

Safety	O
and	O
pharmacodynamic	O
parameters	O
were	O
the	O
primary	O
outcome	O
measures	O
.	O

Safety	O
and	O
GERD	B
symptoms	I
were	O
assessed	O
in	O
all	O
participants	O
.	O

Intragastric	O
/	O
intraesophageal	O
pH	O
monitoring	O
was	O
performed	O
in	O
a	O
subset	O
of	O
six	O
neonates	O
and	O
six	O
infants	O
at	O
baseline	O
and	O
on	O
dose	O
administration	O
days	O
1	O
and	O
5	O
.	O

RESULTS	O
:	O
Over	O
5	O
days	O
of	O
daily	O
dose	O
administration	O
,	O
lansoprazole	O
was	O
well	O
tolerated	O
in	O
neonates	O
and	O
infants	O
.	O

Four	O
neonates	O
and	O
one	O
infant	O
experienced	O
mild	O
to	O
moderate	O
treatment	O
-	O
related	O
adverse	O
events	O
during	O
the	O
dose	O
administration	O
period	O
.	O

One	O
neonate	O
experienced	O
a	O
serious	O
adverse	O
event	O
that	O
was	O
unrelated	O
to	O
treatment	O
.	O

Lansoprazole	O
increased	O
the	O
percentage	O
of	O
time	O
that	O
intragastric	O
pH	O
was	O
above	O
3	O
,	O
4	O
,	O
5	O
,	O
and	O
6	O
over	O
the	O
24	O
-	O
hour	O
post	O
-	O
dose	O
period	O
on	O
days	O
1	O
and	O
5	O
when	O
compared	O
with	O
baseline	O
.	O

Mean	O
24	O
-	O
hour	O
integrated	O
gastric	O
acidity	O
decreased	O
from	O
baseline	O
to	O
day	O
5	O
in	O
both	O
populations	O
.	O

The	O
daily	O
number	O
of	O
episodes	O
of	O
regurgitation	B
/	O
vomiting	B
was	O
lower	O
than	O
at	O
baseline	O
among	O
neonates	O
after	O
5	O
days	O
of	O
lansoprazole	O
treatment	O
;	O
among	O
infants	O
,	O
both	O
the	O
prevalence	O
and	O
the	O
average	O
daily	O
number	O
of	O
episodes	O
of	O
several	O
individual	O
GERD	B
-	I
associated	I
symptoms	I
were	O
lower	O
than	O
at	O
baseline	O
.	O

CONCLUSIONS	O
:	O
After	O
5	O
days	O
of	O
open	O
-	O
label	O
administration	O
,	O
lansoprazole	O
was	O
well	O
tolerated	O
and	O
increased	O
intragastric	O
pH	O
in	O
pediatric	O
subjects	O
<	O
1	O
year	O
of	O
age	O
.	O

A	O
decrease	O
in	O
the	O
frequency	O
of	O
GERD	B
symptoms	I
was	O
also	O
observed	O
.	O

Low	O
-	O
dose	O
interleukin	O
-	O
2	O
immunotherapy	O
does	O
not	O
improve	O
outcome	O
of	O
patients	O
age	O
60	O
years	O
and	O
older	O
with	O
acute	B
myeloid	I
leukemia	I
in	O
first	O
complete	O
remission	O
:	O
Cancer	B
and	O
Leukemia	B
Group	O
B	O
Study	O
9720	O
.	O

PURPOSE	O
:	O
Cancer	B
and	O
Leukemia	B
Group	O
B	O
(	O
CALGB	O
)	O
9720	O
evaluated	O
subcutaneous	O
low	O
-	O
dose	O
recombinant	O
interleukin	O
-	O
2	O
(	O
rIL	O
-	O
2	O
)	O
maintenance	O
immunotherapy	O
as	O
a	O
strategy	O
for	O
prolonging	O
remission	O
in	O
older	O
patients	O
with	O
acute	B
myeloid	I
leukemia	I
(	O
AML	B
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
AML	B
patients	O
age	O
60	O
years	O
and	O
older	O
in	O
first	O
complete	O
remission	O
after	O
induction	O
and	O
consolidation	O
chemotherapy	O
were	O
randomly	O
assigned	O
to	O
no	O
further	O
therapy	O
or	O
a	O
90	O
-	O
day	O
regimen	O
of	O
14	O
-	O
day	O
cycles	O
of	O
low	O
-	O
dose	O
rIL	O
-	O
2	O
,	O
aimed	O
at	O
expanding	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
,	O
followed	O
by	O
3	O
-	O
day	O
higher	O
doses	O
aimed	O
at	O
activating	O
cytotoxicity	O
of	O
expanded	O
NK	O
cells	O
to	O
lyse	O
residual	O
AML	O
cells	O
.	O

All	O
randomly	O
assigned	O
patients	O
were	O
included	O
in	O
an	O
intention	O
-	O
to	O
-	O
treat	O
analysis	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
163	O
(	O
64	O
%	O
)	O
of	O
254	O
patients	O
who	O
completed	O
induction	O
and	O
consolidation	O
chemotherapy	O
on	O
CALGB	O
9720	O
were	O
randomly	O
assigned	O
to	O
rIL	O
-	O
2	O
(	O
n	O
=	O
81	O
)	O
or	O
no	O
further	O
therapy	O
(	O
n	O
=	O
82	O
)	O
;	O
the	O
most	O
common	O
reasons	O
for	O
lack	O
of	O
random	O
assignment	O
were	O
patient	O
refusal	O
and	O
relapse	O
.	O

Fifteen	O
patients	O
randomly	O
assigned	O
to	O
rIL	O
-	O
2	O
never	O
initiated	O
it	O
because	O
of	O
refusal	O
,	O
intercurrent	O
medical	O
problems	O
,	O
or	O
relapse	O
,	O
and	O
24	O
patients	O
initiated	O
rIL	O
-	O
2	O
but	O
stopped	O
early	O
because	O
of	O
toxicity	O
or	O
relapse	O
.	O

Grade	O
4	O
toxicities	O
during	O
rIL	O
-	O
2	O
therapy	O
included	O
thrombocytopenia	B
(	O
65	O
%	O
)	O
and	O
neutropenia	B
(	O
64	O
%	O
)	O
,	O
and	O
grade	O
3	O
toxicities	O
included	O
anemia	B
(	O
33	O
%	O
)	O
,	O
infection	B
(	O
24	O
%	O
)	O
and	O
malaise	B
/	O
fatigue	B
(	O
14	O
%	O
)	O
.	O

Forty	O
-	O
two	O
patients	O
(	O
52	O
%	O
)	O
randomly	O
assigned	O
to	O
rIL	O
-	O
2	O
completed	O
the	O
full	O
90	O
-	O
day	O
course	O
.	O

Patients	O
in	O
both	O
arms	O
had	O
similar	O
distributions	O
of	O
both	O
disease	O
-	O
free	O
(	O
combined	O
median	O
=	O
6.1	O
months	O
;	O
P	O
=	O
.47	O
)	O
and	O
overall	O
survival	O
(	O
combined	O
median	O
=	O
14.7	O
months	O
;	O
P	O
=	O
.61	O
)	O
after	O
random	O
assignment	O
.	O

Moreover	O
,	O
the	O
42	O
patients	O
who	O
completed	O
all	O
planned	O
therapy	O
did	O
not	O
show	O
prolongation	O
of	O
disease	O
-	O
free	O
or	O
overall	O
survival	O
.	O

CONCLUSION	O
:	O
Low	O
-	O
dose	O
rIL	O
-	O
2	O
maintenance	O
immunotherapy	O
is	O
not	O
a	O
successful	O
strategy	O
in	O
older	O
AML	B
patients	O
.	O

Prostaglandin	O
receptor	O
EP2	O
protects	O
dopaminergic	O
neurons	O
against	O
6	O
-	O
OHDA	O
-	O
mediated	O
low	O
oxidative	O
stress	O
.	O

Dopaminergic	O
neurons	O
in	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
selectively	O
die	O
in	O
Parkinson	B
's	I
disease	I
(	O
PD	B
)	O
,	O
but	O
it	O
is	O
unclear	O
how	O
and	O
why	O
this	O
occurs	O
.	O

Recent	O
findings	O
implicate	O
prostaglandin	O
E	O
(	O
2	O
)	O
(	O
PGE	O
(	O
2	O
)	O
)	O
and	O
two	O
of	O
its	O
four	O
receptors	O
,	O
namely	O
EP1	O
and	O
EP2	O
,	O
as	O
mediators	O
of	O
degenerative	O
and	O
protective	O
events	O
in	O
situations	O
of	O
acute	O
and	O
chronic	B
neuronal	I
death	I
.	O

EP1	O
activation	O
can	O
exacerbate	O
excitotoxic	O
damage	O
in	O
stroke	B
models	O
and	O
our	O
recent	O
study	O
showed	O
that	O
EP1	O
activation	O
may	O
explain	O
the	O
selective	O
sensitivity	O
of	O
dopaminergic	O
neurons	O
to	O
oxidative	O
stress	O
.	O

Conversely	O
,	O
EP2	O
activation	O
may	O
be	O
neuroprotective	O
,	O
although	O
toxic	O
effects	O
have	O
also	O
been	O
demonstrated	O
.	O

Here	O
we	O
investigated	O
if	O
and	O
how	O
EP2	O
activation	O
might	O
alter	O
the	O
survival	O
of	O
dopaminergic	O
neurons	O
following	O
selective	O
low	O
-	O
level	O
oxidative	O
injury	O
evoked	O
by	O
the	O
neurotoxin	O
6	O
-	O
hydroxydopamine	O
(	O
6	O
-	O
OHDA	O
)	O
in	O
primary	O
neuronal	O
cultures	O
prepared	O
from	O
embryonic	O
rat	O
midbrain	O
.	O

We	O
found	O
that	O
cultured	O
dopaminergic	O
neurons	O
displayed	O
EP2	O
receptors	O
.	O

Butaprost	O
,	O
a	O
selective	O
EP2	O
agonist	O
,	O
significantly	O
reduced	O
6	O
-	O
OHDA	O
neurotoxicity	B
.	O

EP2	O
receptors	O
are	O
coupled	O
to	O
stimulatory	O
G	O
-	O
proteins	O
(	O
Gs	O
)	O
,	O
which	O
activate	O
adenylate	O
cyclase	O
,	O
increasing	O
cAMP	O
synthesis	O
,	O
which	O
then	O
activates	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O

Both	O
dibutyryl	O
cAMP	O
and	O
forskolin	O
reduced	O
dopaminergic	O
cell	O
loss	O
after	O
6	O
-	O
OHDA	O
exposure	O
.	O

Conversely	O
,	O
KT5720	O
and	O
H	O
-	O
89	O
,	O
two	O
structurally	O
distinct	O
high	O
-	O
affinity	O
PKA	O
inhibitors	O
,	O
abolished	O
the	O
protective	O
effect	O
of	O
butaprost	O
,	O
implicating	O
cAMP	O
-	O
dependent	O
PKA	O
activity	O
in	O
the	O
neuroprotection	O
by	O
EP2	O
activation	O
.	O

Finally	O
,	O
we	O
show	O
that	O
melanized	O
dopaminergic	O
neurons	O
in	O
the	O
human	O
SN	O
express	O
EP2	O
.	O

This	O
pathway	O
warrants	O
consideration	O
as	O
a	O
neuroprotective	O
strategy	O
for	O
PD	B
.	O

Utility	O
of	O
published	O
guidelines	O
on	O
the	O
use	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
in	O
the	O
elderly	O
.	O

Canadian	O
Consensus	O
guidelines	O
regarding	O
appropriate	O
use	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAID	O
)	O
were	O
recently	O
published	O
.	O

This	O
study	O
was	O
done	O
to	O
evaluate	O
the	O
application	O
of	O
these	O
guidelines	O
on	O
NSAID	O
practice	O
patterns	O
in	O
frail	O
elderly	O
patients	O
referred	O
to	O
a	O
specialist	O
Geriatric	O
Assessment	O
Clinic	O
.	O

A	O
retrospective	O
chart	O
review	O
was	O
undertaken	O
of	O
referrals	O
who	O
were	O
currently	O
prescribed	O
NSAIDs	O
.	O

Data	O
were	O
captured	O
on	O
age	O
,	O
sex	O
,	O
weight	O
,	O
diagnoses	O
,	O
medications	O
and	O
dosages	O
,	O
indication	O
for	O
NSAID	O
treatment	O
,	O
lying	O
BP	O
(	O
as	O
assessed	O
in	O
the	O
clinic	O
)	O
and	O
recent	O
serum	O
creatinine	O
result	O
.	O

Creatinine	O
clearance	O
was	O
subsequently	O
calculated	O
use	O
the	O
Cockcroft	O
-	O
Gault	O
equation	O
.	O

Complete	O
data	O
were	O
available	O
on	O
107	O
patients	O
(	O
68	O
%	O
women	O
,	O
average	O
age	O
80.6	O
years	O
)	O
.	O

Thirty	O
percent	O
were	O
on	O
a	O
traditional	O
NSAID	O
,	O
the	O
remainder	O
were	O
on	O
a	O
Coxib	O
.	O

Concomitant	O
aspirin	O
was	O
prescribed	O
in	O
37	O
%	O
.	O

Cytoprotection	O
was	O
being	O
used	O
in	O
38	O
%	O
and	O
did	O
not	O
increase	O
appreciably	O
in	O
patients	O
with	O
additional	O
risk	O
factors	O
for	O
GI	B
toxicity	I
,	O
i.e.	O
,	O
concomitant	O
aspirin	O
usage	O
(	O
35	O
%	O
)	O
,	O
and	O
history	O
of	O
GI	B
toxicity	I
(	O
48	O
%	O
)	O
.	O

Sixty	O
-	O
seven	O
were	O
taking	O
anti	O
-	O
hypertensive	O
medications	O
,	O
although	O
more	O
than	O
two	O
thirds	O
of	O
these	O
patients	O
were	O
uncontrolled	O
.	O

Newly	O
diagnosed	O
hypertension	B
was	O
present	O
in	O
19.6	O
%	O
.	O

Calculated	O
creatinine	O
clearance	O
revealed	O
moderate	O
to	O
severe	O
renal	B
impairment	I
in	O
79	O
%	O
of	O
subjects	O
,	O
although	O
serum	O
creatinine	O
was	O
only	O
elevated	O
in	O
18	O
%	O
.	O

In	O
total	O
,	O
70	O
%	O
of	O
subjects	O
were	O
found	O
to	O
have	O
relative	O
or	O
absolute	O
risk	O
factors	O
for	O
NSAID	O
therapy	O
.	O

Given	O
the	O
high	O
prevalence	O
of	O
potential	O
contraindications	O
to	O
anti	O
-	O
inflammatory	O
drug	O
usage	O
in	O
this	O
study	O
,	O
we	O
advocate	O
the	O
dissemination	O
and	O
application	O
of	O
these	O
guidelines	O
in	O
geriatric	O
patients	O
in	O
an	O
attempt	O
to	O
reduce	O
potential	O
morbidity	O
and	O
mortality	O
.	O

Practical	O
model	O
-	O
based	O
dose	O
finding	O
in	O
early	O
-	O
phase	O
clinical	O
trials	O
:	O
optimizing	O
tissue	O
plasminogen	O
activator	O
dose	O
for	O
treatment	O
of	O
ischemic	B
stroke	I
in	O
children	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
A	O
safe	O
and	O
effective	O
tissue	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
dose	O
for	O
childhood	O
stroke	B
has	O
not	O
been	O
established	O
.	O

This	O
article	O
describes	O
a	O
Bayesian	O
outcome	O
-	O
adaptive	O
method	O
for	O
determining	O
the	O
best	O
dose	O
of	O
an	O
experimental	O
agent	O
and	O
explains	O
how	O
this	O
method	O
was	O
used	O
to	O
design	O
a	O
dose	O
-	O
finding	O
trial	O
for	O
tPA	O
in	O
childhood	O
.	O

METHODS	O
:	O
The	O
method	O
assigns	O
doses	O
to	O
successive	O
cohorts	O
of	O
patients	O
on	O
the	O
basis	O
of	O
each	O
dose	O
's	O
desirability	O
,	O
quantified	O
in	O
terms	O
of	O
the	O
tradeoff	O
between	O
efficacy	O
and	O
toxicity	O
.	O

The	O
tradeoff	O
function	O
is	O
constructed	O
from	O
several	O
pairs	O
of	O
equally	O
desirable	O
(	O
efficacy	O
,	O
toxicity	O
)	O
probabilities	O
specified	O
by	O
the	O
physicians	O
planning	O
the	O
trial	O
.	O

Each	O
cohort	O
's	O
dose	O
is	O
chosen	O
adaptively	O
,	O
based	O
on	O
dose	O
-	O
outcome	O
data	O
from	O
the	O
patients	O
treated	O
previously	O
in	O
the	O
trial	O
,	O
to	O
optimize	O
the	O
efficacy	O
-	O
toxicity	O
tradeoff	O
.	O

Application	O
of	O
the	O
method	O
to	O
design	O
the	O
tPA	O
trial	O
is	O
described	O
,	O
including	O
a	O
computer	O
simulation	O
study	O
to	O
establish	O
design	O
properties	O
.	O

A	O
hypothetical	O
cohort	O
-	O
by	O
-	O
cohort	O
example	O
is	O
given	O
to	O
illustrate	O
how	O
the	O
method	O
works	O
during	O
trial	O
conduct	O
.	O

RESULTS	O
:	O
Because	O
only	O
a	O
dose	O
that	O
is	O
both	O
safe	O
and	O
efficacious	O
may	O
be	O
selected	O
and	O
the	O
method	O
combines	O
phase	O
I	O
and	O
phase	O
II	O
by	O
integrating	O
efficacy	O
and	O
toxicity	O
to	O
choose	O
doses	O
,	O
it	O
avoids	O
the	O
more	O
time	O
-	O
consuming	O
and	O
expensive	O
conventional	O
approach	O
of	O
conducting	O
a	O
phase	O
I	O
trial	O
based	O
on	O
toxicity	O
alone	O
followed	O
by	O
a	O
phase	O
II	O
trial	O
based	O
on	O
efficacy	O
alone	O
.	O

This	O
is	O
especially	O
useful	O
in	O
settings	O
with	O
low	O
accrual	O
rates	O
,	O
such	O
as	O
trials	O
of	O
tPA	O
for	O
pediatric	O
acute	B
ischemic	I
stroke	I
.	O

Pre	O
-	O
clinical	O
evidence	O
for	O
altered	O
absorption	O
and	O
biliary	O
excretion	O
of	O
irinotecan	O
(	O
CPT	O
-	O
11	O
)	O
in	O
combination	O
with	O
quercetin	O
:	O
possible	O
contribution	O
of	O
P	O
-	O
glycoprotein	O
.	O

P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
is	O
found	O
to	O
play	O
a	O
very	O
significant	O
role	O
in	O
intestinal	O
and	O
biliary	O
transport	O
of	O
irinotecan	O
and	O
its	O
active	O
metabolite	O
,	O
SN	O
-	O
38	O
.	O

This	O
makes	O
P	O
-	O
gp	O
inhibition	O
a	O
logical	O
strategy	O
for	O
improving	O
irinotecan	O
's	O
oral	O
efficacy	O
and	O
reducing	O
its	O
toxicity	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
identify	O
the	O
most	O
suitable	O
P	O
-	O
gp	O
inhibitor	O
,	O
amongst	O
various	O
commonly	O
used	O
herbal	O
components	O
via	O
in	O
vitro	O
screening	O
;	O
followed	O
by	O
determination	O
of	O
in	O
vivo	O
effects	O
in	O
rats	O
.	O

Caco	O
-	O
2	O
cell	O
monolayers	O
were	O
used	O
to	O
investigate	O
the	O
influence	O
of	O
various	O
components	O
(	O
quercetin	O
,	O
hesperitin	O
,	O
piperine	O
,	O
curcumin	O
and	O
naringenin	O
)	O
on	O
the	O
transport	O
of	O
irinotecan	O
.	O

The	O
secretory	O
transport	O
(	O
basolateral	O
-	O
to	O
-	O
apical	O
)	O
was	O
significantly	O
decreased	O
by	O
all	O
components	O
(	O
p	O
<	O
0.05	O
)	O
except	O
piperine	O
.	O

In	O
the	O
apical	O
-	O
to	O
-	O
basolateral	O
transport	O
,	O
quercetin	O
showed	O
the	O
highest	O
absorptive	O
permeability	O
enhancement	O
and	O
P	O
-	O
gp	O
interaction	O
potential	O
making	O
it	O
an	O
appropriate	O
candidate	O
for	O
further	O
in	O
vivo	O
studies	O
in	O
female	O
Wistar	O
rats	O
.	O

Quercetin	O
pre	O
-	O
treatment	O
resulted	O
in	O
increased	O
irinotecan	O
C	O
(	O
max	O
)	O
and	O
area	O
under	O
curve	O
(	O
AUC	O
)	O
with	O
a	O
concomitant	O
decrease	O
in	O
t	O
(	O
max	O
)	O
,	O
plasma	O
clearance	O
and	O
volume	O
of	O
distribution	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
absolute	O
bioavailability	O
(	O
F	O
)	O
of	O
irinotecan	O
control	O
was	O
33	O
%	O
,	O
which	O
was	O
increased	O
to	O
43	O
%	O
(	O
1.3	O
fold	O
)	O
by	O
quercetin	O
administration	O
.	O

The	O
amounts	O
of	O
irinotecan	O
and	O
SN	O
-	O
38	O
eliminated	O
in	O
bile	O
in	O
control	O
rats	O
,	O
is	O
reduced	O
to	O
almost	O
half	O
when	O
treated	O
with	O
quercetin	O
.	O

Our	O
studies	O
not	O
only	O
propose	O
a	O
safe	O
approach	O
for	O
bioavailability	O
enhancement	O
and	O
reducing	O
toxicity	O
of	O
irinotecan	O
by	O
P	O
-	O
gp	O
inhibition	O
but	O
in	O
another	O
way	O
also	O
reiterate	O
the	O
significance	O
of	O
elucidating	O
herb	O
-	O
drug	O
interactions	O
for	O
future	O
insights	O
.	O

Fragrance	O
material	O
review	O
on	O
geraniol	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
geraniol	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

A	O
phase	O
II	O
trial	O
of	O
tetrathiomolybdate	O
after	O
surgery	O
for	O
malignant	B
mesothelioma	I
:	O
final	O
results	O
.	O

BACKGROUND	O
:	O
Tetrathiomolybdate	O
(	O
TM	O
)	O
is	O
an	O
oral	O
copper	O
-	O
depleting	O
agent	O
that	O
has	O
been	O
shown	O
to	O
inhibit	O
angiogenesis	O
,	O
and	O
angiogenesis	O
is	O
a	O
predictor	O
of	O
poor	O
prognosis	O
in	O
malignant	B
pleural	I
mesothelioma	I
.	O

We	O
hypothesized	O
that	O
cytoreduction	O
of	O
malignant	B
pleural	I
mesothelioma	I
followed	O
by	O
TM	O
will	O
delay	O
time	O
to	O
progression	O
.	O

METHODS	O
:	O
Between	O
November	O
2000	O
and	O
August	O
2003	O
,	O
30	O
patients	O
with	O
malignant	B
pleural	I
mesothelioma	I
received	O
postoperative	O
TM	O
beginning	O
4	O
to	O
6	O
weeks	O
after	O
surgery	O
at	O
a	O
dose	O
adjusted	O
to	O
keep	O
ceruloplasmin	O
between	O
5	O
and	O
15	O
mg	O
/	O
dL	O
)	O
.	O

Time	O
to	O
progression	O
was	O
compared	O
with	O
the	O
55	O
stage	O
I	O
and	O
II	O
patients	O
and	O
109	O
stage	O
III	O
patients	O
previously	O
treated	O
with	O
cytoreduction	O
by	O
one	O
of	O
us	O
(	O
H	O
.	O

P	O
.	O
)	O
.	O

RESULTS	O
:	O
The	O
30	O
patients	O
(	O
25	O
men	O
,	O
5	O
women	O
;	O
13	O
stage	O
I	O
and	O
II	O
,	O
17	O
stage	O
III	O
)	O
,	O
median	O
age	O
67	O
years	O
(	O
range	O
,	O
49	O
-	O
81	O
years	O
)	O
,	O
remained	O
on	O
TM	O
a	O
median	O
of	O
14.9	O
months	O
(	O
range	O
,	O
2	O
to	O
57	O
months	O
)	O
.	O

All	O
patients	O
reached	O
target	O
ceruloplasmin	O
levels	O
at	O
a	O
mean	O
of	O
34	O
+	O
/	O
-	O
2	O
days	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
30	O
to	O
39	O
days	O
)	O
,	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
levels	O
at	O
baseline	O
(	O
ceruloplasmin	O
=	O
45.2	O
+	O
/	O
-	O
2	O
mg	O
/	O
dL	O
)	O
decreased	O
from	O
2,086	O
+	O
/	O
-	O
390	O
pg	O
/	O
mL	O
to	O
1,250	O
+	O
/	O
-	O
712	O
pg	O
/	O
mL	O
(	O
p	O
<	O
0.002	O
)	O
at	O
target	O
ceruloplasmin	O
(	O
13	O
+	O
/	O
-	O
2	O
mg	O
/	O
dL	O
;	O
p	O
<	O
0.0001	O
from	O
baseline	O
)	O
.	O

The	O
time	O
to	O
progression	O
for	O
all	O
stage	O
I	O
or	O
II	O
TM	O
patients	O
was	O
20	O
months	O
whereas	O
that	O
of	O
55	O
stage	O
I	O
or	O
II	O
non	O
-	O
TM	O
-	O
treated	O
patients	O
was	O
10	O
months	O
(	O
p	O
=	O
0.046	O
versus	O
TM	O
)	O
.	O

No	O
differences	O
in	O
time	O
to	O
progression	O
for	O
the	O
stage	O
III	O
TM	O
patents	O
from	O
surgery	O
were	O
seen	O
(	O
7	O
months	O
)	O
.	O

CONCLUSIONS	O
:	O
Tetrathiomolybdate	O
has	O
antiangiogenic	O
effects	O
in	O
malignant	B
pleural	I
mesothelioma	I
patients	O
after	O
resection	O
of	O
gross	B
disease	I
,	O
and	O
exhibits	O
minimal	O
toxicity	O
and	O
comparable	O
efficacy	O
to	O
previous	O
multimodality	O
trials	O
.	O

Tetrathiomolybdate	O
should	O
be	O
evaluated	O
for	O
efficacy	O
in	O
combination	O
with	O
standard	O
malignant	B
pleural	I
mesothelioma	I
regimens	O
,	O
as	O
well	O
as	O
for	O
postsurgical	O
maintenance	O
therapy	O
.	O

Role	O
of	O
physical	O
chemical	O
properties	O
in	O
drug	O
relay	O
into	O
skin	O
compartments	O
.	O

The	O
ability	O
of	O
a	O
drug	O
to	O
reach	O
the	O
interstitial	O
fluid	O
is	O
an	O
important	O
aspect	O
of	O
drug	O
efficacy	O
-	O
as	O
a	O
possible	O
indicator	O
of	O
skin	O
and	O
cell	O
compartment	O
concentration	O
.	O

This	O
overview	O
addresses	O
the	O
relationship	O
of	O
the	O
physical	O
properties	O
of	O
several	O
antibiotics	O
to	O
their	O
ability	O
to	O
enter	O
the	O
interstitial	O
fluid	O
utilizing	O
a	O
cantharidin	O
blister	O
model	O
.	O

By	O
collecting	O
pharmacokinetic	O
data	O
for	O
12	O
antibiotics	O
administered	O
orally	O
and	O
11	O
intravenously	O
,	O
we	O
compared	O
the	O
fraction	O
of	O
drug	O
that	O
reaches	O
the	O
interstitial	O
fluid	O
(	O
AUC	O
(	O
blister	O
)	O
/	O
AUC	O
(	O
serum	O
)	O
)	O
to	O
partition	O
coefficients	O
.	O

Following	O
data	O
analysis	O
,	O
we	O
found	O
no	O
correlation	O
(	O
p	O
=	O
0.98	O
and	O
0.09	O
,	O
respectively	O
)	O
between	O
hydrophobicity	O
and	O
the	O
ability	O
to	O
reach	O
the	O
interstitium	O
.	O

Both	O
orally	O
and	O
intravenously	O
administered	O
antibiotics	O
display	O
a	O
strong	O
linear	O
correlation	O
(	O
p	O
<	O
0.001	O
and	O
p	O
=	O
0.006	O
,	O
respectively	O
)	O
in	O
the	O
total	O
concentration	O
found	O
in	O
the	O
serum	O
and	O
interstitial	O
fluid	O
indicating	O
that	O
serum	O
concentration	O
may	O
be	O
an	O
important	O
factor	O
in	O
dictating	O
interstitial	O
fluid	O
concentration	O
.	O

This	O
correlation	O
may	O
prove	O
useful	O
in	O
clinical	O
application	O
as	O
a	O
means	O
of	O
determining	O
interstitial	O
fluid	O
concentration	O
by	O
measuring	O
only	O
serum	O
levels	O
.	O

Systemic	O
therapy	O
for	O
unresectable	O
and	O
metastatic	B
transitional	I
cell	I
carcinoma	I
of	I
the	I
urothelium	I
:	O
first	O
-	O
line	O
and	O
beyond	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
The	O
review	O
aims	O
to	O
provide	O
an	O
overview	O
of	O
recent	O
advances	O
and	O
future	O
research	O
direction	O
in	O
the	O
management	O
of	O
patients	O
with	O
advanced	O
transitional	B
cell	I
carcinoma	I
.	O

RECENT	O
FINDINGS	O
:	O
Early	O
data	O
of	O
the	O
randomized	O
phase	O
III	O
study	O
comparing	O
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
with	O
gemcitabine	O
plus	O
cisplatin	O
for	O
advanced	O
urothelial	B
cancer	I
detected	O
no	O
survival	O
difference	O
.	O

A	O
phase	O
II	O
study	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
trastuzumab	O
,	O
carboplatin	O
,	O
gemcitabine	O
,	O
and	O
paclitaxel	O
in	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
-	O
2	O
/	O
neu	O
-	O
positive	O
advanced	O
urothelial	B
carcinoma	I
and	O
reported	O
promising	O
results	O
.	O

Renal	O
-	O
sparing	O
regimens	O
are	O
under	O
active	O
development	O
.	O

A	O
nonrandomized	O
comparison	O
of	O
the	O
3	O
-	O
week	O
with	O
the	O
4	O
-	O
week	O
schedule	O
for	O
gemcitabine	O
and	O
cisplatin	O
showed	O
that	O
the	O
3	O
-	O
week	O
schedule	O
had	O
less	O
hematological	B
toxicity	I
and	O
better	O
dose	O
intensity	O
.	O

Potential	O
molecular	O
markers	O
such	O
as	O
excision	O
repair	O
cross	O
-	O
complementation	O
group	O
1	O
,	O
emmprin	O
,	O
and	O
survivin	O
for	O
survival	O
and	O
/	O
or	O
platinum	O
resistance	O
in	O
patients	O
with	O
transitional	B
cell	I
carcinoma	I
showed	O
promise	O
.	O

SUMMARY	O
:	O
Recent	O
data	O
do	O
not	O
support	O
change	O
in	O
the	O
current	O
standard	O
of	O
care	O
for	O
advanced	O
transitional	B
cell	I
carcinoma	I
.	O

Clinical	O
testing	O
of	O
emerging	O
anticancer	O
therapies	O
using	O
new	O
agents	O
,	O
new	O
combinations	O
,	O
and	O
new	O
approaches	O
is	O
under	O
active	O
investigation	O
.	O

Rational	O
combination	O
and	O
new	O
strategy	O
in	O
clinical	O
trial	O
design	O
are	O
critical	O
for	O
new	O
drug	O
development	O
for	O
transitional	B
cell	I
carcinoma	I
.	O

Catalase	O
ameliorates	O
polychlorinated	O
biphenyl	O
-	O
induced	O
cytotoxicity	B
in	O
nonmalignant	O
human	O
breast	O
epithelial	O
cells	O
.	O

Polychlorinated	O
biphenyls	O
(	O
PCBs	O
)	O
are	O
environmental	O
chemical	O
contaminants	O
believed	O
to	O
adversely	O
affect	O
cellular	O
processes	O
.	O

We	O
investigated	O
the	O
hypothesis	O
that	O
PCB	O
-	O
induced	O
changes	O
in	O
the	O
levels	O
of	O
cellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
induce	O
DNA	O
damage	O
resulting	O
in	O
cytotoxicity	B
.	O

Exponentially	O
growing	O
cultures	O
of	O
human	O
nonmalignant	O
breast	O
epithelial	O
cells	O
(	O
MCF10A	O
)	O
were	O
incubated	O
with	O
PCBs	O
for	O
3	O
days	O
and	O
assayed	O
for	O
cell	O
number	O
,	O
ROS	O
levels	O
,	O
DNA	O
damage	O
,	O
and	O
cytotoxicity	B
.	O

Exposure	O
to	O
2,2	O
'	O
,	O
4,4	O
'	O
,	O
5,5	O
'	O
-	O
hexachlorobiphenyl	O
(	O
PCB153	O
)	O
or	O
2	O
-	O
(	O
4	O
-	O
chlorophenyl	O
)	O
benzo	O
-	O
1,4	O
-	O
quinone	O
(	O
4	O
-	O
Cl	O
-	O
BQ	O
)	O
,	O
a	O
metabolite	O
of	O
4	O
-	O
chlorobiphenyl	O
(	O
PCB3	O
)	O
,	O
significantly	O
decreased	O
cell	O
number	O
and	O
MTS	O
reduction	O
and	O
increased	O
the	O
percentage	O
of	O
cells	O
with	O
sub	O
-	O
G1	O
DNA	O
content	O
.	O

Results	O
from	O
electron	O
paramagnetic	O
resonance	O
(	O
EPR	O
)	O
spectroscopy	O
showed	O
a	O
4	O
-	O
fold	O
increase	O
in	O
the	O
steady	O
-	O
state	O
levels	O
of	O
ROS	O
,	O
which	O
was	O
suppressed	O
in	O
cells	O
pretreated	O
with	O
catalase	O
.	O

EPR	O
measurements	O
in	O
cells	O
treated	O
with	O
4	O
-	O
Cl	O
-	O
BQ	O
detected	O
the	O
presence	O
of	O
a	O
semiquinone	O
radical	O
,	O
suggesting	O
that	O
the	O
increased	O
levels	O
of	O
ROS	O
could	O
be	O
due	O
to	O
the	O
redox	O
cycling	O
of	O
4	O
-	O
Cl	O
-	O
BQ	O
.	O

A	O
dose	O
-	O
dependent	O
increase	O
in	O
micronuclei	O
frequency	O
was	O
observed	O
in	O
PCB	O
-	O
treated	O
cells	O
,	O
consistent	O
with	O
an	O
increase	O
in	O
histone	O
2AX	O
phosphorylation	O
.	O

Treatment	O
of	O
cells	O
with	O
catalase	O
blunted	O
the	O
PCB	O
-	O
induced	O
increase	O
in	O
micronuclei	O
frequency	O
and	O
H2AX	O
phosphorylation	O
that	O
was	O
consistent	O
with	O
an	O
increase	O
in	O
cell	O
survival	O
.	O

Our	O
results	O
demonstrate	O
a	O
PCB	O
-	O
induced	O
increase	O
in	O
cellular	O
levels	O
of	O
ROS	O
causing	O
DNA	O
damage	O
,	O
resulting	O
in	O
cell	O
killing	O
.	O

Inhibition	O
of	O
class	O
I	O
histone	O
deacetylase	O
with	O
an	O
apicidin	O
derivative	O
prevents	O
cardiac	B
hypertrophy	I
and	O
failure	O
.	O

AIMS	O
:	O
Recent	O
studies	O
have	O
demonstrated	O
the	O
importance	O
of	O
chromatin	O
remodelling	O
via	O
histone	O
acetylation	O
/	O
deacetylation	O
for	O
the	O
control	O
of	O
cardiac	O
gene	O
expression	O
.	O

Specific	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
can	O
,	O
in	O
fact	O
,	O
play	O
a	O
positive	O
or	O
negative	O
role	O
in	O
determining	O
cardiac	O
myocyte	O
(	O
CM	O
)	O
size	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
effect	O
on	O
hypertrophy	B
development	O
of	O
three	O
inhibitors	O
(	O
HDACi	O
)	O
of	O
class	O
I	O
HDACs	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
compounds	O
were	O
first	O
analysed	O
in	O
vitro	O
by	O
scoring	O
hypertrophy	B
,	O
expression	O
of	O
foetal	O
genes	O
,	O
and	O
apoptosis	O
of	O
neonatal	O
rat	O
CMs	O
stimulated	O
with	O
phenylephrine	O
,	O
an	O
alpha1	O
-	O
adrenergic	O
agonist	O
.	O

This	O
initial	O
screening	O
indicated	O
that	O
a	O
truncated	O
derivative	O
of	O
apicidin	O
with	O
class	O
I	O
HDAC	O
specificity	O
,	O
denoted	O
API	O
-	O
D	O
,	O
had	O
the	O
highest	O
efficacy	O
to	O
toxicity	O
ratio	O
,	O
and	O
was	O
thus	O
selected	O
for	O
further	O
analysis	O
in	O
vivo	O
.	O

Administration	O
of	O
this	O
drug	O
significantly	O
decreased	O
myocardial	B
hypertrophy	I
and	O
foetal	O
gene	O
expression	O
after	O
1	O
week	O
of	O
pressure	O
overload	O
induced	O
by	O
thoracic	O
aortic	O
constriction	O
(	O
TAC	O
)	O
in	O
mice	O
.	O

After	O
9	O
weeks	O
of	O
TAC	O
,	O
when	O
manifest	O
heart	B
failure	I
is	O
encountered	O
,	O
mice	O
treated	O
with	O
API	O
-	O
D	O
presented	O
with	O
significantly	O
improved	O
echocardiographic	O
and	O
haemodynamic	O
parameters	O
of	O
cardiac	O
function	O
when	O
compared	O
with	O
untreated	O
TAC	O
-	O
operated	O
mice	O
.	O

CONCLUSION	O
:	O
The	O
apicidin	O
derivative	O
,	O
API	O
-	O
D	O
,	O
is	O
capable	O
of	O
reducing	O
hypertrophy	B
and	O
,	O
consequently	O
,	O
the	O
transition	O
to	O
heart	B
failure	I
in	O
mice	O
subjected	O
to	O
TAC	O
.	O

Treatment	O
with	O
this	O
substance	O
,	O
therefore	O
,	O
holds	O
promise	O
as	O
an	O
important	O
therapeutic	O
option	O
for	O
heart	B
failure	I
.	O

Application	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
metabolism	O
and	O
in	O
metabolism	B
-	I
mediated	I
toxicity	I
studies	O
.	O

Stable	O
isotope	O
-	O
labeled	O
compounds	O
have	O
been	O
synthesized	O
and	O
utilized	O
by	O
scientists	O
from	O
various	O
areas	O
of	O
biomedical	O
research	O
during	O
the	O
last	O
several	O
decades	O
.	O

Compounds	O
labeled	O
with	O
stable	O
isotopes	O
,	O
such	O
as	O
deuterium	O
and	O
carbon	O
-	O
13	O
,	O
have	O
been	O
used	O
effectively	O
by	O
drug	O
metabolism	O
scientists	O
and	O
toxicologists	O
to	O
gain	O
better	O
understanding	O
of	O
drugs	O
'	O
disposition	O
and	O
their	O
potential	O
role	O
in	O
target	B
organ	I
toxicities	I
.	O

The	O
combination	O
of	O
stable	O
isotope	O
-	O
labeling	O
techniques	O
with	O
mass	O
spectrometry	O
and	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
spectroscopy	O
,	O
which	O
allows	O
rapid	O
acquisition	O
and	O
interpretation	O
of	O
data	O
,	O
has	O
promoted	O
greater	O
use	O
of	O
these	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
absorption	O
,	O
distribution	O
,	O
metabolism	O
,	O
and	O
excretion	O
(	O
ADME	O
)	O
studies	O
.	O

Examples	O
of	O
the	O
use	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
elucidating	O
structures	O
of	O
metabolites	O
and	O
delineating	O
complex	O
metabolic	O
pathways	O
are	O
presented	O
in	O
this	O
review	O
.	O

The	O
application	O
of	O
labeled	O
compounds	O
in	O
mechanistic	O
toxicity	O
studies	O
will	O
be	O
discussed	O
by	O
providing	O
an	O
example	O
of	O
how	O
strategic	O
placement	O
of	O
a	O
deuterium	O
atom	O
in	O
a	O
drug	O
molecule	O
mitigated	O
specific	O
-	O
specific	O
renal	B
toxicity	I
.	O

Other	O
examples	O
from	O
the	O
literature	O
demonstrating	O
the	O
application	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
understanding	O
metabolism	B
-	I
mediated	I
toxicities	I
are	O
presented	O
.	O

Furthermore	O
,	O
an	O
example	O
of	O
how	O
a	O
stable	O
isotope	O
-	O
labeled	O
compound	O
was	O
utilized	O
to	O
better	O
understand	O
some	O
of	O
the	O
gene	O
changes	O
in	O
toxicogenomic	O
studies	O
is	O
discussed	O
.	O

The	O
interpretation	O
of	O
large	O
sets	O
of	O
data	O
produced	O
from	O
toxicogenomics	O
studies	O
can	O
be	O
a	O
challenge	O
.	O

One	O
approach	O
that	O
could	O
be	O
used	O
to	O
simplify	O
interpretation	O
of	O
the	O
data	O
,	O
especially	O
from	O
studies	O
designed	O
to	O
link	O
gene	O
changes	O
with	O
the	O
formation	O
of	O
reactive	O
metabolites	O
thought	O
to	O
be	O
responsible	O
for	O
toxicities	O
,	O
is	O
through	O
the	O
use	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
.	O

This	O
is	O
a	O
relatively	O
unexplored	O
territory	O
and	O
needs	O
to	O
be	O
further	O
investigated	O
.	O

The	O
employment	O
of	O
analytical	O
techniques	O
,	O
especially	O
mass	O
spectrometry	O
and	O
NMR	O
,	O
used	O
in	O
conjunction	O
with	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
to	O
establish	O
and	O
understand	O
mechanistic	O
link	O
between	O
reactive	O
metabolite	O
formation	O
,	O
genomic	O
,	O
and	O
proteomic	O
changes	O
and	O
onset	O
of	O
toxicity	O
is	O
proposed	O
.	O

The	O
use	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
early	O
human	O
ADME	O
studies	O
as	O
a	O
way	O
of	O
identifying	O
and	O
possibly	O
quantifying	O
all	O
drug	O
-	O
related	O
components	O
present	O
in	O
systemic	O
circulation	O
is	O
suggested	O
.	O

Delayed	O
initiation	O
of	O
breast	O
development	O
in	O
girls	O
with	O
higher	O
prenatal	O
dioxin	O
exposure	O
;	O
a	O
longitudinal	O
cohort	O
study	O
.	O

OBJECTIVES	O
:	O
While	O
many	O
studies	O
have	O
assessed	O
the	O
health	O
impacts	O
of	O
PCDD	O
/	O
Fs	O
and	O
PCBs	O
on	O
animals	O
and	O
humans	O
,	O
long	O
-	O
term	O
consequences	O
for	O
especially	O
adolescents	O
,	O
have	O
not	O
(	O
yet	O
)	O
been	O
well	O
documented	O
.	O

This	O
is	O
certainly	O
also	O
true	O
for	O
the	O
effects	O
of	O
PBDE	O
exposure	O
.	O

As	O
part	O
of	O
a	O
longitudinal	O
cohort	O
study	O
,	O
now	O
well	O
into	O
its	O
second	O
decade	O
,	O
effects	O
of	O
perinatal	O
and	O
current	O
PCDD	O
/	O
F	O
exposure	O
,	O
as	O
well	O
as	O
current	O
dl	O
-	O
PCB	O
and	O
PBDE	O
exposures	O
,	O
on	O
puberty	O
,	O
were	O
assessed	O
.	O

STUDY	O
DESIGN	O
:	O
Prenatal	O
,	O
lactational	O
and	O
current	O
PCDD	O
/	O
F	O
,	O
dl	O
-	O
PCB	O
and	O
PBDE	O
concentrations	O
were	O
determined	O
using	O
GC	O
-	O
MS	O
.	O

Pubertal	O
development	O
and	O
growth	O
were	O
assessed	O
by	O
means	O
of	O
physical	O
examination	O
and	O
the	O
Tanner	O
scale	O
.	O

33	O
Children	O
(	O
born	O
between	O
1986	O
and	O
1991	O
)	O
consented	O
to	O
the	O
current	O
follow	O
-	O
up	O
study	O
.	O

Outcomes	O
were	O
evaluated	O
using	O
linear	O
regression	O
or	O
the	O
non	O
parametric	O
Spearman	O
's	O
correlation	O
coefficient	O
.	O

RESULTS	O
:	O
A	O
delay	O
in	O
initiation	O
of	O
breast	O
development	O
was	O
found	O
in	O
girls	O
(	O
n	O
=	O
18	O
)	O
with	O
higher	O
prenatal	O
(	O
p	O
=	O
0.023	O
)	O
and	O
lactational	O
PCDD	O
/	O
F	O
exposure	O
(	O
p	O
=	O
0.048	O
)	O
.	O

The	O
males	O
revealed	O
a	O
negative	O
trend	O
with	O
age	O
at	O
first	O
ejaculation	O
.	O

For	O
other	O
endpoints	O
on	O
puberty	O
and	O
growth	O
(	O
pubic	O
hair	O
,	O
axillary	O
hair	O
,	O
genital	O
stage	O
,	O
length	O
,	O
BMI	O
,	O
testicular	O
volume	O
,	O
menarche	O
)	O
no	O
significant	O
relation	O
was	O
found	O
with	O
any	O
of	O
the	O
measured	O
compounds	O
.	O

DISCUSSION	O
AND	O
CONCLUSION	O
:	O
A	O
relation	O
between	O
prenatal	O
PCDD	O
/	O
F	O
exposure	O
and	O
later	O
initiation	O
of	O
breast	O
development	O
was	O
seen	O
.	O

A	O
Belgian	O
study	O
found	O
a	O
delay	O
in	O
breast	O
development	O
with	O
higher	O
current	O
serum	O
concentrations	O
of	O
dioxin	O
-	O
like	O
compounds	O
.	O

The	O
initiation	O
of	O
puberty	O
is	O
a	O
complex	O
process	O
and	O
it	O
is	O
yet	O
not	O
clear	O
how	O
dioxin	O
-	O
like	O
compounds	O
precisely	O
affect	O
this	O
process	O
prenatally	O
.	O

Further	O
follow	O
-	O
up	O
into	O
adulthood	O
is	O
warranted	O
,	O
in	O
order	O
to	O
detect	O
the	O
possibility	O
of	O
developing	O
malignancies	B
and	O
fertility	O
problems	O
.	O

Preparation	O
of	O
BMP	O
-	O
2	O
containing	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
nanoparticles	O
stabilized	O
by	O
polymer	O
coating	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
preparation	O
process	O
of	O
bone	O
morphogenetic	O
protein	O
-	O
2	O
(	O
BMP	O
-	O
2	O
)	O
containing	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
nanoparticles	O
(	O
NPs	O
)	O
,	O
and	O
to	O
assess	O
the	O
bioactivity	O
of	O
BMP	O
-	O
2	O
encapsulated	O
in	O
such	O
NPs	O
.	O

METHODS	O
:	O
The	O
NPs	O
were	O
prepared	O
by	O
a	O
coacervation	O
method	O
,	O
and	O
the	O
effects	O
of	O
process	O
parameters	O
on	O
NP	O
size	O
and	O
polydispersity	O
were	O
examined	O
.	O

Polymer	O
coated	O
NPs	O
were	O
characterized	O
with	O
respect	O
to	O
amount	O
of	O
adsorbed	O
polymer	O
,	O
particle	O
size	O
and	O
zeta	O
potential	O
.	O

Using	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSC	O
)	O
,	O
biocompatibility	O
of	O
the	O
NPs	O
was	O
investigated	O
by	O
the	O
3	O
-	O
(	O
4,5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
2,5	O
-	O
diphenyl	O
-	O
tetrazolium	O
bromide	O
(	O
MTT	O
)	O
Assay	O
,	O
and	O
bioactivity	O
of	O
the	O
encapsulated	O
BMP	O
-	O
2	O
was	O
investigated	O
by	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
induction	O
and	O
calcification	O
.	O

RESULTS	O
:	O
The	O
size	O
of	O
NPs	O
could	O
be	O
controlled	O
in	O
the	O
50	O
-	O
400	O
nm	O
range	O
by	O
process	O
parameters	O
including	O
BSA	O
concentration	O
,	O
non	O
-	O
solvent	O
:	O
solvent	O
ratio	O
and	O
pH	O
value	O
.	O

After	O
coating	O
with	O
cationic	O
polymers	O
,	O
the	O
particle	O
size	O
and	O
zeta	O
potential	O
were	O
significantly	O
increased	O
.	O

MTT	O
assay	O
indicated	O
no	O
toxicity	O
of	O
both	O
the	O
uncoated	O
and	O
coated	O
NPs	O
on	O
BMSC	O
.	O

Based	O
on	O
ALP	O
induction	O
and	O
calcification	O
,	O
full	O
retention	O
of	O
BMP	O
-	O
2	O
bioactivity	O
was	O
retained	O
in	O
the	O
polymer	O
-	O
coated	O
NPs	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
described	O
a	O
preparation	O
procedure	O
for	O
BSA	O
NPs	O
with	O
controllable	O
particle	O
size	O
,	O
and	O
such	O
polymer	O
-	O
coated	O
BSA	O
NPs	O
are	O
promising	O
delivery	O
agents	O
for	O
local	O
and	O
systemic	O
administration	O
of	O
BMP	O
-	O
2	O
in	O
bone	O
regeneration	O
.	O

Effect	O
of	O
cement	O
dust	O
exposure	O
on	O
phagocytic	O
function	O
of	O
polymorphonuclear	O
neutrophils	O
in	O
cement	O
mill	O
workers	O
.	O

OBJECTIVES	O
:	O
Exposure	O
to	O
cement	O
dust	O
can	O
cause	O
various	O
occupational	O
health	O
problems	O
due	O
to	O
its	O
increasing	O
incidence	O
and	O
long	O
-	O
term	O
complications	O
.	O

However	O
,	O
the	O
influence	O
of	O
cement	O
dust	O
on	O
phagocytic	O
function	O
of	O
polymorphonuclear	O
neutrophils	O
(	O
PMNs	O
)	O
,	O
has	O
not	O
as	O
yet	O
been	O
investigated	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
study	O
was	O
to	O
measure	O
the	O
phagocytic	O
activity	O
of	O
PMNs	O
by	O
assessing	O
chemilumiscence	O
(	O
CL	O
)	O
response	O
in	O
cement	O
mill	O
workers	O
and	O
controls	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
50	O
volunteer	O
males	O
,	O
aged	O
25	O
-	O
60	O
years	O
,	O
apparently	O
healthy	O
and	O
nonsmoking	O
,	O
were	O
randomly	O
selected	O
from	O
among	O
cement	O
mill	O
workers	O
.	O

These	O
workers	O
were	O
further	O
classified	O
into	O
subgroups	O
based	O
on	O
exposure	O
duration	O
of	O
less	O
than	O
10	O
,	O
10	O
-	O
20	O
,	O
and	O
more	O
than	O
20	O
years	O
.	O

The	O
controls	O
were	O
50	O
healthy	O
,	O
nonsmoking	O
,	O
males	O
who	O
matched	O
the	O
study	O
group	O
with	O
respect	O
to	O
age	O
,	O
height	O
,	O
weight	O
,	O
and	O
socioeconomic	O
status	O
.	O

The	O
phagocytic	O
function	O
of	O
PMNs	O
,	O
stimulated	O
with	O
opsonized	O
zymosan	O
,	O
was	O
determined	O
by	O
measuring	O
CL	O
response	O
.	O

RESULTS	O
:	O
The	O
findings	O
show	O
a	O
significant	O
decrease	O
in	O
phagocytic	O
activity	O
of	O
PMNs	O
[	O
PMNs	O
OPZ	O
p	O
<	O
0.005	O
]	O
in	O
cement	O
mill	O
workers	O
compared	O
to	O
controls	O
.	O

CONCLUSION	O
:	O
It	O
is	O
concluded	O
that	O
exposure	O
to	O
cement	O
dust	O
can	O
impair	O
the	O
phagocytic	O
function	O
of	O
PMNs	O
which	O
is	O
reflected	O
in	O
decreased	O
chemiluminescence	O
response	O
.	O

Tadalafil	O
administered	O
once	O
daily	O
for	O
lower	O
urinary	B
tract	I
symptoms	I
secondary	O
to	O
benign	B
prostatic	I
hyperplasia	I
:	O
a	O
dose	O
finding	O
study	O
.	O

PURPOSE	O
:	O
Phosphodiesterase	O
type	O
5	O
inhibitors	O
are	O
widely	O
used	O
to	O
treat	O
erectile	B
dysfunction	I
.	O

Preliminary	O
data	O
have	O
suggested	O
phosphodiesterase	O
type	O
5	O
inhibitor	O
efficacy	O
in	O
men	O
with	O
lower	O
urinary	B
tract	I
symptoms	I
associated	O
with	O
clinical	O
benign	B
prostatic	I
hyperplasia	I
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
After	O
a	O
4	O
-	O
week	O
placebo	O
run	O
-	O
in	O
period	O
1,058	O
men	O
with	O
benign	B
prostatic	I
hyperplasia	I
lower	I
urinary	I
tract	I
symptoms	I
were	O
randomly	O
allocated	O
to	O
receive	O
12	O
-	O
week	O
,	O
once	O
daily	O
treatment	O
with	O
placebo	O
or	O
tadalafil	O
(	O
2.5	O
,	O
5	O
,	O
10	O
or	O
20	O
mg	O
)	O
.	O

RESULTS	O
:	O
The	O
International	O
Prostate	O
Symptom	O
Score	O
least	O
squares	O
mean	O
change	O
from	O
baseline	O
to	O
end	O
point	O
was	O
significantly	O
improved	O
for	O
2.5	O
(	O
-	O
3.9	O
,	O
p	O
=	O
0.015	O
)	O
,	O
5	O
(	O
-	O
4.9	O
,	O
p	O
<	O
0.001	O
)	O
,	O
10	O
(	O
-	O
5.2	O
,	O
p	O
<	O
0.001	O
)	O
and	O
20	O
mg	O
(	O
-	O
5.2	O
,	O
p	O
<	O
0.001	O
)	O
tadalafil	O
compared	O
to	O
placebo	O
(	O
-	O
2.3	O
)	O
.	O

International	O
Prostate	O
Symptom	O
Score	O
improvements	O
at	O
4	O
,	O
8	O
and	O
12	O
weeks	O
were	O
significant	O
for	O
all	O
tadalafil	O
doses	O
and	O
they	O
demonstrated	O
a	O
dose	O
-	O
response	O
relationship	O
.	O

Tadalafil	O
(	O
2.5	O
mg	O
)	O
significantly	O
improved	O
the	O
International	O
Prostate	O
Symptom	O
Score	O
obstructive	O
subscore	O
and	O
the	O
International	O
Index	O
of	O
Erectile	O
Function	O
-	O
Erectile	O
Function	O
domain	O
,	O
the	O
latter	O
in	O
sexually	O
active	O
men	O
with	O
a	O
history	O
of	O
erectile	B
dysfunction	I
.	O

Statistically	O
significant	O
improvements	O
were	O
noted	O
for	O
5	O
,	O
10	O
and	O
20	O
mg	O
tadalafil	O
compared	O
to	O
placebo	O
,	O
as	O
assessed	O
by	O
the	O
International	O
Prostate	O
Symptom	O
Score	O
irritative	O
and	O
obstructive	O
subscores	O
,	O
International	O
Prostate	O
Symptom	O
Score	O
Quality	O
of	O
Life	O
,	O
Benign	B
Prostatic	I
Hyperplasia	I
Impact	O
Index	O
(	O
nonsignificant	O
for	O
10	O
mg	O
)	O
,	O
Global	O
Assessment	O
Question	O
and	O
International	O
Index	O
of	O
Erectile	O
Function	O
-	O
Erectile	O
Function	O
domain	O
.	O

No	O
statistically	O
significant	O
effect	O
of	O
treatment	O
compared	O
to	O
placebo	O
was	O
noted	O
for	O
peak	O
flow	O
at	O
any	O
tadalafil	O
dose	O
.	O

Treatment	O
emergent	O
adverse	O
events	O
were	O
infrequent	O
in	O
all	O
tadalafil	O
groups	O
.	O

CONCLUSIONS	O
:	O
Once	O
daily	O
tadalafil	O
demonstrated	O
clinically	O
meaningful	O
and	O
statistically	O
significant	O
efficacy	O
and	O
it	O
was	O
well	O
tolerated	O
in	O
men	O
with	O
benign	B
prostatic	I
hyperplasia	I
lower	I
urinary	I
tract	I
symptoms	I
.	O

Of	O
the	O
doses	O
studied	O
5	O
mg	O
tadalafil	O
appeared	O
to	O
provide	O
a	O
positive	O
risk	O
-	O
benefit	O
profile	O
.	O

Mitochondrial	O
dysfunction	O
and	O
delayed	O
hepatotoxicity	B
:	O
another	O
lesson	O
from	O
troglitazone	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
Troglitazone	O
was	O
approved	O
for	O
treatment	O
of	O
type	B
2	I
diabetes	I
mellitus	I
,	O
but	O
by	O
2000	O
it	O
had	O
been	O
removed	O
from	O
all	O
world	O
markets	O
due	O
to	O
severe	O
drug	O
-	O
induced	O
liver	B
injury	I
.	O

Even	O
today	O
,	O
we	O
still	O
do	O
not	O
know	O
how	O
many	O
patients	O
sustained	O
a	O
long	O
-	O
term	O
liver	B
injury	I
.	O

No	O
system	O
is	O
in	O
place	O
to	O
acquire	O
that	O
knowledge	O
.	O

Regarding	O
toxicity	O
mechanisms	O
,	O
controversy	O
persists	O
as	O
to	O
which	O
ones	O
are	O
class	O
effects	O
of	O
thiazolidinediones	O
(	O
TZDs	O
)	O
and	O
which	O
are	O
unique	O
to	O
troglitazone	O
.	O

This	O
study	O
aims	O
to	O
provide	O
long	O
-	O
term	O
outcome	O
data	O
and	O
new	O
insights	O
on	O
mechanisms	O
of	O
troglitazone	O
-	O
induced	O
liver	B
injury	I
.	O

METHODS	O
:	O
This	O
case	O
series	O
reports	O
the	O
liver	O
injuries	O
sustained	O
by	O
eleven	O
type	O
2	O
diabetic	O
patients	O
treated	O
with	O
troglitazone	O
between	O
1997	O
and	O
2000	O
.	O

Exhaustive	O
review	O
of	O
medical	O
records	O
was	O
performed	O
for	O
all	O
patients	O
.	O

Long	O
-	O
term	O
outcomes	O
were	O
available	O
for	O
all	O
the	O
non	O
-	O
fatal	O
cases	O
.	O

A	O
comprehensive	O
literature	O
review	O
was	O
also	O
performed	O
.	O

RESULTS	O
:	O
Long	O
-	O
term	O
liver	B
injury	I
progressing	O
to	O
cirrhosis	B
was	O
identified	O
in	O
seven	O
patients	O
.	O

All	O
eleven	O
cases	O
had	O
liver	B
injury	I
patterns	O
consistent	O
with	O
troglitazone	O
toxicity	O
.	O

Analysis	O
of	O
these	O
cases	O
and	O
of	O
the	O
experimental	O
troglitazone	O
toxicity	O
data	O
points	O
to	O
mitochondrial	B
toxicity	I
as	O
a	O
central	O
factor	O
.	O

The	O
general	O
clinical	O
patterns	O
of	O
mitochondrial	B
hepatotoxic	I
events	I
are	O
reviewed	O
,	O
as	O
are	O
the	O
implications	O
for	O
other	O
members	O
of	O
the	O
TZD	O
family	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
This	O
analysis	O
enables	O
the	O
liver	B
injury	I
induced	O
by	O
troglitazone	O
to	O
be	O
better	O
understood	O
.	O

In	O
future	O
cases	O
of	O
delayed	O
drug	O
-	O
induced	O
liver	B
injury	I
that	O
progresses	O
after	O
discontinuation	O
,	O
the	O
possibility	O
of	O
mitochondrial	B
toxicity	I
should	O
be	O
considered	O
.	O

When	O
appropriate	O
,	O
this	O
can	O
then	O
be	O
evaluated	O
experimentally	O
.	O

Such	O
proactive	O
investigation	O
may	O
anticipate	O
clinical	O
risk	O
before	O
a	O
large	O
-	O
scale	O
therapeutic	O
misadventure	O
occurs	O
.	O

Drug	O
-	O
induced	O
liver	B
injury	I
due	O
to	O
mitochondrial	O
hepatotoxins	O
may	O
be	O
less	O
unpredictable	O
than	O
has	O
previously	O
been	O
surmised	O
.	O

Understanding	O
the	O
genetic	O
causes	O
of	O
inter	O
-	O
patient	O
variability	O
.	O

Clinical	O
relevance	O
with	O
focus	O
on	O
cardiovascular	O
drugs	O
.	O

There	O
is	O
a	O
large	O
inter	O
-	O
patient	O
variability	O
concerning	O
the	O
response	O
to	O
drug	O
therapy	O
and	O
a	O
great	O
interest	O
for	O
determining	O
the	O
causes	O
of	O
this	O
variability	O
.	O

This	O
review	O
takes	O
into	O
discussion	O
some	O
aspects	O
of	O
cardiovascular	O
drugs	O
metabolism	O
and	O
transport	O
,	O
pointing	O
out	O
the	O
effects	O
of	O
genetic	O
variation	O
.	O

Isoenyzmes	O
belonging	O
to	O
the	O
Cytochrome	O
P450	O
super	O
family	O
have	O
an	O
important	O
role	O
in	O
cardiovascular	O
drug	O
metabolism	O
,	O
namely	O
CYP	O
1A2	O
;	O
CYP	O
3A	O
;	O
CYP	O
2C19	O
;	O
CYP2C9	O
;	O
CYP	O
2D6	O
,	O
involved	O
in	O
the	O
oxidative	O
phase	O
and	O
also	O
N	O
-	O
acetyltransferase	O
2	O
,	O
involved	O
in	O
the	O
conjungative	O
phase	O
of	O
the	O
metabolism	O
.	O

P	O
-	O
glycoprotein	O
is	O
implied	O
in	O
cardiovascular	O
drug	O
transport	O
.	O

Polymorphisms	O
of	O
those	O
enzymes	O
and	O
transport	O
protein	O
result	O
in	O
different	O
phenotypes	O
,	O
that	O
is	O
the	O
case	O
of	O
CYP	O
isoenyzmes	O
with	O
abolished	O
,	O
low	O
or	O
increased	O
activity	O
and	O
in	O
the	O
case	O
of	O
N	O
-	O
acetyltransferase	O
2	O
,	O
slow	O
,	O
intermediate	O
and	O
rapid	O
acetylator	O
phenotypes	O
.	O

There	O
is	O
hope	O
that	O
,	O
in	O
the	O
future	O
,	O
a	O
more	O
individualized	O
treatment	O
of	O
a	O
certain	O
disease	O
,	O
with	O
minimum	O
adverse	O
effects	O
and	O
a	O
maximum	O
therapeutic	O
effect	O
,	O
will	O
be	O
available	O
,	O
by	O
means	O
of	O
genetic	O
testing	O
.	O

The	O
islet	O
beta	O
-	O
cell	O
:	O
fuel	O
responsive	O
and	O
vulnerable	O
.	O

The	O
pancreatic	O
beta	O
-	O
cell	O
senses	O
blood	O
nutrient	O
levels	O
and	O
is	O
modulated	O
by	O
neurohormonal	O
signals	O
so	O
that	O
it	O
secretes	O
insulin	O
according	O
to	O
the	O
need	O
of	O
the	O
organism	O
.	O

Nutrient	O
sensing	O
involves	O
marked	O
metabolic	O
activation	O
,	O
resulting	O
in	O
the	O
production	O
of	O
coupling	O
signals	O
that	O
promote	O
insulin	O
biosynthesis	O
and	O
secretion	O
.	O

The	O
beta	O
-	O
cell	O
's	O
high	O
capacity	O
for	O
nutrient	O
sensing	O
,	O
however	O
,	O
necessitates	O
reduced	O
protection	O
to	O
nutrient	B
toxicity	I
.	O

This	O
potentially	O
explains	O
why	O
in	O
susceptible	O
individuals	O
,	O
chronic	O
fuel	O
surfeit	O
results	O
in	O
beta	O
-	O
cell	O
failure	O
and	O
type	B
2	I
diabetes	I
.	O

Here	O
we	O
discuss	O
recent	O
insights	O
into	O
first	O
,	O
the	O
biochemical	O
basis	O
of	O
beta	O
-	O
cell	O
signaling	O
in	O
response	O
to	O
glucose	O
,	O
amino	O
acids	O
and	O
fatty	O
acids	O
,	O
and	O
second	O
,	O
beta	O
-	O
cell	O
nutrient	O
detoxification	O
.	O

We	O
emphasize	O
the	O
emerging	O
role	O
of	O
glycerolipid	O
/	O
fatty	O
acid	O
cycling	O
in	O
these	O
processes	O
.	O

Recurrent	O
seizures	B
in	O
patients	O
with	O
dementia	B
:	O
frequency	O
,	O
seizure	B
types	O
,	O
and	O
treatment	O
outcome	O
.	O

OBJECTIVE	O
:	O
Patients	O
with	O
a	O
primary	O
neurodegenerative	B
disorder	I
associated	O
with	O
cognitive	B
impairment	I
are	O
at	O
increased	O
risk	O
for	O
epilepsy	B
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
characterize	O
seizure	B
type	O
(	O
s	O
)	O
,	O
etiological	O
diagnosis	O
of	O
dementia	B
,	O
electroencephalogram	O
(	O
EEG	O
)	O
and	O
imaging	O
findings	O
,	O
and	O
response	O
to	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
therapy	O
in	O
these	O
individuals	O
.	O

METHODS	O
:	O
A	O
retrospective	O
study	O
was	O
performed	O
identifying	O
patients	O
in	O
the	O
Mayo	O
Alzheimer	B
Disease	I
Patient	O
Registry	O
(	O
ADPR	O
)	O
and	O
Alzheimer	B
Disease	I
Research	O
Center	O
(	O
ADRC	O
)	O
who	O
were	O
classified	O
as	O
having	O
dementia	B
and	O
epilepsy	B
from	O
1986	O
to	O
2006	O
.	O

Multiple	O
clinical	O
parameters	O
were	O
extracted	O
from	O
patient	O
charts	O
and	O
evaluated	O
to	O
characterize	O
the	O
primary	O
neurodegenerative	B
disorder	I
and	O
seizure	B
outcomes	O
.	O

RESULTS	O
:	O
Sixty	O
-	O
three	O
of	O
the	O
1738	O
ADPR	O
and	O
ADRC	O
patients	O
(	O
3.6	O
%	O
)	O
had	O
epilepsy	B
.	O

Twenty	O
-	O
four	O
of	O
the	O
63	O
patients	O
were	O
excluded	O
because	O
of	O
insufficient	O
information	O
regarding	O
their	O
epilepsy	B
.	O

The	O
remaining	O
39	O
patients	O
were	O
analyzed	O
.	O

Twenty	O
-	O
eight	O
of	O
the	O
63	O
patients	O
(	O
72	O
%	O
)	O
experienced	O
complex	B
partial	I
seizures	I
.	O

Head	O
MRI	O
was	O
performed	O
in	O
35	O
patients	O
(	O
90	O
%	O
)	O
.	O

Fourteen	O
patients	O
(	O
36	O
%	O
)	O
had	O
MRI	O
-	O
identified	O
structural	O
lesions	O
that	O
included	O
remote	O
stroke	B
and	O
prior	O
intracerebral	B
hemorrhage	I
.	O

EEGs	O
were	O
obtained	O
in	O
29	O
patients	O
(	O
74	O
%	O
)	O
.	O

Fifteen	O
patients	O
(	O
38	O
%	O
)	O
had	O
epileptiform	O
discharges	O
.	O

Overall	O
,	O
it	O
was	O
found	O
that	O
79	O
%	O
had	O
an	O
excellent	O
response	O
to	O
AED	O
therapy	O
.	O

Approximately	O
one	O
-	O
third	O
of	O
the	O
patients	O
had	O
dose	B
-	I
related	I
side	I
effects	I
from	O
an	O
AED	O
.	O

CONCLUSION	O
:	O
The	O
present	O
study	O
indicated	O
that	O
most	O
individuals	O
with	O
the	O
comorbidity	O
of	O
epilepsy	B
and	O
dementia	B
have	O
complex	B
partial	I
seizures	I
that	O
may	O
be	O
adequately	O
controlled	O
on	O
AED	O
therapy	O
.	O

The	O
long	O
-	O
term	O
effect	O
of	O
seizure	B
activity	O
on	O
the	O
neurodegenerative	B
disorder	I
is	O
unknown	O
.	O

Pharmacokinetic	O
-	O
directed	O
dosing	O
of	O
vandetanib	O
and	O
docetaxel	O
in	O
a	O
mouse	O
model	O
of	O
human	O
squamous	B
cell	I
carcinoma	I
.	O

Docetaxel	O
,	O
usually	O
administered	O
according	O
to	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
can	O
inhibit	O
endothelial	O
cell	O
proliferation	O
at	O
low	O
nanomolar	O
concentrations	O
.	O

Docetaxel	O
may	O
exert	O
antiangiogenic	O
effects	O
if	O
dosed	O
so	O
plasma	O
levels	O
are	O
maintained	O
at	O
low	O
nanomolar	O
concentrations	O
over	O
a	O
prolonged	O
time	O
.	O

We	O
evaluated	O
metronomic	O
and	O
MTD	O
-	O
based	O
dosing	O
of	O
docetaxel	O
with	O
and	O
without	O
vandetanib	O
,	O
a	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
2	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
with	O
antiangiogenic	O
and	O
antitumor	O
activity	O
,	O
in	O
a	O
head	O
and	O
neck	O
xenograft	O
model	O
.	O

A	O
murine	O
physiologically	O
based	O
pharmacokinetic	O
model	O
was	O
modified	O
to	O
predict	O
docetaxel	O
distribution	O
following	O
i	O
.	O

p	O
.	O

administration	O
to	O
design	O
dosing	O
regimens	O
that	O
target	O
prespecified	O
plasma	O
concentrations	O
,	O
for	O
antiendothelial	O
effects	O
(	O
metronomic	O
)	O
,	O
or	O
exposure	O
,	O
to	O
mimic	O
30	O
mg	O
/	O
m2	O
(	O
weekly	O
/	O
MTD	O
)	O
docetaxel	O
in	O
humans	O
.	O

Animals	O
were	O
treated	O
for	O
28	O
days	O
with	O
1	O
mg	O
/	O
kg	O
/	O
d	O
(	O
DTX1	O
)	O
or	O
6	O
mg	O
/	O
kg	O
q4d	O
(	O
DTX6	O
)	O
docetaxel	O
with	O
or	O
without	O
vandetanib	O
(	O
15	O
mg	O
/	O
kg	O
/	O
d	O
p	O
.	O

o	O
.	O
)	O
in	O
mice	O
bearing	O
UMSCC2	O
tumor	B
xenografts	O
.	O

The	O
DTX1	O
dosing	O
scheme	O
was	O
adjusted	O
to	O
treatment	O
for	O
10	O
days	O
followed	O
by	O
9	O
days	O
off	O
due	O
to	O
severe	O
gastrointestinal	B
toxicity	I
.	O

All	O
treatment	O
groups	O
significantly	O
reduced	O
tumor	B
volume	O
,	O
tumor	B
proliferation	O
(	O
Ki	O
-	O
67	O
)	O
,	O
and	O
tumor	O
endothelial	O
cell	O
proliferation	O
(	O
Ki	O
-	O
67	O
/	O
von	O
Willebrand	O
factor	O
)	O
compared	O
with	O
control	O
.	O

Addition	O
of	O
vandetanib	O
to	O
docetaxel	O
treatment	O
significantly	O
enhanced	O
tumor	B
growth	O
inhibition	O
over	O
single	O
-	O
agent	O
therapy	O
.	O

A	O
positive	O
correlation	O
of	O
tumor	O
endothelial	O
cell	O
proliferation	O
with	O
tumor	B
growth	O
rates	O
demonstrates	O
vandetanib	O
and	O
docetaxel	O
antiangiogenic	O
effects	O
.	O

Due	O
to	O
the	O
morbidity	O
observed	O
with	O
DTX1	O
treatment	O
,	O
it	O
is	O
difficult	O
to	O
clearly	O
ascertain	O
if	O
metronomic	O
schedules	O
will	O
be	O
effective	O
for	O
treatment	O
.	O

Docetaxel	O
with	O
vandetanib	O
is	O
effective	O
in	O
treating	O
UMSCC2	O
xenografts	O
at	O
concentrations	O
relevant	O
to	O
exposures	O
in	O
humans	O
.	O

Prospective	O
evaluation	O
of	O
sexual	O
function	O
in	O
patients	O
receiving	O
cryosurgery	O
as	O
a	O
primary	O
radical	O
treatment	O
for	O
localized	O
prostate	B
cancer	I
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
prospectively	O
the	O
sexual	O
function	O
of	O
patients	O
undergoing	O
cryosurgery	O
as	O
a	O
primary	O
radical	O
treatment	O
for	O
localized	O
prostate	B
cancer	I
,	O
as	O
the	O
development	O
of	O
17	O
G	O
cryotherapy	O
probes	O
has	O
improved	O
the	O
delivery	O
of	O
this	O
treatment	O
,	O
but	O
one	O
of	O
the	O
side	O
-	O
effects	O
of	O
cryosurgery	O
is	O
the	O
development	O
of	O
erectile	B
dysfunction	I
(	O
ED	B
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Between	O
July	O
2003	O
and	O
May	O
2008	O
,	O
53	O
patients	O
were	O
treated	O
using	O
an	O
argon	O
-	O
based	O
third	O
-	O
generation	O
cryotherapy	O
system	O
(	O
Oncura	O
,	O
Arlington	O
Heights	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Prospective	O
data	O
were	O
collected	O
at	O
6	O
weeks	O
,	O
3	O
months	O
,	O
then	O
3	O
-	O
monthly	O
up	O
to	O
1	O
year	O
and	O
subsequently	O
6	O
-	O
monthly	O
.	O

Patients	O
were	O
followed	O
up	O
for	O
up	O
to	O
54	O
months	O
,	O
with	O
a	O
median	O
(	O
mean	O
)	O
follow	O
-	O
up	O
36	O
(	O
30.5	O
)	O
months	O
.	O

RESULTS	O
:	O
All	O
53	O
patients	O
were	O
followed	O
after	O
receiving	O
cryosurgery	O
as	O
primary	O
treatment	O
for	O
prostate	B
cancer	I
;	O
51	O
(	O
96.3	O
%	O
)	O
had	O
ED	O
at	O
6	O
weeks	O
while	O
two	O
(	O
3.7	O
%	O
)	O
were	O
experiencing	O
partial	O
erections	O
.	O

By	O
9	O
months	O
one	O
(	O
2.4	O
%	O
)	O
of	O
42	O
patients	O
was	O
fully	O
potent	O
using	O
phosphodiesterase	O
type	O
-	O
5	O
inhibitors	O
,	O
and	O
six	O
(	O
14.3	O
%	O
)	O
were	O
experiencing	O
partial	O
erections	O
.	O

By	O
18	O
months	O
eight	O
(	O
21	O
%	O
)	O
of	O
39	O
patients	O
followed	O
up	O
had	O
regained	O
full	O
potency	O
and	O
by	O
24	O
months	O
eight	O
(	O
24	O
%	O
)	O
of	O
33	O
patients	O
were	O
fully	O
potent	O
and	O
three	O
(	O
9	O
%	O
)	O
experienced	O
partial	O
erections	O
.	O

CONCLUSION	O
:	O
While	O
ED	B
is	O
a	O
significant	O
side	O
-	O
effect	O
of	O
cryotherapy	O
,	O
a	O
considerable	O
proportion	O
of	O
patients	O
who	O
have	O
no	O
ED	B
before	O
treatment	O
(	O
39	O
%	O
)	O
recover	O
full	O
sexual	O
function	O
afterward	O
.	O

Focal	O
nerve	O
-	O
sparing	O
cryosurgery	O
might	O
be	O
the	O
way	O
forward	O
in	O
an	O
attempt	O
to	O
preserve	O
erectile	O
function	O
in	O
men	O
who	O
had	O
no	O
ED	B
before	O
treatment	O
.	O

Erectile	O
aids	O
should	O
be	O
made	O
available	O
for	O
those	O
patients	O
for	O
whom	O
sexual	B
dysfunction	I
compromises	O
the	O
quality	O
of	O
their	O
life	O
and	O
relationships	O
.	O

A	O
single	O
dose	O
of	O
anti	O
-	O
D	O
immunoglobulin	O
raises	O
platelet	O
count	O
as	O
efficiently	O
as	O
intravenous	O
immunoglobulin	O
in	O
newly	O
diagnosed	O
immune	B
thrombocytopenic	I
purpura	I
in	O
Korean	O
children	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
single	O
dose	O
of	O
anti	O
-	O
D	O
immunoglobulin	O
(	O
anti	O
-	O
D	O
)	O
at	O
50	O
mug	O
/	O
kg	O
to	O
intravenous	O
immunoglobulin	O
(	O
IVIG	O
)	O
in	O
Korean	O
children	O
with	O
acute	B
immune	I
thrombocytopenic	I
purpura	I
(	O
ITP	B
)	O
.	O

METHODS	O
:	O
We	O
performed	O
this	O
study	O
prospectively	O
by	O
randomly	O
administering	O
2	O
consecutive	O
doses	O
of	O
IVIG	O
at	O
a	O
dose	O
of	O
1.0	O
g	O
/	O
kg	O
/	O
dor	O
a	O
single	O
dose	O
of	O
anti	O
-	O
D	O
at	O
50	O
microg	O
/	O
kg	O
to	O
children	O
upon	O
initial	O
diagnosis	O
of	O
acute	B
ITP	I
.	O

The	O
platelet	O
count	O
and	O
adverse	O
events	O
,	O
including	O
hemoglobin	O
concentration	O
,	O
were	O
then	O
serially	O
evaluated	O
,	O
and	O
the	O
responses	O
were	O
compared	O
.	O

RESULTS	O
:	O
The	O
likelihood	O
of	O
having	O
a	O
platelet	O
count	O
greater	O
than	O
20x10	O
/	O
mm	O
after	O
3	O
days	O
of	O
treatment	O
in	O
the	O
IVIG	O
and	O
anti	O
-	O
D	O
group	O
was	O
93	O
%	O
and	O
92	O
%	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
hemoglobin	O
concentration	O
in	O
the	O
anti	O
-	O
D	O
group	O
had	O
declined	O
more	O
than	O
that	O
of	O
the	O
IVIG	O
group	O
(	O
1.49	O
g	O
/	O
dL	O
vs.	O
0.80	O
g	O
/	O
dL	O
,	O
P	O
=	O
0.014	O
)	O
3	O
days	O
after	O
treatment	O
.	O

Fever	B
,	O
chills	B
,	O
and	O
headache	B
occurred	O
less	O
frequently	O
in	O
the	O
anti	O
-	O
D	O
group	O
than	O
the	O
IVIG	O
group	O
,	O
however	O
,	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
25	O
%	O
vs.	O
45	O
%	O
,	O
P	O
=	O
0.494	O
)	O
.	O

CONCLUSIONS	O
:	O
A	O
single	O
dose	O
of	O
50	O
microg	O
/	O
kg	O
of	O
anti	O
-	O
D	O
raised	O
platelet	O
count	O
as	O
efficiently	O
as	O
IVIG	O
in	O
newly	O
diagnosed	O
cases	O
of	O
ITP	B
in	O
Korean	O
children	O
.	O

Although	O
50	O
microg	O
/	O
kg	O
of	O
anti	O
-	O
D	O
had	O
a	O
greater	O
effect	O
on	O
the	O
hemoglobin	O
concentration	O
than	O
IVIG	O
,	O
the	O
adverse	O
effects	O
were	O
found	O
to	O
be	O
acceptable	O
,	O
and	O
no	O
serious	O
events	O
were	O
observed	O
.	O

Right	O
-	O
sided	O
vagus	O
nerve	O
stimulation	O
in	O
humans	O
:	O
an	O
effective	O
therapy	O
?	O

Vagus	O
nerve	O
stimulation	O
(	O
VNS	O
)	O
is	O
an	O
additive	O
treatment	O
option	O
for	O
refractory	B
epilepsy	I
.	O

The	O
electrode	O
is	O
placed	O
on	O
the	O
cervical	O
trunk	O
of	O
the	O
left	O
vagus	O
nerve	O
.	O

In	O
patients	O
who	O
are	O
not	O
suitable	O
for	O
left	O
-	O
sided	O
vagus	O
nerve	O
stimulation	O
(	O
L	O
-	O
VNS	O
)	O
right	O
-	O
sided	O
vagus	O
nerve	O
stimulation	O
(	O
R	O
-	O
VNS	O
)	O
may	O
be	O
as	O
effective	O
.	O

In	O
animal	O
models	O
epilepsy	B
is	O
sufficiently	O
suppressed	O
by	O
R	O
-	O
VNS	O
.	O

In	O
a	O
16	O
years	O
old	O
boy	O
suffering	O
from	O
medically	O
refractory	B
psychomotoric	I
seizures	I
with	O
secondary	O
generalisation	O
,	O
L	O
-	O
VNS	O
reduced	O
the	O
frequency	O
of	O
generalized	O
seizures	B
.	O

A	O
deep	O
wound	B
infection	I
required	O
the	O
removal	O
of	O
the	O
system	O
eight	O
weeks	O
later	O
.	O

Cicatrisation	O
did	O
not	O
allow	O
preparation	O
of	O
the	O
left	O
vagus	O
nerve	O
,	O
therefore	O
we	O
implanted	O
R	O
-	O
VNS	O
with	O
sufficient	O
seizure	B
suppression	O
.	O

However	O
,	O
compared	O
to	O
L	O
-	O
VNS	O
,	O
the	O
effect	O
occurred	O
months	O
later	O
and	O
cardiac	B
symptoms	I
were	O
induced	O
by	O
stimulation	O
of	O
the	O
right	O
vagus	O
nerve	O
.	O

R	O
-	O
VNS	O
seems	O
to	O
be	O
an	O
effective	O
and	O
alternative	O
therapy	O
in	O
selected	O
patients	O
responding	O
to	O
L	O
-	O
VNS	O
where	O
a	O
left	O
-	O
sided	O
reimplantation	O
is	O
not	O
possible	O
.	O

Placement	O
and	O
adjustment	O
of	O
the	O
device	O
should	O
be	O
performed	O
under	O
ECG	O
control	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
compare	O
the	O
efficacy	O
of	O
L	O
-	O
VNS	O
and	O
R	O
-	O
VNS	O
.	O

Astaxanthin	O
,	O
canthaxanthin	O
and	O
beta	O
-	O
carotene	O
differently	O
affect	O
UVA	O
-	O
induced	O
oxidative	O
damage	O
and	O
expression	O
of	O
oxidative	O
stress	O
-	O
responsive	O
enzymes	O
.	O

Carotenoids	O
are	O
used	O
for	O
systemic	O
photoprotection	O
in	O
humans	O
.	O

Regarding	O
mechanisms	O
underlying	O
photoprotective	O
effects	O
of	O
carotenoids	O
,	O
here	O
we	O
compared	O
the	O
modulation	O
of	O
UVA	O
-	O
related	O
injury	O
by	O
carotenoids	O
.	O

Human	O
dermal	O
fibroblasts	O
(	O
HDF	O
)	O
were	O
exposed	O
to	O
moderate	O
doses	O
of	O
UVA	O
,	O
which	O
stimulated	O
apoptosis	O
,	O
increased	O
levels	O
of	O
reactive	O
oxygen	O
species	O
and	O
thiobarbituric	O
acid	O
reactive	O
substances	O
,	O
decreased	O
antioxidant	O
enzymes	O
activities	O
,	O
promoted	O
membrane	O
perturbation	O
,	O
and	O
induced	O
the	O
expression	O
of	O
heme	O
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
.	O

The	O
carotenoids	O
astaxanthin	O
(	O
AX	O
)	O
,	O
canthaxanthin	O
(	O
CX	O
)	O
and	O
beta	O
-	O
carotene	O
(	O
betaC	O
)	O
were	O
delivered	O
to	O
HDF	O
24	O
h	O
before	O
exposure	O
to	O
UVA	O
.	O

Astaxanthin	O
exhibited	O
a	O
pronounced	O
photoprotective	O
effect	O
and	O
counteracted	O
all	O
of	O
the	O
above	O
-	O
mentioned	O
UVA	O
-	O
induced	O
alterations	O
to	O
a	O
significant	O
extent	O
.	O

beta	O
-	O
Carotene	O
only	O
partially	O
prevented	O
the	O
UVA	O
-	O
induced	O
decline	O
of	O
catalase	O
and	O
superoxide	O
dismutase	O
activities	O
,	O
but	O
it	O
increased	O
membrane	O
damage	O
and	O
stimulated	O
HO	O
-	O
1	O
expression	O
.	O

Moreover	O
,	O
betaC	O
dose	O
-	O
dependently	O
induced	O
caspase	O
-	O
3	O
activity	O
following	O
UVA	O
exposure	O
.	O

In	O
contrast	O
,	O
CX	O
had	O
no	O
effect	O
on	O
oxidative	O
damage	O
,	O
except	O
for	O
HO	O
-	O
1	O
expression	O
,	O
which	O
was	O
augmented	O
.	O

Uptake	O
of	O
AX	O
by	O
fibroblasts	O
was	O
higher	O
than	O
that	O
of	O
the	O
other	O
two	O
carotenoids	O
.	O

The	O
photostability	O
of	O
the	O
three	O
compounds	O
in	O
fibroblasts	O
was	O
AX	O
>	O
CX	O
>	O
>	O
betaC	O
.	O

The	O
data	O
indicate	O
that	O
the	O
oxo	O
-	O
carotenoid	O
AX	O
has	O
a	O
superior	O
preventive	O
effect	O
towards	O
photo	O
-	O
oxidative	O
changes	O
in	O
cell	O
culture	O
.	O

Protective	O
effect	O
of	O
Pycnogenol	O
in	O
human	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
following	O
acrolein	O
-	O
induced	O
cytotoxicity	B
.	O

Oxidative	O
stress	O
is	O
one	O
of	O
the	O
hypotheses	O
involved	O
in	O
the	O
etiology	O
of	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
.	O

Considerable	O
attention	O
has	O
been	O
focused	O
on	O
increasing	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
levels	O
in	O
many	O
neurodegenerative	B
diseases	I
,	O
including	O
AD	B
.	O

Pycnogenol	O
(	O
PYC	O
)	O
has	O
antioxidant	O
properties	O
and	O
stabilizes	O
intracellular	O
antioxidant	O
defense	O
systems	O
including	O
glutathione	O
levels	O
.	O

The	O
present	O
study	O
investigated	O
the	O
protective	O
effects	O
of	O
PYC	O
on	O
acrolein	O
-	O
induced	O
oxidative	B
cell	I
toxicity	I
in	O
cultured	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
.	O

Decreased	O
cell	O
survival	O
in	O
SH	O
-	O
SY5Y	O
cultures	O
treated	O
with	O
acrolein	O
correlated	O
with	O
oxidative	O
stress	O
,	O
increased	O
NADPH	O
oxidase	O
activity	O
,	O
free	O
radical	O
production	O
,	O
protein	O
oxidation	O
/	O
nitration	O
(	O
protein	O
carbonyl	O
,	O
3	O
-	O
nitrotyrosine	O
)	O
,	O
and	O
lipid	O
peroxidation	O
(	O
4	O
-	O
hydroxy	O
-	O
2	O
-	O
nonenal	O
)	O
.	O

Pretreatment	O
with	O
PYC	O
significantly	O
attenuated	O
acrolein	O
-	O
induced	O
cytotoxicity	B
,	O
protein	O
damage	O
,	O
lipid	O
peroxidation	O
,	O
and	O
cell	O
death	O
.	O

A	O
dose	O
-	O
response	O
study	O
suggested	O
that	O
PYC	O
showed	O
protective	O
effects	O
against	O
acrolein	B
toxicity	I
by	O
modulating	O
oxidative	O
stress	O
and	O
increasing	O
GSH	O
.	O

These	O
findings	O
provide	O
support	O
that	O
PYC	O
may	O
provide	O
a	O
promising	O
approach	O
for	O
the	O
treatment	O
of	O
oxidative	O
stress	O
-	O
related	O
neurodegenerative	B
diseases	I
such	O
as	O
AD	B
.	O

Lipid	O
nanoparticles	O
for	O
parenteral	O
delivery	O
of	O
actives	O
.	O

The	O
present	O
review	O
compiles	O
the	O
applications	O
of	O
lipid	O
nanoparticles	O
mainly	O
solid	O
lipid	O
nanoparticles	O
(	O
SLN	O
)	O
,	O
nanostructured	O
lipid	O
carriers	O
(	O
NLC	O
)	O
and	O
lipid	O
drug	O
conjugates	O
(	O
LDC	O
)	O
in	O
parenteral	O
delivery	O
of	O
pharmaceutical	O
actives	O
.	O

The	O
attempts	O
to	O
incorporate	O
anticancer	O
agents	O
,	O
imaging	O
agents	O
,	O
antiparasitics	O
,	O
antiarthritics	O
,	O
genes	O
for	O
transfection	O
,	O
agents	O
for	O
liver	O
,	O
cardiovascular	O
and	O
central	O
nervous	O
system	O
targeting	O
have	O
been	O
summarized	O
.	O

The	O
utility	O
of	O
lipid	O
nanoparticles	O
as	O
adjuvant	O
has	O
been	O
discussed	O
separately	O
.	O

A	O
special	O
focus	O
of	O
this	O
review	O
is	O
on	O
toxicity	O
caused	O
by	O
these	O
kinds	O
of	O
lipid	O
nanoparticles	O
with	O
a	O
glance	O
on	O
the	O
fate	O
of	O
lipid	O
nanoparticles	O
after	O
their	O
parenteral	O
delivery	O
in	O
vivo	O
viz	O
the	O
protein	O
adsorption	O
patterns	O
.	O

Orally	O
administrated	O
Juzen	O
-	O
taiho	O
-	O
to	O
/	O
TJ	O
-	O
48	O
ameliorates	O
erythropoietin	B
(	I
rHuEPO	I
)	I
-	I
resistant	I
anemia	I
in	O
patients	O
on	O
hemodialysis	O
.	O

Maintenance	O
of	O
the	O
red	O
blood	O
cell	O
volume	O
is	O
a	O
fundamental	O
aspect	O
of	O
ensuring	O
oxygen	O
supply	O
to	O
the	O
tissue	O
.	O

Recombinant	O
human	O
erythropoietin	O
(	O
rHuEPO	O
)	O
was	O
approved	O
for	O
marketing	O
in	O
Japan	O
in	O
1990	O
for	O
the	O
treatment	O
of	O
anemia	B
in	O
patients	O
on	O
dialysis	O
.	O

Recombinant	O
human	O
erythropoietin	O
caused	O
a	O
significant	O
increase	O
in	O
hemoglobin	O
(	O
Hb	O
)	O
levels	O
in	O
patients	O
on	O
dialysis	O
.	O

However	O
,	O
not	O
all	O
have	O
a	O
good	O
response	O
to	O
rHuEPO	O
therapy	O
;	O
the	O
causes	O
of	O
rHuEPO	O
failure	O
include	O
iron	B
deficiency	I
,	O
infection	B
,	O
uremia	B
,	O
and	O
interaction	O
of	O
some	O
drugs	O
.	O

Juzen	O
-	O
taiho	O
-	O
to	O
(	O
TJ	O
-	O
48	O
)	O
,	O
a	O
mixture	O
of	O
extracts	O
from	O
10	O
medicinal	O
herbs	O
,	O
has	O
been	O
used	O
traditionally	O
to	O
treat	O
patients	O
with	O
anemia	B
,	O
anorexia	B
,	O
or	O
fatigue	B
.	O

To	O
clarify	O
the	O
effect	O
of	O
TJ	O
-	O
48	O
on	O
erythropoietin	B
-	I
resistant	I
anemia	I
,	O
we	O
studied	O
the	O
effect	O
of	O
TJ	O
-	O
48	O
in	O
patients	O
on	O
hemodialysis	O
with	O
erythropoietin	B
-	I
resistant	I
anemia	I
.	O

We	O
divided	O
42	O
end	O
-	O
stage	O
renal	B
disease	I
patients	O
on	O
hemodialysis	O
with	O
erythropoietin	B
-	I
resistant	I
anemia	I
(	O
Hb	O
<	O
10.0	O
g	O
/	O
dL	O
with	O
rHuEPO	O
9000	O
U	O
/	O
wk	O
or	O
15	O
U	O
/	O
kg	O
/	O
wk	O
treatment	O
)	O
into	O
2	O
groups	O
as	O
follows	O
:	O
a	O
TJ	O
-	O
48	O
-	O
treated	O
group	O
(	O
TJ	O
-	O
48	O
group	O
,	O
7.5	O
g	O
/	O
d	O
,	O
n	O
=	O
22	O
)	O
and	O
a	O
TJ	O
-	O
48	O
nontreated	O
(	O
control	O
group	O
,	O
n	O
=	O
20	O
)	O
.	O

At	O
the	O
beginning	O
of	O
this	O
study	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
in	O
age	O
,	O
sex	O
,	O
serum	O
creatinine	O
,	O
blood	O
urea	O
nitrogen	O
,	O
serum	O
iron	O
,	O
and	O
ferritin	O
.	O

After	O
12	O
weeks	O
of	O
treatment	O
,	O
the	O
Hb	O
level	O
had	O
significantly	O
increased	O
from	O
8.4	O
+	O
/	O
-	O
1.1	O
to	O
9.5	O
+	O
/	O
-	O
1.3	O
g	O
/	O
dL	O
(	O
P	O
=	O
0.0272	O
)	O
in	O
the	O
TJ	O
-	O
48	O
group	O
.	O

C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
had	O
significantly	O
decreased	O
from	O
1.4	O
+	O
/	O
-	O
1.7	O
to	O
0.6	O
+	O
/	O
-	O
0.8	O
mg	O
/	O
dL	O
(	O
P	O
=	O
0.0438	O
)	O
.	O

There	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
Hb	O
and	O
CRP	O
in	O
the	O
TJ	O
-	O
48	O
group	O
(	O
r	O
(	O
2	O
)	O
=	O
0.121	O
,	O
P	O
=	O
0.0066	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
control	O
group	O
,	O
Hb	O
and	O
CRP	O
showed	O
no	O
significant	O
changes	O
throughout	O
this	O
study	O
.	O

Nor	O
was	O
there	O
a	O
significant	O
correlation	O
between	O
Hb	O
and	O
CRP	O
in	O
the	O
control	O
group	O
.	O

In	O
conclusion	O
,	O
TJ	O
-	O
48	O
was	O
effective	O
in	O
improving	O
erythropoietin	B
-	I
resistant	I
anemia	I
in	O
end	O
-	O
stage	O
renal	B
disease	I
patients	O
.	O

This	O
effect	O
was	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
TJ	O
-	O
48	O
in	O
patients	O
on	O
hemodialysis	O
.	O

Fragrance	O
material	O
review	O
on	O
1	O
-	O
ethynylcyclohexyl	O
acetate	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
1	O
-	O
ethynylcyclohexyl	O
acetate	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

Vitamin	O
K	O
supplementation	O
in	O
postmenopausal	O
women	O
with	O
osteopenia	B
(	O
ECKO	O
trial	O
)	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
:	O
Vitamin	O
K	O
has	O
been	O
widely	O
promoted	O
as	O
a	O
supplement	O
for	O
decreasing	O
bone	B
loss	I
in	O
postmenopausal	O
women	O
,	O
but	O
the	O
long	O
-	O
term	O
benefits	O
and	O
potential	O
harms	O
are	O
unknown	O
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
whether	O
daily	O
high	O
-	O
dose	O
vitamin	O
K1	O
supplementation	O
safely	O
reduces	O
bone	B
loss	I
,	O
bone	O
turnover	O
,	O
and	O
fractures	O
.	O

METHODS	O
AND	O
FINDINGS	O
:	O
This	O
single	O
-	O
center	O
study	O
was	O
designed	O
as	O
a	O
2	O
-	O
y	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
trial	O
,	O
extended	O
for	O
earlier	O
participants	O
for	O
up	O
to	O
an	O
additional	O
2	O
y	O
because	O
of	O
interest	O
in	O
long	O
-	O
term	O
safety	O
and	O
fractures	O
.	O

A	O
total	O
of	O
440	O
postmenopausal	O
women	O
with	O
osteopenia	B
were	O
randomized	O
to	O
either	O
5	O
mg	O
of	O
vitamin	O
K1	O
or	O
placebo	O
daily	O
.	O

Primary	O
outcomes	O
were	O
changes	O
in	O
BMD	O
at	O
the	O
lumbar	O
spine	O
and	O
total	O
hip	O
at	O
2	O
y	O
.	O

Secondary	O
outcomes	O
included	O
changes	O
in	O
BMD	O
at	O
other	O
sites	O
and	O
other	O
time	O
points	O
,	O
bone	O
turnover	O
markers	O
,	O
height	O
,	O
fractures	O
,	O
adverse	O
effects	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
.	O

This	O
study	O
has	O
a	O
power	O
of	O
90	O
%	O
to	O
detect	O
3	O
%	O
differences	O
in	O
BMD	O
between	O
the	O
two	O
groups	O
.	O

The	O
women	O
in	O
this	O
study	O
were	O
vitamin	O
D	O
replete	O
,	O
with	O
a	O
mean	O
serum	O
25	O
-	O
hydroxyvitamin	O
D	O
level	O
of	O
77	O
nmol	O
/	O
l	O
at	O
baseline	O
.	O

Over	O
2	O
y	O
,	O
BMD	O
decreased	O
by	O
-	O
1.28	O
%	O
and	O
-	O
1.22	O
%	O
(	O
p	O
=	O
0.84	O
)	O
(	O
difference	O
of	O
-	O
0.06	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
-	O
0.67	O
%	O
to	O
0.54	O
%	O
)	O
at	O
the	O
lumbar	O
spine	O
and	O
-	O
0.69	O
%	O
and	O
-	O
0.88	O
%	O
(	O
p	O
=	O
0.51	O
)	O
(	O
difference	O
of	O
0.19	O
%	O
;	O
95	O
%	O
CI	O
-	O
0.37	O
%	O
to	O
0.75	O
%	O
)	O
at	O
the	O
total	O
hip	O
in	O
the	O
vitamin	O
K	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
changes	O
in	O
BMD	O
at	O
any	O
site	O
between	O
the	O
two	O
groups	O
over	O
the	O
2	O
-	O
to	O
4	O
-	O
y	O
period	O
.	O

Daily	O
vitamin	O
K1	O
supplementation	O
increased	O
serum	O
vitamin	O
K1	O
levels	O
by	O
10	O
-	O
fold	O
,	O
and	O
decreased	O
the	O
percentage	O
of	O
undercarboxylated	O
osteocalcin	O
and	O
total	O
osteocalcin	O
levels	O
(	O
bone	O
formation	O
marker	O
)	O
.	O

However	O
,	O
C	O
-	O
telopeptide	O
levels	O
(	O
bone	O
resorption	O
marker	O
)	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Fewer	O
women	O
in	O
the	O
vitamin	O
K	O
group	O
had	O
clinical	O
fractures	O
(	O
nine	O
versus	O
20	O
,	O
p	O
=	O
0.04	O
)	O
and	O
fewer	O
had	O
cancers	O
(	O
three	O
versus	O
12	O
,	O
p	O
=	O
0.02	O
)	O
.	O

Vitamin	O
K	O
supplements	O
were	O
well	O
-	O
tolerated	O
over	O
the	O
4	O
-	O
y	O
period	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
adverse	O
effects	O
or	O
health	O
-	O
related	O
quality	O
of	O
life	O
between	O
the	O
two	O
groups	O
.	O

The	O
study	O
was	O
not	O
powered	O
to	O
examine	O
fractures	O
or	O
cancers	O
,	O
and	O
their	O
numbers	O
were	O
small	O
.	O

CONCLUSIONS	O
:	O
Daily	O
5	O
mg	O
of	O
vitamin	O
K1	O
supplementation	O
for	O
2	O
to	O
4	O
y	O
does	O
not	O
protect	O
against	O
age	O
-	O
related	O
decline	O
in	O
BMD	O
,	O
but	O
may	O
protect	O
against	O
fractures	O
and	O
cancers	O
in	O
postmenopausal	O
women	O
with	O
osteopenia	B
.	O

More	O
studies	O
are	O
needed	O
to	O
further	O
examine	O
the	O
effect	O
of	O
vitamin	O
K	O
on	O
fractures	O
and	O
cancers	O
.	O

Trial	O
registration	O
:	O
ClinicalTrials	O
.	O

gov	O
(	O
#	O
NCT00150969	O
)	O
and	O
Current	O
Controlled	O
Trials	O
(	O
#	O
ISRCTN61708241	O
)	O
.	O

Peptide	O
-	O
mediated	O
cellular	O
uptake	O
of	O
cryptophane	O
.	O

Cryptophane	O
-	O
A	O
has	O
generated	O
considerable	O
interest	O
based	O
on	O
its	O
high	O
affinity	O
for	O
xenon	O
and	O
potential	O
for	O
creating	O
biosensors	O
for	O
(	O
129	O
)	O
Xe	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
spectroscopy	O
.	O

Here	O
,	O
we	O
report	O
the	O
cellular	O
delivery	O
of	O
three	O
peptide	O
-	O
functionalized	O
cryptophane	O
biosensors	O
.	O

Cryptophanes	O
were	O
delivered	O
using	O
two	O
cationic	O
cell	O
penetrating	O
peptides	O
into	O
several	O
human	O
cancer	B
and	O
normal	O
cell	O
lines	O
.	O

An	O
RGD	O
peptide	O
targeting	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
receptor	O
was	O
shown	O
to	O
increase	O
specificity	O
of	O
cryptophane	O
cell	O
uptake	O
.	O

Labeling	O
the	O
peptides	O
with	O
Cy3	O
made	O
it	O
possible	O
to	O
monitor	O
cellular	O
delivery	O
using	O
confocal	O
laser	O
scanning	O
microscopy	O
.	O

The	O
peptido	O
-	O
cryptophanes	O
were	O
determined	O
to	O
be	O
relatively	O
nontoxic	O
by	O
MTT	O
assay	O
at	O
the	O
micromolar	O
cryptophane	O
concentrations	O
that	O
are	O
required	O
for	O
(	O
129	O
)	O
Xe	O
NMR	O
biosensing	O
experiments	O
.	O

Effectiveness	O
and	O
tolerability	O
of	O
open	O
label	O
olanzapine	O
in	O
children	O
and	O
adolescents	O
with	O
Tourette	B
syndrome	I
.	O

OBJECTIVES	O
:	O
The	O
primary	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
effectiveness	O
and	O
tolerability	O
of	O
open	O
-	O
label	O
olanzapine	O
on	O
motor	O
and	O
vocal	O
tics	O
in	O
children	O
and	O
adolescents	O
with	O
Tourette	B
syndrome	I
(	O
TS	B
)	O
.	O

Secondary	O
aims	O
included	O
assessing	O
the	O
response	O
of	O
TS	O
-	O
associated	O
disruptive	B
behaviors	I
to	O
olanzapine	O
exposure	O
.	O

METHOD	O
:	O
Twelve	O
children	O
and	O
adolescents	O
(	O
mean	O
age	O
11.3	O
+	O
/	O
-	O
2.4	O
years	O
,	O
range	O
7	O
-	O
14	O
years	O
)	O
with	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B
Disorders	I
,	O
4th	O
edition	O
(	O
DSM	O
-	O
IV	O
)	O
TS	B
were	O
enrolled	O
in	O
a	O
single	O
-	O
site	O
,	O
6	O
-	O
week	O
,	O
open	O
-	O
label	O
,	O
prospective	O
,	O
flexible	O
-	O
dose	O
design	O
in	O
outpatients	O
receiving	O
monotherapy	O
with	O
olanzapine	O
.	O

Standardized	O
ratings	O
of	O
tic	B
symptoms	I
,	O
disruptive	B
behaviors	I
,	O
and	O
aggression	B
were	O
obtained	O
,	O
along	O
with	O
adverse	O
events	O
and	O
safety	O
data	O
.	O

RESULTS	O
:	O
Over	O
the	O
6	O
-	O
week	O
trial	O
,	O
olanzapine	O
administration	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
total	O
tic	B
severity	O
as	O
measured	O
by	O
the	O
Yale	O
Global	O
Tic	B
Severity	O
Scale	O
(	O
30	O
%	O
reduction	O
by	O
week	O
6	O
;	O
effect	O
size	O
0.49	O
)	O
.	O

A	O
significant	O
majority	O
of	O
subjects	O
were	O
rated	O
as	O
""""	O
much	O
improved	O
""""	O
or	O
""""	O
very	O
much	O
improved	O
""""	O
on	O
the	O
Clinical	O
Global	O
Impressions	O
-	O
Improvement	O
Scale	O
(	O
GCI	O
-	O
I	O
)	O
by	O
both	O
clinicians	O
(	O
67	O
%	O
;	O
8	O
/	O
12	O
)	O
and	O
parents	O
(	O
64	O
%	O
;	O
7	O
/	O
11	O
)	O
.	O

Attention	B
-	I
deficit	I
/	I
hyperactivity	I
disorder	I
(	O
ADHD	B
)	O
symptoms	O
showed	O
significant	O
improvements	O
from	O
baseline	O
for	O
both	O
inattention	O
(	O
33	O
%	O
decrease	O
)	O
and	O
hyperactive	O
/	O
impulsivity	O
(	O
50	O
%	O
decrease	O
)	O
scores	O
(	O
effect	O
sizes	O
0.44	O
and	O
0.43	O
,	O
respectively	O
)	O
.	O

Aggression	B
was	O
also	O
decreased	O
as	O
assessed	O
by	O
fewer	O
numbers	O
of	O
aggressive	O
episodes	O
on	O
the	O
Overt	O
Aggression	B
Scale	O
(	O
OAS	O
)	O
.	O

Little	O
change	O
in	O
anxiety	B
symptoms	O
was	O
noted	O
.	O

The	O
most	O
widely	O
reported	O
side	O
effects	O
were	O
drowsiness	B
/	O
sedation	B
and	O
weight	O
gain	O
;	O
adverse	O
events	O
were	O
generally	O
well	O
tolerated	O
.	O

Mean	O
weight	O
gain	O
of	O
4.1	O
+	O
/	O
-	O
2.0	O
kg	O
was	O
observed	O
over	O
the	O
6	O
-	O
week	O
trial	O
,	O
a	O
mean	O
percent	O
change	O
of	O
8.4	O
+	O
/	O
-	O
4.4	O
(	O
p	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O
Additional	O
studies	O
of	O
the	O
benefits	O
of	O
olanzapine	O
treatment	O
for	O
tic	B
control	O
as	O
well	O
as	O
the	O
commonly	O
associated	O
co	O
-	O
morbid	O
features	O
of	O
TS	B
are	O
indicated	O
,	O
especially	O
if	O
approaches	O
to	O
predict	O
or	O
minimize	O
weight	O
gain	O
can	O
be	O
determined	O
.	O

